Clustering O 0 6.579290356967249e-07
of O 0 1.4705065609632584e-07
missense O 0 3.132168160391302e-07
mutations O 0 3.9892653624917784e-09
in O 0 1.006628647104435e-08
the O 0 1.5725880757599953e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 9.90931766864378e-06
in O 0 8.982255650380466e-08
a O 0 1.7033748633821233e-08
sporadic B-Disease 0 2.3722127480141353e-06
T I-Disease 0 0.01166944857686758
- I-Disease 0 0.007201876491308212
cell I-Disease 0 0.07310926169157028
leukaemia I-Disease 1 1.0
. O 0 4.399165845825337e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.000406744860811159
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.936451023622283e-10
is O 0 3.5034027762170794e-11
a O 0 1.324709786310052e-10
recessive B-Disease 0 1.2245150671219562e-08
multi I-Disease 0 2.345896245969925e-05
- I-Disease 1 0.9999723434448242
system I-Disease 0 0.00010430200927658007
disorder I-Disease 1 0.9999992847442627
caused O 0 5.853405538047696e-10
by O 0 2.3863826496481333e-13
mutations O 0 1.1435502067849712e-12
in O 0 2.8431387452676482e-11
the O 0 6.492192339280223e-10
ATM O 0 8.97722074455487e-08
gene O 0 2.446513436282771e-09
at O 0 7.185002459664247e-08
11q22 O 0 1.8990003809449263e-06
- O 0 2.074649501082604e-06
q23 O 0 2.075189740935457e-06
( O 0 4.883973225844329e-10
ref O 0 1.0152577090138948e-07
. O 0 5.651930590211407e-10
3 O 0 1.0631265645599797e-08
) O 0 1.2308556396334325e-09
. O 0 3.870411546813557e-08

The O 0 3.050864734177594e-07
risk O 0 4.1755367874429794e-07
of O 0 5.1105195630896105e-09
cancer B-Disease 0 7.687108194431858e-08
, O 0 4.529412123144283e-10
especially O 0 3.3020548517725956e-09
lymphoid B-Disease 0 2.539317620176007e-06
neoplasias I-Disease 0 0.00010241639392916113
, O 0 6.993834400503829e-10
is O 0 1.2032454026200678e-11
substantially O 0 9.24636367471976e-10
elevated O 0 3.3108336072729116e-09
in O 0 3.781638557853739e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.8342365112621337e-06
and O 0 2.5730545472057997e-10
has O 0 3.68904837233508e-11
long O 0 1.9565352810113623e-11
been O 0 2.372008665874059e-11
associated O 0 4.879625037368385e-10
with O 0 3.7405603614537597e-10
chromosomal O 1 1.0
instability O 1 1.0
. O 0 4.437573352333857e-06

By O 0 1.027693308230937e-08
analysing O 0 7.1612782903685e-07
tumour B-Disease 1 1.0
DNA O 0 3.253598279684411e-08
from O 0 1.817365424816586e-10
patients O 0 2.8625752809818827e-11
with O 0 2.4152037249487723e-13
sporadic B-Disease 0 6.252851125765346e-09
T I-Disease 0 4.931516741635278e-06
- I-Disease 0 0.0001545536651974544
cell I-Disease 1 0.9996503591537476
prolymphocytic I-Disease 1 0.9999998807907104
leukaemia I-Disease 1 1.0
( O 0 1.4825615179958618e-09
T B-Disease 0 2.6286107868145336e-07
- I-Disease 0 1.8469239648766234e-07
PLL I-Disease 0 2.00574004338705e-06
) O 0 2.984180680343229e-10
, O 0 9.055420302495065e-11
a O 0 4.2565798108462616e-10
rare O 0 3.9315923849869705e-09
clonal B-Disease 0 9.960843527778707e-08
malignancy I-Disease 0 1.4385642543857102e-07
with O 0 2.171240617854231e-12
similarities O 0 7.182279770923117e-11
to O 0 1.962789375475893e-10
a O 0 3.8986142092412024e-10
mature B-Disease 0 4.3069153576880126e-08
T I-Disease 0 1.5295385082936264e-06
- I-Disease 0 5.276857564240345e-07
cell I-Disease 0 6.827300467193709e-07
leukaemia I-Disease 0 0.00010013014980359003
seen O 0 1.3496868067619516e-09
in O 0 6.187017564940334e-10
A B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
, O 0 3.582950325320411e-10
we O 0 9.956480084838404e-11
demonstrate O 0 3.4594133113685643e-10
a O 0 8.708513077326785e-11
high O 0 4.522385244065674e-10
frequency O 0 1.0525821991791418e-08
of O 0 3.448229257685398e-09
ATM O 0 2.518002247597906e-06
mutations O 0 5.293909666193031e-08
in O 0 6.464989041887748e-07
T B-Disease 0 0.0003227095876354724
- I-Disease 0 0.00013876482262276113
PLL I-Disease 0 0.0006143937353044748
. O 0 2.7763608159148134e-06

In O 0 5.081011611451913e-09
marked O 0 2.5639144141109682e-09
contrast O 0 1.7369294891267373e-10
to O 0 2.695180745249104e-10
the O 0 1.286671463818223e-10
ATM O 0 4.857371393995891e-08
mutation O 0 1.1258480953069139e-10
pattern O 0 5.118376902868427e-11
in O 0 1.7411960762103718e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 2.7172688543686263e-09
the O 0 3.552275140705774e-10
most O 0 1.0918875179011245e-11
frequent O 0 3.640911357127852e-12
nucleotide O 0 8.04660005293556e-10
changes O 0 8.311627497370466e-10
in O 0 1.097078317080502e-09
this O 0 3.3392966169998317e-09
leukaemia B-Disease 0 6.751372893631924e-06
were O 0 1.9015718777382062e-08
missense O 0 5.612301947621745e-07
mutations O 0 7.84451188451385e-08
. O 0 4.7010345838316425e-07

These O 0 4.216711868565426e-09
clustered O 0 7.222409892371218e-10
in O 0 2.5317142826608574e-10
the O 0 4.958595756221484e-10
region O 0 5.453935081334293e-10
corresponding O 0 5.156165272524049e-09
to O 0 3.6789213453403136e-08
the O 0 1.3325696990307279e-08
kinase O 0 2.733749404626451e-08
domain O 0 9.384599763961887e-09
, O 0 8.790988770268626e-11
which O 0 6.136990221561334e-12
is O 0 1.4881915144648872e-12
highly O 0 1.467368587748652e-11
conserved O 0 4.707200601528072e-11
in O 0 8.480507407426785e-10
ATM O 0 1.65327492140932e-07
- O 0 2.3454511222098517e-08
related O 0 2.227299678025929e-09
proteins O 0 1.3975906543173267e-10
in O 0 2.459332959503513e-09
mouse O 0 5.1294872349672005e-08
, O 0 3.4444280760936863e-10
yeast O 0 4.578227574825178e-09
and O 0 1.4202449216682567e-09
Drosophila O 0 2.5632465394664905e-07
. O 0 1.9552143726286886e-07

The O 0 5.056694476479606e-07
resulting O 0 3.5576082524357844e-08
amino O 0 5.559431315305119e-08
- O 0 8.198835388384396e-08
acid O 0 2.5590008334575032e-08
substitutions O 0 1.0534538574802355e-08
are O 0 5.347811082856424e-11
predicted O 0 6.95633373126725e-09
to O 0 8.447997856819711e-09
interfere O 0 1.5588359758567094e-07
with O 0 2.7672337754580667e-09
ATP O 0 9.607777428755071e-06
binding O 0 7.086195807914919e-08
or O 0 1.2586855113738693e-08
substrate O 0 1.8725692996213184e-08
recognition O 0 7.813466140760283e-08
. O 0 1.0975481501418471e-07

Two O 0 6.562265042475701e-08
of O 0 1.227658064095749e-08
seventeen O 0 1.4110683821400016e-07
mutated O 0 4.722918944821686e-08
T B-Disease 0 1.391240289194684e-06
- I-Disease 0 6.950255055926391e-07
PLL I-Disease 0 8.382772648474202e-06
samples O 0 5.6126715719528875e-08
had O 0 7.522318323793797e-10
a O 0 5.054483220856554e-11
previously O 0 1.8525347922349056e-10
reported O 0 3.003723492156496e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
allele O 0 2.8466240564739564e-06
. O 0 5.467735491038184e-07

In O 0 3.3119658127134244e-08
contrast O 0 8.41071301493912e-09
, O 0 4.063407943455388e-10
no O 0 8.888411673346752e-10
mutations O 0 5.009281878187721e-10
were O 0 1.0822638341068114e-09
detected O 0 2.4279840360463822e-09
in O 0 2.2535846522231395e-09
the O 0 1.6141232350719292e-08
p53 O 0 8.911297477709468e-09
gene O 0 6.736307511800987e-09
, O 0 2.1848325371109922e-09
suggesting O 0 3.244476332042723e-08
that O 0 2.360654172139931e-10
this O 0 7.128171386483473e-10
tumour B-Disease 1 1.0
suppressor O 0 7.568694400106324e-07
is O 0 1.876629129871077e-10
not O 0 7.007878305431703e-11
frequently O 0 4.2430489677336425e-11
altered O 0 2.1622057477799217e-09
in O 0 1.6768697541635902e-09
this O 0 5.079994203072147e-09
leukaemia B-Disease 0 2.505113479855936e-05
. O 0 1.8123935774383426e-07

Occasional O 0 2.5931101390597178e-06
missense O 0 2.229323399660643e-06
mutations O 0 2.1349832124428758e-08
in O 0 4.339061998592797e-09
ATM O 0 7.318683401535964e-07
were O 0 1.0496150615324495e-08
also O 0 6.578186884098614e-10
found O 0 7.496990528377268e-11
in O 0 3.8790545775491125e-10
tumour B-Disease 1 1.0
DNA O 0 1.9106135340507535e-08
from O 0 1.282041417471902e-10
patients O 0 1.2338118027255263e-10
with O 0 1.4490890041726767e-12
B B-Disease 0 1.6909358180328127e-07
- I-Disease 0 1.293242632982583e-07
cell I-Disease 0 0.0006572403945028782
non I-Disease 1 1.0
- I-Disease 1 1.0
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.9999994039535522
( O 0 1.1303687846853094e-10
B B-Disease 0 1.3018323308244817e-08
- I-Disease 0 2.18162599097127e-09
NHL I-Disease 0 6.213976178059966e-08
) O 0 3.1123260219034776e-11
and O 0 8.046349697643507e-11
a O 0 3.5184399838072977e-09
B B-Disease 0 4.219449465381331e-07
- I-Disease 0 9.359685293475195e-08
NHL I-Disease 0 8.644247486699896e-07
cell O 0 2.4426756795037363e-07
line O 0 3.7021300158812664e-07
. O 0 2.417251607766957e-07

The O 0 9.516802634834676e-08
evidence O 0 2.3538092364105978e-08
of O 0 1.2045876518484988e-09
a O 0 1.411898237213549e-10
significant O 0 2.1837565089555255e-10
proportion O 0 1.9492576996960054e-10
of O 0 1.0492182678234485e-09
loss O 0 3.763914957488623e-09
- O 0 6.100042782009041e-08
of O 0 1.3935174081325385e-07
- O 0 4.8204171321231115e-08
function O 0 1.997628062966328e-09
mutations O 0 5.711998929402995e-11
and O 0 6.9020704950018e-12
a O 0 1.725906084715234e-10
complete O 0 3.2115739401206156e-08
absence O 0 6.215516918928188e-07
of O 0 8.903143111638201e-09
the O 0 6.926673123963667e-10
normal O 0 2.4115396346502393e-09
copy O 0 3.107834345428273e-08
of O 0 2.51589726829593e-09
ATM O 0 6.550084918899302e-08
in O 0 3.3942386679086667e-09
the O 0 8.13297962309889e-09
majority O 0 2.9844882121210503e-10
of O 0 7.84361020578217e-09
mutated O 0 3.0963383323978633e-07
tumours B-Disease 1 1.0
establishes O 0 6.01808380906732e-08
somatic O 0 1.3911261476096115e-07
inactivation O 0 1.227813157811397e-07
of O 0 1.1852028691805572e-08
this O 0 1.0106985387503542e-10
gene O 0 3.725279112964941e-11
in O 0 2.17202561492158e-10
the O 0 4.2700376567950116e-10
pathogenesis O 0 6.612774541281397e-07
of O 0 4.250359175728136e-09
sporadic B-Disease 0 1.0280999731548945e-06
T I-Disease 0 0.00019556576444301754
- I-Disease 0 0.00037760406848974526
PLL I-Disease 0 0.21369101107120514
and O 0 5.251600043720828e-08
suggests O 0 4.9484722097759004e-08
that O 0 2.7970478364003348e-11
ATM O 0 2.7594083462645358e-08
acts O 0 2.98321500835641e-09
as O 0 7.3521193577619215e-09
a O 0 8.183836541775236e-08
tumour B-Disease 1 1.0
suppressor O 0 5.586679981206544e-05
. O 0 1.2432360563252587e-06

As O 0 1.827232125606315e-07
constitutional O 0 3.7380218032012635e-07
DNA O 0 3.160884887165594e-08
was O 0 8.94846330368182e-09
not O 0 1.079253700297933e-10
available O 0 1.3705699908328484e-09
, O 0 4.1907057685142135e-11
a O 0 4.335477532535492e-10
putative O 0 6.780304033782159e-07
hereditary O 1 0.9298926591873169
predisposition O 1 0.9999387264251709
to O 0 7.32380140107125e-05
T B-Disease 0 0.0017682993784546852
- I-Disease 0 2.0757557649631053e-05
PLL I-Disease 0 2.417708128632512e-05
will O 0 4.0453147498453745e-09
require O 0 1.2251709646804443e-09
further O 0 4.650783091975086e-10
investigation O 0 2.913090324518919e-10
. O 0 1.3528310693899925e-09
. O 0 5.3302937175203624e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 2.837872159489052e-07
kinase O 0 4.7972115169159224e-08
is O 0 3.800746523063836e-11
involved O 0 8.948107879658274e-12
in O 0 4.458320171374375e-11
the O 0 4.777410689271733e-10
modulation O 0 2.8268670959619158e-08
of O 0 5.504330324868079e-09
the O 0 1.2884729727602462e-08
Ca2 O 0 2.1622372514684685e-06
+ O 0 5.685150426870678e-06
homeostasis O 0 1.8254535234518698e-06
in O 0 4.560885713544849e-08
skeletal O 0 9.972807674785145e-06
muscle O 0 5.259489626041614e-07
cells O 0 4.4055457237845985e-07
. O 0 2.0658389132677257e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.568262046537711e-07
DM B-Disease 1 1.0
) O 0 7.452957362374946e-09
, O 0 5.294025218205434e-10
the O 0 1.0979324116533462e-09
most O 0 4.376395912331077e-10
prevalent O 0 5.406256775586371e-08
muscular B-Disease 0 3.279948757040074e-08
disorder I-Disease 0 1.2128278825684902e-08
in O 0 2.6393519314549252e-11
adults O 0 1.596557608340987e-11
, O 0 1.6993475853918638e-12
is O 0 3.0885754023768364e-12
caused O 0 2.3153206782366986e-11
by O 0 1.5307626693994436e-11
( O 0 1.2140857763576207e-10
CTG O 0 5.205219011372719e-08
) O 0 9.344616747064549e-11
n O 0 1.6240632172426217e-09
- O 0 3.847724361349947e-09
repeat O 0 2.4034441103992776e-09
expansion O 0 1.6099408473024823e-09
in O 0 3.0491564828594164e-10
a O 0 1.0717600418264084e-10
gene O 0 2.963634546104821e-11
encoding O 0 7.776423394112442e-10
a O 0 5.153795612500289e-09
protein O 0 1.4324280428468228e-08
kinase O 0 4.535187088094972e-07
( O 0 7.460167594786071e-09
DM B-Disease 1 1.0
protein O 0 6.611135461298545e-08
kinase O 0 4.126701114159914e-08
; O 0 2.6255958518461853e-10
DMPK O 0 4.6090886485217197e-07
) O 0 2.0961751431847198e-11
and O 0 5.406080964831528e-12
involves O 0 1.3760378253513394e-11
changes O 0 2.3506124824379526e-10
in O 0 9.364873321260347e-10
cytoarchitecture O 0 6.87099259266688e-07
and O 0 6.889691039901891e-09
ion O 0 2.2948350306251086e-05
homeostasis O 1 0.85170578956604
. O 0 5.1046532462351024e-05

To O 0 4.9962903148070836e-08
obtain O 0 2.361497166702975e-07
clues O 0 2.765668796200771e-07
to O 0 4.341959680687069e-09
the O 0 1.1770425745183388e-09
normal O 0 1.0348570889107123e-08
biological O 0 2.2235019159211333e-08
role O 0 3.421514094270606e-08
of O 0 1.772907012309588e-07
DMPK O 0 0.00023815901658963412
in O 0 3.135371571261203e-07
cellular O 0 3.7394449918792816e-06
ion O 0 4.310615622671321e-06
homeostasis O 0 6.509014929179102e-05
, O 0 1.5056219382358904e-08
we O 0 8.040236920692223e-09
have O 0 6.900813254162586e-10
compared O 0 5.866058194747836e-10
the O 0 7.483679231867768e-10
resting O 0 4.19863255274322e-08
[ O 0 2.9217684271998223e-08
Ca2 O 0 6.663660911954139e-08
+ O 0 5.678766967776028e-08
] O 0 2.922465114352235e-08
i O 0 7.1996235639915085e-09
, O 0 1.2256026749035698e-10
the O 0 1.3019325895147205e-10
amplitude O 0 1.1723553239306739e-09
and O 0 1.6959883497591477e-10
shape O 0 1.672264993146655e-08
of O 0 2.2599563109793053e-08
depolarization O 0 1.8454380779076018e-07
- O 0 6.857991508013583e-08
induced O 0 4.3047389652883794e-08
Ca2 O 0 1.9241191751007136e-08
+ O 0 1.3661755282612376e-08
transients O 0 2.9355755604143496e-09
, O 0 8.71698373205998e-12
and O 0 4.560145663856652e-12
the O 0 6.376925376638809e-11
content O 0 7.437346849492599e-10
of O 0 2.362365858488147e-10
ATP O 0 4.437034206716817e-08
- O 0 2.047659286574799e-08
driven O 0 3.901653045090825e-08
ion O 0 7.857659767296354e-08
pumps O 0 8.36890308164584e-08
in O 0 1.814053085524847e-08
cultured O 0 0.00025522266514599323
skeletal O 0 0.001055452972650528
muscle O 0 2.845085873559583e-07
cells O 0 5.510877443271056e-08
of O 0 6.654992668053694e-10
wild O 0 7.65923546808267e-10
- O 0 6.890948922588791e-10
type O 0 1.230911927940781e-09
and O 0 4.758731186882414e-10
DMPK O 0 5.740224423789186e-06
[ O 0 3.9261990991690254e-07
- O 0 4.193888798909029e-06
/ O 0 5.9508725826162845e-05
- O 0 5.571220026467927e-05
] O 0 3.6850003652943997e-06
knockout O 0 1.529671499156393e-05
mice O 0 1.0219960131507833e-05
. O 0 7.739392913208576e-07

In O 0 2.3142256111441384e-07
vitro O 0 1.0448840157550876e-06
- O 0 1.5925674290429015e-07
differentiated O 0 1.5410040532515268e-07
DMPK O 0 4.764366622111993e-06
[ O 0 1.453341269552766e-07
- O 0 4.231675916344102e-07
/ O 0 1.6235023849731078e-06
- O 0 1.2722014162136475e-06
] O 0 1.4102785428349307e-07
myotubes O 0 1.6391142310112627e-07
exhibit O 0 6.828724696816835e-09
a O 0 5.052308016395557e-10
higher O 0 7.914648492146625e-09
resting O 0 1.165291649840583e-07
[ O 0 9.726389293973625e-08
Ca2 O 0 8.434426490566693e-07
+ O 0 8.339534360857215e-07
] O 0 1.5008687626050232e-07
i O 0 2.0507080478182615e-08
than O 0 4.5690479177906695e-10
do O 0 1.7097049331837866e-09
wild O 0 5.442091666196802e-09
- O 0 6.20601392498088e-09
type O 0 9.504120157544094e-09
myotubes O 0 8.367065902348259e-07
because O 0 1.4052361496652566e-09
of O 0 9.22117882051765e-10
an O 0 3.2473131822419177e-11
altered O 0 3.730416864300423e-09
open O 0 1.1904727870160059e-08
probability O 0 2.720779823661701e-09
of O 0 3.171008178259882e-10
voltage O 0 2.9892182062951633e-09
- O 0 2.3770986956606066e-08
dependent O 0 7.944370850054838e-08
l O 0 7.068403817811486e-08
- O 0 2.6294523891579047e-08
type O 0 1.9665948869374006e-08
Ca2 O 0 1.0386403914708353e-07
+ O 0 9.156514835240159e-08
and O 0 1.5135450670555883e-09
Na O 0 7.974671234478592e-07
+ O 0 6.563879537679895e-07
channels O 0 4.200266516818374e-07
. O 0 1.1635703600632041e-07

The O 0 3.375258529558778e-06
mutant O 0 7.507825898755982e-07
myotubes O 0 2.180397359552444e-06
exhibit O 0 3.165095918689076e-08
smaller O 0 9.607860063098883e-10
and O 0 5.717135653782179e-10
slower O 0 8.097630654901877e-08
Ca2 O 0 6.153623530735786e-07
+ O 0 4.600279339683766e-07
responses O 0 5.965670180074767e-09
upon O 0 6.4101501884294976e-09
triggering O 0 3.3285754152956315e-09
by O 0 3.135420395539157e-11
acetylcholine O 0 4.912367845832932e-09
or O 0 3.725439068347214e-09
high O 0 1.7007648622779925e-08
external O 0 5.8460816632077695e-08
K O 0 8.826146995488671e-07
+ O 0 1.187555994874856e-06
. O 0 6.420552978170235e-08

In O 0 1.7186653167300392e-07
addition O 0 6.266093777185233e-08
, O 0 1.3270902154971509e-09
we O 0 2.228073059384883e-09
observed O 0 1.4917405088965552e-09
that O 0 4.098784159300983e-11
these O 0 3.097811729357858e-10
Ca2 O 0 9.299934617956751e-07
+ O 0 3.3389339932909934e-06
transients O 0 3.085779383127374e-07
partially O 0 1.65193778656203e-08
result O 0 8.71717073525069e-11
from O 0 4.208961304486003e-11
an O 0 1.1204533828523822e-11
influx O 0 2.9514513055772795e-10
of O 0 6.294006982265898e-11
extracellular O 0 2.91718815770281e-10
Ca2 O 0 1.577583397249782e-08
+ O 0 7.857461348237393e-09
through O 0 8.55918669273592e-11
the O 0 2.766593898417824e-10
l O 0 3.10586534268964e-09
- O 0 3.756004840482774e-09
type O 0 4.98653873748367e-09
Ca2 O 0 3.5598625913735304e-07
+ O 0 6.939307581887988e-07
channel O 0 2.4794462660793215e-07
. O 0 8.721857369664576e-08

Neither O 0 2.004481757467147e-06
the O 0 1.4467830489195421e-08
content O 0 5.856647167234996e-09
nor O 0 2.0789929777720317e-08
the O 0 2.1626539448149629e-10
activity O 0 6.077808811788543e-10
of O 0 5.602494024259386e-10
Na O 0 2.1887569801037898e-07
+ O 0 4.0996198436005216e-07
/ O 0 6.093438287280151e-07
K O 0 3.087265838530584e-07
+ O 0 3.5964356470685743e-07
ATPase O 0 2.072245251838467e-06
and O 0 7.87316789541137e-09
sarcoplasmic O 0 2.015345307881944e-05
reticulum O 0 7.644967467967945e-07
Ca2 O 0 8.960846571426373e-07
+ O 0 4.336880294886214e-07
- O 0 1.0119981652678689e-07
ATPase O 0 5.534514571081672e-07
are O 0 1.6918075274041655e-10
affected O 0 5.289261251206767e-10
by O 0 1.6066974140027668e-10
DMPK O 0 1.9322991647641174e-05
absence O 0 1.0812511845870176e-06
. O 0 2.1855342424714763e-07

In O 0 4.0521896949030634e-08
conclusion O 0 6.636162197537487e-08
, O 0 2.442307911465491e-09
our O 0 1.3941097165570682e-08
data O 0 4.666976138878454e-09
suggest O 0 1.7782563199730816e-09
that O 0 4.407656878369082e-11
DMPK O 0 1.8184809391641465e-07
is O 0 4.0388650757172684e-11
involved O 0 4.319866686586238e-11
in O 0 2.592261127976059e-10
modulating O 0 1.0380026793654906e-07
the O 0 4.231490180472974e-08
initial O 0 1.2911076652244446e-08
events O 0 3.063703069017265e-09
of O 0 2.3189914433174863e-09
excitation O 0 5.375501928028825e-07
- O 0 3.3924395665962948e-06
contraction O 0 3.4656906677810184e-08
coupling O 0 4.351643045907849e-09
in O 0 5.370877964594456e-09
skeletal O 0 8.809008704702137e-07
muscle O 0 9.294785741076339e-08
. O 0 1.9003065787615014e-08
. O 0 4.068996162231997e-08

Constitutional O 0 9.927647624863312e-05
RB1 O 0 0.003513472620397806
- O 0 2.0247829525033012e-05
gene O 0 5.1958945590513395e-08
mutations O 0 2.6099206351659632e-08
in O 0 2.977711854867948e-09
patients O 0 5.1968038761174284e-09
with O 0 2.703097294609602e-11
isolated O 0 1.2878857091891405e-08
unilateral B-Disease 0 2.0541647245408967e-06
retinoblastoma I-Disease 1 0.9699100852012634
. O 0 0.00017563567962497473

In O 0 1.3957759392724256e-07
most O 0 2.7127686763606107e-09
patients O 0 8.227243886160807e-10
with O 0 1.289205981552799e-11
isolated O 0 8.136641582723314e-09
unilateral B-Disease 0 7.475410939150606e-07
retinoblastoma I-Disease 0 0.12127924710512161
, O 0 2.3771395518679128e-08
tumor B-Disease 0 6.512824484161683e-07
development O 0 9.132062928074447e-08
is O 0 1.3247425378892785e-10
initiated O 0 1.2022877138306853e-09
by O 0 8.025561985813834e-12
somatic O 0 1.1327116133941217e-08
inactivation O 0 7.570182702920647e-08
of O 0 3.199266984665883e-08
both O 0 1.7828750698001272e-09
alleles O 0 1.1022548429551193e-09
of O 0 3.911814872026298e-09
the O 0 3.1583475390561944e-08
RB1 O 0 2.1267476768116467e-05
gene O 0 7.805065393995392e-08
. O 0 5.886686835765431e-07

However O 0 2.411978528016334e-07
, O 0 2.022868539341971e-09
some O 0 2.8277377661645176e-10
of O 0 1.6268587865742035e-10
these O 0 5.637963013116476e-11
patients O 0 6.362006754745408e-11
can O 0 7.669040402724647e-11
transmit O 0 1.2815245753472482e-08
retinoblastoma B-Disease 0 9.702021088742185e-07
predisposition O 0 2.23501342588861e-06
to O 0 3.876295068039326e-06
their O 0 3.2134787488757866e-06
offspring O 0 6.527314326376654e-06
. O 0 1.2999423688597744e-06

To O 0 1.2297180163045596e-08
determine O 0 2.255588382737983e-09
the O 0 8.603612822177809e-10
frequency O 0 3.058461572891247e-08
and O 0 4.677497833505129e-10
nature O 0 7.087531006533254e-09
of O 0 5.61000357279795e-09
constitutional O 0 5.146833927938133e-07
RB1 O 0 3.681108137243427e-05
- O 0 1.093022660825227e-06
gene O 0 5.880938402924585e-09
mutations O 0 2.2630868290463013e-09
in O 0 6.971166421898545e-10
patients O 0 1.1271851230176821e-09
with O 0 6.078683997129408e-12
isolated O 0 2.954246403064076e-09
unilateral B-Disease 0 1.3953498978480638e-07
retinoblastoma I-Disease 0 8.316808089148253e-05
, O 0 1.4083279431531537e-08
we O 0 1.5945179399068365e-08
analyzed O 0 5.75009950765093e-09
DNA O 0 1.0673690375995193e-08
from O 0 3.745031396107379e-09
peripheral O 0 9.190439413941931e-07
blood O 0 6.217307202405209e-08
and O 0 5.105317057996217e-09
from O 0 5.667596614244985e-09
tumor B-Disease 0 1.0921224884441472e-06
tissue O 0 4.7670661729171115e-07
. O 0 3.323762314266787e-07

The O 0 2.0436763747966324e-07
analysis O 0 4.0502193598968006e-08
of O 0 2.3749098687630976e-08
tumors B-Disease 1 1.0
from O 0 4.151899712923068e-09
54 O 0 2.77684737426398e-08
( O 0 1.5326186153519217e-10
71 O 0 3.637434176084753e-08
% O 0 4.3592007781256825e-10
) O 0 8.674561763344357e-11
of O 0 5.764592136969782e-10
76 O 0 4.6922824736839175e-08
informative O 0 1.7454198086852557e-08
patients O 0 4.223859484397963e-09
showed O 0 1.3595150560874458e-09
loss O 0 2.784334540706368e-09
of O 0 6.6101746298841135e-09
constitutional O 0 2.178561999244266e-06
heterozygosity O 0 0.0010490817949175835
( O 0 8.88184217728849e-07
LOH O 1 0.9999998807907104
) O 0 1.0251071103084541e-08
at O 0 2.2724488246694818e-07
intragenic O 0 4.246927801432321e-06
loci O 0 5.028144869356765e-07
. O 0 3.224014903935313e-07

Three O 0 1.278378221059029e-07
of O 0 1.929197601668875e-08
13 O 0 4.371478325992939e-07
uninformative O 0 5.173009049030952e-05
patients O 0 2.1993507459683315e-07
had O 0 4.575244716420457e-08
constitutional O 0 2.477362158970209e-06
deletions O 0 4.131933565076906e-06
. O 0 2.7597352527664043e-06

For O 0 6.544527764162922e-08
39 O 0 1.8014338820648845e-07
randomly O 0 1.9385147709272132e-08
selected O 0 7.572275535494555e-07
tumors B-Disease 1 1.0
, O 0 1.2081437716915389e-07
SSCP O 0 6.485433550551534e-05
, O 0 8.377299742790001e-09
hetero O 0 4.410094049944746e-07
- O 0 1.547548222902151e-08
duplex O 0 5.512275791375032e-08
analysis O 0 4.9463366735835734e-09
, O 0 2.448224262208143e-11
sequencing O 0 3.2233593572073005e-10
, O 0 1.1145242367893715e-10
and O 0 2.5792554203540874e-10
Southern O 0 7.263571433213656e-08
blot O 0 2.159837180215618e-07
analysis O 0 1.2944529892422452e-09
were O 0 4.809043163689353e-10
used O 0 1.2910602587012932e-09
to O 0 6.548783293425231e-09
identify O 0 5.77273979729398e-08
mutations O 0 1.9389592864627048e-07
. O 0 2.2209644612303236e-06

Mutations O 0 2.440624484734144e-07
were O 0 6.509953021094361e-09
detected O 0 1.2320158226941658e-09
in O 0 3.410161042438631e-10
21 O 0 6.373395677883309e-08
( O 0 2.4051580171935427e-10
91 O 0 7.043734484568631e-08
% O 0 3.2740077315907e-10
) O 0 1.0281941964507268e-10
of O 0 2.0305610526349938e-09
23 O 0 4.218091817165259e-06
tumors B-Disease 1 1.0
with O 0 4.680752226704499e-06
LOH O 1 1.0
. O 0 2.6876870833802968e-05

In O 0 3.8669803359425714e-08
6 O 0 1.5534784836290783e-07
( O 0 3.9345607327767596e-10
38 O 0 1.4614018439829124e-08
% O 0 3.119857983069352e-10
) O 0 2.242486751846684e-10
of O 0 1.817071826337724e-09
16 O 0 3.499929164263449e-07
tumors B-Disease 1 1.0
without O 0 1.766826790117193e-05
LOH O 1 1.0
, O 0 3.815691762554252e-09
one O 0 3.628491951346291e-10
mutation O 0 2.753700878432852e-10
was O 0 6.725930368212119e-10
detected O 0 6.785887407545488e-10
, O 0 1.6233243915753093e-11
and O 0 1.0797102795168101e-11
in O 0 2.3991925113264756e-10
9 O 0 4.218765070618247e-08
( O 0 2.9038427218353036e-10
56 O 0 5.745779851906718e-09
% O 0 1.8169633853037936e-10
) O 0 2.2429401391743653e-10
of O 0 2.2821071699041795e-09
the O 0 2.9236637999474624e-08
tumors B-Disease 1 1.0
without O 0 7.174317579483613e-05
LOH O 1 1.0
, O 0 5.830243843263361e-09
both O 0 1.1657240728268903e-09
mutations O 0 5.416861958984498e-10
were O 0 2.012869426692987e-09
found O 0 4.738643699653267e-09
. O 0 7.818400860060137e-08

Thus O 0 2.769759177567721e-08
, O 0 2.2591178927555688e-10
a O 0 4.328091218752661e-10
total O 0 6.731962765016419e-10
of O 0 6.445222133777406e-10
45 O 0 1.2907728219602177e-08
mutations O 0 1.9788148897248448e-09
were O 0 4.352224358683543e-09
identified O 0 3.812107252088026e-08
in O 0 9.922993626787502e-08
tumors B-Disease 1 1.0
of O 0 5.689320232704631e-07
36 O 0 2.028271381959712e-07
patients O 0 9.279548685015016e-09
. O 0 3.9093553283464644e-08

Thirty O 0 4.4821666733696475e-07
- O 0 2.8063246304554923e-07
nine O 0 2.7715348238643855e-08
of O 0 1.7670783725165506e-09
the O 0 9.35771349297454e-10
mutations O 0 2.551502342740264e-10
- O 0 1.1084051898535563e-08
including O 0 8.185218058898158e-10
34 O 0 4.4976329149903904e-07
small O 0 3.636100753823257e-09
mutations O 0 1.62427458150205e-08
, O 0 3.352647492960159e-09
2 O 0 1.6738848671593587e-06
large O 0 4.292342481448941e-08
structural O 0 1.5795840226928703e-05
alterations O 0 5.4144238674780354e-05
, O 0 4.1157175445505345e-09
and O 0 1.1129782651053688e-09
hypermethylation O 0 5.09711117047118e-06
in O 0 8.049324407011227e-08
3 O 0 2.4976015993161127e-05
tumors O 1 1.0
- O 0 1.355944277747767e-06
were O 0 5.489065646457902e-09
not O 0 6.091387394491221e-10
detected O 0 5.124465296546532e-10
in O 0 1.3423384626065626e-10
the O 0 1.4471135401095125e-09
corresponding O 0 5.049207718599291e-09
peripheral O 0 1.9021963737486658e-07
blood O 0 2.0748732509900947e-08
DNA O 0 3.3954769662614126e-08
. O 0 1.4270889892031846e-07

In O 0 1.3824298150666436e-08
6 O 0 7.589512307504265e-08
( O 0 1.2250300773786194e-10
17 O 0 3.1356688356964924e-09
% O 0 4.4692183981398514e-11
) O 0 1.087750983036484e-11
of O 0 7.836843674002836e-11
the O 0 1.9022010355751462e-10
36 O 0 1.9963557473801075e-09
patients O 0 3.612815602238584e-10
, O 0 1.7304739238777067e-11
a O 0 3.084945632281233e-10
mutation O 0 5.027142035984866e-10
was O 0 2.016062428111809e-09
detected O 0 1.8222119368971335e-09
in O 0 5.233545818938978e-10
constitutional O 0 2.0846474768632106e-08
DNA O 0 1.6882882869495575e-09
, O 0 8.388515576607247e-11
and O 0 2.01105715413874e-10
1 O 0 1.9597732148213254e-07
of O 0 7.351824926615791e-09
these O 0 5.14510101190524e-10
mutations O 0 2.0972319714207543e-10
is O 0 9.635395779861167e-12
known O 0 9.626161673326195e-11
to O 0 5.750930287540257e-10
be O 0 2.367855911344918e-10
associated O 0 9.46285605429864e-10
with O 0 7.964780918134906e-11
reduced O 0 7.264652168714747e-08
expressivity O 0 1.5122724335014937e-06
. O 0 1.626684422717517e-07

The O 0 6.907496441499461e-08
presence O 0 1.229260782054098e-08
of O 0 5.368337774314114e-09
a O 0 3.3475995309117934e-09
constitutional O 0 5.05726838184728e-08
mutation O 0 1.726782938860083e-09
was O 0 7.878932506422132e-10
not O 0 7.580936572937347e-11
associated O 0 5.6288945726734596e-11
with O 0 2.1087738760056096e-12
an O 0 6.012553302459089e-12
early O 0 1.3655392372413644e-09
age O 0 8.356086933503093e-10
at O 0 2.686108668825682e-09
treatment O 0 2.5309780937732285e-08
. O 0 6.864155466246302e-08

In O 0 3.790436053918711e-08
1 O 0 3.6724088658957044e-07
patient O 0 2.2295944290817715e-07
, O 0 1.322287057625715e-09
somatic O 0 4.802192279385054e-07
mosaicism O 0 1.3335124094737694e-05
was O 0 7.602262286354744e-08
demonstrated O 0 6.077463865494792e-09
by O 0 2.7877009728394242e-11
molecular O 0 2.8720270606186205e-10
analysis O 0 1.774088376205185e-10
of O 0 2.2319979198215378e-10
DNA O 0 2.2946851363503384e-10
and O 0 1.3011632049586552e-10
RNA O 0 4.787885643509071e-09
from O 0 7.43301153960374e-09
peripheral O 0 1.5643790902686305e-06
blood O 0 3.8613649167018593e-07
. O 0 4.1330940803163685e-07

In O 0 1.3099314344344748e-07
2 O 0 4.0810911627886526e-07
patients O 0 1.498585611159342e-08
without O 0 5.216457044099343e-09
a O 0 8.28077517667225e-09
detectable O 0 1.7997064105657046e-06
mutation O 0 8.204275481205059e-09
in O 0 6.2150400381710824e-09
peripheral O 0 4.794129836227512e-06
blood O 0 7.617820756422589e-07
, O 0 6.8893095672706295e-09
mosaicism O 0 1.6560679796384647e-06
was O 0 6.04497873979426e-09
suggested O 0 7.444898031394587e-10
because O 0 4.178964119194717e-11
1 O 0 1.3523648867419524e-08
of O 0 9.009804569082291e-10
the O 0 9.670129141881034e-10
patients O 0 5.130805558195561e-09
showed O 0 3.9476216073808246e-08
multifocal O 1 0.7009903788566589
tumors B-Disease 1 1.0
and O 0 1.2462496101761644e-07
the O 0 5.03468925217021e-07
other O 0 7.645096999908674e-09
later O 0 3.776241896957799e-08
developed O 0 2.0502191944160586e-08
bilateral B-Disease 0 3.945951539208181e-05
retinoblastoma I-Disease 0 0.15036718547344208
. O 0 3.125333932985086e-06

In O 0 1.8397019019289473e-08
conclusion O 0 2.6618739212835862e-08
, O 0 9.26419385649524e-10
our O 0 4.647575213567734e-09
results O 0 1.3305117008144407e-09
emphasize O 0 7.391700140857438e-09
that O 0 2.4101437859358477e-11
the O 0 2.785512376313193e-10
manifestation O 0 1.4742212783858122e-08
and O 0 3.0160882125152e-10
transmissibility O 0 2.2048193670798355e-07
of O 0 1.5057418645270104e-09
retinoblastoma B-Disease 0 2.8955993158774618e-08
depend O 0 7.058444495555705e-09
on O 0 8.962400599443754e-09
the O 0 9.687519675338763e-10
nature O 0 3.0678182216803407e-10
of O 0 3.378992363689548e-10
the O 0 2.4010146648656416e-10
first O 0 4.928610852772408e-10
mutation O 0 4.2748839190753785e-11
, O 0 5.202071846205358e-12
its O 0 1.5036281247882144e-11
time O 0 1.0836141706160873e-10
in O 0 6.92612772690282e-11
development O 0 9.184423221952898e-10
, O 0 5.6828538402831086e-11
and O 0 1.1801712385128837e-10
the O 0 1.9005848006514725e-09
number O 0 1.3422316591515937e-09
and O 0 4.1125922112250635e-10
types O 0 1.6879992514873265e-08
of O 0 2.6303539346628213e-09
cells O 0 8.879633695002553e-10
that O 0 1.4773716972005246e-11
are O 0 6.931424184619672e-12
affected O 0 5.7669646835734056e-11
. O 0 1.4589863761571564e-09
. O 0 1.446204294097697e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.6149869561195374
the I-Disease 0 1.7959455362870358e-05
fifth I-Disease 0 2.913215666922042e-06
component I-Disease 0 7.093660059354079e-08
of I-Disease 0 2.4444473112339438e-09
complement I-Disease 0 1.980046704375127e-08
in O 0 2.2638613472736324e-07
man O 0 7.402633855235763e-06
. O 0 5.798037364002084e-06

I O 0 0.00102912331931293
. O 0 1.3015330296184402e-05

Clinical O 0 7.1705912887409795e-06
, O 0 4.985178936323109e-09
immunochemical O 0 1.0958638085867278e-06
, O 0 1.9169310583322385e-09
and O 0 9.034480941139122e-10
family O 0 9.975308579157627e-09
studies O 0 6.817613495968544e-08
. O 0 1.7581272970801365e-07

The O 0 8.205325343624281e-07
first O 0 4.379857543312937e-08
recognized O 0 9.153055202659743e-09
human O 0 1.3071393745178739e-08
kindred O 0 1.6253572539426386e-05
with O 0 3.4980043306376274e-09
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999984502792358
the I-Disease 0 0.0026364054065197706
fifth I-Disease 0 1.9731793145183474e-05
component I-Disease 0 3.9320445921475766e-07
of I-Disease 0 1.9376061288767232e-07
complement I-Disease 0 1.4822987850493519e-06
( O 0 3.640529655513092e-08
C5 O 0 0.4035460948944092
) O 0 9.214608631680221e-09
is O 0 4.937975806029726e-09
described O 0 5.432771033042627e-08
. O 0 2.0632045050206216e-07

The O 0 2.467759827595728e-07
proband O 0 2.8592621674761176e-06
, O 0 6.071737002066868e-10
a O 0 5.303666950062791e-10
20 O 0 1.316476372359432e-09
- O 0 1.4993051244971412e-09
year O 0 1.0052294552309604e-09
- O 0 7.224745246503517e-08
old O 0 8.006511365010738e-08
black O 0 1.7036275723469885e-09
female O 0 1.3684359201349139e-09
with O 0 2.5935320557834984e-10
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9999998807907104
age O 0 0.08472127467393875
11 O 0 3.834630661003757e-06
, O 0 4.143000609246883e-09
lacked O 0 2.941754644325556e-07
serum O 0 4.967195721405915e-08
hemolytic O 0 2.1592558852034927e-08
complement O 0 6.60200960567181e-09
activity O 0 1.5599594505033565e-08
, O 0 1.178672992541152e-10
even O 0 2.819529887343464e-10
during O 0 4.103990480786024e-09
remission O 0 6.659251994278748e-08
. O 0 2.6144745035594497e-08

C5 O 0 0.0006186732789501548
was O 0 2.8283179744903464e-06
undetectable O 0 3.035846930288244e-06
in O 0 6.682201902918905e-09
her O 0 3.5326419567383027e-09
serum O 0 9.730728223189544e-09
by O 0 2.1129310801004664e-10
both O 0 2.7675715053021577e-09
immunodiffusion O 0 2.894489853133564e-06
and O 0 1.8376468347014452e-08
hemolytic O 0 2.8686031328106765e-06
assays O 0 5.89229193792562e-06
. O 0 4.081357928953366e-06

Other O 0 2.444215319030718e-08
complement O 0 5.8273421643662004e-09
components O 0 1.95659772828094e-08
were O 0 2.649503061391556e-09
normal O 0 3.4939787951770995e-08
during O 0 6.1327987133097395e-09
remission O 0 1.413029053765058e-07
of O 0 1.1893555029729441e-09
lupus O 0 9.386376831344023e-08
, O 0 5.446907369588416e-10
but O 0 4.315012347433367e-09
C1 O 0 0.0002139924035873264
, O 0 3.422649896833718e-08
C4 O 0 0.00034851880627684295
, O 0 6.288159681844263e-08
C2 O 0 6.696299533359706e-05
, O 0 5.8851123974079655e-09
and O 0 6.641110772420689e-09
C3 O 0 0.0130479596555233
levels O 1 0.5678585767745972
fell O 0 0.00012387546303216368
during O 0 8.977251582109602e-07
exacerbations O 0 0.0018271688604727387
. O 0 1.144225507232477e-06

A O 0 2.1690693756681867e-06
younger O 0 5.873340569451102e-08
half O 0 1.192868381849621e-08
- O 0 7.288024050922104e-08
sister O 0 4.202486181270615e-08
, O 0 1.228214863147059e-09
who O 0 1.389328319056915e-09
had O 0 9.885964047384732e-09
no O 0 1.6280525372280863e-08
underlying O 0 2.0609916191460798e-06
disease O 0 6.437623056854136e-08
, O 0 5.548638631891478e-11
was O 0 6.434882848793677e-09
also O 0 4.195780611837563e-09
found O 0 1.107914204823146e-09
to O 0 6.641265315465716e-08
lack O 0 3.618809842009796e-06
immunochemically O 0 6.357164966175333e-05
detectable O 0 2.480088187439833e-05
C5 O 0 2.433256850054022e-05
. O 0 2.4875396320567233e-06

By O 0 1.1838275071340831e-07
hemolytic O 0 7.620446467626607e-06
assay O 0 9.525171549285005e-07
, O 0 4.3614902800470645e-09
she O 0 2.6908147932047655e-10
exhibited O 0 7.326120821105064e-10
1 O 0 8.05689293059686e-09
- O 0 2.1811111139413697e-08
2 O 0 1.9845346699298716e-08
% O 0 9.816867319045741e-10
of O 0 5.972646266449999e-10
the O 0 6.320138301596501e-10
normal O 0 2.081861971703347e-08
serum O 0 1.0084393409215409e-07
C5 O 0 2.938334091595607e-07
level O 0 1.2652354541842215e-07
and O 0 2.5814026471948637e-09
normal O 0 6.764661719671494e-08
concentrations O 0 7.426750414651906e-08
of O 0 1.7175721955808854e-09
other O 0 6.15383716207063e-11
complement O 0 4.197341141320976e-09
components O 0 3.2480674150292543e-08
. O 0 1.276575005704217e-07

C5 O 0 3.465811096248217e-05
levels O 0 6.727212849000352e-07
of O 0 3.2335090160984237e-09
other O 0 1.224509244002192e-10
family O 0 7.858607514732441e-11
members O 0 4.4733119985984615e-11
were O 0 5.0551288849343123e-11
either O 0 1.3159735801071548e-10
normal O 0 1.1839782487754746e-08
or O 0 2.33570773833236e-10
approximately O 0 2.12667678606282e-11
half O 0 1.6816348313852814e-10
- O 0 3.973204876217551e-09
normal O 0 2.1878861389268422e-08
, O 0 1.929001625100568e-09
consistent O 0 5.902685984437994e-08
with O 0 3.078398091993506e-10
autosomal O 0 3.147451366203313e-07
codominant O 0 2.8153178277534607e-07
inheritance O 0 8.183707933540063e-09
of O 0 2.1691286544722743e-09
the O 0 6.914146477576821e-10
gene O 0 4.853756951916921e-09
determining O 0 2.9207430998212658e-06
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.756480171228759e-05

Normal O 0 8.639346197014675e-05
hemolytic O 0 3.1970954296411946e-05
titers O 0 6.192056844156468e-06
were O 0 1.286829931501643e-08
restored O 0 1.6440017702734622e-07
to O 0 1.4299657458138881e-08
both O 0 4.02204936023054e-09
homozygous O 0 0.001468188245780766
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 6.780310286558233e-07
C5D B-Disease 1 1.0
) O 0 4.500221528758175e-09
sera O 0 9.419105850838605e-08
by O 0 2.941586557669851e-11
addition O 0 7.518875522194435e-10
of O 0 1.5952108523009656e-09
highly O 0 4.3280216743823985e-08
purified O 0 5.437035497379838e-07
human O 0 2.0172680592622783e-07
C5 O 0 8.603222522651777e-05
. O 0 1.3570879673352465e-06

In O 0 2.8630009296648495e-07
specific O 0 1.817343644461289e-07
C5 O 0 1.0632781595631968e-05
titrations O 0 1.4210985455065384e-06
, O 0 6.608456559753506e-10
however O 0 2.563248224785042e-10
, O 0 2.8645415900419025e-11
it O 0 1.631444458694009e-11
was O 0 5.584357420929109e-10
noted O 0 4.3138581595769665e-10
that O 0 6.358582497340004e-12
when O 0 2.6450671514188784e-11
limited O 0 1.122439474698922e-09
amounts O 0 8.218680735971873e-10
of O 0 5.891331311680403e-10
C5 O 0 7.479861352521766e-08
were O 0 6.757437276405653e-09
assayed O 0 1.3812100974064379e-07
in O 0 2.7052970974494883e-09
the O 0 4.042862045139373e-09
presence O 0 3.4026781392526573e-09
of O 0 2.487534844775041e-09
low O 0 2.862230452649328e-08
dilutions O 0 3.4214363608953136e-07
of O 0 3.991555974636185e-09
either O 0 4.786856067084955e-08
C5D B-Disease 1 1.0
serum O 0 5.554936706175795e-07
, O 0 5.455453866431981e-10
curving O 0 3.3875251492787584e-09
rather O 0 6.100060456759593e-10
than O 0 7.117367112341455e-11
linear O 0 3.467049425331936e-10
dose O 0 1.0100890079911551e-07
- O 0 4.337103121088148e-08
response O 0 6.53844933751202e-09
plots O 0 2.674759080889544e-09
were O 0 8.123940631321602e-09
consistently O 0 4.642011663946732e-09
obtained O 0 3.147887284171702e-09
, O 0 4.0513123411578533e-10
suggesting O 0 3.3460034742915923e-09
some O 0 7.000049845329315e-11
inhibitory O 0 5.735348551638708e-08
effect O 0 1.9998827838207944e-07
. O 0 7.017116558927228e-07

Further O 0 5.655062409459788e-07
studies O 0 2.893539985393545e-08
suggested O 0 8.655662853129797e-09
that O 0 1.1369312435949297e-10
low O 0 2.7375218536462853e-08
dilutions O 0 2.4208839022321627e-06
of O 0 8.449853794445517e-08
C5D B-Disease 1 1.0
serum O 0 1.5861165536534827e-07
contain O 0 1.3234148221741293e-09
a O 0 2.2110324682245164e-10
factor O 0 2.2214607930948205e-10
( O 0 9.642051046476752e-12
or O 0 7.291670045539433e-11
factors O 0 1.5278785181482846e-10
) O 0 2.6809004669003933e-11
interfering O 0 1.632822099750797e-09
at O 0 1.7210624037033995e-08
some O 0 4.3026168738968806e-10
step O 0 7.56587859029878e-09
in O 0 1.1563082713550443e-09
the O 0 3.1121392130017966e-09
hemolytic O 0 3.464898554739193e-07
assay O 0 5.313069095791434e-07
of O 0 1.338376932835672e-06
C5 O 0 1.1635903319984209e-05
, O 0 9.519464105878228e-10
rather O 0 4.803799025232536e-10
than O 0 2.1318356802080274e-10
a O 0 1.6605137265202075e-09
true O 0 2.483809780073898e-08
C5 O 0 3.370864305907162e-06
inhibitor O 0 2.546852329032845e-07
or O 0 3.069126464083638e-08
inactivator O 0 8.02691556600621e-06
. O 0 2.939003707069787e-07

Of O 0 2.0713837329822127e-06
clinical O 0 1.9048445665248437e-06
interest O 0 9.659888178248366e-08
are O 0 2.7333765806325516e-10
( O 0 9.738758410815507e-11
a O 0 1.8087832343027799e-09
) O 0 1.9131897455171298e-10
the O 0 1.689789641545758e-09
documentation O 0 1.2303091807552846e-06
of O 0 6.596083323984203e-08
membranous O 1 0.9960097074508667
glomerulonephritis B-Disease 1 1.0
, O 0 7.558725769740704e-07
vasculitis B-Disease 1 1.0
, O 0 7.971491022829014e-09
and O 0 3.5522766950180085e-09
arthritis B-Disease 1 1.0
in O 0 6.714397926543825e-09
an O 0 1.6910009503767753e-10
individual O 0 3.8138853186708843e-10
lacking O 0 4.0649629795552755e-07
C5 O 0 4.252472081134329e-06
( O 0 4.19577012022998e-10
and O 0 1.4367387835001466e-10
its O 0 2.510986973902618e-10
biologic O 0 5.851209738949592e-09
functions O 0 1.7218092229764892e-10
) O 0 8.182791250144206e-12
, O 0 1.0553608334462616e-11
and O 0 3.401143255921113e-11
( O 0 3.028272424487888e-11
b O 0 9.697285641152575e-09
) O 0 2.069135661419974e-11
a O 0 2.722917169517558e-10
remarkable O 0 2.371508989185145e-09
propensity O 0 8.158977493621933e-08
to O 0 6.1977809551194696e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 2.595937353966349e-10
the O 0 3.5643152318520777e-10
proband O 0 2.0724209903733026e-08
, O 0 4.62443902615739e-11
even O 0 1.426270629378834e-10
during O 0 1.2218127620755581e-09
periods O 0 5.3513190323428717e-08
of O 0 1.2001157845276111e-09
low O 0 4.1271945860898995e-09
- O 0 8.033503307025569e-10
dose O 0 4.352689320086256e-09
or O 0 1.472087174381187e-10
alternate O 0 1.4444724527606922e-08
- O 0 1.7370977900554863e-07
day O 0 4.524978081121844e-08
corticosteroid O 0 4.1418421460548416e-05
therapy O 0 2.715998562052846e-05
. O 0 9.619144947237146e-08

Other O 0 1.05595077570797e-07
observations O 0 6.415913134105722e-08
indicate O 0 1.377358138654472e-08
that O 0 1.0849336012919153e-10
the O 0 3.3337281823975218e-09
C5D B-Disease 1 1.0
state O 0 2.4563138190103473e-09
is O 0 7.794863365884197e-11
compatible O 0 2.5419065963205867e-08
with O 0 2.960928030537602e-11
normal O 0 1.0719800158653925e-08
coagulation O 0 7.57114315685925e-10
function O 0 1.074722644212045e-09
and O 0 3.2107558278759996e-10
the O 0 1.8081417474391515e-09
capacity O 0 4.531436115229326e-09
to O 0 1.0845912612467146e-08
mount O 0 3.1144204513111617e-06
a O 0 2.239997343167488e-07
neutrophilic O 0 0.0013023458886891603
leukocytosis O 0 0.000140737000037916
during O 0 5.0227472456754185e-06
pyogenic B-Disease 0 0.00046941032633185387
infection I-Disease 0 2.436338490952039e-07
. O 0 2.064946880153684e-09
. O 0 9.761531138963164e-09

Susceptibility O 0 5.007873187423684e-05
to O 0 4.605859430739656e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 8.936823405747418e-07
twins O 0 1.2972138563327462e-07
: O 0 1.154025000560388e-10
the O 0 9.529196182134214e-11
role O 0 1.193336540694645e-09
of O 0 3.2167402075344853e-09
genes O 0 1.7149665021420901e-09
, O 0 1.3314968017041906e-09
HLA O 0 8.406757842749357e-06
, O 0 7.610790220269337e-09
and O 0 7.588322858964602e-09
the O 0 5.504815590029466e-07
environment O 0 9.61477667260624e-07
. O 0 1.704931094081985e-07

OBJECTIVE O 0 8.715438525541686e-06
To O 0 1.525736870178207e-08
determine O 0 3.178560747940651e-09
the O 0 1.542546645971754e-09
relative O 0 2.159400622758767e-07
effects O 0 1.3235136293587857e-06
of O 0 3.942828641356755e-08
genetic O 0 1.0228630387132398e-08
and O 0 2.9198046758160956e-10
environmental O 0 3.15956732999112e-10
factors O 0 1.3687197208955837e-10
in O 0 8.97126817278604e-11
susceptibility O 0 4.262051334080752e-08
to O 0 1.341804477306141e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 4.2123566856844263e-08
AS B-Disease 1 1.0
) O 0 6.686176612369366e-10
. O 0 6.271699160009803e-09

METHODS O 0 6.947213933017338e-06
Twins O 0 2.441684273435385e-06
with O 0 4.3143519312671685e-10
AS B-Disease 1 1.0
were O 0 3.1956040591474277e-10
identified O 0 1.948361888493011e-10
from O 0 7.576802379949399e-11
the O 0 1.913796454644512e-09
Royal O 0 3.0534133657056373e-06
National O 0 1.0585939662632882e-06
Hospital O 0 3.1893287086859345e-06
for O 0 1.4166499973100599e-08
Rheumatic B-Disease 0 4.192604683339596e-05
Diseases I-Disease 0 2.961165773740504e-05
database O 0 7.425461490129237e-08
. O 0 1.432861722605594e-07

Clinical O 0 1.1166594049427658e-05
and O 0 1.9205259604859748e-08
radiographic O 0 1.4984418612584705e-06
examinations O 0 4.864872948928678e-07
were O 0 5.305167416480572e-09
performed O 0 4.770011052812606e-09
to O 0 8.362086134638957e-09
establish O 0 4.6913786633240306e-08
diagnoses O 0 1.8125713268091204e-06
, O 0 5.05724406796304e-10
and O 0 6.791585072107864e-10
disease O 0 6.705262478590157e-08
severity O 0 2.636898841501534e-07
was O 0 7.271802271446859e-09
assessed O 0 1.6931908319861577e-08
using O 0 7.00200653014349e-09
a O 0 4.39283986963801e-09
combination O 0 1.1745090233716837e-08
of O 0 4.239946616024781e-09
validated O 0 6.920274842059371e-08
scoring O 0 4.058648173099755e-08
systems O 0 1.1329259308467954e-07
. O 0 2.677622035207605e-07

HLA O 0 6.443716847570613e-05
typing O 0 3.6728613395098364e-06
for O 0 8.778431315192847e-09
HLA O 0 3.8476608210658014e-07
- O 0 2.557810887537926e-07
B27 O 0 1.0204524869550369e-06
, O 0 1.3754088146189503e-10
HLA O 0 1.0742108536021533e-08
- O 0 1.609441113714638e-08
B60 O 0 3.1500277941631794e-07
, O 0 7.195855022956721e-11
and O 0 1.1007374178806373e-10
HLA O 0 5.624981440632837e-06
- O 0 0.08761902153491974
DR1 O 1 0.9999970197677612
was O 0 6.395107448042836e-07
performed O 0 1.4009977178375266e-08
by O 0 4.796511521298896e-10
polymerase O 0 3.3794211873328095e-08
chain O 0 1.2984671116100799e-08
reaction O 0 8.459892786305545e-10
with O 0 5.911766735866575e-12
sequence O 0 6.629916060596486e-11
- O 0 1.51778312140749e-09
specific O 0 1.082656186923714e-09
primers O 0 4.674853570918458e-08
, O 0 4.6287915167475546e-10
and O 0 8.478696078562109e-10
zygosity O 0 5.662910211867711e-07
was O 0 9.585039428827713e-09
assessed O 0 1.1628421781040288e-08
using O 0 1.016379158613745e-08
microsatellite O 0 5.920184662500105e-07
markers O 0 1.6565087435083115e-07
. O 0 4.073687023264938e-07

Genetic O 0 4.854731741943397e-06
and O 0 1.0715220710721951e-08
environmental O 0 4.521317986672102e-09
variance O 0 7.920790690008062e-10
components O 0 4.5715435881277244e-09
were O 0 5.696150773282227e-10
assessed O 0 9.62633617263009e-09
with O 0 3.500310458148803e-11
the O 0 1.9058774558544656e-09
program O 0 1.973334828875295e-09
Mx O 0 3.24493427683592e-08
, O 0 2.6435135330737936e-11
using O 0 5.1913893323041194e-11
data O 0 9.057130739842378e-11
from O 0 2.839008108462826e-12
this O 0 4.806269097989979e-12
and O 0 1.6350580611668164e-11
previous O 0 3.6966504857183224e-10
studies O 0 1.5842456513315284e-10
of O 0 1.842397068241297e-10
twins O 0 7.224067122280076e-09
with O 0 1.3978120050328613e-10
AS B-Disease 1 1.0
. O 0 4.687841226314049e-07

RESULTS O 0 1.310359152739693e-06
Six O 0 9.083265695153386e-08
of O 0 4.889008309305609e-09
8 O 0 8.091375889307528e-07
monozygotic O 0 1.7576358004589565e-05
( O 0 5.1204356310563526e-08
MZ O 0 0.0003896484267897904
) O 0 1.3216900462964531e-08
twin O 0 3.4748057942124433e-07
pairs O 0 2.448223312967457e-08
were O 0 7.661328460528694e-09
disease O 0 1.5296471644887788e-08
concordant O 0 2.5084032628797104e-09
, O 0 1.8305881116509326e-11
compared O 0 6.56355803041464e-11
with O 0 4.3366061609761974e-12
4 O 0 4.5535145432040736e-08
of O 0 9.355612284878134e-09
15 O 0 7.979709693017867e-08
B27 O 0 1.0307398952136282e-06
- O 0 6.630455686718051e-07
positive O 0 1.85695512300299e-08
dizygotic O 0 6.41731185169192e-06
( O 0 6.446590372632954e-09
DZ O 0 0.00022751750657334924
) O 0 2.1862496257796238e-09
twin O 0 1.2723259601443715e-07
pairs O 0 1.935174465117484e-09
( O 0 3.490895766899982e-11
27 O 0 8.94508378479486e-09
% O 0 6.380428824170892e-11
) O 0 2.717218160544488e-12
and O 0 1.0446404158370726e-11
4 O 0 1.1226456209101343e-08
of O 0 9.849487447866068e-09
32 O 0 3.465149802650558e-07
DZ O 0 0.00016493799921590835
twin O 0 5.231310638009745e-07
pairs O 0 3.40897932105122e-09
overall O 0 3.669670789463453e-08
( O 0 1.6297875549131646e-10
12 O 0 5.617370124610943e-09
. O 0 1.8304388560430596e-10
5 O 0 3.6044545126401317e-09
% O 0 2.385712738472989e-10
) O 0 4.467958780729475e-10
. O 0 1.1861074789010218e-08

Nonsignificant O 0 1.379212972096866e-05
increases O 0 5.949171377750417e-09
in O 0 2.576423518974025e-10
similarity O 0 3.304384266211713e-10
with O 0 2.6249271853351352e-12
regard O 0 2.12052242432037e-09
to O 0 8.58554782823262e-10
age O 0 1.9793131578182965e-09
at O 0 4.6298973543912325e-09
disease O 0 1.2525491754900031e-09
onset O 0 1.442858899025623e-08
and O 0 6.254013973361339e-11
all O 0 5.204776609701867e-10
of O 0 1.5197210156969732e-09
the O 0 1.2739493904234678e-09
disease O 0 9.893749153278009e-10
severity O 0 7.353476161320316e-10
scores O 0 5.8180075340752424e-11
assessed O 0 5.140294301320125e-10
were O 0 9.657834532106335e-10
noted O 0 5.581591633330163e-09
in O 0 5.052367857416584e-09
disease O 0 5.521946633280095e-08
- O 0 1.517825012342655e-07
concordant O 0 6.630911002503126e-07
MZ O 0 6.28384223091416e-05
twins O 0 2.1067646116534888e-07
compared O 0 2.491116291025719e-08
with O 0 7.946803770586541e-10
concordant O 0 1.3750643120147288e-05
DZ O 1 0.9929034113883972
twins O 0 0.00010707179899327457
. O 0 2.19447429117281e-06

HLA O 0 1.738789796945639e-05
- O 0 5.929116923653055e-06
B27 O 0 3.381347823960823e-06
and O 0 4.841919087894553e-10
B60 O 0 5.833250327214046e-08
were O 0 8.08249647765713e-11
associated O 0 3.468035025822047e-10
with O 0 5.740458889486044e-12
the O 0 7.767114729162472e-10
disease O 0 1.1574247116286074e-09
in O 0 6.553925457897236e-11
probands O 0 2.6001075070780644e-08
, O 0 4.410095205686915e-11
and O 0 1.0317460080733198e-10
the O 0 4.536486741812951e-09
rate O 0 3.828141643680283e-07
of O 0 1.5192921365425605e-09
disease O 0 1.070528665714221e-09
concordance O 0 2.766658679931311e-09
was O 0 1.1297593971448805e-09
significantly O 0 4.75702721658422e-09
increased O 0 1.4367020462202618e-08
among O 0 1.4450007856936509e-09
DZ O 0 3.2456144253956154e-05
twin O 0 5.752406551096101e-08
pairs O 0 4.524075836176422e-10
in O 0 6.128633156521346e-10
which O 0 8.86700365909654e-11
the O 0 4.3571227181793404e-10
co O 0 5.946358072606017e-09
- O 0 7.751493313890023e-08
twin O 0 1.2678130190124648e-07
was O 0 9.372400633367306e-09
positive O 0 6.367059657286234e-10
for O 0 7.291739434478473e-11
both O 0 3.534305070829191e-10
B27 O 0 2.793152816593647e-06
and O 0 4.5380986080090224e-08
DR1 O 0 0.0039028560277074575
. O 0 3.6404505863174563e-06

Additive O 0 1.836990236370184e-06
genetic O 0 1.4321002161921115e-08
effects O 0 9.202488548964993e-09
were O 0 5.767121225019878e-10
estimated O 0 7.737803453533587e-11
to O 0 1.2235799873305808e-10
contribute O 0 1.3307757118496966e-09
97 O 0 1.7751436587332137e-07
% O 0 5.490696231014169e-10
of O 0 2.2520880993415204e-10
the O 0 9.145907642338358e-11
population O 0 3.4579188470940103e-12
variance O 0 4.728349378702035e-10
. O 0 2.3450665409541216e-08

CONCLUSION O 0 1.2036153975714114e-06
Susceptibility O 0 6.831664336459653e-07
to O 0 4.2674283662336165e-08
AS B-Disease 1 1.0
is O 0 3.0387001248577405e-10
largely O 0 1.0177206299921693e-10
genetically O 0 8.525167377593235e-11
determined O 0 5.65799240792586e-10
, O 0 1.7544030117555565e-10
and O 0 8.829086906025907e-10
the O 0 1.003163330182133e-08
environmental O 0 3.908533052765506e-09
trigger O 0 1.9759420766263247e-08
for O 0 8.592755951219999e-10
the O 0 2.8386117900680574e-09
disease O 0 6.053470169575803e-09
is O 0 2.6259451210708384e-11
probably O 0 3.2263443028313077e-09
ubiquitous O 0 2.4040144808168407e-07
. O 0 1.0285624085781819e-07

HLA O 0 7.287088919838425e-06
- O 0 3.404082917768392e-07
B27 O 0 4.2790594534380944e-07
accounts O 0 4.980433843115861e-10
for O 0 2.485237189653322e-11
a O 0 5.4982390168545336e-11
minority O 0 1.22715518302563e-11
of O 0 6.886061165722879e-10
the O 0 3.1603706318605873e-09
overall O 0 1.0048277232499458e-07
genetic O 0 1.3085063699236343e-08
susceptibility O 0 3.3498942286769307e-08
to O 0 2.3290954231924843e-07
AS B-Disease 1 1.0
. O 0 1.117385909310542e-05

Cell O 0 6.998697017479572e-07
cycle O 0 6.422830978181082e-08
- O 0 9.607135353917329e-08
dependent O 0 9.663573763418754e-08
colocalization O 0 3.52362417288532e-06
of O 0 5.12075786218702e-08
BARD1 O 0 1.2277268069738057e-05
and O 0 1.2345428679338966e-08
BRCA1 O 0 6.507606897798723e-09
proteins O 0 1.4169214412884656e-10
in O 0 1.5553003329671355e-09
discrete O 0 1.636005819705133e-08
nuclear O 0 5.636465516545286e-07
domains O 0 2.0583356672432274e-06
. O 0 1.5531007875324576e-06

Germ O 0 5.754635640187189e-05
- O 0 1.8597838788991794e-06
line O 0 5.786188594925079e-08
mutations O 0 4.7695833949035205e-09
of O 0 5.604859243391047e-09
the O 0 1.9512832238888222e-08
BRCA1 O 0 6.123590878814866e-08
gene O 0 7.03603797447272e-09
predispose O 0 1.856700748703588e-07
women O 0 7.889624509260784e-10
to O 0 2.932686316015065e-10
early O 0 7.810201623215107e-07
- O 0 0.00015048701607156545
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.204959971801145e-07
compromising O 0 1.5377758018075838e-06
the O 0 4.481790227828242e-08
genes O 0 5.759626997559053e-09
presumptive O 0 1.5040527046039642e-07
function O 0 6.350422854239923e-09
as O 0 7.331017126688266e-09
a O 0 1.1239761121828451e-08
tumor B-Disease 0 3.398406249743857e-07
suppressor O 0 6.984947503951844e-06
. O 0 1.0708804438763764e-06

Although O 0 2.5636475697865535e-07
the O 0 2.2910663588504576e-08
biochemical O 0 1.4615949339713552e-07
properties O 0 1.4880235994496616e-06
of O 0 2.331631208107865e-07
BRCA1 O 0 2.1298300012517757e-08
polypeptides O 0 2.4897375272558975e-09
are O 0 7.284841133103903e-12
not O 0 3.9413111663222367e-11
understood O 0 5.530320645874554e-10
, O 0 3.158065822739253e-11
their O 0 2.868960902180362e-10
expression O 0 4.971723477353862e-09
pattern O 0 5.988856077721039e-10
and O 0 7.817077540828166e-11
subcellular O 0 2.8822819331253413e-07
localization O 0 1.1867341527249664e-06
suggest O 0 2.041832658505882e-08
a O 0 8.266284323710238e-10
role O 0 2.755646377750054e-09
in O 0 5.294532812172292e-09
cell O 0 2.2417069089897268e-07
- O 0 2.6608594794197415e-07
cycle O 0 8.71926246759358e-08
regulation O 0 1.0297239896317478e-06
. O 0 1.921966656937002e-07

When O 0 7.101619985405705e-07
resting O 0 9.700254395283991e-07
cells O 0 1.4750425769705089e-08
are O 0 2.3579891511582574e-11
induced O 0 9.392081556924836e-10
to O 0 6.843046962412558e-11
proliferate O 0 4.2990239146334375e-10
, O 0 4.186399490957449e-11
the O 0 2.6428595423233503e-10
steady O 0 1.5420383192576992e-08
- O 0 1.7779374639204093e-09
state O 0 4.478587639633602e-11
levels O 0 3.6357470367676115e-09
of O 0 2.4318852487326126e-10
BRCA1 O 0 1.6690193671564657e-10
increase O 0 4.567582076453469e-11
in O 0 2.978312596546573e-10
late O 0 2.1426448881811666e-07
G1 O 0 2.8588912570626235e-08
and O 0 9.640989395709454e-11
reach O 0 1.2491183642993064e-09
a O 0 4.405437820098612e-11
maximum O 0 8.533793671716694e-10
during O 0 3.1758213836496907e-09
S O 0 1.9245894122832397e-07
phase O 0 5.0775071258613025e-08
. O 0 5.78329718337045e-07

Moreover O 0 3.3481885708397385e-08
, O 0 3.9739908586078343e-10
in O 0 5.589845808451344e-10
S O 0 9.72182689906731e-08
phase O 0 2.3118291281321035e-08
cells O 0 2.152614797523711e-08
, O 0 2.3784851865826795e-09
BRCA1 O 0 2.950270694412893e-09
polypeptides O 0 2.1743520317585308e-09
are O 0 2.536876542169608e-10
hyperphosphorylated O 0 1.034766725638292e-07
and O 0 1.0251437476682668e-09
accumulate O 0 6.534260688084714e-09
into O 0 2.826250788956486e-09
discrete O 0 2.6007475284473003e-08
subnuclear O 0 1.7826907878770726e-06
foci O 0 8.477489359393076e-07
termed O 0 2.2352557493832137e-07
" O 0 1.7091736026486615e-07
BRCA1 O 0 9.675819967469579e-08
nuclear O 0 5.562007459047891e-07
dots O 0 5.836955665472487e-07
. O 0 1.0634621503413655e-06

" O 0 7.727320735284593e-06
BRCA1 O 0 5.187663646211149e-06
associates O 0 2.3042142061058257e-07
in O 0 1.9366744652415946e-08
vivo O 0 2.3117206637834897e-06
with O 0 4.923170759951745e-10
a O 0 3.747803845044473e-09
structurally O 0 3.3858214010251686e-08
related O 0 6.015272191461918e-08
protein O 0 2.040031148453636e-07
termed O 0 1.2378553719827323e-06
BARD1 O 0 0.0002564410388004035
. O 0 8.051916893236921e-07

Here O 0 4.054555091670409e-08
we O 0 2.7086222154082407e-09
show O 0 6.932647234059175e-10
that O 0 7.896104776972113e-12
the O 0 1.2025715145913551e-10
steady O 0 1.8409725299761703e-08
- O 0 3.022983641187693e-09
state O 0 4.84739644257548e-11
levels O 0 1.2293591922230007e-08
of O 0 9.220422758637881e-10
BARD1 O 0 2.4464011971758737e-07
, O 0 3.8193431056710025e-11
unlike O 0 2.1153505336268807e-10
those O 0 7.265250900889697e-11
of O 0 2.2304828817265587e-10
BRCA1 O 0 1.5988721457915744e-09
, O 0 1.3641378304729557e-10
remain O 0 6.652850714772285e-09
relatively O 0 1.9544335039256566e-09
constant O 0 3.0841060816300114e-09
during O 0 2.6776276751405703e-09
cell O 0 9.560920055662336e-09
cycle O 0 1.4640884948846633e-08
progression O 0 7.62337535320512e-08
. O 0 1.3378431162891502e-07

However O 0 2.1673479011496966e-07
, O 0 5.2669548722406034e-09
immunostaining O 0 1.3517068282453693e-06
revealed O 0 3.69743666794875e-08
that O 0 2.563111389797257e-10
BARD1 O 0 1.6922567738220096e-06
resides O 0 2.6042718204166704e-08
within O 0 2.3438668783626326e-09
BRCA1 O 0 3.42286998744612e-09
nuclear O 0 4.993984603629542e-08
dots O 0 8.126514572381893e-09
during O 0 1.6436521832474682e-07
S O 0 2.895727106988488e-07
phase O 0 2.7852550488205452e-08
of O 0 6.730014323608202e-09
the O 0 1.6005442526889624e-09
cell O 0 1.15826837010502e-09
cycle O 0 1.1873421690289376e-10
, O 0 4.941802609487178e-12
but O 0 4.873889920126162e-12
not O 0 7.555559650151977e-11
during O 0 3.778322099634579e-09
the O 0 4.545615883699838e-09
G1 O 0 1.5729990821000683e-07
phase O 0 7.080629416122974e-08
. O 0 2.2822567302682728e-07

Nevertheless O 0 4.405412710184464e-06
, O 0 1.4864101949285669e-08
BARD1 O 0 7.595405122629018e-07
polypeptides O 0 4.558430521939272e-09
are O 0 1.8572358928548027e-11
found O 0 1.0126507271612795e-11
exclusively O 0 6.082050835187758e-11
in O 0 1.199886301428421e-10
the O 0 2.727834902405135e-10
nuclear O 0 1.0023982532914033e-08
fractions O 0 8.769410975162373e-09
of O 0 3.8452374617747864e-09
both O 0 3.3772401542009334e-10
G1 O 0 2.855534120271841e-08
- O 0 4.531006325692033e-08
and O 0 2.2662225429570526e-09
S O 0 2.6516309503676894e-07
- O 0 1.006077710030695e-08
phase O 0 2.3415266170445648e-08
cells O 0 9.962002422980731e-08
. O 0 1.4706550643950322e-07

Therefore O 0 1.6479292241911025e-07
, O 0 7.331264484378153e-10
progression O 0 1.4686194482749215e-08
to O 0 4.449252077876054e-09
S O 0 5.5043752666961154e-08
phase O 0 1.0631469038457908e-08
is O 0 2.1526536109206518e-10
accompanied O 0 3.759602851260979e-09
by O 0 1.1301338337377231e-10
the O 0 2.6020259280556957e-09
aggregation O 0 7.332635054702052e-10
of O 0 1.432268859069552e-09
nuclear O 0 5.6166875594954035e-08
BARD1 O 0 1.0920433851424605e-05
polypeptides O 0 4.392800008190534e-07
into O 0 9.734407058203942e-08
BRCA1 O 0 2.5066310627153143e-07
nuclear O 0 9.048782771969854e-07
dots O 0 7.409241220557305e-07
. O 0 1.743455413816264e-06

This O 0 2.0121181165677626e-08
cell O 0 1.0564398245094253e-08
cycle O 0 1.6829706517285103e-09
- O 0 8.70991634371876e-09
dependent O 0 1.3543214549827098e-08
colocalization O 0 8.839911060931627e-07
of O 0 9.267520972855436e-09
BARD1 O 0 4.617307695298223e-06
and O 0 5.381890932909528e-09
BRCA1 O 0 1.9006002105470543e-08
indicates O 0 1.9208401536019437e-09
a O 0 1.3441012192139112e-10
role O 0 2.681817545813203e-10
for O 0 5.544684711367154e-10
BARD1 O 0 1.974188126041554e-05
in O 0 1.4931366365544818e-07
BRCA1 O 0 2.2851563699077815e-06
- O 0 3.94867993236403e-06
mediated O 0 3.230550873922766e-06
tumor B-Disease 0 6.080921957618557e-05
suppression O 0 0.00021713037858717144
. O 0 7.158410539886972e-07

Ethnic O 0 9.33625265986393e-09
differences O 0 5.440306871662415e-09
in O 0 6.0384790501188945e-09
the O 0 1.552032458107533e-08
HFE O 0 3.538269811542705e-05
codon O 0 1.4758692259420059e-06
282 O 0 4.830301350011723e-07
( O 0 2.7091919818644783e-08
Cys O 0 0.11154812574386597
/ O 0 0.0003420468419790268
Tyr O 0 0.00010580502566881478
) O 0 3.721667862777167e-09
polymorphism O 0 5.959503255326126e-07
. O 0 1.7601504964659398e-07

Recent O 0 4.0741603868355014e-08
studies O 0 9.327153493998708e-10
have O 0 6.643866012900901e-11
shown O 0 7.059396955888531e-10
that O 0 5.395046631662126e-09
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 5.8474530106877864e-08
HH B-Disease 0 8.022956171771511e-05
) O 0 9.9610007742168e-11
is O 0 4.455138948727955e-12
likely O 0 3.928679950804259e-11
to O 0 1.3584931790600052e-10
be O 0 4.874378678465519e-10
caused O 0 3.1730712501953917e-10
by O 0 1.555660635033096e-11
homozygosity O 0 2.892977057911139e-08
for O 0 7.619747610654315e-10
a O 0 2.974175794534517e-09
Cys282Tyr O 0 2.844586504124891e-07
mutation O 0 2.883086269722668e-10
in O 0 5.698106431140104e-10
the O 0 9.103346521044386e-09
HFE O 0 4.10534221373382e-06
gene O 0 1.3689456679344403e-08
located O 0 4.9588058104177435e-09
4 O 0 8.214337299250474e-07
. O 0 5.431091949503752e-07

5 O 0 2.211524588346947e-05
Mb O 0 0.00052629568381235
telomeric O 0 2.711097477003932e-05
to O 0 6.409492812053941e-07
HLA O 0 1.5002583495515864e-05
- O 0 1.817489646782633e-05
A O 0 9.252612471755128e-06
. O 0 4.359621357252763e-07

Population O 0 5.931100055533989e-09
studies O 0 1.0068437639176864e-08
of O 0 1.3878159732527706e-09
this O 0 9.739984513368327e-11
polymorphism O 0 2.291441036916808e-09
are O 0 5.9034960080139864e-12
facilitated O 0 6.181143374917042e-10
by O 0 3.0081465096643e-11
the O 0 5.891848120498366e-10
fact O 0 2.1364965352432819e-10
that O 0 2.2939750793371516e-11
the O 0 6.985541589621391e-10
Cys282Tyr O 0 2.141949380529695e-06
mutation O 0 5.62792301650461e-09
creates O 0 1.379518610455932e-09
a O 0 6.989290035619433e-09
Rsal O 0 3.355475655553164e-06
restriction O 0 3.933530194899504e-07
site O 0 1.7722578604661976e-07
. O 0 9.36947301966029e-08

We O 0 8.98844234598073e-08
have O 0 9.665150901838615e-10
studied O 0 2.9006612667359377e-09
the O 0 3.411952054221956e-09
codon O 0 7.655226141878302e-08
282 O 0 1.2861323739343788e-07
( O 0 1.7773347238403403e-08
Cys O 0 0.0035586769226938486
/ O 0 8.847039134707302e-05
Tyr O 0 1.3681355085282121e-05
) O 0 1.9298435072201414e-10
polymorphism O 0 2.247686481382516e-09
in O 0 7.600758217263248e-11
different O 0 5.592367714746249e-12
ethnic O 0 1.1492621958264504e-11
groups O 0 3.166588172232032e-11
. O 0 4.787027219066431e-09

In O 0 1.8136136148427795e-08
agreement O 0 2.797559162104335e-08
with O 0 2.1456850185508358e-10
previous O 0 1.2664547455187858e-07
observations O 0 6.790347839569222e-08
the O 0 8.36385627422942e-09
Tyr O 0 6.189293344505131e-06
allele O 0 2.0117919774520487e-08
appeared O 0 1.2334460564034089e-08
to O 0 1.481153977245242e-09
be O 0 3.3970737334243495e-10
rare O 0 2.2255333131937505e-09
or O 0 8.4222989693572e-10
absent O 0 1.6678976422213054e-08
in O 0 1.3338021798148247e-09
Asiatic O 0 1.7053588408089126e-07
( O 0 1.3734322013014832e-10
Indian O 0 6.129404206411948e-10
, O 0 2.9163078202332215e-11
Chinese O 0 6.252776629800394e-10
) O 0 5.0458817679732704e-11
populations O 0 4.685508092627799e-10
. O 0 7.684950453779038e-09

The O 0 6.750586578618822e-08
highest O 0 4.352392579676234e-08
allele O 0 8.530543382789801e-09
frequency O 0 3.6404446124294054e-09
( O 0 1.1650604959945188e-11
7 O 0 1.2511570668394256e-09
. O 0 5.651582674071065e-11
5 O 0 1.2807540583636978e-09
% O 0 4.1120881005829446e-11
) O 0 1.001945575118679e-11
was O 0 6.297215526807065e-10
found O 0 1.699018703504862e-10
in O 0 7.055735440353317e-10
Swedes O 0 5.197877044338384e-07
. O 0 1.0842028785873481e-07

Saamis O 0 3.876732080243528e-05
( O 0 6.353787496138352e-10
2 O 0 9.32728205782496e-09
% O 0 2.937713683426324e-10
) O 0 3.924545757816311e-11
and O 0 9.483303725632553e-11
Mordvinians O 0 1.1801841282021996e-07
( O 0 9.205986667426558e-12
1 O 0 1.2571301777342114e-09
. O 0 9.055420302495065e-11
8 O 0 3.299788220445521e-09
% O 0 1.2280924888141698e-10
) O 0 2.9843218174452346e-11
had O 0 1.6359510968122493e-10
significantly O 0 6.893302040289484e-10
lower O 0 1.777747504760896e-09
frequencies O 0 8.4641422759546e-09
of O 0 4.675948517274264e-09
the O 0 4.6590624691589255e-08
Tyr O 0 3.92337424273137e-05
allele O 0 6.936382987987599e-07
. O 0 5.443245640890382e-07

Comparisons O 0 2.419881184323458e-07
with O 0 8.366436987650161e-10
allele O 0 4.64765754770724e-08
frequencies O 0 1.504387725503875e-08
based O 0 5.598840835396857e-10
on O 0 3.832160366812332e-09
prevalence O 0 3.501023115859425e-08
estimates O 0 3.857032193632648e-10
of O 0 9.094057729086558e-10
HH B-Disease 1 0.8707045316696167
showed O 0 2.19337402995734e-06
some O 0 1.1437925273583005e-08
disagreements O 0 2.7307738292847716e-08
with O 0 1.8424883840850725e-10
the O 0 1.0221199886473187e-08
RFLP O 0 5.872612405255495e-07
data O 0 3.0685627372406543e-09
, O 0 4.0837392495385316e-11
particularly O 0 2.5160737382456944e-10
in O 0 3.0506879244995844e-09
Finns O 0 1.8998753148480318e-06
. O 0 1.660473856190947e-07

The O 0 2.594896386654e-06
newly O 0 4.4651710595644545e-06
described O 0 1.90520651699444e-07
HFE O 0 0.00029814656591042876
marker O 0 5.159252509656653e-07
provides O 0 7.2915242732563e-09
a O 0 1.4425106942272947e-10
new O 0 1.5552996390777452e-10
approach O 0 7.19699744244906e-10
to O 0 5.742720188273154e-10
the O 0 1.6927499679741942e-10
screening O 0 5.925096413506026e-09
of O 0 6.828841936368235e-09
HH B-Disease 0 5.78328144911211e-05
as O 0 9.729651750944868e-09
well O 0 1.2026685203281318e-09
as O 0 8.964100989272694e-11
studies O 0 1.629346241260876e-10
of O 0 5.541678921305859e-11
the O 0 5.758435395186723e-11
relationship O 0 1.934619825449957e-10
between O 0 4.3057529763856905e-10
the O 0 1.588877296399005e-08
HFE O 0 0.0017025902634486556
Tyr O 0 6.347066664602607e-05
allele O 0 6.268161456546295e-08
and O 0 6.546619357727934e-10
different O 0 4.993753410786894e-09
disorders O 0 0.00034072838025167584
including O 0 9.917204124576529e-08
cancer B-Disease 0 0.0004696551477536559

Autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 0.9999452829360962
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999144077301025
associated O 0 4.461287161916516e-08
with O 0 1.0792824967076342e-10
a O 0 5.7798104080575285e-09
missense O 0 9.824611879594158e-08
mutation O 0 1.1128763466317082e-09
encoding O 0 1.201481492074663e-08
Gly23 O 0 3.932212621293729e-06
- O 0 1.3980426956550218e-05
- O 0 1.1529244147823192e-05
> O 0 9.186792340187822e-06
Val O 0 9.721545666252496e-07
in O 0 1.9738966017257553e-08
neurophysin O 0 7.1265649239649065e-06
II O 0 0.03988803178071976
. O 0 2.915005325121456e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 4.4563694956423205e-09
ADNDI B-Disease 0 5.673365012626164e-05
) O 0 1.0324473498357634e-09
is O 0 4.3183692732817747e-10
an O 0 1.0793407279052758e-09
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 4.135376730118878e-05
by O 0 1.7337949131945862e-10
progressive O 0 5.409092409536242e-07
degeneration O 0 6.0196947742952034e-05
of O 0 1.25897363645322e-08
the O 0 3.715214136335021e-09
magnocellular O 0 1.5553433740933542e-07
neurons O 0 1.3379637842092507e-08
of O 0 1.4837843842485654e-08
the O 0 3.592719366452002e-08
hypothalamus O 0 2.991843928157323e-07
leading O 0 8.752883751128593e-09
to O 0 1.3566657797170478e-09
decreased O 0 5.512504230864579e-09
ability O 0 8.158487219134258e-10
to O 0 4.539342679521496e-09
produce O 0 1.2372348479061657e-08
the O 0 4.4220968220543e-08
hormone O 0 7.06293178609485e-07
arginine O 0 5.579954631684814e-07
vasopressin O 0 4.268399607099127e-06
( O 0 7.775923904773663e-09
AVP O 0 2.3946562578203157e-05
) O 0 5.239701117432105e-09
. O 0 1.1175442438116079e-07

Affected O 0 2.4014528321458783e-07
individuals O 0 1.5409078180095293e-10
are O 0 2.463593218315907e-11
not O 0 2.2537466337624323e-10
symptomatic O 0 4.17653778228555e-09
at O 0 7.30290550254864e-10
birth O 0 6.438689137411302e-09
, O 0 5.2168599301571916e-11
but O 0 2.244556797370567e-11
usually O 0 2.715500879713062e-10
develop O 0 1.4270285397799398e-08
diabetes B-Disease 0 3.322908378322609e-05
insipidus I-Disease 0 6.3221609707397874e-06
at O 0 4.1158926933348994e-08
1 O 0 1.051462504619849e-06
- O 0 4.112300666747615e-05
6 O 0 4.444691148819402e-05
yr O 0 0.00020991670317016542
of O 0 3.0397409034321754e-08
age O 0 6.324714973970913e-08
. O 0 1.0767303137981798e-07

The O 0 1.8973101134633907e-07
genetic O 0 2.5564640182551557e-08
locus O 0 3.3809168797915845e-08
of O 0 1.6790716594883293e-09
the O 0 7.309287619605698e-10
disease O 0 1.8168603288515328e-09
is O 0 1.215025649536905e-11
the O 0 5.841918060411899e-10
AVP O 0 8.938061364460737e-05
- O 0 1.2712452189589385e-05
neurophysin O 0 0.0007816211436875165
II O 1 1.0
( O 0 1.3560661926703688e-08
NPII O 0 1.0023285540228244e-05
) O 0 3.9119321670888496e-10
gene O 0 2.117555686353967e-09
, O 0 7.765040832552472e-10
and O 0 7.913331101505605e-10
mutations O 0 5.482755582875143e-09
that O 0 3.270425041890235e-10
cause O 0 3.968932738018793e-09
ADNDI B-Disease 0 4.5135740833757154e-07
have O 0 1.562030227386657e-10
been O 0 3.4234018397860666e-11
found O 0 8.886757649206878e-12
in O 0 1.716797537465453e-11
both O 0 4.823435748035898e-11
the O 0 5.676400460785658e-10
signal O 0 3.033362450111099e-09
peptide O 0 1.0555087914809747e-09
of O 0 4.146146537209461e-09
the O 0 1.8977093674266143e-08
prepro O 0 2.663889608811587e-05
- O 0 1.1822736269095913e-05
AVP O 0 0.00036123720929026604
- O 0 1.3010375141675468e-06
NPII O 0 6.207653768797172e-06
precursor O 0 2.5230210098925454e-07
and O 0 7.065997786881439e-10
within O 0 2.697748469060457e-09
NPII O 0 4.136380539421225e-06
itself O 0 6.7665690828278e-09
. O 0 2.004158972113146e-08

An O 0 2.469749516009756e-09
affected O 0 1.301287855248745e-09
girl O 0 4.5775028212347024e-09
who O 0 1.3879211668843539e-10
presented O 0 3.671767334623155e-10
at O 0 2.3223021283769185e-09
9 O 0 1.1397506050059292e-08
months O 0 5.519866785874683e-10
of O 0 4.620911986386034e-11
age O 0 8.605512136217186e-11
and O 0 7.802151980040861e-11
her O 0 5.182053119945351e-10
similarly O 0 5.880374520650378e-10
affected O 0 1.7548046349347146e-10
younger O 0 8.524114747388012e-10
brother O 0 2.2034356561562163e-08
and O 0 2.5178368279199503e-09
father O 0 8.80531558777875e-08
were O 0 5.536444636078386e-09
all O 0 1.669369642520735e-10
found O 0 1.822933123896142e-11
to O 0 1.318941345029856e-10
have O 0 7.249775085815813e-11
a O 0 1.6833742733091128e-10
novel O 0 2.586291625306103e-09
missense O 0 5.1059821259968885e-08
mutation O 0 8.676849239108719e-10
( O 0 1.6073250369563752e-11
G1758 O 0 1.0191046229124368e-08
- O 0 9.496002206788035e-09
- O 0 1.5309547407582613e-08
> O 0 4.7698673455442986e-08
T O 0 1.3383261610044883e-08
) O 0 6.674269210221739e-12
encoding O 0 2.9276170376846267e-10
the O 0 6.76083744544087e-10
amino O 0 5.975414607561902e-10
acid O 0 7.682630642769084e-10
substitution O 0 3.6870966280133644e-09
Gly23 O 0 1.5174936152106966e-06
- O 0 1.0158723853237461e-06
- O 0 1.3033748018642655e-06
> O 0 5.212747964833397e-06
Val O 0 1.5276565363819827e-06
within O 0 6.161338461652122e-08
NPII O 0 9.889578359434381e-05
. O 0 1.940528022714716e-07

The O 0 1.336221544079308e-06
mutation O 0 4.345076831668848e-08
was O 0 3.780053958735152e-08
confirmed O 0 7.763297560359206e-09
by O 0 1.5202276937298365e-10
restriction O 0 6.290534315667173e-08
endonuclease O 0 2.881523357700644e-07
analysis O 0 3.556468186616257e-08
. O 0 8.580694554893853e-08

A O 0 3.3261385397054255e-06
T1 O 0 6.515695986308856e-06
- O 0 4.2308283809688874e-07
weighted O 0 1.236602997778391e-07
magnetic O 0 9.048785898357892e-08
resonance O 0 2.3844191332500486e-07
imaging O 0 0.00021757509966846555
of O 0 2.541539288358763e-06
the O 0 3.5005007248400943e-06
fathers O 0 0.00047539686784148216
pituitary O 0 0.0007898663752712309
gland O 0 9.999931535276119e-06
demonstrates O 0 3.925974567664525e-07
an O 0 1.0656048266000084e-09
attenuated O 0 2.908308545102045e-07
posterior O 0 1.2412890271207289e-07
pituitary O 0 0.05518297106027603
bright O 0 0.002326829358935356
spot O 0 0.00026892017922364175
. O 0 1.0128958365385188e-06

This O 0 8.732943257427905e-08
mutation O 0 1.82781718649494e-08
may O 0 2.22615725853359e-09
be O 0 1.2214259603737787e-09
valuable O 0 8.876407520119756e-08
for O 0 3.9591019351803425e-10
developing O 0 3.0638431791629728e-09
models O 0 1.7914556948994687e-08
of O 0 1.103702729210454e-08
dominantly B-Disease 0 4.089173671673052e-06
inherited I-Disease 1 0.5140874981880188
neurodegeneration I-Disease 1 1.0
, O 0 2.794878772860443e-10
as O 0 2.7983126232866695e-11
the O 0 2.9283360458709495e-11
early O 0 8.632378700745846e-10
age O 0 4.541748088726649e-10
of O 0 3.2972888308613335e-10
onset O 0 8.73174394655507e-06
of O 0 4.749921700408777e-08
symptoms O 0 2.579679630798637e-06
suggests O 0 2.1076763445648794e-08
that O 0 6.453793055527512e-11
this O 0 2.5176241646995834e-10
mutation O 0 3.621736244241447e-10
may O 0 9.841314430047987e-10
be O 0 1.4057294217550975e-09
particularly O 0 1.7184701439632022e-09
deleterious O 0 1.1656817378025153e-07
to O 0 1.5719822954451956e-07
the O 0 1.6047243889261154e-07
magnocellular O 0 5.034698460804066e-06
neuron O 0 6.858213623672782e-07
. O 0 3.7028144106443506e-08
. O 0 2.585233289664757e-07

Frequent O 0 1.3673805199232447e-07
inactivation O 0 2.4919966108427616e-06
of O 0 1.8206134200227098e-06
PTEN O 1 0.9118047952651978
/ O 0 0.001977756153792143
MMAC1 O 0 0.0003595429298002273
in O 0 1.1617342465797265e-07
primary O 0 0.026830170303583145
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.07853331125807e-05

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 4.288504555916006e-07
the O 0 3.3487363992890096e-09
most O 0 6.539839503272304e-11
common O 0 3.2761859197760757e-11
male B-Disease 0 1.1551012750465883e-11
cancer I-Disease 0 1.5054331045649683e-11
in O 0 9.929469572955707e-12
the O 0 4.182139634600901e-10
Western O 0 9.435609626962105e-09
world O 0 1.5682852794185465e-09
, O 0 1.220921627687055e-11
yet O 0 2.8342158481242663e-11
many O 0 4.652677115107862e-12
of O 0 1.7612621430740383e-11
the O 0 8.93147084068957e-11
major O 0 4.5811077153956603e-10
genetic O 0 5.198724783994635e-10
events O 0 5.8037095962415464e-11
involved O 0 3.940860138218483e-11
in O 0 3.1439495451479615e-10
the O 0 1.6118734125214473e-09
progression O 0 3.616342070245082e-08
of O 0 3.384797997441069e-10
this O 0 1.962587176107533e-10
often O 0 1.0076385281720945e-09
fatal O 0 1.3224465966743537e-08
cancer B-Disease 0 3.8539475610832596e-08
remain O 0 4.950548770921159e-08
to O 0 2.447550961903744e-08
be O 0 4.410287246514599e-08
elucidated O 0 9.586316082277335e-06
. O 0 4.324739165895153e-06

Numerous O 0 2.5835402084339876e-07
cytogenetic O 0 1.3329910871107131e-05
and O 0 2.779894536786287e-08
allelotype O 0 9.560801572661148e-07
studies O 0 6.342699698791421e-09
have O 0 2.460913139934462e-10
reported O 0 1.5838166889103888e-10
frequent O 0 1.0780686066080847e-10
loss O 0 1.9437120801768515e-09
of O 0 6.808384522827282e-09
heterozygosity O 0 1.2517884897533804e-05
on O 0 9.5209304618038e-07
chromosomal O 0 5.705985586246243e-07
arm O 0 8.147296739480225e-07
10q O 0 3.1692145512352e-06
in O 0 6.02987171305358e-08
sporadic B-Disease 1 0.9999277591705322
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.156987365102395e-05

Deletion O 0 1.3450250662572216e-05
mapping O 0 2.7694272830558475e-07
studies O 0 1.32961943677401e-08
have O 0 6.620037851234883e-10
unambiguously O 0 6.1186145039471285e-09
identified O 0 1.6772281341559392e-09
a O 0 1.8153085701300142e-09
region O 0 7.062888940367884e-09
of O 0 1.3265898601844128e-08
chromosome O 0 8.111124571996697e-08
10q23 O 0 4.4376437813298253e-07
to O 0 1.5088180704836418e-09
be O 0 4.643541384741212e-10
the O 0 4.5352557820343975e-10
minimal O 0 4.217164217834579e-08
area O 0 5.521964663302015e-09
of O 0 3.4356639755372953e-09
loss O 0 2.5653196900066177e-08
. O 0 1.0258958837994214e-07

A O 0 1.1054577271352173e-06
new O 0 3.753972421804974e-08
tumor B-Disease 0 7.419388481366695e-08
suppressor O 0 3.5086617344859405e-07
gene O 0 2.001942966955994e-08
, O 0 6.446762235157166e-09
PTEN O 0 2.5551791623001918e-05
/ O 0 1.0905781891779043e-05
MMAC1 O 0 1.1440713933552615e-05
, O 0 5.323876894891555e-10
was O 0 5.1720427940438185e-09
isolated O 0 3.68881281076483e-09
recently O 0 3.3136557386903576e-10
at O 0 1.9297330400291912e-10
this O 0 2.0886044629908618e-11
region O 0 6.022303766783921e-10
of O 0 1.0639333858364353e-09
chromosome O 0 8.641294790834309e-09
10q23 O 0 1.0003854100659737e-07
and O 0 2.1605967015503325e-10
found O 0 6.518121459242465e-11
to O 0 1.53137960645644e-10
be O 0 5.062819954937403e-11
inactivated O 0 2.3958144357294486e-09
by O 0 7.324495870930647e-11
mutation O 0 1.7309972344392577e-09
in O 0 4.947544596234366e-09
three O 0 2.137322496764682e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 1.9018408181636914e-07
lines O 0 1.5678821796427655e-08
. O 0 2.0054251592682704e-07

We O 0 1.0751680292742094e-06
screened O 0 3.96578298023087e-06
80 O 0 2.5845829441095702e-05
prostate B-Disease 1 0.9999544620513916
tumors I-Disease 1 1.0
by O 0 5.500405020342214e-09
microsatellite O 0 4.39846736810523e-08
analysis O 0 1.0862530874788945e-09
and O 0 1.0685249213215897e-10
found O 0 3.9277001095960884e-10
chromosome O 0 5.021806526173123e-09
10q23 O 0 1.2289847006741184e-07
to O 0 1.886355294189457e-09
be O 0 9.765325215127518e-10
deleted O 0 2.9103775389671682e-08
in O 0 2.4005486487510552e-09
23 O 0 9.145275470245906e-08
cases O 0 1.6156840310088683e-09
. O 0 2.6043611711656922e-08

We O 0 4.923955287949866e-08
then O 0 4.168656808634097e-10
proceeded O 0 7.286571346298842e-10
with O 0 8.982388400788355e-13
sequence O 0 1.7838382680712694e-12
analysis O 0 1.0276447227897112e-11
of O 0 4.169227116324059e-11
the O 0 1.934435250872113e-10
entire O 0 1.0510935233298824e-08
PTEN O 0 4.52473723271396e-05
/ O 0 5.7894500059774145e-05
MMAC1 O 0 4.544057810562663e-05
coding O 0 2.104568693539477e-06
region O 0 5.307538586407645e-08
and O 0 2.0610277928767573e-09
tested O 0 1.228105439565752e-08
for O 0 1.0511130854595763e-09
homozygous O 0 1.9762735448125568e-08
deletion O 0 8.09731837136951e-09
with O 0 4.3618435252579246e-11
new O 0 6.36766994688287e-09
intragenic O 0 1.9555835706341895e-07
markers O 0 9.472372886065727e-10
in O 0 1.924785192342071e-10
these O 0 5.0820340991020174e-11
23 O 0 1.5055350299775228e-09
cases O 0 1.1090230296606496e-11
with O 0 5.01206715020075e-12
10q23 O 0 1.4466583024841384e-06
loss O 0 1.3286134503687208e-07
of O 0 2.0449748205919605e-07
heterozygosity O 0 0.0004682100552599877
. O 0 8.938484825193882e-06

The O 0 8.3726829913644e-09
identification O 0 1.7459857559742886e-08
of O 0 4.080060733713253e-09
the O 0 2.186358205591432e-09
second O 0 1.6952977688333704e-08
mutational O 0 2.841485127191845e-07
event O 0 1.7240052718747734e-09
in O 0 8.30592261635843e-10
10 O 0 1.1817086864596149e-08
( O 0 3.987657981596726e-10
43 O 0 6.365984717149331e-08
% O 0 7.413274438761164e-09
) O 0 3.316472785286351e-08
tumors B-Disease 1 1.0
establishes O 0 8.923460882215295e-06
PTEN O 0 0.00045776445767842233
/ O 0 4.076759796589613e-05
MMAC1 O 0 1.2177545613667462e-05
as O 0 3.6909522105332826e-09
a O 0 8.48329073654952e-10
main O 0 1.0381105974843763e-09
inactivation O 0 8.38017655269141e-09
target O 0 8.261402228981751e-09
of O 0 2.1768251645681858e-09
10q O 0 1.0055809980258346e-06
loss O 0 2.1268665051366042e-08
in O 0 1.887882561391052e-08
sporadic B-Disease 0 0.2672944962978363
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9580711807520856e-07
. O 0 1.0698743579951042e-07

Risk O 0 1.268530195375206e-05
reversals O 0 4.837760343434638e-07
in O 0 6.086883885814132e-09
predictive O 0 6.550422426698788e-08
testing O 0 1.6231938460009587e-08
for O 0 1.0550222917515839e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.3518615560315084e-06

The O 0 2.2084516615450411e-07
first O 0 5.857005103138135e-09
predictive O 0 4.222361571493138e-09
testing O 0 5.818431847437466e-10
for O 0 1.6736234620395862e-09
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 8.57785092955865e-11
HD B-Disease 0 1.6388922574606113e-07
) O 0 5.1309567705715153e-11
was O 0 9.386851296255827e-10
based O 0 1.1271759220443656e-10
on O 0 4.400588338171474e-09
analysis O 0 2.4771471540674384e-09
of O 0 7.961792891642006e-10
linked O 0 1.6694341464784657e-09
polymorphic O 0 1.1896186258297803e-09
DNA O 0 1.0778965497948434e-09
markers O 0 1.7656084927430982e-10
to O 0 2.1963883489739544e-10
estimate O 0 2.846710644988093e-10
the O 0 8.127327283391494e-11
likelihood O 0 3.28265681304174e-09
of O 0 3.5697871325623964e-09
inheriting O 0 3.144589015846577e-07
the O 0 1.868085632850125e-07
mutation O 0 1.4060250741465552e-08
for O 0 5.935389069122721e-09
HD B-Disease 0 2.5519158953102306e-05
. O 0 7.468591434189875e-07

Limits O 0 3.9025317732921394e-07
to O 0 9.823203583891882e-09
accuracy O 0 1.4436627004954516e-08
included O 0 7.058522100145126e-10
recombination O 0 2.0278741186263716e-10
between O 0 1.3896322981210574e-10
the O 0 9.626771602100348e-10
DNA O 0 4.673921805142811e-10
markers O 0 6.796068707792813e-10
and O 0 1.019364592735883e-09
the O 0 7.788912625983357e-09
mutation O 0 4.064479863785664e-09
, O 0 2.5221422172982955e-10
pedigree O 0 8.09125033640612e-09
structure O 0 3.922783431420385e-09
, O 0 5.720298679179336e-10
and O 0 2.0539706047095763e-10
whether O 0 4.980338919047256e-10
DNA O 0 2.4865860481781965e-09
samples O 0 3.1081706097779715e-09
were O 0 1.6544776659799254e-10
available O 0 6.952659337144951e-09
from O 0 9.517303611872308e-10
family O 0 5.1052002625340265e-09
members O 0 5.02122210477296e-09
. O 0 8.017468644538894e-08

With O 0 1.4784923285660057e-09
direct O 0 1.1573193958724914e-08
tests O 0 1.0758507418273666e-09
for O 0 2.1680852946293072e-10
the O 0 2.960450995459496e-09
HD B-Disease 0 7.962823474372271e-06
mutation O 0 2.3401411919365955e-09
, O 0 1.01611462299811e-10
we O 0 2.9216654096053674e-10
have O 0 3.4942534976600825e-11
assessed O 0 1.6107855049796171e-09
the O 0 5.394179547479894e-10
accuracy O 0 7.286758574309715e-08
of O 0 4.6173749268518804e-09
results O 0 3.0028357578260056e-09
obtained O 0 1.0387428694969003e-08
by O 0 4.6637856770948005e-11
linkage O 0 5.09673303561442e-10
approaches O 0 8.913826343714959e-10
when O 0 1.1438132385688249e-10
requested O 0 5.414055426200548e-09
to O 0 1.9586952060279827e-09
do O 0 1.4424013095037935e-09
so O 0 2.4901064543669804e-10
by O 0 3.725243724606031e-11
the O 0 5.537096336993841e-10
test O 0 4.741796955087807e-10
individuals O 0 3.356777703023006e-11
. O 0 2.4408377541362825e-08

For O 0 3.067690101943299e-07
six O 0 5.0485819969026124e-09
such O 0 6.049862694146313e-11
individuals O 0 9.514716271807888e-12
, O 0 2.0792834468097432e-11
there O 0 1.4726171670975674e-11
was O 0 3.567001416460158e-10
significant O 0 2.674175880734708e-10
disparity O 0 1.6635759436667286e-09
between O 0 2.9801253131900296e-10
the O 0 1.2229722123890951e-08
tests O 0 1.527635440368158e-08
. O 0 4.839246514620754e-08

Three O 0 9.798898759072472e-08
went O 0 3.877157439546863e-08
from O 0 6.278674247184313e-10
a O 0 7.498996423827009e-10
decreased O 0 5.332436714411415e-09
risk O 0 4.748539894627868e-10
to O 0 2.3578103358623537e-10
an O 0 1.9223555039471485e-11
increased O 0 1.0387121718302694e-10
risk O 0 1.8599592699342082e-10
, O 0 3.481160021703844e-12
while O 0 2.5039982240460112e-11
in O 0 7.229117998663881e-11
another O 0 1.1839929037193997e-10
three O 0 3.864475059400796e-11
the O 0 2.7497540355803096e-10
risk O 0 1.3663208342507005e-09
was O 0 5.269869429724849e-09
decreased O 0 8.812455831730404e-08
. O 0 1.0969244357283969e-07

Knowledge O 0 2.0271083940315293e-06
of O 0 1.8858383299402703e-08
the O 0 1.1709385683289497e-09
potential O 0 2.404974275282967e-10
reasons O 0 8.039113263969e-10
for O 0 3.358955127930052e-11
these O 0 7.837377448416394e-12
changes O 0 1.7398672780277735e-10
in O 0 1.3770679041513745e-10
results O 0 4.4860448689121313e-10
and O 0 7.456973233344044e-11
impact O 0 1.0141425477172561e-08
of O 0 7.33658078733157e-10
these O 0 8.043019722459022e-11
risk O 0 2.425705469821793e-10
reversals O 0 6.250820971942517e-10
on O 0 1.032559593383553e-09
both O 0 6.062974428067136e-11
patients O 0 2.551599764810675e-10
and O 0 1.8503620510812446e-11
the O 0 7.070932728225898e-10
counseling O 0 5.7106430695341714e-09
team O 0 3.0039384174562755e-11
can O 0 1.120538817983574e-11
assist O 0 2.6212338966047355e-09
in O 0 1.4079323262805588e-09
the O 0 7.532099388640745e-09
development O 0 2.852812208686828e-08
of O 0 1.1069615224457152e-09
strategies O 0 3.017217364842395e-09
for O 0 1.34619468350472e-10
the O 0 8.764168557551244e-11
prevention O 0 3.3821279110668456e-09
and O 0 4.576238693543289e-12
, O 0 4.424745292386234e-12
where O 0 2.1704095118368905e-11
necessary O 0 5.728272078897589e-09
, O 0 1.613650602028116e-10
management O 0 1.7325892942565702e-09
of O 0 7.931614809386645e-10
a O 0 5.254410240240759e-10
risk O 0 1.294895080050651e-09
reversal O 0 6.466265300986151e-10
in O 0 2.0536496114775815e-10
any O 0 2.479008109901315e-10
predictive O 0 2.015404954036626e-09
testing O 0 3.0893973490542237e-10
program O 0 1.0530354366267147e-09
. O 0 1.5556147481277094e-09
. O 0 5.303146721757912e-08

A O 0 2.652073760600615e-07
novel O 0 1.713084429866285e-08
common O 0 7.6672934667954e-09
missense O 0 1.4708179207900685e-07
mutation O 0 2.60042831712326e-09
G301C O 0 4.2473711658885804e-08
in O 0 1.338233635017616e-09
the O 0 3.7151359766340875e-09
N O 0 2.4036287626927333e-08
- O 0 6.293727494721679e-08
acetylgalactosamine O 0 1.5254275922416127e-06
- O 0 2.6458792490302585e-07
6 O 0 7.301609343812743e-07
- O 0 6.35526021142141e-07
sulfate O 0 2.755856201019924e-07
sulfatase O 0 1.5796782690813416e-06
gene O 0 1.4544027315821495e-08
in O 0 2.901918882969312e-08
mucopolysaccharidosis B-Disease 0 9.803188731893897e-05
IVA I-Disease 0 0.0008999945712275803
. O 0 5.881821380171459e-06

Mucopolysaccharidosis B-Disease 0 0.0029892227612435818
IVA I-Disease 1 0.9934693574905396
( O 0 2.4866717467375565e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.0147833623695988e-08
is O 0 1.6280145009872626e-09
an O 0 1.7065838742169603e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 1.1954813317061053e-07
by O 0 4.804291686699713e-11
a O 0 1.9187507405149518e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 5.22076743436628e-06
N O 0 2.452124135743361e-06
- O 0 1.0468777418282116e-06
acetylgalactosamine O 0 2.6935627829516307e-05
- O 0 7.561692200397374e-06
6 O 0 0.00010415630094939843
- O 0 0.0002797897031996399
sulfate O 0 1.5394149158964865e-05
sulfatase O 0 2.601472442620434e-05
( O 0 7.41451455787967e-10
GALNS O 0 2.929865786427399e-06
) O 0 2.1571391339847423e-09
. O 0 4.301849543253411e-08

In O 0 2.896174748912017e-07
previous O 0 6.519821482697807e-08
studies O 0 5.7254756491431635e-09
, O 0 2.6883625880991247e-10
we O 0 6.480489478377649e-10
have O 0 1.453347581170661e-10
found O 0 1.1525929516364997e-10
two O 0 1.044381942039152e-10
common O 0 9.171276516006799e-10
mutations O 0 2.1540050298973767e-10
in O 0 3.056090935871225e-10
Caucasians O 0 1.1476693373424496e-08
and O 0 3.425402461676441e-10
Japanese O 0 2.2248642039812694e-07
, O 0 4.52826276475804e-10
respectively O 0 1.786876069331811e-08
. O 0 6.318781942127316e-08

To O 0 1.3449134428356047e-07
characterize O 0 1.4906410683579452e-07
the O 0 2.869511206426978e-08
mutational O 0 8.252330189861823e-06
spectrum O 0 2.5340547438190697e-08
in O 0 2.0839258096927438e-10
various O 0 5.3505967018141476e-11
ethnic O 0 5.3108897488107765e-12
groups O 0 1.0669679115921094e-12
, O 0 2.7339055498620812e-12
mutations O 0 1.4028512726471654e-11
in O 0 2.951766608916273e-10
the O 0 2.9174342941473697e-09
GALNS O 0 2.241976346795127e-07
gene O 0 1.1367344843193905e-09
in O 0 5.163546479280967e-09
Colombian O 0 2.967543332488276e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 7.134732982194691e-07
were O 0 3.972962403508973e-09
investigated O 0 4.924037178000162e-09
, O 0 4.905464368043511e-10
and O 0 6.164448396184241e-10
genetic O 0 7.754236697188333e-10
backgrounds O 0 1.22952281689237e-09
were O 0 1.5322833002429093e-09
extensively O 0 1.8882631014349727e-09
analyzed O 0 2.218527361819156e-09
to O 0 2.467880122480892e-09
identify O 0 6.514598194229393e-09
racial O 0 4.2018727386405885e-10
origin O 0 9.256470590024435e-11
, O 0 1.3811706119082334e-11
based O 0 8.142249027787152e-12
on O 0 6.808121288948144e-10
mitochondrial O 0 1.3864402959029576e-09
DNA O 0 5.712168515970006e-09
( O 0 7.784110578334946e-10
mtDNA O 0 2.6282290122026097e-08
) O 0 2.9401199252987453e-09
lineages O 0 6.105746308548987e-08
. O 0 1.0304199804522796e-07

Three O 0 1.996197482867501e-07
novel O 0 2.3575437069212057e-07
missense O 0 6.566855518030934e-06
mutations O 0 1.054564009450587e-07
never O 0 2.3976539864634105e-07
identified O 0 1.35211726259854e-08
previously O 0 7.783283351159298e-09
in O 0 3.15043269250026e-10
other O 0 1.2792124130800442e-11
populations O 0 6.672347570291226e-12
and O 0 9.495711508766824e-13
found O 0 4.409336177430001e-12
in O 0 4.791589694463916e-11
16 O 0 8.603042722654664e-09
out O 0 1.816928690834274e-10
of O 0 6.684851006077963e-10
19 O 0 1.0897487356942293e-07
Colombian O 0 9.087413673114497e-06
MPS B-Disease 1 0.999995231628418
IVA I-Disease 1 0.9999996423721313
unrelated O 0 1.3283043642786652e-07
alleles O 0 1.4405702186692793e-09
account O 0 1.243840475062541e-09
for O 0 1.066285948425616e-09
84 O 0 4.6048268131926307e-07
. O 0 2.912444188041263e-07

2 O 0 3.270198192240059e-07
% O 0 6.75676714578799e-09
of O 0 2.2371562380385512e-09
the O 0 8.220248370882643e-10
alleles O 0 2.249658098696372e-10
in O 0 5.760437682411634e-10
this O 0 5.301603600571525e-10
study O 0 2.729064307871454e-09
. O 0 1.4443126694629882e-08

The O 0 7.615947197336936e-07
G301C O 0 2.3401346425089287e-06
and O 0 4.4501349272252355e-09
S162F O 0 3.422575503009284e-07
mutations O 0 5.567936112171878e-10
account O 0 5.291118099215453e-10
for O 0 1.3387697617162075e-09
68 O 0 1.089326360670384e-06
. O 0 6.109533501330588e-07

4 O 0 9.534641662867216e-07
% O 0 7.2047474652947585e-09
and O 0 9.667436851046318e-10
10 O 0 8.619800695441882e-08
. O 0 1.0356394142263525e-07

5 O 0 5.139011136634508e-07
% O 0 6.8832286537201526e-09
of O 0 2.675662136297774e-09
mutations O 0 6.538483643403481e-10
, O 0 1.052552975333576e-10
respectively O 0 1.8665242684789973e-09
, O 0 1.4736351028332706e-10
whereas O 0 2.4592485825536414e-09
the O 0 5.304560346530707e-09
remaining O 0 1.2478145094974025e-07
F69V O 0 1.8640010921444627e-06
is O 0 5.43327015323225e-11
limited O 0 7.165466553438193e-10
to O 0 1.0947872608468856e-09
a O 0 2.005236199309479e-09
single O 0 2.1351828749516244e-08
allele O 0 1.0846206066617015e-07
. O 0 1.7172006039345433e-07

The O 0 1.677459948723481e-07
skewed O 0 7.270390511848746e-08
prevalence O 0 9.300336500928097e-08
of O 0 5.708941097637421e-10
G301C O 0 3.948985138890748e-08
in O 0 5.207954623109856e-10
only O 0 3.310345886298194e-10
Colombian O 0 1.4641444501251044e-08
patients O 0 7.646478450418215e-10
and O 0 4.306539153065003e-11
haplotype O 0 9.445260573670566e-09
analysis O 0 1.183860232067957e-09
by O 0 9.891442526166472e-11
restriction O 0 7.746125518792724e-09
fragment O 0 8.692602748716638e-10
length O 0 6.243215666668078e-11
polymorphisms O 0 3.1285176671502768e-09
in O 0 1.256784898373553e-09
the O 0 8.160498943254879e-09
GALNS O 0 2.3417444481310667e-06
gene O 0 7.518478284396224e-09
suggest O 0 7.864582762806549e-09
that O 0 6.038760463900061e-11
G301C O 0 2.1150057705199288e-08
originated O 0 1.019041961924927e-09
from O 0 1.4489907884662756e-10
a O 0 1.1064043015096559e-09
common O 0 1.7784868022729938e-09
ancestor O 0 1.8954852976094116e-07
. O 0 1.0667506700201557e-07

Investigation O 0 2.830034588896524e-07
of O 0 3.3581404323967945e-08
the O 0 9.314944371396905e-09
genetic O 0 1.2507967994679348e-09
background O 0 7.986036276719233e-10
by O 0 2.1701692526354677e-11
means O 0 1.0049634902031812e-08
of O 0 7.309013394518615e-09
mtDNA O 0 1.0164610131369045e-07
lineages O 0 1.4097093270493133e-08
indicate O 0 9.565771286190738e-09
that O 0 5.794717136686778e-11
all O 0 1.572363905744112e-10
our O 0 1.5344562287467056e-09
patients O 0 5.2079021650719426e-11
are O 0 6.017609912971345e-13
probably O 0 1.92644539209752e-10
of O 0 3.178074192700109e-10
native O 0 1.1410775435649612e-08
American O 0 2.9849466045561712e-06
descent O 0 8.425997657468542e-05

Low O 0 1.929361587826861e-06
frequency O 0 2.263774945276964e-07
of O 0 2.5363275923950823e-08
BRCA1 O 0 2.0244411302883236e-07
germline O 0 1.141800112236524e-06
mutations O 0 2.7158646442870804e-09
in O 0 1.2806685711908017e-09
45 O 0 5.861366147996705e-08
German O 0 0.05411938950419426
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.840535201670718e-07
. O 0 3.048322696486139e-07

In O 0 2.915600205710689e-08
this O 0 3.1175678705253063e-10
study O 0 8.485842584171621e-11
we O 0 4.0484674640461904e-11
investigated O 0 2.0626390873079714e-10
45 O 0 9.477057361095831e-09
German O 0 0.12057472765445709
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.939861130206282e-09
for O 0 1.8225178033404177e-09
germline O 0 4.326222224904086e-08
mutations O 0 4.2785242015952463e-10
in O 0 3.4474929577754665e-09
the O 0 3.565182282727619e-08
BRCA1 O 0 4.513169216124879e-08
gene O 0 1.8430666770541393e-08
. O 0 6.778843157917436e-07

We O 0 8.876119750311773e-08
identified O 0 8.208282054056326e-09
four O 0 3.998078312861253e-09
germline O 0 5.636370588035788e-06
mutations O 0 2.9611076257651803e-08
in O 0 2.5013624949110635e-08
three O 0 3.216527133531599e-08
breast B-Disease 0 4.66607116322848e-06
cancer I-Disease 0 6.228951576758845e-08
families O 0 8.572110382631948e-11
and O 0 3.331119061145138e-11
in O 0 8.018994357428255e-09
one O 0 0.013774783350527287
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.290461003780365
. O 0 6.270910013483899e-09
among O 0 1.7998337195623826e-11
these O 0 7.591003346740788e-12
were O 0 1.4479299703662463e-10
one O 0 3.4799021997322654e-10
frameshift O 0 1.1721328263547548e-07
mutation O 0 1.0699999775098945e-09
, O 0 4.35604247117638e-10
one O 0 4.221081262301141e-09
nonsense O 0 1.1733676075209587e-07
mutation O 0 7.914302102562942e-09
, O 0 2.0856397164870089e-10
one O 0 1.272190686130159e-10
novel O 0 8.371816573315982e-10
splice O 0 9.097240649680316e-08
site O 0 2.056520997939515e-08
mutation O 0 7.164988602426092e-10
, O 0 1.1092859270034339e-10
and O 0 3.922197844286046e-10
one O 0 1.452052345030097e-08
missense O 0 4.720010565506527e-06
mutation O 0 3.3176377201016294e-07
. O 0 2.2014924070390407e-06

The O 0 2.1697976535506314e-06
missense O 0 5.808507921756245e-06
mutation O 0 3.330609033014298e-08
was O 0 1.629655521639961e-08
also O 0 2.5966703787183576e-10
found O 0 3.650557980905411e-11
in O 0 3.06163344676591e-10
2 O 0 3.202735285867675e-07
. O 0 2.044420881475162e-07

8 O 0 2.8545710506477917e-07
% O 0 2.5125310720852667e-09
of O 0 8.478922564059133e-10
the O 0 3.964830130875896e-10
general O 0 9.853334814735604e-10
population O 0 1.4100567935493302e-11
, O 0 1.5585742765833466e-11
suggesting O 0 2.3097465606802814e-10
that O 0 2.2745293062204075e-12
it O 0 4.9048235091497805e-12
is O 0 4.83507591603205e-12
not O 0 1.0653949944483543e-10
disease O 0 5.538258740500623e-10
associated O 0 3.527887981746858e-09
. O 0 1.420097106574758e-07

The O 0 3.8422040660179846e-08
average O 0 5.801679137107385e-09
age O 0 9.238396159183537e-10
of O 0 6.156399834367221e-10
disease O 0 3.5711900103763128e-09
onset O 0 1.502022968224992e-07
in O 0 9.650745758094104e-10
those O 0 6.971858090842886e-10
families O 0 4.682184640003584e-10
harbouring O 0 6.029848975686036e-08
causative O 0 2.2575092017973475e-08
mutations O 0 6.598849466854517e-09
was O 0 3.4214490796102837e-08
between O 0 9.364788056132056e-09
32 O 0 4.880719188804505e-06
. O 0 6.559267262673529e-07

3 O 0 3.0498190426442306e-06
and O 0 5.224525168046057e-08
37 O 0 2.243743892904604e-06
. O 0 3.692679797495657e-07

4 O 0 3.428485229051148e-07
years O 0 5.989773121939379e-09
, O 0 1.1625195250886122e-10
whereas O 0 4.856653412765866e-10
the O 0 9.388086974482235e-10
family O 0 3.791200686720231e-09
harbouring O 0 1.372985252601211e-06
the O 0 3.834824013893012e-08
missense O 0 6.485806238742953e-07
mutation O 0 4.241168305441079e-09
had O 0 2.2088375573048324e-09
an O 0 1.1993044578273437e-11
average O 0 8.181046812216763e-11
age O 0 1.3845369295495402e-10
of O 0 6.143801578595287e-10
onset O 0 1.13435453386046e-06
of O 0 9.984353965819537e-08
51 O 0 1.6296048670483287e-06
. O 0 1.0506996659387369e-06

2 O 0 5.629193765344098e-06
years O 0 4.527775274709711e-07
. O 0 5.3678837730331e-07

These O 0 6.280009046122359e-08
findings O 0 4.484372695401362e-08
show O 0 2.6181174561656917e-08
that O 0 6.0631272225109e-10
BRCA1 O 0 1.4300829853652886e-08
is O 0 3.394508840681709e-10
implicated O 0 7.272505930799866e-10
in O 0 3.735726450404542e-10
a O 0 3.7020478349525376e-10
small O 0 3.1484245766044694e-11
fraction O 0 2.4987765190331857e-09
of O 0 5.937011238188461e-08
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.252460759194946e-08
suggesting O 0 2.578706137512654e-09
the O 0 3.516640034728624e-10
involvement O 0 8.534819517791448e-10
of O 0 2.939002652357914e-10
another O 0 3.114275226590024e-10
susceptibility O 0 2.312295688255972e-09
gene O 0 1.6364762878140482e-09
( O 0 1.0691844742893863e-08
s O 0 1.912800689751748e-05
) O 0 5.166835421732685e-07

Paternal O 0 0.00033124577021226287
transmission O 0 0.0007117632776498795
of O 0 3.0497574698529206e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.996775209903717

We O 0 7.133345434340299e-07
report O 0 2.433641554944188e-08
a O 0 9.769832720607496e-10
rare O 0 2.5920596780082406e-09
case O 0 2.0767250141773275e-09
of O 0 7.675165392129202e-09
paternally O 1 0.9999864101409912
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.421793040724879e-08
DM B-Disease 1 1.0
) O 0 2.3637024781919536e-08
. O 0 1.7611176872378564e-07

The O 0 4.86999738313898e-07
proband O 0 2.1281423414620804e-06
is O 0 3.183771302150973e-10
a O 0 3.339199472485177e-10
23 O 0 6.155980170063913e-09
year O 0 1.2326364373649312e-09
old O 0 9.546090495859971e-08
, O 0 6.993051027137653e-09
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 2.7979490369034465e-06
who O 0 9.494773678397905e-08
suffers O 0 7.731758159934543e-06
severe O 0 7.886314415372908e-05
muscular B-Disease 1 0.9999997615814209
weakness I-Disease 1 1.0
. O 0 0.003598717972636223

He O 0 9.214225116238595e-08
presented O 0 8.712446231129434e-08
with O 0 2.3553530237307996e-09
respiratory O 0 2.243608105345629e-05
and O 0 1.6916212874917846e-09
feeding O 0 1.0534096261949344e-08
difficulties O 0 4.657824792531073e-09
at O 0 3.141770577030911e-08
birth O 0 3.1090964967006585e-06
. O 0 2.465972329446231e-06

His O 0 6.771749212930445e-06
two O 0 2.650197643561114e-07
sibs O 0 0.0003701596288010478
suffer O 0 3.2572842201261665e-07
from O 0 7.316600658668904e-09
childhood O 0 3.602559081627987e-05
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.0004142369143664837

Their O 0 5.0731120637692584e-08
late O 0 3.9272767935472075e-06
father O 0 1.0464032129675616e-07
had O 0 1.450062292462917e-08
the O 0 3.1904517916458985e-10
adult O 0 4.0641290333098823e-10
type O 0 1.0687211116078288e-09
of O 0 5.0876542978528505e-09
DM B-Disease 1 1.0
, O 0 1.1703251701078443e-08
with O 0 3.05890174301382e-10
onset O 0 0.006061746273189783
around O 0 2.147143574049437e-09
30 O 0 2.2288690004756972e-08
years O 0 4.157502342394537e-09
. O 0 4.553323407208154e-08

Only O 0 9.39237523311931e-08
six O 0 2.039048929702858e-09
other O 0 1.2531261618653478e-11
cases O 0 8.392416102342981e-12
of O 0 5.1535345435560487e-11
paternal O 0 1.7699989257380366e-05
transmission O 1 0.9999985694885254
of O 0 0.29410314559936523
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 7.240330432978226e-06
been O 0 5.671998426493019e-09
reported O 0 8.35065405713209e-10
recently O 0 2.7984756734156235e-09
. O 0 1.765950408127992e-08

We O 0 2.064958550818119e-07
review O 0 3.4130017922962e-08
the O 0 1.8024257641968688e-09
sex O 0 3.0435839959430666e-10
related O 0 6.759286880209103e-11
effects O 0 8.124572681289521e-10
on O 0 1.869777443985754e-09
transmission O 0 1.0900501479227387e-07
of O 0 4.661818309159571e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.010630832985043526

Decreased O 0 9.33189039642457e-06
fertility O 0 2.1257437765598297e-07
of O 0 3.009009152954434e-10
males O 0 1.1363220087101666e-10
with O 0 2.0510091021386234e-12
adult O 0 1.0210540857258366e-08
onset O 0 2.4614151698187925e-05
DM B-Disease 1 1.0
and O 0 2.4122170927398656e-08
contraction O 0 8.354167135848911e-08
of O 0 2.49506171279279e-09
the O 0 6.094920124155578e-10
repeat O 0 8.950267749163743e-10
upon O 0 6.063474167206095e-10
male O 0 3.6234706901616676e-10
transmission O 0 2.4053781189081747e-10
contribute O 0 1.2260516213391526e-10
to O 0 6.129275975652604e-10
the O 0 1.5099523853479013e-09
almost O 0 1.4940526593676395e-09
absent O 0 1.4634491840581632e-08
occurrence O 0 3.42375816586582e-09
of O 0 2.804357024377424e-10
paternal O 0 1.5056714346428635e-06
transmission O 0 1.6302719814120792e-05
of O 0 5.010767836211016e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00041928241262212396

Also O 0 3.190077890735665e-08
the O 0 9.101553954948827e-10
fathers O 0 1.9674953222192926e-08
of O 0 1.567821650283463e-09
the O 0 1.289145901139932e-09
reported O 0 7.505778776284444e-10
congenitally O 0 1.4908699768056977e-06
affected O 0 5.680136916375034e-10
children O 0 2.553741940136689e-10
showed O 0 2.807080956568342e-10
, O 0 2.6513152784346516e-11
on O 0 5.172447359313992e-09
average O 0 6.2609184503514825e-09
, O 0 1.187731718532703e-10
shorter O 0 7.34144407488202e-08
CTG O 0 7.940308933029883e-06
repeat O 0 8.238540090133029e-07
lengths O 0 3.5987346791443997e-07
and O 0 7.1604295825977715e-09
hence O 0 1.677311978198759e-08
less O 0 4.728820446331383e-09
severe O 0 4.536512498987122e-09
clinical O 0 7.1264754097910554e-09
symptoms O 0 2.8192626011502853e-09
than O 0 1.683559541776347e-11
the O 0 7.543924512853906e-11
mothers O 0 5.212575371338346e-10
of O 0 3.4839249540841166e-11
children O 0 2.260048814761717e-10
with O 0 7.365140164417028e-10
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9999954700469971

We O 0 1.2966906126621325e-07
conclude O 0 2.2901188856394583e-07
that O 0 5.115617374151782e-10
paternal O 0 2.6035324935946846e-06
transmission O 0 0.00011198427091585472
of O 0 1.316131601925008e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 1.528208741774506e-07
rare O 0 5.594947172227194e-09
and O 0 6.279254893826192e-12
preferentially O 0 1.812614988661032e-11
occurs O 0 2.529992925229263e-12
with O 0 1.9882236319563457e-13
onset O 0 2.2241981412207679e-07
of O 0 3.293036954232775e-08
DM B-Disease 1 1.0
past O 0 1.0376043135806867e-08
30 O 0 2.305047486217404e-09
years O 0 6.907645289100373e-11
in O 0 3.1314402459958757e-11
the O 0 1.795990439701356e-10
father O 0 4.563728950301993e-09
. O 0 3.9981093991059424e-09
. O 0 4.4375589425271755e-08

The O 0 2.0848979147558566e-06
RB1 O 0 5.173739918973297e-05
gene O 0 6.215102388296145e-08
mutation O 0 3.756972510871037e-09
in O 0 2.690805578353661e-09
a O 0 3.271463810960995e-08
child O 0 1.300022972827719e-06
with O 0 4.88815352639449e-08
ectopic B-Disease 1 0.999998927116394
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.0003017085837200284

The O 0 2.9084799280099105e-06
RB1 O 0 0.0005041537806391716
gene O 0 2.96193320536986e-07
mutation O 0 1.8975898186113227e-08
was O 0 1.6410279357614854e-08
investigated O 0 4.5661145975373074e-09
in O 0 3.6811516057611016e-09
a O 0 3.346733024045534e-08
child O 0 6.294645231719187e-07
with O 0 8.041203258812857e-09
ectopic B-Disease 0 0.2509181797504425
intracranial I-Disease 1 0.9932524561882019
retinoblastoma I-Disease 0 3.290617314632982e-05
using O 0 1.6941212876986356e-08
DNA O 0 4.790515983899013e-09
obtained O 0 2.4775262730258873e-08
from O 0 1.3858797442978243e-09
both O 0 1.7417940423314349e-09
the O 0 1.0358681024058569e-08
pineal B-Disease 0 1.8321983588975854e-05
and I-Disease 0 1.0156043828146721e-07
retinal I-Disease 0 0.41573837399482727
tumours I-Disease 1 1.0
of O 0 5.28866166860098e-07
the O 0 2.0073647633012115e-08
patient O 0 8.851909427676219e-08
. O 0 2.7824247794683288e-08

A O 0 1.6180554212041898e-06
nonsense O 0 3.736699625278561e-07
mutation O 0 4.933616626345838e-09
in O 0 1.294406137830606e-09
exon O 0 1.6432549543310415e-08
17 O 0 1.359495627184515e-07
( O 0 4.003181119927035e-10
codon O 0 1.2543715399715438e-08
556 O 0 6.811657904393087e-09
) O 0 3.4974556584188576e-10
of O 0 2.6001507613671038e-09
the O 0 2.6919364515265443e-08
RB1 O 0 9.105752724281047e-06
gene O 0 2.0828032631925453e-08
was O 0 2.5983030838006016e-08
found O 0 3.652001201448485e-10
to O 0 4.5071946175312405e-10
be O 0 3.237407564249395e-10
present O 0 4.161538613711713e-10
homozygously O 0 2.0770477249243413e-07
in O 0 3.431956940858072e-09
both O 0 4.508572626349405e-09
the O 0 9.219038865637685e-09
retinal B-Disease 0 3.4982238616976247e-07
and I-Disease 0 5.041107797865152e-08
the I-Disease 0 8.868215104484989e-07
pineal I-Disease 1 0.9999954700469971
tumours I-Disease 1 1.0
. O 0 1.868917479441734e-06

The O 0 9.601365036360221e-08
same O 0 5.290414328840143e-09
mutation O 0 1.4523230396079612e-09
was O 0 1.874812749491639e-09
present O 0 2.1762139312819784e-10
heterozygously O 0 5.9002886132475396e-08
in O 0 1.1608249916861269e-09
the O 0 8.271079376953594e-10
DNA O 0 1.2158429818498462e-09
from O 0 5.890297694044477e-10
the O 0 2.3268689197664116e-09
constitutional O 0 1.5749797910302732e-08
cells O 0 1.2888237144181858e-09
of O 0 3.975583195980903e-10
the O 0 2.7379262745874655e-10
patient O 0 2.5626187838412307e-09
, O 0 4.25469451337257e-11
proving O 0 4.804928899204697e-09
it O 0 2.2111154920900766e-11
to O 0 2.497850815075253e-10
be O 0 5.748276854511403e-10
of O 0 3.1606419703678057e-09
germline O 0 1.4298560699899099e-06
origin O 0 3.760687405929275e-08
. O 0 2.142910773272888e-07

The O 0 1.4964838612741005e-07
initial O 0 2.8888745617905442e-08
mutation O 0 2.6020061660858573e-09
was O 0 1.6411555447959358e-09
shown O 0 8.077723490096389e-10
to O 0 1.2402726623506055e-09
have O 0 8.026086739665317e-11
occurred O 0 4.1623085533792903e-10
in O 0 3.0556596142261583e-10
the O 0 2.700739631933402e-09
paternally O 0 9.656993142925785e-07
derived O 0 5.230198780736828e-07
RB1 O 0 0.00016835455608088523
allele O 0 1.0687266467357404e-06
. O 0 3.8276195368780463e-07

The O 0 1.7261325524486892e-07
mutation O 0 1.4032593975699115e-09
is O 0 1.5140458331508455e-11
in O 0 1.0589984618392112e-11
an O 0 4.75101728791838e-12
area O 0 8.69843572171014e-11
of O 0 4.218881632933602e-10
the O 0 7.000400259471462e-10
gene O 0 8.505097737199208e-10
that O 0 7.908020349667311e-10
encodes O 0 1.3111989272118763e-09
the O 0 1.5494319161035719e-09
protein O 0 1.537895366610087e-10
- O 0 7.87875209518063e-10
binding O 0 1.6588201923184442e-09
region O 0 3.4757778877292367e-09
known O 0 1.5803381936407845e-09
as O 0 2.569307822053446e-10
the O 0 2.819782740637322e-10
pocket O 0 7.819077723070222e-07
region O 0 3.1885312168355995e-09
and O 0 2.9100971632445294e-10
has O 0 2.1772766922723008e-10
been O 0 3.557143191112999e-10
detected O 0 1.1909990771385992e-09
in O 0 1.9270481044220134e-10
other O 0 2.3486182443299697e-10
cases O 0 2.446764180152883e-10
of O 0 5.970083871709164e-10
retinoblastoma B-Disease 0 8.973214704610655e-08
. O 0 2.0475500406291758e-08
. O 0 2.3087761746865e-07

Low O 0 2.1038118575233966e-05
levels O 0 2.663883265086042e-07
of O 0 5.05306152476237e-09
beta O 0 7.118462974631257e-08
hexosaminidase O 0 7.284680236807617e-07
A O 0 3.169910911537954e-08
in O 0 1.8311659966130378e-09
healthy O 0 2.8975938093367404e-08
individuals O 0 1.898097477803784e-11
with O 0 3.1075093887000804e-11
apparent O 0 1.7425033149720548e-07
deficiency O 0 5.55769911443349e-05
of O 0 4.336997790232999e-06
this O 0 2.9792927236371725e-08
enzyme O 0 1.569452194871701e-07
. O 0 2.9966869874442637e-07

Appreciable O 0 3.902921889675781e-06
beta O 0 5.593108767243393e-07
hexosaminidase O 0 5.746183433075203e-06
A O 0 6.349952741402376e-07
( O 0 1.4814731663648217e-09
hex O 0 4.460436571207538e-07
A O 0 5.124920221533102e-07
) O 0 7.611133945317761e-10
activity O 0 7.226947928984373e-09
has O 0 8.501330195365142e-11
been O 0 1.024582294006926e-10
detected O 0 2.4127773112780915e-09
in O 0 2.0697743963182802e-08
cultured O 1 1.0
skin O 1 1.0
fibroblasts O 1 1.0
and O 0 1.2875046877525165e-06
melanoma B-Disease 1 0.9999890327453613
tissue O 0 2.462977590766968e-07
from O 0 3.7291766896707657e-10
healthy O 0 4.293658761866936e-09
individuals O 0 7.013959291840566e-12
previously O 0 4.0444331217415197e-10
reported O 0 1.2659941150960918e-10
as O 0 6.583471545695829e-10
having O 0 1.0207099165882028e-07
deficiency B-Disease 0 0.010707044042646885
of I-Disease 0 1.4162415027385578e-06
hex I-Disease 0 1.4491907904812251e-06
A I-Disease 0 8.398197337555757e-08
activity O 0 3.4808067539415788e-09
indistinguishable O 0 1.2580656516547606e-09
from O 0 5.2325825963817074e-12
that O 0 5.279577773228961e-13
of O 0 1.8399789070838724e-12
patients O 0 2.3783648661623857e-11
with O 0 2.8675220531404477e-10
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 9.298221748110791e-09
TSD B-Disease 0 0.00017605384346097708
) O 0 5.938231240065761e-09
. O 0 1.3855452607458574e-07

Identification O 0 4.968702569385641e-07
and O 0 1.6943410230396694e-08
quantitation O 0 0.00019449037790764123
of O 0 2.6440632154844934e-06
hex O 0 3.7152271943341475e-06
A O 0 2.7768271593231475e-07
, O 0 4.0667344491929214e-10
amounting O 0 3.074075216602523e-09
to O 0 3.2831890539597453e-09
3 O 0 2.027652499236865e-07
. O 0 1.9990322641660896e-07

5 O 0 6.902741347403207e-07
% O 0 1.647438274687829e-08
- O 0 2.339471478762789e-07
6 O 0 1.0611371408231207e-06
. O 0 4.2539909372862894e-07

9 O 0 1.046548391059332e-06
% O 0 1.8173741622717898e-08
of O 0 1.0331728361734349e-08
total O 0 5.074851650022083e-09
beta O 0 6.456325962744813e-08
hexosaminidase O 0 6.784042625440634e-07
activity O 0 2.527176867772596e-08
, O 0 2.753685057754751e-10
has O 0 5.917263901089598e-11
been O 0 1.1002021516048899e-10
obtained O 0 2.8680433583616605e-09
by O 0 1.9961454711392435e-10
cellulose O 0 5.43732085134252e-07
acetate O 0 1.3318932587935706e-06
gel O 0 1.272349436476361e-06
electrophoresis O 0 5.275581749231151e-09
, O 0 1.909099961450167e-10
DEAE O 0 3.292403505383845e-07
- O 0 5.901275912378878e-09
cellulose O 0 4.326634694962195e-08
ion O 0 3.112675699412648e-07
- O 0 1.5784103197802324e-06
exchange O 0 3.528479965098086e-06
chromatography O 0 1.236291780060128e-07
, O 0 5.532989622025752e-10
radial O 0 5.43774403283237e-09
immunodiffusion O 0 4.436458880263672e-07
, O 0 1.0532442695776467e-09
and O 0 2.1042609876786855e-09
radioimmunoassay O 0 8.936345693655312e-06
. O 0 3.0992691790743265e-07

Previous O 0 7.537367491750047e-05
family O 0 5.378835510327917e-08
studies O 0 4.174843226678604e-08
suggested O 0 8.597351275341225e-09
that O 0 1.0923791385342163e-11
these O 0 6.1226449257767435e-12
individuals O 0 2.893843151219322e-12
may O 0 1.4472341380855624e-10
be O 0 1.3617360017370572e-10
compound O 0 3.6646747858526396e-09
heterozygotes O 0 8.110734306399081e-09
for O 0 3.772962497983201e-10
the O 0 9.252079657962042e-10
common O 0 2.6145927645160327e-09
mutant O 0 2.6357440674473764e-08
TSD B-Disease 0 6.984414540056605e-07
gene O 0 2.354827444150942e-09
and O 0 6.741625035999732e-10
a O 0 9.173398041184555e-09
rare O 0 2.3995976761170823e-08
( O 0 5.591487828304764e-10
allelic O 0 8.833710296585195e-08
) O 0 3.393744729685011e-10
mutant O 0 1.4087792266082033e-08
gene O 0 1.3954025490647837e-08
. O 0 2.0784031562470773e-07

Thus O 0 2.9185889616201166e-07
, O 0 4.051886381972736e-09
the O 0 2.821887834514314e-09
postulated O 0 5.713609851909496e-08
rate O 0 1.6778432865294235e-08
mutant O 0 1.9224013492191716e-09
gene O 0 3.7308917066880554e-10
appears O 0 7.943136148824692e-10
to O 0 2.908210339214179e-10
code O 0 1.6506511435476767e-10
for O 0 1.0228991265126552e-10
the O 0 3.072631593603603e-10
expression O 0 3.2104392477805277e-09
of O 0 2.768150986209861e-10
low O 0 1.4329519792966039e-09
amounts O 0 2.2324747606106143e-10
of O 0 8.309249399651719e-10
hex O 0 2.679116448689456e-07
A O 0 8.207376254176779e-07
. O 0 9.221290042660257e-07

Heterozygotes O 0 1.294759931624867e-05
for O 0 6.232754401480634e-08
the O 0 2.8941691709860606e-08
rare O 0 2.6196309121928607e-08
mutant O 0 2.73368172543087e-08
may O 0 2.4710311574693833e-09
be O 0 3.035062479117556e-10
indistinguishable O 0 1.3084832106713407e-09
from O 0 8.057945283246326e-11
heterozygotes O 0 1.3789800412666864e-08
for O 0 1.4622235644523585e-09
the O 0 7.86866483082349e-09
common O 0 4.2793288912434946e-08
TSD B-Disease 0 4.314735997468233e-05
mutant O 0 3.257653986565856e-07
. O 0 1.557153979092618e-07

However O 0 9.226817354601735e-08
, O 0 2.881420657629974e-10
direct O 0 1.6908986433250561e-09
visualization O 0 5.1335980799649406e-08
and O 0 6.333580881978662e-10
quantitation O 0 7.140226080082357e-05
of O 0 5.011054895476263e-07
hex O 0 6.43006330847129e-07
A O 0 1.0410044382069827e-07
by O 0 1.1617813655551146e-10
the O 0 5.283756210339163e-10
methods O 0 6.312311118250591e-09
described O 0 6.769637628245562e-10
may O 0 1.196993060226248e-09
prevent O 0 2.751896266417475e-09
false O 0 2.4969434520016875e-08
- O 0 3.284155525307142e-08
positive O 0 1.0490261992401884e-09
prenatal O 0 5.482428946379514e-07
diagnosis O 0 1.2239065654284786e-06
of O 0 7.046459415960271e-09
TSD B-Disease 0 1.5634048395440914e-05
in O 0 2.1930334881403724e-08
fetuses O 0 8.625504506198922e-07
having O 0 2.547734911928501e-09
the O 0 2.550681221791251e-09
incomplete O 0 2.8873541779717016e-08
hex B-Disease 0 1.8243293880004785e-06
A I-Disease 0 2.049417616944993e-06
deficiency I-Disease 0 0.05094962567090988
of O 0 3.5155755995219806e-06
the O 0 2.6272823561157566e-07
type O 0 2.2676643141039676e-07
described O 0 5.99208149765218e-09
in O 0 1.954455930430754e-09
the O 0 4.373262996182348e-08
four O 0 3.5840479029047856e-08
healthy O 0 5.920986723140231e-07
individuals O 0 7.532414691979739e-09

The O 0 1.5377171393993194e-06
tumor B-Disease 0 4.738339157484006e-06
suppressor O 0 8.940676707425155e-06
gene O 0 1.2482887541409582e-06
Smad4 O 0 0.00023931371106300503
/ O 0 3.340287730679847e-05
Dpc4 O 0 1.4584702512365766e-05
is O 0 4.2332939931277735e-10
required O 0 2.801309739730584e-10
for O 0 2.612517702171857e-10
gastrulation O 0 8.904795123498843e-08
and O 0 1.6859576235095375e-10
later O 0 3.969765849376472e-09
for O 0 4.2293071822463446e-10
anterior O 0 9.166607473076738e-10
development O 0 7.694193726592857e-08
of O 0 3.595783581999967e-08
the O 0 1.989639919486308e-08
mouse O 0 3.4531147719008004e-08
embryo O 0 2.976220159212062e-08
. O 0 8.435635123760221e-08

Mutations O 0 7.41774712764709e-08
in O 0 1.1586489989667825e-08
the O 0 5.667935099040733e-08
SMAD4 O 0 0.003922794014215469
/ O 0 7.359113806160167e-05
DPC4 O 0 2.6641564545570873e-05
tumor B-Disease 0 3.6603807984647574e-07
suppressor O 0 7.379335897894634e-08
gene O 0 3.992622232829035e-09
, O 0 1.654667097783502e-10
a O 0 2.8776543370412355e-09
key O 0 4.901775128018926e-07
signal O 0 1.048632384481607e-06
transducer O 0 4.681001257722528e-07
in O 0 6.665071339284623e-08
most O 0 2.732274317907013e-08
TGFbeta O 0 3.5599409784481395e-06
- O 0 1.3064108372873307e-07
related O 0 5.810959713414832e-09
pathways O 0 2.0217501006669636e-09
, O 0 8.924688245370849e-12
are O 0 2.477978488634597e-13
involved O 0 1.693794735545262e-12
in O 0 4.8432004934317874e-11
50 O 0 1.2718989239601797e-07
% O 0 2.1045511999773225e-08
of O 0 1.3977938806419843e-07
pancreatic B-Disease 1 0.9990764856338501
cancers I-Disease 1 0.9999998807907104
. O 0 0.008460869081318378

Homozygous O 0 5.830483132740483e-05
Smad4 O 0 5.830683221574873e-05
mutant O 0 6.442720632549026e-07
mice O 0 3.6729478125607784e-08
die O 0 1.9140676599249673e-08
before O 0 5.9632814242149834e-09
day O 0 4.220825644551951e-08
7 O 0 1.1436985687396373e-06
. O 0 5.47133481632045e-07

5 O 0 3.8982902879070025e-06
of O 0 1.806397165182716e-07
embryogenesis O 0 2.562147710705176e-05
. O 0 2.0960999336239183e-06

Mutant O 0 3.793141729602212e-07
embryos O 0 3.3991380377074165e-08
have O 0 7.8944267789538e-10
reduced O 0 9.51008161109712e-10
size O 0 6.233200067207179e-10
, O 0 6.112149675274736e-10
fail O 0 1.6818650294680992e-07
to O 0 3.0790058502816464e-08
gastrulate O 0 1.7203294646606082e-06
or O 0 9.582663551555015e-09
express O 0 6.06586025853062e-09
a O 0 1.360438539599329e-09
mesodermal O 0 1.7362182802571624e-07
marker O 0 7.944476720922466e-08
, O 0 1.9103136850162628e-09
and O 0 2.7932602897351444e-09
show O 0 3.4177253382949857e-07
abnormal O 0 5.947863428445999e-07
visceral O 0 1.8256312159792287e-06
endoderm O 0 6.958610902074724e-05
development O 0 1.7840445707406616e-06
. O 0 1.4595489119528793e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 3.412338287489547e-07
the O 0 3.7923740592304966e-08
Smad4 O 0 1.4379006643139292e-05
- O 0 5.718569582313648e-07
deficient O 0 8.855624855641508e-08
embryos O 0 5.528132618337622e-08
results O 0 2.2590166182112625e-08
from O 0 2.4299946499439784e-09
reduced O 0 3.342841381481776e-08
cell O 0 9.9824497112877e-08
proliferation O 0 4.986323460798303e-07
rather O 0 1.7712895594712563e-09
than O 0 2.62956489915922e-10
increased O 0 1.0468773625760264e-09
apoptosis O 0 6.175834244004363e-08
. O 0 1.0683429252367205e-07

Aggregation O 0 3.416676008782815e-07
of O 0 1.0686098761425455e-07
mutant O 0 1.1380349462797312e-07
Smad4 O 0 2.2724213977198815e-06
ES O 0 3.238120370951947e-06
cells O 0 9.322462801719666e-09
with O 0 3.8743570851540454e-11
wild O 0 5.926655610721809e-09
- O 0 6.013331166343505e-09
type O 0 1.311424657757243e-08
tetraploid O 0 5.479266178554099e-07
morulae O 0 2.8019996989314677e-06
rescues O 0 4.464441474283376e-07
the O 0 6.43126583099729e-08
gastrulation B-Disease 0 7.143930997699499e-05
defect I-Disease 0 6.040732387191383e-06
. O 0 4.1737925471352355e-07

These O 0 9.233859543655853e-08
results O 0 4.8056552515163276e-08
indicate O 0 4.9880537034141526e-08
that O 0 3.5513741947212907e-10
Smad4 O 0 2.1825849216838833e-07
is O 0 7.55691481613141e-11
initially O 0 3.4155381301026466e-10
required O 0 2.146868099961452e-10
for O 0 3.8239372779358405e-10
the O 0 1.232201451983883e-09
differentiation O 0 6.709225619516701e-09
of O 0 7.785867062182206e-09
the O 0 7.945216928817445e-09
visceral O 0 4.406007647617116e-08
endoderm O 0 9.057304737325467e-07
and O 0 3.68183816767953e-10
that O 0 8.162685805057635e-11
the O 0 5.707417316536123e-10
gastrulation B-Disease 0 5.556398718908895e-07
defect I-Disease 0 4.175050349886078e-08
in O 0 4.2289545199025724e-09
the O 0 2.684378941353316e-08
epiblast O 0 1.6076017345767468e-05
is O 0 1.053746256918231e-10
secondary O 0 2.8717930256050295e-09
and O 0 1.4034194639744868e-10
non O 0 9.93317939901317e-07
- O 0 2.0521656551864e-06
cell O 0 1.759312544891145e-05
autonomous O 0 1.1698496109602274e-06
. O 0 2.8096499136154307e-06

Rescued O 0 3.419295171624981e-05
embryos O 0 2.46679519477766e-07
show O 0 3.655127613910736e-07
severe O 0 4.560398636499485e-08
anterior O 0 1.0246814241554603e-07
truncations O 0 9.815723024075851e-05
, O 0 2.7793058521297098e-08
indicating O 0 6.782619976775095e-08
a O 0 9.663809308335658e-09
second O 0 6.57790177882589e-09
important O 0 1.125187498729474e-09
role O 0 4.350016791221378e-09
for O 0 5.682957215924489e-09
Smad4 O 0 3.6331400679046055e-06
in O 0 2.830352130445135e-08
anterior O 0 3.672048478620127e-07
patterning O 0 0.0001491427974542603
during O 1 0.9999401569366455
embryogenesis O 0 0.0011091306805610657
. O 0 5.219495164965338e-07

Prevalence O 0 2.8537910111481324e-05
of O 0 1.85750064218837e-08
p16 O 0 6.827646075180382e-07
and O 0 6.206557934262946e-09
CDK4 O 0 0.00034126281389035285
germline O 0 0.00010750607907539234
mutations O 0 6.576837563443405e-08
in O 0 1.4441528861652841e-08
48 O 0 1.3195511883168365e-06
melanoma B-Disease 0 7.801091123837978e-05
- O 0 9.37516142585082e-06
prone O 0 4.835334621589027e-08
families O 0 4.942901643545383e-10
in O 0 6.247176997931092e-09
France O 0 8.759482170717092e-07
. O 0 4.393546078063082e-07

The O 0 1.1656794413283933e-05
French O 0 0.00011514883226482198
Familial B-Disease 0 0.07433189451694489
Melanoma I-Disease 1 0.9999992847442627
Study O 0 2.6228756055957092e-08
Group O 0 6.665485385859427e-10
. O 0 3.0636211345580477e-09

Germline O 0 7.888434629421681e-05
mutations O 0 1.2536162330434308e-07
in O 0 2.4052338787328154e-08
the O 0 5.245083301019804e-08
p16 O 0 9.615455383027438e-07
and O 0 1.2443298835762562e-08
CDK4 O 0 1.6107607052617823e-06
genes O 0 1.5591853363972064e-09
have O 0 3.2356359258578493e-10
been O 0 2.3048705999340058e-10
reported O 0 1.949320843630531e-10
in O 0 3.554925243065554e-10
a O 0 7.581956396052192e-09
subset O 0 2.1855717591279245e-07
of O 0 1.1634854857334176e-08
melanoma B-Disease 0 3.2707268928788835e-06
pedigrees O 0 1.115589185474164e-07
, O 0 5.693326365907581e-10
but O 0 1.9614010415835992e-10
their O 0 1.4568841688600287e-09
prevalence O 0 3.241804336084897e-08
is O 0 5.280033354981839e-12
not O 0 4.8339072328262844e-11
well O 0 4.093981265107516e-10
known O 0 2.7194635876526263e-08
. O 0 3.0042642151784094e-07

We O 0 1.9200538758923358e-07
searched O 0 9.936687916933806e-08
for O 0 1.4747886245558561e-09
such O 0 2.00326377708393e-09
germline O 0 1.0643382665875833e-05
mutations O 0 2.6746276304834282e-08
in O 0 2.6709724210149943e-08
48 O 0 5.7530050980858505e-06
French O 0 4.22647963205236e-06
melanoma B-Disease 0 0.24218444526195526
- O 0 1.0533891327213496e-05
prone O 0 7.96545762682399e-09
families O 0 1.2423548301221388e-11
selected O 0 1.2494656698169848e-10
according O 0 4.6600865527546276e-11
to O 0 1.5590299884404857e-10
two O 0 1.6454761164741427e-11
major O 0 1.1325959614616465e-10
criteria O 0 4.599669256588612e-10
families O 0 1.5536850235184363e-12
with O 0 4.54749681921135e-13
at O 0 1.4230675526860637e-09
least O 0 3.2442565300883075e-10
three O 0 1.006462552188836e-10
affected O 0 2.2990398473865525e-10
members O 0 1.6894212417906118e-10
( O 0 2.6768451344416633e-10
n O 0 4.5259966441335564e-08
= O 0 1.0830103036596483e-07
20 O 0 5.0829211950542685e-09
) O 0 3.9180835659236024e-11
or O 0 8.151498920305755e-11
families O 0 3.406049314119697e-12
with O 0 3.168083200291716e-13
two O 0 3.8217896729253464e-12
affected O 0 2.1497106178491876e-11
members O 0 8.2087080188753e-12
, O 0 5.458737628583066e-12
one O 0 2.8200448920490118e-11
of O 0 5.212463446979676e-11
them O 0 3.0588634923611746e-12
affected O 0 1.0444292132538724e-11
before O 0 6.81266432156491e-11
the O 0 1.5906344297267339e-10
age O 0 8.675508644806484e-10
of O 0 5.688962634309291e-10
50 O 0 4.822088506273303e-09
( O 0 5.2427149427325404e-11
n O 0 4.8115227357925505e-09
= O 0 7.097598597738397e-08
28 O 0 2.5997406893907282e-08
) O 0 1.5927140162297349e-10
, O 0 9.027328884414487e-11
and O 0 3.978630619405621e-11
one O 0 2.6178337275695185e-11
additional O 0 3.402235160265832e-10
minor O 0 2.529750631197203e-09
criterion O 0 3.169492629240267e-06
. O 0 7.559692107861338e-07

Sixteen O 0 1.9843662357743597e-06
different O 0 3.131361125952026e-08
p16 O 0 4.372805960883852e-06
germline O 0 9.102166586671956e-06
mutations O 0 3.682977700592005e-09
were O 0 7.033833515635024e-10
found O 0 4.6460106595258566e-11
in O 0 2.8049333689050826e-11
21 O 0 2.959253952994345e-09
families O 0 2.174577878877315e-11
, O 0 1.573386039510627e-11
while O 0 7.526649442590738e-11
one O 0 9.893484920198148e-10
germline O 0 1.6346713209713926e-06
mutation O 0 1.1211819028744685e-08
, O 0 1.0649140458340867e-09
Arg24His O 0 2.124395223290776e-06
, O 0 2.416300270979832e-09
was O 0 1.7581568201308073e-08
detected O 0 3.275545834569016e-09
in O 0 1.7896549797669081e-09
the O 0 1.0936191507937565e-08
CDK4 O 0 6.389038844645256e-06
gene O 0 4.9561609927195605e-08
. O 0 7.144524261093466e-07

The O 0 5.9336716873303885e-08
frequency O 0 8.786189908960296e-08
of O 0 5.342209785652585e-09
p16 O 0 5.478232267819294e-08
gene O 0 5.981074302496836e-09
mutation O 0 1.2762549905787068e-09
in O 0 5.181875484261411e-10
our O 0 6.504739857859931e-09
sample O 0 7.78574371640417e-10
( O 0 3.734043282910271e-11
44 O 0 1.2507729296729053e-09
% O 0 1.25268947992474e-10
) O 0 1.7081452571843236e-11
is O 0 4.84250530299879e-12
among O 0 1.2507424566529646e-12
the O 0 7.768618213999101e-12
highest O 0 1.6582815676180473e-10
rates O 0 3.92727322884312e-10
yet O 0 5.461760557712303e-11
reported O 0 5.9201088475902e-11
and O 0 9.412627621774305e-11
the O 0 4.8562851517885974e-09
CDK4 O 0 1.6685347645761794e-06
mutation O 0 9.306201920189494e-10
is O 0 2.673776651473947e-11
the O 0 4.867698466526349e-10
second O 0 2.323269221449209e-08
mutation O 0 2.7916728928545353e-09
detected O 0 8.909525894829073e-10
in O 0 1.4604167875020835e-10
this O 0 3.229464196063958e-10
gene O 0 4.471183423504499e-09
worldwide O 0 2.6783133932894998e-08
. O 0 1.750034215319829e-07

In O 0 1.1207499817089683e-08
summary O 0 2.2212009298527846e-07
, O 0 1.232221963354263e-10
our O 0 1.0860108368149213e-09
results O 0 5.167760663837839e-10
show O 0 1.0371448144752549e-09
frequent O 0 5.015954873677231e-10
involvement O 0 4.694723720888305e-09
of O 0 6.012000675070794e-09
the O 0 1.1958412926560413e-08
p16 O 0 1.9527695371834852e-07
gene O 0 2.562043377452028e-08
in O 0 2.9141325796899764e-08
familial B-Disease 0 1.3093997495161602e-06
melanoma I-Disease 0 0.0006119252648204565
and O 0 1.2583656339160143e-09
confirm O 0 3.399773618184554e-08
the O 0 3.619576638413946e-09
role O 0 4.9230539644895543e-08
of O 0 3.7085118265167694e-07
the O 0 9.695717295699069e-08
CDK4 O 0 2.972908077936154e-05
gene O 0 1.8912160726358707e-08
as O 0 9.891942376327734e-09
a O 0 3.580877105946456e-08
melanoma B-Disease 0 5.608247647614917e-06
- O 0 4.3948787720182736e-07
predisposing O 0 7.530535981459252e-07
gene O 0 2.0409878231930634e-08
. O 0 3.080521437937023e-08
. O 0 2.133211154387027e-07

Progression O 0 7.1464992288383655e-06
of O 0 2.0638263720229588e-07
somatic O 0 2.9411867217277177e-06
CTG O 0 4.972910573997069e-06
repeat O 0 8.947987595320228e-08
length O 0 2.999618553545247e-09
heterogeneity O 0 1.7056670742476854e-08
in O 0 5.503931088668423e-09
the O 0 3.2352363010801355e-09
blood O 0 5.747333164940471e-10
cells O 0 4.712756851432687e-09
of O 0 6.356627668679948e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 3.2272837415803224e-05
. O 0 7.418779546242149e-07

The O 0 3.470175613529136e-08
genetic O 0 3.7454026546868135e-09
basis O 0 2.0078703144577048e-08
of O 0 4.680117271504969e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.0354875118755444e-07
DM B-Disease 1 1.0
) O 0 5.242637435287634e-10
is O 0 4.962358302051939e-11
the O 0 4.5819709137973064e-11
expansion O 0 1.4509053958278173e-09
of O 0 3.8703559801511744e-10
an O 0 4.26784545204395e-11
unstable O 0 2.570436530291431e-09
CTG O 0 1.24753370300823e-07
repeat O 0 3.0123410432736364e-09
in O 0 1.1199203786560474e-09
the O 0 2.425114553616936e-09
34 O 0 1.6086556087202553e-08
UTR O 0 8.680314635967079e-07
of O 0 1.2118821501871935e-08
the O 0 2.7963322324353612e-08
DM B-Disease 1 1.0
protein O 0 3.0800574535305714e-08
kinase O 0 5.756873378004457e-08
gene O 0 1.7089650805601764e-09
on O 0 2.5702320272102952e-08
chromosome O 0 4.209481474504173e-08
19 O 0 3.269186663601431e-06
. O 0 7.418878453790967e-07

One O 0 5.992129814558211e-08
of O 0 8.080007773969555e-09
the O 0 1.9332890843770656e-09
principal O 0 2.0526178090563008e-08
features O 0 1.4326055897129208e-08
of O 0 2.5486789567708e-08
the O 0 7.218491191451903e-07
DM B-Disease 1 1.0
mutation O 0 1.634780630865862e-07
is O 0 2.0940421618931282e-10
an O 0 5.3806539085377025e-11
extraordinarily O 0 4.2239101105678856e-08
high O 0 6.287380074354587e-07
level O 0 1.5209160665108357e-05
of O 0 1.5845078848997218e-07
somatic O 0 3.6226704196451465e-06
mosaicism O 0 2.852964826161042e-06
, O 0 3.325800468356732e-10
due O 0 3.54229046095611e-09
to O 0 3.990955121935258e-09
an O 0 7.460871503939259e-11
extremely O 0 3.549552318737881e-10
high O 0 4.617724813638091e-10
degree O 0 4.662982888703482e-08
of O 0 1.7484985903593042e-08
somatic O 0 2.7769328880822286e-06
instability O 0 2.9678145097022934e-07
both O 0 6.564788157525925e-10
within O 0 9.912179410598299e-11
and O 0 3.150755698011487e-11
between O 0 2.0529748040454265e-11
different O 0 3.346468102627398e-10
tissues O 0 4.2418172085945116e-08
. O 0 1.0543165274157218e-07

This O 0 7.421270709073724e-08
instability O 0 7.226164910889565e-08
appears O 0 9.372539411245384e-10
to O 0 8.432855802542605e-11
be O 0 2.2237361257948507e-11
biased O 0 4.541973186444892e-10
towards O 0 7.293662340757123e-10
further O 0 3.7391412188725326e-10
expansion O 0 3.4576586038781443e-10
and O 0 6.020440396214966e-11
continuous O 0 2.5148514382067333e-09
throughout O 0 2.5928395541718885e-10
the O 0 2.3198219734066328e-10
life O 0 8.911497650920808e-10
of O 0 2.0001625355980934e-10
an O 0 1.4373850200366523e-11
individual O 0 2.0588961091583258e-11
, O 0 2.384774322461425e-11
features O 0 4.413699405958482e-10
that O 0 3.45474126736689e-12
could O 0 2.3316425179498168e-11
be O 0 1.4490952708612337e-11
associated O 0 1.655446751902545e-10
with O 0 1.258827590777667e-11
the O 0 4.317062263226035e-09
progressive O 0 1.1326753934781664e-07
nature O 0 2.1847073039538145e-09
of O 0 3.270306525582356e-10
the O 0 1.0992965426837031e-09
disease O 0 4.216872184770182e-09
. O 0 1.6046778128497863e-08

Although O 0 9.227397868016851e-08
increasing O 0 9.862967331741856e-09
measured O 0 6.717779665876833e-09
allele O 0 9.187055560744284e-09
size O 0 1.5211101267453842e-09
between O 0 1.6392870394454917e-10
patients O 0 7.670423407546423e-09
clearly O 0 9.493770214419328e-10
correlates O 0 5.330115238066924e-10
with O 0 2.8469572619510553e-12
an O 0 6.396510057737892e-12
increased O 0 1.3251545694092925e-10
severity O 0 1.1608604078006124e-09
of O 0 6.277736663840017e-11
symptoms O 0 9.57651957733674e-10
and O 0 7.972832463676305e-12
an O 0 6.21360818700567e-12
earlier O 0 6.16815001852622e-11
age O 0 3.007918913944252e-10
of O 0 5.061914221116126e-10
onset O 0 2.9079027186185158e-08
, O 0 2.0869519654076463e-11
this O 0 8.561403322393524e-12
correlation O 0 6.258345230936158e-11
is O 0 5.434884313426647e-12
not O 0 1.1386717957417858e-10
precise O 0 3.306852747186895e-08
and O 0 5.9915103989283125e-09
measured O 0 1.2208005273350864e-07
allele O 0 2.7159595461512254e-08
length O 0 1.1000452770915103e-09
cannot O 0 3.84042886381053e-09
be O 0 2.8382204919630283e-10
used O 0 7.088176157132864e-10
as O 0 1.4084124144719823e-10
an O 0 1.2385929087921355e-11
accurate O 0 3.334192255621815e-09
predictor O 0 3.1987053006332644e-08
of O 0 1.5016977661375108e-09
age O 0 3.497205725011554e-08
of O 0 2.214647487619459e-08
onset O 0 2.1883213776163757e-05
. O 0 2.7884954079127056e-07

In O 0 1.1328995519477303e-08
order O 0 1.739858146443396e-09
to O 0 6.766242566236258e-10
further O 0 2.0959922686358823e-10
characterize O 0 2.0754105101161713e-09
the O 0 1.9183137300871067e-09
dynamics O 0 1.3369229279192041e-08
of O 0 1.3714394242470007e-07
DM B-Disease 1 1.0
CTG O 0 5.493948992807418e-05
repeat O 0 4.210433246498724e-07
somatic O 0 1.8380976598564303e-06
instability O 0 1.2485953959640028e-07
, O 0 6.343080227733111e-11
we O 0 6.464424828767079e-11
have O 0 8.019746325360622e-12
studied O 0 3.628463918214919e-10
repeat O 0 9.05181596344562e-10
length O 0 2.1245576131700972e-10
changes O 0 4.930623132004541e-10
over O 0 2.818270443405435e-11
time O 0 2.6532742669616027e-10
in O 0 1.0687822848964856e-09
111 O 0 1.8385693465461372e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.2311360819694528e-07
with O 0 5.1217242252876716e-12
varying O 0 2.058147263728216e-10
clinical O 0 6.951280884237576e-09
severity O 0 1.8311739680143546e-08
and O 0 3.0008817653026654e-10
CTG O 0 1.8880341201565898e-07
repeat O 0 1.0317076970522976e-08
size O 0 1.0983617348969688e-09
over O 0 1.5402613906534413e-10
time O 0 2.3179598518385802e-10
intervals O 0 1.1173615505066792e-10
of O 0 2.877448279647865e-11
1 O 0 1.2729730602956124e-09
- O 0 1.9299227105307182e-08
7 O 0 5.679470760355798e-08
years O 0 3.044069174507058e-08
. O 0 9.316617877175304e-08

We O 0 1.83692208111097e-07
have O 0 6.737871371953474e-10
found O 0 9.751211643704849e-11
a O 0 2.49069428276405e-11
direct O 0 2.5467425390779397e-10
progression O 0 8.273922880164264e-09
of O 0 1.0451874921102444e-09
the O 0 1.134862759322175e-09
size O 0 1.5416523613254185e-09
heterogeneity O 0 5.762681887233612e-09
over O 0 1.2770214052881812e-10
time O 0 3.0136385054113646e-10
related O 0 1.320940912208357e-09
to O 0 2.008980315437725e-09
initial O 0 8.52062420619859e-09
CTG O 0 3.029005029020482e-07
repeat O 0 1.7899255411180093e-08
size O 0 2.1814345885218245e-09
and O 0 1.0636067582225905e-09
the O 0 3.4992857500526497e-09
time O 0 3.5616123383874765e-09
interval O 0 1.02762220954844e-09
and O 0 5.8106661843249086e-11
always O 0 9.29582411046681e-10
biased O 0 1.2270769955691208e-09
towards O 0 1.926218295977833e-09
further O 0 2.408643728912807e-09
expansion O 0 9.630306863073201e-08
. O 0 3.425851105021138e-07

Attempts O 0 8.868908025760902e-07
to O 0 1.4013799010115235e-08
mathematically O 0 3.59620884182732e-08
model O 0 8.127354078624194e-08
the O 0 2.7686924752856612e-08
dynamics O 0 7.228729259622924e-08
have O 0 6.787949313746822e-09
proved O 0 5.939344305261329e-08
only O 0 7.427565229534139e-10
partially O 0 8.815377761095533e-09
successful O 0 7.744485053251537e-09
suggesting O 0 5.357505550307451e-09
that O 0 2.1076973499845053e-11
individual O 0 1.055302460001295e-11
specific O 0 2.5388804947290566e-10
genetic O 0 2.3575328356173486e-09
and O 0 3.129998038531312e-09
/ O 0 0.018742255866527557
or O 0 3.0443999321505544e-08
environmental O 0 4.957548149775448e-09
factors O 0 8.210001012365353e-10
also O 0 9.622985047696986e-11
play O 0 1.4785233037883927e-09
a O 0 1.6566257254879702e-09
role O 0 8.062212231152444e-09
in O 0 2.127767473325548e-08
somatic O 0 1.8628459201863734e-06
mosaicism O 0 8.429735316894948e-06
. O 0 3.890817978913219e-08
. O 0 2.823155398345989e-07

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 3.827429040370589e-08
Palestinian O 0 8.428058322351717e-07
Arabs O 0 3.0179617738212983e-07
. O 0 4.579802137527622e-08

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 4.502285719354404e-06
AGU B-Disease 1 1.0
) O 0 1.035826624473657e-08
is O 0 6.771290750329229e-10
a O 0 1.8828973935569593e-09
rare O 0 1.6808709801807709e-07
disorder B-Disease 1 0.999997615814209
of I-Disease 0 7.652593012608122e-06
glycoprotein I-Disease 0 7.170393473643344e-06
metabolism I-Disease 0 0.012761848978698254
caused O 0 1.1099351127086265e-07
by O 0 1.958544854074873e-10
the O 0 5.422449689262976e-08
deficiency B-Disease 0 5.51499797438737e-05
of I-Disease 0 3.1589795526087983e-06
the I-Disease 0 3.208008365618298e-07
lysosomal I-Disease 0 8.147769221977796e-06
enzyme I-Disease 0 1.6225382637458097e-07
aspartylglucosaminidase I-Disease 0 5.841043275722768e-06
( O 0 9.389609090248996e-10
AGA O 0 6.957583991606953e-06
) O 0 1.497362767111099e-08
. O 0 1.0982852671759247e-07

AGU B-Disease 1 1.0
is O 0 4.080607496348421e-08
inherited O 0 2.0330740824192617e-07
as O 0 2.0172365111648105e-08
an O 0 2.322922298958474e-09
autosomal O 0 0.004004866816103458
recessive O 0 0.00036564035690389574
trait O 0 9.248062724509509e-07
and O 0 2.5683866144987633e-10
occurs O 0 8.700161424624042e-11
with O 0 2.8960723250960607e-13
a O 0 4.1509854581400774e-11
high O 0 1.3464162007537084e-09
frequency O 0 4.810534193211424e-08
in O 0 2.083224437399167e-08
Finland O 0 2.996904129304312e-07
because O 0 2.3031929696770703e-09
of O 0 7.15720682720189e-09
a O 0 6.794556028921761e-09
founder O 0 5.6247497326467055e-08
effect O 0 2.1134733074745782e-08
. O 0 8.580089172482985e-08

While O 0 8.170157883569118e-08
very O 0 4.122851837706776e-09
few O 0 2.5822890492577244e-09
patients O 0 9.46888567554538e-10
with O 0 4.603493974908446e-11
AGU B-Disease 1 1.0
have O 0 4.0029162207133595e-09
been O 0 2.947783128703918e-10
reported O 0 4.589501348406522e-11
from O 0 1.4793680169766787e-11
non O 0 2.643401764146347e-08
- O 0 3.7563648191962784e-08
Finnish O 0 9.09018140760054e-08
origin O 0 1.6422044835096017e-09
, O 0 3.1727669103087663e-11
we O 0 2.9226071562860056e-10
diagnosed O 0 8.569392662138853e-08
the O 0 3.2548941319987534e-09
disorder O 0 2.7854733275489707e-07
in O 0 3.7667069463509506e-10
8 O 0 1.1286721779413256e-08
patients O 0 1.1574330383012921e-10
originating O 0 2.4361457295896116e-11
from O 0 2.5545640255919544e-11
3 O 0 3.4161391493370274e-09
unrelated O 0 9.66891122722302e-10
families O 0 3.281595828408257e-11
, O 0 1.054590182542059e-11
all O 0 8.881419905071297e-12
Palestinian O 0 3.99474009427081e-09
Arabs O 0 1.2346410560581944e-09
from O 0 3.9837640131157315e-11
the O 0 7.936211410264349e-11
region O 0 2.452408554010077e-10
of O 0 4.1589598431812647e-10
Jerusalem O 0 1.5924200624795048e-06
. O 0 7.40762331474798e-08

The O 0 1.1532300447925081e-07
clinical O 0 3.8410396996368945e-07
diagnosis O 0 0.16620978713035583
of O 0 1.8167420421377756e-06
AGU B-Disease 1 1.0
is O 0 2.7107049938024375e-09
often O 0 2.325455800145093e-11
difficult O 0 3.785907351505635e-11
, O 0 2.130735908892345e-12
in O 0 5.232982016462051e-12
particular O 0 3.144307730851281e-11
early O 0 1.8815871083432967e-09
in O 0 1.0294599200877386e-10
the O 0 3.3338473648392153e-10
course O 0 2.7143423064757144e-09
of O 0 2.5198917952273803e-10
the O 0 1.4703192829923495e-10
disease O 0 1.0965799102091722e-10
, O 0 1.6230264745023537e-12
and O 0 3.8552190953500265e-12
most O 0 3.377161050810429e-11
of O 0 1.7275000874228397e-10
the O 0 8.455243449834171e-11
patients O 0 1.0900023071636067e-11
are O 0 4.63476533627688e-13
diagnosed O 0 1.4174242335407428e-10
after O 0 3.3922045727940997e-10
the O 0 9.036204007273341e-10
age O 0 5.035839301115175e-09
of O 0 2.1892625490238515e-09
5 O 0 4.874429748724651e-08
years O 0 2.288070533040809e-08
. O 0 1.443203530016035e-07

However O 0 2.444337212637038e-07
, O 0 2.3607726884478097e-09
since O 0 1.672889382575704e-09
these O 0 1.651690312298726e-10
patients O 0 1.4098208711565974e-10
excrete O 0 1.8626726827619677e-09
early O 0 1.6379814171685325e-09
large O 0 1.2527397175166044e-10
amounts O 0 2.741251226012764e-09
of O 0 8.063580914097201e-09
aspartylglucosamine O 0 2.195257138737361e-06
in O 0 6.984176081914484e-08
urine O 0 2.144676614079799e-08
, O 0 1.0450414839047184e-10
biochemical O 0 7.190726902805977e-10
screening O 0 4.75113326459109e-09
is O 0 1.3269029208728966e-09
easy O 0 4.6234315931314995e-08
by O 0 1.2395819926069862e-09
urine O 0 5.028295557707452e-09
chromatography O 0 3.2990521425801944e-09
. O 0 8.287727837341663e-09
. O 0 9.765818020923689e-08

Detection O 0 4.032816377730342e-06
of O 0 2.3777426250148892e-08
heterozygous O 0 4.585531121481523e-10
carriers O 0 1.2861610387826516e-10
of O 0 1.1664513799303222e-09
the O 0 1.435955994111282e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 4.665269415227158e-08
ATM O 0 2.3935835997690447e-06
) O 0 3.337435605654804e-10
gene O 0 6.238314864681627e-10
by O 0 2.907411533747961e-10
G2 O 0 2.5262593794650456e-07
phase O 0 9.88568444881821e-08
chromosomal O 0 5.071042323834263e-07
radiosensitivity O 0 1.523540686321212e-05
of O 0 1.3489339778516296e-07
peripheral O 0 6.094082436902681e-06
blood O 0 3.9107581528696755e-07
lymphocytes O 0 2.838890225120849e-07
. O 0 5.342721820511542e-08

In O 0 5.276188517200353e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 6.985231448197737e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3386626251943312e-09
patients O 0 1.0963739249802984e-08
, O 0 1.7867880786059942e-11
mutations O 0 2.172654417487152e-11
in O 0 1.688242323716338e-10
a O 0 7.902983822916099e-10
single O 0 9.377796317266984e-10
gene O 0 6.043614497741601e-10
, O 0 2.1842479214218002e-10
ATM O 0 7.103326993274095e-08
, O 0 4.504975212316076e-11
result O 0 5.321925192203203e-11
in O 0 3.998701925134185e-10
an O 0 5.285615856109871e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.2336907495580363e-08
embraces O 0 1.20879728449097e-09
a O 0 4.8843061539738386e-11
variety O 0 1.2587803022157118e-10
of O 0 1.9433847586736164e-10
clinical O 0 3.777291812667727e-09
features O 0 5.792557544737065e-09
and O 0 4.729404090575429e-10
manifests O 0 4.2143879497302805e-09
extreme O 0 4.732736869073051e-09
radiosensitivity O 0 1.8206842256063283e-08
and O 0 1.3504715401513323e-10
a O 0 1.4016445781805942e-08
strong O 0 6.780886963042576e-08
pre O 0 0.0001301110751228407
- O 0 1.6842157492646948e-05
disposition O 0 6.0605791077250615e-05
to O 0 4.92057051815209e-06
malignancy B-Disease 0 0.0001978632208192721
. O 0 3.2067939059743367e-07

Heterozygotes O 0 3.1856627629167633e-06
for O 0 2.685095878973698e-08
the O 0 1.1340129724146664e-08
ATM O 0 8.412768579546537e-07
gene O 0 8.05884425858494e-09
have O 0 3.6896977140266074e-10
no O 0 1.183105696744846e-10
clinical O 0 2.3715487906805777e-10
expression O 0 6.790924489408212e-10
of O 0 2.7715227890467986e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.1239904562643233e-09
may O 0 7.929860657007737e-10
be O 0 5.895512966702654e-10
cancer B-Disease 0 9.050284077716242e-09
prone O 0 2.1875876110577508e-10
with O 0 2.188499381716724e-12
a O 0 7.787452349639068e-10
moderate O 0 2.2673121158334197e-09
increase O 0 3.1184121951355337e-10
in O 0 1.1342762284982655e-09
in O 0 2.372903828984363e-08
vitro O 0 2.9983275453560054e-06
radiosensitivity O 0 7.339634521486005e-06
. O 0 5.256150075183541e-07

We O 0 4.1487510316073895e-08
performed O 0 1.9394173378373125e-08
a O 0 1.8435869719723996e-08
blind O 0 1.858440441537823e-07
chromosomal O 0 5.5841606894091456e-08
analysis O 0 1.7440587640749072e-08
on O 0 1.915967118293338e-08
G2 O 0 2.07235775206982e-08
- O 0 4.1640575432211335e-09
phase O 0 1.765310742030124e-08
lymphocytes O 0 3.138438842142932e-09
from O 0 2.0883376625202565e-11
7 O 0 1.6214446452167408e-09
unrelated O 0 6.30573140369961e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.318584612723498e-07
, O 0 1.7030085674996087e-11
13 O 0 6.017263909363635e-10
obligate O 0 9.474874218540208e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 8.133059054671321e-06
( O 0 3.694498526551904e-11
parents O 0 1.8019642722411078e-10
of O 0 5.124746113582823e-11
the O 0 2.1490793519762796e-11
patients O 0 9.13685446746193e-12
) O 0 2.039842361863109e-13
, O 0 1.272063292374892e-12
and O 0 8.050275723814337e-12
14 O 0 1.0166234964970045e-08
normal O 0 4.805797857443395e-07
controls O 0 2.8360003057059657e-07
following O 0 1.461429732785291e-08
X O 0 1.89747481726954e-07
- O 0 2.0285723323354432e-08
irradiation O 0 1.9703270126569805e-08
with O 0 4.632649125424493e-11
1 O 0 3.7992521129126544e-08
Gy O 0 3.31078967974463e-06
in O 0 1.3874817961223584e-10
order O 0 1.6844212136213343e-10
to O 0 5.435843442036514e-10
evaluate O 0 6.775738636832784e-09
this O 0 7.069691498884367e-10
cytogenetic O 0 1.6985676154490648e-07
method O 0 1.978449759576506e-08
as O 0 3.377808699411844e-09
a O 0 1.9432710995914704e-09
tool O 0 6.26016856131173e-08
for O 0 4.5520684444078086e-10
detection O 0 1.3322485870048695e-07
of O 0 1.776850133694552e-08
ATM O 0 6.014744030835573e-06
carriers O 0 1.1072877725837316e-07
. O 0 8.76565763974213e-07

Both O 0 5.700133556274523e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 3.138197644148022e-05
and O 0 6.690236808992722e-09
heterozygotes O 0 1.5958742096700007e-06
showed O 0 3.212111465700218e-09
significantly O 0 2.1717283527067366e-09
increased O 0 1.5650668538924606e-09
levels O 0 7.345349217757757e-09
of O 0 9.0915258654789e-10
radiation O 0 7.162000656535383e-06
- O 0 5.639021310344106e-06
induced O 0 2.8755218863807386e-06
chromatid O 0 9.80025106400717e-07
damage O 0 5.99499898612521e-08
relative O 0 2.8499405502202535e-08
to O 0 1.3924242869833847e-09
that O 0 5.12912733119375e-11
of O 0 5.883381004601063e-10
normal O 0 1.1535226462910941e-07
controls O 0 1.073147927854734e-06
. O 0 6.153658773655479e-07

These O 0 7.951250324822468e-09
results O 0 3.997567610269925e-09
show O 0 3.70569530616649e-09
that O 0 8.33391133880923e-11
the O 0 1.0889976698180703e-09
G2 O 0 3.8046769645916356e-07
- O 0 3.830369337265438e-07
phase O 0 1.000057068267779e-06
chromosomal O 0 4.928972884954419e-06
radiosensitivity O 0 1.09947122837184e-05
assay O 0 2.6258689445057826e-08
can O 0 1.5521907370530386e-10
be O 0 1.8601498813497486e-11
used O 0 4.7462464514147484e-11
for O 0 1.712206418313933e-11
the O 0 9.596989869464778e-12
detection O 0 3.659952785284304e-09
of O 0 5.476641806723137e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.0001736878475639969
. O 0 1.1112130096080364e-06

In O 0 2.688437632514251e-07
combination O 0 2.2128156729195325e-07
with O 0 4.4472309168597235e-10
molecular O 0 3.693165595564096e-08
genetic O 0 1.1444035941110542e-08
analyses O 0 3.1589906246409782e-09
, O 0 9.486813418169149e-11
this O 0 4.053853086549708e-11
test O 0 1.769019930542015e-10
may O 0 4.998265343281183e-11
be O 0 1.0230025160318235e-10
of O 0 5.431674554579047e-11
value O 0 3.6326605612480023e-10
in O 0 4.268781508831587e-11
studies O 0 1.3521243014125162e-09
of O 0 8.81261619234408e-10
familial B-Disease 0 1.726428067172492e-08
and I-Disease 0 4.820341015232543e-09
sporadic I-Disease 0 3.4996418207811075e-07
cancers I-Disease 0 1.017888919818688e-07
aimed O 0 1.002195944010964e-07
at O 0 3.1001203382174936e-08
determination O 0 1.6464730379084358e-07
of O 0 1.480162694633691e-07
the O 0 1.7426653897700817e-08
potential O 0 1.022652362792087e-08
involvement O 0 9.474349838001217e-08
of O 0 7.423719949883889e-08
ATM O 0 0.00020370219135656953
mutations O 0 1.6492404597556742e-07
in O 0 2.6377659168019818e-08
tumor B-Disease 0 4.487552359933034e-06
risk O 0 5.6302020823295607e-08
or O 0 3.441433527040516e-10
development O 0 1.0025507091171448e-09
. O 0 1.7714247846356557e-09
. O 0 3.521113711713042e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 4.767052814713679e-07
identification O 0 1.8022930703409656e-07
and O 0 1.0541240796912987e-10
detection O 0 6.312890832305129e-08
of O 0 4.652506824243119e-09
founder O 0 7.670119828162569e-08
- O 0 1.738727739564183e-08
effect O 0 1.0253515370095556e-08
mutations O 0 5.588214890828169e-10
in O 0 1.6541344960430138e-09
the O 0 3.3098863649883015e-09
ATM O 0 5.2618570833828926e-08
gene O 0 2.485987249389865e-10
in O 0 6.968600696488636e-10
ethnic O 0 2.4141938448352107e-10
populations O 0 1.1723464421464769e-09
. O 0 2.1395285543235332e-08

To O 0 4.69418921511533e-08
facilitate O 0 1.1102526542572377e-07
the O 0 7.529413537099572e-09
evaluation O 0 6.580765443686687e-08
of O 0 2.7906841282288042e-08
ATM O 0 6.456821665778989e-06
heterozygotes O 0 1.765209844961646e-06
for O 0 5.210698983404427e-09
susceptibility O 0 1.1717661863031026e-07
to O 0 2.0002026701604336e-08
other O 0 1.401563642922099e-09
diseases O 0 1.1406514488498942e-07
, O 0 3.668405509915651e-11
such O 0 1.0608487005514533e-10
as O 0 1.0344939127548969e-08
breast B-Disease 0 1.6669966953486437e-06
cancer I-Disease 0 9.131765921210899e-08
, O 0 3.2244906744693935e-10
we O 0 1.1071537020512778e-09
have O 0 2.0174885373425155e-10
attempted O 0 1.8290019498934385e-09
to O 0 1.312685182774942e-09
define O 0 1.3922072383820705e-08
the O 0 3.319895247599902e-09
most O 0 3.0725438859846577e-10
common O 0 3.3393587894892107e-10
mutations O 0 1.687977535524965e-11
and O 0 1.8768779933009405e-12
their O 0 2.2389468751216057e-11
frequencies O 0 6.970953814189329e-10
in O 0 3.817700822139614e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.0028792530647479e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.408924502210311e-10
homozygotes O 0 8.8945931508988e-08
from O 0 1.84897305799403e-10
10 O 0 4.235095329985228e-10
ethnic O 0 1.0809836532843509e-11
populations O 0 2.452689162879551e-10
. O 0 7.124844714212486e-09

Both O 0 1.4995525532413012e-07
genomic O 0 2.5812079229581286e-07
mutations O 0 1.1029009705509907e-08
and O 0 3.379134194680944e-10
their O 0 4.847611756453318e-10
effects O 0 7.34705896121568e-09
on O 0 2.056183490140029e-08
cDNA O 0 4.513341522738301e-08
were O 0 1.3033851331556434e-08
characterized O 0 1.712836095180137e-08
. O 0 1.4099705936132523e-07

Protein O 0 7.115870204188468e-08
- O 0 4.662422625756335e-08
truncation O 0 3.6404884440344176e-08
testing O 0 6.21703177827726e-09
of O 0 8.01299693264923e-10
the O 0 7.16375903042632e-10
entire O 0 2.429735301845426e-09
ATM O 0 1.3568481449510728e-07
cDNA O 0 5.939072522664901e-08
detected O 0 9.854731253255977e-09
92 O 0 4.1835082953411984e-08
( O 0 1.161785737058274e-10
66 O 0 7.1252252986653275e-09
% O 0 2.5643434597988346e-10
) O 0 8.068233581237649e-11
truncating O 0 2.9341773455371367e-08
mutations O 0 1.409969363486141e-09
in O 0 1.3876784166200196e-09
140 O 0 2.193627324231784e-08
mutant O 0 2.4814326593514124e-08
alleles O 0 2.157237721789329e-09
screened O 0 7.937131130120179e-08
. O 0 8.000357638593414e-07

The O 0 1.006803472591855e-06
haplotyping O 0 3.1400144507642835e-05
of O 0 4.3373098890242545e-08
patients O 0 1.9260358641304265e-08
with O 0 4.406311773785809e-11
identical O 0 2.412189559208855e-08
mutations O 0 2.930586617821973e-08
indicates O 0 7.074945784779629e-08
that O 0 2.0301652026155637e-10
almost O 0 1.5201819802967975e-09
all O 0 4.904079919931803e-10
of O 0 4.418863053246014e-10
these O 0 3.037157331187146e-11
represent O 0 2.470389171005394e-10
common O 0 9.289354285790807e-10
ancestry O 0 2.760823125669276e-09
and O 0 4.931506869532143e-10
that O 0 2.363799156412938e-10
very O 0 6.185211787190781e-10
few O 0 3.807977932979156e-09
spontaneously O 0 2.73304423537013e-09
recurring O 0 2.338197191420477e-08
ATM O 0 2.041454990830971e-06
mutations O 0 4.271606002248518e-08
exist O 0 2.113683308380132e-07
. O 0 3.8808053659522557e-07

Assays O 0 1.199051098410564e-06
requiring O 0 4.3522764059389374e-08
minimal O 0 3.561200117019325e-07
amounts O 0 9.211936990993763e-09
of O 0 5.050845519605218e-09
genomic O 0 3.603829012988058e-09
DNA O 0 1.3640761853395134e-09
were O 0 1.7395553053578539e-10
designed O 0 1.8015734459808641e-09
to O 0 2.2412220967993335e-09
allow O 0 8.939246010086777e-10
rapid O 0 8.377135651826961e-10
screening O 0 2.923304098789714e-10
for O 0 5.594208429826608e-10
common O 0 1.6822035986407968e-09
ethnic O 0 6.304823330083309e-10
mutations O 0 7.336598439877662e-09
. O 0 9.081828267198944e-08

These O 0 9.949242496531951e-08
rapid O 0 3.530529113504599e-07
assays O 0 2.7838933647217345e-07
detected O 0 1.1588435100406969e-08
mutations O 0 4.4800424481294954e-10
in O 0 7.112688771293563e-10
76 O 0 6.772976490765359e-08
% O 0 5.258400381791262e-10
of O 0 4.052974067469961e-10
Costa O 0 1.2400319882033273e-08
Rican O 0 1.2918866332256584e-07
patients O 0 3.72980446528004e-09
( O 0 5.676599815207517e-12
3 O 0 6.002373598157362e-10
) O 0 2.8234246537972574e-11
, O 0 2.430548470822025e-11
50 O 0 1.5739459735542027e-09
% O 0 8.779443144701915e-11
of O 0 1.2341437594098892e-10
Norwegian O 0 1.9956067021098534e-08
patients O 0 2.154737499537873e-09
( O 0 3.912801506411601e-12
1 O 0 8.974267995398577e-10
) O 0 3.143552085305146e-11
, O 0 2.4848579791014735e-11
25 O 0 6.598456225859195e-10
% O 0 9.162984260235874e-11
of O 0 1.2412777750103743e-10
Polish O 0 9.46210221286492e-09
patients O 0 1.2757488399017802e-09
( O 0 5.050856868166198e-12
4 O 0 4.854958657318775e-10
) O 0 1.9800286410465162e-11
, O 0 1.0935423573610326e-11
and O 0 1.041512882882234e-11
14 O 0 9.955611890433147e-10
% O 0 8.275256868639502e-11
of O 0 1.429277113329519e-10
Italian O 0 1.787342163162009e-09
patients O 0 1.0158360819190193e-09
( O 0 4.4640532589901305e-12
1 O 0 2.9038553783777843e-09
) O 0 1.63668759101121e-10
, O 0 5.57071680451493e-11
as O 0 8.142315294223934e-11
well O 0 2.8918306985148412e-11
as O 0 1.222923585314506e-11
in O 0 5.991774784663839e-12
patients O 0 2.1283769885416248e-11
of O 0 5.6105332185696355e-11
Amish O 0 2.968771184441721e-07
/ O 0 2.543823711675941e-06
Mennonite O 0 9.38487005441857e-07
and O 0 3.793877212387997e-09
Irish O 0 1.6632435873020768e-08
English O 0 2.265687903957314e-08
backgrounds O 0 2.0823108570766635e-08
. O 0 1.0799347194279107e-07

Additional O 0 2.272559243010619e-07
mutations O 0 3.822947292064782e-09
were O 0 1.3669828602402845e-09
observed O 0 8.980209353914859e-10
in O 0 6.806692987026963e-10
Japanese O 0 1.354141261344921e-07
, O 0 2.5649793400361887e-10
Utah O 0 5.8477400699530335e-09
Mormon O 0 1.3222088979247815e-09
, O 0 2.0738216699456302e-11
and O 0 1.8122139205933863e-11
African O 0 4.026040389959462e-09
American O 0 3.6791021340576435e-09
patients O 0 3.3609772742693167e-09
. O 0 1.964952822675059e-08

These O 0 2.2416507761136018e-08
assays O 0 1.0162105823496859e-08
should O 0 2.1089129054185918e-10
facilitate O 0 7.292087073063058e-11
screening O 0 1.743238747797804e-10
for O 0 6.413500841517816e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 6.515110158034076e-07
in O 0 1.188956266773289e-09
the O 0 2.249036096246826e-10
populations O 0 3.036300030845318e-11
studied O 0 9.89524018280008e-10
. O 0 2.5510560330843646e-09
. O 0 8.28822095400028e-08

The O 0 1.815937321225647e-05
von B-Disease 1 0.999997615814209
Hippel I-Disease 1 0.9999970197677612
- I-Disease 1 0.9688433408737183
Lindau I-Disease 0 0.0018023512093350291
tumor I-Disease 0 6.19607963017188e-05
suppressor O 0 1.5017135410744231e-06
gene O 0 1.9475649537525896e-08
is O 0 9.219240648672411e-11
required O 0 2.3947030469706476e-10
for O 0 3.381687707637582e-10
cell O 0 3.524148972644525e-09
cycle O 0 5.865322449949417e-09
exit O 0 1.4420335148201957e-08
upon O 0 1.0398668592870308e-08
serum O 0 4.20110772836324e-08
withdrawal O 0 4.144465322042379e-07
. O 0 4.960965611644497e-07

The O 0 2.5282187721131777e-07
inactivation O 0 4.538810117082903e-06
of O 0 1.134687749981822e-06
the O 0 1.158388158728485e-06
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 0.9999997615814209
( I-Disease 0 4.91444154704368e-07
VHL I-Disease 0 0.011836656369268894
) I-Disease 0 1.3869968995550153e-07
tumor I-Disease 0 4.834646824747324e-05
suppressor O 0 0.0007584445411339402
gene O 0 6.424770162993809e-06
predisposes O 0 1.0443569635754102e-06
affected O 0 1.3336318716028472e-09
individuals O 0 1.0631127922433592e-11
to O 0 1.9453256783208417e-09
the O 0 1.1167085922636488e-08
human O 0 9.54995812207926e-07
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 6.161642307489501e-09
is O 0 7.824327297178968e-11
associated O 0 4.765706718146134e-10
with O 0 4.74117932414142e-11
sporadic B-Disease 0 5.137701009516604e-06
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 1.6131266988850257e-07
RCC B-Disease 0 0.0003176495956722647
) O 0 3.1681096857028024e-08
and O 0 5.476268327697653e-08
brain B-Disease 0 0.0002729299885686487
hemangioblastomas I-Disease 0 0.00036894925870001316
. O 0 5.056226655142382e-07

VHL O 0 0.00045828495058231056
- O 0 8.379487553611398e-06
negative O 0 6.102173415456491e-07
786 O 0 5.582495305134216e-06
- O 0 3.2828284020069987e-05
0 O 0 1.2779092912751366e-06
RCC B-Disease 0 5.4111951612867415e-06
cells O 0 3.055908166516019e-07
are O 0 9.537219902711058e-10
tumorigenic O 0 8.790311198936251e-07
in O 0 4.866626213129166e-08
nude O 0 9.922888239088934e-06
mice O 0 5.571320116359857e-08
which O 0 8.053934602569868e-11
is O 0 1.1107801310694665e-11
suppressed O 0 5.821707005360111e-10
by O 0 1.5181753423854083e-11
the O 0 6.345697856069421e-10
reintroduction O 0 1.2075332733729738e-07
of O 0 9.607626694219107e-09
VHL B-Disease 0 3.435625330894254e-05
. O 0 1.9037076981476275e-06

Remarkably O 0 9.68402764556231e-06
, O 0 7.775533550358205e-10
this O 0 3.338242529626889e-11
occurs O 0 5.1219316982153984e-11
without O 0 3.437679307882746e-11
affecting O 0 8.903083825728686e-11
the O 0 5.544248046773781e-11
growth O 0 2.7604216135124204e-10
rate O 0 3.8144696290487445e-09
and O 0 4.1658808347389e-11
cell O 0 5.720367290962258e-09
cycle O 0 6.262602436635234e-09
profile O 0 8.897507619565204e-09
of O 0 1.4749125254454043e-09
these O 0 3.2299676822056256e-11
cells O 0 1.9316037658256846e-10
in O 0 2.683987199159077e-10
culture O 0 2.6402421582361058e-08
. O 0 5.97020317627539e-08

The O 0 2.0332737449280103e-07
786 O 0 5.109898779664945e-07
- O 0 9.272109195990197e-07
0 O 0 1.2431300433490833e-07
cell O 0 1.0485268830962013e-07
line O 0 3.52036160222724e-08
, O 0 4.532505759602401e-10
like O 0 6.855069289990467e-10
many O 0 2.9599805939639623e-10
cancer B-Disease 0 8.010215823972544e-10
cells O 0 4.728754610106023e-10
, O 0 1.2856019027118748e-10
fails O 0 6.1603140366628395e-09
to O 0 6.030284271929531e-09
exit O 0 1.2950050631843624e-07
the O 0 2.9556455061197084e-08
cell O 0 8.848091148649928e-09
cycle O 0 9.754601570932664e-10
upon O 0 2.069449722696959e-09
serum O 0 1.4324226249584626e-08
withdrawal O 0 1.4547195803515933e-07
. O 0 2.441043136514054e-07

Here O 0 2.0374412201817904e-07
, O 0 4.694148958428457e-10
it O 0 6.085504929836949e-12
is O 0 8.204274390931354e-13
shown O 0 3.911301837966619e-12
that O 0 6.67426563235457e-13
reintroduction O 0 1.5264695063521572e-09
of O 0 6.251250073141534e-10
the O 0 1.6937004021500002e-09
wild O 0 2.4596625181061427e-08
- O 0 1.7197235635535435e-08
type O 0 1.929183035542792e-08
VHL B-Disease 0 3.5655673400469823e-06
gene O 0 3.684595739628094e-08
restores O 0 7.069872026477242e-06
the O 0 1.845022268298635e-08
ability O 0 1.4043124885176894e-08
of O 0 2.35260646519464e-08
VHL O 0 0.005716689862310886
- O 0 0.001245772698894143
negative O 0 2.1192785482071486e-07
RCC B-Disease 0 1.3258154467621353e-05
cancer I-Disease 0 3.049046597425331e-07
cells O 0 2.0819919122061492e-09
to O 0 3.4148099903319462e-09
exit O 0 1.4499073941465213e-08
the O 0 1.6549488446315763e-09
cell O 0 2.1774479996850005e-09
cycle O 0 9.022461666674531e-10
and O 0 4.5277273597044143e-10
enter O 0 6.155454457257292e-07
G0 O 0 9.675878391135484e-05
/ O 0 0.00014131632633507252
quiescence O 0 1.7137668692157604e-05
in O 0 1.419435164962124e-07
low O 0 6.253533229028108e-07
serum O 0 1.4018750960076432e-07
. O 0 3.6121026170121695e-08

Both O 0 1.6150028159245267e-06
VHL O 0 0.0009619779302738607
- O 0 5.3087838750798255e-05
positive O 0 2.204916143000446e-07
and O 0 1.3881820137839895e-08
VHL O 0 0.00014122122956905514
- O 0 1.031035753840115e-05
negative O 0 5.404132963349184e-08
RCC B-Disease 0 2.7362671062292065e-06
cells O 0 8.406713050135295e-07
exit O 0 1.2330318668318796e-06
the O 0 1.472344202113618e-08
cell O 0 2.0237878928242026e-08
cycle O 0 2.9414379820735803e-09
by O 0 3.0335925438329525e-10
contact O 0 1.1505804309308587e-07
inhibition O 0 1.0522829825276858e-06
. O 0 3.8749402619941975e-07

The O 0 1.0709655725804623e-05
cyclin O 0 5.0419002946000546e-05
- O 0 9.430154932488222e-06
dependent O 0 1.9636490833363496e-06
kinase O 0 1.2535484756881488e-06
inhibitor O 0 2.424515059828991e-07
, O 0 1.6392941448728493e-09
p27 O 0 2.1732228105975082e-06
, O 0 6.387994022638566e-10
accumulates O 0 1.299668039855817e-09
upon O 0 3.116830682436955e-10
serum O 0 2.349390015865538e-09
withdrawal O 0 6.8293499744243036e-09
, O 0 2.814241895077174e-11
only O 0 3.734079018213876e-11
in O 0 4.397295028102377e-11
the O 0 3.1852714910129976e-10
presence O 0 7.879744079453133e-10
of O 0 1.901581780927586e-09
VHL B-Disease 0 2.4271300844702637e-06
, O 0 3.7650976780767564e-10
as O 0 2.794569575748085e-10
a O 0 1.7573369148760065e-10
result O 0 1.2698368745400757e-10
of O 0 2.695900447324817e-10
the O 0 1.4002349280062276e-10
stabilization O 0 4.2679496914388437e-07
of O 0 6.130415641791842e-08
the O 0 3.8591995377146304e-08
protein O 0 4.148743215637296e-08
. O 0 1.0251818594042561e-07

We O 0 8.651041660812098e-09
propose O 0 4.921389518131036e-09
that O 0 4.544128615058263e-11
the O 0 3.1165331426663556e-10
loss O 0 6.009432951259441e-09
of O 0 3.127098135990991e-09
wild O 0 6.238270344738339e-09
- O 0 9.347229656953004e-09
type O 0 2.674198995578081e-08
VHL B-Disease 0 3.0049088309169747e-05
gene O 0 1.3961299316633813e-07
results O 0 1.6848382244916138e-07
in O 0 2.3975022855893258e-08
a O 0 2.903779261487216e-08
specific O 0 2.388834730027156e-07
cellular O 0 4.3029435801145155e-06
defect O 0 4.691405592893716e-07
in O 0 8.657512040599613e-09
serum O 0 2.353953476585957e-07
- O 0 4.89386309254769e-07
dependent O 0 2.942024082130956e-07
growth O 0 2.406973109714272e-08
control O 0 4.19494234904505e-08
, O 0 1.7177090305686704e-10
which O 0 3.0434897657638516e-11
may O 0 1.0615496259802626e-09
initiate O 0 3.751281241193283e-08
tumor B-Disease 0 8.353704572527931e-08
formation O 0 6.813765196511667e-08
. O 0 5.321349476616888e-07

This O 0 2.0544547396639246e-08
is O 0 4.906250405944945e-10
corrected O 0 1.2479902444795243e-08
by O 0 3.0333246331393227e-11
the O 0 4.799092234719637e-10
reintroduction O 0 5.1831854364081664e-08
of O 0 2.2377322217437268e-09
wild O 0 2.842134527725193e-08
- O 0 7.492827336363916e-08
type O 0 1.3888976013731735e-07
VHL B-Disease 0 0.09526994824409485
, O 0 1.778797127371945e-07
implicating O 0 2.6334628273616545e-05
VHL B-Disease 1 0.9986975193023682
as O 0 3.4613614730005793e-07
the O 0 2.5165176609220907e-08
first O 0 3.6082170584705864e-09
tumor B-Disease 0 1.8261087086912653e-09
suppressor O 0 9.252120847236256e-09
involved O 0 2.8478730484948755e-10
in O 0 2.223695894087996e-09
the O 0 6.400671992423668e-08
regulation O 0 5.747740488004638e-06
of O 0 3.469977016834491e-08
cell O 0 9.217490770652148e-09
cycle O 0 3.106540580333217e-09
exit O 0 6.9466419283514824e-09
, O 0 6.10217570917726e-11
which O 0 8.077406798978615e-12
is O 0 5.173239007311148e-12
consistent O 0 3.112149427053623e-10
with O 0 3.055143594707377e-12
its O 0 1.818912104267767e-10
gatekeeper O 0 6.9808834268769715e-09
function O 0 4.01090799462267e-10
in O 0 4.1924902438594813e-10
the O 0 3.2396576532534027e-09
kidney O 0 5.0299284737320704e-08
. O 0 9.46755385200504e-09
. O 0 7.082222452936549e-08

Piebaldism B-Disease 1 1.0
with O 0 1.5037247067084536e-05
deafness B-Disease 1 1.0
: O 0 2.3763144341160114e-08
molecular O 0 5.776085387765306e-09
evidence O 0 1.909312041803446e-09
for O 0 1.8435218629431205e-10
an O 0 2.680007327171552e-10
expanded O 0 3.5352497889107326e-06
syndrome O 1 0.9999996423721313
. O 0 3.7339677874115296e-06

In O 0 4.963859101536627e-09
a O 0 1.1952818734783932e-09
South O 0 4.601128367198726e-09
African O 0 1.0498953706417069e-08
girl O 0 7.093508003208626e-09
of O 0 7.634280430046658e-10
Xhosa O 0 6.36954951005464e-07
stock O 0 5.452734086475175e-08
with O 0 1.8850082952881486e-11
severe O 0 1.874583821503961e-09
piebaldism B-Disease 0 5.7416205123672626e-08
and O 0 4.812695242328857e-10
profound O 0 1.1304130111966515e-06
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 4.302317790916277e-07
identified O 0 5.687208037841174e-09
a O 0 5.481488041247928e-10
novel O 0 8.049362842932339e-10
missense O 0 3.097311074284903e-09
substitution O 0 6.743981817436406e-09
at O 0 5.278966597188628e-08
a O 0 5.132136493557482e-09
highly O 0 3.86009579855795e-09
conserved O 0 3.4301637086286973e-09
residue O 0 1.54557255882537e-07
in O 0 2.266102860914998e-08
the O 0 3.945657311987816e-08
intracellular O 0 3.3774503549466317e-07
kinase O 0 2.603879920570762e-07
domain O 0 2.904632090405812e-08
of O 0 6.229150972814068e-09
the O 0 1.2161496698581686e-08
KIT O 0 7.722022564848885e-05
proto O 0 0.00019225958385504782
- O 0 3.4683243939070962e-06
oncogene O 0 0.0002449375460855663
, O 0 1.2986108188783874e-08
R796G O 0 5.507700734597165e-06
. O 0 1.1649205333696955e-07

Though O 0 4.32707253139597e-07
auditory B-Disease 0 6.747047336830292e-06
anomalies I-Disease 0 1.2302715504119988e-06
have O 0 1.5847059220419624e-09
been O 0 2.599752635390473e-10
observed O 0 1.0583265513952611e-10
in O 0 3.592366404348013e-10
mice O 0 9.106629228483598e-09
with O 0 7.166187782070566e-11
dominant O 0 1.2471626575916162e-07
white O 0 3.07825445133858e-08
spotting O 0 2.796818080241792e-06
( O 0 8.195923051346199e-09
W O 1 0.737459123134613
) O 0 2.391755238306814e-09
due O 0 1.7639885641074216e-07
to O 0 5.2785534165877834e-08
KIT O 0 3.220759754185565e-05
mutations O 0 2.0845686776738148e-07
, O 0 2.448611091665498e-08
deafness B-Disease 1 1.0
is O 0 9.045240112470765e-10
not O 0 2.1812671113785598e-10
typical O 0 7.843890537095888e-10
in O 0 2.2534717147859595e-10
human O 0 1.0053886612126917e-09
piebaldism B-Disease 0 1.0526443929848028e-06
. O 0 1.5768711136843194e-07

Thus O 0 2.2717115299997204e-08
, O 0 1.2594598974846605e-10
the O 0 4.8266474150793215e-11
occurrence O 0 1.3124299425015806e-09
of O 0 4.506457873532099e-09
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 5.388344652601518e-05
this O 0 1.8925693012761258e-08
patient O 0 5.438646422106785e-09
extends O 0 2.6064345126641797e-11
considerably O 0 5.416828097182247e-11
the O 0 6.023104931474066e-11
phenotypic O 0 3.822028915578812e-09
range O 0 1.7655496620250233e-08
of O 0 3.4262928050310393e-09
piebaldism B-Disease 0 8.895336804926046e-07
due O 0 1.5296740230041905e-07
to O 0 1.083919514144327e-07
KIT O 0 1.0809421837620903e-05
gene O 0 8.811010587805868e-08
mutation O 0 7.45146522262985e-09
in O 0 1.4359122779694644e-09
humans O 0 4.993229829608481e-09
and O 0 4.0156541980529425e-10
tightens O 0 5.1763585418029834e-08
the O 0 2.9750211183454667e-09
clinical O 0 9.301556858076765e-09
similarity O 0 2.2682669631457486e-10
between O 0 5.929567253870616e-11
piebaldism B-Disease 0 1.178202708729259e-07
and O 0 2.280113181596377e-10
the O 0 3.185642027947466e-10
various O 0 7.977035004769206e-11
forms O 0 8.283614905124637e-10
of O 0 5.179723761017385e-09
Waardenburg B-Disease 1 1.0
syndrome I-Disease 0 0.00012584839714691043
. O 0 1.0978722819743325e-08
. O 0 8.791169392452503e-08

Cycloheximide O 0 3.3295725643256446e-06
facilitates O 0 4.32094431346286e-08
the O 0 1.0587550836049786e-09
identification O 0 2.3016351491378373e-08
of O 0 1.8414993974147364e-08
aberrant O 0 6.611324465666257e-08
transcripts O 0 4.500884998037691e-08
resulting O 0 3.733847897535725e-09
from O 0 4.172705792004905e-10
a O 0 5.076804532322399e-10
novel O 0 8.554849606490222e-10
splice O 0 7.905161680810124e-08
- O 0 5.921438628320175e-08
site O 0 3.052785046975259e-08
mutation O 0 1.0434246799917446e-09
in O 0 6.096245730446981e-10
COL17A1 O 0 4.428602096595569e-06
in O 0 8.702111919944855e-09
a O 0 2.0734885808337822e-08
patient O 0 1.1421666812339026e-07
with O 0 1.010970862580507e-09
generalized O 0 0.0038300356827676296
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9997155070304871
. O 0 3.4474073800083715e-06

Patients O 0 1.0428409950691275e-05
with O 0 7.194942419630479e-09
generalized O 0 7.355527486652136e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 0 0.48131999373435974
often O 0 2.211151484132756e-09
show O 0 1.0400964534085233e-09
decreased O 0 6.719073741834336e-09
expression O 0 2.3499635570800592e-09
of O 0 2.2318629167017434e-09
type O 0 6.444859224075117e-08
XVII O 0 4.438926407601684e-05
collagen O 0 8.057493801061355e-07
, O 0 1.1550920220315675e-08
a O 0 2.007946875437483e-08
transmembrane O 0 1.0275678086202333e-08
hemidesmosomal O 0 4.343394621741936e-08
protein O 0 9.993166294464118e-10
encoded O 0 7.773443000402835e-10
by O 0 6.976567101801834e-10
COL17A1 O 0 2.950800262624398e-05
. O 0 6.872565450066759e-07

This O 0 1.7836308430219106e-08
report O 0 5.5805591259172616e-09
documents O 0 1.3447384539233553e-08
a O 0 3.893629862972148e-09
novel O 0 5.348642861946473e-09
splice O 0 3.858022523672844e-07
- O 0 1.1212893014089786e-07
site O 0 2.2674084831919572e-08
mutation O 0 1.1496448237835466e-09
in O 0 5.113129919465109e-10
COL17A1 O 0 1.8533972934164922e-06
in O 0 7.711526528453305e-09
a O 0 1.5630272187650007e-08
patient O 0 8.235132753497965e-08
with O 0 4.1010150830800285e-10
generalized O 0 0.00043895241105929017
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9048774242401123
, O 0 2.5769359979221917e-09
and O 0 6.458003576348403e-11
applies O 0 1.1768989116589523e-09
a O 0 9.668907341442434e-11
new O 0 8.967726561337486e-11
methodology O 0 1.2897927170740786e-09
to O 0 6.027843224565288e-10
define O 0 8.326610512199295e-09
and O 0 1.3711584090358997e-09
characterize O 0 4.36136744497162e-08
the O 0 1.4213051180433922e-08
resulting O 0 2.5447772777908995e-09
mRNA O 0 1.0404243688810766e-08
splice O 0 1.81425789946843e-07
variants O 0 1.7282177111610508e-07
. O 0 4.342128079315444e-07

Mutational O 0 2.275175393151585e-05
analysis O 0 7.210537944501993e-08
of O 0 9.797269662215058e-09
COL17A1 O 0 1.4524960533890408e-05
identified O 0 1.6311427941673173e-07
a O 0 3.7936327856868957e-08
maternally O 0 1.2437590157787781e-06
inherited O 0 3.022737018909538e-06
G O 0 3.3246037673961837e-06
- O 0 7.558120387329836e-07
to O 0 3.630053413417045e-07
- O 0 5.524671450984897e-06
T O 0 8.009396310626471e-07
transversion O 0 9.3284064917043e-08
at O 0 1.5785368567833302e-09
the O 0 1.1933176669032264e-10
- O 0 1.054400122768584e-09
1 O 0 1.1258062926344792e-08
position O 0 4.621377414082417e-08
of O 0 5.155309956705878e-09
exon O 0 1.7114098227466457e-07
32 O 0 7.258917094077333e-07
. O 0 5.09254050484742e-07

This O 0 1.0270309935833666e-08
acceptor O 0 1.0286266949321998e-08
splice O 0 3.1718948889647436e-07
- O 0 1.9288965802388702e-07
site O 0 4.129070774183674e-08
mutation O 0 1.9882884227939712e-09
led O 0 5.88207926810469e-10
to O 0 5.790775636782541e-10
the O 0 6.230145843666435e-10
formation O 0 3.3308236169204974e-09
of O 0 1.520304593327637e-08
aberrant O 0 6.611740843709413e-08
transcripts O 0 1.3660287834227347e-07
present O 0 3.0054216892949626e-08
at O 0 5.640924882754916e-06
extremely O 0 1.917460622280487e-06
low O 0 6.151878096716246e-06
levels O 0 5.951199568698939e-07
. O 0 1.3870126736037491e-07

Based O 0 1.0590990306980075e-08
on O 0 2.4830708156287074e-08
our O 0 7.807310353769026e-09
recent O 0 5.186374107957192e-10
finding O 0 1.2875853716565189e-09
that O 0 4.295128488984723e-11
cycloheximide O 0 2.2592284665279294e-07
stabilized O 0 1.3325653753781808e-06
mutant O 0 1.0866291688671481e-07
COL17A1 O 0 2.665288548087119e-06
transcripts O 0 8.457029565533958e-08
in O 0 9.568271508442194e-09
keratinocytes O 0 1.8587023760119337e-06
homozygous O 0 1.1318175729968516e-08
for O 0 6.83130108036778e-10
a O 0 4.583452284379064e-09
frameshift O 0 3.115312665613601e-07
mutation O 0 1.2659004955395403e-09
, O 0 7.077013974843283e-11
the O 0 4.356200122845877e-10
effects O 0 1.31349040088935e-07
of O 0 1.0178481346656554e-07
the O 0 1.309884734013167e-08
splice O 0 6.344493641563531e-08
- O 0 1.577607555702798e-08
site O 0 7.629451737045656e-09
mutation O 0 8.5776379055158e-11
on O 0 5.091835841852799e-10
splicing O 0 1.0966730634720534e-08
of O 0 3.644962731641499e-08
COL17A1 O 0 5.362258889363147e-06
transcripts O 0 9.39015478707006e-08
were O 0 3.236878098888951e-09
determined O 0 2.4421031863397502e-09
using O 0 8.042241872452394e-10
reverse O 0 4.956233645714292e-09
transcriptase O 0 3.3807865396084935e-09
polymerase O 0 8.206383905751125e-10
chain O 0 5.4872022481333715e-09
reaction O 0 7.167886284520364e-10
of O 0 1.0472588352072876e-09
total O 0 4.2343842321379555e-10
RNA O 0 3.3257940845743406e-10
from O 0 4.58324878049865e-10
keratinocytes O 0 3.9916113081517324e-08
incubated O 0 2.510356145180026e-09
for O 0 3.2230521029852355e-10
2 O 0 2.1221094215206904e-08
. O 0 6.805699825918055e-08

5 O 0 6.991425607338897e-07
h O 0 1.39644285468421e-07
in O 0 1.2602823229457272e-09
the O 0 5.443812067795761e-10
presence O 0 1.237892788275019e-09
or O 0 1.458046017255299e-09
absence O 0 1.0321016929992766e-07
of O 0 6.4385781151088395e-09
10 O 0 5.497135546761456e-08
microg O 0 1.3169237718102522e-06
cycloheximide O 0 1.7123352336056996e-06
per O 0 3.541090336511843e-07
ml O 0 9.168814358417876e-06
. O 0 2.918917516581132e-07

Using O 0 3.8963730020213916e-08
this O 0 5.376614709007299e-10
approach O 0 5.739668296200762e-09
, O 0 3.346372068335768e-10
an O 0 2.4076915461357373e-10
abnormally O 0 2.391382558641908e-08
spliced O 0 1.700404794746646e-08
transcript O 0 1.8730038675585092e-07
was O 0 1.4700242445542244e-07
identified O 0 1.2997110054868699e-08
that O 0 3.4180647895398764e-11
contains O 0 5.804636719203282e-12
an O 0 6.213605476500239e-13
extra O 0 1.3025759637574907e-10
264 O 0 3.076014998271148e-10
bases O 0 7.282263680963297e-10
upstream O 0 6.016839249056716e-10
from O 0 6.267750207733513e-10
exon O 0 8.10526046279847e-09
32 O 0 9.943604162288011e-09
, O 0 5.972153327427066e-11
resulting O 0 5.554229298709856e-11
in O 0 1.0753823526110651e-10
a O 0 8.567079823329493e-10
premature O 0 1.4190758790277869e-08
termination O 0 3.449586216675016e-08
codon O 0 2.0288129576329084e-07
27 O 0 1.0077429806187865e-06
bp O 0 4.0973060322357924e-07
downstream O 0 1.2567520357720241e-08
from O 0 1.0906361147533516e-08
the O 0 7.962226078461754e-08
cryptic O 0 3.9591517975168244e-07
splice O 0 3.852250358704623e-07
site O 0 2.6921836138171784e-07
. O 0 7.164175030993647e-08

Three O 0 3.014107505805441e-07
other O 0 7.050354744464471e-10
splice O 0 1.684230177545487e-08
variants O 0 5.970861138848704e-09
, O 0 1.0227898389336687e-10
including O 0 1.8082570163446832e-11
one O 0 5.197172553428331e-12
derived O 0 5.3445071285240786e-11
from O 0 4.3643897523759634e-11
the O 0 4.920823748477687e-10
skipping O 0 8.955907127017326e-09
of O 0 3.311199980871038e-09
exon O 0 2.8057776546575042e-08
32 O 0 1.6389689960760734e-07
, O 0 1.1164332791580023e-09
were O 0 3.1092615149219682e-09
also O 0 2.7822217862905063e-09
identified O 0 9.035433734538856e-09
. O 0 6.754849835033383e-08

These O 0 3.126616476833988e-08
results O 0 2.2774685248805326e-08
indicate O 0 1.5913611761675384e-08
the O 0 2.290990952502625e-09
usefulness O 0 1.8876075102980394e-07
of O 0 1.8538541812773701e-09
cycloheximide O 0 3.307994589363261e-08
treatment O 0 1.5137010533905482e-09
in O 0 3.3430022639002743e-11
evaluating O 0 5.787176293736707e-10
the O 0 3.204926768418659e-09
abnormal O 0 4.2265050126388815e-08
processing O 0 1.4565452488568553e-07
of O 0 1.3619535366160562e-07
mRNA O 0 3.4686074457113136e-08
due O 0 1.5980367606971413e-06
to O 0 6.277230824025537e-08
splice O 0 2.57212093401904e-07
- O 0 1.7537900021125097e-07
site O 0 1.4888872357232685e-08
mutations O 0 7.955083813904196e-10
, O 0 4.1845152343178427e-11
because O 0 4.15424847299839e-11
( O 0 1.3311431124041206e-10
i O 0 3.150808325358412e-08
) O 0 4.954095467191166e-10
aberrant O 0 7.484439734639636e-09
splicing O 0 1.5276878428949203e-08
often O 0 3.822799576891356e-10
generates O 0 9.076205065294829e-11
a O 0 9.291955399559626e-11
premature O 0 2.9746580754164142e-09
termination O 0 9.106317477858283e-09
codon O 0 2.4123918862528626e-08
, O 0 7.459580730895254e-10
( O 0 6.250281542330427e-11
ii O 0 3.214694004327612e-07
) O 0 1.0976748399116332e-09
transcripts O 0 7.14536980694902e-08
with O 0 1.8084099495663253e-10
premature O 0 4.101184174487571e-07
termination O 0 7.128422652158406e-08
codons O 0 1.3565370160506518e-08
can O 0 9.271547418698844e-10
occur O 0 1.0557100749153392e-09
at O 0 2.664703302457383e-08
low O 0 1.8525514633438434e-07
or O 0 2.699874324108009e-09
undetectable O 0 8.667594642020049e-08
levels O 0 2.875514493183573e-09
due O 0 2.195392756476622e-09
to O 0 4.510464890472576e-09
nonsense O 0 1.4159718730866189e-08
- O 0 6.182750311722884e-09
mediated O 0 2.810194743574357e-09
mRNA O 0 8.926961392319299e-10
decay O 0 1.0464127342402207e-08
, O 0 6.594576967833277e-11
and O 0 2.0459542046658008e-11
( O 0 1.182690057000002e-11
iii O 0 8.98258178949618e-08
) O 0 2.4334174675288978e-09
the O 0 1.324193288354536e-08
levels O 0 9.375086307272795e-08
of O 0 6.2947058676599e-10
these O 0 1.0249243120874496e-10
transcripts O 0 7.407112256885284e-09
can O 0 2.33268931948416e-10
be O 0 1.5584353252329208e-10
increased O 0 5.03710462229634e-10
by O 0 2.2394049115082026e-10
cycloheximide O 0 1.2077318842784734e-06
. O 0 2.3951812977429654e-07

A O 0 4.208367954561254e-06
deletion O 0 1.086431780095154e-06
mutation O 0 2.4201437298643214e-08
in O 0 4.6180619328595185e-09
COL17A1 O 0 4.514686224865727e-06
in O 0 8.919511351734855e-09
five O 0 4.185301882841941e-09
Austrian O 0 2.528811293700528e-08
families O 0 5.639094746712203e-10
with O 0 1.522029308143047e-10
generalized O 0 1.4928711607353762e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9453266859054565
represents O 0 5.967423000186045e-09
propagation O 0 4.164790112781702e-08
of O 0 4.164669054063097e-09
an O 0 7.008523206231132e-10
ancestral O 0 6.883487003506161e-06
allele O 0 2.214927690147306e-06
. O 0 5.208188440519734e-07

Patients O 0 8.496643204125576e-06
with O 0 8.40686364966814e-09
generalized O 0 0.00014282380288932472
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999884366989136
, O 0 1.7127772977687528e-08
a O 0 2.503274920684362e-09
usually O 0 2.1781280945543102e-10
nonlethal O 0 7.210317676253908e-07
form O 0 7.8518125334881e-09
of O 0 1.6844828678586055e-06
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999912977218628
, O 0 3.95763386507042e-08
have O 0 3.7135066133231476e-09
generalized O 0 2.363682796158173e-07
blistering B-Disease 0 9.088636261367355e-07
, O 0 8.536207296572229e-09
nail B-Disease 1 0.9999992847442627
dystrophy I-Disease 1 1.0
, O 0 1.6635520978525165e-06
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 7.496372234072624e-08
and O 0 3.740172189736768e-07
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.0012329508317634463

Skin B-Disease 1 1.0
fragility I-Disease 0 0.22812198102474213
in O 0 8.36593105901784e-09
most O 0 3.8436056420954046e-11
cases O 0 2.149959680772251e-12
is O 0 3.0516594026058774e-13
due O 0 4.4773237201090055e-11
to O 0 8.289557373863943e-10
mutations O 0 1.6943844938221986e-10
in O 0 1.0892344803892229e-09
the O 0 3.5020968347510006e-09
gene O 0 1.2492995526969253e-09
encoding O 0 3.249709479291596e-08
type O 0 4.2255605876562186e-06
XVII O 0 0.008161276578903198
collagen O 0 3.0185424293449614e-06
( O 0 4.152034271953653e-09
COL17A1 O 0 5.2259129006415606e-06
) O 0 2.8443836175284787e-09
. O 0 5.5990707181763355e-08

Recently O 0 1.1637806665021344e-06
, O 0 1.9522501393254288e-09
we O 0 3.6693750260496927e-09
reported O 0 2.0047428161973357e-09
five O 0 7.717526617767589e-10
Austrian O 0 3.250689317724209e-08
families O 0 2.0916641751966836e-09
with O 0 4.837156231118911e-10
generalized O 0 1.8351887774770148e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999527931213379
who O 0 7.575989968700014e-08
share O 0 2.4233679951635168e-08
the O 0 7.805151192030735e-09
same O 0 2.204860827248467e-08
COL17A1 O 0 5.893370689591393e-05
mutation O 0 7.83243052637772e-08
. O 0 1.065120187604407e-07

Affected O 0 1.6522504608929012e-07
individuals O 0 1.3367941475994627e-10
in O 0 4.635868910973784e-10
three O 0 7.357695008813891e-11
families O 0 1.0271215301893566e-11
are O 0 1.3199843778774478e-12
homozygous O 0 1.0958648571923746e-10
for O 0 1.879566502438479e-10
4003delTC O 0 1.9563589859217245e-08
, O 0 1.5615209125741103e-10
whereas O 0 1.3091346895421907e-09
those O 0 4.222955041210952e-10
in O 0 4.941667075542e-10
two O 0 1.2658926684672167e-10
others O 0 2.2665586074666066e-10
are O 0 4.6391217256580575e-11
compound O 0 6.743739788817038e-08
heterozygotes O 0 1.9434444311627885e-06
. O 0 2.1155548779461242e-07

To O 0 3.820747807026237e-08
determine O 0 3.201822806886412e-09
if O 0 1.6037192684947854e-09
the O 0 1.8308448090920137e-09
occurrence O 0 1.4228892730727694e-08
of O 0 1.935908988670576e-09
4003delTC O 0 5.2323933630304964e-08
in O 0 5.67801416995195e-10
these O 0 1.2767462087559522e-10
unrelated O 0 9.044170967698051e-10
families O 0 5.428701932430613e-11
signifies O 0 1.9238759474404787e-09
propagation O 0 1.0029222785590264e-08
of O 0 6.118984763325841e-10
an O 0 1.0589121246518118e-10
ancestral O 0 5.656227699546434e-07
allele O 0 2.1331602795271465e-07
or O 0 7.1284329550280745e-09
a O 0 2.582965485942168e-08
mutational O 0 5.4981628636596724e-05
hot O 0 5.7542070862837136e-05
spot O 0 9.72800080489833e-07
, O 0 1.258379955793032e-09
haplotypes O 0 2.2457420811861084e-08
were O 0 2.1636124003521218e-09
determined O 0 5.1973785275549744e-09
for O 0 3.931577285953836e-09
polymorphisms O 0 1.1550682899041931e-07
both O 0 1.3720145020101882e-08
within O 0 1.3231757911569275e-08
and O 0 6.5755307865345e-09
flanking O 0 8.950119081418961e-07
COL17A1 O 0 0.00013956498878542334
. O 0 1.0451809657752165e-06

Five O 0 4.1464974742666527e-07
intragenic O 0 9.686101520856027e-07
polymorphisms O 0 8.615034374770403e-08
were O 0 2.9877933460653594e-09
chosen O 0 1.5317864754393895e-09
based O 0 5.371592060043895e-10
on O 0 1.3746234373002153e-08
their O 0 1.7420939357748466e-08
informativeness O 0 6.680549631710164e-06
. O 0 3.682572753405111e-07

One O 0 4.01797954907579e-08
of O 0 1.5933437902404535e-09
these O 0 4.648838605736394e-11
, O 0 1.1115536442674046e-11
not O 0 2.96968873103598e-11
previously O 0 1.0176623432833765e-10
reported O 0 4.547466569970737e-11
, O 0 1.3415237670733049e-11
was O 0 1.6765052679446057e-09
2988 O 0 2.439158492961724e-07
A O 0 9.749569329642327e-08
or O 0 5.4383972880600595e-09
C O 0 6.476479370576271e-07
that O 0 1.7571550117723156e-11
introduces O 0 5.170284755884325e-10
a O 0 2.040180246964951e-10
new O 0 4.046747936747863e-10
restriction O 0 5.686882076361144e-09
site O 0 2.4362085682128054e-09
for O 0 2.9716964999870754e-10
Eco0109 O 0 8.778892492955492e-07
I O 0 1.7899719750857912e-06
. O 0 3.786090587709623e-07

All O 0 5.836700367467529e-08
the O 0 8.42649683363561e-09
4003delTC O 0 2.0366992714571097e-07
alleles O 0 9.997479288870181e-09
showed O 0 6.930442886243782e-09
the O 0 7.796860379549742e-10
same O 0 1.5892764881897392e-09
haplotype O 0 5.688176329954331e-08
for O 0 2.372468221878421e-09
these O 0 9.613451146250895e-10
five O 0 1.3033445434018631e-09
polymorphic O 0 9.753267526946274e-09
markers O 0 7.360526410593593e-08
. O 0 5.678381853613246e-07

Fourteen O 0 1.5977549310264294e-06
microsatellite O 0 2.687015410174354e-07
polymorphisms O 0 5.77400669499184e-08
were O 0 1.6168185679177327e-09
selected O 0 6.502974825295382e-10
based O 0 6.760834253549675e-11
on O 0 2.654541253477305e-09
their O 0 2.0260888522471987e-09
high O 0 2.90739254893424e-08
heterozygosity O 0 2.590431051885389e-07
and O 0 7.441320337697732e-10
their O 0 1.5576664402772167e-09
location O 0 2.8063986690085585e-08
within O 0 2.4187949421161647e-09
10q23 O 0 5.512664529305766e-07
- O 0 1.8189838613125175e-07
q25 O 0 4.500173872656887e-06
near O 0 9.158364377981343e-07
COL17A1 O 0 0.0001118458530982025
. O 0 7.856727961552679e-07

Three O 0 2.6392454444135183e-08
families O 0 8.2514767241193e-10
shared O 0 2.7589912576786446e-09
microsatellite O 0 4.8509090078141526e-08
polymorphisms O 0 2.599438744255167e-07
covering O 0 5.895068966310646e-08
at O 0 2.0735596351073582e-08
most O 0 9.685967583550337e-10
19 O 0 6.183802270243177e-08
cM O 0 2.6349297854721954e-08
, O 0 2.5653609792009036e-10
whereas O 0 3.326785513735331e-09
the O 0 2.790693454102211e-09
others O 0 2.0748207596454904e-09
shared O 0 4.809263542959741e-10
smaller O 0 6.064870827771074e-11
regions O 0 1.2422891881858078e-10
consistent O 0 1.8906922694128525e-09
with O 0 1.3826353256751744e-12
cross O 0 5.766384592043039e-10
- O 0 6.492879833785992e-08
over O 0 1.3003078613849084e-09
events O 0 2.8153063214020335e-10
during O 0 6.959383069826686e-10
passage O 0 8.483225233391067e-10
of O 0 3.151134214673945e-11
this O 0 5.740907315504584e-12
mutation O 0 7.279298691598157e-12
through O 0 1.1482280404262468e-11
several O 0 6.501929550317698e-11
generations O 0 6.770571214786969e-09
. O 0 6.323218570969402e-08

These O 0 5.642985101417253e-08
results O 0 2.4169377610405718e-08
indicate O 0 4.984523016560161e-09
that O 0 3.181553978603979e-11
4003delTC O 0 6.459760282240268e-09
occurs O 0 7.990831607518345e-11
on O 0 4.0582265325994626e-10
a O 0 3.391020797494093e-10
single O 0 4.505942285959463e-09
ancestral O 0 6.936177783245512e-07
allele O 0 1.368575510696246e-07
. O 0 1.4831561756523115e-08
. O 0 1.6446510642253998e-07

The O 0 1.0624382866808446e-06
haptoglobin O 0 2.6169644115725532e-05
- O 0 1.148128831118811e-06
gene O 0 1.987216435850314e-08
deletion O 0 2.7761378973423234e-08
responsible O 0 1.7450537015406553e-08
for O 0 1.4995292119124315e-08
anhaptoglobinemia B-Disease 0 7.038214971544221e-05
. O 0 9.458232170800329e-07

We O 0 2.84477664536098e-07
have O 0 9.83523484876514e-10
found O 0 7.811175317673502e-11
an O 0 3.0473699952349165e-11
allelic O 0 2.3486743216949435e-08
deletion O 0 6.739728064530937e-08
of O 0 1.4817062776728562e-07
the O 0 5.063861294729577e-07
haptoglobin O 0 0.00010277897672494873
( O 0 1.3630618855842158e-09
Hp O 0 2.606348736833297e-08
) O 0 3.991049504770139e-11
gene O 0 2.624434281006671e-10
from O 0 3.382345514779672e-10
an O 0 9.590040567220015e-11
individual O 0 3.6017088617112947e-11
with O 0 1.1404931860026224e-10
anhaptoglobinemia B-Disease 0 3.2468342396896333e-06
. O 0 2.3035902074752812e-07

The O 0 4.783068447977712e-07
Hp O 0 9.99426106318424e-08
gene O 0 1.6965456817175095e-09
cluster O 0 5.234364608419639e-10
consists O 0 2.2490533047037076e-10
of O 0 3.714737129012491e-10
coding O 0 1.0739183409214093e-07
regions O 0 2.0533226674501748e-08
of O 0 8.295763791466015e-07
the O 0 1.850488899890479e-07
alpha O 0 1.4851269725113525e-07
chain O 0 2.8047704159206432e-09
and O 0 3.295664782743124e-11
beta O 0 1.6859423856985245e-09
chain O 0 1.1666938526389004e-09
of O 0 2.776622265443507e-10
the O 0 1.0190263077802797e-09
haptoglobin O 0 2.4938600517998566e-07
gene O 0 1.4048930907506474e-09
( O 0 5.7311298068407623e-11
Hp O 0 6.516587269800311e-09
) O 0 2.2127230603352643e-11
and O 0 7.676709268267246e-11
of O 0 1.9198875822468153e-09
the O 0 1.883428746296545e-09
alpha O 0 1.8107378707554744e-08
chain O 0 1.2567178409028656e-09
and O 0 1.8959193590073475e-11
beta O 0 2.6754376492021947e-09
chain O 0 2.8187141509761204e-09
of O 0 4.877587223006685e-10
the O 0 1.3304914947553925e-09
haptoglobin O 0 1.4112690678302897e-06
- O 0 9.112783772025068e-08
related O 0 1.6837098826272268e-08
gene O 0 2.0580304127548743e-09
( O 0 7.233338233936237e-11
Hpr O 0 4.0308371751507366e-08
) O 0 9.403440526245532e-11
, O 0 3.73787702179218e-11
in O 0 5.0350276031840835e-11
tandem O 0 2.3462374265648123e-09
from O 0 5.088748866732828e-10
the O 0 6.482668624130383e-09
5 O 0 1.4653883795290312e-07
side O 0 3.9692075404218485e-08
. O 0 1.9811164975180873e-07

Southern O 0 1.3263743312563747e-05
blot O 0 1.4903192095516715e-05
and O 0 7.680231561835171e-09
PCR O 0 5.401237146429594e-08
analyses O 0 1.9261046091401113e-09
have O 0 1.6807755187642215e-10
indicated O 0 6.282495634835072e-10
that O 0 1.072248279748722e-11
the O 0 5.2961437319032356e-11
individual O 0 1.7873811805624307e-11
with O 0 5.610636955033499e-12
anhaptoglobinemia B-Disease 0 9.839764913976978e-08
was O 0 7.25382154342924e-09
homozygous O 0 1.4932407532697312e-09
for O 0 3.609137710913757e-10
the O 0 9.255539668018287e-10
gene O 0 2.099082019313414e-09
deletion O 0 1.1721168036160634e-08
and O 0 8.212568958221311e-10
that O 0 2.0777306264374573e-10
the O 0 5.550017112554428e-10
gene O 0 3.071155274536608e-10
deletion O 0 3.507906409794259e-09
was O 0 4.874836534440874e-09
included O 0 9.093260588954877e-10
at O 0 3.008654658742671e-09
least O 0 1.8281708091816284e-10
from O 0 3.696288761179112e-11
the O 0 2.827780787306722e-10
promoter O 0 3.890907152026557e-08
region O 0 1.6815378955925553e-07
of O 0 5.581253503805783e-07
Hp O 0 4.1222197069146205e-06
to O 0 1.534928912860778e-07
Hpr O 0 3.126700391931081e-07
alpha O 0 3.120188551974934e-08
but O 0 5.730039220885885e-10
not O 0 1.0080384305055645e-09
to O 0 4.7487143106650365e-09
Hpr O 0 7.72195036802259e-08
beta O 0 4.496740402260002e-08
( O 0 7.725803885527682e-10
Hpdel O 0 9.81958805823524e-07
) O 0 2.197927395641841e-09
. O 0 3.7658484330904685e-08

In O 0 2.599448123419279e-08
addition O 0 2.7839097693771464e-09
, O 0 8.603952966756978e-11
we O 0 2.5580515483625277e-10
found O 0 5.5372203350279037e-11
seven O 0 3.7078690812153425e-11
individuals O 0 2.5159509892125342e-12
with O 0 3.2484577094232803e-12
hypohaptoglobinemia B-Disease 0 4.4909462815212464e-08
in O 0 7.556789083373872e-10
three O 0 7.040380084477604e-11
families O 0 6.18084272999142e-12
, O 0 2.4693547987647557e-12
and O 0 1.0541918900319747e-11
the O 0 1.0720121457197251e-09
genotypes O 0 1.2615264388671221e-08
of O 0 6.660227480637104e-09
six O 0 1.8614018770790608e-08
of O 0 5.447585493811857e-09
the O 0 4.366858874504942e-09
seven O 0 1.9327167644078713e-10
individuals O 0 8.915020414598795e-13
were O 0 1.1257622611893225e-10
found O 0 1.0574629366599808e-10
to O 0 4.655738017333988e-09
be O 0 5.531517999202151e-08
Hp2 O 0 0.0014165194006636739
/ O 0 0.11899474263191223
Hpdel O 0 0.001376330736093223
. O 0 2.992083182107308e-06

The O 0 5.132080787006998e-07
phenotypes O 0 1.4601960174331907e-07
and O 0 4.977480649870358e-10
genotypes O 0 5.311769246674203e-09
in O 0 7.473109353561824e-10
one O 0 1.896752199748164e-10
of O 0 7.483361152971213e-11
these O 0 7.012233241981969e-12
three O 0 2.096605875023805e-12
families O 0 2.860827243503228e-12
showed O 0 1.221830830955284e-10
the O 0 1.4201412268377567e-10
father O 0 1.1759975215852592e-08
to O 0 2.826899248020709e-08
be O 0 2.6290862820133043e-08
hypohaptoglobinemic B-Disease 0 1.3497797226591501e-06
( O 0 1.1952271394832792e-09
Hp2 O 0 1.4768858136449126e-06
) O 0 2.962629863656474e-10
and O 0 4.12917700032267e-10
Hp2 O 0 2.0012537333968794e-06
/ O 0 4.981959591532359e-07
Hpdel O 0 1.4278257367550395e-06
, O 0 3.2270872085682356e-10
the O 0 6.340978853103252e-10
mother O 0 1.047626430050741e-09
to O 0 5.876651387737297e-10
be O 0 6.057783441537623e-11
Hp2 O 0 1.5882470449923858e-08
- O 0 8.830085107547347e-09
1 O 0 2.0835186020917718e-08
and O 0 1.233083080087738e-09
Hp1 O 0 1.4089990827415022e-06
/ O 0 1.6785418210929492e-07
Hp2 O 0 1.9597169398366532e-07
, O 0 3.909215312569714e-11
one O 0 1.6095614424616045e-11
of O 0 4.6663749253550435e-11
the O 0 6.677940145305428e-11
two O 0 5.651946358847804e-12
children O 0 2.8161264986614754e-11
to O 0 1.392460730054168e-10
be O 0 1.598347787457044e-09
hypohaptoglobinemic B-Disease 0 1.2661010941883433e-06
( O 0 2.3447432884182717e-09
Hp2 O 0 5.610569587588543e-06
) O 0 1.273891103714675e-09
and O 0 1.9967785203078847e-09
Hp2 O 0 1.412663004884962e-05
/ O 0 2.797223487505107e-06
Hpdel O 0 5.414013685367536e-06
, O 0 3.229291556383629e-10
and O 0 8.833343778658076e-11
the O 0 2.888034256187666e-10
other O 0 3.548109028805868e-11
child O 0 6.624989445924712e-10
to O 0 5.956116710947867e-10
be O 0 1.6087191578861848e-09
Hp1 O 0 9.423092706128955e-07
and O 0 8.065502932197433e-09
Hp1 O 0 3.205882239853963e-05
/ O 0 7.208610895759193e-06
Hpdel O 0 5.685003998223692e-06
, O 0 1.1993812609745191e-09
showing O 0 6.349962777818519e-09
an O 0 1.5819991150411994e-10
anomalous O 0 5.2883386558733037e-08
inheritance O 0 8.380338272218069e-07
of O 0 6.75280216455576e-06
Hp O 0 1.0226190170214977e-06
phenotypes O 0 8.772170545512381e-09
in O 0 7.117913480847449e-10
the O 0 1.472820976289313e-09
child O 0 1.390890691510549e-08
with O 0 4.0530975797814506e-10
Hp1 O 0 3.0229673939174972e-05
. O 0 7.438942475346266e-07

The O 0 8.445375897281338e-06
Hp2 O 0 0.0018882864387705922
/ O 0 5.8488265494816005e-05
Hpdel O 0 1.0743505299615208e-05
individuals O 0 1.667515125980401e-09
had O 0 5.4121347403679465e-09
an O 0 7.067638835289713e-11
extremely O 0 2.082341632458906e-09
low O 0 7.819220826377205e-08
level O 0 1.4238426615520439e-07
of O 0 2.456586756238721e-08
Hp O 0 9.447840909615479e-08
( O 0 9.502858916432544e-11
mean O 0 1.2301256679947414e-09
+ O 0 1.843283747859914e-09
/ O 0 4.965166056081216e-09
- O 0 1.861004328418403e-08
SD O 0 3.260640824009897e-07
= O 0 7.020048542472068e-08
0 O 0 4.3013059780605545e-09
. O 0 1.3304958523807642e-10
049 O 0 1.8700035298024886e-07
+ O 0 1.160987306292327e-08
/ O 0 1.4740638043519994e-08
- O 0 2.4550597998995727e-08
0 O 0 6.647143280247292e-09
. O 0 5.979086115104337e-10
043 O 0 1.5880463024586788e-06
mg O 0 1.251486878572905e-06
/ O 0 8.172995080713008e-08
ml O 0 4.453338320331568e-08
; O 0 3.7329823260323636e-11
n O 0 9.077421592174062e-10
= O 0 1.443491215447068e-09
6 O 0 3.418575422742265e-10
) O 0 2.221611132904866e-12
, O 0 1.3412059006803756e-12
compared O 0 4.055769175365098e-12
with O 0 8.334060980393077e-13
the O 0 9.310032605958085e-11
level O 0 1.4629042421887561e-09
( O 0 2.452686491405398e-12
1 O 0 2.9486155184166307e-10
. O 0 7.618392722230638e-11
64 O 0 5.191946872429298e-10
+ O 0 6.781423755874982e-10
/ O 0 3.6087541843699e-09
- O 0 8.143659968595784e-09
1 O 0 6.892372450550965e-09
. O 0 1.712142649878956e-09
07 O 0 8.050473638832045e-07
mg O 0 2.40858867073257e-06
/ O 0 2.2408455890854384e-07
ml O 0 1.3968890755222674e-07
) O 0 4.2560094337673604e-11
obtained O 0 5.882856424221927e-09
from O 0 7.291743320259059e-10
52 O 0 4.4301337709384825e-08
healthy O 0 3.640668921889301e-08
volunteers O 0 7.066271123790102e-09
having O 0 7.725305728456533e-09
phenotype O 0 8.149086028197416e-08
Hp2 O 0 3.0171265734679764e-06
, O 0 7.203658225485299e-10
whereas O 0 3.888961153108994e-09
the O 0 1.5042176393365025e-09
serum O 0 8.968966902500597e-09
Hp O 0 1.6284312565062464e-08
level O 0 1.6204314334800074e-08
of O 0 4.679907572580078e-10
an O 0 2.663322166973625e-11
individual O 0 3.771507411931552e-11
with O 0 3.809186993608549e-11
Hp1 O 0 1.2023790077364538e-05
/ O 0 8.140771569742355e-06
Hpdel O 0 5.2035193220945075e-06
was O 0 1.167467402751754e-07
0 O 0 3.7382824302767403e-07
. O 0 9.788195143300982e-08

50 O 0 9.690567821962759e-06
mg O 0 7.589216693304479e-05
/ O 0 5.0052840379066765e-06
ml O 0 3.126466708636144e-06
, O 0 5.19533416287743e-10
which O 0 1.4697326689017132e-11
was O 0 1.4113059332299116e-10
approximately O 0 4.485955010236076e-12
half O 0 4.3052908460516903e-11
the O 0 1.395049908925472e-10
level O 0 2.4668214138046096e-09
of O 0 4.809786458004339e-10
Hp O 0 1.7209506708582012e-08
in O 0 1.0699754415810503e-09
control O 0 4.590260971326643e-08
sera O 0 1.0824319929270132e-07
from O 0 1.7474433011699375e-10
the O 0 5.127349655964508e-10
Hp1 O 0 1.549746571072319e-07
phenotype O 0 2.34050612224479e-10
( O 0 5.576983102759114e-13
1 O 0 7.038634258771381e-11
. O 0 1.4574496123853642e-11
26 O 0 5.051440377101812e-10
+ O 0 9.690291902231252e-10
/ O 0 1.884456590772743e-09
- O 0 2.9836020321027945e-09
0 O 0 1.008142236358367e-09
. O 0 6.860310930445479e-11
33 O 0 4.4746646388205136e-09
mg O 0 9.29104686520077e-08
/ O 0 2.4958151101373005e-08
ml O 0 2.6751784787393262e-08
; O 0 3.436361611930394e-11
n O 0 5.734653307776227e-10
= O 0 2.418601097176065e-09
9 O 0 8.149436125926002e-10
) O 0 3.4677819643613716e-11
, O 0 7.133104523715517e-11
showing O 0 3.921975633147667e-09
a O 0 2.9905300458210604e-09
gene O 0 4.878129011842702e-09
- O 0 1.0392447080675993e-07
dosage O 0 1.0866950788113172e-06
effect O 0 1.3140366661446023e-07
. O 0 2.3415361738443607e-07

The O 0 6.131117515906226e-07
other O 0 1.0031862451853613e-08
allele O 0 8.550159691367298e-08
( O 0 2.283394723301413e-10
Hp2 O 0 4.0516570720683376e-07
) O 0 1.7781467964717024e-10
of O 0 2.7207994190980855e-10
individuals O 0 2.3785145727983625e-11
with O 0 5.973566086225901e-11
Hp2 O 0 0.00016643665730953217
/ O 0 6.908993236720562e-05
Hpdel O 0 1.4737153833266348e-05
was O 0 2.789790087831534e-08
found O 0 3.0467089962016303e-10
to O 0 2.1912582859329177e-10
have O 0 2.5845136794599988e-11
, O 0 1.1311554123927259e-11
in O 0 1.2352717460029083e-10
all O 0 6.722159495708979e-10
exons O 0 9.180785021101201e-09
, O 0 5.35798294620804e-10
no O 0 7.63364393918664e-09
mutation O 0 4.065718317569633e-10
, O 0 4.751255291979284e-11
by O 0 2.936244650197928e-11
DNA O 0 1.5294743249683052e-09
sequencing O 0 5.430978688991672e-08
. O 0 4.2680755996116204e-07

On O 0 4.0414303725810896e-07
the O 0 2.1355401891298698e-09
basis O 0 5.109954237525471e-09
of O 0 5.239468858775354e-10
the O 0 2.3066296095386463e-10
present O 0 4.6677103154868504e-11
study O 0 2.3212205768619043e-10
, O 0 3.9433942222721896e-11
the O 0 3.212299592991741e-10
mechanism O 0 4.277206855363147e-08
of O 0 1.4355103772345501e-08
anhaptoglobinemia B-Disease 0 2.9256449352033087e-07
and O 0 1.5913816930890334e-09
the O 0 7.616656638731456e-09
mechanism O 0 1.2557293871395814e-07
of O 0 6.816622821759211e-09
anomalous O 0 4.2804308009181113e-07
inheritance O 0 1.502680675002921e-06
of O 0 2.0940938156854827e-06
Hp O 0 1.425917957931233e-06
phenotypes O 0 6.189029022607428e-08
were O 0 2.067177318210156e-09
well O 0 3.440634666063147e-09
explained O 0 1.187524958368158e-07
. O 0 6.529603524541017e-08

However O 0 1.0554936835660556e-07
, O 0 1.4476049248202116e-09
the O 0 8.699336806472502e-10
mechanism O 0 6.051602241541332e-08
of O 0 1.457312848174297e-08
hypohaptoglobinemia B-Disease 0 1.484281074226601e-05
remains O 0 1.3872590898245107e-06
unknown O 0 1.322347998211626e-05

ATM O 0 8.659999002702534e-05
mutations O 0 1.2347504707577173e-07
and O 0 1.6008985248561203e-09
phenotypes O 0 1.9796735273303057e-07
in O 0 2.3062629850301164e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 5.449874151963741e-07
in O 0 7.843850013955489e-09
the O 0 2.911175522868348e-09
British O 0 2.56919303609493e-08
Isles O 0 2.777070733372966e-07
: O 0 7.260129719632857e-10
expression O 0 1.1283337597589593e-09
of O 0 1.476862521165856e-10
mutant O 0 8.62783566812908e-10
ATM O 0 6.427194421121385e-08
and O 0 3.8854297557122663e-10
the O 0 2.7276176872703672e-09
risk O 0 2.1521181281514146e-08
of O 0 1.6627417220860252e-09
leukemia B-Disease 1 0.8050355315208435
, O 0 8.975131038369e-08
lymphoma B-Disease 1 1.0
, O 0 2.0559461972879944e-06
and O 0 8.684887689014431e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 1 0.8366159796714783

We O 0 3.221408206854903e-08
report O 0 2.8123987583228427e-09
the O 0 3.260011982586519e-10
spectrum O 0 2.83913714760331e-09
of O 0 7.323703865580455e-10
59 O 0 2.304037671763126e-08
ATM O 0 3.137363933092274e-07
mutations O 0 1.5170247280593685e-09
observed O 0 1.0419549667517458e-09
in O 0 1.7781484729084696e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.003640142036601901
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 9.85652531815262e-11
patients O 0 3.0561256303407447e-10
in O 0 5.402362238116076e-11
the O 0 1.9339270185270152e-09
British O 0 2.403336054612737e-07
Isles O 0 1.1939110663661268e-05
. O 0 4.5651415803149575e-07

Of O 0 5.432741090771742e-06
51 O 0 4.085544333065627e-06
ATM O 0 5.729706572310533e-06
mutations O 0 1.113308023548143e-08
identified O 0 3.630085787520443e-09
in O 0 1.8923219935462754e-10
families O 0 5.743604897245902e-11
native O 0 2.903776108453826e-10
to O 0 1.2144986127893276e-09
the O 0 2.5261970293399827e-09
British O 0 3.0318833665887723e-08
Isles O 0 3.7369849792412424e-07
, O 0 4.724400315403443e-10
11 O 0 3.754873301176076e-09
were O 0 1.351046718944815e-09
founder O 0 1.6417356363263025e-08
mutations O 0 7.149562608610438e-10
, O 0 6.763284376987144e-11
and O 0 7.409647895251226e-11
2 O 0 3.42867423341886e-08
of O 0 5.704535954720313e-09
these O 0 3.6450145679545187e-10
11 O 0 8.230292891653335e-09
conferred O 0 1.1845366998386453e-07
a O 0 1.4090158373392114e-08
milder O 0 3.273330406727837e-08
clinical O 0 4.927109387153905e-09
phenotype O 0 9.138013679077517e-10
with O 0 1.5691663246553134e-11
respect O 0 5.6993050279174895e-09
to O 0 1.4128559655546269e-08
both O 0 9.111946752682343e-09
cerebellar B-Disease 0 0.0003838272823486477
degeneration I-Disease 1 0.9999996423721313
and O 0 1.1492815588098892e-08
cellular O 0 2.8179798050587124e-07
features O 0 1.0099310543409956e-07
. O 0 1.7526630813335942e-07

We O 0 1.1807894217952253e-08
report O 0 3.5602928938338607e-10
, O 0 1.7753253294533478e-12
in O 0 5.122593755430005e-12
two O 0 3.153545133360858e-11
A B-Disease 1 1.0
- I-Disease 1 0.9999949932098389
T I-Disease 1 1.0
families O 0 3.1502644937120294e-10
, O 0 1.5948319054270854e-11
an O 0 1.8048286823391102e-11
ATM O 0 1.5112156006580335e-06
mutation O 0 7.979630289867146e-09
( O 0 1.6926435253417083e-10
7271T O 0 7.328293349928572e-07
- O 0 3.5091375139018055e-06
- O 0 8.21027879283065e-06
> O 0 5.881322067580186e-06
G O 0 4.5275075422068767e-07
) O 0 5.93026808215491e-11
that O 0 1.8649023297845346e-12
may O 0 1.999856183432236e-11
be O 0 3.064611758807345e-11
associated O 0 2.537457188811487e-10
with O 0 4.487803358099729e-12
an O 0 6.367685025099323e-12
increased O 0 1.5027515343213338e-10
risk O 0 2.9530293765844817e-09
of O 0 1.3103164109296017e-09
breast B-Disease 0 6.173997917358065e-07
cancer I-Disease 0 1.0888740575865086e-07
in O 0 2.610996041596536e-08
both O 0 4.1972391784383944e-08
homozygotes O 0 1.06092261376034e-06
and O 0 3.396557035628689e-09
heterozygotes O 0 6.629115745226954e-08
( O 0 6.403960001177822e-11
relative O 0 7.814372260384062e-09
risk O 0 9.429379499437118e-10
12 O 0 1.1210739281342086e-10
. O 0 1.2715690479725428e-11
7 O 0 1.739994259786215e-09
; O 0 2.704305390732742e-10
P O 0 9.02078269859885e-08
= O 0 1.9437798925991956e-08
. O 0 1.700302537654963e-10
0025 O 0 4.106303208573081e-07
) O 0 8.282535768344701e-11
, O 0 1.0257393025236983e-11
although O 0 1.6758769719182887e-11
there O 0 3.690658022248439e-12
is O 0 4.0977169032084537e-13
a O 0 2.054642480459057e-12
less O 0 6.230106708304817e-11
severe O 0 1.3865445680494304e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 7.550913672105253e-09
in O 0 4.862907646008274e-11
terms O 0 2.3333165954930735e-10
of O 0 1.984739803062574e-11
the O 0 1.561814913508819e-11
degree O 0 4.1398409145188e-09
of O 0 4.465762870609069e-09
cerebellar B-Disease 0 1.1786430150095839e-05
degeneration I-Disease 0 0.020324448123574257
. O 0 2.4499991013726685e-07

This O 0 1.3953653343889982e-08
mutation O 0 1.5635541750214088e-09
( O 0 2.2281091902054406e-11
7271T O 0 5.7622674631829796e-08
- O 0 5.571553529648554e-08
- O 0 9.326858219083078e-08
> O 0 2.0321803617662226e-07
G O 0 7.659724587938399e-08
) O 0 3.3519281100735654e-11
also O 0 3.233764991894539e-11
allows O 0 2.490257479392799e-11
expression O 0 1.9157056496688085e-10
of O 0 6.386541295810844e-11
full O 0 6.542562602795954e-10
- O 0 1.7673816854468782e-09
length O 0 2.1933073413027415e-10
ATM O 0 1.898061015026542e-07
protein O 0 2.973500778935545e-09
at O 0 9.929673971953434e-09
a O 0 1.7694998799555606e-09
level O 0 2.147647393258012e-09
comparable O 0 1.3366648898838207e-09
with O 0 7.036161150247855e-12
that O 0 2.7391054702174955e-11
in O 0 2.1142573802812592e-10
unaffected O 0 1.7102310678751564e-08
individuals O 0 1.711606412158062e-10
. O 0 1.9749171187299908e-08

In O 0 7.3729027327829044e-09
addition O 0 1.0460531330025447e-09
, O 0 3.9665375151098914e-11
we O 0 3.613089688547788e-11
have O 0 1.1424253470310175e-12
studied O 0 7.522056588715742e-11
18 O 0 4.717220036809522e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.061228687149196e-07
, O 0 4.5042168779485525e-12
in O 0 4.2440018513389965e-12
15 O 0 1.9519624805397484e-10
families O 0 9.799460722048625e-12
, O 0 1.6334902180892286e-11
who O 0 7.675157037700941e-11
developed O 0 4.724691304858197e-09
leukemia B-Disease 1 1.0
, O 0 3.621132691478124e-07
lymphoma B-Disease 1 1.0
, O 0 4.0697614167584106e-07
preleukemic O 1 0.9997531771659851
T O 0 0.2835456430912018
- O 0 3.309796375106089e-05
cell O 0 1.4864413060422521e-05
proliferation O 1 0.9999912977218628
, O 0 2.7986585493522398e-08
or O 0 1.2141341585447663e-06
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.1677803996311695e-09
mostly O 0 2.737644555494967e-10
in O 0 3.2356542445377556e-10
childhood O 0 1.8060474360481749e-07
. O 0 9.984620419345447e-08

A O 0 9.796478479984216e-06
wide O 0 2.3394625259243185e-07
variety O 0 3.822278316079064e-08
of O 0 3.1211943252174024e-08
ATM O 0 2.4665159799042158e-05
mutation O 0 1.9768203074477242e-08
types O 0 6.71307853750136e-09
, O 0 9.76428160548437e-10
including O 0 1.308830155366536e-09
missense O 0 2.607781652841368e-07
mutations O 0 4.572738188102221e-09
and O 0 6.100130400810144e-10
in O 0 9.555177094000555e-09
- O 0 8.036589065341104e-07
frame O 0 1.1029241022697533e-06
deletions O 0 1.0735045918863761e-07
, O 0 6.095327020894103e-10
were O 0 7.608724206242812e-10
seen O 0 1.1362185636798472e-09
in O 0 1.9618798252629688e-10
these O 0 3.405896953356802e-10
patients O 0 2.1726647148057054e-09
. O 0 1.7860957157722623e-08

We O 0 5.223648713581497e-08
also O 0 5.520529589020384e-10
show O 0 5.735634883707874e-11
that O 0 5.531472090265777e-13
25 O 0 6.420593223754878e-11
% O 0 1.4105677563491792e-11
of O 0 5.023746349475111e-11
all O 0 4.92323681822171e-10
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.8383195045717e-08
carried O 0 4.560506972062228e-10
in O 0 4.864728619935477e-10
- O 0 1.2817841366086213e-07
frame O 0 8.84785663401999e-07
deletions O 0 1.3882530538467108e-06
or O 0 5.106410227995184e-08
missense O 0 2.3942811822053045e-07
mutations O 0 3.280547611339557e-09
, O 0 9.06406061318421e-11
many O 0 2.1274640035762182e-11
of O 0 3.954104058068175e-11
which O 0 3.3557707394132885e-12
were O 0 3.409255516784171e-11
also O 0 1.1530519594682431e-11
associated O 0 9.537942657900089e-11
with O 0 1.97043666105845e-11
expression O 0 5.3860429005681e-08
of O 0 1.972748542300451e-08
mutant O 0 2.5426388106097875e-08
ATM O 0 7.379397857221193e-07
protein O 0 8.149909547228162e-08
. O 0 2.0916856158237351e-07

The O 0 1.1124567436127109e-06
DMPK O 0 4.793614425580017e-05
gene O 0 2.4368611661884643e-07
of O 0 6.606370561712538e-08
severely O 0 0.0001135678612627089
affected O 0 4.295042799640214e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 5.738557592849247e-05
is O 0 8.171533588674507e-11
hypermethylated O 0 4.137551634642023e-09
proximal O 0 1.3777181173679764e-08
to O 0 3.1936881583760623e-08
the O 0 1.7055661771792074e-08
largely O 0 1.3523004049886822e-08
expanded O 0 1.8318166539188496e-08
CTG O 0 3.858070158457849e-06
repeat O 0 4.1386158500245074e-07
. O 0 5.643403824251436e-07

Using O 0 5.478169100570085e-07
methylation O 0 1.2482823876780458e-05
- O 0 2.9890548830735497e-05
sensitive O 0 2.162456075893715e-05
restriction O 0 8.855453756950737e-07
enzymes O 0 1.0393408356179634e-09
, O 0 3.724525896031672e-11
we O 0 1.1121119997126172e-10
characterized O 0 1.6374558653442506e-10
the O 0 5.768856919941001e-11
methylation O 0 8.238738580246263e-10
pattern O 0 3.121637948133582e-10
on O 0 2.2975503721767154e-09
the O 0 3.7987193945987485e-10
5 O 0 4.471882864010013e-09
side O 0 9.010389101504757e-10
of O 0 7.65714713857335e-10
the O 0 1.1696706936348278e-09
CTG O 0 5.39576376468176e-07
repeat O 0 2.97704918494901e-08
in O 0 8.25127699499717e-09
the O 0 1.2914081359838292e-08
DMPK O 0 2.352627689106157e-06
gene O 0 1.774915858732129e-08
of O 0 4.575486212132773e-09
normal O 0 8.15549228150303e-08
individuals O 0 5.001908262580734e-11
and O 0 1.025008411481565e-10
of O 0 4.2231729224795345e-10
patients O 0 5.469268926638904e-10
affected O 0 3.38612804462457e-10
with O 0 6.593071644189763e-10
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.944291483368943e-08
showing O 0 7.155950942916434e-09
expansions O 0 1.7068613189508142e-08
of O 0 1.2009774508214832e-08
the O 0 5.930477886550989e-09
repetitive O 0 5.682523784855675e-09
sequence O 0 4.62063454165218e-09
. O 0 1.8464362483427976e-07

The O 0 2.188821639492744e-07
gene O 0 4.049004687090019e-09
segment O 0 4.8176387323906056e-09
analyzed O 0 3.126763958860579e-09
corresponds O 0 1.1613321415637756e-09
to O 0 2.751644245790885e-09
the O 0 2.263799148138901e-09
genomic O 0 3.4340672527832794e-08
SacI O 0 2.3351678919425467e-06
- O 0 7.47565422898333e-08
HindIII O 0 2.564738110777398e-07
fragment O 0 2.049115765956344e-09
carrying O 0 2.812209631830598e-10
exons O 0 1.6766075194851737e-09
11 O 0 1.2484330014217448e-08
- O 0 2.0904812458866218e-07
15 O 0 5.708238859369885e-07
. O 0 2.926744571141171e-07

There O 0 1.8648561805889585e-08
is O 0 2.145860988900239e-10
constitutive O 0 2.3752269484589306e-08
methylation O 0 1.6896267140964483e-07
in O 0 6.985401057590934e-08
intron O 0 4.147816525801318e-06
12 O 0 3.576734286525607e-07
at O 0 7.300531734699689e-08
restriction O 0 1.105125022604625e-07
sites O 0 7.551792080562336e-09
of O 0 8.137894802473511e-10
SacII O 0 2.1850715370419493e-07
and O 0 9.376616150191808e-10
HhaI O 0 8.464321012979781e-07
, O 0 1.2975992502717304e-10
localized O 0 1.460893850335765e-09
1 O 0 3.337921050672321e-09
, O 0 4.4450575165111417e-11
159 O 0 6.361233206853001e-10
- O 0 8.185175204289408e-09
1 O 0 8.003717510973729e-08
, O 0 2.440101010137141e-09
232 O 0 1.4375763690566146e-08
bp O 0 3.197814635313989e-08
upstream O 0 8.192359679526362e-09
of O 0 4.963470967567218e-09
the O 0 3.3475373584224144e-08
CTG O 0 1.147165494330693e-05
repeat O 0 3.0356073921211646e-07
, O 0 6.122721218915217e-10
whereas O 0 2.254057385187025e-09
most O 0 5.4447234915100395e-11
, O 0 1.904072385872091e-12
if O 0 4.0241763914206086e-12
not O 0 1.540833606539227e-11
all O 0 1.2466821845691367e-11
, O 0 2.1089158197540314e-11
of O 0 2.065394799632969e-10
the O 0 3.323194497362181e-10
other O 0 4.502793277127992e-11
sites O 0 2.3970438967069185e-09
of O 0 7.072200047808508e-10
SacII O 0 4.568686904349306e-07
, O 0 6.781734618321877e-10
HhaI O 0 2.9886552965763258e-06
, O 0 9.06873409700637e-10
and O 0 3.432348016918496e-10
HpaII O 0 5.986931910229032e-07
in O 0 8.33808078137821e-10
this O 0 3.852150265437615e-10
region O 0 2.4074999771528383e-09
are O 0 1.2919784686538094e-10
unmethylated O 0 3.1534241884401126e-07
, O 0 1.6973215888338444e-10
in O 0 1.811123057082753e-10
normal O 0 5.247592582691141e-09
individuals O 0 1.3400354610670906e-11
and O 0 3.3094537527089685e-11
most O 0 1.7177483047081665e-10
of O 0 1.4717418950205285e-10
the O 0 3.417662541860267e-10
patients O 0 7.179242755839255e-10
. O 0 6.457210321997309e-09

In O 0 1.8181300021069546e-08
a O 0 2.585586189596256e-09
number O 0 3.7942585184858046e-10
of O 0 1.6988309370358223e-10
young O 0 6.053212930900997e-10
and O 0 3.8217279341168364e-10
severely O 0 2.767199021036504e-07
affected O 0 2.5307498319193655e-09
patients O 0 1.4587804297860885e-09
, O 0 2.0601373038053872e-11
however O 0 2.5675150894244325e-10
, O 0 1.0706301817320352e-10
complete O 0 8.285356400961064e-09
methylation O 0 6.293151244562978e-08
of O 0 1.1969662594424335e-08
these O 0 9.70434843594603e-10
restriction O 0 9.709870241181306e-09
sites O 0 4.906307027319201e-10
was O 0 6.030764221343077e-10
found O 0 9.979485293687418e-11
in O 0 2.2492377405036734e-10
the O 0 2.395028619872619e-09
mutated O 0 3.74302651096059e-08
allele O 0 2.903475433413405e-07
. O 0 2.412995456779754e-07

In O 0 6.090579773854188e-08
most O 0 2.4911626095303063e-09
of O 0 1.238314867313406e-10
these O 0 3.599687822125608e-12
patients O 0 9.574190398820015e-12
, O 0 7.696376088522916e-13
the O 0 1.3479617595735238e-11
onset O 0 2.457630330354732e-07
of O 0 4.9124708745296175e-09
the O 0 9.005822754204473e-09
disease O 0 3.8835519688973363e-08
was O 0 9.728764638339271e-08
congenital O 1 0.9999979734420776
. O 0 3.831137655652128e-05

Preliminary O 0 9.367915367874957e-07
in O 0 5.337201400834601e-07
vivo O 0 0.0013735153479501605
footprinting O 0 0.0014251968823373318
data O 0 1.7590497236597002e-07
gave O 0 1.3501251672209946e-08
evidence O 0 4.215111371053126e-09
for O 0 2.607231097684348e-10
protein O 0 9.540094270121813e-10
- O 0 1.2126128545730808e-08
DNA O 0 3.2352566847748676e-08
contact O 0 3.9957865283213323e-07
in O 0 7.458460515863408e-09
normal O 0 2.444672873025411e-07
genes O 0 3.7355576409936475e-09
at O 0 1.8637786425301783e-08
an O 0 4.5810991111672195e-10
Sp1 O 0 6.166570898358259e-08
consensus O 0 2.3153065242809134e-08
binding O 0 1.5005324760508643e-09
site O 0 1.1977884462055499e-08
upstream O 0 1.6512375911048593e-09
of O 0 2.019044931245162e-09
the O 0 4.7381374379540375e-09
CTG O 0 1.471905420658004e-06
repeat O 0 3.451929231346185e-08
and O 0 4.090391081401634e-10
for O 0 1.7800945439905291e-10
a O 0 5.6956914878947273e-11
significant O 0 5.133962352465993e-11
reduction O 0 5.477100994966122e-09
of O 0 2.3821491446085474e-09
this O 0 2.1100353408964878e-10
interaction O 0 6.250105433203146e-10
in O 0 3.6800548719462256e-10
cells O 0 8.259948836020214e-10
with O 0 7.612829117098485e-11
a O 0 6.533724672408425e-09
hypermethylated O 0 2.5706884798637475e-07
DMPK O 0 9.051458391695633e-07
gene O 0 5.981142248145943e-09
. O 0 2.2703424917835946e-08
. O 0 3.567288047179318e-07

The O 0 4.204660945106298e-05
hemochromatosis B-Disease 1 1.0
gene O 0 1.769096655834801e-07
product O 0 3.554804894889685e-09
complexes O 0 1.4252189428631823e-09
with O 0 7.083050118650291e-11
the O 0 4.572973555383442e-09
transferrin O 0 1.8709775417846686e-07
receptor O 0 7.900727183596246e-09
and O 0 1.9059935851828413e-09
lowers O 0 1.7939763097274408e-07
its O 0 1.293821161318931e-09
affinity O 0 1.2910331692594923e-09
for O 0 4.892402039047283e-10
ligand O 0 7.976647786733793e-09
binding O 0 7.618054809199748e-08
. O 0 4.1138682149721717e-07

We O 0 2.983808542467159e-07
recently O 0 6.03405965193815e-08
reported O 0 9.066836170745773e-09
the O 0 1.0658751659065047e-09
positional O 0 1.3559839828758413e-07
cloning O 0 8.963771591652403e-08
of O 0 1.3503897999811443e-09
a O 0 9.614807838786987e-10
candidate O 0 4.659628682901484e-09
gene O 0 4.149566379396674e-08
for O 0 4.182800694252364e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.999860405921936
HFE O 0 0.03475911170244217
. O 0 7.616324637638172e-07

The O 0 1.1194259030844478e-07
gene O 0 4.4774797758329044e-10
product O 0 2.892422412692497e-10
, O 0 2.994962264302181e-11
a O 0 1.5488105242766892e-10
member O 0 5.861136576079673e-10
of O 0 1.6025122562268734e-08
the O 0 1.719558753165984e-07
major O 0 1.8871268991915713e-07
histocompatibility O 0 5.0790217756002676e-06
complex O 0 1.4905886018823367e-06
class O 0 3.538929149726755e-08
I O 0 1.5945688858209905e-07
- O 0 2.0336242911866975e-08
like O 0 4.851199997268907e-10
family O 0 4.779689422029776e-10
, O 0 1.3714603237791057e-11
was O 0 2.063418186315502e-10
found O 0 2.98030003453853e-11
to O 0 2.789914965717344e-10
have O 0 3.350089095022213e-10
a O 0 1.730079635109405e-09
mutation O 0 6.715726863504301e-10
, O 0 1.1155068535551038e-10
Cys O 0 9.543630312691675e-07
- O 0 8.179324595403159e-07
282 O 0 1.5660733652111958e-06
- O 0 0.00022927988902665675
- O 0 3.209090937161818e-05
> O 0 7.624458703503478e-06
Tyr O 0 9.94997208181303e-06
( O 0 1.1611117449461528e-11
C282Y O 0 4.987109392118327e-09
) O 0 1.7178711795087787e-12
, O 0 1.0895570470154103e-12
in O 0 7.101241036172601e-12
85 O 0 4.52387149962874e-09
% O 0 3.0389377125850103e-10
of O 0 1.3281512556417852e-09
patient O 0 1.8230855047818295e-08
chromosomes O 0 6.021643628173479e-08
. O 0 4.743570514165185e-07

This O 0 6.854212841744811e-08
mutation O 0 1.3580748969843626e-08
eliminates O 0 9.23810503650202e-08
the O 0 4.797117370003434e-09
ability O 0 1.2464060006323052e-08
of O 0 1.9483453073121382e-08
HFE O 0 0.00011288980749668553
to O 0 1.6811050329579302e-07
associate O 0 2.617738630306121e-07
with O 0 5.324059526579106e-10
beta2 O 0 6.95835187798366e-05
- O 0 2.1130610548425466e-05
microglobulin O 0 0.00012147480447310954
( O 0 2.063080817293894e-09
beta2m O 0 1.5186576547421282e-06
) O 0 4.3139075645015623e-10
and O 0 1.5737769420987036e-10
prevents O 0 9.432437053646936e-10
cell O 0 4.541336906527249e-08
- O 0 4.3642762648232747e-07
surface O 0 1.394570432466935e-07
expression O 0 1.4618948398492648e-06
. O 0 2.798221601096884e-07

A O 0 1.4832186025159899e-05
second O 0 8.917454579204787e-07
mutation O 0 5.961461990722228e-09
that O 0 3.130687376007302e-11
has O 0 1.603176272291229e-11
no O 0 2.8359571635494518e-11
effect O 0 4.206435477716042e-10
on O 0 9.255932909013609e-09
beta2m O 0 5.688853548235784e-07
association O 0 2.9054507688641706e-09
, O 0 2.1265318672636369e-10
H63D O 0 4.356545844075299e-07
, O 0 6.295339249895449e-11
was O 0 4.2186001913968596e-10
found O 0 2.2208283823044184e-11
in O 0 4.073890183531326e-11
eight O 0 2.1084785306602072e-10
out O 0 2.4214697955105002e-11
of O 0 1.0748409801086822e-10
nine O 0 5.884323583948969e-10
patients O 0 8.022795622286694e-11
heterozygous O 0 1.5539830533484178e-10
for O 0 1.7099821558730355e-09
the O 0 3.3526877274425715e-08
C282Y O 0 4.779968094226206e-06
mutant O 0 4.152971939674899e-07
. O 0 8.612887540948577e-07

In O 0 1.2384152370259471e-08
this O 0 3.389326597158515e-10
report O 0 4.826447019823377e-10
, O 0 1.5973160294446842e-11
we O 0 1.3615256144738908e-10
demonstrate O 0 3.3341669425368536e-09
in O 0 3.026052519672362e-09
cultured O 0 2.3728100586595247e-06
293 O 0 2.229613613735637e-07
cells O 0 4.5830964268134267e-07
overexpressing O 0 1.3148407560947817e-05
wild O 0 6.644356176366273e-07
- O 0 4.310358860948327e-07
type O 0 3.0830847208562773e-07
or O 0 8.549898922183274e-08
mutant O 0 1.2864254017586063e-07
HFE O 0 8.480044471070869e-07
proteins O 0 8.748985563800105e-11
that O 0 1.8843145793701055e-11
both O 0 7.680370922580337e-11
the O 0 2.43206277339425e-09
wild O 0 8.005579843484156e-08
- O 0 7.893139297721063e-08
type O 0 1.1758286433405374e-07
and O 0 3.658551506191543e-08
H63D O 0 0.0001269058557227254
HFE O 0 3.6634439311455935e-05
proteins O 0 3.0664975003702466e-09
form O 0 1.5710844847305339e-09
stable O 0 8.615872104655864e-08
complexes O 0 1.773950542016678e-09
with O 0 1.1970563429386516e-10
the O 0 4.850018164859193e-09
transferrin O 0 1.6784554190962808e-07
receptor O 0 7.431083304254571e-09
( O 0 2.2010854250353873e-10
TfR O 0 9.887850183076807e-07
) O 0 1.4669782055776182e-09
. O 0 2.6995770951998566e-08

The O 0 1.1493382316984935e-06
C282Y O 0 1.955115112650674e-05
mutation O 0 1.933983462265587e-08
nearly O 0 1.4783033686072145e-09
completely O 0 1.429370621863768e-09
prevents O 0 2.1207315070714827e-10
the O 0 2.0363469244166765e-10
association O 0 4.4838552315518143e-10
of O 0 1.526795689876792e-09
the O 0 5.21356247062954e-09
mutant O 0 3.148681670950282e-08
HFE O 0 2.3462264380214037e-06
protein O 0 5.870638641880532e-09
with O 0 9.60637056013347e-11
the O 0 3.317193986163147e-08
TfR O 0 3.990225013694726e-05
. O 0 3.941693762499199e-07

Studies O 0 5.081421932118246e-07
on O 0 4.644387630037272e-08
cell O 0 2.443614199876265e-08
- O 0 5.186498697185016e-08
associated O 0 1.2631298673682068e-08
transferrin O 0 1.1956342405028408e-07
at O 0 1.5217434423675513e-08
37 O 0 1.5823268029180326e-08
degrees O 0 1.2733833898437297e-07
C O 0 1.8992598427303164e-07
suggest O 0 8.464735024027448e-10
that O 0 4.280954757351907e-11
the O 0 1.68267533240396e-09
overexpressed O 0 1.076640387509542e-06
wild O 0 7.076685619722412e-07
- O 0 4.207467156902567e-07
type O 0 2.568816341863567e-07
HFE O 0 1.7549893527757376e-05
protein O 0 6.2082392560114386e-09
decreases O 0 2.702738921556147e-09
the O 0 2.6911328721013206e-10
affinity O 0 3.897991263102085e-09
of O 0 5.472214681390142e-09
the O 0 1.1011416667372487e-08
TfR O 0 2.7067337668995606e-06
for O 0 7.354868269970893e-09
transferrin O 0 1.6115811831696192e-06
. O 0 4.0541073076383327e-07

The O 0 2.1883048248128034e-05
overexpressed O 0 0.0007026734529063106
H63D O 0 0.00016887852689251304
protein O 0 5.617897969045771e-08
does O 0 5.906903854935308e-10
not O 0 1.6008855352467322e-10
have O 0 1.19118864078116e-11
this O 0 4.267631387167015e-12
effect O 0 1.661168702593585e-10
, O 0 2.54695986523501e-11
providing O 0 1.4737370213069312e-09
the O 0 2.2262836019137922e-10
first O 0 2.986823011141837e-10
direct O 0 6.981306088782446e-10
evidence O 0 6.541539532278762e-10
for O 0 1.0349310991530913e-10
a O 0 2.5774901657449334e-10
functional O 0 7.712261940184817e-09
consequence O 0 1.9210608215303182e-08
of O 0 2.1965904650755874e-09
the O 0 7.726720596679115e-09
H63D O 0 1.0911211575148627e-05
mutation O 0 3.1458242233384226e-08
. O 0 6.001451424708648e-08

Addition O 0 8.565696703044523e-07
of O 0 2.1057240928712417e-07
soluble O 0 1.2957452781847678e-06
wild O 0 2.1948750372757786e-07
- O 0 1.1120754095372831e-07
type O 0 5.842837254022015e-07
HFE O 1 1.0
/ O 1 1.0
beta2m O 1 0.9562139511108398
heterodimers O 0 8.542043360648677e-05
to O 0 1.5352071613961016e-07
cultured O 0 3.1809221923140285e-07
cells O 0 1.606417221466927e-08
also O 0 2.5801313863205166e-10
decreased O 0 9.13656705847643e-10
the O 0 9.079408058720873e-11
apparent O 0 3.555949423805771e-10
affinity O 0 1.4825642935534233e-09
of O 0 4.0058187877889395e-09
the O 0 2.841352708671252e-09
TfR O 0 1.2727787179755978e-07
for O 0 1.2791299963677005e-10
its O 0 1.3725150356524995e-11
ligand O 0 4.019945487598875e-10
under O 0 6.956078490993889e-10
steady O 0 1.5057253222039435e-08
- O 0 1.7330983315133608e-09
state O 0 7.226802489768147e-11
conditions O 0 1.5864880964500117e-08
, O 0 7.687522840527095e-11
both O 0 3.37277705764194e-11
in O 0 2.3719015640466523e-10
293 O 0 1.1679898159755453e-09
cells O 0 7.076342845024897e-10
and O 0 5.300310190747837e-10
in O 0 9.288013025354758e-09
HeLa O 0 1.077666638593655e-06
cells O 0 8.799607087439654e-08
. O 0 1.5778037720792781e-07

Furthermore O 0 1.0945147721486137e-07
, O 0 3.295842487816003e-10
at O 0 1.2345092725851714e-09
4 O 0 2.10467145933535e-08
degrees O 0 1.911836761792074e-06
C O 0 3.917666617780924e-06
, O 0 1.2301419882732034e-09
the O 0 9.011527524194207e-09
added O 0 9.861955163614766e-08
soluble O 0 1.2759251433180907e-07
complex O 0 7.261576939754377e-08
of O 0 5.7737093328569244e-08
HFE O 0 0.0071046240627765656
/ O 0 7.193397323135287e-05
beta2m O 0 4.240784164721845e-06
inhibited O 0 2.0033799330576585e-07
binding O 0 2.1029020302876233e-08
of O 0 2.763616890888443e-08
transferrin O 0 1.7069140767489444e-06
to O 0 1.805806277843658e-07
HeLa O 0 6.087907422624994e-06
cell O 0 1.8668033874291723e-07
TfR O 0 8.622100153843348e-07
in O 0 1.6693385562760454e-09
a O 0 2.601266757551457e-09
concentration O 0 1.435552121620276e-07
- O 0 4.8012303466293815e-08
dependent O 0 2.7165032889797658e-08
manner O 0 1.5889992255324614e-07
. O 0 4.5176480512054695e-07

Scatchard O 0 0.0005418781074695289
plots O 0 9.233804121322464e-07
of O 0 1.0651486093138374e-07
these O 0 4.614575388472986e-09
data O 0 1.2156743167679451e-08
indicate O 0 1.024894036305568e-08
that O 0 3.4309211027760966e-10
the O 0 6.0527316492198224e-09
added O 0 3.7403502517463494e-08
heterodimer O 0 1.031282792496313e-08
substantially O 0 2.0273654754987547e-08
reduced O 0 4.70009986486275e-09
the O 0 9.07601938049396e-10
affinity O 0 8.068488099866045e-09
of O 0 8.343620905293392e-09
TfR O 0 1.0905155249929521e-06
for O 0 2.7411046765735136e-09
transferrin O 0 9.38239963943488e-07
. O 0 6.54802420285705e-07

These O 0 7.263516010880267e-08
results O 0 3.777243406943853e-08
establish O 0 1.993414429080076e-07
a O 0 4.856072433057079e-09
molecular O 0 8.201271661789633e-09
link O 0 2.8277677088794917e-08
between O 0 1.1037969427363237e-09
HFE O 0 0.05605597048997879
and O 0 4.0376388454888e-08
a O 0 1.0290529672829507e-07
key O 0 3.353586919274676e-07
protein O 0 3.0619271562670747e-09
involved O 0 4.897126038017063e-10
in O 0 1.950694494823324e-09
iron O 0 2.8483052574301837e-06
transport O 0 1.295956337798998e-07
, O 0 7.047235017765274e-10
the O 0 3.0324600608366836e-09
TfR O 0 6.703305643895874e-07
, O 0 8.149524804990094e-11
and O 0 1.7238523108975556e-11
raise O 0 3.0059015276862056e-09
the O 0 1.1405459909852311e-09
possibility O 0 2.5057542707429548e-09
that O 0 2.8025002457576775e-11
alterations O 0 4.639896022951007e-09
in O 0 1.5718578660894877e-09
this O 0 2.023280432084107e-10
regulatory O 0 4.5022113814852105e-10
mechanism O 0 5.6530975456325905e-09
may O 0 1.056935206023013e-09
play O 0 1.7689533171605376e-09
a O 0 1.636712709807142e-10
role O 0 3.976485529744167e-10
in O 0 4.87882456656763e-10
the O 0 1.5837964273401894e-09
pathogenesis O 0 0.0008650915115140378
of O 0 2.639130229908915e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 3.7636909837601706e-06
. O 0 4.5263075065804514e-08

Genomic O 0 4.1164778963320714e-07
organization O 0 4.14912300072956e-08
of O 0 7.998342432813388e-09
the O 0 3.14599226669543e-08
UBE3A O 0 0.40123772621154785
/ O 0 0.000402363803004846
E6 O 0 1.4547889804816805e-05
- O 0 5.125193274579942e-05
AP O 0 0.000475717504741624
gene O 0 3.2393380422490736e-08
and O 0 1.7196439827671384e-09
related O 0 2.3085025446789587e-08
pseudogenes O 0 1.8817081581801176e-06
. O 0 7.68568497733213e-07

The O 0 3.2915747283368546e-07
UBE3A O 0 4.25467851528083e-06
gene O 0 7.683719438489334e-09
encodes O 0 1.0118602622455342e-09
the O 0 1.2776237845457672e-09
E6 O 0 8.494681225101886e-08
- O 0 4.599744443112286e-07
AP O 0 2.0190273062326014e-05
ubiquitin O 0 3.0856494248610034e-08
- O 0 1.2066533550125769e-08
protein O 0 2.651665553798921e-10
ligase O 0 1.0059391097883008e-09
and O 0 2.0543859668986642e-10
has O 0 7.153051068131688e-11
recently O 0 6.186507556238396e-11
been O 0 4.5350372762653635e-11
shown O 0 7.465127821459916e-11
to O 0 2.369147933389826e-10
be O 0 3.322452868381731e-10
mutated O 0 4.0645904419989165e-08
in O 0 1.6000574021290959e-07
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 2.2190929485077504e-06
who O 0 7.866619577967526e-10
lack O 0 1.0672469130668105e-08
15q11 O 0 1.4990134786785347e-06
- O 0 8.618762308287842e-07
q13 O 0 6.004508122714469e-06
deletions O 0 2.0301638414821355e-07
or O 0 1.178894581954637e-08
chromosome O 0 1.5228911820486246e-07
15 O 0 3.0600890568166506e-06
paternal O 1 0.6774875521659851
uniparental B-Disease 1 0.9999995231628418
disomy I-Disease 0 0.007698793895542622
. O 0 5.834323474118719e-06

Previous O 0 4.275052106095245e-06
UBE3A O 0 2.167175625800155e-05
cDNA O 0 2.2578629454983457e-07
analysis O 0 1.5279383092092758e-08
has O 0 5.650978990301425e-11
shown O 0 5.943063402513715e-11
a O 0 2.5451690754962897e-10
coding O 0 1.941234373248335e-08
region O 0 6.405896701977554e-09
of O 0 1.7784461681102925e-09
approximately O 0 3.964535366662858e-10
2 O 0 8.07010778203221e-08
. O 0 1.3470210546984163e-07

6 O 0 1.0549101716605946e-05
kb O 0 8.876610081642866e-06
and O 0 4.109105500305077e-09
a O 0 1.0601095112861003e-08
3 O 0 1.1797025223359014e-07
- O 0 4.6981395485090616e-07
untranslated O 0 4.724009340861812e-05
region O 0 3.955181071546576e-08
( O 0 2.795038922531745e-10
UTR O 0 2.5318768166471273e-06
) O 0 9.263981803897536e-10
of O 0 1.6981061001786202e-09
< O 0 3.9964419329407974e-07
50 O 0 1.6437854810646968e-07
bp O 0 1.5750998727526166e-08
, O 0 5.6533288467219833e-11
whereas O 0 1.3053971237297901e-09
Northern O 0 1.1252646592296855e-09
analysis O 0 5.753640341943367e-10
has O 0 1.5773013103959066e-11
indicated O 0 2.246723987409105e-11
mRNA O 0 1.8440906787708933e-11
sizes O 0 1.6053743057131697e-10
of O 0 3.7187783408221264e-10
5 O 0 1.7239470295749015e-08
- O 0 3.912250292614772e-07
8 O 0 1.3066528481431305e-06
kb O 0 8.711917325854301e-05
. O 0 2.151348326151492e-06

We O 0 1.7895349628815893e-06
have O 0 1.46817979995717e-08
analyzed O 0 2.191168491094686e-08
additional O 0 1.549757655538997e-08
cDNA O 0 8.5105256175666e-08
clones O 0 5.600875851996534e-08
and O 0 9.680500845377082e-10
provide O 0 5.590583995740417e-09
evidence O 0 4.2444675552033573e-10
for O 0 6.24357301970413e-11
an O 0 2.5638921541393245e-11
additional O 0 3.3228411133734426e-09
0 O 0 2.2904617935637361e-07
. O 0 2.0995298655179795e-07

5 O 0 1.6284831190205296e-06
kb O 0 5.683323706762167e-06
of O 0 1.3355064254483295e-07
5 O 0 5.25839652709692e-07
- O 0 6.313480866992904e-07
UTR O 0 3.2145708246389404e-05
and O 0 4.862281688389203e-09
> O 0 8.853699284827599e-08
2 O 0 4.283640464564087e-08
kb O 0 1.1660470136121148e-06
of O 0 1.941397265170508e-08
3 O 0 4.981133088222123e-07
- O 0 3.1083079647942213e-06
UTR O 0 0.00034867055364884436
. O 0 2.385639163549058e-06

We O 0 1.5039320544474322e-07
have O 0 1.2034532259619368e-09
established O 0 2.659893194589813e-09
the O 0 8.551586661020849e-10
genomic O 0 8.860892464213066e-09
organization O 0 3.3139166966122957e-09
of O 0 1.458646869956226e-09
UBE3A O 0 2.2312610781227704e-06
and O 0 2.9070028606525966e-09
the O 0 8.060767164863591e-09
sequence O 0 7.553863645703984e-10
of O 0 7.513503597067483e-09
intron O 0 3.912250292614772e-07
- O 0 4.439692418145569e-07
exon O 0 3.931137371182558e-07
borders O 0 9.204580919686123e-08
. O 0 3.9624984538022545e-07

We O 0 1.3652569350597332e-06
have O 0 1.9338468604246373e-08
also O 0 8.029187092972734e-09
mapped O 0 2.4081533211983697e-08
two O 0 8.890446157039378e-10
highly O 0 5.748739706490369e-09
homologous O 0 1.798565740784852e-09
processed O 0 1.7489321990638018e-08
pseudogenes O 0 8.031488363258177e-08
, O 0 1.881568900685693e-09
UBE3AP1 O 0 6.823909188824473e-07
and O 0 5.908593614378788e-10
UBE3AP2 O 0 5.994970706524327e-07
, O 0 1.1235784524998849e-10
to O 0 2.463115267303806e-10
chromosomes O 0 7.645234445519122e-11
2 O 0 8.392392891742873e-10
and O 0 5.6466692432977084e-11
21 O 0 8.408804319515184e-09
, O 0 1.5600562508488736e-10
respectively O 0 2.1049755272173343e-09
, O 0 7.436492394097272e-11
and O 0 6.424893256307129e-11
determined O 0 1.8653747435593004e-09
their O 0 3.6178098294925576e-09
genomic O 0 6.598764201726226e-08
organization O 0 3.1930120769629866e-08
. O 0 1.3720124059091177e-07

These O 0 1.795772952561947e-08
results O 0 2.8078641634010637e-09
will O 0 2.006306371038491e-10
form O 0 2.1774167538457512e-11
the O 0 1.2271793303764156e-10
basis O 0 3.8712419381248253e-10
for O 0 2.2754719983253402e-11
studies O 0 4.1729522615163717e-10
of O 0 3.207976939645363e-10
mutation O 0 2.685431044202602e-10
and O 0 6.882818204267949e-10
imprinting O 0 3.963189101341413e-06
of O 0 1.5169379139479133e-06
UBE3A O 0 0.0019256325904279947
. O 0 5.891359251108952e-06

Mutation O 0 1.0303782573828357e-06
spectrum O 0 1.523254269386598e-07
and O 0 3.7150651444051164e-09
genotype O 0 1.00491558896465e-06
- O 0 6.665175078524044e-06
phenotype O 0 1.8793970468777843e-07
analyses O 0 2.3286995443072556e-08
in O 0 6.834576016245819e-09
Cowden B-Disease 0 0.00011656311835395172
disease I-Disease 0 3.409007831578492e-07
and O 0 1.2386225378691051e-09
Bannayan B-Disease 1 0.9999977350234985
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.4996661124608863e-09
two O 0 4.0097019038398685e-09
hamartoma B-Disease 0 0.014886826276779175
syndromes I-Disease 0 1.140422227763338e-05
with O 0 1.934843218975857e-08
germline O 1 0.9261419177055359
PTEN O 0 0.00762340659275651
mutation O 0 7.608701366734749e-07
. O 0 4.7566487637595856e-07

The O 0 2.127551124431193e-05
tumour B-Disease 1 1.0
suppressor O 0 0.0002150188956875354
gene O 0 9.974814929591957e-07
PTEN O 0 4.950391939928522e-06
, O 0 1.996816711979932e-09
which O 0 3.182136498747212e-11
maps O 0 3.273584736618318e-09
to O 0 1.1167085922636488e-08
10q23 O 0 3.4728618629742414e-06
. O 0 3.0127739591989666e-07

3 O 0 3.3015845701811486e-07
and O 0 1.7663672746692782e-09
encodes O 0 1.0791884053062972e-09
a O 0 1.685527717398827e-09
403 O 0 2.944154919859443e-09
amino O 0 1.8960442105253605e-09
acid O 0 1.0273954131889695e-08
dual O 0 1.7064226653928927e-07
specificity O 0 1.289144961447164e-06
phosphatase O 0 0.0010241243289783597
( O 0 2.685930766688216e-08
protein O 0 1.184859854674869e-07
tyrosine O 0 2.6669869157558423e-07
phosphatase O 0 3.8685780623382016e-07
; O 0 2.1117142756654772e-10
PTPase O 0 1.1350380191288423e-07
) O 0 1.5961039781520192e-11
, O 0 6.403638903862419e-12
was O 0 1.4826907757115038e-10
shown O 0 1.576198199737533e-10
recently O 0 7.75394082275227e-10
to O 0 7.361586895626715e-10
play O 0 1.368676816326797e-08
a O 0 4.5116697044989e-09
broad O 0 6.261611229518849e-09
role O 0 8.411916496697813e-09
in O 0 3.4482308564065534e-08
human O 0 9.701821568341984e-08
malignancy B-Disease 0 3.366780583746731e-05
. O 0 3.5704772471945034e-07

Somatic O 0 0.0007048188708722591
PTEN O 0 0.0006898461142554879
deletions O 0 1.7369565057379077e-06
and O 0 1.2263053683625458e-08
mutations O 0 1.6773112898604836e-09
were O 0 8.693314956786935e-10
observed O 0 3.0791674765495713e-10
in O 0 4.0375194854114227e-10
sporadic B-Disease 0 1.615015321476676e-06
breast I-Disease 0 0.34666386246681213
, I-Disease 0 2.0650077203754336e-07
brain I-Disease 1 0.9999996423721313
, I-Disease 0 1.3868186670151772e-06
prostate I-Disease 1 1.0
and I-Disease 1 0.8293401598930359
kidney I-Disease 1 1.0
cancer I-Disease 1 0.6018240451812744
cell O 0 1.4456225017056568e-06
lines O 0 5.96589799783942e-09
and O 0 4.859259217226963e-09
in O 0 3.359978961725574e-08
several O 0 8.702576437258358e-09
primary O 0 8.817665957394638e-07
tumours B-Disease 1 1.0
such O 0 9.214822682679369e-08
as O 0 1.0078726518258918e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 0.0006524547934532166
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 0 5.205204070080072e-05
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.06219090521335602

In O 0 7.179413330504758e-08
addition O 0 2.304837565247908e-08
, O 0 2.7825612924914367e-09
PTEN O 0 7.09836785972584e-06
was O 0 6.109532790787853e-08
identified O 0 9.378552157102149e-09
as O 0 1.188067644264379e-09
the O 0 7.822182346295392e-10
susceptibility O 0 1.8548375058102806e-09
gene O 0 6.836175514557397e-10
for O 0 2.0118253729606295e-09
two O 0 6.83683438751359e-08
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 0 0.11047639697790146
( O 0 6.804923985415101e-11
CD B-Disease 0 7.996696353984589e-07
; O 0 6.01719740700446e-09
MIM O 0 1.8680031644180417e-05
158350 O 0 4.300955822600372e-07
) O 0 2.01433550395258e-10
and O 0 5.262905666825191e-10
Bannayan B-Disease 0 2.6617819457896985e-05
- I-Disease 0 1.6822012185002677e-05
Zonana I-Disease 0 0.008539674803614616
( I-Disease 0 5.243350642558653e-09
BZS I-Disease 0 1.8630682461662218e-05
) I-Disease 0 7.833200754703284e-10
or I-Disease 0 1.123973358829744e-09
Ruvalcaba I-Disease 0 5.917265752941603e-06
- I-Disease 0 3.94784365198575e-06
Riley I-Disease 0 0.0001276577531825751
- I-Disease 1 1.0
Smith I-Disease 1 0.9997703433036804
syndrome I-Disease 1 1.0
( O 0 2.655160358244757e-08
MIM O 0 0.00023186234466265887
153480 O 0 3.9101341826608405e-06
) O 0 1.519839809560608e-09
. O 0 2.070571802903487e-08

Constitutive O 0 3.227988372600521e-06
DNA O 0 1.0023718033380646e-07
from O 0 2.7277478054088533e-09
37 O 0 3.777293855478092e-08
CD B-Disease 0 8.668608870721073e-07
families O 0 8.580112731415568e-10
and O 0 4.927623864503516e-10
seven O 0 5.173305783756632e-09
BZS B-Disease 0 5.631492058455478e-06
families O 0 1.0504436209757273e-09
was O 0 4.781615547955198e-09
screened O 0 1.9902927306247875e-08
for O 0 4.6744258241915304e-08
germline O 0 7.820799510227516e-05
PTEN O 0 0.00012397224782034755
mutations O 0 9.582225857229787e-07
. O 0 1.4743752672075061e-06

PTEN O 0 0.00018165384244639426
mutations O 0 4.134595243954209e-08
were O 0 2.2130670629394444e-09
identified O 0 1.0202632072520146e-09
in O 0 2.942587007392916e-10
30 O 0 3.5638155537753846e-08
of O 0 7.538250024197168e-09
37 O 0 1.4707337925301545e-07
( O 0 7.058831852368996e-10
81 O 0 1.2496175827436673e-07
% O 0 4.182394985896565e-10
) O 0 3.691434311003938e-11
CD B-Disease 0 1.3480413940669678e-07
families O 0 3.0456048794036406e-10
, O 0 2.900591919430262e-11
including O 0 1.4009589321961613e-10
missense O 0 1.574933889969543e-07
and O 0 1.019921302969351e-08
nonsense O 0 9.159953719972691e-07
point O 0 4.2524945342847786e-07
mutations O 0 1.0793206328685301e-08
, O 0 1.1166995106393074e-09
deletions O 0 1.2574066232673431e-08
, O 0 1.5881250758909005e-09
insertions O 0 3.985000773809588e-08
, O 0 1.0511772563503996e-09
a O 0 1.033839058806052e-08
deletion O 0 9.968823633244028e-07
/ O 0 1.5856847312534228e-05
insertion O 0 8.36673052617698e-07
and O 0 2.356302175599012e-08
splice O 0 3.2251975881081307e-06
site O 0 6.099555207583762e-07
mutations O 0 5.957349813456858e-08
. O 0 8.561942621554408e-08

These O 0 3.9728806910943604e-08
mutations O 0 3.6964193927957467e-09
were O 0 1.0109014736414679e-09
scattered O 0 6.396345675341308e-10
over O 0 1.246452246972396e-10
the O 0 7.677474211931212e-10
entire O 0 1.372128966004027e-09
length O 0 1.2114678149544034e-09
of O 0 1.1046077386112074e-09
PTEN O 0 9.348212870463612e-08
, O 0 8.838636073038586e-11
with O 0 4.561311398032508e-12
the O 0 1.963995216458514e-10
exception O 0 2.163623724626973e-10
of O 0 3.561568054366582e-11
the O 0 3.841267581794483e-11
first O 0 3.0877772561055394e-10
, O 0 4.6742405085398175e-11
fourth O 0 3.409642568286131e-09
and O 0 3.701708939374271e-10
last O 0 2.758750561326906e-08
exons O 0 3.2228714985649276e-07
. O 0 1.902501196582307e-07

A O 0 2.6415063985041343e-05
hot O 0 5.350326682673767e-05
spot O 0 1.4033398656465579e-06
for O 0 1.233653001975199e-08
PTEN O 0 9.1558476924547e-06
mutation O 0 2.1743199241086586e-08
in O 0 2.0881245621495736e-09
CD B-Disease 0 2.982596015499439e-06
was O 0 3.4532860127001186e-08
identified O 0 5.2495243707539885e-09
in O 0 1.4611251097917943e-09
exon O 0 3.867629416731688e-08
5 O 0 5.4813884986515404e-08
that O 0 3.597179498715519e-10
contains O 0 4.832121369702236e-10
the O 0 8.275624074904897e-10
PTPase O 0 1.9468711798253935e-07
core O 0 5.456393115110814e-09
motif O 0 4.3138087546523707e-10
, O 0 5.028431664111377e-12
with O 0 4.731508696127762e-13
13 O 0 2.0538424294613833e-09
of O 0 1.2803705873309923e-09
30 O 0 4.0419230629140657e-08
( O 0 3.3835587109898313e-10
43 O 0 3.184824848290191e-08
% O 0 6.055591583731257e-10
) O 0 1.569783886212761e-10
CD B-Disease 0 4.962820980836113e-07
mutations O 0 5.417701398613417e-09
identified O 0 3.973985585048467e-09
in O 0 8.826881447987489e-10
this O 0 4.113339890920997e-09
exon O 0 2.5570011530362535e-07
. O 0 2.7293842208564456e-07

Seven O 0 1.905493718368234e-07
of O 0 3.9113601246754115e-09
30 O 0 4.556277133360709e-08
( O 0 1.277301459046143e-10
23 O 0 1.6191307850021985e-08
% O 0 1.730676157940536e-10
) O 0 2.748017265130631e-11
were O 0 1.5261776564745588e-10
within O 0 1.751454120624274e-10
the O 0 1.7145830588649602e-10
core O 0 5.222298149476501e-10
motif O 0 4.427949396035302e-10
, O 0 9.901818948110375e-12
the O 0 4.8354379528214864e-11
majority O 0 8.125525426116997e-12
( O 0 8.377926824509885e-12
five O 0 1.2326098475234915e-10
of O 0 6.716158879038758e-11
seven O 0 8.529395939538276e-11
) O 0 3.6550935889057e-11
of O 0 2.227387996267538e-10
which O 0 6.207712122119347e-11
were O 0 1.5616378190586033e-09
missense O 0 3.2556904727698566e-08
mutations O 0 4.453981183871747e-09
, O 0 3.7826469734270063e-10
possibly O 0 1.7740461544235586e-08
pointing O 0 1.7746181413258455e-08
to O 0 1.6787907952675596e-08
the O 0 4.865918779017875e-09
functional O 0 1.6852810702516763e-08
significance O 0 1.4102067957821873e-08
of O 0 6.731654678127086e-10
this O 0 1.3846344903978292e-10
region O 0 2.7987638873128162e-09
. O 0 3.846449558864151e-08

Germline O 0 0.0038457391783595085
PTEN O 0 4.600565807777457e-05
mutations O 0 1.3574998902754487e-08
were O 0 7.530501222596797e-10
identified O 0 4.4282874589463006e-10
in O 0 2.6383720208578154e-10
four O 0 7.314671646163617e-10
of O 0 5.57594914685211e-10
seven O 0 1.400826010744538e-09
( O 0 9.843130477360518e-11
57 O 0 5.995147489556985e-08
% O 0 2.466962412128737e-09
) O 0 1.3199336068581147e-09
BZS B-Disease 0 1.6295103705488145e-05
families O 0 2.5557751470728363e-09
studied O 0 3.6708823358821974e-07
. O 0 6.791584041820897e-07

Interestingly O 0 6.265568117669318e-07
, O 0 4.306214940186237e-09
none O 0 2.471023208272527e-08
of O 0 1.3150007749374026e-09
these O 0 1.6595408380837284e-10
mutations O 0 4.5923409519588176e-10
was O 0 3.910024748421392e-09
observed O 0 1.829050799706522e-09
in O 0 4.647450868588976e-09
the O 0 5.837947369968788e-08
PTPase O 0 8.381549378100317e-06
core O 0 1.7361879827149096e-06
motif O 0 4.838443601329345e-07
. O 0 2.8624822334677447e-07

It O 0 1.596234255885065e-08
is O 0 1.0881125861450514e-10
also O 0 1.354564811012482e-11
worthy O 0 9.676844880956992e-10
of O 0 6.866519575154939e-10
note O 0 6.1318865540727074e-09
that O 0 4.422056124053775e-11
a O 0 3.3080985173405963e-10
single O 0 1.9550077112739928e-09
nonsense O 0 2.1340591516150198e-08
point O 0 4.510946727265264e-09
mutation O 0 2.0706804326753314e-10
, O 0 2.4261250994306316e-11
R233X O 0 3.1283583723507036e-08
, O 0 8.831002595854898e-11
was O 0 5.952618953308786e-10
observed O 0 4.54356774426401e-10
in O 0 7.868975471225781e-10
the O 0 5.525641721959573e-09
germline O 0 1.3703660783903615e-07
DNA O 0 5.1267652345643455e-09
from O 0 5.025368454703028e-10
two O 0 8.25619642097486e-11
unrelated O 0 6.097827243145559e-10
CD B-Disease 0 3.0217000812626793e-07
families O 0 1.1479680400716674e-10
and O 0 1.501187230079637e-10
one O 0 2.0292680869005153e-09
BZS B-Disease 0 0.00029459231882356107
family O 0 2.8726444156745856e-07
. O 0 7.851903660593962e-07

Genotype O 0 2.4385901269852184e-05
- O 0 2.0832299924222752e-05
phenotype O 0 9.159694513982686e-08
studies O 0 7.046083272399528e-09
were O 0 2.982917524096962e-10
not O 0 3.3651820913194186e-11
performed O 0 2.1281630624425674e-10
on O 0 1.7850834144184091e-09
this O 0 9.38720420839978e-11
small O 0 3.2677499595124004e-10
group O 0 1.4026753369922318e-10
of O 0 1.7572304722435206e-09
BZS B-Disease 0 3.586136517697014e-05
families O 0 1.4162474748502518e-08
. O 0 1.5042735412862385e-07

However O 0 6.096123428278588e-08
, O 0 1.3192967829311897e-09
genotype O 0 8.126114892093028e-08
- O 0 6.18358455994894e-07
phenotype O 0 1.9533318607045658e-07
analysis O 0 1.3590699232679526e-08
inthe O 0 8.877980235411087e-07
group O 0 6.19329865170215e-10
of O 0 2.489066730504419e-10
CD B-Disease 0 7.249726877489593e-06
families O 0 7.427707338081291e-10
revealed O 0 2.8790378969745234e-09
two O 0 6.467471003190894e-11
possible O 0 2.352384120829498e-10
associations O 0 1.6351642262435462e-11
worthy O 0 1.9582929056127796e-08
of O 0 2.5434392370016212e-08
follow O 0 3.117975211353041e-08
- O 0 1.1005290190269079e-07
up O 0 7.75934516639154e-09
in O 0 2.32010610723421e-09
independent O 0 1.728483134399994e-09
analyses O 0 4.5004473037124626e-08
. O 0 1.7528670070987573e-07

The O 0 8.841784904234373e-08
first O 0 1.6453279627626216e-08
was O 0 8.092562175932017e-09
an O 0 5.2004678341432964e-11
association O 0 1.8030946527525238e-11
noted O 0 8.737762596799925e-11
in O 0 1.7028113641348597e-10
the O 0 1.8359713749305229e-09
group O 0 6.365502569494197e-11
of O 0 1.889458450810011e-10
CD B-Disease 0 1.53464079630794e-05
families O 0 3.680042492959501e-09
with O 0 2.5798572167445855e-09
breast B-Disease 1 0.9107102751731873
disease I-Disease 0 0.00028111113351769745
. O 0 7.938257112982683e-06

A O 0 4.231413299748965e-07
correlation O 0 5.126491231521868e-09
was O 0 1.4372822931818519e-09
observed O 0 1.3602978465865334e-10
between O 0 6.6999188315375324e-12
the O 0 1.259654602847604e-10
presence O 0 5.1189874561430315e-09
/ O 0 1.901944779092446e-05
absence O 0 1.3043769513387815e-06
of O 0 1.7671128560436955e-08
a O 0 1.6386852763616844e-08
PTEN O 0 2.441174274281366e-06
mutation O 0 2.1280830431180675e-09
and O 0 5.207862266431995e-11
the O 0 1.1808203304042308e-09
type O 0 4.421050903147261e-08
of O 0 2.6118627260984795e-08
breast O 0 1.6616395441815257e-05
involvement O 0 7.278340490302071e-07
( O 0 1.325623610881621e-08
unaffected O 0 6.244369433261454e-05
versus O 1 0.9974697828292847
benign O 1 0.9990829229354858
versus O 0 2.731146196310874e-05
malignant O 0 1.3298599697009195e-06
) O 0 4.570811285020682e-09
. O 0 6.598764201726226e-08

Specifically O 0 1.7556810405494616e-07
and O 0 2.7378532774235964e-10
more O 0 1.5950874301950968e-11
directly O 0 3.6750446436029094e-11
, O 0 1.3880899034368621e-11
an O 0 3.2654681042521005e-11
association O 0 3.7290914800536257e-10
was O 0 6.400254548566409e-09
also O 0 3.1223879037867164e-10
observed O 0 1.4986555052498574e-10
between O 0 1.1507625581608227e-11
the O 0 3.9686584574205597e-10
presence O 0 8.889123326305537e-10
of O 0 1.1895551210727717e-09
a O 0 1.731889653910912e-08
PTEN O 0 0.15084005892276764
mutation O 0 2.6336234441259876e-05
and O 0 8.220520726354152e-07
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9875494241714478
. O 0 5.96786946971406e-07

Secondly O 0 4.429138698469615e-06
, O 0 1.5706779876722976e-08
there O 0 1.049446418655009e-09
appeared O 0 1.0289211260783304e-08
to O 0 2.1385320181366296e-09
be O 0 2.2126280807555077e-09
an O 0 1.027798623987053e-09
interdependent O 0 4.2176591819043097e-07
association O 0 4.228504835168678e-08
between O 0 8.13620726347608e-09
mutations O 0 1.2131494919742636e-08
upstream O 0 3.5796461350656728e-09
and O 0 6.766539550895345e-10
within O 0 3.3832117107834847e-09
the O 0 8.163627995827483e-09
PTPase O 0 3.2424415508103266e-07
core O 0 1.3450514479984577e-08
motif O 0 7.308092797586596e-09
, O 0 2.3978247165601374e-10
the O 0 5.761734422904397e-10
core O 0 1.93624956068561e-08
motif O 0 9.319848892630489e-09
containing O 0 7.767736454056262e-10
the O 0 1.4891528288263345e-10
majority O 0 4.7762238608584084e-11
of O 0 2.0264832034655456e-09
missense O 0 1.2959168316228897e-07
mutations O 0 6.832816534796393e-09
, O 0 7.675950985941427e-10
and O 0 1.2496569334885521e-09
the O 0 5.42183897778159e-07
involvement O 0 0.0012665166286751628
of O 0 3.3954060199903324e-05
all O 0 4.397326591742967e-08
major O 0 8.771790049877382e-08
organ O 0 4.540164809441194e-06
systems O 0 7.075683970469981e-05
( O 0 4.3145536920974337e-08
central O 1 1.0
nervous O 1 1.0
system O 1 1.0
, O 0 2.440838500206155e-07
thyroid O 0 0.01164731103926897
, O 0 1.1335993121974752e-07
breast O 1 0.9999384880065918
, O 0 2.5600904791645007e-06
skin O 1 1.0
and O 0 6.074238172004698e-06
gastrointestinal O 1 0.8406632542610168
tract O 0 2.3838038032408804e-06
) O 0 4.122977514953163e-09
. O 0 1.3997001246934815e-07

However O 0 1.802193452249412e-07
, O 0 1.1716579928489068e-09
these O 0 8.245463339884296e-11
observations O 0 9.640291342982721e-11
would O 0 1.2655740344591493e-10
need O 0 1.0026425245612813e-09
to O 0 1.0400071914773434e-09
be O 0 1.1434080349204123e-09
confirmed O 0 2.098261342453611e-09
by O 0 6.960215737095155e-11
studying O 0 6.156168019799679e-09
a O 0 1.476083144602569e-09
larger O 0 2.306185381550918e-10
number O 0 5.81082348904971e-10
of O 0 2.0169382830559357e-10
CD B-Disease 0 8.982527219814074e-07
families O 0 4.102417516804735e-09
. O 0 6.462165913490026e-08

Molecular O 0 0.00011701593030011281
defects O 1 0.9429958462715149
leading O 0 5.425852691587352e-07
to O 0 8.161961773112125e-09
human O 0 1.7964606469078603e-09
complement B-Disease 0 2.9612382945742866e-07
component I-Disease 1 0.9999998807907104
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 5.271679093254988e-09
an O 0 9.765803443695376e-11
African O 0 1.1513878739322081e-08
- O 0 1.792846937576087e-08
American O 0 1.0565971209075542e-08
family O 0 6.46626885369983e-09
. O 0 1.5426090627101985e-08

Complement B-Disease 0 1.5875375538598746e-06
component I-Disease 1 0.9990959167480469
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.3696833944809583e-10
C6D B-Disease 0 1.208040032452118e-07
) O 0 1.2738947050006111e-11
was O 0 1.6340738484554862e-10
diagnosed O 0 1.6926225754332336e-08
in O 0 1.92372812124475e-10
a O 0 3.4850031194189057e-10
16 O 0 5.875889774742404e-10
- O 0 4.524576546760528e-10
year O 0 7.444528327127387e-10
- O 0 1.08671365239843e-08
old O 0 8.132207796052171e-08
African O 0 8.890725666788057e-08
- O 0 1.3133520937458343e-08
American O 0 6.937104779503045e-10
male O 0 7.11099346073496e-10
with O 0 8.403216317232065e-11
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.679457710679344e-07

The O 0 3.582933416623746e-08
patients O 0 1.4078982424337028e-08
father O 0 6.3440186437446755e-09
and O 0 9.37450672644502e-10
two O 0 1.046049136199656e-09
brothers O 0 2.2530234389250836e-07
also O 0 4.558050292757798e-08
had O 0 3.19283550709315e-08
C6D B-Disease 0 1.1239192645007279e-05
, O 0 6.036011690468968e-10
but O 0 2.1171829567290246e-10
gave O 0 7.317801031803128e-09
no O 0 2.5984254747868363e-09
history O 0 3.042250673601643e-09
of O 0 2.8409299357434747e-09
meningitis B-Disease 1 1.0
or O 0 1.2061143195296609e-09
other O 0 7.17608028555361e-10
neisserial B-Disease 0 1.3110769032209646e-05
infection I-Disease 0 1.4652446225227322e-06
. O 0 1.6299735250413505e-07

By O 0 2.160729817290985e-09
using O 0 2.223517814314846e-09
exon O 0 6.765639604111584e-09
- O 0 5.061550290008654e-09
specific O 0 1.1542590216961912e-09
polymerase O 0 4.916445028868566e-09
chain O 0 1.147253492206346e-08
reaction O 0 1.09955022864483e-09
( O 0 1.7034958513240106e-11
PCR O 0 3.3289182521656357e-09
) O 0 6.120639411966167e-11
/ O 0 6.878779323926665e-09
single O 0 3.239200463411862e-09
- O 0 1.4989391949882247e-09
strand O 0 9.37811939216715e-10
conformation O 0 4.963629507415135e-10
polymorphism O 0 1.1064802407645402e-09
as O 0 8.991190431073548e-11
a O 0 4.895983965469419e-11
screening O 0 1.3430094536470705e-10
step O 0 1.136819083313867e-09
and O 0 3.197882930683349e-11
nucleotide O 0 8.774977966474751e-10
sequencing O 0 2.4359438910437348e-09
of O 0 5.20441201246058e-09
target O 0 2.2530270982201728e-08
exons O 0 1.5180415147142412e-08
, O 0 2.657691011709318e-10
we O 0 3.534601500376766e-10
determined O 0 6.237790839414004e-10
that O 0 4.712968210141e-11
the O 0 5.325908047915107e-10
proband O 0 2.496286981568119e-07
was O 0 7.839392246467014e-09
a O 0 1.143373173917439e-09
compound O 0 1.294545093344368e-08
heterozygote O 0 8.862079425853153e-08
for O 0 6.421232989772818e-10
two O 0 5.88899484732508e-10
C6 O 0 8.924056601244956e-06
gene O 0 7.680396407749868e-08
mutations O 0 1.6863235430264467e-07
. O 0 6.289886869126349e-07

The O 0 2.4395095010731893e-07
first O 0 1.2508929003729463e-08
, O 0 9.022250307966218e-11
1195delC O 0 3.2120561765935918e-09
located O 0 1.436705893143042e-10
in O 0 1.7561306575597513e-10
exon O 0 1.3502023499256666e-08
7 O 0 9.456188365675189e-08
, O 0 3.769660694707966e-10
is O 0 2.9688283081918954e-11
a O 0 4.2586077025896785e-11
novel O 0 9.247206472773328e-11
mutation O 0 3.062274392395814e-11
, O 0 3.928348098203305e-12
while O 0 1.3646576924042364e-11
the O 0 1.4270815085204447e-10
second O 0 1.0158515140190616e-09
, O 0 3.705875190052055e-11
1936delG O 0 2.967387446872749e-09
in O 0 1.718121894755953e-10
exon O 0 8.417918806458147e-09
12 O 0 2.535650445167903e-08
, O 0 3.6038411144190263e-10
has O 0 2.5324662505932238e-11
been O 0 1.9511798426963267e-11
described O 0 1.767531607188566e-11
before O 0 2.1172394393254024e-10
to O 0 1.2545529060048466e-09
cause O 0 1.4624244037975132e-09
C6D B-Disease 0 2.2958197121170087e-07
in O 0 4.142524101524714e-10
an O 0 5.4359964446470954e-11
unrelated O 0 7.702706916745683e-09
African O 0 7.851876659970003e-08
- O 0 3.909936907575684e-08
American O 0 3.113648716634998e-08
individual O 0 3.681916993514278e-09
. O 0 4.764166661175295e-08

Both O 0 7.09842424839735e-08
mutations O 0 3.833140027609261e-09
result O 0 1.4549791371720744e-09
in O 0 2.872872162384965e-09
premature O 0 1.740716157883071e-07
termination O 0 1.7423522535864322e-07
codons O 0 1.9635369596926466e-07
and O 0 3.2509252179124815e-08
C6 O 0 5.115096064400859e-05
null O 0 1.395545837112877e-06
alleles O 0 1.3386994623942883e-07
. O 0 2.557479206188873e-07

Allele O 0 1.6983408102078101e-07
- O 0 4.003651454809187e-08
specific O 0 3.419711847030271e-09
PCR O 0 6.901478144527573e-08
indicated O 0 4.2898848917616306e-09
that O 0 1.3897668606210889e-11
the O 0 1.5485447646401695e-10
probands O 0 5.732330166097199e-08
two O 0 2.990380165712736e-10
brothers O 0 8.957649733076778e-09
also O 0 1.3148653277283984e-09
inherited O 0 2.7812680158945113e-08
the O 0 4.068623482567091e-08
1195delC O 0 1.3056946102096845e-07
mutation O 0 2.0333312811260384e-10
from O 0 5.284267468042003e-11
their O 0 4.730856817403151e-10
heterozygous O 0 9.762642916300024e-10
mother O 0 1.915608116576095e-09
and O 0 5.481205489488161e-10
the O 0 4.846171908212682e-09
1936delG O 0 2.531808540595648e-08
mutation O 0 1.094828533387826e-10
from O 0 9.972178638406604e-11
their O 0 1.7757074699531472e-09
homozygous O 0 3.5673316745032935e-08
father O 0 6.998564572313626e-08
. O 0 3.2295169205553975e-08
. O 0 3.3277999023084703e-07

PAX6 O 0 0.0016358521534129977
mutations O 0 4.9203031267097685e-06
reviewed O 0 8.662925210956018e-06
. O 0 4.899129635305144e-06

Mutations O 0 8.034198231143819e-07
in O 0 2.8111291072718814e-08
PAX6 O 0 9.51791116676759e-06
are O 0 3.3831457080246707e-10
responsible O 0 9.014514690264264e-10
for O 0 1.9814512253191197e-09
human O 0 1.909929210341943e-07
aniridia B-Disease 1 1.0
and O 0 1.262450766148504e-08
have O 0 2.1243358183653527e-09
also O 0 3.651917657165882e-10
been O 0 8.251110905632686e-11
found O 0 1.7290485015974966e-11
in O 0 4.086084595678052e-11
patients O 0 2.765195850074065e-10
with O 0 3.4876615484513707e-11
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.3205788462755663e-08
with O 0 1.6202150732169684e-08
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 2.4449335001008876e-08
with O 0 2.1087609436420962e-09
autosomal B-Disease 1 0.9999884366989136
dominant I-Disease 1 0.9999200105667114
keratitis I-Disease 1 1.0
, O 0 1.1000076405309756e-09
and O 0 3.195665121413782e-10
with O 0 6.730014323608202e-09
isolated B-Disease 1 1.0
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 1 0.9999996423721313

No O 0 3.623392558438354e-06
locus O 0 3.8307382510538446e-07
other O 0 1.3184464631166293e-09
than O 0 2.450220304428541e-10
chromosome O 0 3.026879369372182e-08
11p13 O 0 2.332732947252225e-06
has O 0 1.0805003558544968e-09
been O 0 7.986067362963922e-10
implicated O 0 4.314238744029808e-09
in O 0 1.328179788373518e-08
aniridia B-Disease 1 1.0
, O 0 3.5675271625734695e-09
and O 0 8.048257615911325e-10
PAX6 O 0 2.4821087208692916e-05
is O 0 9.573725145983758e-10
clearly O 0 2.1088897295129527e-09
the O 0 1.0165337460676938e-09
major O 0 3.0191402711210458e-09
, O 0 5.869479902109731e-11
if O 0 4.554549792867846e-11
not O 0 1.5967654976023482e-10
only O 0 1.343117145280459e-10
, O 0 8.316602267965933e-11
gene O 0 1.2017604689162908e-09
responsible O 0 1.7106788163800957e-07
. O 0 3.3293822525592986e-06

Twenty O 0 2.2685749456741178e-07
- O 0 1.414927623955009e-07
eight O 0 5.390818902384353e-09
percent O 0 3.6711109707709966e-09
of O 0 2.1875123934478324e-10
identified O 0 5.452481577350454e-09
PAX6 O 0 2.888589006033726e-05
mutations O 0 2.4212518212607392e-08
are O 0 6.451851830568955e-10
C O 0 5.143907401361503e-05
- O 0 5.2269413572503254e-05
T O 0 4.787601574207656e-05
changes O 0 1.0660407667728578e-07
at O 0 8.043615196129394e-08
CpG O 0 4.319898039284453e-07
dinucleotides O 0 1.924831849464681e-07
, O 0 1.3900565420943423e-10
20 O 0 2.637271290240051e-09
% O 0 1.3979799262653358e-10
are O 0 6.621407849100036e-12
splicing O 0 2.3631332446427677e-09
errors O 0 3.7224367588351015e-08
, O 0 2.2385039655237193e-10
and O 0 5.777324452171939e-11
more O 0 9.647256951628158e-12
than O 0 8.078146658541119e-12
30 O 0 6.65558941292943e-10
% O 0 1.1317732168114603e-10
are O 0 4.3814885747339716e-11
deletion O 0 4.357989080716607e-09
or O 0 1.0976979325505454e-09
insertion O 0 3.974978568521692e-09
events O 0 1.1623099815949445e-08
. O 0 8.007550178490419e-08

There O 0 4.271858600191081e-08
is O 0 8.873911050422123e-10
a O 0 2.7827684601078317e-09
noticeably O 0 2.542312245168432e-07
elevated O 0 9.192247318878799e-08
level O 0 5.0909477522509405e-08
of O 0 1.4781172952282873e-09
mutation O 0 3.335857146069543e-10
in O 0 7.749564323589198e-10
the O 0 3.147010652071458e-09
paired O 0 1.53582069284397e-09
domain O 0 9.9117691831907e-10
compared O 0 1.1510616765297854e-10
with O 0 1.0785034974467034e-12
the O 0 1.5116459473052402e-10
rest O 0 8.464412504238794e-10
of O 0 4.862186764320597e-10
the O 0 8.747405577658185e-10
gene O 0 6.3302878494653214e-09
. O 0 3.575493110474781e-07

Increased O 0 2.0550157842080807e-07
mutation O 0 2.9903586273860583e-09
in O 0 7.421249725858559e-10
the O 0 3.6452596496872047e-09
homeodomain O 0 1.0483069701194836e-07
is O 0 6.20670598250328e-11
accounted O 0 2.4433505219079166e-10
for O 0 2.5702573749897262e-11
by O 0 1.899212904998837e-11
the O 0 3.6770397837671e-09
hypermutable O 0 1.0042604117188603e-06
CpG O 0 9.685695658845361e-07
dinucleotide O 0 1.034803744914825e-06
in O 0 4.235349493342255e-08
codon O 0 3.6691812965727877e-07
240 O 0 3.37033299047107e-07
. O 0 1.8435927984228329e-07

Very O 0 6.088710051699309e-07
nearly O 0 3.674279014376225e-08
all O 0 5.384547807629758e-10
mutations O 0 2.960121869843846e-10
appear O 0 1.6545163017411824e-09
to O 0 2.073495375398693e-09
cause O 0 7.704763049787289e-09
loss O 0 1.0939321448688588e-08
of O 0 4.584405299823402e-09
function O 0 7.621597575280248e-09
of O 0 1.3723547631627753e-08
the O 0 4.5896459965888425e-09
mutant O 0 1.4308115581229686e-08
allele O 0 1.882717759471575e-09
, O 0 4.3135103128255636e-11
and O 0 1.7704096869075592e-11
more O 0 8.78669272758037e-12
than O 0 5.798063851952806e-12
80 O 0 4.802864772557314e-10
% O 0 1.2405465543707805e-10
of O 0 5.927025537033614e-10
exonic O 0 7.573056848286797e-08
substitutions O 0 3.1933760080704587e-09
result O 0 1.6531347402093388e-09
in O 0 7.102173071871221e-09
nonsense O 0 3.612774719385925e-07
codons O 0 6.485274184342416e-07
. O 0 3.5214907256886363e-07

In O 0 1.4300876216566394e-07
a O 0 2.500007667549653e-08
gene O 0 3.1030349401106605e-09
with O 0 4.5623227418190027e-11
such O 0 1.786483294630159e-09
extraordinarily O 0 1.028584009077349e-07
high O 0 2.5163592098920162e-08
sequence O 0 1.7891148285098524e-10
conservation O 0 1.4134671211252225e-09
throughout O 0 2.243282504199584e-10
evolution O 0 8.688044172977527e-10
, O 0 4.4898175455276856e-11
there O 0 4.636954015202477e-11
are O 0 7.927950657071747e-11
presumed O 0 6.915431640663883e-07
undiscovered O 0 9.263200627174228e-05
missense O 0 2.553089325374458e-05
mutations O 0 6.15273165749386e-07
, O 0 3.67732022610312e-09
these O 0 5.849153938974894e-10
are O 0 4.9173592281404055e-11
hypothesized O 0 9.461573746705199e-10
to O 0 3.426448014209882e-10
exist O 0 6.926290097020171e-10
in O 0 4.773766937304913e-10
as O 0 2.316524527756769e-09
- O 0 4.652615359646006e-08
yet O 0 8.251386240942793e-09
unidentified O 0 4.348202153892089e-08
phenotypes O 0 1.976367869360729e-08
. O 0 3.0684164098460087e-09
. O 0 3.235435386272911e-08

Genetic O 0 1.0949622719635954e-06
heterogeneity O 0 1.1193426985300903e-07
and O 0 1.2672267679647575e-09
penetrance O 0 8.228397518905695e-08
analysis O 0 4.9936770274428e-09
of O 0 8.325435452150032e-09
the O 0 4.66202294546747e-08
BRCA1 O 0 6.831189836020712e-08
and O 0 9.642139531251814e-09
BRCA2 O 0 9.62516395475177e-08
genes O 0 7.784144884226407e-09
in O 0 1.1291076162933678e-07
breast B-Disease 0 0.0074525694362819195
cancer I-Disease 0 2.1270194338285364e-05
families O 0 4.553549004526758e-08
. O 0 1.0527326139708748e-06

The O 0 0.0006554382271133363
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 4.129963599552866e-06
Consortium O 0 5.808015401953526e-08
. O 0 1.4418168348129257e-07

The O 0 2.1992830667727503e-08
contribution O 0 4.576379097898098e-08
of O 0 1.6610941955264025e-08
BRCA1 O 0 4.852963542134603e-08
and O 0 1.1288552315136258e-08
BRCA2 O 0 0.00041504367254674435
to O 0 0.017804140225052834
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9958986639976501
assessed O 0 3.7849244449716934e-07
by O 0 1.534912863476734e-09
linkage O 0 6.506058269906134e-08
and O 0 1.27437238539585e-09
mutation O 0 1.760161322250653e-10
analysis O 0 4.074503928697126e-11
in O 0 4.54219648005072e-11
237 O 0 2.0990968685463685e-10
families O 0 5.241273127315482e-12
, O 0 1.6935298649545238e-12
each O 0 1.594466204034306e-12
with O 0 2.4774550900358294e-12
at O 0 6.101774197020404e-09
least O 0 6.594065293796803e-10
four O 0 9.14861172929271e-11
cases O 0 4.1729764088671573e-10
of O 0 8.32768964897923e-09
breast B-Disease 0 9.491119271842763e-05
cancer I-Disease 0 2.3362927095149644e-06
, O 0 3.111462421045985e-09
collected O 0 1.4735100251073163e-08
by O 0 3.524202707438917e-09
the O 0 2.6042725949082524e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 1.7622194263822166e-06
Consortium O 0 2.9781736188283503e-08
. O 0 2.412521382666455e-07

Families O 0 5.528635771412382e-09
were O 0 4.024042210559742e-10
included O 0 5.4631254381432015e-11
without O 0 1.1935499810711292e-10
regard O 0 2.076752991797548e-09
to O 0 2.168003776503724e-09
the O 0 2.716600278063197e-09
occurrence O 0 2.9042564619885525e-07
of O 0 6.101957978899009e-07
ovarian B-Disease 1 0.9999994039535522
or I-Disease 0 4.274061939213425e-05
other I-Disease 0 1.9617398265836528e-06
cancers I-Disease 0 0.08467341214418411
. O 0 3.998602096544346e-06

Overall O 0 9.826288987824228e-06
, O 0 8.846032351073063e-09
disease O 0 3.8484088804580097e-08
was O 0 4.915582607623037e-09
linked O 0 9.124537569960012e-09
to O 0 7.04267044682183e-09
BRCA1 O 0 6.275504560449008e-09
in O 0 6.78654799024514e-10
an O 0 2.3507322824412036e-11
estimated O 0 3.2407049266325316e-11
52 O 0 3.2216262990658606e-10
% O 0 2.1303835431862872e-11
of O 0 2.654184164119222e-11
families O 0 5.644943713856154e-12
, O 0 1.0868509217609734e-11
to O 0 1.1261986898603027e-09
BRCA2 O 0 5.993658902525567e-09
in O 0 5.029040517356975e-10
32 O 0 6.9893304477375295e-09
% O 0 1.984665209953107e-10
of O 0 7.225341158711984e-11
families O 0 5.44833579294024e-12
, O 0 4.095500414497133e-12
and O 0 5.610337281553024e-12
to O 0 3.2968799912325153e-10
neither O 0 5.464430574697587e-10
gene O 0 5.278032177979952e-11
in O 0 7.271825919197283e-10
16 O 0 1.3998064929410248e-08
% O 0 2.3471405374841936e-10
( O 0 2.2218791043138175e-11
95 O 0 2.6100998695710587e-08
% O 0 7.200169349630414e-10
confidence O 0 1.615598677062735e-08
interval O 0 9.128436673222495e-09
[ O 0 8.343831581214545e-08
CI O 0 4.9752920858736616e-06
] O 0 5.946474601614682e-08
6 O 0 2.0537298084377653e-08
% O 0 6.700628385480911e-10
- O 0 6.874018687597072e-09
28 O 0 1.0337167566376593e-08
% O 0 4.0915301702248996e-10
) O 0 1.0004107958705433e-10
, O 0 9.531522099370804e-11
suggesting O 0 3.0687850038901843e-09
other O 0 2.6116606099968465e-10
predisposition O 0 7.775378207952599e-08
genes O 0 1.1270486055536821e-07
. O 0 8.84915550614096e-07

The O 0 8.700241238557282e-08
majority O 0 4.065780490059012e-10
( O 0 7.697999182543214e-11
81 O 0 1.0356626667373803e-08
% O 0 7.534031037925715e-11
) O 0 1.2578197164381244e-11
of O 0 2.2857477022242279e-10
the O 0 2.475861720085959e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.672510100003137e-09
were O 0 6.535054719591926e-10
due O 0 3.1935096789226236e-09
to O 0 6.431361221359566e-09
BRCA1 O 0 3.0029159159283836e-09
, O 0 1.594419041239803e-10
with O 0 1.1571277790112244e-11
most O 0 2.0569032588291236e-10
others O 0 1.0566243019427546e-10
( O 0 1.2481978124700976e-11
14 O 0 1.2465645182757612e-09
% O 0 9.678131906998289e-11
) O 0 6.598804835888927e-11
due O 0 1.0213716095108794e-08
to O 0 2.4422774913546164e-07
BRCA2 O 0 3.5667135307448916e-06
. O 0 6.356781341310125e-07

Conversely O 0 2.4326166681021277e-07
, O 0 5.531586300122626e-10
the O 0 4.0337630458076035e-10
majority O 0 2.3088865888643006e-11
of O 0 1.70817873734741e-10
families O 0 2.6604383626671613e-11
with O 0 8.427738541760821e-12
male B-Disease 0 2.7640529864925156e-09
and I-Disease 0 3.2172189357027037e-09
female I-Disease 0 2.873381390600116e-07
breast I-Disease 0 0.0006911843665875494
cancer I-Disease 0 0.164889395236969
were O 0 1.335928391199559e-05
due O 1 0.9999924898147583
to O 1 0.9998756647109985
BRCA2 O 0 2.430994072710746e-06
( O 0 1.054237142028569e-09
76 O 0 5.493141657098022e-07
% O 0 2.191526959904877e-09
) O 0 1.104211833080626e-09
. O 0 4.563992206385592e-08

The O 0 1.5416038934290555e-07
largest O 0 2.7321374052036163e-09
proportion O 0 4.1679648621339993e-10
( O 0 2.9615209590216907e-11
67 O 0 1.096727419991339e-08
% O 0 1.3946402366293853e-10
) O 0 3.325506883755658e-11
of O 0 1.0015258067319621e-10
families O 0 2.355993004854451e-11
due O 0 3.076075394403688e-09
to O 0 1.9929280448138798e-09
other O 0 5.207554526487357e-11
genes O 0 9.153883206991509e-11
was O 0 5.827917037848351e-10
found O 0 4.5623577832332174e-11
in O 0 2.4970350440134403e-11
families O 0 1.8967657305912766e-11
with O 0 2.5607875195343688e-12
four O 0 1.0477498035843524e-10
or O 0 5.681282527758569e-11
five O 0 4.0553688879230165e-11
cases O 0 2.9433993437022465e-11
of O 0 5.02478336716905e-10
female O 0 9.130094014153656e-08
breast B-Disease 0 2.0022725948365405e-05
cancer I-Disease 0 6.451934495999012e-06
only O 0 7.018026622063189e-07
. O 0 4.729143711301731e-06

These O 0 2.5330013642133054e-08
estimates O 0 1.9154984265412622e-09
were O 0 2.351836780878358e-10
not O 0 1.597786070117735e-10
substantially O 0 3.4464537890244173e-09
affected O 0 9.871050504761669e-11
either O 0 6.710754868466395e-11
by O 0 2.583409701439887e-11
changing O 0 5.017909643356688e-09
the O 0 2.3381248048792713e-09
assumed O 0 3.396772640940071e-08
penetrance O 0 5.086773668949718e-08
model O 0 5.740565800493869e-09
for O 0 2.9939086765295997e-09
BRCA1 O 0 1.3244938479317625e-08
or O 0 4.719393209562384e-10
by O 0 2.441867714975121e-11
including O 0 1.8524534683983518e-10
or O 0 8.757822800298243e-10
excluding O 0 9.378090481959589e-08
BRCA1 O 0 8.027966202917014e-08
mutation O 0 8.818606289651143e-09
data O 0 2.2101490415593616e-08
. O 0 1.1557403922779486e-07

Among O 0 2.428373058194211e-09
those O 0 8.464698386667635e-11
families O 0 1.2977124583257726e-11
with O 0 2.7099102042210665e-12
disease O 0 1.7100996174690408e-09
due O 0 1.3886234739857173e-07
to O 0 3.8465785223706916e-07
BRCA1 O 0 5.313474105150817e-08
that O 0 1.146703731969012e-09
were O 0 1.208984024003712e-09
tested O 0 7.128620471696934e-10
by O 0 1.6916293019142437e-11
one O 0 3.141899518332991e-10
of O 0 3.197860309889222e-10
the O 0 1.490670226145241e-10
standard O 0 1.7601421431479025e-09
screening O 0 3.0040944731801744e-10
methods O 0 1.2016212025400819e-08
, O 0 4.0610059759416117e-10
mutations O 0 7.932371981489439e-10
were O 0 9.149942470365602e-10
detected O 0 2.86120260817313e-09
in O 0 1.1961485135714156e-09
the O 0 5.190899265983262e-09
coding O 0 1.86187794071202e-08
sequence O 0 3.3849012481823593e-10
or O 0 3.537063142378116e-10
splice O 0 2.120999598176354e-09
sites O 0 2.3431237505811e-10
in O 0 2.4259263001202847e-11
an O 0 2.779406479275215e-12
estimated O 0 1.3398182736878983e-11
63 O 0 2.4645356866415113e-09
% O 0 1.6930536139714292e-10
( O 0 4.5532296683026274e-11
95 O 0 5.343353493003633e-08
% O 0 1.0666846295137589e-09
CI O 0 6.699387995467987e-07
51 O 0 4.360211391940538e-08
% O 0 1.1864212945411623e-09
- O 0 4.687604260311673e-08
77 O 0 2.716881475350874e-08
% O 0 7.834934367956237e-10
) O 0 6.063242685705461e-10
. O 0 1.973610430638928e-08

The O 0 9.262806344167984e-08
estimated O 0 2.3385973157985518e-09
sensitivity O 0 2.6002611619446725e-08
was O 0 1.4227833133872991e-08
identical O 0 1.2194520948582976e-09
for O 0 2.2408062905210357e-10
direct O 0 4.44239811603353e-10
sequencing O 0 7.935276880033371e-10
and O 0 6.277069974913729e-10
other O 0 1.0114299398011894e-09
techniques O 0 2.6405150492792018e-06
. O 0 7.64985372825322e-07

The O 0 1.4124296967565897e-06
penetrance O 0 2.1932773961452767e-05
of O 0 9.302214039053069e-07
BRCA2 O 0 1.297918174714141e-06
was O 0 8.345276469867713e-09
estimated O 0 4.4340999622027866e-11
by O 0 7.676554704405536e-13
maximizing O 0 9.893749153278009e-10
the O 0 1.6003856018187435e-09
LOD O 0 9.767317351361271e-06
score O 0 1.1110174114037363e-07
in O 0 1.7723822409720924e-08
BRCA2 O 0 6.401697874025558e-07
- O 0 3.8197867979761213e-07
mutation O 0 1.9163974851466037e-09
families O 0 1.1776753183756483e-10
, O 0 4.054812041687228e-11
over O 0 2.5762355790326374e-11
all O 0 2.258187387083055e-10
possible O 0 3.731555064945269e-09
penetrance O 0 2.049312826102323e-07
functions O 0 2.2592220716433076e-07
. O 0 9.688984619060648e-07

The O 0 2.0500900532738342e-08
estimated O 0 2.469169035901331e-10
cumulative O 0 3.883639188018151e-09
risk O 0 1.4862089336986628e-08
of O 0 1.1686588585746449e-08
breast B-Disease 0 1.1583069863263518e-05
cancer I-Disease 0 1.0824438732015551e-06
reached O 0 6.028918164702191e-07
28 O 0 1.2587771891503508e-07
% O 0 4.746086301743446e-10
( O 0 2.3892724604346327e-11
95 O 0 1.6594347229670348e-08
% O 0 1.9620145785825827e-10
CI O 0 9.144542190142602e-08
9 O 0 7.575552629646154e-09
% O 0 2.3535107196437366e-10
- O 0 2.250328812181124e-09
44 O 0 6.186852141709664e-10
% O 0 2.2609619038105322e-11
) O 0 9.83184453989816e-13
by O 0 6.654893107936599e-13
age O 0 2.9926665312540734e-11
50 O 0 2.6120691720699085e-10
years O 0 1.0028633305736445e-11
and O 0 7.073838910465202e-12
84 O 0 3.484008193055388e-09
% O 0 8.968752823745874e-11
( O 0 1.4572718032290766e-11
95 O 0 2.4035783141584943e-08
% O 0 4.885333804161007e-10
CI O 0 3.5368719863981823e-07
43 O 0 1.283094785975436e-08
% O 0 1.3435295931341074e-10
- O 0 2.048736735815737e-09
95 O 0 6.515691985953254e-09
% O 0 3.5584171026448175e-11
) O 0 1.542767866583028e-12
by O 0 9.995095029413648e-13
age O 0 2.6456942192609745e-10
70 O 0 5.566027638792548e-09
years O 0 1.885714917548853e-09
. O 0 4.5025597472658774e-08

The O 0 3.6617043406295124e-06
corresponding O 1 0.9999998807907104
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 3.1433236813427357e-07
were O 0 3.6057403729472526e-09
0 O 0 1.9087600833245233e-07
. O 0 6.938778795984035e-08

4 O 0 4.717490185157658e-07
% O 0 3.3753613237763602e-09
( O 0 5.143410697350248e-11
95 O 0 2.3577992891432586e-08
% O 0 5.466411767685031e-10
CI O 0 3.7703267707911436e-07
0 O 0 7.601418161584661e-09
% O 0 5.172718503532181e-11
- O 0 5.060736829598511e-10
1 O 0 8.924867511694856e-10
% O 0 3.0238110626523707e-11
) O 0 1.1037847068642859e-12
by O 0 5.472599912299814e-13
age O 0 2.6038704178943384e-11
50 O 0 1.0944611189556142e-10
years O 0 6.9285688297782144e-12
and O 0 7.969153982545496e-12
27 O 0 2.2389405884837288e-09
% O 0 9.114196203308111e-11
( O 0 1.45672710005762e-11
95 O 0 1.2991533182571402e-08
% O 0 2.1495560886819476e-10
CI O 0 2.539966601489141e-07
0 O 0 7.104245636213591e-09
% O 0 9.164907027736646e-11
- O 0 2.403801824257812e-09
47 O 0 4.8680166564452065e-09
% O 0 5.0165649412292623e-11
) O 0 4.470324284355787e-12
by O 0 2.161538526293527e-12
age O 0 3.9440881116625803e-10
70 O 0 6.604050195591071e-09
years O 0 4.347561421980117e-09
. O 0 3.75794151352693e-08

The O 0 5.2803361683118055e-08
lifetime O 0 5.835720457980642e-07
risk O 0 5.802799591947405e-07
of O 0 6.571721655745932e-08
breast B-Disease 0 0.00022498065663967282
cancer I-Disease 0 8.336019732269051e-07
appears O 0 4.0580654392385895e-09
similar O 0 2.591821202102551e-10
to O 0 8.045912380794107e-09
the O 0 2.2084341466666046e-08
risk O 0 3.658000480299961e-08
in O 0 1.2037339125470226e-08
BRCA1 O 0 7.111132127590736e-09
carriers O 0 7.838132920490182e-10
, O 0 7.530396445298848e-11
but O 0 3.5500043876757204e-11
there O 0 6.160872506599802e-11
was O 0 8.460118716691056e-10
some O 0 5.750686038474839e-11
suggestion O 0 1.70695491075179e-09
of O 0 4.465573466561068e-10
a O 0 1.2562817452987929e-09
lower O 0 1.216989709007521e-08
risk O 0 5.93346483057644e-09
in O 0 3.946738935667327e-09
BRCA2 O 0 3.346145760474428e-08
carriers O 0 9.466465389351697e-10
< O 0 8.491117853282049e-08
50 O 0 2.550400601819547e-08
years O 0 1.0002433326050664e-09
of O 0 7.616696162671133e-10
age O 0 1.5434920896950644e-08
. O 0 6.953391817887677e-08

Eye B-Disease 1 0.9998582601547241
movement I-Disease 0 4.104174877284095e-05
abnormalities I-Disease 0 1.6408910596510395e-05
correlate O 0 1.3257556474854937e-07
with O 0 1.5689785581862736e-10
genotype O 0 3.058753463847097e-07
in O 0 9.66777733424351e-08
autosomal O 1 0.5327457189559937
dominant O 0 0.01468633208423853
cerebellar B-Disease 1 0.999984860420227
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 3.4928361856145784e-05

We O 0 9.948090564648737e-07
compared O 0 2.516643178296363e-07
horizontal O 0 2.3633431283087702e-06
eye O 0 0.0008202356984838843
movements O 0 1.138118932431098e-06
( O 0 4.250091834023806e-09
visually O 0 7.628000275872182e-08
guided O 0 7.315682637454302e-07
saccades O 0 6.1773525885655545e-06
, O 0 1.4609189413761214e-09
antisaccades O 0 9.93697213402811e-08
, O 0 9.971037884248801e-11
and O 0 2.6691350518692758e-11
smooth O 0 2.444396018930206e-09
pursuit O 0 1.9629972314305633e-08
) O 0 3.087870237283852e-11
in O 0 1.9467980005849483e-10
control O 0 5.967959992858596e-08
subjects O 0 6.658324309682939e-07
( O 0 2.3715215902164744e-10
n O 0 1.1978637637355405e-08
= O 0 8.983609944834825e-08
14 O 0 8.24168200352915e-09
) O 0 1.0134126177119285e-10
and O 0 4.2931876803598e-11
patients O 0 3.7671665786831454e-10
with O 0 1.5975468560872064e-12
three O 0 1.5894386501402735e-11
forms O 0 2.0069799988586823e-10
of O 0 6.03310290614445e-09
autosomal O 0 5.198827238928061e-06
dominant O 0 4.05747505283216e-06
cerebellar B-Disease 0 0.00011613553942879662
ataxias I-Disease 0 6.810227205278352e-05
type I-Disease 0 5.628136023005936e-06
I I-Disease 0 2.59523767454084e-05
spinocerebellar B-Disease 0 0.0005022911936976016
ataxias I-Disease 0 7.323497811739799e-06
1 I-Disease 0 1.8269288659666927e-07
and I-Disease 0 1.178840025595207e-09
2 I-Disease 0 3.0789824023713663e-08
( O 0 1.965595464170633e-10
SCA1 B-Disease 0 5.306951607053634e-07
, O 0 7.294660708812017e-11
n O 0 9.297650427342319e-10
= O 0 5.441862960253729e-09
11 O 0 5.065024510919613e-10
; O 0 3.063828357685594e-11
SCA2 B-Disease 0 9.231447251067948e-08
, O 0 4.87527830606016e-11
n O 0 3.7224542892566603e-10
= O 0 8.072921886537188e-09
10 O 0 9.862961558582128e-10
) O 0 7.818554137450917e-11
and O 0 6.60029364496495e-10
SCA3 B-Disease 1 1.0
/ O 0 4.7640467528253794e-05
Machado B-Disease 0 7.375718382718333e-07
- I-Disease 0 1.315739950769057e-06
Joseph I-Disease 0 8.69023779159761e-07
disease I-Disease 0 0.00330311618745327
( O 0 8.750909441523902e-10
MJD B-Disease 1 1.0
) O 0 5.802893721096325e-10
( O 0 4.8609047342829115e-11
n O 0 4.78012918136983e-09
= O 0 3.630502831697413e-08
16 O 0 1.6669467584051745e-08
) O 0 1.6051606710476563e-09
. O 0 3.545232374335683e-08

In O 0 3.0262563655014674e-07
SCA1 B-Disease 0 1.931687438627705e-05
, O 0 3.311427354546481e-09
saccade O 0 1.162741114058008e-06
amplitude O 0 1.1612109496184075e-08
was O 0 5.020035054315031e-09
significantly O 0 3.1231759400895953e-09
increased O 0 4.5488485200806394e-10
, O 0 1.7505281946217366e-11
resulting O 0 1.037290670025115e-10
in O 0 7.920065714372981e-10
hypermetria B-Disease 0 1.0693016747609363e-06
. O 0 1.2402691140778188e-07

The O 0 7.780234341225878e-07
smooth O 0 1.2478210464905715e-06
pursuit O 0 3.918571110261837e-06
gain O 0 2.539821252867114e-06
was O 0 3.973388729150429e-08
decreased O 0 7.859757999995054e-08
. O 0 4.7492328292264574e-08

In O 0 6.37883204035461e-07
SCA2 B-Disease 0 4.740594158647582e-05
, O 0 9.615619411817988e-09
saccade O 0 1.939620915436535e-06
velocity O 0 2.0335509987035039e-07
was O 0 5.6863974862153555e-08
markedly O 0 3.5778325013779977e-07
decreased O 0 5.426422262644337e-07
. O 0 8.79861730140874e-08

The O 0 5.354045029548615e-08
percentage O 0 1.0288272989100733e-07
of O 0 3.896460043506522e-09
errors O 0 1.306023307279247e-07
in O 0 1.349620593060763e-08
antisaccades O 0 5.4423403526016045e-06
was O 0 2.611618654668746e-08
greatly O 0 8.813565699483661e-08
increased O 0 5.392844837359689e-09
and O 0 8.228275699684318e-11
was O 0 4.823373367379702e-10
significantly O 0 5.979725048455009e-10
correlated O 0 1.0669003458474435e-09
with O 0 6.59734203031781e-12
age O 0 6.411152941865339e-09
at O 0 2.5616085252977427e-08
disease O 0 1.58822288653937e-08
onset O 0 4.6719836177544494e-07
. O 0 1.595309697677294e-07

In O 0 1.3575362167728144e-08
addition O 0 2.7452278228423665e-09
, O 0 1.2789641568033971e-10
a O 0 1.548007277918373e-10
correlation O 0 1.2981388186616982e-10
between O 0 4.467155811926915e-11
smooth O 0 1.9466403600176818e-08
pursuit O 0 5.158312532671516e-08
gain O 0 6.638416039095318e-08
and O 0 5.1102126003010895e-11
the O 0 1.8864551587505218e-10
number O 0 2.1179624720701895e-10
of O 0 3.5910233120439727e-10
trinucleotide O 0 4.6310037760122214e-07
repeats O 0 9.976411696754894e-09
was O 0 4.159344513254837e-08
found O 0 9.807103573677978e-09
. O 0 1.59697648882684e-07

In O 0 1.7195978898598696e-06
SCA3 B-Disease 1 1.0
, O 0 1.4723616459377808e-07
gaze B-Disease 0 6.31707880529575e-05
- I-Disease 0 5.7131339417537674e-05
evoked I-Disease 0 3.231290065741632e-06
nystagmus I-Disease 0 2.8495212973211892e-05
was O 0 1.2042208119567022e-08
often O 0 2.8733954451909405e-11
present O 0 4.007564419206133e-11
as O 0 1.0137799627552013e-10
was O 0 9.34198385316165e-10
saccade O 0 2.635108842241607e-07
hypometria O 0 2.1584412479569437e-07
and O 0 3.1004199207984584e-09
smooth O 0 6.083486141506e-07
pursuit O 0 1.4729413123859558e-05
gain O 0 1.013397104543401e-05
was O 0 5.245983558666012e-08
markedly O 0 1.0838988373507163e-07
decreased O 0 1.4846710882920888e-07
. O 0 2.9373412147037925e-08

Three O 0 5.36862749811462e-08
major O 0 1.52427670485622e-08
criteria O 0 8.0620921494301e-08
, O 0 1.070696198368637e-09
saccade O 0 1.1890973610206856e-06
amplitude O 0 3.404023374287135e-08
, O 0 7.324723605428574e-10
saccade O 0 3.4383148772576533e-07
velocity O 0 1.680379746460403e-08
, O 0 1.593564863400232e-10
and O 0 1.0461802951722277e-10
presence O 0 6.6003975618400545e-09
of O 0 4.196254721477999e-08
gaze B-Disease 0 6.525758362840861e-05
- I-Disease 0 1.473659085604595e-05
evoked I-Disease 0 5.71629016121733e-07
nystagmus I-Disease 0 8.851392863107321e-07
, O 0 3.045987073679868e-11
permitted O 0 3.735698139717414e-10
the O 0 8.191773648302814e-11
correct O 0 2.459196846160694e-09
assignment O 0 4.762692462634277e-09
of O 0 3.4612218646756787e-10
90 O 0 2.4930733033556862e-09
% O 0 1.6982573680657254e-10
of O 0 1.5545344178580223e-10
the O 0 2.0158652525026355e-10
SCA1 B-Disease 0 7.684923986062131e-08
, O 0 1.745537048236656e-11
90 O 0 1.1665781673997344e-09
% O 0 8.281587915437427e-11
of O 0 1.6127275903610183e-10
the O 0 2.667711329618072e-10
SCA2 B-Disease 0 1.7412641284408892e-07
, O 0 4.434015307697159e-11
and O 0 2.3837466722742562e-11
93 O 0 7.612531938150369e-09
% O 0 9.591467203806658e-11
of O 0 8.110184746001892e-11
the O 0 7.280732960968095e-11
patients O 0 8.720114214044727e-11
with O 0 1.2529612763989562e-11
SCA3 B-Disease 1 1.0
to O 0 2.4527156483600265e-07
their O 0 2.700514301068324e-08
genetically O 0 2.1881406908619283e-08
confirmed O 0 1.969312535265999e-08
patient O 0 2.0273932932468597e-07
group O 0 9.472534978627323e-10
and O 0 4.559680688576151e-10
, O 0 1.2703092744370537e-10
therefore O 0 1.3736319859347645e-09
, O 0 7.448800604104022e-11
may O 0 3.807186121917994e-09
help O 0 3.470658782589453e-08
orient O 0 1.923071749843075e-06
diagnoses O 0 2.1227355318842456e-05
of O 0 2.7949244696401365e-08
SCA1 B-Disease 0 1.457761027268134e-05
, O 0 1.4441493556560658e-09
SCA2 B-Disease 0 2.2574677132070065e-06
, O 0 8.629350012334669e-10
and O 0 1.1723598758450748e-09
SCA3 B-Disease 1 1.0
at O 0 4.8228635307623335e-08
early O 0 3.857006447560707e-08
clinical O 0 7.567219739712527e-09
stages O 0 9.288579683186526e-09
of O 0 9.79839054338072e-09
the O 0 1.3380914154481616e-08
diseases O 0 5.717927109571974e-08
. O 0 3.7466172386757535e-09
. O 0 4.422130217562881e-08

Genetic O 0 3.141867352951522e-07
basis O 0 5.394524649204868e-08
and O 0 3.2573768682375714e-10
molecular O 0 8.869071588257782e-10
mechanism O 0 1.2071485855358333e-07
for O 0 1.9218163060941151e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.0006234467728063464

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 4.138067595249595e-07
more O 0 5.8121403523347936e-11
than O 0 7.832535835194943e-12
300 O 0 1.7734422264048533e-10
, O 0 5.916165994601652e-12
000 O 0 2.3831502105053914e-08
sudden O 0 1.353835266115766e-09
deaths O 0 5.487782797630736e-11
each O 0 1.182441297653547e-12
year O 0 6.050324824480313e-11
in O 0 6.54233833774498e-10
the O 0 1.526767334780743e-08
USA O 0 6.893761792525765e-07
alone O 0 1.1069118954765145e-07
. O 0 1.2242983871146862e-07

In O 0 2.8067304924661585e-08
approximately O 0 3.5406472198573624e-10
5 O 0 6.016015241527839e-09
- O 0 4.1526778460365676e-08
12 O 0 3.06951832840241e-08
% O 0 1.696199403156129e-09
of O 0 2.4799162723354584e-10
these O 0 8.04247900915156e-12
cases O 0 1.451075544445235e-11
, O 0 4.076398940622283e-12
there O 0 6.1319239616497434e-12
are O 0 1.2017867603852928e-11
no O 0 1.416908701479258e-09
demonstrable O 0 8.66162827151129e-06
cardiac O 1 0.9999914169311523
or O 0 6.259130032049143e-07
non O 1 1.0
- O 1 0.9999938011169434
cardiac O 1 1.0
causes O 0 1.8841669202629419e-07
to O 0 3.123174219243907e-10
account O 0 7.885844061084057e-11
for O 0 5.3637469465961374e-11
the O 0 9.573433157328282e-10
episode O 0 1.5861946423001427e-08
, O 0 2.0048833426766777e-10
which O 0 1.2325527751211318e-11
is O 0 2.081409263693379e-12
therefore O 0 4.7329484081926054e-11
classified O 0 4.19652257388492e-10
as O 0 1.0047009446623179e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 4.251754059936275e-09
IVF B-Disease 1 1.0
) O 0 1.6380126144355245e-09
. O 0 1.1631105856224622e-08

A O 0 2.4480748379573924e-06
distinct O 0 2.7041894057333593e-08
group O 0 6.670410446218966e-09
of O 0 6.7871468445446226e-09
IVF B-Disease 1 1.0
patients O 0 1.8052759287456865e-07
has O 0 1.6342413533543265e-11
been O 0 1.4669487846674656e-11
found O 0 6.655886779227682e-12
to O 0 7.117693240354939e-11
present O 0 1.0005749007113707e-10
with O 0 4.861015756585374e-11
a O 0 9.522282518048542e-09
characteristic O 0 1.767126356355675e-08
electrocardiographic O 0 1.0110428547704942e-06
pattern O 0 1.2681365291200564e-08
. O 0 8.895882075421468e-08

Because O 0 3.41756170030294e-08
of O 0 1.3731296988339636e-08
the O 0 3.6594918206844795e-09
small O 0 3.4129721271369817e-10
size O 0 4.2811714173751625e-09
of O 0 1.4356876798515827e-09
most O 0 9.346577678481793e-11
pedigrees O 0 1.2729487464113731e-09
and O 0 3.8280219272213145e-11
the O 0 1.5631092253887147e-10
high O 0 1.0032278341398637e-09
incidence O 0 3.1580507098283306e-09
of O 0 2.74824912827043e-10
sudden B-Disease 0 4.2200745120624106e-09
death I-Disease 0 5.550231385598181e-09
, O 0 1.684511280464207e-10
however O 0 8.288356112551298e-10
, O 0 1.421322642913836e-10
molecular O 0 1.7351555747779912e-09
genetic O 0 1.3373712137720872e-09
studies O 0 7.456128159333275e-09
of O 0 1.4635078038338634e-08
IVF B-Disease 1 1.0
have O 0 4.902399375339428e-09
not O 0 5.797627378179016e-10
yet O 0 6.862015955455547e-10
been O 0 7.413086811070002e-10
done O 0 4.016577648258135e-08
. O 0 2.203877471629312e-07

Because O 0 5.491711476679484e-07
IVF B-Disease 1 1.0
causes O 0 3.6895787616231246e-06
cardiac O 1 0.9999909400939941
rhythm O 0 0.027797678485512733
disturbance O 0 1.1256075822529965e-06
, O 0 4.1593009592055807e-10
we O 0 2.07991623923931e-09
investigated O 0 6.211733794003749e-09
whether O 0 9.975384074323301e-09
malfunction O 0 2.768894592009019e-05
of O 0 6.39716901673637e-08
ion O 0 3.2647699299559463e-07
channels O 0 1.0565551633590076e-07
could O 0 1.0789666937682796e-08
cause O 0 6.662603357909802e-09
the O 0 1.9458412658934776e-09
disorder O 0 1.3367265516706084e-08
by O 0 6.545252187462047e-12
studying O 0 3.20442367085505e-10
mutations O 0 4.354877222723097e-11
in O 0 1.8509066501692928e-10
the O 0 5.190226470830339e-09
cardiac O 0 1.525035077065695e-05
sodium O 0 1.2244470326550072e-06
channel O 0 4.508901696453904e-08
gene O 0 2.22991509701842e-08
SCN5A O 0 2.324508568563033e-05
. O 0 1.8716285694608814e-06

We O 0 6.523130480218242e-08
have O 0 4.417202714712687e-10
now O 0 2.3133354953852603e-10
identified O 0 1.989289843962183e-09
a O 0 6.302830257709502e-09
missense O 0 5.583744950854452e-07
mutation O 0 1.569473973006552e-08
, O 0 6.643768313274734e-10
a O 0 1.8550213587431585e-09
splice O 0 3.7136075548005465e-08
- O 0 3.115627222882722e-08
donor O 0 1.2701844909202009e-08
mutation O 0 8.8429907840748e-10
, O 0 3.2861678656015414e-11
and O 0 5.448566944843414e-11
a O 0 1.5108395645668793e-09
frameshift O 0 2.0805401845791494e-08
mutation O 0 6.552537679116455e-11
in O 0 1.1374669955932504e-10
the O 0 9.31390853331493e-10
coding O 0 3.046590180133535e-08
region O 0 7.361618870049824e-09
of O 0 8.74954508844894e-09
SCN5A O 0 1.3413670103545883e-06
in O 0 2.1676893613431503e-09
three O 0 7.039309135592475e-10
IVF B-Disease 1 1.0
families O 0 3.1592737315122577e-09
. O 0 1.68400848821193e-08

We O 0 8.16881851051221e-08
show O 0 6.017656595247445e-09
that O 0 5.3113683590177985e-11
sodium O 0 3.6955170035213314e-09
channels O 0 5.1419613011916e-10
with O 0 2.0602160602511965e-11
the O 0 6.35798569348367e-09
missense O 0 1.6517918766112416e-06
mutation O 0 8.554108177349917e-08
recover O 0 7.842548939152039e-07
from O 0 6.548333875144863e-09
inactivation O 0 1.8683599023461284e-07
more O 0 7.103063137670063e-10
rapidly O 0 9.829795866167501e-10
than O 0 9.64977837220049e-12
normal O 0 1.1333804728064223e-10
and O 0 1.913809215270401e-11
that O 0 2.781072941382412e-11
the O 0 1.2680488881144925e-09
frameshift O 0 1.18048524200276e-06
mutation O 0 1.0508810710518901e-08
causes O 0 1.9626593683597093e-09
the O 0 1.4820525917613736e-09
sodium O 0 7.233045806742666e-08
channel O 0 1.1612087291723583e-08
to O 0 1.2859312503721299e-09
be O 0 1.2096574852904496e-09
non O 0 3.019824816874461e-07
- O 0 2.400916798706021e-07
functional O 0 5.2030407005077e-07
. O 0 2.9475791052391287e-07

Our O 0 5.385764438869955e-07
results O 0 2.5624881772046137e-08
indicate O 0 1.0111680381896804e-08
that O 0 6.438153482557496e-11
mutations O 0 2.69885364057032e-10
in O 0 6.888609682675906e-10
cardiac O 0 7.815074241079856e-07
ion O 0 4.6417571297752147e-07
- O 0 2.5960398488678038e-05
channel O 0 2.5121065050370817e-07
genes O 0 8.378893689986455e-10
contribute O 0 1.3333774084856032e-09
to O 0 2.1735351296570116e-09
the O 0 1.6601241492608665e-09
risk O 0 5.596644037098031e-09
of O 0 7.057162632051472e-10
developing O 0 3.3477416394589454e-08
IVF B-Disease 1 1.0
. O 0 7.272041102623916e-08
. O 0 2.0619415863620816e-07

Molecular O 0 2.524836020256771e-07
heterogeneity O 0 6.241902639203545e-08
in O 0 1.5587193757937712e-08
mucopolysaccharidosis B-Disease 0 6.208204467839096e-06
IVA I-Disease 0 1.4245236343413126e-05
in O 0 4.1156489771765337e-08
Australia O 0 7.0848140687473915e-09
and O 0 2.5429406844135194e-11
Northern O 0 9.023166658295168e-10
Ireland O 0 8.122806316457343e-10
: O 0 2.6627089422248673e-10
nine O 0 3.131405690304234e-10
novel O 0 4.6165621325755524e-10
mutations O 0 4.219380678183171e-10
including O 0 2.07381084527114e-10
T312S O 0 3.566842394775449e-07
, O 0 7.701292381590008e-10
a O 0 2.2610071592765735e-09
common O 0 2.817305722047081e-09
allele O 0 4.8471329172627975e-09
that O 0 6.409189845513197e-11
confers O 0 3.51418947275306e-08
a O 0 2.115461583684919e-08
mild O 0 1.842490746639669e-07
phenotype O 0 4.6814388809934826e-08
. O 0 1.1064559402029772e-07

Mucopolysaccharidosis B-Disease 0 0.002384982304647565
IVA I-Disease 1 0.99565589427948
( O 0 2.6215259367745603e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 3.1406742095896334e-08
is O 0 2.471351789878895e-09
an O 0 2.7713749073399185e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 1.0107635972644857e-07
by O 0 3.246774377130279e-11
a O 0 6.794157059175632e-08
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 5.246711680229055e-06
N O 0 1.2427286719685071e-06
- O 0 4.858196120949287e-07
acetylgalactosamine O 0 6.268960532906931e-06
- O 0 3.2453046969749266e-06
6 O 0 6.806052260799333e-05
- O 0 0.00023651568335480988
sulfate O 0 2.5553596060490236e-05
sulfatase O 0 3.6162724427413195e-05
( O 0 7.530744916550702e-10
GALNS O 0 1.7695467704470502e-06
) O 0 1.8379684441072186e-09
. O 0 2.558083522785637e-08

Previous O 0 9.73201252918443e-08
studies O 0 7.757997799728855e-09
of O 0 2.879838312264127e-10
patients O 0 5.5853772995551054e-11
from O 0 1.2462281206992998e-11
a O 0 1.425348727934761e-10
British O 0 2.437347434991466e-09
- O 0 1.2414377970060286e-08
Irish O 0 6.718186562615358e-10
population O 0 1.828114222501842e-11
showed O 0 9.08881650496518e-11
that O 0 2.7895398664601334e-12
the O 0 1.3957685007781606e-10
I113F O 0 1.489249967789874e-07
mutation O 0 1.8679131574828034e-09
is O 0 1.13694421932653e-10
the O 0 3.248324387250534e-10
most O 0 7.404039187308697e-11
common O 0 2.4969171175115434e-10
single O 0 2.0702115577364566e-09
mutation O 0 3.2166420638191084e-09
among O 0 8.377023519301474e-10
MPS B-Disease 1 0.999998927116394
IVA I-Disease 1 1.0
patients O 0 4.232400442560902e-06
and O 0 1.8850390137714612e-09
produces O 0 5.273999570398757e-10
a O 0 3.1779787690311423e-09
severe O 0 2.18842028942845e-08
clinical O 0 1.079860609820571e-07
phenotype O 0 6.710213540372933e-08
. O 0 4.2372971620352473e-07

We O 0 2.0214103813032125e-07
studied O 0 4.6568949585434893e-08
mutations O 0 2.615101468705916e-09
in O 0 3.1974349834484883e-09
the O 0 6.156121390432645e-09
GALNS O 0 4.7131374003583915e-07
gene O 0 5.814038694929025e-10
from O 0 1.8598138307179823e-10
23 O 0 2.612889282715969e-08
additional O 0 1.9454715527444932e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.0625082040860434e-06
( O 0 2.939752608011048e-11
15 O 0 2.5026305472408694e-09
from O 0 3.39809763660881e-10
Australia O 0 8.672580431579036e-10
, O 0 1.0207410437723663e-11
8 O 0 4.309836654226018e-10
from O 0 6.146060049783131e-11
Northern O 0 5.26112930998579e-10
Ireland O 0 1.0884618761863862e-09
) O 0 9.695962782663159e-11
, O 0 8.121469469157816e-11
with O 0 5.247113941259096e-12
various O 0 4.27215568477024e-10
clinical O 0 4.51029507075873e-08
phenotypes O 0 6.471502445037913e-08
( O 0 7.312676575388366e-10
severe O 0 2.568370405242604e-07
, O 0 3.7838157607161804e-10
16 O 0 5.714020812064291e-09
cases O 0 9.2466596879337e-11
; O 0 8.669181691955963e-12
intermediate O 0 5.903074140611864e-10
, O 0 8.375466119259212e-12
4 O 0 6.039719835371216e-10
cases O 0 7.47266415412895e-11
; O 0 1.916626579667735e-10
mild O 0 1.093418955377956e-08
, O 0 2.719775793469381e-11
3 O 0 1.6347790898763037e-09
cases O 0 4.262705743940387e-10
) O 0 5.738986508241339e-10
. O 0 7.265538926048976e-08

We O 0 5.625993253488559e-07
found O 0 1.3726949354975204e-08
two O 0 4.5526066250189956e-10
common O 0 4.1578654408347404e-10
mutations O 0 2.873605242648125e-10
that O 0 9.763992565858803e-12
together O 0 2.798813047641402e-12
accounted O 0 4.039576173564541e-10
for O 0 7.836006149508634e-11
32 O 0 2.2117093934070908e-08
% O 0 1.0103906600278378e-09
of O 0 3.5382792251681394e-09
the O 0 5.4530433502009146e-09
44 O 0 1.9300994580362385e-08
unrelated O 0 5.47630740754812e-09
alleles O 0 9.227548725121437e-10
in O 0 1.5817255283323561e-09
these O 0 2.5581650131556444e-09
patients O 0 9.164549119589083e-09
. O 0 3.04586365018622e-08

One O 0 3.9090945591624404e-08
is O 0 5.467370445266795e-10
the O 0 1.5035521716555422e-09
T312S O 0 1.1681862588375225e-06
mutation O 0 9.40484845557421e-09
, O 0 2.1398202654232534e-10
a O 0 7.122123446556827e-10
novel O 0 3.994115260752551e-09
mutation O 0 2.2532062882163473e-09
found O 0 1.6704748695417493e-10
exclusively O 0 9.635717779232778e-10
in O 0 1.0368441660801864e-09
milder O 0 1.3050745906184602e-07
patients O 0 2.0838562875269417e-08
. O 0 6.124572138332951e-08

The O 0 1.931407354049952e-07
other O 0 5.624174459484266e-10
is O 0 5.629012186925131e-11
the O 0 1.2687496886432115e-10
previously O 0 3.0946063489523112e-09
described O 0 1.7678705166446207e-09
I113F O 0 8.07340256869793e-08
that O 0 3.83180605301181e-11
produces O 0 5.792904697599077e-11
a O 0 1.2280884087445543e-09
severe O 0 1.5484518556263538e-08
phenotype O 0 9.443715498491656e-08
. O 0 3.4647399616005714e-07

The O 0 9.749306855155737e-07
I113F O 0 1.0150260095542762e-05
and O 0 1.0034810316028597e-08
T312S O 0 1.6491097767357132e-06
mutations O 0 2.043405666896092e-09
accounted O 0 1.8940742307904657e-09
for O 0 2.619123529168377e-10
8 O 0 2.111732477771966e-08
( O 0 6.9397480817468e-11
18 O 0 2.1977095698844096e-09
% O 0 4.283094712231872e-11
) O 0 4.150001522984503e-12
and O 0 8.4437960096162e-12
6 O 0 1.6125037971548295e-09
( O 0 2.4898678605000946e-11
14 O 0 1.1050629300513037e-09
% O 0 2.9046388558273684e-11
) O 0 1.617334911829804e-11
of O 0 1.1604990579616725e-10
44 O 0 8.695538178393747e-10
unrelated O 0 1.7315386902083674e-09
alleles O 0 9.084124563685236e-10
, O 0 5.845305905971543e-10
respectively O 0 6.040762201564576e-08
. O 0 1.5594902436077973e-07

The O 0 8.197503689189034e-07
relatively O 0 1.5954344689816935e-07
high O 0 5.705724959170766e-08
residual O 0 4.211200064219156e-07
GALNS O 0 1.2651258884943672e-06
activity O 0 1.1003102429185674e-08
seen O 0 1.878248667708249e-09
when O 0 3.3196656534784097e-10
the O 0 1.517088454860982e-09
T312S O 0 4.881165693859657e-08
mutant O 0 7.126176981842036e-09
cDNA O 0 4.2506290043320405e-08
is O 0 2.184740832689158e-09
overexpressed O 0 3.944265642985556e-07
in O 0 5.632325716931064e-09
mutant O 0 7.78129471967759e-09
cells O 0 2.75182254760864e-09
provides O 0 5.886658382969756e-10
an O 0 3.4378611069030285e-12
explanation O 0 1.5409637454943947e-10
for O 0 2.838229824775329e-11
the O 0 6.788515305444776e-10
mild O 0 9.743096995862288e-09
phenotype O 0 3.37559935559284e-09
in O 0 1.9665290229564647e-10
patients O 0 1.8236920307224125e-10
with O 0 6.743517961919909e-13
this O 0 1.2528950099621738e-10
mutation O 0 1.378576919286445e-09
. O 0 2.8847559008227108e-08

The O 0 8.236825443930229e-09
distribution O 0 9.533085432167354e-11
and O 0 6.002847958291868e-12
relative O 0 5.119375479090138e-10
frequencies O 0 1.1132330612895203e-09
of O 0 3.769423384536452e-10
the O 0 1.2646528269044666e-09
I113F O 0 6.217639025862809e-08
and O 0 4.323297830843842e-10
T312S O 0 9.819235202712662e-08
mutations O 0 4.46674891518839e-10
in O 0 7.189451811662195e-10
Australia O 0 2.7372490940535954e-09
corresponded O 0 1.8552256952908408e-10
to O 0 2.7188745699291417e-10
those O 0 1.7311208022618985e-11
observed O 0 6.694302057130841e-11
in O 0 1.0621566820523398e-10
Northern O 0 2.351842498526935e-09
Ireland O 0 1.9755568292367798e-09
and O 0 9.903260156374216e-11
are O 0 9.539901854593857e-12
unique O 0 8.861829325912396e-11
to O 0 2.2044883973837415e-10
these O 0 2.131224884072136e-11
two O 0 1.1600115833176883e-11
populations O 0 1.4310439985787404e-11
, O 0 2.001245003047103e-11
suggesting O 0 8.9348828336e-10
that O 0 3.204837784043235e-11
both O 0 1.1406584704554135e-10
mutations O 0 1.59589161330409e-10
were O 0 3.281847849034847e-10
probably O 0 8.726890321497649e-10
introduced O 0 2.2528152676670743e-09
to O 0 3.5489111649411598e-09
Australia O 0 1.0988625565033772e-09
by O 0 8.372016621627232e-12
Irish O 0 4.95437968428547e-10
migrants O 0 2.261171028195008e-09
during O 0 1.6060640595227937e-09
the O 0 5.592287743994007e-10
19th O 0 4.453278634741764e-08
century O 0 3.7535579622272053e-07
. O 0 1.1621364137681667e-07

Haplotype O 0 1.2315827007114422e-05
analysis O 0 1.1792931076115565e-07
using O 0 3.44166046772898e-08
6 O 0 2.5921261226358183e-07
RFLPs O 0 1.752179628056183e-06
provides O 0 5.850618656211282e-09
additional O 0 1.0964089636189556e-09
data O 0 1.404809935046103e-09
that O 0 8.618226271517315e-11
the O 0 1.6512723410855301e-09
I113F O 0 3.6843007933384797e-07
mutation O 0 2.528504905452422e-10
originated O 0 4.64073474093496e-10
from O 0 1.4946133219950752e-10
a O 0 8.320636957215299e-10
common O 0 1.4702947748190809e-09
ancestor O 0 1.3944374188668007e-07
. O 0 7.9828915033886e-08

The O 0 2.4103596274471784e-07
other O 0 8.530245954041504e-10
9 O 0 2.3693040418493183e-08
novel O 0 3.2670850469429524e-09
mutations O 0 2.6757283055900416e-09
identified O 0 1.9503223480654697e-09
in O 0 3.740161236276407e-10
these O 0 1.7517882977546861e-10
23 O 0 1.5777127160276905e-08
patients O 0 5.431926020094124e-10
were O 0 3.034534429291469e-11
each O 0 8.835361262060637e-12
limited O 0 1.3618846050889033e-09
to O 0 2.4491841887908095e-09
a O 0 3.888990907086054e-09
single O 0 4.9759194098442094e-08
family O 0 3.35082113167573e-08
. O 0 2.6271823116985615e-07

These O 0 1.941446043929318e-07
data O 0 3.2318091314209596e-08
provide O 0 1.6576372496857061e-09
further O 0 2.0961722635437496e-10
evidence O 0 2.141943566957849e-10
for O 0 9.6237566526991e-11
extensive O 0 3.3011229305657253e-09
allelic O 0 5.079502329863317e-08
heterogeneity O 0 1.7990675615919827e-08
in O 0 4.7028823502159867e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
in O 0 9.01787515772412e-08
British O 0 5.634412900690222e-07
- O 0 8.033968015297432e-07
Irish O 0 1.243709912834845e-09
patients O 0 3.538379034218053e-10
and O 0 8.433088754221385e-13
provide O 0 7.323166378858659e-12
evidence O 0 1.1914976817684053e-11
for O 0 1.6313790596189648e-11
their O 0 6.669262364589201e-10
transmission O 0 1.0334373001796848e-07
to O 0 2.963842504755121e-08
Australia O 0 1.7002815155819917e-08
by O 0 2.050455777391491e-10
British O 0 1.8097441056852404e-07
- O 0 2.2076156369621458e-07
Irish O 0 3.5838407796973115e-09
migrants O 0 3.0860363153806247e-09
. O 0 3.5858901958896183e-10
. O 0 8.45276826311192e-09

Identification O 0 3.2570685561950086e-06
of O 0 7.394565386675822e-07
constitutional O 0 6.13624943071045e-05
WT1 O 0 0.004789633676409721
mutations O 0 2.0066994466105825e-07
, O 0 5.117764545481407e-10
in O 0 2.5451932228470753e-10
patients O 0 2.966961398787049e-10
with O 0 1.844009667184565e-11
isolated O 0 7.758223574683143e-08
diffuse B-Disease 0 0.002043194370344281
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 8.101921800118816e-09
and O 0 1.885224892861359e-10
analysis O 0 4.942620979164758e-09
of O 0 2.727666092994241e-08
genotype O 0 2.564107262514881e-06
/ O 0 2.5166405976051465e-05
phenotype O 0 2.1503947067458284e-08
correlations O 0 2.413705624260132e-10
by O 0 2.3683291439091647e-11
use O 0 4.487570759437176e-09
of O 0 4.172843404148807e-09
a O 0 9.5636911723318e-09
computerized O 0 3.3917524433491053e-07
mutation O 0 9.928404764991683e-09
database O 0 8.346203372866512e-08
. O 0 2.523622697481187e-07

Constitutional O 0 1.00341894722078e-05
mutations O 0 1.5959091115291812e-07
of O 0 3.3109994745927906e-08
the O 0 1.673381611055902e-08
WT1 O 0 2.825977617249009e-06
gene O 0 1.3319241709552898e-08
, O 0 5.163642291527992e-10
encoding O 0 1.5060241054243306e-08
a O 0 8.781650251421524e-08
zinc O 0 0.0006142056081444025
- O 0 0.00010244882287224755
finger O 0 3.902266598743154e-06
transcription O 0 1.1763652310037287e-06
factor O 0 1.8962229830776778e-07
involved O 0 3.644529789070816e-09
in O 0 1.2768936130669317e-08
renal O 1 1.0
and O 0 3.4343927381996764e-06
gonadal O 1 1.0
development O 1 0.9999897480010986
, O 0 1.9803856332600844e-09
are O 0 3.879666726769315e-11
found O 0 5.043485767908251e-11
in O 0 4.815814760861237e-11
most O 0 3.484403390818791e-11
patients O 0 6.154189657880949e-11
with O 0 1.3801198031626605e-11
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.155200024527403e-08
DDS B-Disease 1 1.0
) O 0 1.237002944520782e-09
, O 0 2.783727692801108e-10
or O 0 6.1453984123716054e-09
diffuse B-Disease 0 0.045414701104164124
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.0237354963749112e-08
DMS B-Disease 0 4.387573426356539e-05
) O 0 1.0076380702050969e-10
associated O 0 1.700673268878461e-09
with O 0 8.785993460547203e-11
pseudohermaphroditism B-Disease 1 1.0
and O 0 5.708740502541332e-08
/ O 0 0.006366737652570009
or O 0 3.3574622193555115e-07
Wilms B-Disease 1 0.882458508014679
tumor I-Disease 0 5.72054268559441e-05
( O 0 5.698957306066177e-09
WT B-Disease 1 0.9999997615814209
) O 0 1.1650134190688277e-08
. O 0 9.473319551034365e-08

Most O 0 1.2738533428091614e-07
mutations O 0 3.205827070473788e-08
in O 0 2.1828592267070235e-08
DDS B-Disease 1 1.0
patients O 0 3.2391887998528546e-06
lie O 0 9.403324341406005e-09
in O 0 3.1100488850910324e-10
exon O 0 8.975676202283012e-09
8 O 0 1.0564765773324325e-07
or O 0 8.027625675310901e-09
exon O 0 5.400804781174884e-08
9 O 0 2.258022249179703e-07
, O 0 5.620864218514043e-09
encoding O 0 3.707168332311994e-07
zinc O 0 0.4967617392539978
finger O 0 6.504106568172574e-05
2 O 0 9.38609355216613e-06
or O 0 2.993978966969735e-07
zinc O 0 0.00017724299686960876
finger O 0 5.545953740693221e-07
3 O 0 6.007739017377389e-08
, O 0 1.4557390015657035e-10
respectively O 0 6.981678568607208e-10
, O 0 1.6770472163751826e-11
with O 0 3.0293857700147697e-12
a O 0 3.0176432463946412e-09
hot O 0 5.366374580262345e-07
spot O 0 2.78022334043726e-08
( O 0 9.778926279846445e-11
R394W O 0 6.374040140144643e-08
) O 0 6.498916682584621e-11
in O 0 1.2973523366710538e-09
exon O 0 1.1132659238910492e-07
9 O 0 1.0848332294699503e-06
. O 0 6.241295409381564e-07

We O 0 1.1964668544806045e-07
analyzed O 0 3.023780692501532e-08
a O 0 1.9951795771078196e-09
series O 0 8.390024230919835e-10
of O 0 1.7348965319907705e-10
24 O 0 6.1660627714843486e-09
patients O 0 6.747002401219504e-10
, O 0 3.204978296644789e-11
10 O 0 3.137062387637002e-09
with O 0 6.127721108306616e-10
isolated B-Disease 0 2.1239636680547846e-06
DMS I-Disease 1 0.9639173150062561
( O 0 2.8795446027629623e-08
IDMS B-Disease 0 0.0002995332470163703
) O 0 8.408158613804062e-10
, O 0 1.6802530200532573e-10
10 O 0 2.7571813721039007e-09
with O 0 2.664405918118007e-10
DDS B-Disease 1 1.0
, O 0 2.2967265866924436e-09
and O 0 2.5583929419426e-10
4 O 0 5.038474171215057e-08
with O 0 1.2479705047141465e-09
urogenital B-Disease 0 9.582348866388202e-05
abnormalities I-Disease 0 0.0020994413644075394
and O 0 7.654949030211355e-08
/ O 1 0.99989914894104
or O 0 2.720231714192778e-05
WT B-Disease 1 1.0
. O 0 4.699179953604471e-06

We O 0 1.5083057860465487e-06
report O 0 2.625000945499778e-07
WT1 O 0 0.0001388111268170178
heterozygous O 0 8.0782541544977e-08
mutations O 0 1.3054594072414716e-09
in O 0 4.869685765740428e-10
16 O 0 6.338031877106687e-09
patients O 0 1.032589125316008e-09
, O 0 1.3906657075901663e-11
4 O 0 4.995973412746935e-09
of O 0 1.349663603100737e-09
whom O 0 5.812577974495525e-09
presented O 0 7.280326741465615e-08
with O 0 2.7462030871561183e-08
IDMS B-Disease 1 0.9999953508377075
. O 0 3.7432775570778176e-05

One O 0 1.0404526307183914e-07
male O 0 1.4113019197736776e-08
and O 0 7.535300161620739e-10
two O 0 8.807423679257909e-10
female O 0 6.181182232722904e-09
IDMS B-Disease 0 0.00015085841005202383
patients O 0 2.068058364557146e-07
with O 0 3.2694662532861685e-09
WT1 O 1 0.9997932314872742
mutations O 0 1.8179958715336397e-05
underwent O 0 0.04810597375035286
normal O 0 1.9686460291268304e-05
puberty O 0 1.8167896996601485e-05
. O 0 2.7914464340028644e-07

Two O 0 9.938618177329772e-07
mutations O 0 8.620852298690806e-08
associated O 0 2.6454173962520144e-07
with O 0 2.952252220467244e-09
IDMS B-Disease 0 0.0017454569460824132
are O 0 2.8994592837783273e-10
different O 0 6.351046771824187e-11
from O 0 1.9352988656073933e-10
those O 0 1.9691077934869128e-10
described O 0 1.2694741924335062e-09
in O 0 8.685662855612009e-09
DDS B-Disease 1 1.0
patients O 0 8.742406976125494e-07
. O 0 5.5725738690171056e-08

No O 0 8.53538131195819e-06
WT1 O 0 6.289165321504697e-05
mutations O 0 1.8191175854553876e-07
were O 0 1.4988685848038585e-08
detected O 0 1.2489618228528343e-08
in O 0 2.377927188490503e-09
the O 0 1.4254154301340805e-08
six O 0 1.3283469435521056e-08
other O 0 8.645857363376308e-10
IDMS B-Disease 0 0.01862819492816925
patients O 0 7.85882861009668e-08
, O 0 3.498403233770375e-10
suggesting O 0 7.037514127006261e-09
genetic O 0 7.0421872777615135e-09
heterogeneity O 0 4.452616408912036e-08
of O 0 2.02509298219411e-08
this O 0 7.836282733819644e-09
disease O 0 7.329887807827618e-08
. O 0 7.311763283723849e-08

We O 0 2.4558478344260948e-06
analyzed O 0 2.000834001592011e-06
genotype O 0 7.902937795734033e-06
/ O 0 2.8388076316332445e-05
phenotype O 0 9.224758201753502e-08
correlations O 0 2.044895142105929e-09
, O 0 3.360634340254798e-11
on O 0 2.1831027263718994e-10
the O 0 1.9189923955442723e-11
basis O 0 6.329509139035849e-11
of O 0 2.2154975770627416e-11
the O 0 4.906772210766519e-11
constitution O 0 8.372507132037299e-09
of O 0 1.1976369895805306e-09
a O 0 2.5229516253943984e-09
WT1 O 0 4.370346232462907e-06
mutation O 0 3.315927310509892e-09
database O 0 4.324685498602321e-09
of O 0 1.5349334026026895e-09
84 O 0 1.596792174041184e-07
germ O 0 0.0008098878897726536
- O 0 0.0001832407433539629
line O 0 8.986331181404239e-07
mutations O 0 3.775548762519065e-09
, O 0 8.741896789787873e-11
to O 0 6.652783879346202e-10
compare O 0 6.541193364739684e-09
the O 0 5.97530136481339e-10
distribution O 0 2.477628102681706e-10
and O 0 1.1087655793495799e-10
type O 0 5.028671878903879e-08
of O 0 1.3947267341052338e-08
mutations O 0 4.418483634527348e-10
, O 0 4.9304886562406836e-11
according O 0 1.985581421504179e-10
to O 0 7.50440487529147e-10
the O 0 5.450710993670782e-10
different O 0 7.950791136579483e-10
symptoms O 0 2.426916410058766e-07
. O 0 1.1884903017289616e-07

This O 0 1.2538453830757135e-08
demonstrated O 0 3.5520482555284616e-08
( O 0 4.267063785645675e-11
1 O 0 5.457934104668993e-09
) O 0 4.270151732210792e-10
the O 0 2.5204314191284993e-09
association O 0 6.044629241586108e-10
between O 0 5.563241187167556e-11
mutations O 0 1.8483947705760784e-10
in O 0 3.291740213740013e-10
exons O 0 2.653792074980288e-09
8 O 0 5.774146494275101e-09
and O 0 5.936869329481453e-10
9 O 0 4.065264747055153e-08
and O 0 3.106007451236792e-09
DMS B-Disease 0 3.1521121854893863e-06
; O 0 7.105217525449348e-10
( O 0 5.858529633639975e-11
2 O 0 4.481095938757562e-09
) O 0 7.325474254971098e-11
among O 0 1.5870154149166815e-11
patients O 0 8.910065740774797e-11
with O 0 3.0242995607832057e-12
DMS B-Disease 0 3.660562697405112e-07
, O 0 2.185264885712357e-10
a O 0 3.212097532401259e-10
higher O 0 3.7135490238426883e-09
frequency O 0 6.313539024915826e-09
of O 0 5.093603872019514e-10
exon O 0 1.6226707089117554e-08
8 O 0 7.177975902550315e-08
mutations O 0 6.5601848397989215e-09
among O 0 4.0768538545066235e-10
46 O 0 2.2759877538192086e-08
, O 0 3.78625752972539e-09
XY O 0 0.00016660890833009034
patients O 0 6.822634901482161e-08
with O 0 1.8007549618115348e-10
female O 0 3.711708052023255e-09
phenotype O 0 3.6572311845617378e-09
than O 0 2.734815707228222e-10
among O 0 1.0237715536431935e-10
46 O 0 5.373493294769105e-08
, O 0 8.397712747409969e-09
XY O 0 0.0007635851507075131
patients O 0 3.487600253038181e-08
with O 0 4.210647802649348e-11
sexual O 0 3.086648492356403e-09
ambiguity O 0 2.509446650478253e-09
or O 0 1.4824709237970524e-09
male O 0 4.132945097268248e-09
phenotype O 0 2.1674816108596673e-10
; O 0 2.131647462710884e-11
and O 0 1.3193313108672555e-10
( O 0 4.225402666646616e-11
3 O 0 2.043586100342054e-08
) O 0 2.337151583375885e-10
statistically O 0 2.4533921560987437e-09
significant O 0 3.013166938181655e-10
evidence O 0 1.1716400072359079e-09
that O 0 2.926917735956991e-11
mutations O 0 9.104050152641818e-11
in O 0 6.52363441044912e-10
exons O 0 3.551315019834078e-09
8 O 0 1.8661868494973533e-08
and O 0 1.6143595349404904e-09
9 O 0 6.828233267697215e-08
preferentially O 0 4.562223487880601e-09
affect O 0 1.0535041283787905e-08
amino O 0 3.6439806727628365e-09
acids O 0 8.111937233046262e-10
with O 0 3.8173678627850816e-12
different O 0 1.667853875841896e-11
functions O 0 9.424164781890454e-10
. O 0 2.038127444592419e-09
. O 0 2.6696429955563872e-08

The O 0 1.7967721532841097e-06
185delAG O 0 1.90316768566845e-05
BRCA1 O 0 3.3331264148728224e-07
mutation O 0 6.717007505763206e-10
originated O 0 8.779732496577708e-10
before O 0 4.960941657472517e-10
the O 0 5.617643156208274e-11
dispersion O 0 2.0333672523520363e-09
of O 0 1.2597602128128216e-10
Jews O 0 4.9412612890265e-10
in O 0 6.280934800040328e-11
the O 0 3.739602377761386e-11
diaspora O 0 2.858724645893318e-10
and O 0 2.0787045695858097e-11
is O 0 3.4741686524147886e-12
not O 0 2.3108912353131394e-11
limited O 0 1.9729959888081794e-09
to O 0 3.1621208762544484e-08
Ashkenazim O 0 1.4134553566691466e-05
. O 0 9.215101499648881e-07

The O 0 3.625493434356031e-07
185delAG O 0 1.3857054455002071e-06
mutation O 0 1.926013659669934e-08
in O 0 6.359974769054588e-09
BRCA1 O 0 7.077672137256741e-08
is O 0 7.005769853130062e-10
detected O 0 3.4608009791270433e-09
in O 0 1.0504677128153617e-09
Ashkenazi O 0 2.1328952826138448e-08
Jews O 0 2.0448795989835844e-09
both O 0 4.226627728365351e-11
in O 0 3.511693713598163e-10
familial B-Disease 0 0.10921597480773926
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.4273069837145158e-06
in O 0 1.651195020713203e-07
the O 0 3.740935383689248e-08
general O 0 1.665262416850055e-08
population O 0 1.533384669238913e-10
. O 0 8.746274815507604e-09

All O 0 1.533917725282663e-06
tested O 0 9.673962040324113e-07
Ashkenazi O 0 4.6584673896177264e-07
mutation O 0 2.1441153297274695e-09
carriers O 0 4.679880927227487e-10
share O 0 1.5865053715202748e-09
the O 0 2.481799488140979e-10
same O 0 5.162204552711103e-10
allelic O 0 1.897159407349136e-08
pattern O 0 1.0952008189235585e-09
at O 0 3.0830605624032614e-08
the O 0 8.60562323623526e-08
BRCA1 O 0 1.446033195406926e-07
locus O 0 3.330616209495929e-07
. O 0 6.717141332046594e-07

Our O 0 1.9106901163468137e-06
previous O 0 5.6536396897399754e-08
study O 0 2.429457079955455e-09
showed O 0 1.6008495640207343e-09
that O 0 2.1203908420752704e-11
this O 0 4.785755680636328e-10
Ashkenazi O 0 3.5884292515220295e-07
mutation O 0 3.6618379439801174e-09
also O 0 1.4061415920529896e-10
occurs O 0 3.131200854156191e-11
in O 0 2.7855108844510035e-11
Iraqi O 0 8.66306226754432e-09
Jews O 0 3.4018865502360995e-09
with O 0 6.427169560452306e-12
a O 0 1.8165267900993598e-10
similar O 0 1.2437924301611503e-10
allelic O 0 6.069507918482486e-08
pattern O 0 8.303391751951494e-09
. O 0 1.7723948531056521e-07

We O 0 1.4128835346127744e-07
extended O 0 5.434211658439381e-08
our O 0 4.074337311976706e-09
analysis O 0 4.0235817455602785e-10
to O 0 4.888409121939219e-10
other O 0 1.0779740294841744e-10
non O 0 1.1697810009536624e-07
- O 0 6.323255519191662e-08
Ashkenazi O 0 2.0772338871211105e-07
subsets O 0 4.825455590662386e-09
354 O 0 6.351948744764968e-09
of O 0 4.31130020572823e-10
Moroccan O 0 6.986267067077279e-07
origin O 0 6.315225231645627e-09
, O 0 5.738504671448652e-10
200 O 0 9.683939872218161e-09
Yemenites O 0 6.930405334060197e-07
and O 0 6.957511233807168e-10
150 O 0 1.3408403276571335e-08
Iranian O 0 2.340776461551286e-08
Jews O 0 7.830026049759908e-08
. O 0 7.930215417673026e-08

Heteroduplex O 0 2.020082865783479e-05
analysis O 0 2.4347745153363576e-08
complemented O 0 5.166531202860369e-09
by O 0 5.5687832817286065e-11
direct O 0 1.4862193697950943e-09
DNA O 0 1.5211565340678135e-09
sequencing O 0 1.9375574922264605e-08
of O 0 3.7733979496579195e-08
abnormally O 0 1.1372885921900888e-07
migrating O 0 5.249824575059847e-09
bands O 0 5.992835561130505e-09
were O 0 1.7727632695141438e-09
employed O 0 1.248895529215588e-07
. O 0 2.456442302900541e-07

Four O 0 1.4078101173709e-07
of O 0 1.4939764980681502e-08
Moroccan O 0 9.121039511228446e-06
origin O 0 1.6648933343077488e-09
( O 0 6.707065892258557e-12
1 O 0 3.671249138026411e-10
. O 0 9.875451151275527e-12
1 O 0 6.494174087379179e-10
% O 0 2.1166731561939045e-11
) O 0 5.956110604721232e-12
and O 0 1.076874006633588e-11
none O 0 1.6947409031686789e-09
of O 0 4.406683906665876e-10
the O 0 9.65858948376308e-10
Yemenites O 0 3.164404915878549e-07
or O 0 8.157398645458613e-10
Iranians O 0 2.1407204897627707e-08
was O 0 4.4318131386944515e-09
a O 0 1.3811239651939644e-10
carrier O 0 1.9279304541708342e-10
of O 0 2.844181556937997e-10
the O 0 1.7686495601410002e-09
185delAG O 0 4.6126240249577677e-07
mutation O 0 1.2882002131675563e-08
. O 0 4.582772916705835e-08

BRCA1 O 0 7.76453161961399e-05
allelic O 0 1.0401743111287942e-06
patterns O 0 5.507627687251215e-09
were O 0 4.984045398614967e-10
determined O 0 3.4196317999501957e-10
for O 0 9.239735643262748e-10
four O 0 1.0486280732635578e-09
of O 0 1.864039894661218e-10
these O 0 4.3500680488306465e-12
individuals O 0 4.223158281413397e-13
and O 0 1.9628959915807265e-12
for O 0 2.4394564493435134e-11
12 O 0 3.595151065738378e-09
additional O 0 1.702406926540334e-08
non O 0 9.921885066432878e-06
- O 0 7.509146144002443e-06
Ashkenazi O 0 2.5542449293425307e-06
185delAG O 0 2.305528710166982e-07
mutation O 0 8.257239336728617e-10
carriers O 0 1.828415058247046e-10
who O 0 3.2082354550766468e-09
had O 0 5.8890054788207635e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999668598175049

Six O 0 1.3447482842821046e-06
non O 0 9.476602826907765e-06
- O 0 2.3868269636295736e-06
Ashkenazi O 0 1.0443291103001684e-06
individuals O 0 4.635267447650193e-10
shared O 0 7.651310696132896e-09
the O 0 8.542849205817049e-10
common O 0 9.30098498219678e-10
Ashkenazi O 0 2.722458702919539e-07
haplotype O 0 3.993447137418116e-07
, O 0 5.672763370156986e-10
four O 0 1.9065973244636325e-09
had O 0 6.14085227113037e-09
a O 0 1.2128943405187442e-09
closely O 0 8.34673302696487e-11
related O 0 6.152525711122792e-10
pattern O 0 2.8083127490141635e-10
, O 0 1.3775399224091878e-11
and O 0 1.948405499441197e-11
the O 0 4.142613363455894e-09
rest O 0 1.1365812291330712e-08
( O 0 7.472122226515054e-11
n O 0 3.2540623529087043e-09
= O 0 2.1109954673192988e-08
6 O 0 6.740973113039672e-09
) O 0 9.578943888088887e-11
displayed O 0 5.403882674670513e-09
a O 0 4.312659118710371e-09
distinct O 0 6.842179711696872e-09
BRCA1 O 0 6.986746825532464e-07
allelic O 0 4.522657093275484e-07
pattern O 0 4.377527318411012e-08
. O 0 2.3133826232424326e-07

We O 0 5.7508707129727554e-08
conclude O 0 7.900715104369738e-08
that O 0 4.586467039491282e-10
the O 0 4.788908380959356e-09
185delAG O 0 3.027370212294045e-06
BRCA1 O 0 5.330090289135114e-07
mutation O 0 2.5531003977619093e-09
occurs O 0 2.2023788348590756e-10
in O 0 1.322667253500498e-10
some O 0 2.2750999695286822e-10
non O 0 4.1186652310898353e-07
- O 0 9.038726602739189e-07
Ashkenazi O 0 5.334921411304094e-07
populations O 0 1.6960474136240578e-09
at O 0 8.231042514239562e-10
rates O 0 5.963824434296328e-10
comparable O 0 2.368628349014301e-10
with O 0 7.635321194743305e-12
that O 0 3.8502406818352597e-10
of O 0 1.3767644801987444e-08
Ashkenazim O 0 4.002806690550642e-06
. O 0 3.4201872267658473e-07

The O 0 3.483937405235338e-07
majority O 0 4.182636459404421e-09
of O 0 1.3428775424983996e-08
Jewish O 0 2.2436746860421408e-07
185delAG O 0 2.700092807117471e-07
mutation O 0 1.1101373154076555e-09
carriers O 0 1.609642141797707e-10
have O 0 3.094132727810006e-10
a O 0 9.57158907688438e-10
common O 0 1.4696948102965735e-09
allelic O 0 2.9100666765202732e-08
pattern O 0 2.547854982548614e-10
, O 0 2.2029994148353715e-11
supporting O 0 1.0690636154109256e-09
the O 0 4.84419393487201e-09
founder O 0 2.0566700342783406e-08
effect O 0 3.519017077735498e-09
notion O 0 3.483051402852766e-09
, O 0 1.851110410788781e-11
but O 0 6.137868425321047e-12
dating O 0 1.5415435594690052e-09
the O 0 1.4732584596721665e-10
mutations O 0 2.1545709660841794e-11
origin O 0 8.340335366785467e-11
to O 0 1.4857143293411923e-10
an O 0 1.0845358465461086e-11
earlier O 0 2.456800041183982e-10
date O 0 2.249548813892943e-08
than O 0 6.776937344632472e-10
currently O 0 4.911400175444669e-10
estimated O 0 8.479634217017917e-10
. O 0 2.709264279587842e-08

However O 0 3.1247981979731776e-08
, O 0 1.34544514418522e-10
the O 0 2.8612978306141734e-11
different O 0 1.0606215558595089e-11
allelic O 0 1.169416918855859e-08
pattern O 0 1.7480176195405761e-09
at O 0 1.9197567979745145e-08
the O 0 2.0730929861656477e-08
BRCA1 O 0 2.5102904643858892e-08
locus O 0 1.5842232414797763e-08
even O 0 1.6461055851735296e-09
in O 0 6.351146275562769e-10
some O 0 1.0643082942740634e-10
Jewish O 0 3.6494129940223274e-09
mutation O 0 1.461570448002547e-10
carriers O 0 4.060647651460414e-11
, O 0 2.5547248344581774e-11
might O 0 1.4254880609243514e-09
suggest O 0 3.4775085033800224e-09
that O 0 1.2927943437990308e-10
the O 0 2.0427433078396007e-09
mutation O 0 5.986799944679433e-10
arose O 0 5.900192556751449e-10
independently O 0 1.7500926263736005e-09
. O 0 4.450720236803818e-09
. O 0 1.0374979098060066e-07

Crystal O 0 6.513519679174351e-07
structure O 0 9.63836100709159e-07
of O 0 2.2793515199737158e-06
the O 0 1.9234348656027578e-06
hemochromatosis B-Disease 1 1.0
protein O 0 7.695645081184921e-07
HFE O 0 9.375830813951325e-06
and O 0 1.5281184095883305e-09
characterization O 0 3.3812458610782414e-08
of O 0 4.090863114925014e-08
its O 0 5.243780076824578e-09
interaction O 0 2.1789146043005303e-09
with O 0 6.020233617176629e-11
transferrin O 0 3.061286690808629e-07
receptor O 0 4.661658081772657e-08
. O 0 1.3594981851383636e-07

HFE O 0 0.049921147525310516
is O 0 1.4025410166595975e-07
an O 0 2.441381319329139e-09
MHC O 0 8.686525916346e-07
- O 0 3.1084153306437656e-05
related O 0 5.5979348871915136e-06
protein O 0 5.550393566977618e-08
that O 0 6.798074603242554e-11
is O 0 2.2551851878993556e-12
mutated O 0 1.6908784095104323e-10
in O 0 7.961868941919192e-10
the O 0 4.8233967930855215e-08
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0003691679157782346

HFE O 0 0.0001677816326264292
binds O 0 2.3493693390719272e-07
to O 0 5.611804354543892e-08
transferrin O 0 3.138590898288385e-07
receptor O 0 1.8421177472305317e-08
( O 0 3.6402900138732264e-10
TfR O 0 1.0371105645390344e-06
) O 0 2.1399630678597958e-10
and O 0 5.746322168098672e-11
reduces O 0 2.9152371627816365e-09
its O 0 1.905970797855261e-10
affinity O 0 1.358563816999947e-09
for O 0 2.733023363177267e-09
iron O 0 2.8140107133367565e-07
- O 0 1.674650036420644e-07
loaded O 0 3.527836156536068e-08
transferrin O 0 2.887657899464102e-07
, O 0 5.4160178564188755e-09
implicating O 0 1.3179112556827022e-06
HFE O 0 0.00023815107124391943
in O 0 7.662192729185335e-07
iron O 1 0.5767355561256409
metabolism O 1 0.7294926643371582
. O 0 1.5005755358288297e-06

The O 0 6.606540523534932e-07
2 O 0 1.6511745570824132e-06
. O 0 6.590348675672431e-07

6 O 0 3.591458880691789e-05
A O 0 4.439262283995049e-06
crystal O 0 2.770695175513538e-07
structure O 0 6.312301366051543e-07
of O 0 1.3545251249524881e-06
HFE O 1 0.9984442591667175
reveals O 0 3.2641784741826996e-07
the O 0 2.8211721847526405e-09
locations O 0 1.8805508261721116e-08
of O 0 5.55062626972358e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 8.472900958622631e-08
and O 0 3.2137354999406398e-09
a O 0 6.721075465065951e-07
patch O 1 0.9999597072601318
of O 0 1.0490572094568051e-05
histidines O 0 3.066503631998785e-05
that O 0 1.7668752572141955e-10
could O 0 5.389017010415387e-10
be O 0 4.1446265863775977e-10
involved O 0 5.879286502086245e-10
in O 0 5.591096030599374e-09
pH O 0 4.3969762373308185e-06
- O 0 5.568705887526448e-07
dependent O 0 1.3401046317085274e-07
interactions O 0 2.2894676376949974e-08
. O 0 9.380774201872555e-08

We O 0 1.1342648349454976e-06
also O 0 1.581614661461117e-08
demonstrate O 0 5.944025005533149e-08
that O 0 2.673973487077319e-09
soluble O 0 2.6936578478853335e-07
TfR O 0 1.9421029264776735e-06
and O 0 1.3493753892035443e-09
HFE O 0 3.2077009564090986e-06
bind O 0 3.128674563868117e-08
tightly O 0 6.419904252652486e-08
at O 0 5.6488001831667134e-08
the O 0 3.4715044172628495e-09
basic O 0 6.224901198947919e-07
pH O 0 8.44567864533019e-07
of O 0 6.848708267170878e-09
the O 0 7.454477923829472e-09
cell O 0 5.679525116875084e-08
surface O 0 2.7046058725943567e-09
, O 0 1.6544808578711212e-10
but O 0 1.093755780390282e-10
not O 0 1.5048317036914227e-09
at O 0 2.5371887701908236e-08
the O 0 4.27507806932681e-08
acidic O 0 1.290309683099622e-06
pH O 0 1.1912120498891454e-05
of O 0 1.851629320981374e-07
intracellular O 0 1.7639410998526728e-06
vesicles O 0 9.814695658860728e-06
. O 0 1.0833032320078928e-06

TfR O 0 0.00013185350690037012
HFE O 0 5.5370568588841707e-05
stoichiometry O 0 3.538497992394696e-07
( O 0 6.269902375066749e-10
2 O 0 1.219513112715731e-08
1 O 0 2.2281890110775748e-08
) O 0 3.050162622475483e-10
differs O 0 3.6106475587160958e-09
from O 0 4.503860617788291e-10
TfR O 0 2.1950593520614348e-07
transferrin O 0 1.540741756400621e-08
stoichiometry O 0 2.4589201785829573e-09
( O 0 1.766328576457976e-11
2 O 0 7.290227310718933e-10
2 O 0 3.2319429354998874e-09
) O 0 2.289862605087123e-10
, O 0 1.1282341727536505e-10
implying O 0 6.305067135059517e-09
a O 0 6.022821130713396e-10
different O 0 5.632470531646838e-11
mode O 0 4.315277735145173e-08
of O 0 5.700454552837186e-10
binding O 0 4.238450923566006e-09
for O 0 9.74969704969908e-09
HFE O 0 5.522355422726832e-05
and O 0 2.459700176871138e-08
transferrin O 0 1.3677264405487222e-06
to O 0 5.2793794225181045e-08
TfR O 0 1.947192004081444e-06
, O 0 7.279486458067197e-10
consistent O 0 1.334029331445663e-08
with O 0 5.044803463860603e-11
our O 0 2.007985244745214e-08
demonstration O 0 1.0197754640728363e-08
that O 0 2.8469604451686337e-10
HFE O 0 2.9278853617142886e-06
, O 0 2.8524733686197123e-09
transferrin O 0 1.2995354836675688e-07
, O 0 1.266772464703081e-09
and O 0 3.834600692531609e-10
TfR O 0 1.0478127023816342e-06
form O 0 6.8138766851078e-10
a O 0 4.116345930782472e-09
ternary O 0 5.4042359920458694e-08
complex O 0 8.293303039863531e-07
. O 0 1.0360972737544216e-06

Identification O 0 2.1445862330438104e-06
of O 0 1.270674516717918e-07
three O 0 1.3274598087420486e-09
novel O 0 1.297966178981369e-09
mutations O 0 3.741038590021617e-10
and O 0 4.41524629357648e-11
a O 0 2.554307043656223e-10
high O 0 3.909427892523354e-09
frequency O 0 1.375709786088919e-07
of O 0 2.1613738354631096e-08
the O 0 2.8891280479115267e-08
Arg778Leu O 0 9.128907549893484e-07
mutation O 0 9.197009820383073e-10
in O 0 4.1124198491004904e-10
Korean O 0 1.9899518122201698e-07
patients O 0 2.593592896005248e-09
with O 0 4.3556082351958736e-11
Wilson B-Disease 0 2.6696642407841864e-07
disease I-Disease 0 8.363014813994596e-08
. O 0 1.0166490937990602e-07

Four O 0 2.5429978123270303e-08
mutations O 0 3.115956659360819e-10
- O 0 6.1821725516608694e-09
- O 0 3.3729556037087605e-08
R778L O 0 4.666604525027651e-07
, O 0 1.5082878002115052e-10
A874V O 0 5.360482191463234e-08
, O 0 4.9086255893282527e-11
L1083F O 0 1.1245808728688189e-08
, O 0 1.428698565703046e-11
and O 0 1.7521707825970956e-12
2304delC O 0 4.812236165108175e-10
- O 0 4.4235937135539416e-10
- O 0 4.667136010994e-09
in O 0 1.8381928201804953e-09
the O 0 4.644367113115777e-09
copper O 0 2.1783090886628997e-08
- O 0 3.0517355309456207e-09
transporting O 0 1.3092297246330986e-09
enzyme O 0 1.9364296832691252e-09
, O 0 3.5709907253433926e-10
P O 0 2.3790043712779152e-07
- O 0 9.869349781865822e-08
type O 0 1.1183929871094733e-07
ATPase O 0 1.22009578262805e-05
( O 0 5.118848123153441e-10
ATP7B O 0 9.162373544313596e-07
) O 0 4.8281944414751976e-11
, O 0 8.461788561509032e-12
were O 0 3.142389473631546e-11
identified O 0 1.9237135495675517e-10
in O 0 1.1150218248712207e-10
Korean O 0 6.83957281921721e-08
Patients O 0 3.713803931049142e-09
with O 0 2.940773319304313e-11
Wilson B-Disease 0 2.2346461037159315e-07
disease I-Disease 0 1.5828601362954942e-07
. O 0 1.60069689059128e-07

Arg778Leu O 0 9.086018508241978e-06
, O 0 2.8746152125336266e-09
the O 0 9.383468446699794e-10
most O 0 7.639665983161237e-11
frequently O 0 1.6658263657376438e-10
reported O 0 1.732324006464836e-10
mutation O 0 3.3024688539384783e-10
of O 0 3.287511374239216e-10
this O 0 3.895104030982033e-11
enzyme O 0 5.3042716052775774e-11
, O 0 1.6552722734153313e-11
was O 0 3.3245256547687063e-10
found O 0 4.9382439110123855e-11
in O 0 7.402330831629556e-11
six O 0 7.200499085868728e-10
of O 0 1.1688851275781786e-10
eight O 0 1.7036656807523087e-10
unrelated O 0 4.779525109022131e-10
patients O 0 1.146700998044814e-10
studied O 0 2.129073584100638e-09
, O 0 2.0431629998984846e-10
an O 0 1.4163001327283098e-10
allele O 0 3.051316532776127e-09
frequency O 0 5.135341396567128e-08
of O 0 2.7594767360028527e-08
37 O 0 3.2654349979566177e-06
. O 0 1.2045064750054735e-06

5 O 0 2.5113592982961563e-06
% O 0 1.312262831731914e-08
, O 0 2.1883637957298419e-10
which O 0 9.978185812331564e-12
is O 0 2.4681259640224606e-12
considerably O 0 1.3107531726674893e-10
higher O 0 5.420148774248901e-10
than O 0 9.56579346983455e-12
those O 0 1.9831731742914194e-11
in O 0 1.8620037456340555e-10
other O 0 6.040641320481654e-10
Asian O 0 6.311867650765635e-08
populations O 0 4.99859442726347e-09
. O 0 4.088624194764634e-08

The O 0 1.5622826765593345e-07
novel O 0 4.003931852736287e-09
single O 0 2.2018591394612486e-09
nucleotide O 0 6.986334000202987e-08
deletion O 0 4.8097543725589276e-08
, O 0 4.809584397413857e-10
2304delC O 0 2.8492884496245097e-08
, O 0 1.1372175423574049e-10
was O 0 8.717158661575297e-10
found O 0 1.215091222084297e-10
in O 0 2.555145262039815e-10
one O 0 6.430867505180515e-10
patient O 0 1.7593643875102316e-08
. O 0 6.17636430888524e-08

Since O 0 9.355365193641774e-08
a O 0 3.507371060251785e-09
mutation O 0 1.934151172555687e-10
at O 0 6.068102131884245e-10
cDNA O 0 1.4690173522069472e-08
nucleotide O 0 3.440873399540578e-07
2302 O 0 6.928879884071648e-05
( O 0 7.10986769458799e-10
2302insC O 0 4.104892781242597e-08
) O 0 2.4467036729980407e-10
had O 0 1.6899056598518314e-09
been O 0 2.536823251464426e-10
previously O 0 7.267167978497469e-10
described O 0 1.1921029441364084e-10
, O 0 4.05502671371738e-12
this O 0 5.762585721102997e-12
region O 0 5.528253410602701e-10
of O 0 2.523933506637377e-09
the O 0 4.326417890609946e-09
ATP7B O 0 2.780666591206682e-06
gene O 0 4.447351376057895e-09
may O 0 5.428987037703337e-09
be O 0 3.72376263158003e-09
susceptible O 0 4.189025304413008e-08
to O 0 3.145764537748619e-08
gene O 0 7.204090479717706e-08
rearrangements O 0 1.0579607987892814e-05
causing O 0 2.511915226932615e-06
Wilson B-Disease 0 1.7356254829792306e-05
disease I-Disease 0 9.667774065746926e-07
. O 0 1.3391387199135352e-07

Disruption O 0 2.2297668692772277e-05
of O 0 1.3870604220755922e-07
splicing O 0 4.6345299153927044e-08
regulated O 0 9.752917407013229e-08
by O 0 1.3699793521837478e-09
a O 0 7.295502868487347e-09
CUG O 0 5.397940867624129e-07
- O 0 3.1475750894571775e-09
binding O 0 2.4575415036309778e-09
protein O 0 1.7953038167206614e-08
in O 0 4.269724485084225e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.8760583770927042e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 7.43195755603665e-07
DM B-Disease 1 1.0
) O 0 1.2247019398614611e-08
is O 0 6.50095310916754e-10
caused O 0 6.215440384593762e-10
by O 0 2.6527264759823588e-11
a O 0 6.982877609473803e-10
CTG O 0 2.1897061941444917e-08
expansion O 0 1.9495711711670083e-09
in O 0 3.0968841380207834e-10
the O 0 2.646799446281989e-10
3 O 0 5.61959945244439e-09
untranslated O 0 5.001897420697787e-07
region O 0 8.683079144589101e-09
of O 0 4.531470754187694e-09
the O 0 6.896767246189484e-08
DM B-Disease 1 1.0
gene O 0 3.904981440427946e-07
. O 0 1.5580824310745811e-06

One O 0 6.879133707116125e-09
model O 0 1.26881882778207e-08
of O 0 3.411283699961132e-08
DM B-Disease 1 1.0
pathogenesis O 1 0.9999942779541016
suggests O 0 7.986835726114805e-08
that O 0 1.1498498334039375e-11
RNAs O 0 2.375188101755299e-10
from O 0 2.238377039276429e-09
the O 0 5.04633890230366e-09
expanded O 0 1.218118317325434e-08
allele O 0 1.4630661127057465e-09
create O 0 4.4792541203930725e-11
a O 0 2.540997690037017e-10
gain O 0 1.6513581613253336e-08
- O 0 7.76144659653255e-09
of O 0 1.920327230564567e-09
- O 0 2.39184205774734e-09
function O 0 3.2583893916360296e-10
mutation O 0 5.443186179565629e-11
by O 0 5.737930096338939e-12
the O 0 1.6866041896435036e-10
inappropriate O 0 9.593759120463119e-10
binding O 0 1.0287085627780357e-09
of O 0 1.2749266087297428e-09
proteins O 0 1.6229684263180388e-11
to O 0 1.5954664256412343e-09
the O 0 5.784508427808532e-09
CUG O 0 6.395414857252035e-06
repeats O 0 8.322881939193394e-08
. O 0 1.2833424989366904e-07

Data O 0 3.39273270810736e-07
presented O 0 2.2986430536775515e-08
here O 0 1.6630723465027586e-08
indicate O 0 1.8028943671311026e-08
that O 0 2.8696725551391467e-10
the O 0 9.869021155850533e-10
conserved O 0 5.500174538042302e-09
heterogeneous O 0 7.820876390951526e-08
nuclear O 0 5.329124519448669e-07
ribonucleoprotein O 0 1.034524416354543e-06
, O 0 2.848200342242535e-09
CUG O 0 4.852639676755643e-07
- O 0 1.0540869510577977e-08
binding O 0 7.806342239291553e-09
protein O 0 3.655376001887589e-09
( O 0 5.155098223297294e-11
CUG O 0 3.738710177003668e-07
- O 0 4.243403495252096e-08
BP O 0 7.86367166938362e-08
) O 0 6.029472754409682e-11
, O 0 2.748452333778406e-11
may O 0 7.053367334641791e-10
mediate O 0 5.23410044195316e-08
the O 0 2.3035575669183572e-09
trans O 0 3.107395940560309e-08
- O 0 4.2636695951614456e-08
dominant O 0 9.181625237886237e-09
effect O 0 1.4553406479933528e-08
of O 0 1.5300782862937012e-09
the O 0 9.69018087992879e-10
RNA O 0 9.185461280480922e-09
. O 0 1.0352424339998834e-07

CUG O 0 0.0008114752708934247
- O 0 5.971587233943865e-05
BP O 0 2.112086576744332e-06
was O 0 2.341955429585596e-08
found O 0 1.218977002670485e-10
to O 0 4.006441012283091e-11
bind O 0 8.700028891750478e-11
to O 0 1.6276293646200202e-09
the O 0 1.0606713285454816e-09
human O 0 6.154876608377435e-09
cardiac O 1 0.9729803204536438
troponin O 0 0.00011100477422587574
T O 0 2.198491984017892e-06
( O 0 2.7497962240552454e-10
cTNT O 0 7.273816748920581e-08
) O 0 7.655887035440401e-11
pre O 0 2.0966886893347692e-07
- O 0 7.326277806640746e-09
messenger O 0 1.2724898912352955e-09
RNA O 0 4.992208313403523e-10
and O 0 1.052904430309809e-10
regulate O 0 8.918077942787761e-10
its O 0 2.764489193118891e-10
alternative O 0 1.4324990971203988e-08
splicing O 0 4.654657104197213e-08
. O 0 1.251945889180206e-07

Splicing O 0 1.0199310054304078e-06
of O 0 4.1335513856211037e-07
cTNT O 0 8.31957640912151e-06
was O 0 2.0033951386722038e-07
disrupted O 0 6.284538471845735e-07
in O 0 1.3414368993380776e-07
DM B-Disease 1 1.0
striated O 0 3.72476497432217e-05
muscle O 0 7.546813094450044e-07
and O 0 1.8889332320526364e-09
in O 0 1.1531851029644713e-09
normal O 0 1.5027817212853734e-08
cells O 0 3.0692826058498213e-09
expressing O 0 6.139794783699415e-10
transcripts O 0 2.704487078730722e-09
that O 0 2.5884319687641266e-10
contain O 0 1.1255185228264963e-08
CUG O 0 5.931764007982565e-06
repeats O 0 3.0461052347163786e-07
. O 0 2.322441332580638e-07

Altered O 0 6.373447376972763e-06
expression O 0 1.4000688679516315e-06
of O 0 4.109937989937862e-08
genes O 0 2.9350044616904825e-09
regulated O 0 4.053132585113417e-08
posttranscriptionally O 0 3.0647103699266154e-07
by O 0 1.1025702573164153e-09
CUG O 0 9.470586519455537e-05
- O 0 7.1182298597705085e-06
BP O 0 5.455214591165714e-07
therefore O 0 1.3534608989118624e-09
may O 0 2.455310121884935e-10
contribute O 0 3.137936133157382e-09
to O 0 3.4991941788575787e-08
DM B-Disease 1 1.0
pathogenesis O 0 0.0007691214559599757
. O 0 7.783286548601609e-08
. O 0 1.7431716514693107e-07

Identification O 0 7.861449375923257e-07
of O 0 6.524748386027568e-08
a O 0 1.1920177733770743e-08
novel O 0 9.292230096491494e-09
nonsense O 0 9.48527087984985e-08
mutation O 0 2.5193356290031943e-09
and O 0 1.4286993810230797e-10
a O 0 7.671268065223558e-10
missense O 0 2.5795374725134934e-09
substitution O 0 6.624158999102292e-09
in O 0 4.177621359957584e-09
the O 0 8.852445887441718e-09
vasopressin O 0 1.4813348343523103e-06
- O 0 1.6204461417146376e-07
neurophysin O 0 2.3510906999035797e-07
II O 0 2.8898336950078374e-06
gene O 0 7.0637109494953165e-09
in O 0 6.3501079949901396e-09
two O 0 1.7241236216491984e-09
Spanish O 0 1.2467226895296335e-07
kindreds O 0 3.925943474314408e-06
with O 0 7.299623128176336e-09
familial B-Disease 1 0.9997205138206482
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 5.633629825751996e-06

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 7.261535017732967e-08
FNDI B-Disease 1 1.0
) O 0 1.0720923704354846e-08
is O 0 1.6368508770625567e-09
an O 0 3.130427916886447e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 8.304551357696255e-08
by O 0 8.175337490312629e-11
deficiency O 0 1.2620972711374634e-07
in O 0 7.695485493286469e-08
the O 0 9.797438451641938e-07
antidiuretic O 0 1.9617078578448854e-05
hormone O 0 4.246358855652943e-07
arginine O 0 1.3211032978688309e-07
vasopressin O 0 2.3576762941956986e-07
( O 0 1.0666107580492579e-10
AVP O 0 2.2747948946744145e-07
) O 0 4.6096243142002e-12
encoded O 0 2.886391820000611e-11
by O 0 3.988918917396944e-11
the O 0 3.968100514839534e-09
AVP O 0 2.2844678824185394e-05
- O 0 4.063087146732869e-07
neurophysin O 0 3.5721157018997474e-06
II O 1 0.9880639910697937
( O 0 1.405735527981733e-08
AVP O 0 8.266835357062519e-05
- O 0 4.840852625420666e-07
NPII O 0 4.003799404017627e-06
) O 0 2.109085683876799e-10
gene O 0 1.1631920981969301e-09
on O 0 7.509051158649527e-08
chromosome O 0 4.6885520532669034e-07
20p13 O 0 5.954209336778149e-05
. O 0 1.1279189493507147e-06

In O 0 2.415145239353933e-08
this O 0 6.032834787284003e-10
study O 0 5.687497695028298e-10
, O 0 3.8855169082196994e-11
we O 0 1.1992457027432124e-10
analyzed O 0 7.90235044068055e-10
two O 0 5.6453768743081056e-11
families O 0 5.3186371973268365e-11
with O 0 4.9619704178827106e-11
FNDI B-Disease 1 1.0
using O 0 5.142160031113008e-09
direct O 0 5.0478887736460365e-09
automated O 0 7.675519952954346e-08
fluorescent O 0 3.5612060855783056e-08
, O 0 5.16149567530988e-10
solid O 0 4.013787524570489e-09
phase O 0 2.7221398468668667e-09
, O 0 3.964987019267063e-11
single O 0 3.196073683486844e-10
- O 0 1.724058007468443e-09
stranded O 0 2.0999388894438198e-09
DNA O 0 6.320340084631226e-11
sequencing O 0 9.590996885577852e-10
of O 0 3.4538572002418277e-09
PCR O 0 1.8035464108834276e-06
- O 0 1.0217874660156667e-05
amplified O 0 2.2098487534094602e-05
AVP O 0 0.00030355394119396806
- O 0 1.7555649947098573e-06
NPII O 0 9.107993719226215e-06
DNA O 0 1.199176438149152e-07
. O 0 1.3503716900231666e-07

In O 0 1.4061565245526708e-08
one O 0 5.980751449641275e-10
of O 0 1.8640931853664e-10
the O 0 7.054009459883659e-11
families O 0 6.705121700922856e-12
, O 0 4.439996547506153e-12
affected O 0 7.619638427158737e-12
individuals O 0 1.2847573482507868e-12
presented O 0 1.6323862261913291e-09
a O 0 3.719702101889766e-09
novel O 0 7.915297750571426e-09
nonsense O 0 1.96329690282937e-08
mutation O 0 1.4494856703795023e-10
in O 0 9.946040518959975e-11
exon O 0 1.210419209307645e-09
3 O 0 1.376129166175133e-08
of O 0 2.7980167072172435e-09
the O 0 4.6297449207699515e-10
gene O 0 3.373517090676792e-11
, O 0 1.3852863300911622e-11
consisting O 0 6.963452384156632e-12
in O 0 5.111655196343712e-11
a O 0 4.0374037446611055e-10
G O 0 2.021037559529759e-08
to O 0 1.2780192903960597e-08
T O 0 1.5582637047373282e-07
transition O 0 2.2188247683629925e-08
at O 0 1.575839192469175e-08
nucleotide O 0 1.5864941360632656e-08
2101 O 0 1.2105015230190475e-06
, O 0 3.442063856162747e-10
which O 0 3.976398203764386e-12
produces O 0 2.0006791362492393e-12
a O 0 1.3396776743501704e-11
stop O 0 1.3743441107383347e-10
signal O 0 2.4409854137985576e-09
in O 0 2.731767478891811e-09
codon O 0 1.858830245282661e-07
82 O 0 1.4002824855197105e-06
( O 0 1.4187130581433394e-08
Glu O 0 4.8513982619624585e-05
) O 0 9.8357650912817e-09
of O 0 5.2899828517638525e-08
NPII O 0 0.0001547857973491773
. O 0 7.754205171295325e-07

The O 0 2.650182580055116e-07
premature O 0 1.8895450466516195e-06
termination O 0 1.5886628546013526e-07
eliminates O 0 7.901181930947132e-08
part O 0 2.5160509231625383e-09
of O 0 2.3851464803215094e-08
the O 0 2.3459165277017746e-08
C O 0 3.0079968382779043e-07
- O 0 2.7140574232475956e-09
terminal O 0 8.548003194164266e-09
domain O 0 1.7841786714711816e-08
of O 0 1.813270311679105e-09
NPII O 0 8.501664865434577e-07
, O 0 7.146177399830478e-11
including O 0 2.174818485023433e-11
a O 0 3.3061117732380296e-10
cysteine O 0 3.023806482982394e-10
residue O 0 7.795614820338415e-09
in O 0 3.2535163452251936e-09
position O 0 4.204129879781249e-07
85 O 0 1.0358680810895748e-06
, O 0 2.3804674897931477e-10
which O 0 3.671049575437735e-12
could O 0 7.402354770813524e-12
be O 0 6.209721972738613e-12
involved O 0 1.0578538045535879e-11
in O 0 1.2495419976499278e-10
the O 0 2.5518442914318484e-09
correct O 0 4.4094548456996563e-07
folding O 0 2.651077295467985e-07
of O 0 2.1506162184437017e-08
the O 0 1.1798375254556959e-07
prohormone O 0 0.00045423192204907537
. O 0 6.84704502873501e-07

In O 0 7.287825898316669e-09
the O 0 3.0711333476318714e-09
second O 0 8.605077539414197e-09
family O 0 3.8086078735233286e-10
, O 0 2.5167635336886818e-11
a O 0 3.028191586373907e-11
G279A O 0 5.365345945307354e-10
substitution O 0 1.2148176908866049e-10
at O 0 4.2052242243961757e-10
position O 0 7.501314014390914e-10
- O 0 6.074265535005452e-09
1 O 0 1.28165098089994e-07
of O 0 5.594317453727626e-09
the O 0 1.657899595386425e-09
signal O 0 7.359119980065998e-09
peptide O 0 6.579705114084788e-10
was O 0 2.4173558710316456e-09
observed O 0 9.023975455768607e-10
in O 0 5.357267962580181e-10
all O 0 2.688762545943746e-10
affected O 0 3.783079682850854e-10
individuals O 0 7.286483916235653e-11
. O 0 2.518702579834553e-08

This O 0 3.833873734038207e-07
missense O 0 8.10363872005837e-06
mutation O 0 1.1765543916908427e-07
, O 0 3.3033398239012968e-09
which O 0 1.0126364191620496e-09
replaces O 0 1.2860050446761306e-06
Ala O 0 0.00016056846652645618
with O 0 8.092130521220042e-09
Thr O 1 0.9990972280502319
, O 0 6.869063984282775e-09
is O 0 1.385213194149415e-10
frequent O 0 4.1973549635976326e-10
among O 0 1.1158068913275088e-10
FNDI B-Disease 1 1.0
patients O 0 2.384787762821361e-07
and O 0 3.1010807810538665e-10
is O 0 1.1713892356102207e-10
thought O 0 9.520462196377366e-10
to O 0 1.1545584488459326e-09
reduce O 0 5.7499462968735315e-09
the O 0 4.537299869156186e-09
efficiency O 0 4.886736348908016e-08
of O 0 1.2430204421320923e-08
cleavage O 0 2.756392891711812e-09
by O 0 1.2377344704717075e-09
signal O 0 2.841257185082213e-07
peptidases O 0 1.1867136890941765e-06
. O 0 3.425144612378972e-08
. O 0 1.7711123234676052e-07

Genetic O 0 9.511981602372543e-07
heterogeneity O 0 8.126514785544714e-07
of O 0 1.429738603064834e-07
Saethre B-Disease 1 0.9999884366989136
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.115285251986677e-10
due O 0 3.346975319118428e-08
to O 0 3.204995380201581e-08
TWIST O 0 1.184792495223519e-06
and O 0 2.917569474902848e-08
FGFR O 0 0.0002602685708552599
mutations O 0 1.0309369713468186e-07
. O 0 4.1162618913404003e-07

Thirty O 0 1.7029067748808302e-05
- O 0 1.004636851575924e-05
two O 0 2.4998159098288397e-09
unrelated O 0 7.134771884409474e-09
patients O 0 2.2129742482945858e-09
with O 0 1.764307233295681e-12
features O 0 1.2735024146337537e-09
of O 0 4.93706480142464e-08
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.9793247041377526e-09
a O 0 6.3160441321485905e-09
common O 0 2.4942144705164537e-07
autosomal B-Disease 0 0.18101246654987335
dominant I-Disease 0 0.21036723256111145
condition I-Disease 1 1.0
of O 1 0.9998350143432617
craniosynostosis B-Disease 1 1.0
and O 0 7.241255389089929e-06
limb B-Disease 1 1.0
anomalies I-Disease 1 0.996816098690033
, O 0 1.7665021667667702e-09
were O 0 9.89860082789562e-10
screened O 0 3.87845755511762e-09
for O 0 1.639382318785465e-08
mutations O 0 1.2886172129356055e-09
in O 0 1.7456594392228908e-08
TWIST O 0 6.960788709875487e-07
, O 0 6.004941432991018e-09
FGFR2 O 0 6.699677669530502e-06
, O 0 1.9851356114486407e-09
and O 0 2.919945174539862e-09
FGFR3 O 0 8.287579112220556e-05
. O 0 6.904676865815418e-07

Nine O 0 2.2518246112213092e-07
novel O 0 1.1867546056976153e-08
and O 0 8.275576335314838e-10
three O 0 7.16384063181863e-10
recurrent O 0 3.739815213066322e-08
TWIST O 0 2.0552195678646967e-07
mutations O 0 1.0969402053362387e-09
were O 0 8.163748566047957e-10
found O 0 1.8111576127743945e-10
in O 0 3.120476654849824e-10
12 O 0 4.5586418195853184e-08
families O 0 1.6322398987966835e-09
. O 0 4.447829127229852e-08

Seven O 0 1.785945791255017e-08
families O 0 2.5798448446967548e-11
were O 0 2.4174643190044698e-11
found O 0 1.1248558508258899e-11
to O 0 3.438127005317426e-10
have O 0 4.958519705944298e-10
the O 0 3.8934291346492955e-09
FGFR3 O 0 2.1962956452625804e-05
P250R O 0 2.140922333637718e-06
mutation O 0 2.438872659382696e-09
, O 0 9.662270289423347e-11
and O 0 7.253150163810673e-11
one O 0 7.961667436440223e-11
individual O 0 2.512614595551188e-11
was O 0 6.452885448204881e-10
found O 0 3.3766330009843415e-11
to O 0 8.075628499248921e-10
have O 0 3.374059087679626e-10
an O 0 1.27831550900126e-10
FGFR2 O 0 6.250337492019753e-07
VV269 O 0 5.071119630883913e-07
- O 0 2.1689109530598216e-07
270 O 0 1.6349615350463864e-07
deletion O 0 8.524251029484731e-07
. O 0 3.7960907661727106e-07

To O 0 4.314454926657163e-08
date O 0 1.304446328731501e-07
, O 0 1.0670589967176625e-09
our O 0 1.2421523809535984e-09
detection O 0 2.605890170315206e-09
rate O 0 3.396697922930514e-10
for O 0 3.917814336840131e-11
TWIST O 0 4.251318230785728e-08
or O 0 2.3060689358089803e-08
FGFR O 0 6.087344445404597e-06
mutations O 0 2.5916098156386624e-09
is O 0 4.401171441181795e-11
68 O 0 4.5459795927627056e-09
% O 0 2.0978400960824928e-10
in O 0 3.9357467285228154e-10
our O 0 2.0006298839803094e-08
Saethre B-Disease 0 0.0005436268984340131
- I-Disease 1 0.9898887276649475
Chotzen I-Disease 1 0.9999313354492188
syndrome I-Disease 1 0.9999990463256836
patients O 0 8.658292216523478e-08
, O 0 1.0470620898095362e-11
including O 0 6.974617931809757e-12
our O 0 3.590929553709543e-09
five O 0 2.729724224437291e-10
patients O 0 5.336104128006447e-11
elsewhere O 0 9.372467246748784e-10
reported O 0 1.4528216407683203e-09
with O 0 3.5808667142589456e-10
TWIST O 0 8.704374522494618e-06
mutations O 0 4.387085539292457e-07
. O 0 1.3652661436935887e-06

More O 0 1.9757761648975247e-08
than O 0 7.811745694752403e-10
35 O 0 1.16734666377738e-08
different O 0 2.3548532568362646e-10
TWIST O 0 5.239174427629223e-08
mutations O 0 7.315438810273633e-10
are O 0 2.6143906484143997e-11
now O 0 4.530628303078821e-11
known O 0 9.976478670958855e-11
in O 0 1.7593894396927823e-10
the O 0 4.885035154167383e-10
literature O 0 7.14343251217997e-09
. O 0 2.6409574971353322e-08

The O 0 6.527536129397049e-07
most O 0 3.123300951202168e-09
common O 0 6.429285437370424e-10
phenotypic O 0 5.4176911845615905e-09
features O 0 8.264030570970249e-10
, O 0 2.106447481720064e-11
present O 0 2.8784748890009482e-11
in O 0 4.476418541399241e-11
more O 0 3.6852769100259586e-12
than O 0 5.691007994718111e-12
a O 0 1.9068362167029562e-10
third O 0 5.879682074549919e-09
of O 0 8.661736328186009e-10
our O 0 8.475644186489717e-09
patients O 0 1.4332635078773137e-09
with O 0 1.2118733100363599e-11
TWIST O 0 1.6944515834893537e-07
mutations O 0 2.3364719936580514e-08
, O 0 2.405856625031788e-09
are O 0 1.109210390204396e-09
coronal B-Disease 0 5.76388288209273e-07
synostosis I-Disease 0 1.2677645827352535e-05
, O 0 1.354344725257306e-08
brachycephaly B-Disease 0 4.339470251579769e-05
, O 0 9.735057204807163e-08
low B-Disease 0 0.0005989621859043837
frontal I-Disease 1 0.9999932050704956
hairline I-Disease 1 1.0
, O 0 1.0063801028081798e-06
facial B-Disease 1 0.9999994039535522
asymmetry I-Disease 1 0.9999988079071045
, O 0 2.524908211398724e-07
ptosis B-Disease 1 0.9590199589729309
, O 0 2.4288096867053355e-08
hypertelorism B-Disease 0 0.00044678011909127235
, O 0 8.285672592478477e-09
broad B-Disease 0 1.6048054476414109e-06
great I-Disease 0 0.04499051719903946
toes I-Disease 0 0.018158406019210815
, O 0 1.2019397921392283e-08
and O 0 1.0503520719851167e-08
clinodactyly B-Disease 0 3.7958256143610924e-05
. O 0 5.589664056060428e-07

Significant O 0 1.6728412219890743e-06
intra O 0 0.00013246192247606814
- O 0 3.614701881815563e-06
and O 0 1.1194511095879989e-08
interfamilial O 0 3.506551820464665e-06
phenotypic O 0 7.699302528862972e-08
variability O 0 2.584710045994143e-08
is O 0 2.9930946610079445e-11
present O 0 1.136776697080455e-11
for O 0 1.2617272504567012e-10
either O 0 3.064585696321842e-09
TWIST O 0 3.812886006926419e-07
mutations O 0 4.5850637064859256e-08
or O 0 3.5533222586536795e-08
FGFR O 0 1.9444458303041756e-05
mutations O 0 1.8418739955450292e-07
. O 0 3.4948126881317876e-07

The O 0 3.6952059190298314e-07
overlap O 0 8.773141324525113e-09
in O 0 6.220492454467319e-10
clinical O 0 2.8313551503345025e-09
features O 0 4.5454051633697645e-10
and O 0 2.5926752064697745e-11
the O 0 1.7291550136189215e-10
presence O 0 6.428681198489272e-11
, O 0 7.481916128315724e-12
in O 0 4.175522427818379e-11
the O 0 1.3623906169879518e-10
same O 0 1.1085583145886702e-10
genes O 0 2.592464021233809e-10
, O 0 1.7778009619995316e-10
of O 0 5.593119856150963e-10
mutations O 0 1.4388999713954576e-10
for O 0 2.1681678674667637e-10
more O 0 2.7016435963367336e-11
than O 0 9.234656789258722e-11
one O 0 1.7923185158252863e-10
craniosynostotic B-Disease 0 1.9153684149841865e-07
condition I-Disease 0 1.0392382137069944e-06
- O 0 8.312650123798448e-08
such O 0 2.3995965214851367e-09
as O 0 3.786604363398283e-09
Saethre B-Disease 0 1.5120907619348145e-06
- I-Disease 0 8.754941660527038e-08
Chotzen I-Disease 0 2.258540234834072e-06
, I-Disease 0 1.091757351190381e-09
Crouzon I-Disease 0 1.146734575740993e-05
, I-Disease 0 2.2378987551974205e-09
and I-Disease 0 2.078968330820885e-09
Pfeiffer I-Disease 0 8.222110409406014e-06
syndromes I-Disease 0 0.00012260873336344957
- O 0 0.0617973692715168
support O 0 0.012582039460539818
the O 0 1.0053412324850797e-06
hypothesis O 0 2.530529030764228e-08
that O 0 6.752595878289913e-12
TWIST O 0 1.959450157684728e-09
and O 0 1.5575021827807234e-10
FGFRs O 0 6.0986351968495e-08
are O 0 3.2865127286285656e-11
components O 0 4.071881942735445e-09
of O 0 6.249774919808715e-09
the O 0 4.291914823539855e-09
same O 0 5.423343996113772e-10
molecular O 0 8.627863701260452e-11
pathway O 0 9.017880192585537e-11
involved O 0 1.7284946043916172e-11
in O 0 1.016855211144474e-10
the O 0 2.333575999102777e-09
modulation O 0 3.858908712572884e-06
of O 0 1.2919753089590813e-07
craniofacial O 1 1.0
and O 0 2.293395056085501e-07
limb O 0 9.05707202036865e-06
development O 0 1.49421651940429e-07
in O 0 2.172453328341817e-09
humans O 0 8.963353947955e-10
. O 0 3.767727241310581e-10
. O 0 1.1628289442455753e-08

Mutation O 0 1.0344786005589413e-07
analysis O 0 5.902289323955756e-09
of O 0 9.930109179379087e-09
UBE3A O 1 0.9335529208183289
in O 0 7.258942787302658e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.6879153918125667e-05
. O 0 3.302944406868846e-08

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.5332912656494955e-08
AS B-Disease 1 1.0
) O 0 3.5789890495685484e-10
is O 0 3.7329608154612615e-11
caused O 0 4.94888956203976e-11
by O 0 6.954718051455089e-12
chromosome O 0 9.516726962033317e-09
15q11 O 0 2.6081647774844896e-06
- O 0 1.4299541817308636e-06
q13 O 0 3.165435828123009e-06
deletions O 0 9.403041190125805e-08
of O 0 1.7893682091596474e-09
maternal O 0 6.64601742528248e-08
origin O 0 6.672468688684319e-10
, O 0 3.754038746528465e-11
by O 0 4.554932125921951e-11
paternal O 1 0.7330215573310852
uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999070167541504
( O 0 6.148296449737245e-08
UPD B-Disease 1 1.0
) O 0 1.687567086072761e-09
15 O 0 2.9018634606359228e-08
, O 0 2.0538061529240537e-10
by O 0 1.340657446169402e-10
imprinting O 0 1.290100954065565e-05
defects O 0 1.5849289411562495e-05
, O 0 1.8305934545992386e-09
and O 0 3.4517874669681703e-10
by O 0 1.1364087448839655e-10
mutations O 0 2.9459956696342715e-10
in O 0 3.9870440282641084e-09
the O 0 4.6582982804466155e-08
UBE3A O 0 1.9205815988243558e-05
gene O 0 1.3327900205695187e-07
. O 0 1.6097808384074597e-06

UBE3A O 0 0.0007112787570804358
encodes O 0 4.786546128343616e-07
a O 0 4.264255082375712e-08
ubiquitin O 0 7.354562825412359e-08
- O 0 9.981116733115414e-08
protein O 0 5.366576960597058e-09
ligase O 0 1.7689812281673767e-08
and O 0 4.763255567752367e-09
shows O 0 5.226658217338809e-08
brain O 0 4.029561466722953e-07
- O 0 9.3210964280388e-08
specific O 0 4.114118823395074e-08
imprinting O 0 2.9295273634488694e-05
. O 0 1.984483333217213e-06

Here O 0 2.056148957763071e-07
we O 0 1.55689203751308e-08
describe O 0 2.8486038416986048e-08
UBE3A O 0 6.583903450518847e-05
coding O 0 8.281542977783829e-05
- O 0 0.00014012558676768094
region O 0 1.1736243550330983e-06
mutations O 0 2.7379795142223884e-07
detected O 0 3.526383096641439e-08
by O 0 8.019139519088725e-11
SSCP O 0 2.2506739583150193e-07
analysis O 0 3.90592280741231e-10
in O 0 2.9811086932340913e-10
13 O 0 2.6020176235874715e-08
AS B-Disease 1 0.9999996423721313
individuals O 0 3.193713696281186e-11
or O 0 4.923985524873942e-11
families O 0 3.8055780748891266e-11
. O 0 2.7228512777810465e-09

Two O 0 7.129741419475977e-08
identical O 0 1.8711626026401973e-08
de O 0 3.525969987094868e-07
novo O 0 3.447866561145929e-07
5 O 0 9.891094805425382e-07
- O 0 9.57705424298183e-07
bp O 0 1.4754286326024157e-07
duplications O 0 9.56721635247959e-08
in O 0 3.035540174778362e-08
exon O 0 1.7632520155075326e-07
16 O 0 2.5608227360862656e-07
were O 0 1.8159363790459793e-08
found O 0 9.1486214159886e-09
. O 0 6.056082213490299e-08

Among O 0 3.178610796794601e-08
the O 0 3.93828702982546e-09
other O 0 7.545247759921381e-11
11 O 0 2.9160991399379554e-09
unique O 0 1.2259914194956423e-09
mutations O 0 1.1079226425181332e-09
, O 0 1.6752130238550933e-10
8 O 0 6.022722942589098e-08
were O 0 1.930272475192396e-08
small O 0 6.434821120393508e-09
deletions O 0 9.51527852066647e-08
or O 0 1.3407175813995309e-08
insertions O 0 2.2928979603875632e-08
predicted O 0 4.954154420033774e-09
to O 0 8.885427948968072e-10
cause O 0 2.2679609301690107e-09
frameshifts O 0 3.7321548518320924e-08
, O 0 6.904944671592972e-11
1 O 0 1.3938040055450074e-08
was O 0 6.762801429971432e-09
a O 0 7.994799267052599e-10
mutation O 0 1.1793431509143915e-10
to O 0 2.6287025334248426e-10
a O 0 2.1628891733183053e-10
stop O 0 5.758899468411016e-10
codon O 0 2.091361084310961e-09
, O 0 9.156048835778918e-11
1 O 0 9.889546070951383e-09
was O 0 2.1260433413772262e-08
a O 0 3.887151933668065e-09
missense O 0 3.72250070768132e-08
mutation O 0 3.019265393255921e-10
, O 0 1.4104736476006074e-11
and O 0 1.93726250319326e-11
1 O 0 2.4029732870189946e-08
was O 0 1.7482850722672083e-08
predicted O 0 9.855389393464975e-09
to O 0 1.8877013285845123e-09
cause O 0 9.185649463283596e-10
insertion O 0 1.3854726255146943e-09
of O 0 4.371792261537166e-09
an O 0 7.343805008552806e-10
isoleucine O 0 1.1132717645523371e-06
in O 0 9.567906467111698e-09
the O 0 2.7720528095187547e-08
hect O 0 4.788184924109373e-07
domain O 0 2.6432958932787187e-08
of O 0 4.714024726126809e-09
the O 0 6.223711768171825e-09
UBE3A O 0 2.9222142075013835e-06
protein O 0 1.0455229570993652e-08
, O 0 2.0021166668993118e-10
which O 0 1.1310864571345558e-11
functions O 0 1.7890738890358193e-10
in O 0 9.499077080477036e-10
E2 O 0 1.0688116702795014e-07
binding O 0 1.9928378947042802e-08
and O 0 2.990718117601432e-09
ubiquitin O 0 3.792576563910188e-08
transfer O 0 9.992162404159899e-07
. O 0 7.846813900869165e-07

Eight O 0 5.974258669994015e-07
of O 0 6.568548815977238e-09
the O 0 3.236956813701397e-10
cases O 0 4.107870987812845e-11
were O 0 3.040682983179721e-10
familial O 0 5.000454272874322e-09
, O 0 6.72485289676672e-10
and O 0 4.4440254254318745e-10
five O 0 4.215095383841572e-09
were O 0 5.510002232256284e-09
sporadic O 0 5.955282063041523e-07
. O 0 9.463817605137592e-07

In O 0 2.532137557409442e-07
two O 0 5.050209583856713e-09
familial O 0 1.936951399272857e-08
cases O 0 5.052076534894923e-10
and O 0 3.535658224529392e-11
one O 0 5.4594901516269445e-11
sporadic O 0 5.9590514744911616e-09
case O 0 1.598609911113158e-09
, O 0 7.681165148376579e-10
mosaicism O 0 1.5468862329726107e-05
for O 0 9.600595518577393e-08
UBE3A O 0 5.14427010784857e-05
mutations O 0 1.9635889358937675e-08
was O 0 7.059427264977103e-09
detected O 0 4.1624992341837697e-10
in O 0 6.887726500259816e-11
the O 0 2.1802271099602422e-10
mother O 0 5.658941648611915e-10
of O 0 4.0892053632113345e-10
three O 0 1.0204846689898517e-10
AS B-Disease 1 0.9999991655349731
sons O 0 2.0968981218061344e-08
, O 0 2.6403995309620676e-11
in O 0 3.3642193197902515e-11
the O 0 1.1802725463638808e-10
maternal O 0 1.0090374189530849e-06
grandfather O 0 0.0026371090207248926
of O 0 0.0038105424027889967
two O 0 2.9022876901763084e-07
AS B-Disease 1 1.0
first O 0 4.7971752792363986e-08
cousins O 0 1.0952515339113233e-08
, O 0 6.859578183249226e-11
and O 0 1.733539527204453e-11
in O 0 1.2559582263094171e-09
the O 0 2.990536884794892e-08
mother O 0 2.2331839488742844e-08
of O 0 1.0560494700939671e-07
an O 0 4.671090181318505e-09
AS B-Disease 1 1.0
daughter O 0 0.0004979922669008374
. O 0 2.3373704607365653e-05

The O 0 2.79392310176263e-07
frequencies O 0 2.147247180062095e-08
with O 0 7.959238129684465e-11
which O 0 1.618573192141426e-10
we O 0 1.5231598204934471e-09
detected O 0 1.4864094399769101e-09
mutations O 0 6.178889344621297e-11
were O 0 3.9104700033654183e-10
5 O 0 4.746622206397433e-09
( O 0 8.739096252208256e-11
14 O 0 2.5815061199807587e-09
% O 0 8.85372053449629e-11
) O 0 2.458908077151989e-11
of O 0 9.021664665320728e-11
35 O 0 1.4190101316202686e-09
in O 0 7.349658381894386e-11
sporadic O 0 1.3015063471399912e-09
cases O 0 4.2013257456341435e-11
and O 0 4.489175350896879e-11
8 O 0 1.3127460896100729e-08
( O 0 9.825254498885272e-11
80 O 0 4.534963959912375e-09
% O 0 7.738482077357389e-11
) O 0 2.3482585667644607e-11
of O 0 1.0542769435240018e-10
10 O 0 1.7417940423314349e-09
in O 0 3.9468800450137564e-10
familial O 0 7.787263278657974e-09
cases O 0 7.981635352649619e-10
. O 0 1.1215149919863165e-09
. O 0 3.9579735044981135e-08

The O 0 2.258815584355034e-06
hemochromatosis B-Disease 1 1.0
845 O 0 4.104862512122054e-07
G O 0 2.6076067527469604e-08
- O 0 9.702798564603654e-09
- O 0 1.4860587427278915e-08
> O 0 8.459593914267316e-08
A O 0 3.159563055632475e-09
and O 0 2.015586482440046e-12
187 O 0 7.610375524214064e-11
C O 0 1.224258117105137e-08
- O 0 5.339899900036471e-08
- O 0 1.2284050399102853e-06
> O 0 3.678981011034921e-05
G O 0 5.834090188727714e-06
mutations O 0 4.783050044920856e-08
: O 0 2.715619951132453e-10
prevalence O 0 2.129277731910406e-08
in O 0 1.92623958450433e-10
non O 0 2.696325509532471e-07
- O 0 4.926613996758533e-07
Caucasian O 0 2.200617927883286e-07
populations O 0 4.297183764379042e-08
. O 0 5.4553449757577255e-08

Hemochromatosis B-Disease 0 0.11168555170297623
, O 0 5.11900992705705e-08
the O 0 1.2717404160866863e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 8.86197781824194e-08
leads O 0 5.912111191719305e-07
, O 0 1.4664298664257558e-09
if O 0 2.661122699976204e-08
untreated O 0 4.1312873690912966e-06
, O 0 1.2787256808977077e-09
to O 0 1.616693339201447e-06
progressive O 1 0.999998927116394
iron B-Disease 1 1.0
overload I-Disease 1 1.0
and O 0 2.826619720508461e-07
premature B-Disease 0 2.2998719941824675e-05
death I-Disease 0 1.1019106750609353e-05
. O 0 7.936492920634919e-07

The O 0 1.970080666069407e-05
hemochromatosis B-Disease 1 1.0
gene O 0 4.0846134652383626e-06
, O 0 1.582894171292537e-08
HFE O 0 0.0005256364238448441
, O 0 1.6796107615846267e-08
recently O 0 3.0952278962104174e-08
has O 0 6.906578087217952e-11
been O 0 3.749472954339694e-11
identified O 0 1.7516345318657756e-10
, O 0 4.576040241177637e-11
and O 0 7.376763783151219e-11
characterization O 0 1.0973510100598105e-08
of O 0 1.320002240845497e-08
this O 0 5.193431795724734e-10
gene O 0 4.4171860613673175e-10
has O 0 6.309344019461705e-11
shown O 0 3.352292748948216e-11
that O 0 2.850369679868736e-12
it O 0 2.3349835519964612e-12
contains O 0 5.78363919256919e-12
two O 0 2.8105712202020072e-12
mutations O 0 5.0151462843706085e-12
that O 0 2.3350282211259676e-12
result O 0 1.44735490953396e-11
in O 0 1.0309355452653435e-10
amino O 0 1.8388125744284167e-10
acid O 0 1.3882653360219877e-10
substitutions O 0 3.063045303508538e-11
- O 0 2.3069364127326075e-11
cDNA O 0 3.214530863715481e-10
nucleotides O 0 1.5101703221276352e-10
845 O 0 1.0737801758864407e-09
G O 0 1.234033653041422e-09
- O 0 3.989059749187618e-09
- O 0 1.0701515229527558e-08
> O 0 7.70511974224064e-08
A O 0 2.858531189531277e-08
( O 0 1.0987168640175238e-11
C282Y O 0 6.658792184310869e-09
) O 0 1.7002359806519984e-12
and O 0 1.1047114828813265e-12
187 O 0 1.5471808556544175e-10
C O 0 2.654339859020638e-08
- O 0 8.973642451337582e-08
- O 0 9.644807050790405e-07
> O 0 3.0188821256160736e-06
G O 0 6.203920861480583e-07
( O 0 6.717852940596458e-10
H63D O 0 2.8104541343054734e-06
) O 0 1.920122061349616e-09
. O 0 4.044043677708942e-08

Although O 0 9.114483873418067e-06
hemochromatosis B-Disease 1 1.0
is O 0 2.4399335885050277e-09
common O 0 1.9810117435348218e-10
in O 0 4.682164031488689e-11
Caucasians O 0 1.1862386628536115e-08
, O 0 3.4131135417947434e-11
affecting O 0 3.428533290605884e-10
> O 0 2.9827670999793554e-08
= O 0 3.353781252712906e-08
1 O 0 1.2140684013672853e-08
/ O 0 6.574705935236125e-08
300 O 0 6.835358057344365e-09
individuals O 0 1.7988178654948506e-11
of O 0 1.7430958065833835e-10
northern O 0 1.4509385914962536e-09
European O 0 1.9254764449527784e-09
origin O 0 1.1991547754774956e-09
, O 0 7.37594776922812e-11
it O 0 1.5432483416177867e-11
has O 0 2.203834770925228e-12
not O 0 3.4313756263476547e-12
been O 0 1.1740010873173556e-11
recognized O 0 1.3378449736922704e-10
in O 0 1.7008863761880377e-10
other O 0 1.5880030623804942e-10
populations O 0 7.472326091217951e-10
. O 0 1.039700325833337e-08

The O 0 2.475269127444335e-07
present O 0 8.266020756764192e-09
study O 0 1.217239753437127e-09
used O 0 3.805107895438198e-10
PCR O 0 1.0658025573206942e-08
and O 0 2.367264440028549e-10
restriction O 0 1.3899890127788694e-08
- O 0 6.233604743499654e-10
enzyme O 0 6.649418515802807e-11
digestion O 0 8.656615979596438e-10
to O 0 9.011793394853029e-11
analyze O 0 2.525391562535617e-10
the O 0 6.801472579587298e-11
frequency O 0 3.3034910362772507e-09
of O 0 1.7479033498357666e-10
the O 0 2.1931231830585318e-10
845 O 0 2.3265140924877414e-09
G O 0 1.27932586746482e-09
- O 0 1.4680445747927706e-09
- O 0 3.7195317936777883e-09
> O 0 2.5588251517660865e-08
A O 0 1.1856228221418519e-09
and O 0 1.4669591496402345e-12
187 O 0 2.1483497272822838e-11
C O 0 1.5923594665068208e-09
- O 0 2.827210465738972e-09
- O 0 1.0006869644030303e-07
> O 0 3.968870714743389e-06
G O 0 6.641163281528861e-07
mutations O 0 5.063259145288157e-09
in O 0 1.2474707933307627e-09
HLA O 0 3.5270360854156024e-07
- O 0 2.838445993802452e-07
typed O 0 1.5640806338979019e-07
samples O 0 3.5628624495132044e-09
from O 0 1.0122033766712946e-10
non O 0 6.06302847927509e-08
- O 0 3.7490785587124265e-08
Caucasian O 0 1.2483354794312618e-08
populations O 0 1.3408396615233187e-09
, O 0 4.011426607553048e-11
comprising O 0 1.5774193062867425e-10
Australian O 0 1.2907113600135744e-08
Aboriginal O 0 3.6447957540985954e-08
, O 0 2.8714888106184944e-11
Chinese O 0 6.29458596357324e-10
, O 0 1.8735811513348466e-11
and O 0 3.946147922317955e-11
Pacific O 0 3.7698441701650154e-08
Islanders O 0 8.716974093658791e-07
. O 0 7.456586104126472e-08

Results O 0 2.748519989381748e-07
showed O 0 1.4188646701995822e-08
that O 0 3.718478649994417e-11
the O 0 1.2192374887476376e-10
845 O 0 4.767854999698784e-09
G O 0 7.071518837165058e-08
- O 0 9.381722776424795e-08
- O 0 2.1322613008578628e-07
> O 0 1.354253981844522e-06
A O 0 3.302818640804617e-08
mutation O 0 2.396937648363462e-10
was O 0 7.523175832302442e-11
present O 0 1.0244430304062746e-11
in O 0 2.0963390745531996e-11
these O 0 9.239990717002655e-12
populations O 0 6.656318291692331e-12
( O 0 2.6816253211048302e-12
allele O 0 2.9492791542296004e-10
frequency O 0 8.744919233194537e-10
0 O 0 5.866729324566222e-10
. O 0 9.583019100478651e-11
32 O 0 1.4161980477211955e-09
% O 0 4.6618108678897485e-11
) O 0 1.4301762898960568e-11
, O 0 1.1776881553293705e-11
and O 0 1.390209648788332e-11
, O 0 5.454075125560509e-12
furthermore O 0 2.755508321516942e-10
, O 0 8.744393230342151e-12
it O 0 5.2531520799981024e-12
was O 0 3.3756686335095765e-10
always O 0 1.0370340142173973e-09
seen O 0 5.015218240700392e-10
in O 0 1.0450295490072037e-10
conjunction O 0 5.254753521199973e-09
with O 0 2.4799162723354584e-10
HLA O 0 1.4383779671334196e-05
haplotypes O 0 2.2169726321408234e-07
common O 0 3.799938586013241e-09
in O 0 2.264216730774038e-10
Caucasians O 0 5.145221138036504e-09
, O 0 2.980334035118659e-11
suggesting O 0 4.814044718415289e-10
that O 0 7.145301711419805e-12
845 O 0 3.1727942495507477e-09
G O 0 7.684835878762897e-08
- O 0 4.852191182180832e-07
- O 0 4.213894499116577e-06
> O 0 6.252460298128426e-05
A O 0 5.313291921993368e-07
may O 0 7.562242387848528e-09
have O 0 1.0840275899148821e-10
been O 0 1.4277259929862396e-11
introduced O 0 2.117069991536269e-10
into O 0 1.9553860267085277e-11
these O 0 7.55149328485194e-12
populations O 0 1.600093842146766e-11
by O 0 1.9968526832059297e-11
Caucasian O 0 6.359685755796818e-08
admixture O 0 3.920026188097836e-07
. O 0 7.964395649651124e-07

187 O 0 9.153966118446988e-08
C O 0 1.0077278744802243e-07
- O 0 1.285431583397667e-08
- O 0 3.503140888483358e-08
> O 0 1.507878693018938e-07
G O 0 6.023286402978556e-08
was O 0 1.8803563150981972e-09
present O 0 7.243859678762732e-11
at O 0 5.254951473965264e-10
an O 0 1.51961221384056e-11
allele O 0 1.0187115595527985e-09
frequency O 0 7.221876874297095e-09
of O 0 4.185652713317722e-09
2 O 0 4.0200805528911587e-07
. O 0 9.278734864892613e-07

68 O 0 9.571932650942472e-07
% O 0 1.8837882365119185e-09
in O 0 7.248617817090519e-10
the O 0 1.0677594364238985e-09
two O 0 5.163068583780017e-11
populations O 0 2.513611541132832e-11
analyzed O 0 1.2836277596406376e-09
( O 0 1.8421167924387305e-09
Australian O 0 8.108183919830481e-07
Aboriginal O 0 2.958018114895822e-07
and O 0 6.219163517506843e-10
Chinese O 0 6.914519623535398e-09
) O 0 1.5950648579732274e-09
. O 0 2.6669761510333956e-08

In O 0 3.055225761272595e-08
the O 0 1.6828108684308063e-08
Australian O 0 3.524943892330157e-08
Aboriginal O 0 7.270360313782476e-09
samples O 0 1.2454208497825192e-10
, O 0 1.0912540402557847e-12
187 O 0 1.1581705039453993e-10
C O 0 1.2129019566486932e-08
- O 0 2.5307800299856353e-08
- O 0 2.932600864369306e-07
> O 0 2.3629893348697806e-06
G O 0 5.704299042008643e-07
was O 0 5.701261684976089e-09
found O 0 1.0898365543354771e-10
to O 0 9.866307076888958e-11
be O 0 9.587735466665137e-11
associated O 0 2.1587771570352743e-09
with O 0 5.139382808216908e-10
HLA O 0 0.00047642597928643227
haplotypes O 0 2.960955043818103e-06
common O 0 2.5617747922979106e-08
in O 0 4.0048384053470443e-10
Caucasians O 0 1.6566076510571293e-08
, O 0 2.8653556957691784e-11
suggesting O 0 4.2087949791991264e-10
that O 0 3.701013454038282e-12
it O 0 8.66427155715721e-12
was O 0 2.1578046294212783e-10
introduced O 0 6.066805946502996e-10
by O 0 1.795369582169304e-11
recent O 0 4.672736642064024e-10
admixture O 0 1.1665921562098447e-08
. O 0 6.022516174652992e-08

In O 0 4.498233252547834e-08
the O 0 1.3359721329209151e-08
Chinese O 0 6.838500876682474e-09
samples O 0 4.945240328346756e-10
analyzed O 0 1.0124871774319644e-10
, O 0 2.2612980932201765e-11
187 O 0 5.434309668927995e-10
C O 0 1.1888661610726103e-08
- O 0 6.519272233163065e-09
- O 0 5.185934526252822e-08
> O 0 2.627036792546278e-07
G O 0 4.4103547480744965e-08
was O 0 5.9467630819654e-10
present O 0 2.7178724548715394e-11
in O 0 3.617019531110266e-11
association O 0 1.0043339770948734e-10
with O 0 5.518386962666266e-12
a O 0 1.3533473230964432e-09
wide O 0 1.8561255865634507e-09
variety O 0 1.2179411923440853e-09
of O 0 3.035145024199437e-09
HLA O 0 1.1074668009314337e-06
haplotypes O 0 1.1905140695489536e-07
, O 0 1.0870759847847467e-09
showing O 0 6.2863341199204115e-09
this O 0 9.940351319848162e-11
mutation O 0 3.358769512518123e-11
to O 0 5.462447855153485e-11
be O 0 1.9313606269832917e-10
widespread O 0 1.2724382658646505e-10
and O 0 8.712196762628022e-12
likely O 0 3.992102481920057e-10
to O 0 1.3220020633752938e-09
predate O 0 7.186989847696168e-08
the O 0 3.4518552460838237e-09
more O 0 7.203627278018487e-11
genetically O 0 1.4053319619122817e-10
restricted O 0 8.010903607136299e-10
845 O 0 1.1098055807678975e-08
G O 0 8.447872090755482e-08
- O 0 5.646537033499044e-07
- O 0 7.182591161836172e-07
> O 0 4.78150923299836e-06
A O 0 1.9985861854365794e-07
mutation O 0 1.8980641058874426e-08
. O 0 1.1702514512990092e-08

Genotype O 0 3.6386398278409615e-05
- O 0 8.83509073901223e-06
phenotype O 0 1.7875943569833908e-07
correlations O 0 7.013156277935195e-08
in O 0 1.8685915392779862e-07
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 8.238237933255732e-05

Germ O 0 0.0025845090858638287
- O 0 8.590892684878781e-05
line O 0 8.061643939072383e-07
mutations O 0 6.599947255381267e-08
of O 0 5.147638759694928e-08
the O 0 4.7608782693941976e-08
tumor B-Disease 0 8.016877472982742e-07
suppressor O 0 2.6793206870934227e-06
APC O 0 1.7504113714039704e-07
are O 0 2.5924540292265874e-10
implicated O 0 9.6622061462881e-09
in O 0 8.372910542675527e-08
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 3.2765225910225126e-07
AAPC B-Disease 1 1.0
) O 0 8.630271497445108e-10
, O 0 2.841837529188318e-11
a O 0 1.2961497153352042e-10
variant O 0 1.2665489634855476e-07
of O 0 5.1020083446928766e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 4.9927276535299825e-08
FAP B-Disease 0 1.451904950044991e-06
) O 0 3.3843221558527148e-09
. O 0 5.693234328418839e-08

AAPC B-Disease 1 1.0
is O 0 1.0561659102847898e-08
recognized O 0 1.6109452660728607e-09
by O 0 3.6871353192857725e-11
the O 0 7.324458262125688e-10
occurrence O 0 7.121909728624587e-09
of O 0 2.080007499571934e-09
< O 0 2.8170065888843965e-06
100 O 0 5.743492010878981e-07
colonic B-Disease 0 1.791027330000361e-06
adenomas I-Disease 0 1.1598372111620847e-06
and O 0 1.8484229424853282e-10
a O 0 1.8021774350618358e-10
later O 0 1.1103321595484772e-09
onset O 0 0.009996119886636734
of O 0 8.12340033462533e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.7814057173826114e-10
age O 0 1.1341897421246472e-09
> O 0 2.124660980484805e-08
40 O 0 7.898075082835021e-09
years O 0 5.645379719254606e-10
) O 0 6.049380996131504e-10
. O 0 4.0829121417118586e-08

The O 0 1.254352923751867e-07
aim O 0 4.6893390504010313e-07
of O 0 1.6198465901950954e-09
this O 0 5.965231780757918e-11
study O 0 1.5471393610688722e-10
was O 0 3.856105157407086e-10
to O 0 5.633719601938481e-10
assess O 0 5.170408456933728e-08
genotype O 0 5.992644105390355e-07
- O 0 8.016480933292769e-06
phenotype O 0 2.1048124665412615e-07
correlations O 0 4.372695627807843e-08
in O 0 1.2838638951961912e-07
AAPC B-Disease 1 1.0
families O 0 6.539423935691957e-08
. O 0 9.787971322339217e-08

By O 0 4.552953847269947e-10
protein O 0 1.19897869410579e-09
- O 0 1.5948312892533067e-08
truncation O 0 1.2712852992535773e-07
test O 0 2.9502272624881698e-08
( O 0 8.853775490536009e-10
PTT O 0 4.856954660681367e-07
) O 0 1.7084580278270423e-11
assay O 0 7.235771426472581e-10
, O 0 4.7226056398841365e-11
the O 0 1.1832501645159255e-10
entire O 0 7.583456640425368e-10
coding O 0 7.571655658011878e-08
region O 0 1.931561399715065e-08
of O 0 1.4867022279929643e-08
the O 0 1.441890518094624e-08
APC B-Disease 0 2.5880495968522155e-08
gene O 0 1.0876441969287498e-09
was O 0 1.7911950811466681e-09
screened O 0 1.256106774150112e-09
in O 0 3.644402557512194e-10
affected O 0 2.1636319125217796e-10
individuals O 0 9.625036878624371e-12
from O 0 4.5125880809848695e-10
11 O 0 2.5642123091529356e-07
AAPC B-Disease 1 1.0
kindreds O 0 9.845281283560325e-07
, O 0 1.1923037002148362e-09
and O 0 1.6592179019614406e-10
their O 0 1.492312495798842e-09
phenotypic O 0 9.55518046907855e-08
differences O 0 2.7832847138142824e-08
were O 0 8.525505279521894e-08
examined O 0 4.4849204527963593e-07
. O 0 1.104988655242778e-06

Five O 0 1.6521023837867688e-07
novel O 0 9.82803793903031e-09
germ O 0 6.325731192191597e-06
- O 0 2.8305521482252516e-06
line O 0 1.7480959968452225e-07
APC B-Disease 0 1.5696242883223022e-07
mutations O 0 3.0353071167610324e-09
were O 0 1.7391516005105245e-09
identified O 0 1.0898813407322905e-08
in O 0 1.4777797652243407e-08
seven O 0 1.0198574784681114e-07
kindreds O 0 3.4229678931296803e-06
. O 0 3.71477000271625e-07

Mutations O 0 1.1373818153970205e-07
were O 0 3.803992676409962e-09
located O 0 5.323064766749042e-10
in O 0 3.424004690888438e-10
three O 0 2.1805172251143645e-11
different O 0 3.0487752079866315e-12
regions O 0 1.3679628263485455e-10
of O 0 1.5261346630879302e-09
the O 0 5.231771904590232e-09
APC B-Disease 0 1.7421070808154582e-08
gene O 0 4.747905402169295e-10
( O 0 2.419069458636791e-11
1 O 0 7.993370410019907e-09
) O 0 1.0918090043166018e-10
at O 0 3.66796149009474e-09
the O 0 4.0484621210978844e-10
5 O 0 1.8364967324657755e-09
end O 0 6.277947051103183e-09
spanning O 0 4.667899400345732e-10
exons O 0 1.337330357564781e-09
4 O 0 7.760865283756857e-10
and O 0 9.97609772568353e-11
5 O 0 2.563127265986509e-09
, O 0 8.480179752856642e-11
( O 0 6.754566524158623e-12
2 O 0 3.2331126664786325e-10
) O 0 1.7740401161980834e-11
within O 0 7.656091732810566e-11
exon O 0 1.7580686906271126e-09
9 O 0 3.954244043313793e-09
, O 0 1.3810923238377626e-10
and O 0 4.389551916395007e-11
( O 0 4.5198454354244966e-12
3 O 0 4.2986794679400475e-10
) O 0 1.797548741799826e-11
at O 0 6.533135143982349e-10
the O 0 1.577022262777561e-10
3 O 0 1.1082439410614597e-09
distal O 0 1.3896868544804875e-08
end O 0 2.8840472054980637e-07
of O 0 1.2115840775095421e-08
the O 0 7.0998158463453365e-09
gene O 0 7.600895912673877e-09
. O 0 1.4877693388370972e-07

Variability O 0 5.813307097923825e-07
in O 0 2.0920163379400947e-08
the O 0 1.3067405824074285e-08
number O 0 8.563048936593987e-09
of O 0 1.1900282004262408e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 9.06510763343249e-07
most O 0 4.460840308251335e-10
apparent O 0 3.8705624816337547e-10
in O 0 4.823996757608029e-11
individuals O 0 2.3487501006613787e-12
with O 0 1.0412542139279224e-12
mutations O 0 4.423633681582828e-11
in O 0 1.834179252924173e-09
region O 0 7.122483225430187e-08
1 O 0 0.0012808984611183405
, O 0 8.356266789633082e-09
and O 0 2.7435330451908158e-08
upper O 1 1.0
- O 1 1.0
gastrointestinal O 1 0.9998375177383423
manifestations O 0 2.988450796692632e-05
were O 0 1.098975799251889e-09
more O 0 6.252331985479032e-11
severe O 0 4.782954032833686e-10
in O 0 1.365642599004957e-10
them O 0 6.355072579289356e-10
. O 0 3.103373913404539e-08

In O 0 3.5312559987232817e-08
individuals O 0 1.3262241305156408e-10
with O 0 1.7838322832752773e-11
mutations O 0 2.6984197862289783e-11
in O 0 5.916834383556946e-11
either O 0 2.3746990485129515e-10
region O 0 7.094735909873862e-10
2 O 0 9.559625091526414e-09
or O 0 3.0947583384843824e-10
region O 0 2.480417815586833e-10
3 O 0 5.234826350175581e-09
, O 0 5.72650780961137e-11
the O 0 2.597120851710599e-10
average O 0 1.3060471593107081e-09
number O 0 4.4989151293250984e-10
of O 0 8.146622820781602e-10
adenomas B-Disease 0 1.358066697321192e-06
tended O 0 6.211641334630258e-08
to O 0 5.77207615037878e-09
be O 0 9.80238556991253e-10
lower O 0 2.4294617428921583e-09
than O 0 6.881567538030708e-11
those O 0 3.5060968017752714e-11
in O 0 3.234356879544542e-11
individuals O 0 7.351379054110208e-12
with O 0 3.7321760265607296e-12
mutations O 0 5.261919372445689e-11
in O 0 1.4256124059031094e-10
region O 0 7.610379548772528e-10
1 O 0 1.8913640431605927e-08
, O 0 1.0704995223598246e-10
although O 0 1.490755574540259e-10
age O 0 7.457262030108325e-10
at O 0 2.3327391129868147e-09
diagnosis O 0 1.8477801688732143e-07
was O 0 4.256727859086595e-09
similar O 0 1.905659408052429e-09
. O 0 6.141252839597655e-08

In O 0 1.4460156307904981e-06
all O 0 6.535846068800311e-07
AAPC B-Disease 1 1.0
kindreds O 0 6.176085662445985e-06
, O 0 1.2945049476797976e-09
a O 0 2.277793065275091e-09
predominance O 0 5.689011004506028e-07
of O 0 4.248740594903211e-07
right O 1 0.9821620583534241
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9831374883651733
rectal B-Disease 1 1.0
polyp I-Disease 0 0.0012587812962010503
sparing O 0 2.581636238119245e-07
was O 0 1.510667502202523e-08
observed O 0 4.019211630179598e-09
. O 0 2.4721639846347898e-08

No O 0 8.04242881713435e-05
desmoid B-Disease 0 0.026803033426404
tumors I-Disease 1 1.0
were O 0 3.728127850877172e-08
found O 0 9.688997382184539e-10
in O 0 9.73308100782333e-10
these O 0 4.684777454855293e-09
kindreds O 0 3.194345026713563e-06
. O 0 4.9157728199134e-07

Our O 0 9.990828402806073e-06
data O 0 9.953265589501825e-08
suggest O 0 1.36801059369418e-09
that O 0 2.3659360928740547e-11
, O 0 3.987541893901714e-11
in O 0 1.2758656353639708e-09
AAPC B-Disease 1 1.0
families O 0 5.699443694773265e-10
, O 0 1.8828882897281574e-11
the O 0 6.057090246036623e-11
location O 0 9.745308560127341e-09
of O 0 9.125616706739947e-09
the O 0 6.695498200315342e-08
APC B-Disease 0 4.027235718240263e-06
mutation O 0 5.3761073814939664e-08
may O 0 2.423571388021628e-08
partially O 0 2.66810076254842e-08
predict O 0 4.679954646036322e-09
specific O 0 2.8008624308739627e-09
phenotypic O 0 2.3632273382645508e-07
expression O 0 9.107881169256871e-07
. O 0 8.261010293608706e-07

This O 0 6.9852785777868576e-09
should O 0 3.5812988130601298e-09
help O 0 3.986481367235228e-09
in O 0 7.121851997027306e-10
the O 0 1.2683294414728152e-09
design O 0 3.69652006781962e-08
of O 0 1.5771080441595586e-08
tailored O 0 2.1358187041187193e-07
clinical O 0 3.427180956805387e-07
- O 0 4.1898647396010347e-07
management O 0 3.3608827720854606e-08
protocols O 0 2.6840236841962906e-06
in O 0 1.1813181544084728e-09
this O 0 1.394033916080062e-10
subset O 0 2.1182584575285546e-09
of O 0 1.387884113190907e-10
FAP B-Disease 0 2.832707046707128e-08
patients O 0 1.4434031747612153e-09
. O 0 4.918946916454559e-10
. O 0 1.492475476538857e-08

Wilms B-Disease 1 0.9982433319091797
' I-Disease 0 4.471291322261095e-05
tumor I-Disease 0 1.9100943973171525e-06
1 O 0 2.403459689048759e-07
and O 0 2.0991459681596325e-09
Dax O 0 0.00039310872671194375
- O 0 2.513247068236524e-07
1 O 0 6.230139319995942e-07
modulate O 0 9.950853154805372e-07
the O 0 2.7402489166661326e-08
orphan O 0 6.038101219019154e-08
nuclear O 0 1.6392887047800286e-08
receptor O 0 4.2568575331358716e-09
SF O 0 3.0420749226323096e-06
- O 0 2.3696999562616838e-07
1 O 0 4.167523925957539e-08
in O 0 6.617311143486404e-10
sex O 0 7.358330611495489e-10
- O 0 2.6942711950361797e-10
specific O 0 8.848655835835828e-11
gene O 0 7.136075064195779e-10
expression O 0 3.730447062366693e-08
. O 0 1.3312782698449155e-07

Products O 0 7.29084547401726e-07
of O 0 2.549952959896018e-08
steroidogenic O 0 2.5254528281948296e-06
factor O 0 1.9464584610773272e-08
1 O 0 8.357848457762884e-08
( O 0 3.8528630286194243e-10
SF O 0 7.0139512899913825e-06
- O 0 9.67589130596025e-07
1 O 0 3.0022189889677975e-07
) O 0 3.248270319389235e-09
and O 0 5.670354408238154e-09
Wilms B-Disease 0 0.0006908330251462758
tumor I-Disease 0 5.11355756316334e-06
1 O 0 3.5380591612010903e-07
( O 0 1.1376867226076115e-09
WT1 O 0 7.203224754448456e-07
) O 0 1.1581374054214777e-10
genes O 0 1.1071700500853154e-10
are O 0 1.3198289683380438e-11
essential O 0 5.2242330461638176e-09
for O 0 4.953094046022954e-10
mammalian O 0 5.686885060640634e-07
gonadogenesis O 0 1.5648521412003902e-06
prior O 0 1.9458241240499774e-07
to O 0 2.6715380130326594e-08
sexual O 0 4.945751808094201e-09
differentiation O 0 4.413922738422116e-08
. O 0 7.1916936406069e-08

In O 0 2.384377673081417e-08
males O 0 2.323473147214372e-08
, O 0 5.329424124234095e-10
SF O 0 5.9044023146270774e-06
- O 0 5.080268579149561e-07
1 O 0 1.7440463295770314e-07
participates O 0 9.242190124325589e-09
in O 0 2.9324401240593545e-10
sexual O 0 5.7130231101432116e-11
development O 0 4.1233509662230716e-11
by O 0 7.480931672743107e-12
regulating O 0 2.780810470781603e-09
expression O 0 3.8964472537372785e-08
of O 0 1.2241320845873815e-08
the O 0 1.46480925167225e-08
polypeptide O 0 7.187538244579628e-07
hormone O 0 4.079892335084878e-07
Mullerian O 0 1.9432998215052066e-06
inhibiting O 0 1.181783488846122e-07
substance O 0 2.148025970427625e-07
( O 0 8.831866349368056e-10
MIS O 0 1.085717485693749e-05
) O 0 7.725070361175312e-09
. O 0 7.561639847608603e-08

Here O 0 1.632397044204481e-07
, O 0 9.524875332900251e-10
we O 0 7.383749167644282e-10
show O 0 1.942570548862932e-09
that O 0 1.1474098754460371e-10
WT1 O 0 5.384098585636821e-06
- O 0 6.13072461419506e-06
KTS O 0 3.911976091330871e-05
isoforms O 0 1.8457689066053717e-07
associate O 0 2.0401206768383418e-07
and O 0 7.632620646624844e-10
synergize O 0 1.479966442730074e-07
with O 0 4.571976963685387e-10
SF O 0 3.793907671933994e-05
- O 0 1.5951620753185125e-06
1 O 0 7.339932039940322e-07
to O 0 3.291015460149538e-08
promote O 0 3.6021407368025393e-07
MIS O 0 0.00020152959041297436
expression O 0 7.849028520467982e-07
. O 0 1.9748385682305525e-07

In O 0 4.728732960757043e-08
contrast O 0 3.735402387405884e-08
, O 0 5.340253572683196e-09
WT1 O 0 9.01518578757532e-05
missense O 0 7.016205017862376e-06
mutations O 0 6.564330590208556e-08
, O 0 7.768211074399289e-10
associated O 0 4.143221765673388e-09
with O 0 5.188934698585612e-11
male B-Disease 0 5.806328751134515e-09
pseudohermaphroditism I-Disease 1 1.0
in O 0 9.177986726172094e-08
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.748158393714675e-09
fail O 0 2.4218297767220065e-07
to O 0 7.95841170742051e-09
synergize O 0 5.703700480808038e-07
with O 0 6.705413113650138e-09
SF O 1 0.9999223947525024
- O 1 0.9513512253761292
1 O 1 0.9728313684463501
. O 0 5.870109816896729e-06

Additionally O 0 1.5144647136366984e-07
, O 0 9.482441498676053e-10
the O 0 1.3386345365518082e-09
X O 0 1.697778770903824e-06
- O 0 6.02518184678047e-07
linked O 0 2.349248404698301e-07
, O 0 9.747064960707874e-11
candidate O 0 5.013888748628403e-10
dosage O 0 7.571279070361925e-07
- O 0 1.756159946353364e-07
sensitive O 0 2.3695575634974375e-07
sex O 0 7.545615687831742e-09
- O 0 6.832268972800648e-09
reversal O 0 4.446825574433433e-09
gene O 0 1.3025145406686534e-09
, O 0 5.748539977368239e-10
Dax O 0 4.870617340202443e-05
- O 0 8.758933489616538e-08
1 O 0 1.401949845103445e-07
, O 0 1.0859320109801729e-09
antagonizes O 0 1.5471881553708045e-08
synergy O 0 2.4300039758173853e-09
between O 0 2.016757594258678e-10
SF O 0 5.117494765727315e-06
- O 0 4.5734910258943273e-07
1 O 0 3.910959662789537e-07
and O 0 6.596949653214779e-09
WT1 O 0 5.928336577198934e-06
, O 0 2.4966029243955745e-10
most O 0 1.4966007599870323e-11
likely O 0 2.786882183358763e-11
through O 0 3.266170320315176e-12
a O 0 3.0464519795714295e-11
direct O 0 1.4135986825536406e-10
interaction O 0 2.4352272975924905e-10
with O 0 4.849661991435106e-11
SF O 0 3.857701813103631e-05
- O 0 1.4134931916487403e-05
1 O 0 1.1538340913830325e-05
. O 0 1.171128815258271e-06

We O 0 2.809754846566648e-07
propose O 0 1.8845516081000824e-07
that O 0 2.0289971924825068e-09
WT1 O 0 9.481231245445088e-06
and O 0 5.355413534857689e-08
Dax O 0 0.00571076013147831
- O 0 3.3557432743691606e-07
1 O 0 8.415547370077547e-08
functionally O 0 8.03441135843741e-09
oppose O 0 5.00057817376387e-09
each O 0 4.417622170849178e-11
other O 0 4.755298932401786e-11
in O 0 7.896249210048722e-10
testis O 0 1.3262562958971102e-07
development O 0 7.988946171266775e-10
by O 0 5.900830518656974e-11
modulating O 0 5.4264432947093155e-08
SF O 0 3.046164601983037e-05
- O 0 1.3498813586920733e-06
1 O 0 1.6466235592815792e-06
- O 0 3.8053519801906077e-07
mediated O 0 3.9502813820035954e-07
transactivation O 0 9.469665201322641e-06
. O 0 3.025084538421652e-08
. O 0 4.5941064286125766e-08

A O 0 1.623688149265945e-06
mouse O 0 4.931860075885197e-08
model O 0 1.3126358666681881e-08
for O 0 7.31887865867975e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.999998927116394
centre O 0 9.950786989065818e-06
mutations O 0 3.015366445424661e-08
. O 0 1.936098215082893e-08

Imprinting O 0 6.553874300152529e-06
in O 0 4.607418446767042e-08
the O 0 2.0848464288292234e-08
15q11 O 0 5.988039788462629e-07
- O 0 8.295986475559403e-08
q13 O 0 2.60212260627668e-07
region O 0 1.464746990365029e-09
involves O 0 1.0507161807282728e-09
an O 0 1.7601077539897148e-10
imprinting O 0 1.5988873656169744e-06
centre O 0 6.554321885232639e-07
( O 0 1.2661485748743928e-10
IC O 0 3.120057456840186e-08
) O 0 1.4572558437730976e-10
, O 0 3.301157264212762e-11
mapping O 0 3.47375461728916e-10
in O 0 5.126193219906483e-11
part O 0 2.1921027493210232e-10
to O 0 1.7082676384561069e-09
the O 0 9.742181505956182e-10
promoter O 0 2.2915296327141732e-08
and O 0 3.7594598545354074e-09
first O 0 3.46780026916349e-08
exon O 0 1.0297559072114382e-07
of O 0 5.078030085314822e-08
SNRPN O 0 6.712155300192535e-05
. O 0 3.7693487797696434e-07

Deletion O 0 1.6391124972869875e-06
of O 0 5.463081720336049e-08
this O 0 3.5485390181833054e-09
IC O 0 4.448295669590152e-07
abolishes O 0 7.647563506907318e-07
local O 0 1.237272595489003e-08
paternally O 0 2.6142352282931824e-08
derived O 0 7.293273207586992e-10
gene O 0 2.7646895883748357e-10
expression O 0 3.612064536362425e-10
and O 0 1.686706330161769e-11
results O 0 3.604817000457672e-10
in O 0 4.069011438900816e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.695620651138597e-06
PWS B-Disease 1 1.0
) O 0 4.793644592382407e-08
. O 0 1.2762902201757242e-07

We O 0 2.672277616966312e-07
have O 0 3.6330434216580443e-09
created O 0 8.590314570788848e-10
two O 0 8.051512234708014e-10
deletion O 0 2.4434834600128852e-08
mutations O 0 7.0863541701271515e-09
in O 0 1.0776791015132403e-08
mice O 0 1.3984991653614998e-07
to O 0 3.5669845743768747e-08
understand O 0 3.010774776157632e-07
PWS B-Disease 1 1.0
and O 0 3.694208317028824e-08
the O 0 3.395282632823182e-08
mechanism O 0 9.062724615205298e-08
of O 0 4.539169928818865e-09
this O 0 1.679571370871713e-09
IC O 0 1.31056538066332e-06
. O 0 4.59504434502378e-07

Mice O 0 0.0003111362748313695
harbouring O 0 6.016296538291499e-05
an O 0 2.039590718538875e-08
intragenic O 0 1.1646437997114845e-05
deletion O 0 8.766685937189322e-07
in O 0 5.182355167221431e-08
Snrpn O 0 9.742737347551156e-06
are O 0 5.914704837017837e-10
phenotypically O 0 4.792410663867486e-07
normal O 0 3.585114711768256e-07
, O 0 1.1133732824575304e-09
suggesting O 0 5.49893641732524e-09
that O 0 1.7202433921781335e-10
mutations O 0 1.8951114011400705e-09
of O 0 4.247449947314408e-09
SNRPN O 0 1.3837800452165538e-06
are O 0 7.322820128052854e-11
not O 0 3.364362122226794e-10
sufficient O 0 3.332350217988278e-08
to O 0 5.202320707553554e-08
induce O 0 6.299963843048317e-06
PWS B-Disease 1 1.0
. O 0 2.3377269826596603e-05

Mice O 0 8.988680747279432e-06
with O 0 2.1951205297909837e-09
a O 0 8.478312274462496e-09
larger O 0 4.207906023623309e-09
deletion O 0 3.295588157925522e-08
involving O 0 1.1058894910931372e-09
both O 0 9.646512477701208e-10
Snrpn O 0 3.296337069969013e-07
and O 0 4.765434158393589e-10
the O 0 3.6532572522673945e-09
putative O 0 9.946242016667384e-07
PWS O 1 1.0
- O 0 7.3969599725387525e-06
IC O 0 2.0040899926243583e-06
lack O 0 8.46397426812473e-07
expression O 0 2.6280584819460273e-08
of O 0 1.9331416467593954e-09
the O 0 1.162890339578837e-09
imprinted O 0 1.6056880269843532e-08
genes O 0 5.0404902474099345e-09
Zfp127 O 0 1.6669044953232515e-06
( O 0 2.339132665341026e-09
mouse O 0 1.6011594539122598e-07
homologue O 0 1.6335258123945096e-06
of O 0 4.8978034072888477e-08
ZNF127 O 0 1.7595206372789107e-05
) O 0 6.007461195167707e-09
, O 0 8.868602741074483e-09
Ndn O 0 7.88811121310573e-06
and O 0 6.4907350605381e-09
Ipw O 0 4.1773240809561685e-05
, O 0 8.785331573335498e-09
and O 0 8.863084710597491e-10
manifest O 0 1.7833112764265024e-08
several O 0 2.875167603999529e-10
phenotypes O 0 9.997784822246558e-09
common O 0 2.814749322510579e-09
to O 0 7.315724559475711e-08
PWS B-Disease 1 1.0
infants O 0 0.001968990545719862
. O 0 1.1589118003030308e-06

These O 0 2.119092101793285e-08
data O 0 4.421757182626607e-09
demonstrate O 0 9.593960070830576e-10
that O 0 4.44810854816069e-12
both O 0 9.425162907084061e-12
the O 0 3.2564820284797236e-10
position O 0 8.683177732393688e-09
of O 0 1.9645094440079447e-09
the O 0 7.359116094285412e-10
IC O 0 1.386308756679e-08
and O 0 9.990416827143633e-11
its O 0 5.248978335314902e-11
role O 0 1.40191580566551e-10
in O 0 3.104927981389949e-10
the O 0 1.0772613912024553e-09
coordinate O 0 2.5000172598765857e-08
expression O 0 9.487406060770809e-08
of O 0 9.208845241914787e-09
genes O 0 1.8114175714956104e-09
is O 0 1.117029108099743e-10
conserved O 0 4.846446577388974e-10
between O 0 3.97358174142326e-10
mouse O 0 1.2699936746685125e-07
and O 0 5.991381279990549e-10
human O 0 1.1735321603367765e-09
, O 0 5.4311978525678484e-11
and O 0 4.112166510084059e-11
indicate O 0 1.5190574353951547e-09
that O 0 1.0157581026293272e-10
the O 0 1.8918970834391757e-09
mouse O 0 4.8770711913448395e-08
is O 0 7.737803453533587e-11
a O 0 5.702604360946495e-11
suitable O 0 9.34750943315521e-10
model O 0 6.584651157659493e-10
system O 0 2.4982083068891825e-10
in O 0 7.579606386975968e-11
which O 0 5.0654275912664914e-11
to O 0 1.4999544939442444e-09
investigate O 0 3.7750949033465986e-09
the O 0 1.3911685137202312e-09
molecular O 0 1.2270535698633012e-09
mechanisms O 0 7.801686763286853e-08
of O 0 3.878967813619738e-09
imprinting O 0 1.3627870387722396e-08
in O 0 5.308535278025772e-10
this O 0 2.0675075540488308e-10
region O 0 1.5036295542003586e-09
of O 0 6.346593250938781e-10
the O 0 3.975901552433214e-10
genome O 0 1.0141280870623604e-10
. O 0 4.859108670984824e-10
. O 0 1.553676298726714e-08

Mutations O 0 1.0077275192088564e-06
of O 0 2.1334024324914935e-07
the O 0 1.0021614826882796e-07
ATM O 0 2.96110738418065e-06
gene O 0 2.0163978931009297e-08
detected O 0 6.6764695993981604e-09
in O 0 6.995505508200495e-09
Japanese O 1 0.9999842643737793
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999954700469971
: O 0 7.690221376366324e-11
possible O 0 8.175275040267493e-11
preponderance O 0 1.2437366692097385e-08
of O 0 1.3060720283064597e-09
the O 0 2.7592015339195086e-09
two O 0 8.804853512955901e-10
founder O 0 8.842256704610918e-08
mutations O 0 4.02580990765955e-09
4612del165 O 0 1.6299298977173748e-07
and O 0 4.1475067824592315e-09
7883del5 O 0 1.2950835298397578e-05
. O 0 4.5512138058256824e-07

The O 0 6.267803343007472e-08
ATM O 0 5.571793735725805e-06
( O 0 3.384698032959932e-08
A O 1 1.0
- O 1 1.0
T O 1 1.0
, O 0 5.60988588915734e-09
mutated O 0 8.926535621789355e-10
) O 0 3.7271696146090605e-11
gene O 0 5.047645634803644e-10
on O 0 1.3919787988925236e-08
human O 0 5.461578744814233e-09
chromosome O 0 8.304060372665845e-08
11q22 O 0 9.57366319198627e-06
. O 0 6.343089467009122e-07

3 O 0 7.4823460636253e-06
has O 0 6.7676788617632155e-09
recently O 0 1.8290192693726226e-09
been O 0 1.0862918897736051e-10
identified O 0 2.506030105653423e-10
as O 0 1.0927923149717245e-10
the O 0 7.166037208072851e-11
gene O 0 5.477283904209429e-11
responsible O 0 2.184714770203655e-10
for O 0 9.091347813461326e-11
the O 0 1.5250668505828457e-09
human O 0 2.5468276376727772e-08
recessive B-Disease 1 0.9992175102233887
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.8272978067398071
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.7088560727861477e-08
. O 0 9.996529826139522e-08

In O 0 9.784701049397881e-09
order O 0 1.7276592378934197e-09
to O 0 8.445060761808065e-10
define O 0 7.771772558839984e-09
the O 0 4.6264522768346694e-10
types O 0 1.4586302166108567e-09
of O 0 1.1995344717519174e-09
disease O 0 2.781438013244042e-08
- O 0 4.968237732327907e-08
causing O 0 3.488290323261367e-09
ATM O 0 7.645230937214365e-08
mutations O 0 1.0056681182257776e-10
in O 0 2.8787400241370165e-10
Japanese O 0 2.9738495868514292e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 9.453284377514137e-08
as O 0 5.55058603246561e-11
well O 0 1.66339025886586e-11
as O 0 3.114582550201028e-11
to O 0 1.8040999250068523e-10
look O 0 7.160507187187193e-10
for O 0 2.472024807076423e-10
possible O 0 7.993523176708095e-09
mutational O 0 8.387677894461376e-07
hotspots O 0 4.2601092786753725e-07
, O 0 5.045758810773293e-10
reverse O 0 5.109310752260399e-09
- O 0 3.734139664146596e-09
transcribed O 0 1.062635424098346e-09
RNA O 0 1.304361202381088e-10
derived O 0 1.827843154611486e-10
from O 0 1.5169886180554926e-11
ten O 0 2.368321094792236e-10
patients O 0 5.105214515022105e-11
belonging O 0 2.6066629757459658e-11
to O 0 6.155199266943967e-11
eight O 0 3.45814488156293e-11
unrelated O 0 2.905992391166734e-10
Japanese O 0 3.3843932669697097e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 6.1376086435416255e-09
was O 0 1.672251337403452e-09
analyzed O 0 2.3150845684938304e-09
for O 0 4.6408674125864025e-10
mutations O 0 4.3358830414952365e-10
by O 0 2.6909019457121985e-10
the O 0 8.577369037254812e-09
restriction O 0 5.618273135610252e-08
endonuclease O 0 2.1671942462830884e-08
fingerprinting O 0 1.280420214300193e-08
method O 0 3.1947422485245625e-08
. O 0 7.970628956854853e-08

As O 0 1.2028405649289198e-07
has O 0 4.2407613531914023e-10
been O 0 1.899915814951303e-11
reported O 0 9.898419757459198e-12
by O 0 1.2736850419844958e-12
others O 0 1.3961093392467205e-10
, O 0 5.522159118864778e-11
mutations O 0 1.1586190340473479e-10
that O 0 3.112717722464353e-11
lead O 0 1.6982485417926796e-09
to O 0 8.701116271936371e-09
exon O 0 3.870381704018655e-08
skipping O 0 5.539172320823127e-08
or O 0 7.753767405915823e-09
premature O 0 8.701020703938411e-08
protein O 0 1.6967235394460545e-09
truncation O 0 1.1235710140056199e-08
were O 0 1.079591860353446e-09
also O 0 1.4142592652532926e-10
predominant O 0 6.080660974738805e-10
in O 0 8.134868889619895e-10
our O 0 4.301242739757072e-08
mutants O 0 1.078423892408864e-07
. O 0 1.1453604997768707e-07

Six O 0 1.7830977583344065e-07
different O 0 3.546020144185036e-10
mutations O 0 2.3509980073832537e-10
were O 0 5.82073798882643e-11
identified O 0 9.832416131283495e-11
on O 0 2.597345227783876e-09
12 O 0 2.646357977198477e-08
of O 0 4.553998955714178e-09
the O 0 3.816885474350329e-09
16 O 0 5.449677331625935e-08
alleles O 0 3.816565286030027e-09
examined O 0 3.3593644843676884e-07
. O 0 1.8806568959917058e-06

Four O 0 3.1244172760125366e-07
were O 0 1.6124216628554677e-08
deletions O 0 1.3562575951198141e-08
involving O 0 9.287795532664234e-10
a O 0 5.587557083686079e-09
loss O 0 1.9089998914978423e-08
of O 0 3.044620555670008e-08
a O 0 1.1836644553397946e-08
single O 0 8.623990410683291e-09
exon O 0 5.7340578507592e-08
exon O 0 1.6700120397672436e-07
7 O 0 2.1194189230300253e-06
, O 0 1.1000144795048072e-08
exon O 0 9.120574162579942e-08
16 O 0 6.900003199916682e-07
, O 0 1.0164064256912297e-08
exon O 0 4.451329971288942e-07
33 O 0 1.5808446960363653e-06
or O 0 3.482402277654728e-08
exon O 0 1.4265654044720577e-06
35 O 0 6.479471721831942e-06
. O 0 9.271782346331747e-07

The O 0 1.6729835294881923e-07
others O 0 1.2246972325158367e-08
were O 0 4.58843807393805e-09
minute O 0 3.4734863874064104e-08
deletions O 0 8.502700765689042e-09
, O 0 2.81543510727289e-10
4649delA O 0 1.820427186771667e-08
in O 0 6.566390764461971e-10
exon O 0 2.181077896068473e-08
33 O 0 8.869553624890614e-08
and O 0 8.294776532302706e-10
7883del5 O 0 3.1305913239521033e-07
in O 0 1.047327291558986e-08
exon O 0 5.570097414420161e-07
55 O 0 1.3802399507767404e-06
. O 0 5.46346143437404e-07

The O 0 2.154169123969041e-06
mutations O 0 1.2864033749337977e-07
4612del165 O 0 8.042891863624391e-07
and O 0 1.4074894583160358e-09
7883del5 O 0 1.2639378610401764e-07
were O 0 1.0078615719777417e-09
found O 0 1.8438522930708245e-10
in O 0 3.706836573802441e-11
more O 0 5.579060650962031e-12
than O 0 2.60448498705379e-12
two O 0 1.658343059228462e-12
unrelated O 0 8.736674578235792e-12
families O 0 5.715317542148712e-13
; O 0 1.3789376541659126e-12
44 O 0 1.5274968789835697e-10
% O 0 1.155839573357964e-11
( O 0 1.972842679151543e-12
7 O 0 1.671001448322329e-09
of O 0 9.221953201077326e-10
16 O 0 6.455560530582716e-09
) O 0 4.5418607763636487e-10
of O 0 2.194187054271879e-09
the O 0 8.54069870381835e-10
mutant O 0 3.0067903722397205e-09
alleles O 0 3.567688644512401e-10
had O 0 1.3883455496355168e-09
one O 0 1.6284980308700625e-10
of O 0 3.4502603551977984e-10
the O 0 1.3050934777325551e-09
two O 0 1.586272335707406e-09
mutations O 0 1.9410455465163068e-08
. O 0 1.6989888251828233e-07

The O 0 2.4402473286500026e-07
4612del165 O 0 7.035798716970021e-07
mutations O 0 1.4611976073553024e-09
in O 0 2.0760983210355022e-10
three O 0 8.379300725502858e-12
different O 0 7.828663390295476e-13
families O 0 1.8939160136011157e-12
were O 0 1.521802128756633e-11
all O 0 1.1260623510034318e-11
ascribed O 0 1.8534934698166694e-09
to O 0 2.927121878215644e-09
the O 0 1.714234088012745e-09
same O 0 2.260481135607506e-09
T O 0 1.3545022881089608e-08
- O 0 6.106326555510577e-09
- O 0 1.6159376059476926e-08
> O 0 9.361898634097088e-08
A O 0 2.7976643224292275e-09
substitution O 0 3.08862713183089e-09
at O 0 2.2167003788098327e-09
the O 0 2.1554311113725078e-10
splice O 0 1.971859786564778e-09
donor O 0 8.801932516178113e-10
site O 0 9.447171045451341e-09
in O 0 3.879300880527126e-09
intron O 0 4.676121079683071e-06
33 O 0 7.055889000184834e-06
. O 0 1.0432858061903971e-06

Microsatellite O 0 1.3544705325330142e-05
genotyping O 0 2.1185621790209552e-06
around O 0 1.9698836339898662e-08
the O 0 2.6580739387327412e-08
ATM O 0 3.4839019917853875e-06
locus O 0 1.8975470084114932e-07
also O 0 6.108167305285406e-09
indicated O 0 2.4712762947132205e-09
that O 0 1.537624715053365e-11
a O 0 1.1111070397085143e-10
common O 0 2.656717901228234e-10
haplotype O 0 8.576272136906482e-09
was O 0 3.212730304014144e-09
shared O 0 2.397207432558446e-10
by O 0 1.0310687199865942e-11
the O 0 2.1789882398426386e-10
mutant O 0 8.659192252125081e-10
alleles O 0 9.520638444282525e-11
in O 0 4.989047508452416e-10
both O 0 2.5402575598576504e-09
mutations O 0 1.3568993928458895e-08
. O 0 2.697609033930348e-07

This O 0 4.275942444564862e-08
suggests O 0 2.0130240585558568e-08
that O 0 1.9763685479845527e-11
these O 0 5.859323443102582e-11
two O 0 3.238704304742157e-10
founder O 0 3.184995378546773e-08
mutations O 0 4.915748363920613e-10
may O 0 8.810851492846439e-10
be O 0 9.9552310839357e-10
predominant O 0 1.2091553536208721e-08
among O 0 2.8339039448432857e-10
Japanese O 0 7.598478646286821e-08
ATM O 0 1.5728176094853552e-06
mutant O 0 1.4746719045888312e-07
alleles O 0 2.3001122784194195e-08
. O 0 2.611041622913035e-07

W474C O 0 1.0152853974432219e-05
amino O 0 1.0400319894188215e-07
acid O 0 6.720701772877646e-09
substitution O 0 2.6944624309521714e-09
affects O 0 1.4069706510966284e-10
early O 0 6.967896815091024e-10
processing O 0 2.2477848471424977e-09
of O 0 9.468199557716162e-10
the O 0 3.080629917828759e-10
alpha O 0 5.511197609386898e-10
- O 0 1.017817705117885e-10
subunit O 0 6.535553209729983e-10
of O 0 2.3209549560032627e-10
beta O 0 1.0618842694043451e-08
- O 0 2.2795502374606258e-08
hexosaminidase O 0 2.637773945934896e-07
A O 0 1.0392126270630797e-08
and O 0 7.153487524558244e-11
is O 0 4.060552675350104e-12
associated O 0 2.2608938332613349e-10
with O 0 4.429298941510673e-11
subacute O 0 1.1177856322319712e-05
G B-Disease 0 9.964822311303578e-06
( I-Disease 0 1.6578838302194754e-09
M2 I-Disease 0 1.9598473954829387e-06
) I-Disease 0 1.362329626886094e-08
gangliosidosis I-Disease 0 1.5729625374660827e-05
. O 0 4.0441599935547856e-07

Mutations O 0 6.676242492176243e-08
in O 0 8.241069160419556e-09
the O 0 7.079383301800135e-09
HEXA O 0 9.447459206057829e-07
gene O 0 1.0070430045416856e-09
, O 0 4.912746598417783e-11
encoding O 0 3.3090261086776707e-10
the O 0 7.012614933188388e-10
alpha O 0 6.089737603076628e-10
- O 0 6.578446815064254e-11
subunit O 0 2.8604538182541717e-10
of O 0 3.3884797745464823e-10
beta O 0 1.0898833835426558e-08
- O 0 2.3737142029744973e-08
hexosaminidase O 0 3.438446185555222e-07
A O 0 2.2865089377432923e-08
( O 0 6.239334743307623e-11
Hex O 0 2.3454600039940487e-08
A O 0 1.0813276496435265e-08
) O 0 1.0694362756469289e-10
, O 0 3.7737448582708666e-11
that O 0 2.3371502649860432e-11
abolish O 0 4.4490934669738635e-07
Hex O 0 4.2398519894959463e-07
A O 0 2.1582017950549925e-08
enzyme O 0 2.310364788371544e-09
activity O 0 1.984160036272442e-08
cause O 0 1.479830370954005e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 7.398608392605865e-10
TSD B-Disease 0 7.844697393011302e-06
) O 0 1.5523063390254777e-10
, O 0 6.68158375849437e-11
the O 0 9.223571351135718e-10
fatal O 0 8.395635120450606e-08
infantile B-Disease 0 1.1354889011272462e-06
form I-Disease 0 1.4449953456008302e-09
of I-Disease 0 4.175273460305107e-08
G I-Disease 0 5.770868369836535e-07
( I-Disease 0 4.0546285773324087e-10
M2 I-Disease 0 1.981014321472685e-07
) I-Disease 0 1.2163509088836122e-09
gangliosidosis I-Disease 0 4.4324073655843677e-07
, I-Disease 0 3.170215756576056e-10
Type I-Disease 0 1.553039474799789e-08
1 I-Disease 0 8.080517659436737e-07
. O 0 4.4011784439135226e-07

Less O 0 9.920910315486253e-07
severe O 0 2.1869279862585245e-06
, O 0 2.3006727634111712e-09
subacute O 0 4.188772436464205e-06
( O 0 2.1684821993606107e-10
juvenile O 0 1.5209099046842312e-06
- O 0 7.407619705190882e-06
onset O 1 1.0
) O 0 3.70837516250333e-09
and O 0 5.373090861127139e-09
chronic O 1 1.0
( O 0 2.592364933828861e-10
adult O 0 1.1389713563403348e-06
- O 0 1.0696310255298158e-06
onset O 1 0.996423065662384
) O 0 7.612208641205598e-10
variants O 0 1.0073200940041716e-08
are O 0 8.805251666688108e-11
characterized O 0 1.3747715466028154e-10
by O 0 1.4131476371026519e-11
a O 0 9.755718455295437e-10
broad O 0 2.604488846813524e-09
spectrum O 0 1.252650072558481e-08
of O 0 5.634117061781296e-10
clinical O 0 5.820410375889651e-09
manifestations O 0 4.655835716960155e-09
and O 0 9.153359320501764e-11
are O 0 8.661925343655952e-12
associated O 0 5.298591565505717e-10
with O 0 1.684863880357934e-11
residual O 0 2.9484885999409016e-06
levels O 0 6.294811100815423e-06
of O 0 2.5762204813872813e-07
Hex O 0 1.4309773632703582e-06
A O 0 2.4382862306993047e-07
enzyme O 0 1.2437745944282597e-08
activity O 0 9.046991067407362e-08
. O 0 6.999832180554222e-08

We O 0 2.8579915323234673e-08
identified O 0 6.582872025262532e-09
a O 0 1.6064164443108098e-09
1422 O 0 1.7223831036972115e-06
G O 0 5.009343908568553e-07
- O 0 1.6231075505857007e-06
- O 0 1.5036812328617088e-06
> O 0 2.127480911440216e-06
C O 0 7.783916089465492e-07
( O 0 7.863101662841654e-12
amino O 0 8.210138124908894e-11
acid O 0 1.6053743057131697e-10
W474C O 0 4.484240201385603e-10
) O 0 4.6826210714934896e-14
substitution O 0 1.9950253254963357e-11
in O 0 1.8710455060300113e-11
the O 0 1.0292969254699358e-10
first O 0 3.6258765434560303e-10
position O 0 7.692253056745813e-09
of O 0 1.4081042998270732e-09
exon O 0 4.226779282134885e-08
13 O 0 2.7314024464430986e-07
of O 0 1.2946988192652498e-07
HEXA O 0 0.38088086247444153
of O 0 1.1150610816912376e-06
a O 0 1.776091949068359e-07
non O 0 2.0322057025623508e-05
- O 0 9.084398584491282e-07
Jewish O 0 5.931362920819083e-07
proband O 0 3.2226678740698844e-05
who O 0 5.154051407885163e-09
manifested O 0 1.0586546750346315e-08
a O 0 5.1862478755992925e-09
subacute O 0 5.381061782827601e-07
variant O 0 5.752470997322234e-07
of O 0 1.8641450196810183e-06
G B-Disease 0 1.765932211128529e-05
( I-Disease 0 5.722735618718389e-09
M2 I-Disease 0 2.8265867513255216e-06
) I-Disease 0 1.5874354275524638e-08
gangliosidosis I-Disease 0 1.8324953998671845e-05
. O 0 3.799281671490462e-07

On O 0 2.3013556074147345e-06
the O 0 1.266777331920821e-07
second O 0 6.998203048169671e-07
maternally O 0 1.9148299543303438e-05
inherited O 0 2.2542801161762327e-05
allele O 0 6.900845619384199e-07
, O 0 6.473150904184877e-10
we O 0 6.76713352021352e-10
identified O 0 1.3341787674647776e-09
the O 0 8.179802946095549e-10
common O 0 6.276751918221635e-08
infantile O 1 0.9998340606689453
disease O 0 1.2278696885914542e-05
- O 0 6.609445790672908e-07
causing O 0 2.589600853752927e-07
4 O 0 4.174794958089478e-05
- O 0 0.00010090770228998736
bp O 0 2.3232751118484885e-06
insertion O 0 4.3010540906607275e-08
, O 0 1.5430556832285447e-09
+ O 0 1.1853819614771055e-07
TATC O 0 1.6162940710273688e-06
1278 O 0 2.695790271900478e-06
, O 0 9.41021038869394e-10
in O 0 1.4738381626244745e-09
exon O 0 2.7775209332503437e-07
11 O 0 7.630093818988826e-07
. O 0 5.089365231469856e-07

Pulse O 0 1.3577257050201297e-05
- O 0 1.5667753814341268e-06
chase O 0 1.0611902467871914e-07
analysis O 0 7.832547055386385e-09
using O 0 1.96788203510323e-08
proband O 0 4.504742719291244e-06
fibroblasts O 0 1.781697937985882e-05
revealed O 0 1.456862719351193e-08
that O 0 5.811065170724383e-11
the O 0 1.8177398475316409e-10
W474C O 0 1.6811362968383037e-08
- O 0 1.5061497604662577e-09
containing O 0 5.240757827706943e-10
alpha O 0 8.31032742620863e-10
- O 0 2.4611429561005593e-10
subunit O 0 2.0886026241839772e-09
precursor O 0 3.9765660631019273e-07
was O 0 5.988427886904901e-08
normally O 0 2.2800403787215373e-09
synthesized O 0 2.308110680360187e-08
, O 0 2.201106241717099e-10
but O 0 5.394073729347859e-11
not O 0 1.8600301854299062e-10
phosphorylated O 0 2.71420774744513e-09
or O 0 5.192758445460299e-10
secreted O 0 4.42827885471786e-10
, O 0 7.463860779433062e-11
and O 0 1.2127711335185865e-10
the O 0 1.5288996735307592e-09
mature O 0 3.140788251698723e-08
lysosomal O 0 9.084233738576586e-07
alpha O 0 4.5597548847808866e-08
- O 0 7.306949711960442e-09
subunit O 0 9.96629356819767e-09
was O 0 9.096044095713296e-08
not O 0 1.353719802921205e-08
detected O 0 5.687557802502852e-08
. O 0 7.155176007245245e-08

When O 0 3.341961729574905e-08
the O 0 5.581889617189972e-09
W474C O 0 4.074883364069137e-08
- O 0 2.4898085815294735e-09
containing O 0 1.421127521217258e-10
alpha O 0 1.3514274421755346e-10
- O 0 3.425773206777727e-11
subunit O 0 3.4869845899621055e-10
was O 0 5.5278976951456116e-09
transiently O 0 5.838871430796644e-08
co O 0 6.757553627778634e-09
- O 0 8.513220706163338e-08
expressed O 0 2.507829277575979e-09
with O 0 9.007131845928384e-12
the O 0 5.357857560395196e-11
beta O 0 5.3305800745695464e-11
- O 0 1.5611359427403215e-11
subunit O 0 5.072640224534908e-11
to O 0 1.626865031578717e-10
produce O 0 5.473693720503547e-10
Hex O 0 7.510683985856303e-08
A O 0 1.607144355375567e-07
( O 0 2.9776195398234506e-10
alphabeta O 0 9.19514135944155e-08
) O 0 4.2224539836821506e-11
in O 0 1.9846727039585232e-10
COS O 0 6.774836691647579e-08
- O 0 2.1924018156482816e-08
7 O 0 1.173035979462611e-08
cells O 0 4.3408996397431565e-09
, O 0 1.540484684259269e-10
the O 0 2.8045762934247875e-10
mature O 0 8.070362156331612e-10
alpha O 0 8.101825321737977e-10
- O 0 1.980717118099662e-10
subunit O 0 7.5773265439949e-10
was O 0 2.032390256090366e-09
present O 0 3.5593761271712765e-10
, O 0 2.7066569471823065e-11
but O 0 1.3809334752090674e-11
its O 0 2.226673186112027e-11
level O 0 2.236796581289724e-10
was O 0 1.0174585479694187e-10
much O 0 6.15041073626088e-11
lower O 0 1.6281626047387476e-10
than O 0 1.1720501305600983e-11
that O 0 2.5339530820844836e-12
from O 0 1.3225656680937448e-11
normal O 0 1.691750295407246e-09
alpha O 0 1.878363464768995e-09
- O 0 1.2215471967280678e-09
subunit O 0 2.462952064519186e-09
transfections O 0 7.760265674505717e-08
, O 0 6.714698241871986e-11
although O 0 5.818695525405815e-11
higher O 0 1.085919576482297e-09
than O 0 1.595857473946083e-11
in O 0 3.5759506467059055e-11
those O 0 6.376243977257445e-11
cells O 0 4.844228906897285e-10
transfected O 0 1.5430034139285453e-08
with O 0 5.384554954690479e-11
an O 0 1.7012821706963166e-10
alpha O 0 3.2245850434264867e-09
- O 0 2.9115196920059816e-09
subunit O 0 6.070663527424358e-09
associated O 0 1.5926069352190098e-07
with O 0 1.3421887601339222e-08
infantile O 1 0.9946038126945496
TSD B-Disease 0 0.003353531239554286
. O 0 7.937621262499306e-07

Furthermore O 0 1.355303993477719e-07
, O 0 6.087182979896966e-10
the O 0 2.4382573737824487e-10
precursor O 0 9.501600395367404e-09
level O 0 9.570976544637233e-08
of O 0 2.9431945769431422e-09
the O 0 2.785832675655797e-09
W474C O 0 2.201511684063462e-08
alpha O 0 3.0850946242111377e-09
- O 0 5.495064958616069e-10
subunit O 0 6.058525903185341e-10
was O 0 3.856636787702428e-09
found O 0 1.2687642603204097e-10
to O 0 8.277450946891918e-11
accumulate O 0 6.946793834616827e-11
in O 0 2.578713284573375e-11
comparison O 0 2.908304708171272e-10
to O 0 9.662939337573562e-10
the O 0 1.474057431671838e-09
normal O 0 1.2186504250166763e-08
alpha O 0 1.3313603552944642e-08
- O 0 5.675937497784389e-09
subunit O 0 9.639620657253545e-09
precursor O 0 3.394354450847459e-07
levels O 0 3.433353867876576e-07
. O 0 9.09328505827034e-08

We O 0 1.175248609541768e-08
conclude O 0 1.560917972653897e-08
that O 0 1.119870654542332e-10
the O 0 5.049937690237982e-10
1422 O 0 9.648187187849544e-06
G O 0 2.6155923933401937e-06
- O 0 5.736245839216281e-06
- O 0 2.79109985967807e-06
> O 0 7.567333796032472e-06
C O 0 1.9268020423623966e-06
mutation O 0 2.3557336636947923e-10
is O 0 2.998407078180776e-12
the O 0 3.996061814781626e-11
cause O 0 2.479226823837166e-09
of O 0 5.062148478174322e-09
Hex B-Disease 0 1.975728764591622e-06
A I-Disease 0 1.7591381720194477e-06
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.3167714030259958e-07
the O 0 1.728753460383814e-07
proband O 0 1.4941103472665418e-05
. O 0 1.0434077069021441e-07

The O 0 1.8128430667729845e-07
resulting O 0 1.2726264486673244e-08
W474C O 0 2.0365010300338326e-07
substitution O 0 7.717842720467161e-08
clearly O 0 1.4298838557635918e-08
interferes O 0 4.345406257044715e-09
with O 0 5.883175890897263e-11
alpha O 0 5.814307701967891e-09
- O 0 9.389126143233284e-10
subunit O 0 1.3208023563748839e-09
processing O 0 1.8952894365042994e-08
, O 0 1.2531482795896665e-10
but O 0 1.9041022231158777e-11
because O 0 4.938118924185941e-12
the O 0 5.9776207421424754e-12
base O 0 1.2343533140057872e-10
substitution O 0 2.636847684645005e-10
falls O 0 2.4768437301148083e-10
at O 0 1.0672070865913597e-10
the O 0 1.6605793129453872e-10
first O 0 2.377646080020668e-09
position O 0 3.932044023713388e-08
of O 0 7.645184041393804e-09
exon O 0 6.01275971234827e-08
13 O 0 2.2633042817687965e-07
, O 0 3.741989829109116e-09
aberrant O 0 1.4107905066396143e-08
splicing O 0 2.1444803266490453e-08
may O 0 1.540362681851093e-08
also O 0 5.056008944848145e-10
contribute O 0 2.2815238587270414e-09
to O 0 1.082297451659997e-08
Hex B-Disease 0 1.8279237110618851e-06
A I-Disease 0 1.4950232980481815e-06
deficiency I-Disease 0 1.0302053397026611e-06
in O 0 1.0627656976680555e-08
this O 0 2.506872931462567e-09
proband O 0 1.5491673366341274e-07
. O 0 1.695212858976447e-09
. O 0 1.0118221815957895e-08

Two O 0 4.296995115282698e-08
frequent O 0 1.2066165844260013e-08
missense O 0 1.0373114491812885e-06
mutations O 0 1.0855850973712222e-07
in O 0 1.5319164958782494e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.5395882655866444e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.3247212216072057e-08
an O 0 9.35183308570231e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 4.58681415693718e-06
by O 0 1.972008320527685e-11
early O 0 9.100937603534476e-08
childhood O 1 0.9999185800552368
deafness B-Disease 1 1.0
and O 0 0.0008561143185943365
goiter B-Disease 1 1.0
. O 0 0.13415701687335968

A O 0 1.5929532537484192e-07
century O 0 1.3913471264004329e-08
after O 0 4.669947761826165e-10
its O 0 7.333187876379377e-12
recognition O 0 8.118062472250998e-11
as O 0 8.290249042808284e-11
a O 0 1.995160481271796e-09
syndrome O 0 1.0079277501517936e-07
by O 0 1.0225441327005313e-10
Vaughan O 0 1.1014235212769563e-07
Pendred O 0 2.687192193207011e-07
, O 0 2.3219290379294932e-10
the O 0 9.339204964931014e-10
disease O 0 4.196540892564826e-09
gene O 0 6.453697576347395e-10
( O 0 1.4708726459033983e-09
PDS O 0 1.4195045878295787e-05
) O 0 2.7352970999316994e-09
was O 0 8.157017106213971e-08
mapped O 0 3.043157548177078e-08
to O 0 2.830622314320408e-08
chromosome O 0 6.524486906300808e-08
7q22 O 0 1.1147846635140013e-05
- O 0 3.517808863762184e-06
q31 O 0 2.0910325474687852e-05
. O 0 3.132884955903137e-07

1 O 0 9.834180900725187e-07
and O 0 5.625690580046694e-09
, O 0 8.421383590473397e-10
recently O 0 2.717885694281108e-09
, O 0 2.6202628955473983e-10
found O 0 2.296843965021722e-10
to O 0 9.544934842509178e-10
encode O 0 6.728474222228442e-09
a O 0 2.6803780528439347e-08
putative O 0 3.1373449473903747e-06
sulfate O 0 3.2093626032292377e-06
transporter O 0 1.3542293118007365e-06
. O 0 7.70723545429064e-07

We O 0 1.6068224795162678e-07
performed O 0 2.2989981474097476e-08
mutation O 0 9.97629201471284e-10
analysis O 0 8.972556031494605e-10
of O 0 1.924088666171997e-09
the O 0 7.79106645865113e-09
PDS B-Disease 0 1.5021561239336734e-07
gene O 0 5.006320358269534e-10
in O 0 1.8837657822512455e-10
patients O 0 4.3257888937553446e-10
from O 0 5.353730306301152e-11
14 O 0 4.8613912895234535e-09
Pendred B-Disease 0 5.4662297799268345e-08
families O 0 2.7650676887036596e-11
originating O 0 1.3247729302445777e-10
from O 0 6.112519518319814e-11
seven O 0 3.123680480943136e-10
countries O 0 9.283752239186427e-11
and O 0 3.213604937712944e-10
identified O 0 7.906124643852763e-09
all O 0 6.621430514996973e-09
mutations O 0 1.6837516270129527e-08
. O 0 2.3268687243671593e-07

The O 0 1.317227656727482e-06
mutations O 0 1.188698384169129e-08
include O 0 3.131896963992631e-09
three O 0 4.176703150005068e-10
single O 0 2.0173818171542734e-09
base O 0 8.999541734056038e-08
deletions O 0 1.259339228454337e-07
, O 0 5.038298667159324e-09
one O 0 3.329388098549657e-09
splice O 0 3.7447907175192086e-07
site O 0 1.3765051676273288e-07
mutation O 0 2.111465668974688e-09
and O 0 1.0762366553507263e-09
10 O 0 5.022106392971182e-07
missense O 0 4.751144842884969e-06
mutations O 0 6.799639891141851e-07
. O 0 5.539110588870244e-06

One O 0 8.83710413290828e-07
missense O 0 4.116208856430603e-06
mutation O 0 1.9212402335710976e-08
( O 0 1.9115958815874023e-10
L236P O 0 6.377785410904835e-08
) O 0 5.1651665583518636e-11
was O 0 4.5338371945646827e-10
found O 0 4.5771227086266464e-11
in O 0 4.9350988573504395e-11
a O 0 1.7586915257439273e-10
homozygous O 0 1.7956924835971222e-10
state O 0 2.334388238267593e-11
in O 0 5.028868432788158e-10
two O 0 9.373141846014121e-11
consanguineous O 0 1.2843140773100004e-08
families O 0 2.3954418310045966e-11
and O 0 7.294573799165871e-12
in O 0 5.7360723809685155e-11
a O 0 4.963535138458042e-10
heterozygous O 0 6.903377175460079e-11
state O 0 3.4177650293232276e-11
in O 0 8.337603940589133e-10
five O 0 6.147294340230758e-10
additional O 0 2.2906194718785855e-09
non O 0 2.429479764032294e-07
- O 0 5.214440648160235e-07
consanguineous O 0 3.364729991517379e-06
families O 0 1.9595780997860857e-08
. O 0 8.176377974677962e-08

Another O 0 7.585408638988156e-07
missense O 0 7.280934369191527e-06
mutation O 0 1.678412964167819e-08
( O 0 1.421631701248316e-10
T416P O 0 5.846393591468768e-08
) O 0 6.538342783857232e-11
was O 0 6.914687711301326e-10
found O 0 4.75223402296443e-11
in O 0 2.949536448415557e-11
a O 0 8.021189268347939e-11
homozygous O 0 2.977356902689188e-11
state O 0 7.499847964886897e-12
in O 0 2.0109995613193377e-10
one O 0 2.0192132688112707e-10
family O 0 4.1476929529826734e-11
and O 0 1.4726171670975674e-11
in O 0 9.151910479454628e-11
a O 0 1.7045562183959362e-10
heterozygous O 0 3.3451068304213294e-11
state O 0 7.868472366723278e-12
in O 0 4.939066378106816e-10
four O 0 1.8305096327608794e-09
families O 0 5.515172762926568e-10
. O 0 2.4465707681997628e-08

Pendred B-Disease 0 2.5896853912854567e-05
patients O 0 3.6338082054498955e-07
in O 0 1.4432104400441403e-09
three O 0 2.3739835097735806e-10
non O 0 6.122959916865511e-08
- O 0 1.1690137569075887e-07
consanguineous O 0 4.176237382580439e-07
families O 0 2.6737681513289147e-10
were O 0 1.65202435065126e-10
shown O 0 1.216185624430821e-10
to O 0 4.721490975967413e-10
be O 0 6.155307930022502e-10
compound O 0 1.2714715502681884e-08
heterozygotes O 0 2.617168703977768e-08
for O 0 1.887888734231069e-09
L236P O 0 2.546920541135478e-07
and O 0 3.1305771308609565e-09
T416P O 0 5.731526925956132e-06
. O 0 1.7057654133623146e-07

In O 0 2.217673866766745e-08
total O 0 6.597276502873228e-09
, O 0 9.258677852175268e-11
one O 0 1.0271122147242906e-10
or O 0 2.9494817699315945e-10
both O 0 4.6344011961352294e-10
of O 0 5.188283691559548e-10
these O 0 4.0763385722453194e-11
mutations O 0 1.838162955181133e-11
were O 0 6.137215735613211e-11
found O 0 4.62854199412277e-11
in O 0 1.5597438618453197e-10
nine O 0 3.159183359358053e-09
of O 0 5.670989788875147e-10
the O 0 1.0947412976136661e-09
14 O 0 1.829212159520921e-08
families O 0 5.755209642188674e-10
analyzed O 0 2.4392180719701173e-08
. O 0 1.577542008135424e-07

The O 0 3.560174022254614e-08
identification O 0 8.841077203669556e-08
of O 0 2.6825464516377906e-08
two O 0 2.231232754112966e-09
frequent O 0 2.6042752399035862e-09
PDS B-Disease 0 1.6040925743254775e-07
mutations O 0 7.073063801321666e-10
will O 0 5.669226754712042e-10
facilitate O 0 8.321580224901481e-08
the O 0 2.809312071860859e-08
molecular O 0 1.8827803671683796e-07
diagnosis O 0 0.3861798644065857
of O 0 4.5629926717083436e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.262116706537199e-06

Insertional O 0 5.609448635368608e-05
mutation O 0 2.3721934638842868e-08
by O 0 1.9921440885806163e-10
transposable O 0 7.351336961392008e-08
element O 0 6.8489427462736785e-09
, O 0 1.10242304174335e-09
L1 O 0 2.1310376041583368e-07
, O 0 3.144549065581259e-10
in O 0 1.3811087828941027e-09
the O 0 8.554891195444725e-08
DMD B-Disease 1 1.0
gene O 0 1.0967717400944821e-07
results O 0 2.6206302905507073e-08
in O 0 3.0589632160626934e-08
X B-Disease 1 1.0
- I-Disease 1 0.99997878074646
linked I-Disease 0 0.00035620862036012113
dilated I-Disease 0 0.005312195047736168
cardiomyopathy I-Disease 1 1.0
. O 0 2.142593621101696e-05

X B-Disease 1 1.0
- I-Disease 1 1.0
linked I-Disease 1 0.9999885559082031
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 4.6345739690423216e-08
XLDCM B-Disease 0 3.6845427530352026e-05
) O 0 1.5039988698895002e-10
is O 0 2.365584117480779e-11
a O 0 1.531140075838877e-10
clinical O 0 6.644810923717159e-09
phenotype O 0 6.41932871303652e-08
of O 0 1.1427877666392305e-07
dystrophinopathy B-Disease 0 5.517257704923395e-06
which O 0 4.16680440151751e-10
is O 0 1.3094206274821829e-11
characterized O 0 2.4152796082588246e-11
by O 0 9.887796310892316e-12
preferential O 0 5.531032343242259e-07
myocardial B-Disease 0 0.0003094279672950506
involvement I-Disease 0 3.591095421029422e-08
without O 0 9.950865687002874e-10
any O 0 3.114405955351174e-10
overt O 0 2.598256942931698e-09
clinical O 0 7.379926358908051e-08
signs O 0 4.1732036493158375e-07
of O 0 8.133609298965894e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0030068608466535807

To O 0 5.5233897455764236e-08
date O 0 2.1534324901040236e-07
, O 0 1.2363848833629731e-09
several O 0 3.9321133155079124e-11
mutations O 0 1.415808442706279e-10
in O 0 1.2859852072111266e-09
the O 0 1.3863832748484128e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 0.9999326467514038
dystrophy I-Disease 1 0.9999998807907104
gene O 0 1.0045448107121047e-05
, O 0 1.0155807785849902e-06
DMD O 1 1.0
, O 0 1.272002858598853e-08
have O 0 3.430463135778439e-10
been O 0 6.038196331825674e-11
identified O 0 7.304824800602461e-11
in O 0 3.329041556310308e-11
patients O 0 9.819747098793741e-11
with O 0 5.2601807458418914e-12
XLDCM B-Disease 0 2.0903685253870208e-06
, O 0 8.834696862969338e-10
but O 0 3.05491354435361e-10
a O 0 5.955185788941719e-10
pathogenic O 0 2.3761046463732782e-09
correlation O 0 2.4190440761628906e-09
of O 0 3.4165887896620006e-09
these O 0 4.669698516757137e-10
cardiospecific O 0 2.0135372835738963e-07
mutations O 0 1.164826235466876e-09
in O 0 3.6662828328815067e-09
DMD O 1 1.0
with O 0 3.7162699584314396e-09
the O 0 8.619784352958959e-08
XLDCM B-Disease 0 0.0002235126739833504
phenotype O 0 1.6257693857824052e-07
has O 0 5.096285615735496e-10
remained O 0 8.236480830703385e-09
to O 0 1.070561306271145e-09
be O 0 2.9935887102539027e-09
elucidated O 0 3.870308773912257e-06
. O 0 8.211807198676979e-07

We O 0 1.7248521544388495e-07
report O 0 4.818778265303081e-09
here O 0 3.364330203314836e-10
the O 0 2.1009954886963556e-10
identification O 0 5.4238844526821595e-09
of O 0 2.3211064181793972e-09
a O 0 1.8199680651420636e-09
unique O 0 2.3196635723365944e-09
de O 0 4.5865681386203505e-07
novo O 0 1.6960100879259699e-07
L1 O 0 2.384846879976976e-07
insertion O 0 5.124663360334125e-09
in O 0 3.2778957326229374e-09
the O 0 5.099935140862044e-09
muscle O 0 2.540024857111689e-09
exon O 0 1.2100735524711581e-08
1 O 0 6.663139373586091e-08
in O 0 1.9647503179953674e-08
DMD O 1 1.0
in O 0 6.279039155288046e-08
three O 0 1.4299923467575582e-09
XLDCM B-Disease 0 8.713432748663763e-07
patients O 0 1.6786171341820477e-09
from O 0 4.375525289312954e-11
two O 0 5.791656390585764e-11
unrelated O 0 1.1042412539907787e-09
Japanese O 0 1.2206736244024796e-07
families O 0 9.247281829161125e-10
. O 0 6.80981360190458e-09

The O 0 6.128732366050826e-08
insertion O 0 1.781686087554135e-08
was O 0 8.3148661289556e-09
a O 0 5.906813371758801e-10
5 O 0 1.6158751003914062e-09
- O 0 1.6410021119739326e-09
truncated O 0 2.726525449858741e-09
form O 0 1.8240052523932349e-10
of O 0 2.2876099625701585e-10
human O 0 9.593150579467746e-11
L1 O 0 1.1105275810052717e-08
inversely O 0 2.23080731664993e-09
integrated O 0 8.185113031800029e-09
in O 0 1.8381367539177518e-09
the O 0 2.7428410653840274e-09
5 O 0 1.3188496517102521e-08
- O 0 3.5443331825035784e-08
untranslated O 0 1.6017353345887386e-06
region O 0 9.280575419268189e-09
in O 0 1.7034846866437192e-09
the O 0 2.30867303052662e-09
muscle O 0 1.0312271037093979e-09
exon O 0 3.330086872921356e-09
1 O 0 5.074929365633807e-09
, O 0 4.673402637100921e-11
which O 0 8.063090993493116e-12
affected O 0 5.0633993525783794e-11
the O 0 2.770949268648959e-11
transcription O 0 4.0792652589161094e-10
or O 0 4.844543100013254e-10
the O 0 1.4575122220250591e-09
stability O 0 7.386787729046773e-06
of O 0 3.09739389692254e-09
the O 0 7.132781587593229e-10
muscle O 0 3.7078584647076696e-09
form O 0 7.184311479058181e-10
of O 0 1.3821996880380993e-09
dystrophin O 0 3.019026095785193e-08
transcripts O 0 6.033850308284627e-09
but O 0 5.501029146093295e-11
not O 0 1.2210712996285622e-10
that O 0 2.8480997074642467e-11
of O 0 1.1699429203204659e-09
the O 0 2.535543863757539e-08
brain O 0 3.183743046974996e-06
or O 0 4.743909443050143e-08
Purkinje O 0 7.5717439358413685e-06
cell O 0 9.248718413346069e-08
form O 0 4.800282393802036e-10
, O 0 1.1843338809658377e-10
probably O 0 4.284717025626605e-09
due O 0 1.2401431881414737e-08
to O 0 6.947516340005677e-09
its O 0 1.3987594416065008e-09
unique O 0 2.1907411440480473e-09
site O 0 5.658534529828785e-09
of O 0 3.23783971856173e-10
integration O 0 9.709907544674934e-09
. O 0 7.85911353773372e-08

We O 0 1.8937416257358564e-07
speculate O 0 3.1836467684343006e-08
that O 0 7.054144074425395e-11
this O 0 2.3669021603778262e-11
insertion O 0 3.955179295189737e-09
of O 0 3.1007156842122185e-09
an O 0 2.2416443701267497e-10
L1 O 0 6.603850977171533e-08
sequence O 0 2.62995758504303e-09
in O 0 2.2554004885932954e-08
DMD O 1 1.0
is O 0 7.423613945789498e-10
responsible O 0 3.1461092064866136e-10
for O 0 5.07291084139716e-11
some O 0 1.80521431136782e-11
of O 0 4.2182198706219864e-11
the O 0 3.442600371439397e-11
population O 0 6.841800346754634e-13
of O 0 5.587505718523955e-12
Japanese O 0 1.8047031646872824e-09
patients O 0 6.181340855837547e-11
with O 0 3.724353724726681e-12
XLDCM B-Disease 0 5.461794216898852e-07
. O 0 1.706864694028809e-08
. O 0 2.8801824214497174e-07

Severe O 0 9.516702994005755e-05
early O 1 0.9996917247772217
- O 1 0.9999959468841553
onset O 1 0.9999997615814209
obesity B-Disease 1 1.0
, O 0 2.1554733553585947e-09
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 6.038170567990164e-07
red O 1 0.9940109848976135
hair O 1 0.9999990463256836
pigmentation O 1 0.9999997615814209
caused O 0 5.05871867062524e-06
by O 0 6.878661196196845e-09
POMC O 0 2.1823361748829484e-05
mutations O 0 1.0610825107448818e-08
in O 0 7.56987628136585e-09
humans O 0 3.0600020295423747e-08
. O 0 5.35484190322677e-08

Sequential O 0 5.513400651580014e-07
cleavage O 0 1.9193765865566093e-07
of O 0 1.2164483109700086e-07
the O 0 4.1771990311190166e-09
precursor O 0 5.131783886724861e-09
protein O 0 9.082374297086915e-10
pre O 0 2.891218287004449e-07
- O 0 1.342803841453133e-07
pro O 0 1.1975072311543045e-06
- O 0 1.0623642765494878e-06
opiomelanocortin O 0 2.0599029539880576e-06
( O 0 6.535603169766091e-10
POMC O 0 4.85867303723353e-06
) O 0 2.6067339953250723e-10
generates O 0 7.334006180137465e-10
the O 0 2.5118984670058353e-09
melanocortin O 0 4.183343207841972e-06
peptides O 0 6.760998161325915e-08
adrenocorticotrophin O 0 8.928321904022596e-07
( O 0 4.5240586277195405e-10
ACTH O 0 1.7186239347211085e-06
) O 0 6.031408150697359e-10
, O 0 1.4438326090271403e-09
melanocyte O 0 9.497257269686088e-05
- O 0 9.400443559570704e-06
stimulating O 0 9.346505066787358e-06
hormones O 0 5.160948603588622e-06
( O 0 3.2833002983068127e-10
MSH O 0 3.4703591609286377e-06
) O 0 9.772064407664871e-11
alpha O 0 4.3966621454671895e-09
, O 0 3.298476075608292e-11
beta O 0 1.7590480183571344e-09
and O 0 7.940632873459919e-11
gamma O 0 5.746020992347667e-09
as O 0 3.33036431765521e-10
well O 0 1.8157923775685703e-10
as O 0 1.0924421783853333e-10
the O 0 4.047517876415441e-11
opioid O 0 1.6739746255822752e-09
- O 0 5.452478468725985e-10
receptor O 0 5.165445293719984e-10
ligand O 0 1.9178500565431023e-08
beta O 0 2.292418457727763e-06
- O 0 1.396504330841708e-06
endorphin O 0 8.156566764228046e-05
. O 0 3.7940750985399063e-07

While O 0 6.141592479025348e-08
a O 0 4.071742498723552e-09
few O 0 5.106940981214336e-10
cases O 0 5.089386898027293e-11
of O 0 9.296214353859966e-10
isolated O 0 1.531476812033361e-07
ACTH B-Disease 1 0.9997418522834778
deficiency I-Disease 0 5.8401765272719786e-05
have O 0 1.5095988459279397e-08
been O 0 9.850409377065716e-09
reported O 0 2.383667041527815e-09
( O 0 2.1720711340655896e-10
OMIM O 0 5.753514869866194e-06
201400 O 0 5.740425876865629e-07
) O 0 8.757722325114514e-10
, O 0 3.4559577422044185e-10
an O 0 6.215771786166613e-10
inherited O 1 0.8681313991546631
POMC O 1 1.0
defect O 1 1.0
has O 0 1.3505321305729012e-08
not O 0 5.076611353516114e-10
been O 0 1.8571942594913793e-10
described O 0 1.1894092655229116e-10
so O 0 3.011403348907038e-10
far O 0 1.7029453402983563e-09
. O 0 1.2890260414621935e-08

Recent O 0 4.442818521965819e-07
studies O 0 1.202150734513907e-08
in O 0 7.443477501034579e-10
animal O 0 1.8335487295129127e-10
models O 0 3.0221286584364293e-10
elucidated O 0 4.634828076888198e-09
a O 0 9.411771362266563e-10
central O 0 8.415142360718164e-09
role O 0 8.495341319303407e-09
of O 0 1.7847948896587695e-08
alpha O 0 2.158414389441532e-07
- O 0 1.6138930902798165e-07
MSH O 0 3.387520700925961e-05
in O 0 6.711823985483534e-09
the O 0 7.181520267351971e-09
regulation O 0 5.9424266396490566e-08
of O 0 3.6778935452730366e-10
food O 0 5.793294732825416e-10
intake O 0 5.6979296281234326e-11
by O 0 1.6149229306247626e-13
activation O 0 7.383580413744539e-10
of O 0 3.1297113789463538e-09
the O 0 1.0115712711922242e-08
brain O 0 2.486350325625608e-08
melanocortin O 0 1.4237313905596238e-07
- O 0 7.707056326466954e-09
4 O 0 1.9773782611309798e-08
- O 0 2.093836748429112e-08
receptor O 0 4.707735090647702e-09
( O 0 1.3404145848827653e-10
MC4 O 0 6.803169526392594e-06
- O 0 5.855555684775027e-08
R O 0 5.64320767892923e-09
; O 0 9.478928059136749e-11
refs O 0 1.1577895975278807e-08
3 O 0 1.623567613684429e-09
- O 0 1.9755377334007562e-09
5 O 0 1.4941494708153868e-09
) O 0 1.3847104018971379e-11
and O 0 2.0642123427228043e-11
the O 0 2.4301372025803403e-10
linkage O 0 3.6475082509923595e-08
of O 0 1.6663165292030158e-09
human O 0 8.582196286965882e-09
obesity B-Disease 1 1.0
to O 0 1.0515562864910066e-09
chromosome O 0 8.76882066958018e-10
2 O 0 1.8221433251142116e-08
in O 0 5.521259005547563e-09
close O 0 3.3002368837742324e-08
proximity O 0 3.799983971930487e-08
to O 0 2.5743187137550194e-08
the O 0 1.7288598996856308e-08
POMC O 0 6.1068230934324674e-06
locus O 0 4.423640476147739e-08
, O 0 6.005648200968494e-10
led O 0 4.2802136834829696e-10
to O 0 4.680684173585803e-10
the O 0 1.5486215088067468e-10
proposal O 0 4.542484444147732e-10
of O 0 1.8323845218937151e-10
an O 0 9.794718508482347e-11
association O 0 9.37693811486895e-10
of O 0 5.074599851440098e-09
POMC O 0 0.004313579760491848
with O 0 4.361215388826167e-09
human O 0 1.8527293832448777e-06
obesity B-Disease 1 1.0
. O 0 2.0563450675581407e-07

The O 0 3.130124781591803e-08
dual O 0 1.7892092785132263e-07
role O 0 2.0182146442948579e-07
of O 0 4.303918217374303e-07
alpha O 0 1.0211902917944826e-05
- O 0 1.0333765203540679e-05
MSH O 0 0.00134831212926656
in O 0 1.0455628363104097e-08
regulating O 0 7.853854100403623e-08
food O 0 4.868427438964318e-08
intake O 0 3.46306094911597e-08
and O 0 2.0499629771464356e-10
influencing O 0 4.618646016751882e-06
hair O 0 0.004855854902416468
pigmentation O 0 0.032893095165491104
predicts O 0 1.3132900278378656e-07
that O 0 1.7777194993850998e-10
the O 0 4.842399259352703e-10
phenotype O 0 1.4436729589561992e-09
associated O 0 9.113210186484366e-10
with O 0 3.579601545733446e-11
a O 0 2.7063036256436135e-09
defect O 0 3.6912570777758447e-08
in O 0 5.411989967285535e-09
POMC O 0 4.597280167217832e-06
function O 0 8.39447888978384e-09
would O 0 5.183933726726764e-09
include O 0 1.7473517743837874e-08
obesity B-Disease 1 1.0
, O 0 9.005183265742289e-10
alteration O 0 4.0059356365418353e-07
in O 0 1.8124592315871269e-07
pigmentation O 1 0.9833287000656128
and O 0 4.3409022509877104e-07
ACTH B-Disease 1 0.9999940395355225
deficiency I-Disease 0 0.0007945872494019568
. O 0 2.0139591470069718e-06

The O 0 7.653444527022657e-07
observation O 0 3.105099494860042e-06
of O 0 2.351299599467893e-09
these O 0 2.3280131988823172e-10
symptoms O 0 1.923851122853648e-08
in O 0 4.948542686733504e-10
two O 0 5.250953560853588e-10
probands O 0 4.787207785739156e-07
prompted O 0 7.850839978118529e-09
us O 0 5.627149857190261e-09
to O 0 5.099283217901984e-09
search O 0 1.249261938340851e-08
for O 0 1.3716946467567936e-09
mutations O 0 1.4047376595271999e-09
within O 0 4.636755424058947e-09
their O 0 6.907905003572523e-08
POMC O 0 2.4219407350756228e-05
genes O 0 9.27942807038562e-08
. O 0 1.2352480780464248e-06

Patient O 0 1.0633257261360995e-05
1 O 0 3.8771062804698886e-07
was O 0 2.6390742036142e-08
found O 0 2.639504448342933e-10
to O 0 3.036463580574633e-10
be O 0 1.802438615028379e-10
a O 0 2.8723998179991383e-10
compound O 0 2.7493149978852216e-09
heterozygote O 0 9.322319804994095e-09
for O 0 1.0898532076808465e-10
two O 0 3.15547657447901e-11
mutations O 0 4.348386581365382e-11
in O 0 3.5942304688063587e-10
exon O 0 6.286981601988373e-09
3 O 0 4.0005673440646206e-08
( O 0 7.523351386318211e-10
G7013T O 0 5.082623601992964e-07
, O 0 4.909442852252255e-10
C7133delta O 0 9.316155313854324e-08
) O 0 4.5757609506980046e-11
which O 0 9.477567168569845e-12
interfere O 0 5.868766028704897e-10
with O 0 2.68473199400987e-12
appropriate O 0 3.4732063891596e-09
synthesis O 0 5.0932399631165026e-08
of O 0 1.97810638979945e-08
ACTH O 0 2.7496839720697608e-06
and O 0 5.15933296085791e-09
alpha O 0 4.388472461869242e-06
- O 0 1.072792201739503e-05
MSH O 0 0.0018112263642251492
. O 0 1.1541953881533118e-06

Patient O 0 1.461722786189057e-05
2 O 0 3.0937820838516927e-07
was O 0 3.0774444326198136e-08
homozygous O 0 2.9092714903811157e-09
for O 0 2.7906493782481334e-10
a O 0 7.24867332824175e-10
mutation O 0 1.4230723544006452e-10
in O 0 7.349465480643858e-10
exon O 0 1.0018610829831687e-08
2 O 0 1.1187641746346344e-07
( O 0 2.1502870595213608e-09
C3804A O 0 2.630240487633273e-07
) O 0 3.0792846050786693e-10
which O 0 3.1003594136436163e-10
abolishes O 0 8.475072377223114e-07
POMC O 0 1.2395173143886495e-05
translation O 0 1.9048445665248437e-06
. O 0 1.0630109272824484e-06

These O 0 1.6438413297237275e-08
findings O 0 5.3497348773134945e-09
represent O 0 7.110450561675918e-10
the O 0 1.110713521157436e-09
first O 0 7.560364001513165e-10
examples O 0 1.779403069335217e-09
of O 0 7.657657841164678e-10
a O 0 6.555344267411556e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 2.398316389928823e-08
the O 0 6.442459898892139e-09
POMC O 0 7.248056590469787e-07
gene O 0 1.4980018336885337e-09
and O 0 1.8133629320349343e-10
define O 0 2.6526798535542184e-08
a O 0 1.5856500112931826e-08
new O 0 1.3018986066981597e-07
monogenic B-Disease 1 1.0
endocrine I-Disease 1 0.9999992847442627
disorder I-Disease 1 0.9999828338623047
resulting O 0 1.7395596074720743e-09
in O 0 2.24979979090989e-10
early O 0 6.591218607354676e-06
- O 0 7.574012852273881e-05
onset O 1 0.9983977675437927
obesity B-Disease 1 1.0
, O 0 2.3073041255372573e-09
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 3.925071268895408e-06
red O 1 0.9423733353614807
hair O 1 0.9063767194747925
pigmentation O 1 0.6919772028923035
. O 0 2.8294678600104817e-07
. O 0 3.531014272084576e-07

A O 0 2.617935933812987e-06
European O 0 2.2635633456502546e-07
multicenter O 0 7.764056135783903e-06
study O 0 1.206738886594394e-07
of O 0 6.213809911059798e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.337409365007261e-08
classification O 0 5.962268900816525e-09
of O 0 2.624605865975127e-09
105 O 0 1.3075238314286253e-07
mutations O 0 9.310925364047762e-10
and O 0 2.338792493006281e-10
a O 0 6.508413363803811e-09
general O 0 2.1266556515797674e-08
system O 0 2.743730576071357e-09
for O 0 3.420101424289612e-10
genotype O 0 1.8080520414187617e-09
- O 0 2.542954113948781e-08
based O 0 7.757850362111185e-09
prediction O 0 9.468295161241258e-07
of O 0 1.3833714618272097e-08
metabolic O 0 2.2772655938751996e-06
phenotype O 0 3.5881657822756097e-07
. O 0 1.4355327948578633e-07

Phenylketonuria B-Disease 0 0.0027759731747210026
( O 0 1.2254590231464135e-08
PKU B-Disease 0 2.4382645278819837e-05
) O 0 7.765311060836666e-09
and O 0 7.476748997703453e-09
mild B-Disease 0 3.3649826946202666e-05
hyperphenylalaninemia I-Disease 1 1.0
( O 0 2.2763696705396796e-08
MHP B-Disease 1 1.0
) O 0 2.4080328842046583e-09
are O 0 3.048082009016184e-09
allelic B-Disease 0 1.7074895367841236e-05
disorders I-Disease 0 0.00010915463644778356
caused O 0 1.2090723089386302e-08
by O 0 3.409521970310081e-11
mutations O 0 5.5103751422924674e-11
in O 0 5.5717602753802e-10
the O 0 3.233410428293837e-09
gene O 0 1.7531931462144712e-09
encoding O 0 1.0483889667511903e-07
phenylalanine O 0 1.413896279700566e-05
hydroxylase O 0 4.085095861228183e-05
( O 0 9.358860353358978e-09
PAH O 0 7.601129618706182e-05
) O 0 2.3366679258174372e-08
. O 0 2.0869038053206168e-07

Previous O 0 1.6107421743072337e-06
studies O 0 3.312319662995833e-08
have O 0 3.832538730819124e-10
suggested O 0 5.641246914045439e-10
that O 0 1.1888961169714829e-11
the O 0 3.404507231685727e-10
highly O 0 1.754846579160585e-08
variable O 0 1.5389641703222878e-06
metabolic O 0 0.0013619593810290098
phenotypes O 0 0.00012673473975155503
of O 0 1.2712475836451631e-05
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9998903274536133
correlate O 0 1.2759614946844522e-05
with O 0 8.116862737495012e-09
PAH O 1 0.9999775886535645
genotypes O 0 3.0102750315563753e-05
. O 0 5.201894168749277e-07

We O 0 1.054330141414539e-06
identified O 0 7.749320474204069e-08
both O 0 4.4087373751722225e-09
causative O 0 1.3914338126141956e-07
mutations O 0 3.4168316176419467e-08
in O 0 5.239401357215456e-09
686 O 0 5.060471863771454e-08
patients O 0 1.3178840241323542e-08
from O 0 1.2494997259082652e-09
seven O 0 4.5973735929294435e-09
European O 0 9.04469299456423e-09
centers O 0 4.850113555221469e-08
. O 0 5.3962949664310145e-08

On O 0 2.504317819784774e-07
the O 0 2.2095325569182478e-09
basis O 0 3.5088565386587334e-09
of O 0 6.177159894704687e-10
the O 0 5.273818048934231e-10
phenotypic O 0 8.919018412711921e-09
characteristics O 0 3.690018246516047e-08
of O 0 2.7960123105685852e-08
297 O 0 1.6598020735614227e-08
functionally O 0 2.6417032117365125e-08
hemizygous O 0 1.0441662823268416e-07
patients O 0 1.5585253088090667e-09
, O 0 1.019462726042919e-11
105 O 0 5.027204608154534e-08
of O 0 2.2949150135787022e-08
the O 0 1.4489620170365924e-08
mutations O 0 2.0494937691406534e-10
were O 0 4.902639960668864e-10
assigned O 0 6.581967859631277e-09
to O 0 2.5379003787406873e-08
one O 0 3.924429670121299e-09
of O 0 2.3766304479977407e-09
four O 0 2.901550666400965e-10
arbitrary O 0 2.838227430856932e-09
phenotype O 0 2.4214259486399214e-09
categories O 0 4.337936676535037e-09
. O 0 5.5710223989535734e-08

We O 0 4.721441655419767e-07
proposed O 0 2.7461350526891692e-08
and O 0 1.4415020288538472e-09
tested O 0 8.232930781559844e-09
a O 0 4.963610633623716e-10
simple O 0 9.319359867143717e-11
model O 0 1.4775471124384154e-10
for O 0 2.0427333435879547e-11
correlation O 0 5.1437736015014224e-11
between O 0 5.6281857646611755e-11
genotype O 0 3.0073237233807504e-09
and O 0 7.384707290114534e-10
phenotypic O 0 3.4067710430463194e-08
outcome O 0 1.8749071273305162e-07
. O 0 1.8578994058771059e-06

The O 0 9.19796505627346e-08
observed O 0 1.502669988440175e-08
phenotype O 0 2.4028631528949518e-08
matched O 0 1.6098832489319648e-08
the O 0 1.093022117260034e-09
predicted O 0 2.783315133925157e-09
phenotype O 0 3.7419592424647874e-10
in O 0 2.205716720382611e-10
79 O 0 1.8546083779824585e-08
% O 0 1.7416734721109606e-10
of O 0 7.18597958915268e-11
the O 0 3.376104604213559e-11
cases O 0 3.4857975880764336e-12
, O 0 1.0858765059004738e-12
and O 0 2.9740348638646052e-12
in O 0 4.2703857811021706e-11
only O 0 5.66191850348563e-11
5 O 0 1.4210903565015087e-09
of O 0 1.27121577153666e-10
184 O 0 5.446263440234134e-10
patients O 0 4.164023847952336e-10
was O 0 2.365306617235774e-09
the O 0 2.99211611043404e-09
observed O 0 4.705140721483758e-09
phenotype O 0 1.1712557590470851e-09
more O 0 2.9059466638559073e-11
than O 0 1.5534101782677112e-11
one O 0 7.987140462906162e-12
category O 0 1.7718598810390063e-10
away O 0 3.855311070388723e-10
from O 0 7.781597588518707e-11
that O 0 2.7565475943513995e-11
expected O 0 2.3765354129068328e-09
. O 0 9.820734447885116e-08

Among O 0 4.118114560469621e-08
the O 0 9.64206581244298e-09
seven O 0 6.130526641889844e-10
contributing O 0 5.014290649363318e-10
centers O 0 2.0665927302765397e-10
, O 0 1.196229573730001e-11
the O 0 9.235572723254037e-11
proportion O 0 2.2444593406056867e-10
of O 0 2.0297315217465695e-10
patients O 0 1.0353930907092135e-10
for O 0 9.950082424659001e-11
whom O 0 2.2647836939171384e-09
the O 0 4.94356378055727e-09
observed O 0 2.35224173472659e-09
phenotype O 0 4.5056994246728266e-10
did O 0 1.1368168628678177e-09
not O 0 3.992102481920057e-10
match O 0 2.21972951131022e-09
the O 0 1.0516866266740976e-09
predicted O 0 2.329311188375982e-09
phenotype O 0 9.679171908416606e-10
was O 0 6.572706268137551e-10
4 O 0 1.9595098876834527e-09
% O 0 1.7808281238540502e-10
- O 0 5.2511563986001875e-09
23 O 0 8.883466406928164e-09
% O 0 6.374447636403602e-10
( O 0 2.0670895550800594e-10
P O 0 9.454132054997899e-08
< O 0 3.5948236387639554e-08
. O 0 3.853634911177295e-10
0001 O 0 5.504424279934028e-06
) O 0 3.017411598360553e-10
, O 0 1.0120103366428879e-10
suggesting O 0 1.2053553710700271e-09
that O 0 2.1509575370837197e-11
differences O 0 7.068286234090948e-11
in O 0 6.787994472068348e-11
methods O 0 1.7234267346566412e-09
used O 0 4.567444755743111e-10
for O 0 3.9553810227133113e-10
mutation O 0 1.756453094081678e-09
detection O 0 8.806574669506517e-08
or O 0 9.954496782427213e-09
phenotype O 0 2.8300986443241527e-08
classification O 0 6.088018977834508e-10
may O 0 3.2230151880696667e-10
account O 0 1.0615733986307774e-10
for O 0 1.6764971355609504e-11
a O 0 6.958622567054817e-11
considerable O 0 7.474121876960282e-10
proportion O 0 4.5333878317954657e-10
of O 0 2.3260260384461162e-09
genotype O 0 6.544602797475818e-07
- O 0 1.6551141015952453e-05
phenotype O 0 1.5528252106378204e-06
inconsistencies O 0 5.614785436591774e-07
. O 0 7.480438739548845e-07

Our O 0 5.332690307113808e-06
data O 0 1.784887473377239e-07
indicate O 0 3.072587873020893e-08
that O 0 1.8217140296261647e-10
the O 0 2.1142421147146706e-09
PAH O 0 1.5311588867916726e-05
- O 0 6.091520958761976e-07
mutation O 0 2.821683331433178e-09
genotype O 0 3.845295637461277e-09
is O 0 2.5421744570541804e-11
the O 0 6.700318772034919e-11
main O 0 2.5937607617265712e-09
determinant O 0 8.87226079271386e-08
of O 0 8.173181953452513e-08
metabolic O 1 0.9818971157073975
phenotype O 0 8.838334792926617e-07
in O 0 9.73702185547154e-09
most O 0 3.0607185674824677e-09
patients O 0 8.071105561668901e-09
with O 0 1.895711587707183e-09
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9999945163726807
. O 0 2.2279175027506426e-05

In O 0 5.853233275843195e-08
the O 0 5.610442332937282e-09
present O 0 6.039051481110391e-10
study O 0 4.162880318236972e-10
, O 0 9.62555035677326e-12
the O 0 1.1975997971092056e-10
classification O 0 5.773857503221791e-10
of O 0 2.8763156301181425e-09
105 O 0 5.621070044981025e-07
PAH O 0 2.5198540242854506e-05
mutations O 0 7.54493889587593e-09
may O 0 9.410191514902522e-10
allow O 0 1.460239262840446e-09
the O 0 1.3696815903685433e-09
prediction O 0 8.782885529967643e-09
of O 0 7.984589101006634e-10
the O 0 1.4632978162509858e-09
biochemical O 0 2.5190677988007337e-08
phenotype O 0 8.128266060225542e-09
in O 0 6.848456246544288e-10
> O 0 8.036330712002382e-08
10 O 0 1.3030371448508049e-08
, O 0 1.4179055152219178e-10
000 O 0 8.126052364332281e-08
genotypes O 0 1.8328721651528213e-08
, O 0 2.4695129274832084e-10
which O 0 1.8115158678666532e-11
may O 0 5.980611839095928e-11
be O 0 7.927825930453825e-12
useful O 0 1.9617750479650198e-10
for O 0 2.067380294734633e-11
the O 0 1.8309766203206124e-10
management O 0 3.995090480657382e-09
of O 0 3.2094411572813897e-09
hyperphenylalaninemia B-Disease 1 1.0
in O 0 3.2949348138799905e-08
newborns O 0 2.2922515086065687e-07
. O 0 4.6950219712016406e-08

Somatic O 0 2.4361776013392955e-05
instability O 0 5.1086494750052225e-06
of O 0 1.2634629342755943e-07
the O 0 9.677425794052397e-08
CTG O 0 6.521472096210346e-05
repeat O 0 6.482312073785579e-07
in O 0 2.7791681844746563e-08
mice O 0 1.4598194653103747e-08
transgenic O 0 7.252520806133589e-09
for O 0 6.238719540974103e-10
the O 0 4.363073102808812e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.0955301351932576e-06
is O 0 7.452015116093946e-10
age O 0 8.088808511885759e-10
dependent O 0 9.278481871710653e-10
but O 0 6.894886571406911e-12
not O 0 2.371945348467186e-11
correlated O 0 4.3044390274360467e-10
to O 0 1.2698181395265351e-09
the O 0 3.6243503753752293e-09
relative O 0 4.0868317796594056e-07
intertissue O 0 1.1783909030782524e-06
transcription O 0 1.3372064699979092e-07
levels O 0 3.614556476350117e-07
and O 0 9.423846591971596e-09
proliferative O 0 0.00016036252782214433
capacities O 0 9.749714081408456e-05
. O 0 5.166286427993327e-06

A O 0 1.6432932170573622e-05
( O 0 9.929105537764826e-09
CTG O 0 2.262778480144334e-06
) O 0 5.413349768446096e-10
nexpansion O 0 5.714470674433869e-08
in O 0 4.445551426979222e-10
the O 0 8.055321965017015e-10
3 O 0 1.4483346966187582e-08
- O 0 9.415388291245108e-08
untranslated O 0 8.659100785735063e-06
region O 0 1.6054983120739053e-08
( O 0 8.6911887409169e-11
UTR O 0 1.2801439197573927e-06
) O 0 4.864533775794655e-10
of O 0 2.3413198046995376e-09
the O 0 2.0077401075013768e-08
DM O 1 1.0
protein O 0 1.1108457442787767e-07
kinase O 0 1.899422983342447e-07
gene O 0 2.5868258646255526e-08
( O 0 2.560741063639682e-10
DMPK O 0 1.0542377140154713e-06
) O 0 7.744152541455662e-11
is O 0 6.5586984628052125e-12
responsible O 0 5.842126782340529e-11
for O 0 3.4932889914074394e-10
causing O 0 3.688460026296525e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.813526063822792e-07
DM B-Disease 1 1.0
) O 0 3.909041978999994e-08
. O 0 1.683129511320658e-07

Major O 0 1.9984876416856423e-05
instability O 0 2.348244197492022e-05
, O 0 3.3881970562532615e-09
with O 0 5.7159773442228e-11
very O 0 4.072299442103855e-10
large O 0 1.167944629898443e-10
expansions O 0 5.059735297407997e-09
between O 0 2.104139640302094e-10
generations O 0 3.2250953019286044e-09
and O 0 2.0017118518289578e-10
high O 0 2.3795334591625306e-09
levels O 0 4.751540938485732e-09
of O 0 9.32660171315547e-10
somatic O 0 1.8011384383953555e-07
mosaicism O 0 1.5244356745824916e-06
, O 0 7.124202339170438e-10
is O 0 3.851068422489057e-11
observed O 0 1.9891141511685362e-10
in O 0 5.022081639438625e-10
patients O 0 5.293755656055055e-09
. O 0 4.1209041512502154e-08

There O 0 2.6901297189851903e-08
is O 0 2.0482825158207874e-10
a O 0 1.4866950726055705e-10
good O 0 3.4322170106015903e-10
correlation O 0 4.610171619456871e-11
between O 0 1.5319280566306048e-11
repeat O 0 3.3179390346305127e-09
size O 0 1.5077306070310215e-09
( O 0 9.110650428523215e-11
at O 0 2.596166392976329e-09
least O 0 2.402425480774184e-10
in O 0 7.369647253563372e-11
leucocytes O 0 1.685406303408854e-08
) O 0 4.931523592266451e-11
, O 0 1.2327903455011668e-11
clinical O 0 1.1721094095307194e-09
severity O 0 4.611266923859603e-09
and O 0 2.4335172765788116e-11
age O 0 2.225350570483897e-09
of O 0 5.625754972982122e-09
onset O 0 2.868474666684051e-06
. O 0 8.259294759227487e-08

The O 0 9.64296759775607e-07
trinucleotide O 0 0.0002771380532067269
repeat O 0 3.697497504617786e-06
instability O 0 2.5743884179973975e-07
mechanisms O 0 6.081675962832378e-08
involved O 0 3.6626484067880938e-09
in O 0 9.842730719356041e-08
DM B-Disease 1 1.0
and O 0 8.567837426198821e-07
other O 0 1.3202464010930726e-08
human O 0 2.357111306139359e-08
genetic B-Disease 1 0.9999994039535522
diseases I-Disease 1 1.0
are O 0 1.418889658544309e-11
unknown O 0 3.728495734378612e-09
. O 0 1.765778634421622e-08

We O 0 4.726987867798016e-07
studied O 0 4.371878503661719e-07
somatic O 0 4.662245828512823e-06
instability O 0 2.4796733555376704e-07
by O 0 3.160489647768827e-10
measuring O 0 4.6819277343956855e-09
the O 0 1.921609538158009e-09
CTG O 0 3.3224154094568803e-07
repeat O 0 1.5103331918453478e-08
length O 0 1.1481766648557823e-09
at O 0 3.4700942119769707e-09
several O 0 5.958591259291879e-11
ages O 0 7.985655470221786e-10
in O 0 2.6838181677035777e-10
various O 0 9.47676381812812e-10
tissues O 0 6.747960412667453e-08
of O 0 4.755884130958066e-09
transgenic O 0 1.4895860545038886e-08
mice O 0 5.303953276580842e-09
carrying O 0 2.783081543000776e-09
a O 0 9.034451409206667e-09
( O 0 1.525683579473025e-09
CTG O 0 1.5223147329379572e-06
) O 0 1.6396567437126919e-09
55expansion O 0 2.9551478064604453e-07
surrounded O 0 4.369475004040169e-09
by O 0 4.2632074953585786e-11
45 O 0 7.876201912893066e-09
kb O 0 4.967906193087401e-07
of O 0 9.710018566977396e-09
the O 0 1.4857383767719057e-08
human O 0 4.776376982817965e-08
DM B-Disease 1 1.0
region O 0 2.0341290962733183e-07
, O 0 7.327071172014143e-10
using O 0 4.204921744133117e-09
small O 0 1.1141576550244281e-08
- O 0 2.830396397257573e-07
pool O 0 3.21559525673365e-07
PCR O 0 7.504454515583348e-07
. O 0 1.473270430096818e-07

These O 0 2.6960350396620925e-07
mice O 0 1.5911344064534205e-07
have O 0 2.0906580633361926e-10
been O 0 8.915607141446458e-11
shown O 0 9.995143601670975e-11
to O 0 5.043738759979988e-10
reproduce O 0 1.6774464484115015e-08
the O 0 4.038638312664489e-09
intergenerational O 0 2.110902919127966e-08
and O 0 1.9717545374220435e-09
somatic O 0 5.564161824622715e-07
instability O 0 1.899564239238316e-07
of O 0 6.887904024921454e-09
the O 0 9.096509323569535e-09
55 O 0 1.4922454738552915e-07
CTG O 0 1.3190341405788786e-06
repeat O 0 6.70683562020713e-08
suggesting O 0 7.661343559561828e-09
that O 0 4.30496228942534e-11
surrounding O 0 3.049044350333929e-11
sequences O 0 5.001069003363057e-11
and O 0 5.674657410636996e-10
the O 0 1.9043220333969657e-09
chromatin O 0 2.6407547260021147e-09
environment O 0 2.051737091335326e-08
are O 0 4.121723101713215e-11
involved O 0 1.1808805322477411e-10
in O 0 9.408360757134915e-10
instability O 0 9.567764180928862e-08
mechanisms O 0 1.0876136684601079e-06
. O 0 3.4478929933356994e-07

As O 0 1.743197231007798e-08
observed O 0 2.547317023982032e-09
in O 0 5.03962260811619e-10
some O 0 2.554730871295874e-10
of O 0 1.2330807486193862e-09
the O 0 2.0501125241878526e-09
tissues O 0 4.64256295629184e-08
of O 0 2.170098056808456e-08
DM B-Disease 1 1.0
patients O 0 1.1957618539781834e-07
, O 0 2.1348539255838794e-11
there O 0 1.825124947008039e-11
is O 0 9.330596191514662e-12
a O 0 1.025260570886033e-10
tendency O 0 1.6649465139906283e-10
for O 0 2.0424928415252452e-10
repeat O 0 5.983356032857046e-09
length O 0 2.8668620810634593e-09
and O 0 4.167283407241484e-09
somatic O 0 1.9618374835772556e-07
mosaicism O 0 2.316521943157568e-07
to O 0 1.0539517036889379e-09
increase O 0 1.6357701304592354e-10
with O 0 4.012534228492459e-12
the O 0 4.109620421743898e-10
age O 0 2.1158921281738685e-09
of O 0 1.9211403579078024e-09
the O 0 6.302013577652588e-09
mouse O 0 3.432659809732286e-07
. O 0 3.3807984323175333e-07

Furthermore O 0 1.1555567880350281e-06
, O 0 2.440250002067046e-09
we O 0 1.2668714965968775e-09
observed O 0 6.215890580030248e-10
no O 0 4.061656844189798e-10
correlation O 0 4.8592175422301764e-11
between O 0 6.249268463820457e-11
the O 0 8.020768937910816e-09
somatic O 0 7.383484444289934e-06
mutation O 0 1.5472035386210337e-07
rate O 0 2.730326684741158e-07
and O 0 5.927029089747293e-09
tissue O 0 8.655699446080689e-08
proliferation O 0 6.131180271040648e-06
capacity O 0 4.6870050596226065e-07
. O 0 2.716400331337354e-07

The O 0 8.30218993996823e-07
somatic O 0 1.1533345968928188e-05
mutation O 0 8.238180981834375e-08
rates O 0 1.0026739971635834e-07
in O 0 1.5623975446743543e-09
different O 0 1.0746817880047388e-09
tissues O 0 1.6902061972245974e-08
were O 0 1.0921844539879544e-09
also O 0 9.856600952096173e-11
not O 0 4.807114775684518e-11
correlated O 0 6.509340844118583e-10
to O 0 6.947155073433464e-10
the O 0 1.70619973705044e-09
relative O 0 2.9966926717861497e-07
inter O 0 1.1072053496263834e-07
- O 0 6.350655326059496e-07
tissue O 0 2.5113918056263174e-08
difference O 0 9.033551129355999e-10
in O 0 3.357302977291532e-11
transcriptional O 0 2.1043844444790238e-10
levels O 0 4.988403023986621e-09
of O 0 7.617175223906258e-10
the O 0 2.5744992804277445e-09
three O 0 4.942750653214034e-10
genes O 0 5.222258181447614e-10
( O 0 4.820200349975323e-10
DMAHP O 0 2.608015620353399e-06
, O 0 1.4818717364306622e-09
DMPK O 0 8.453849886791431e-07
and O 0 8.039143795102177e-10
59 O 0 2.573999680066663e-08
) O 0 2.792331921241953e-10
surrounding O 0 1.6299346317083518e-09
the O 0 2.0122630228769367e-09
repeat O 0 6.539521812953808e-09
. O 0 3.952735916357142e-09
. O 0 4.617183435584593e-08

A O 0 1.0393730462965323e-06
novel O 0 1.7412740760391898e-07
missense O 0 3.349567123223096e-06
mutation O 0 1.946139072117603e-08
in O 0 1.5698863320423584e-09
patients O 0 2.237873220067854e-09
from O 0 1.6992519891179114e-10
a O 0 3.6269505176989014e-09
retinoblastoma B-Disease 0 2.484839114913484e-06
pedigree O 0 2.5970254569074314e-07
showing O 0 1.9056965783192936e-08
only O 0 9.010663881703351e-10
mild O 0 1.3412649657595921e-08
expression O 0 4.4377426178243695e-09
of O 0 3.739107246047979e-09
the O 0 5.508194789172194e-09
tumor B-Disease 0 2.1656950366377714e-07
phenotype O 0 9.795964928116518e-08
. O 0 1.0499718428036431e-07

We O 0 9.051772309476291e-08
have O 0 5.964574945060974e-10
used O 0 2.383765962399309e-10
single O 0 2.590684333725335e-10
strand O 0 4.1719735999201646e-10
conformation O 0 3.252955960153514e-10
polymorphism O 0 1.056489673523231e-09
analysis O 0 1.6946527514605236e-10
to O 0 1.7797006923725434e-10
study O 0 2.929633480253102e-10
the O 0 8.482028412970521e-10
27 O 0 1.349940248474013e-07
exons O 0 9.328193328883572e-08
of O 0 8.801634088229093e-09
the O 0 1.2577111796474583e-08
RB1 O 0 2.3236784727487247e-06
gene O 0 1.2260078507964067e-09
in O 0 4.0872710771466814e-10
individuals O 0 1.2765945418824476e-11
from O 0 1.0605938349783628e-10
a O 0 8.38343394704566e-10
family O 0 1.6847595540880889e-09
showing O 0 1.1922452358703595e-08
mild O 0 1.8755931918690294e-08
expression O 0 1.0320068355440526e-08
of O 0 5.904034594550467e-09
the O 0 1.5598226710267227e-08
retinoblastoma B-Disease 0 3.2154712243936956e-06
phenotype O 0 4.1117814930657914e-07
. O 0 2.869101649594086e-07

In O 0 4.7820467585779625e-08
this O 0 4.759078464644517e-09
family O 0 3.424332817303366e-09
affected O 0 1.1433470836763604e-09
individuals O 0 1.1036926580998419e-11
developed O 0 4.464383529523275e-09
unilateral B-Disease 0 6.440880497393664e-06
tumors I-Disease 1 1.0
and O 0 5.042567252644403e-09
, O 0 1.549277373058544e-10
as O 0 2.137617444164519e-10
a O 0 3.2100702651582935e-10
result O 0 3.887876409702784e-10
of O 0 7.224187359433643e-10
linkage O 0 2.1170558639482806e-08
analysis O 0 8.953841224013104e-09
, O 0 1.6049953588392896e-09
unaffected O 0 1.4632601619268826e-07
mutation O 0 1.5914028983488038e-09
carriers O 0 2.607330462645052e-10
were O 0 6.570675670225512e-10
also O 0 5.842140660128337e-10
identified O 0 9.777215703721254e-10
within O 0 2.310012181538923e-09
the O 0 1.1863247273424804e-08
pedigree O 0 5.041608233113948e-07
. O 0 1.2931833737184206e-07

A O 0 4.6543019038836064e-07
single O 0 1.7973800225945524e-08
band O 0 2.063042536804005e-08
shift O 0 1.0315935661253661e-08
using O 0 2.945997223946506e-09
SSCP O 0 2.042511226818533e-07
was O 0 2.8944326935231857e-09
identified O 0 1.148207307011262e-09
in O 0 4.97809793387205e-10
exon O 0 6.303022992426577e-09
21 O 0 1.4686139415687194e-08
which O 0 2.333551234190434e-11
resulted O 0 1.1977187297507186e-10
in O 0 4.835511852041563e-11
a O 0 5.44663703028192e-10
missense O 0 2.020463440999265e-08
mutation O 0 2.286571904042134e-10
converting O 0 2.4339839033160615e-09
a O 0 4.03268041182514e-09
cys O 0 5.776259513368132e-06
- O 0 9.501378372078761e-06
- O 0 6.732893780281302e-06
> O 0 2.7932139801123412e-06
arg O 0 3.190766051375249e-07
at O 0 6.141086306143961e-09
nucleotide O 0 6.834679933120924e-09
position O 0 4.856130075836518e-08
28 O 0 1.0601726074810358e-07
in O 0 1.7802458174287494e-08
the O 0 1.3363906248287094e-07
exon O 0 2.558601863711374e-06
. O 0 6.204524538588885e-07

The O 0 3.3007233923854074e-06
mutation O 0 2.3526115455752006e-07
destroyed O 0 2.7436699383542873e-06
an O 0 8.470617984812634e-09
NdeI O 0 4.067369900440099e-06
restriction O 0 3.709006932695047e-07
enzyme O 0 1.8575963878220136e-08
site O 0 3.449139569511317e-07
. O 0 1.3841084012256033e-07

Analysis O 0 6.853559142427912e-08
of O 0 7.18332859861448e-09
all O 0 9.55116430390035e-10
family O 0 5.334549468827277e-10
members O 0 3.3591154163792325e-11
demonstrated O 0 1.606217270300192e-09
that O 0 4.464804914672271e-11
the O 0 1.976137031789449e-09
missense O 0 7.203348673101573e-07
mutation O 0 1.3261849396428715e-08
co O 0 1.2475135235945345e-07
- O 0 1.2331116522545926e-05
segregated O 0 7.583607271044457e-07
with O 0 1.0667253746987626e-09
patients O 0 1.6917583423037286e-07
with O 0 1.5736689729095588e-10
tumors B-Disease 1 1.0
or O 0 5.6317457364229995e-09
who O 0 6.793243745306654e-10
, O 0 5.248878068297991e-11
as O 0 9.652051380371063e-10
a O 0 3.110151247653903e-09
result O 0 3.610709287116265e-09
of O 0 9.00049901275679e-09
linkage O 0 2.687052891303665e-08
analysis O 0 4.4815657851415835e-09
had O 0 5.6574336326775665e-09
been O 0 4.732336744694976e-10
predicted O 0 9.870941841683134e-10
to O 0 6.090922766155416e-10
carry O 0 4.891676397278388e-09
the O 0 1.1186293669140923e-08
predisposing O 0 6.45433419776964e-06
mutation O 0 1.2108682767575374e-07
. O 0 3.0822792496110196e-07

These O 0 1.39536000531848e-08
observations O 0 6.203682012539957e-09
point O 0 1.3439351853605785e-09
to O 0 1.248608022530462e-10
another O 0 1.1800316279675371e-10
region O 0 7.657877110212041e-10
of O 0 3.065444786898297e-09
the O 0 8.227436509855579e-09
RB1 O 0 2.882886064980994e-06
gene O 0 3.958809724480261e-09
where O 0 2.060080550592147e-09
mutations O 0 2.254314235283772e-10
only O 0 2.5021948402148553e-10
modify O 0 4.67015492944256e-09
the O 0 1.8626441500302349e-09
function O 0 7.178753591574605e-09
of O 0 3.910740620227671e-09
the O 0 1.373233859958134e-09
gene O 0 3.4448419117261153e-10
and O 0 2.793045794646787e-10
raise O 0 1.0903325353694981e-08
important O 0 1.0452358090162761e-08
questions O 0 4.733801794998271e-09
for O 0 4.644949702647949e-10
genetic O 0 2.691436851165463e-09
counseling O 0 4.794519892215021e-09
in O 0 6.598905449850534e-11
families O 0 1.9416055568877155e-11
with O 0 3.3306660381093867e-12
these O 0 9.941526768475484e-11
distinctive O 0 2.449866309817139e-09
phenotypes O 0 1.4676282411585362e-08
. O 0 5.5453432956653614e-09
. O 0 1.1348193851290489e-07

Maternal B-Disease 0 0.0006606312817893922
disomy I-Disease 0 0.0018295343033969402
and O 0 1.1303934115858283e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.999998927116394
with O 0 2.9473556928394373e-10
gamete O 0 8.161794795569222e-08
complementation O 0 5.7763749339301285e-08
in O 0 4.839694200953204e-10
a O 0 7.386961042854523e-10
case O 0 7.068532426046659e-10
of O 0 7.848006133848173e-10
familial O 0 1.0206062661666238e-08
translocation O 0 1.4954931515376302e-08
( O 0 2.0247772208881187e-11
3 O 0 1.7143517716533552e-09
; O 0 6.468778984691781e-11
15 O 0 1.0901162639243012e-08
) O 0 8.030006520831634e-11
( O 0 3.966416431411268e-11
p25 O 0 4.68299283795659e-08
; O 0 5.1020219299369174e-11
q11 O 0 1.366227664334474e-08
. O 0 5.884544934664504e-11
2 O 0 2.5790012347925995e-09
) O 0 1.1581402503679783e-09
. O 0 3.1221770058209586e-08

Maternal B-Disease 1 1.0
uniparental I-Disease 1 1.0
disomy I-Disease 1 0.9999997615814209
( I-Disease 0 5.988313773741538e-07
UPD I-Disease 1 1.0
) I-Disease 0 4.3558450180114505e-09
for I-Disease 0 9.89929915817811e-10
chromosome I-Disease 0 1.8309433968966005e-08
15 I-Disease 0 4.7440995132319586e-08
is O 0 6.01034361169539e-11
responsible O 0 7.562594994681149e-11
for O 0 4.983985793516332e-11
an O 0 1.2747745567476265e-11
estimated O 0 5.1210525403577734e-11
30 O 0 1.2519711933833833e-09
% O 0 4.321630206471916e-11
of O 0 1.0717533631410259e-11
cases O 0 1.1981429737240035e-11
of O 0 8.601615419934205e-09
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 7.387798177660443e-07
PWS B-Disease 1 1.0
) O 0 1.32338779934571e-08
. O 0 3.073326482194716e-08

We O 0 9.735020256584903e-08
report O 0 5.615227838262626e-09
on O 0 1.024139217875586e-09
an O 0 2.8180017347390063e-11
unusual O 0 1.4125663139186173e-10
case O 0 9.549232515837502e-10
of O 0 1.423048678894645e-09
maternal B-Disease 0 1.8475051547284238e-05
disomy I-Disease 0 1.276910916203633e-05
15 I-Disease 0 7.105751933522697e-07
in O 0 6.19892972508751e-08
PWS B-Disease 1 1.0
that O 0 1.5136403241911012e-09
is O 0 1.5682746767886613e-11
most O 0 6.3094846187994325e-12
consistent O 0 1.8958913605704453e-10
with O 0 2.2449140528284228e-13
adjacent O 0 8.828830028173584e-11
- O 0 2.3273261096079523e-09
1 O 0 2.6474333836290498e-08
segregation O 0 5.967322636024619e-08
of O 0 7.471014917825869e-10
a O 0 1.1699027302469744e-09
paternal O 0 2.012020104302792e-06
t O 0 4.80369415356563e-08
( O 0 8.098000568723673e-12
3 O 0 3.2178557041184774e-10
; O 0 1.528105073034247e-11
15 O 0 1.3220171624084287e-09
) O 0 1.2772180882358874e-11
( O 0 6.38926715354482e-12
p25 O 0 1.3309617408197028e-08
; O 0 1.70406778965404e-11
q11 O 0 5.346531661842846e-09
. O 0 9.526682394345176e-12
2 O 0 1.306794117361676e-10
) O 0 5.468867112640163e-12
with O 0 1.5867995936322266e-12
simultaneous O 0 7.62345830906952e-09
maternal O 0 1.6909951909838128e-06
meiotic O 0 6.040501830284484e-06
nondisjunction O 0 2.044160964942421e-06
for O 0 7.045182659481952e-09
chromosome O 0 3.2639100311371294e-08
15 O 0 1.835970920183172e-06
. O 0 5.113730594530352e-07

The O 0 2.656305753134802e-07
patient O 0 4.772861757373903e-06
( O 0 5.01972574618037e-10
J O 0 2.4152768673957326e-07
. O 0 1.8841464499708138e-10
B O 0 1.662298387827832e-08
. O 0 4.798886114876222e-12
) O 0 4.07907388422224e-12
, O 0 4.6235897055435515e-12
a O 0 6.67226204842386e-11
17 O 0 3.142522631005562e-10
- O 0 2.4049287561389576e-10
year O 0 7.109230426571855e-10
- O 0 3.064639741978681e-08
old O 0 3.8905060506522204e-08
white O 0 1.3294108036632224e-09
male O 0 8.514333127429552e-10
with O 0 2.123632693307176e-11
PWS B-Disease 1 1.0
, O 0 9.766516484432941e-10
was O 0 1.6605643526901304e-09
found O 0 8.877291957087863e-11
to O 0 8.528749928515822e-10
have O 0 9.803582390333077e-10
47 O 0 4.749250948066219e-08
chromosomes O 0 4.378184481623748e-09
with O 0 4.11440492786852e-10
a O 0 4.416449073119111e-08
supernumerary O 0 3.875334732583724e-05
, O 0 1.7800827478708925e-08
paternal O 0 2.4570783352828585e-05
der O 0 0.004918783903121948
( O 0 1.7159841325664615e-09
15 O 0 2.5315623375377072e-08
) O 0 6.009014119623401e-11
consisting O 0 3.1119240517796243e-10
of O 0 1.2332735943587636e-09
the O 0 1.5381660389834906e-09
short O 0 6.9506311817235655e-09
arm O 0 1.0231420155548676e-08
and O 0 1.0416489892861591e-09
the O 0 2.0112892684664985e-08
proximal O 0 1.4411421034310479e-06
long O 0 1.2679508643032023e-07
arm O 0 7.414168123887066e-08
of O 0 1.0860754962038754e-08
chromosome O 0 5.594381846663055e-09
15 O 0 9.94603510662273e-08
, O 0 5.692023519188183e-10
and O 0 1.4966879957611923e-09
distal O 0 1.345471787317365e-06
chromosome O 0 2.934081931016408e-05
arm O 0 0.00014650168304797262
3p O 1 0.9661805033683777
. O 0 5.884564870939357e-06

The O 0 2.425269713057787e-06
t O 0 1.2341195088083623e-07
( O 0 2.086756809016599e-11
3 O 0 3.676974558164403e-10
; O 0 1.5052578974938946e-11
15 O 0 7.713950589405272e-10
) O 0 1.4441837482837006e-11
was O 0 1.8821351421838273e-10
present O 0 2.3318073166800346e-11
in O 0 2.2481815020736207e-11
the O 0 2.6784572823568276e-11
balanced O 0 2.0050783255953775e-10
state O 0 5.755314193972572e-12
in O 0 3.395102948777762e-11
the O 0 7.947482255632465e-11
patients O 0 6.879913999613407e-11
father O 0 3.0132302208940587e-10
and O 0 1.6137828573459245e-10
a O 0 8.29368929089469e-09
sister O 0 1.3474235629473696e-06
. O 0 1.8979304741151282e-06

Fluorescent O 0 1.4943204860173864e-06
in O 0 5.3595623938917925e-08
situ O 0 5.801078941658488e-07
hybridization O 0 1.384828030026597e-09
analysis O 0 2.0452764482037367e-10
demonstrated O 0 4.774103889992887e-10
that O 0 1.1580771931696265e-11
the O 0 3.810700366368991e-10
PWS B-Disease 1 1.0
critical O 0 1.765223913707814e-07
region O 0 1.4672636439172493e-09
resided O 0 1.0669988625977567e-07
on O 0 6.564143006926315e-08
the O 0 2.289649803088878e-09
derivative O 0 7.34341609742728e-09
chromosome O 0 5.335162978070684e-09
3 O 0 1.2085743072987043e-08
and O 0 1.366440016692394e-10
that O 0 9.212520503398824e-12
there O 0 1.0063544615690478e-11
was O 0 5.508570266599122e-10
no O 0 6.168000554751529e-10
deletion O 0 3.018829186629546e-09
of O 0 4.186595070621024e-09
the O 0 7.354489461874891e-09
PWS B-Disease 1 1.0
region O 0 2.3480113853224793e-08
on O 0 3.1378302622897536e-08
the O 0 8.109478089046718e-10
normal O 0 9.56567980381351e-09
pair O 0 4.374645534710453e-09
of O 0 1.492377998957295e-09
15s O 0 3.582674139579467e-07
present O 0 1.6026338034436094e-09
in O 0 6.450639489230525e-08
J O 0 0.00020335696171969175
. O 0 2.206936414950178e-06

B O 0 0.0015449293423444033
. O 0 2.0050802049809135e-06

Methylation O 0 1.5227487892843783e-07
analysis O 0 9.829088654100815e-09
at O 0 1.2506162327952097e-08
exon O 0 8.274428253685073e-09
alpha O 0 4.2951597833962296e-08
of O 0 5.6638902456995766e-09
the O 0 4.371742523545663e-09
small O 0 1.2053094078368076e-09
nuclear O 0 2.135403320835394e-07
ribonucleoprotein O 0 1.0609327318888973e-06
- O 0 4.0936464529295336e-07
associated O 0 1.6488708354245318e-07
polypeptide O 0 1.4666633774140792e-07
N O 0 8.305438825573219e-08
( O 0 5.715126635830181e-11
SNRPN O 0 1.0562246899326055e-07
) O 0 4.0542319501568613e-11
gene O 0 3.5801223097209345e-10
showed O 0 2.6938971053880323e-09
a O 0 5.059646590588329e-10
pattern O 0 4.328330749370224e-10
characteristic O 0 4.014582000166911e-10
of O 0 3.65225211185205e-10
only O 0 7.30359869804964e-11
the O 0 6.120896151040611e-11
maternal O 0 3.5308183043980534e-08
chromosome O 0 6.085374870679061e-09
15 O 0 2.689401981115225e-07
in O 0 1.3741887983087508e-07
J O 0 0.00030664069345220923
. O 0 2.2089116100687534e-06

B O 0 0.0008762070210650563
. O 0 1.4278801927503082e-06

Maternal B-Disease 0 0.0005181379965506494
disomy I-Disease 0 0.00017439911607652903
was O 0 5.057393650531594e-07
confirmed O 0 1.8325575723565635e-08
by O 0 7.546097080535219e-11
polymerase O 0 4.7068100528235846e-09
chain O 0 2.2414998746000947e-09
reaction O 0 1.2854303732545702e-10
analysis O 0 1.5101531136707536e-10
of O 0 5.031401406618841e-10
microsatellite O 0 2.4312383217761635e-08
repeats O 0 9.060474148725461e-09
at O 0 2.0865408956183273e-08
the O 0 6.060887347558719e-09
gamma O 0 9.649336618622328e-08
- O 0 1.0798400040812339e-07
aminobutyric O 0 7.349597694883414e-07
acid O 0 3.5138207010732e-08
receptor O 0 7.855887496077685e-09
beta3 O 0 3.0049832844269986e-07
subunit O 0 2.0897831021216007e-08
( O 0 7.305706040128257e-10
GABRB3 O 0 2.9540954074036563e-06
) O 0 1.688732709226315e-09
locus O 0 2.2678372602058516e-07
. O 0 1.4682098026241874e-07

A O 0 1.62713295139838e-05
niece O 0 9.520287858322263e-05
( O 0 6.821929243727709e-09
B O 0 4.0378014887210156e-07
. O 0 9.825648628059014e-11
B O 0 6.214566194984172e-09
. O 0 4.030951787636905e-12
) O 0 2.284585931891514e-12
with O 0 2.304644105763365e-12
45 O 0 1.3493470785164163e-09
chromosomes O 0 3.825323391382085e-10
and O 0 1.0577937831213191e-10
the O 0 6.044629241586108e-10
derivative O 0 1.3209182636586547e-09
3 O 0 1.5476360193389382e-09
but O 0 3.465566722482549e-11
without O 0 2.485024963583271e-10
the O 0 2.2344430472553967e-10
der O 0 5.710101049771765e-07
( O 0 1.6724993612271533e-10
15 O 0 8.280933272430957e-09
) O 0 3.501841039366127e-10
demonstrated O 0 2.986507041669029e-08
a O 0 3.076386256850583e-09
phenotype O 0 1.0912063252987991e-08
consistent O 0 5.161724825342162e-09
with O 0 2.8615367454049023e-12
that O 0 2.6371066788599684e-12
reported O 0 2.3553730146841367e-11
for O 0 2.0248738449857306e-11
haploinsufficiency O 0 4.436526168660748e-08
of O 0 4.58390703172995e-09
distal O 0 1.8957143765874207e-06
3 O 0 0.007523811422288418
p O 0 0.0001320191950071603
. O 0 3.0233024972403655e-07

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 6.125250138211413e-07
with O 0 4.2913966824542626e-10
unbalanced O 0 1.3099568150209961e-06
segregation O 0 1.4464940250036307e-05
of O 0 1.9451766775091528e-07
non O 0 1.78505179064814e-05
- O 0 3.7562326724582817e-06
Robertsonian O 0 9.850909918895923e-06
translocations O 0 1.5920039686534437e-06
has O 0 6.295930443656061e-10
been O 0 1.1153026419075118e-10
reported O 0 1.0112403275863713e-10
previously O 0 2.656099784559274e-10
but O 0 3.511149010426706e-11
has O 0 1.3423685774061056e-11
not O 0 2.2497299162482776e-11
, O 0 8.699245317156379e-12
to O 0 5.28119659115589e-10
our O 0 6.04560090877726e-09
knowledge O 0 1.2446171204771872e-08
, O 0 5.576350839420208e-11
been O 0 8.399866913144649e-11
observed O 0 7.413945152245915e-11
in O 0 1.7206076841080886e-10
a O 0 2.2830126678030638e-09
case O 0 6.416315034840636e-09
of O 0 5.015347781522905e-08
PWS B-Disease 1 1.0
. O 0 1.334362241323106e-05

Furthermore O 0 2.817933818732854e-06
, O 0 1.1972836055917924e-08
our O 0 2.631032636202235e-08
findings O 0 2.8887079395190085e-09
are O 0 2.8497731952015215e-11
best O 0 8.948970453559468e-10
interpreted O 0 2.397098741724335e-09
as O 0 5.473109188081082e-10
true O 0 5.784805967579132e-09
gamete O 0 2.0301561676205893e-07
complementation O 0 4.516618332672806e-07
resulting O 0 4.190198410469748e-09
in O 0 6.105581373816449e-09
maternal B-Disease 1 0.9919636249542236
UPD I-Disease 1 1.0
15 I-Disease 0 0.0008646547212265432
and O 0 6.146975465526339e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999961853027344
- I-Disease 1 1.0
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 0 1.195028175970947e-06
2 I-Disease 0 7.45150259717775e-07
and O 0 2.3384056913045015e-09
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 2.5764690381180344e-09
a O 0 7.575476912435875e-10
case O 0 8.117380378980243e-11
for O 0 2.05009481613061e-11
" O 0 9.112949284073579e-10
lumping O 0 3.2267566396626535e-09
" O 0 6.905836613668725e-08
. O 0 1.3826836209318571e-07

Recent O 0 1.7116734696287494e-08
studies O 0 1.572619590106683e-09
demonstrated O 0 3.1438309733289316e-09
the O 0 8.94444851518017e-10
existence O 0 6.372263161580349e-09
of O 0 1.6766139587787166e-09
a O 0 1.6555706805476689e-09
genetically O 0 2.0228609898254035e-09
distinct O 0 2.481047034486039e-10
, O 0 5.380510620378587e-11
usually O 0 1.1495385372761735e-11
lethal O 0 1.1871292837639658e-10
form O 0 1.5364520419836047e-11
of O 0 3.285893779292337e-10
the O 0 4.586565349740113e-09
Schwartz B-Disease 1 0.9994144439697266
- I-Disease 1 1.0
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.602949189522974e-09
SJS B-Disease 1 0.5008981823921204
) O 0 3.938393788871508e-08
of O 0 9.117466674979369e-07
myotonia B-Disease 1 1.0
and O 0 1.5392445220641093e-06
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 9.454868887814882e-09
which O 0 2.8639091098625613e-10
we O 0 1.946609762271123e-09
called O 0 8.271619833521981e-09
SJS B-Disease 0 0.00016372832760680467
type I-Disease 0 9.932125976774842e-05
2 I-Disease 0 0.0035794826690107584
. O 0 3.676137566799298e-06

This O 0 6.377274530677823e-08
disorder O 0 1.4746545275556855e-05
is O 0 8.630234027418027e-11
reminiscent O 0 1.2914074254410934e-09
of O 0 2.330959036900282e-10
another O 0 1.0563259988938256e-10
rare O 0 5.070224795566958e-10
condition O 0 2.691813847377489e-07
, O 0 2.0920222498777008e-10
the O 0 1.0737275069061525e-08
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.120408109680284e-06
SWS B-Disease 1 1.0
) O 0 3.4388944469831983e-10
, O 0 3.6988134777260484e-11
which O 0 5.308967848671742e-11
comprises O 0 1.8384338495991415e-10
campomelia B-Disease 0 7.033182924942594e-08
at O 0 1.3040589941226699e-08
birth O 0 8.157138609021786e-07
with O 0 4.078698712106643e-09
skeletal B-Disease 1 0.9999380111694336
dysplasia I-Disease 1 0.9999980926513672
, O 0 1.5359269411874266e-08
contractures B-Disease 0 1.4027873476152308e-06
, O 0 3.0500638126262913e-10
and O 0 1.2277248662151408e-10
early B-Disease 0 3.2556073392697726e-07
death I-Disease 0 1.6407296925535775e-06
. O 0 1.9426980202297273e-07

To O 0 4.821787058517657e-08
test O 0 1.2659994164110344e-09
for O 0 1.1282384748678709e-10
possible O 0 1.23032983800897e-09
nosologic O 0 6.244546852940402e-07
identity O 0 8.072260193614511e-09
between O 0 4.3304612673544796e-10
these O 0 4.660951069546115e-10
disorders O 0 1.3968246115325655e-08
, O 0 2.87065510251594e-12
we O 0 2.0367499353746155e-11
reviewed O 0 1.2456162767904289e-09
the O 0 7.098661658488936e-10
literature O 0 1.246044045721817e-09
and O 0 4.441777501362765e-11
obtained O 0 1.592152854001938e-09
a O 0 1.5805273756441807e-10
follow O 0 2.6516047690883227e-10
- O 0 1.8821864067319893e-09
up O 0 4.541332310203927e-10
of O 0 2.3293633688581394e-10
the O 0 2.0797844002551358e-10
only O 0 6.797529900071098e-11
two O 0 6.378527480505047e-12
surviving O 0 2.1037995789896513e-09
patients O 0 6.399665242184938e-10
, O 0 1.7197439652893998e-11
one O 0 4.1190904853660726e-11
with O 0 3.8276274511028774e-11
SJS B-Disease 0 0.00011356721370248124
type I-Disease 0 0.024453947320580482
2 I-Disease 0 2.5201688913512044e-05
at O 0 5.1425750768885337e-08
age O 0 1.1477694350503498e-09
10 O 0 5.299551908422018e-10
years O 0 9.037992576566012e-11
and O 0 2.8691018311155503e-11
another O 0 3.3092156792591254e-10
with O 0 1.3966794387698656e-10
SWS B-Disease 0 3.53419927705545e-05
at O 0 5.430685678931013e-09
age O 0 3.235927747979872e-09
7 O 0 5.4402576665779634e-08
years O 0 1.1161635171674789e-08
. O 0 1.2005061478248535e-07

Patients O 0 1.9200883798475843e-06
reported O 0 1.0764582558664415e-09
as O 0 1.4184384222737378e-10
having O 0 6.058942236819576e-10
either O 0 2.8116385664134214e-08
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 1 0.9999839067459106
SWS B-Disease 1 0.999992847442627
presented O 0 1.1495007612438712e-08
a O 0 5.272420278146228e-10
combination O 0 4.778203388511315e-10
of O 0 3.9445699484552676e-10
a O 0 8.091416425770603e-10
severe O 0 7.211442998311668e-09
, O 0 1.9373633253216838e-10
prenatal O 0 9.974637941922992e-05
- O 0 5.305948798195459e-05
onset O 1 0.9999754428863525
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 2.870559345780066e-10
with O 0 7.457176542935429e-10
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 1 0.999123752117157
feeding O 1 0.9999998807907104
difficulties O 1 0.9999352693557739
, O 0 1.2814365568658559e-08
tendency O 0 3.243629009830329e-08
to O 0 1.21481008363844e-07
hyperthermia B-Disease 0 8.684048225404695e-05
, O 0 2.535860688102076e-10
and O 0 2.9860582756446874e-11
frequent O 0 1.4528873937269537e-10
death O 0 1.295774598730759e-09
in O 0 6.276590358567091e-10
infancy O 0 6.676446417941406e-08
) O 0 4.9724585560184664e-11
with O 0 9.552392730982628e-12
a O 0 2.0013692925147097e-09
distinct O 0 1.1856912784935503e-08
campomelic B-Disease 1 0.7089890241622925
- I-Disease 1 0.8408809900283813
metaphyseal I-Disease 1 0.9943125247955322
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0002591594820842147

The O 0 2.39604929674897e-07
similarity O 0 1.0998595456612748e-07
of O 0 6.37836947703363e-08
the O 0 2.0728439409367638e-08
clinical O 0 4.6049230206790526e-08
and O 0 8.096541770363785e-10
radiographic O 0 1.7820619859776343e-06
findings O 0 3.8679541347619306e-08
is O 0 4.880900128512167e-10
so O 0 4.1018910490464577e-10
extensive O 0 1.0555456064764712e-08
that O 0 1.8684716274197655e-10
these O 0 3.980150653504211e-10
disorders O 0 3.5998994896146996e-09
appear O 0 4.00498384456327e-10
to O 0 7.097957777091324e-10
be O 0 5.712296191617838e-10
a O 0 1.69288660867295e-09
single O 0 4.58574334061268e-09
entity O 0 1.9363346481782173e-08
. O 0 5.779206162515038e-07

The O 0 2.6902662852990034e-07
follow O 0 5.747602571659627e-08
- O 0 1.1574742586617504e-07
up O 0 5.706614292222412e-09
observation O 0 5.397374707172276e-07
of O 0 2.0299337766260805e-09
an O 0 4.699745453917714e-11
identical O 0 6.371627114809542e-10
and O 0 1.4431546235815773e-10
unique O 0 2.089870854149467e-08
pattern O 0 1.0138992934116686e-07
of O 0 8.407877771787753e-08
progressive O 0 0.000777845794800669
bone B-Disease 1 0.9844433069229126
dysplasia I-Disease 0 0.00023330104886554182
in O 0 6.370089522533817e-08
the O 0 6.909473171390346e-08
two O 0 5.481278764207786e-10
patients O 0 4.856412494369522e-10
( O 0 2.7534565339576433e-12
one O 0 3.51001068488177e-11
with O 0 1.9720421476354666e-11
SJS B-Disease 0 7.279462806764059e-06
type I-Disease 0 2.0110581317567267e-05
2 I-Disease 0 1.2283498108445201e-05
, O 0 1.2084008238488764e-09
one O 0 6.537348440360802e-10
with O 0 2.7686050674269325e-10
SWS B-Disease 0 3.954562998842448e-05
) O 0 2.968863488383988e-10
surviving O 0 8.17190368707088e-08
beyond O 0 1.7329182355751982e-07
infancy O 0 7.832399546714441e-07
adds O 0 1.816144212796189e-08
to O 0 1.5615365667187575e-09
the O 0 6.441338018525755e-10
evidence O 0 5.40438527263376e-10
in O 0 1.1067540633957762e-10
favor O 0 3.491472222449943e-09
of O 0 1.1707442792996403e-09
identity O 0 2.6896884719462832e-08
. O 0 8.29448367767327e-08

The O 0 1.1445190466474742e-06
hypothesis O 0 5.835998422298871e-07
that O 0 4.527911379170746e-09
SWS B-Disease 0 0.00018541055032983422
and O 0 8.556290786998488e-09
SJS B-Disease 0 0.00014963837747927755
type I-Disease 0 9.856190445134416e-06
2 I-Disease 0 3.4659005905268714e-06
are O 0 1.556900053323318e-09
the O 0 3.0169642339927805e-09
same O 0 8.297787346123187e-09
disorder O 0 7.847833671803528e-08
should O 0 3.6446112794408236e-10
be O 0 1.1801666588429072e-10
testable O 0 6.26096341438398e-10
by O 0 1.4043022820986462e-11
molecular O 0 3.7784789186368073e-10
methods O 0 2.0852281679140106e-08
. O 0 5.592887930561119e-09
. O 0 1.290440962975481e-07

A O 0 2.2255844669416547e-06
mouse O 0 7.739054552757807e-08
model O 0 2.1451961984553236e-08
of O 0 7.902128729142532e-09
severe O 0 0.003803460393100977
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.00011341030767653137
defects O 0 0.0006171232671476901
in O 0 5.656314101543103e-07
hemostasis O 0 0.08082069456577301
and O 0 1.6513179446064896e-07
thrombosis B-Disease 0 2.9315255233086646e-05
. O 0 4.065431937760877e-07

von B-Disease 0 0.36000481247901917
Willebrand I-Disease 0 0.007557091303169727
factor I-Disease 0 2.3352535208687186e-05
( I-Disease 0 1.3484580563272175e-07
vWf I-Disease 0 0.00422010850161314
) I-Disease 0 2.589166342659155e-06
deficiency I-Disease 1 1.0
causes O 1 0.9999951124191284
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.816310465335846
humans O 0 9.893547030515037e-07
. O 0 3.992425945398281e-08

We O 0 7.953070735311485e-07
generated O 0 4.799460828763813e-09
a O 0 3.6559200111696555e-09
mouse O 0 1.7247725025981708e-08
model O 0 8.636928505723063e-09
for O 0 1.0013295748123596e-09
this O 0 8.733034850827437e-10
disease O 0 1.3176169044726294e-09
by O 0 1.4120267455286495e-11
using O 0 4.804843745098708e-10
gene O 0 9.55123646839695e-10
targeting O 0 6.806958907645821e-08
. O 0 3.052418549032154e-07

vWf B-Disease 0 0.002457158640027046
- I-Disease 1 0.9918215870857239
deficient I-Disease 0 0.0007810649694874883
mice O 0 1.6585872799623758e-05
appeared O 0 1.3113975683154422e-07
normal O 0 7.814047364718135e-08
at O 0 3.788699576290355e-09
birth O 0 6.098644700358591e-09
; O 0 1.6447553041754048e-10
they O 0 3.1006669454214375e-10
were O 0 4.532816899605052e-10
viable O 0 6.034566268908748e-08
and O 0 4.484079774158545e-09
fertile O 0 2.4177966224669944e-06
. O 0 4.5061207742946863e-07

Neither O 0 1.2397217687976081e-05
vWf O 0 0.0002194179833168164
nor O 0 7.228852336993441e-05
vWf O 0 0.00042651797411963344
propolypeptide O 0 0.0004995307535864413
( O 0 7.364023701939004e-08
von B-Disease 0 0.0008571578655391932
Willebrand I-Disease 0 0.0008446283172816038
antigen O 0 3.826944066531723e-06
II O 1 0.999990701675415
) O 0 5.618637644033697e-08
were O 0 1.9088542302370115e-08
detectable O 0 1.3276762445002532e-07
in O 0 4.870800429657152e-10
plasma O 0 7.355668074637833e-09
, O 0 2.430591561353168e-10
platelets O 0 6.907586058702009e-09
, O 0 7.350811626061216e-10
or O 0 1.0000373862339984e-09
endothelial O 0 1.3266506115883203e-08
cells O 0 1.6305198968780132e-08
of O 0 4.9349719866143005e-09
the O 0 7.419144409936962e-09
homozygous O 0 1.285834230202454e-07
mutant O 0 3.678795792438905e-07
mice O 0 8.195190162041399e-07
. O 0 3.716172898293735e-07

The O 0 4.3672048377629835e-06
mutant O 0 4.036111931782216e-05
mice O 0 7.599602668051375e-06
exhibited O 0 6.817664939262613e-07
defects O 0 4.234172592987306e-06
in O 0 2.3880550870103434e-08
hemostasis O 0 2.0267063973733457e-06
with O 0 1.9294792152901863e-10
a O 0 9.604731232570884e-09
highly O 0 1.8676045954180154e-07
prolonged O 0 4.9049092922359705e-05
bleeding O 0 8.64407468270656e-07
time O 0 1.3985072655486874e-07
and O 0 7.297256132687835e-09
spontaneous O 0 4.359587535418541e-08
bleeding O 0 5.291870408541399e-08
events O 0 3.432164830119433e-10
in O 0 9.445989823664291e-11
approximately O 0 6.4455350778924725e-12
10 O 0 4.162419853237509e-10
% O 0 3.2901961710685157e-10
of O 0 1.6491665810747236e-09
neonates O 0 3.966831627622014e-07
. O 0 2.582429203812353e-07

As O 0 1.7315262113015706e-08
in O 0 2.07408090702188e-09
the O 0 8.554164043772516e-10
human O 0 1.8246384958509054e-10
disease O 0 3.573055185057683e-10
, O 0 1.0822627516393624e-11
the O 0 3.066074893975923e-10
factor O 0 1.2095129342526434e-08
VIII O 0 0.0019067887915298343
level O 1 0.7792156338691711
in O 0 6.031471144751777e-08
these O 0 1.0149689089189451e-08
mice O 0 5.767787314425732e-08
was O 0 3.914875090771375e-09
reduced O 0 3.939301329580758e-09
strongly O 0 8.27379331713729e-10
as O 0 1.8714105265438263e-10
a O 0 2.866368531417862e-10
result O 0 2.9027075187926243e-10
of O 0 5.718706064250512e-10
the O 0 1.1900543883669457e-09
lack O 0 1.2128950288570195e-08
of O 0 4.1760098157261893e-10
protection O 0 2.4955282285077374e-09
provided O 0 7.353854192260201e-10
by O 0 1.3691582589903106e-10
vWf O 0 3.4278582461411133e-06
. O 0 9.396045470566605e-07

Defective O 0 0.0059921955689787865
thrombosis B-Disease 0 0.004231066908687353
in O 0 1.8506690935282677e-07
mutant O 0 6.537641752402124e-07
mice O 0 9.419250091013964e-08
was O 0 4.2366403718574475e-09
also O 0 1.3575607304971982e-10
evident O 0 5.806680136721809e-10
in O 0 3.6217709387109664e-10
an O 0 7.090606574111646e-11
in O 0 2.8798055606849005e-10
vivo O 0 2.659316749031859e-07
model O 0 1.6324095497566304e-07
of O 0 1.7008986219479993e-07
vascular B-Disease 1 0.9999977350234985
injury I-Disease 1 0.9999948740005493
. O 0 1.8105846493199351e-06

In O 0 1.3649149366301572e-08
this O 0 1.591350523577617e-10
model O 0 2.168338619767951e-09
, O 0 2.1606956501774022e-10
the O 0 1.706759511499456e-09
exteriorized O 0 7.426056072290521e-07
mesentery O 0 3.212093815818662e-06
was O 0 6.878519798192428e-08
superfused O 0 3.651239239843562e-07
with O 0 8.08555389308907e-10
ferric O 0 1.1816288861155044e-05
chloride O 0 6.930082236067392e-06
and O 0 3.3355235018461826e-08
the O 0 1.7576277855368971e-07
accumulation O 0 3.5106704672216438e-06
of O 0 1.030207741337108e-07
fluorescently O 0 3.873487912642304e-06
labeled O 0 6.040047395572401e-08
platelets O 0 2.848343072514581e-08
was O 0 1.5754725524175228e-08
observed O 0 5.66239943822211e-09
by O 0 5.944540415470101e-10
intravital O 0 2.4260700683953473e-06
microscopy O 0 4.294993686926318e-06
. O 0 7.700924129494524e-07

We O 0 7.750929853500566e-07
conclude O 0 9.911452707456192e-07
that O 0 1.00321639884271e-09
these O 0 5.875351871686973e-10
mice O 0 3.8487026898792465e-08
very O 0 1.7903685201048347e-09
closely O 0 5.2741757627927655e-08
mimic O 1 0.9118186831474304
severe O 1 0.9998041987419128
human O 0 0.01912304386496544
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.1692138741636882e-06
will O 0 3.07010985522993e-08
be O 0 2.789671604830346e-09
very O 0 1.5862866575844237e-10
useful O 0 1.3099390461235316e-09
for O 0 6.907790311982964e-11
investigating O 0 1.5801776553914237e-10
the O 0 8.452409328008059e-10
role O 0 2.7395850921152487e-08
of O 0 2.8446510924595714e-08
vWf O 0 1.1536034207892953e-06
in O 0 2.1524792614968646e-08
normal O 0 1.0414825055704569e-06
physiology O 0 8.673364391142968e-07
and O 0 9.48453870996957e-10
in O 0 7.63538732240221e-10
disease O 0 4.230904515623024e-10
models O 0 4.1872957878830164e-10
. O 0 6.123935247792645e-10
. O 0 4.739152714705597e-08

Oral O 0 2.2301921489997767e-05
contraceptives O 0 1.5101067219802644e-05
and O 0 3.634503809024636e-10
the O 0 3.2069262800860088e-09
risk O 0 5.823234232593677e-07
of O 0 1.2198817785247229e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003659226349554956

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 0 3.5926066630054265e-05
Study O 0 4.4678611033077686e-08
Group O 0 3.5617344629201853e-09
. O 0 2.1812027739542827e-08

BACKGROUND O 0 4.274901129974751e-06
Women O 0 2.285976741234208e-08
with O 0 9.34867634694303e-12
mutations O 0 2.3308910357400237e-11
in O 0 1.6400375502101383e-10
either O 0 3.408602289312057e-09
the O 0 3.2436037855632094e-08
BRCA1 O 0 9.853137328263983e-08
or O 0 2.5490921373716446e-08
the O 0 3.559902239658186e-08
BRCA2 O 0 2.8159535148120085e-08
gene O 0 5.576311079558138e-10
have O 0 4.025930699924629e-10
a O 0 2.69229333271781e-10
high O 0 9.299743197743737e-10
lifetime O 0 4.6569923028982885e-08
risk O 0 4.034060054891597e-07
of O 0 1.6687590687070042e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0008800278883427382

Oral O 0 9.01219536899589e-05
contraceptives O 1 0.999705970287323
protect O 0 1.0707338333304506e-05
against O 0 0.3647356629371643
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 0.004124589264392853
general O 0 6.327332471300906e-07
, O 0 4.956118293542033e-10
but O 0 1.1730123816722227e-10
it O 0 3.45226625064754e-11
is O 0 3.775096554803348e-12
not O 0 2.219617371845839e-11
known O 0 6.691812381998119e-11
whether O 0 1.2615661293402525e-10
they O 0 4.752481186365287e-10
also O 0 2.1328332433512287e-09
protect O 0 2.0602191952434623e-08
against O 0 1.0666608041276504e-08
hereditary B-Disease 0 0.017196426168084145
forms I-Disease 0 0.0003573736175894737
of I-Disease 1 0.9982420206069946
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3979213690618053e-05

METHODS O 0 1.4610444054596883e-07
We O 0 8.861902323076265e-10
enrolled O 0 2.1817425643888555e-09
207 O 0 1.2047951969407222e-08
women O 0 5.341526776447836e-09
with O 0 6.263713547838279e-09
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.001919074956504e-09
161 O 0 3.8409782021631145e-09
of O 0 1.8081208752462885e-09
their O 0 9.603486006426465e-09
sisters O 0 6.946485342496089e-08
as O 0 7.106332411410676e-09
controls O 0 5.432936589500059e-08
in O 0 2.0429302693969476e-09
a O 0 6.616721393015723e-09
case O 0 4.978138345990146e-09
- O 0 8.786140170968793e-08
control O 0 2.904802158809616e-07
study O 0 5.736595909411335e-08
. O 0 5.172213590753927e-08

All O 0 1.9648238946956553e-07
the O 0 8.433024945020406e-09
patients O 0 1.8528572010012567e-09
carried O 0 5.358852250836321e-10
a O 0 1.578478736607991e-10
pathogenic O 0 4.778650253278727e-10
mutation O 0 2.34167157886489e-10
in O 0 8.770460468987551e-10
either O 0 1.1200448568615684e-08
BRCA1 O 0 1.9719285759833838e-08
( O 0 4.823591873148736e-11
179 O 0 6.79598155528538e-09
women O 0 5.585998330559505e-10
) O 0 6.433857613341587e-11
or O 0 1.4708388951234497e-09
BRCA2 O 0 2.0101925457538528e-08
( O 0 4.819067367378693e-11
28 O 0 3.0793934513440036e-08
women O 0 4.485123383801692e-09
) O 0 1.6423423732092601e-09
. O 0 5.6441582074739927e-08

The O 0 5.666183824359905e-07
control O 0 6.376350256687147e-07
women O 0 2.216015371203639e-09
were O 0 3.982829344106875e-11
enrolled O 0 2.6908969497085877e-10
regardless O 0 1.529243842668393e-09
of O 0 9.289674030021899e-10
whether O 0 2.3745497235161395e-10
or O 0 9.13416176029358e-10
not O 0 1.873200705659883e-09
they O 0 5.702346372871148e-10
had O 0 2.9831010994740836e-09
either O 0 6.38357633420128e-09
mutation O 0 2.4434555712105066e-08
. O 0 2.2476238825674955e-07

Lifetime O 0 1.6328872334270272e-06
histories O 0 6.847769782325486e-07
of O 0 4.2262712440788164e-08
oral O 0 2.0806176053156378e-06
- O 0 3.87971738291526e-07
contraceptive O 0 5.748073590439162e-07
use O 0 7.024743564620906e-10
were O 0 5.507369907342685e-11
obtained O 0 3.342793541971645e-10
by O 0 2.355274135446006e-11
interview O 0 5.15006171042387e-09
or O 0 1.341882854832832e-10
by O 0 4.3900859510170864e-12
written O 0 2.6031553648775407e-11
questionnaire O 0 1.4144952570349645e-12
and O 0 9.420089491438133e-13
were O 0 1.2674285232439075e-11
compared O 0 1.699180032788128e-11
between O 0 2.124198820313561e-12
patients O 0 6.514715850114428e-11
and O 0 5.496851671754621e-12
control O 0 5.486532117515708e-09
women O 0 7.455726036553756e-10
, O 0 3.554509811487527e-11
after O 0 1.0506856495950956e-10
adjustment O 0 1.7103932714590542e-09
for O 0 1.0035527270302325e-10
year O 0 7.176175764733728e-10
of O 0 3.725408870280944e-10
birth O 0 1.2263053683625458e-08
and O 0 1.3772103457654339e-09
parity O 0 1.983474930966622e-06
. O 0 1.4066962705783226e-07

RESULTS O 0 6.693110776723188e-07
The O 0 2.241060848007237e-08
adjusted O 0 1.920182057801867e-07
odds O 0 1.0864363986229364e-07
ratio O 0 8.228780075114628e-07
for O 0 2.504896428945358e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.4340020015879418e-06
with O 0 2.0157038538304306e-10
any O 0 2.264166187870842e-09
past O 0 1.8665917700388945e-09
use O 0 5.155900151265769e-09
of O 0 8.187372446677443e-10
oral O 0 1.880034439238898e-08
contraceptives O 0 2.4992789349198574e-07
was O 0 8.892197200793817e-09
0 O 0 1.915149283604478e-07
. O 0 1.8057822614991892e-07

5 O 0 2.0856703031313373e-07
( O 0 5.654819945632994e-10
95 O 0 3.908342307568091e-07
percent O 0 4.098540173913534e-08
confidence O 0 1.4204595721878377e-08
interval O 0 9.389662380954178e-10
, O 0 5.407733635887091e-11
0 O 0 2.347274596914417e-10
. O 0 1.1149915192520954e-11
3 O 0 2.05012729015408e-10
to O 0 3.020895478211827e-10
0 O 0 4.061656844189798e-10
. O 0 3.803778125810453e-11
8 O 0 4.655595464697626e-09
) O 0 2.0256716304345446e-09
. O 0 5.815642012407807e-08

The O 0 2.499345725937019e-07
risk O 0 6.634277127659516e-08
decreased O 0 6.175855382650752e-09
with O 0 1.8123374979570062e-12
increasing O 0 1.1364543334169142e-10
duration O 0 6.4674532396225e-09
of O 0 9.986986931886932e-11
use O 0 1.7344475855551877e-09
( O 0 2.853560443494274e-10
P O 0 6.577251809858353e-08
for O 0 3.382893964953837e-10
trend O 0 3.383999080952549e-09
, O 0 1.8358434564214043e-11
< O 0 5.3282169787394196e-09
0 O 0 1.1585908898936736e-09
. O 0 4.516409468635629e-11
001 O 0 5.312883466501717e-09
) O 0 3.2487983657458752e-12
; O 0 9.755126394173086e-13
use O 0 9.923679933354634e-11
for O 0 3.091724445902777e-11
six O 0 4.1633228115012244e-11
or O 0 1.7408421926212725e-11
more O 0 1.4326818811166708e-12
years O 0 1.811294690623466e-11
was O 0 1.0979695624913077e-10
associated O 0 1.281034445188567e-10
with O 0 4.6624132506167815e-12
a O 0 7.05126901312525e-10
60 O 0 5.792170743035285e-09
percent O 0 1.7609538827123572e-10
reduction O 0 6.143613950904125e-10
in O 0 2.1435346830855906e-09
risk O 0 9.978261061860394e-08
. O 0 2.819033682044392e-07

Oral O 0 0.00048079583211801946
- O 0 1.5253973288054112e-05
contraceptive O 0 1.9281995264464058e-05
use O 0 1.1800648991311391e-07
protected O 0 0.13559973239898682
against O 1 0.7211650609970093
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.0210386314213338e-08
for O 0 3.275381632583674e-10
carriers O 0 1.9103310600065981e-10
of O 0 1.2729487464113731e-09
the O 0 2.0048355864332734e-08
BRCA1 O 0 9.057523442379534e-08
mutation O 0 3.007052662429288e-10
( O 0 1.7768845422816426e-11
odds O 0 6.029594157297424e-09
ratio O 0 6.868798863024494e-10
, O 0 1.088083009109786e-11
0 O 0 8.896412079240079e-11
. O 0 2.8369726273042017e-12
5 O 0 2.6225214708186506e-11
; O 0 3.6639706026131424e-12
95 O 0 1.287419149065272e-08
percent O 0 1.3225518458170882e-09
confidence O 0 2.1595019106257496e-09
interval O 0 1.8386898947841956e-10
, O 0 1.3627484557465763e-11
0 O 0 1.0995015314874124e-10
. O 0 4.9871018772962294e-12
3 O 0 1.575651137342149e-10
to O 0 2.002299992476253e-10
0 O 0 2.560985590260856e-10
. O 0 2.0580755849541887e-11
9 O 0 1.1674039512854506e-09
) O 0 2.178438679445449e-11
and O 0 1.096884649082197e-11
for O 0 1.6762029264594247e-11
carriers O 0 2.2191018467232482e-10
of O 0 9.696392577751567e-10
the O 0 2.182155611762937e-08
BRCA2 O 0 2.400022367510246e-06
mutation O 0 1.0109419967818667e-09
( O 0 3.473978396617561e-11
odds O 0 1.1021312751324785e-08
ratio O 0 1.307051467058784e-09
, O 0 2.6113108203551505e-11
0 O 0 1.2087021661333353e-10
. O 0 4.3222383137864195e-12
4 O 0 8.146541080611414e-11
; O 0 1.6188349272194813e-11
95 O 0 4.7083567267236504e-08
percent O 0 5.99208149765218e-09
confidence O 0 6.191518853171374e-09
interval O 0 3.3720262693215375e-10
, O 0 1.862556983645014e-11
0 O 0 1.376028041510935e-10
. O 0 6.404811576932179e-12
2 O 0 1.062274226915072e-10
to O 0 7.011434488557455e-11
1 O 0 4.74097427982656e-10
. O 0 1.162534998822018e-10
1 O 0 8.15984524393798e-09
) O 0 2.567839496592228e-09
. O 0 6.897266757732723e-08

CONCLUSIONS O 0 8.66355185280554e-05
Oral O 0 0.0002662076731212437
- O 0 3.51365156348038e-06
contraceptive O 0 1.5358001519416575e-06
use O 0 1.090685541882408e-09
may O 0 1.3772306906023601e-10
reduce O 0 6.283286668740118e-10
the O 0 4.421324695247364e-10
risk O 0 1.0027466146311781e-07
of O 0 7.132039172574878e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 9.65462021440544e-08
women O 0 2.19193241335347e-09
with O 0 6.2915788030804e-12
pathogenic O 0 4.399092201623489e-10
mutations O 0 2.886283156922076e-10
in O 0 9.054599736657565e-09
the O 0 2.4279927401948953e-07
BRCA1 O 0 5.820591013616649e-07
or O 0 8.755723683862016e-07
BRCA2 O 0 2.113218215527013e-05
gene O 0 6.506673344119918e-06

A O 0 6.875069402667577e-07
Japanese O 0 1.4309323432826204e-06
family O 0 2.055963932434679e-08
with O 0 5.326944441108594e-10
adrenoleukodystrophy B-Disease 1 1.0
with O 0 5.872360375747121e-10
a O 0 4.929177510604177e-09
codon O 0 8.010636065591825e-08
291 O 0 2.1362419388992748e-08
deletion O 0 1.6353949661152e-07
: O 0 3.764166311981398e-09
a O 0 3.4092786371786588e-09
clinical O 0 4.435020173332305e-08
, O 0 6.686457498794596e-10
biochemical O 0 9.020163815876003e-08
, O 0 3.057841757581059e-09
pathological O 0 3.638069472344796e-07
, O 0 1.4136181114565716e-09
and O 0 5.869258412616318e-10
genetic O 0 1.2290168882600483e-08
report O 0 3.30306448859119e-08
. O 0 2.673302219591278e-07

We O 0 9.499737529949925e-08
report O 0 3.0987528099046813e-09
a O 0 7.646521749116175e-10
Japanese O 0 1.3220234507116402e-07
family O 0 1.3797350817412735e-08
with O 0 2.5468795961103297e-09
adrenoleukodystrophy B-Disease 1 1.0
( O 0 6.322362366972811e-08
ALD B-Disease 1 1.0
) O 0 1.099381974345448e-10
with O 0 9.191669127217583e-12
a O 0 4.004929998746576e-10
three O 0 5.232245539610325e-11
base O 0 6.21560936053811e-09
pair O 0 5.685569792746037e-09
deletion O 0 4.229115724285748e-09
( O 0 7.095057180661613e-11
delGAG O 0 2.3538316185067742e-08
291 O 0 1.336945332219841e-09
) O 0 2.5318528523721184e-11
in O 0 1.0842184927639664e-09
the O 0 1.1854316994686087e-07
ALD B-Disease 1 1.0
gene O 0 1.1212395065740566e-06
. O 0 1.3494321819962352e-06

A O 0 1.2084415175195318e-06
variety O 0 4.748372361973452e-08
of O 0 9.77854419659252e-09
phenotypes O 0 1.536009008873407e-08
were O 0 9.206557183283337e-10
observed O 0 3.7954744902535253e-10
within O 0 1.3831273626419005e-10
this O 0 2.1936168159708558e-10
family O 0 5.218208087853782e-09
. O 0 5.766863253597876e-08

While O 0 1.3910344875966985e-07
the O 0 4.6492178995549693e-08
proband O 0 6.054412551748101e-06
( O 0 4.90930240903964e-10
patient O 0 5.983837780831891e-08
1 O 0 8.955329633408837e-08
) O 0 8.670430484691849e-10
was O 0 6.2204246198405144e-09
classified O 0 6.676902586377764e-09
as O 0 8.699585496430018e-10
having O 0 1.5644491258015591e-09
a O 0 3.720807550955385e-10
rare O 0 6.488664605619476e-10
intermediate O 0 2.16811946174289e-09
type O 0 1.354933854003093e-08
of O 0 4.27901625243976e-09
adult O 0 4.3362555857129337e-07
cerebral O 0 3.9505377458226576e-07
and O 0 7.066351948026295e-09
cerebello O 1 0.9494113922119141
- O 0 0.4950845539569855
brain O 0 0.2195657342672348
stem O 0 1.4989720398261852e-07
forms O 0 3.2649902226289385e-10
, O 0 1.2320005259025546e-11
his O 0 2.824288025671251e-10
younger O 0 2.6692954513407585e-09
brother O 0 4.387867846844529e-08
( O 0 1.1034448355040638e-10
patient O 0 8.536484408239176e-09
2 O 0 5.2911408587874575e-09
) O 0 8.412806562496655e-11
and O 0 6.20208162604996e-10
nephew O 0 0.0001423020730726421
( O 0 1.4825218830338827e-09
patient O 0 1.0557972700553364e-06
3 O 0 1.3870258896986343e-07
) O 0 8.811775198402927e-10
had O 0 2.28472121222012e-08
a O 0 2.3476889765561282e-08
childhood O 0 1.596872061782051e-05
ALD B-Disease 1 1.0
type O 0 6.0988779296167195e-05
. O 0 3.6980334243708057e-06

Another O 0 1.1007342664015596e-06
nephew O 0 4.826373697142117e-05
( O 0 2.136285592868603e-09
patient O 0 4.915538625027693e-07
4 O 0 1.2675447180754418e-07
) O 0 3.3198999105366056e-10
of O 0 1.4960258587493058e-09
patient O 0 2.539164825066109e-07
1 O 0 4.834458877667203e-07
was O 0 4.471680625783847e-08
classified O 0 1.661880055792153e-08
as O 0 2.9550240032705233e-09
having O 0 8.091173953062025e-09
an O 0 3.656057678824709e-10
adolescent O 0 2.733275117350331e-08
form O 0 7.932522416709276e-10
. O 0 2.5209615728272183e-08

The O 0 1.221187204691887e-07
tau O 0 4.806407005730762e-08
level O 0 3.3241740027278865e-08
in O 0 2.5764443911668877e-09
the O 0 8.936066819842381e-08
cerebrospinal O 0 1.034655451803701e-05
fluid O 0 2.3320558284467552e-07
( O 0 1.3419397815184197e-09
CSF O 0 4.4319594394437445e-07
) O 0 1.0902585778627127e-10
in O 0 7.53294315813946e-10
patient O 0 3.4716194363682007e-07
1 O 0 1.4578000673282077e-07
was O 0 1.36735911482333e-08
as O 0 4.3444428610150965e-10
high O 0 9.922550558982834e-10
as O 0 1.216691469796416e-10
that O 0 9.194667596745809e-12
of O 0 2.987397135223446e-11
patients O 0 4.5274772819681175e-10
with O 0 1.9201062961826665e-10
Alzheimers B-Disease 1 1.0
disease I-Disease 0 1.2259497452760115e-06
( O 0 3.798282868783254e-11
AD B-Disease 0 8.915839089240762e-07
) O 0 6.607704161609718e-09
. O 0 2.186760355016304e-07

His O 0 1.461510964873014e-05
brain O 0 3.786071465583518e-05
magnetic O 0 6.469268782893778e-07
resonance O 0 1.9828856068215828e-07
image O 0 1.022684017470965e-07
( O 0 1.8490162734252635e-09
MRI O 0 4.194892608211376e-05
) O 0 1.3855896874304108e-08
showed O 0 5.2239371939322155e-08
abnormalities B-Disease 0 1.4635001832630223e-07
in I-Disease 0 5.915847811621688e-09
the I-Disease 0 2.67664841402393e-08
bilateral I-Disease 0 0.0009605609811842442
cerebellar I-Disease 1 0.6876586675643921
hemispheres I-Disease 0 8.322314533870667e-05
and O 0 1.85437851740744e-08
brain O 0 1.9837511899822857e-06
stem O 0 3.210257304431252e-08
, O 0 1.0549241168111845e-11
but O 0 2.0965978519277284e-12
not O 0 1.4260577094193927e-11
in O 0 1.641214247838363e-10
the O 0 2.247514840902909e-09
cerebral O 0 8.06372284500867e-08
white O 0 2.285103661847643e-09
matter O 0 1.8408664592683976e-09
, O 0 3.5718129842710056e-11
where O 0 4.928326149955531e-11
marked O 0 1.370867447336721e-10
reductions O 0 6.575304745126687e-09
of O 0 5.432405192351553e-09
the O 0 1.54866448554003e-08
cerebral O 0 1.3409943733222462e-07
blood O 0 1.2188109188571161e-08
flow O 0 1.953647910113432e-08
and O 0 1.1552149237203935e-09
oxygen O 0 2.150952660429084e-08
metabolism O 0 7.59386775683879e-09
were O 0 1.5321429680525966e-09
clearly O 0 2.3485386968502553e-09
demonstrated O 0 9.098291564590966e-10
by O 0 1.0125258270710091e-10
positron O 0 3.082978494717281e-08
emission O 0 6.922730477754158e-08
tomography O 0 1.4620677575294394e-06
( O 0 5.042951833900133e-09
PET O 0 3.752283873836859e-06
) O 0 2.076812277707063e-09
. O 0 6.327791624016754e-08

In O 0 1.69145426553996e-08
patients O 0 2.9344333629666153e-09
2 O 0 1.4120712377163613e-09
and O 0 3.574771034742241e-11
3 O 0 1.2466769838681557e-08
, O 0 2.1935289695740323e-10
the O 0 1.1667606880649828e-09
autopsy O 0 4.581374568601859e-08
findings O 0 2.1728149945943187e-08
showed O 0 3.036976536918701e-08
massive O 0 6.13031048146695e-08
demyelination B-Disease 1 1.0
of I-Disease 0 5.317255613590532e-07
the I-Disease 0 1.3061479364750994e-07
cerebral I-Disease 0 1.6637440012345905e-06
white I-Disease 0 1.0338976341728312e-09
matter I-Disease 0 1.402370441994094e-10
with O 0 7.838210332525297e-13
sparing O 0 4.660304586678876e-09
of O 0 3.171283680103443e-08
the O 0 4.0381519283982925e-07
U O 0 0.0012096697464585304
- O 0 7.295162049558712e-06
fibers O 0 4.255187846524677e-08
, O 0 5.785123491364175e-10
compatible O 0 1.177539914465342e-07
with O 0 5.364115401862435e-11
the O 0 8.05810707049659e-09
findings O 0 2.2732242754841536e-08
of O 0 3.738816545251211e-08
childhood O 0 0.4076020419597626
ALD B-Disease 1 1.0
. O 0 1.3856202713213861e-05

Oleic O 0 0.0014797032345086336
and O 0 7.407502948808542e-07
erucic O 0 0.017634904012084007
acids O 0 3.0837809390504844e-06
( O 0 2.420710298878248e-09
Lorenzos O 0 2.203172698500566e-06
Oil O 0 1.216556171357297e-07
) O 0 7.632500187426672e-11
were O 0 6.031807692208346e-11
administered O 0 7.887498987280139e-11
to O 0 1.032943175438561e-10
patients O 0 1.3157175349221006e-10
1 O 0 1.1189722481930175e-09
and O 0 3.1789776366863975e-10
4 O 0 1.9689670338607357e-08
, O 0 1.1552318823770946e-10
but O 0 1.6856996701286597e-11
sufficient O 0 6.536052254979552e-10
effectiveness O 0 2.5987922924741724e-09
was O 0 1.7884947967061748e-09
not O 0 1.0000716921254593e-09
obtained O 0 3.3169474278338384e-08
. O 0 2.1099573643823533e-07

The O 0 3.7393306229205336e-07
findings O 0 2.5508528622708582e-08
in O 0 1.1153584722478627e-09
this O 0 7.481367192418986e-10
family O 0 1.0657592586227338e-09
suggest O 0 1.1823708678804223e-09
that O 0 5.9570421512278315e-12
delGAG291 O 0 1.1861475135432897e-09
is O 0 4.043164240907782e-12
part O 0 4.080383600446602e-11
of O 0 1.1470405736346834e-09
the O 0 3.816405413914481e-09
cause O 0 5.086295828959919e-09
of O 0 8.08790190376385e-09
Japanese O 0 4.228285888530081e-06
ALD B-Disease 1 1.0
with O 0 1.2750894784474553e-09
phenotypic O 0 1.1512653230738579e-07
variations O 0 1.9260141925769858e-07
. O 0 6.23104256192164e-07

Moreover O 0 1.635781927689095e-07
, O 0 2.554628453221852e-10
although O 0 2.445961766461835e-10
the O 0 7.86448545175844e-11
scale O 0 3.473173526558071e-09
of O 0 1.5318887269799575e-09
the O 0 4.962209532166639e-10
study O 0 1.5450839219166568e-10
is O 0 2.9507164940600905e-12
limited O 0 2.4923493824324794e-10
, O 0 3.723510388908835e-11
there O 0 5.807497191478994e-11
is O 0 7.108440225334078e-11
a O 0 1.2932684922972726e-09
possibility O 0 9.564038450093904e-09
that O 0 1.2319499864688055e-09
PET O 0 3.892966560670175e-06
can O 0 7.954712089031091e-08
detect O 0 6.841464141871256e-07
an O 0 1.0989721133114472e-08
insidious B-Disease 0 3.200554783688858e-05
lesion I-Disease 1 0.9999560117721558
which O 0 1.1828406698555227e-08
is O 0 7.106230881515074e-11
undetectable O 0 2.789671604830346e-09
by O 0 6.054846728165142e-12
computed O 0 3.109368318376937e-09
tomogram O 0 3.828239982794912e-07
( O 0 3.7811465070092254e-10
CT O 0 8.629415970062837e-05
) O 0 1.2712065844411313e-09
or O 0 3.057999187205951e-09
MRI O 0 1.3358545629671426e-06
analysis O 0 2.064683091163033e-09
, O 0 1.6572751851406942e-11
and O 0 1.7189592848090851e-12
that O 0 6.140956883629589e-13
the O 0 1.0426935356799838e-11
higher O 0 9.590338523324249e-10
level O 0 4.136857079117817e-09
of O 0 3.2004840444521676e-10
tau O 0 1.9323085354017167e-09
reflects O 0 5.863193819344303e-10
the O 0 1.282481759679044e-10
process O 0 4.4937864540628425e-10
of O 0 1.3591573422289116e-09
neuronal B-Disease 0 1.989706106542144e-06
degeneration I-Disease 0 0.03760727494955063
in O 0 1.4719853425049223e-07
ALD B-Disease 1 1.0
. O 0 1.825847107284062e-06

Lorenzos O 0 4.435946902958676e-05
Oil O 0 1.0679273287905744e-07
should O 0 2.7433944005395006e-10
be O 0 1.2117808492750903e-11
given O 0 1.3783493443830785e-11
in O 0 1.878003134947459e-11
the O 0 1.083911849164565e-10
early O 0 2.701172396868401e-09
stage O 0 7.398212598097587e-10
. O 0 2.1930239846312816e-09
. O 0 6.243153194418483e-08

Nonsense O 0 8.385427463508677e-06
mutation O 0 4.455411328763148e-08
in O 0 6.356239534710539e-09
exon O 0 1.999859904344703e-07
4 O 0 1.455212441214826e-06
of O 0 8.086439606813656e-08
human O 0 6.848277056548113e-09
complement O 0 3.280474203393169e-08
C9 O 0 3.779668759307242e-06
gene O 0 8.69771454858892e-09
is O 0 3.434299511440031e-10
the O 0 1.145975647709463e-09
major O 0 6.118778372865563e-09
cause O 0 9.123006350364449e-09
of O 0 6.739725666449203e-09
Japanese O 0 1.5905076224953518e-06
complement B-Disease 0 1.4916159670974594e-05
C9 I-Disease 1 0.967924177646637
deficiency I-Disease 0 0.00016078601765912026
. O 0 2.070327127512428e-06

Deficiency B-Disease 0 0.0009960685856640339
of I-Disease 0 5.206060450291261e-06
the I-Disease 0 2.049810518656159e-06
ninth I-Disease 0 1.3492853213392664e-05
component I-Disease 0 2.7601512897490466e-07
of I-Disease 0 9.216541307921489e-09
human I-Disease 0 1.8747376984151742e-09
complement I-Disease 0 2.623145611835298e-08
( O 0 2.9279314528452005e-09
C9 O 0 4.362211257102899e-05
) O 0 2.2509125674474717e-09
is O 0 5.377948641971386e-10
the O 0 1.0799873217948175e-09
most O 0 1.4028520012310253e-10
common O 0 1.6284648074460506e-09
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.1959005159242224e-09
Japan O 0 3.929824998749609e-08
but O 0 3.487747937680474e-11
is O 0 3.702171381958497e-12
rare O 0 3.511396728939076e-11
in O 0 2.9268955314964984e-11
other O 0 3.64654244300322e-11
countries O 0 3.139646875816027e-10
. O 0 2.1688732587676895e-08

We O 0 4.2762363250403723e-07
studied O 0 1.486207992229538e-07
the O 0 7.751401298605742e-09
molecular O 0 7.650682753990168e-09
basis O 0 1.7826955911459663e-08
of O 0 1.3366883599985613e-08
C9 B-Disease 1 0.9999122619628906
deficiency I-Disease 0 0.015197309665381908
in O 0 2.7208596975469845e-07
four O 0 3.7393515839312386e-08
Japanese O 0 6.859233963041333e-07
C9 B-Disease 0 6.393807416316122e-05
- I-Disease 0 1.4707505897604278e-06
deficient I-Disease 0 4.446421257853217e-07
patients O 0 1.1648838693645303e-07
who O 0 1.9746224655392552e-09
had O 0 3.214325161593479e-08
suffered O 0 2.3796856112312526e-06
from O 0 9.254123938262637e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 3.8207741681617335e-07

Direct O 0 4.8268113062022167e-08
sequencing O 0 1.4958096983264113e-08
of O 0 1.8156280034986594e-08
amplified O 0 1.609831912219306e-07
C9 O 0 1.7875905768960365e-06
cDNA O 0 7.368561938392304e-08
and O 0 1.1583412007354355e-09
DNA O 0 3.7784952944264205e-09
revealed O 0 6.709328204124176e-09
a O 0 1.824336681721661e-09
nonsense O 0 2.3183632791301534e-09
substitution O 0 1.29478638921654e-09
( O 0 8.193101752596021e-11
CGA O 0 2.2983303438195435e-07
- O 0 1.8491836328848876e-07
- O 0 2.2519191134051653e-07
> O 0 3.938710051443195e-07
TGA O 0 3.5416144328337396e-06
) O 0 1.416088687283823e-11
at O 0 1.9952775542897427e-10
codon O 0 1.1455538739824078e-09
95 O 0 5.633636224189331e-09
in O 0 1.5285490928551582e-10
exon O 0 5.571689332128926e-09
4 O 0 2.4301535006543418e-08
in O 0 7.218571518308181e-09
the O 0 2.7379188693998913e-08
four O 0 1.6183310691531005e-08
C9 B-Disease 0 3.011409171449486e-05
- I-Disease 0 2.901119387388462e-06
deficient I-Disease 0 9.67447022048873e-07
individuals O 0 3.982203011787533e-09
. O 0 1.2337558530362003e-07

An O 0 8.583428012798322e-08
allele O 0 9.176586956982646e-08
- O 0 5.339818187621859e-08
specific O 0 3.0115383964357534e-08
polymerase O 0 5.861483032276738e-07
chain O 0 2.888864685246517e-07
reaction O 0 6.8577010736703414e-09
system O 0 8.989789468394349e-10
designed O 0 2.7449973405424544e-09
to O 0 3.092954337091669e-09
detect O 0 1.1055816262484086e-09
exclusively O 0 2.32510219411175e-10
only O 0 9.653796512187895e-11
one O 0 2.6153832571873536e-11
of O 0 6.452906264886593e-11
the O 0 1.838367236217664e-10
normal O 0 5.636968225530836e-09
and O 0 3.255475888863657e-10
mutant O 0 6.549832676228107e-09
alleles O 0 1.1933228849514421e-09
indicated O 0 2.0366508479696677e-09
that O 0 3.284551450266626e-11
all O 0 1.150210204858837e-10
the O 0 3.1493271879234896e-10
four O 0 8.05743805010195e-11
patients O 0 4.307557782690097e-11
were O 0 3.150376834404334e-11
homozygous O 0 3.6878403109064095e-10
for O 0 5.639396172263389e-10
the O 0 1.7372419058858668e-09
mutation O 0 4.0133724121815817e-10
in O 0 7.781794653105578e-10
exon O 0 6.881574421413461e-09
4 O 0 2.2170649316421986e-08
and O 0 2.5325735952819173e-10
that O 0 3.2961237905748675e-11
the O 0 1.9825539820939042e-10
parents O 0 2.377463503844268e-10
of O 0 1.9319353061764133e-10
patient O 0 4.546057752463639e-09
2 O 0 2.5431772243678097e-08
were O 0 1.6064724661646324e-08
heterozygous O 0 2.471230509115685e-08
. O 0 7.783388582538464e-07

The O 0 1.3498166140379908e-07
common O 0 1.1029452018362917e-08
mutation O 0 9.350220597781345e-10
at O 0 2.328564896458829e-09
codon O 0 2.4043441015919598e-08
95 O 0 1.894415362357904e-07
in O 0 7.249478350956906e-09
exon O 0 3.6968728522879246e-08
4 O 0 1.0023049412666296e-07
might O 0 8.479719149079301e-09
be O 0 3.15049264454359e-10
responsible O 0 2.658349929074433e-10
for O 0 1.3289817857309316e-10
most O 0 3.0125177352680055e-10
Japanese O 0 7.854405339458026e-07
C9 B-Disease 0 0.0009303665719926357
deficiency I-Disease 0 6.256563551687577e-07
. O 0 1.1884399242489962e-08
. O 0 5.854148810158222e-08

BRCA1 O 0 9.507828053756384e-07
required O 0 3.627748057510871e-08
for O 0 3.2351377132755488e-09
transcription O 0 3.7286474707798334e-07
- O 0 1.762822830642108e-05
coupled O 0 7.3406849878665525e-06
repair O 0 0.0005941989365965128
of O 0 1.4633019418397453e-07
oxidative O 0 4.0522598965253565e-07
DNA O 0 4.582344459436172e-08
damage O 0 2.8125299422754324e-07
. O 0 6.738943625350657e-07

The O 0 4.015939703094773e-05
breast B-Disease 1 1.0
and I-Disease 1 0.9999728202819824
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 1.0273649422742892e-05
gene O 0 1.1882228534432215e-07
BRCA1 O 0 8.469459089610609e-08
encodes O 0 1.2477141098088396e-08
a O 0 7.028153703458884e-08
zinc O 0 2.8470820325310342e-05
finger O 0 3.774327126393473e-07
protein O 0 3.854474517339668e-09
of O 0 8.954946784101026e-10
unknown O 0 4.694831190477089e-09
function O 0 6.744509839506918e-09
. O 0 6.049017287068637e-08

Association O 0 2.653718240708258e-07
of O 0 2.448279445843582e-08
the O 0 2.1794226867655198e-08
BRCA1 O 0 3.1732059202482787e-09
protein O 0 2.2338421390433183e-10
with O 0 7.910637422892108e-12
the O 0 3.8653910627850507e-10
DNA O 0 4.766815830947735e-10
repair O 0 2.389659137236322e-08
protein O 0 2.424809242285164e-09
Rad51 O 0 2.1194235699795172e-08
and O 0 5.67022921671434e-11
changes O 0 2.3844753949120445e-10
in O 0 2.109113994563927e-10
the O 0 1.3821595257201835e-10
phosphorylation O 0 8.737400247760263e-10
and O 0 3.1730831850929064e-10
cellular O 0 1.8052341843599606e-08
localization O 0 6.443863753702317e-07
of O 0 7.771208565543475e-09
the O 0 2.490079475947482e-09
protein O 0 3.3986438108257744e-09
after O 0 1.103988567230374e-09
exposure O 0 3.038761064999562e-08
to O 0 1.022616658019615e-09
DNA O 0 3.888614585889627e-08
- O 0 1.6369785953429528e-06
damaging O 0 7.880893804212974e-08
agents O 0 1.187964038251721e-08
are O 0 8.378873289638378e-11
consistent O 0 1.941755645162857e-09
with O 0 1.2329424590659666e-12
a O 0 1.2674677973834036e-10
role O 0 6.845988220760546e-10
for O 0 2.4702018208699883e-09
BRCA1 O 0 8.67055138797923e-09
in O 0 1.3301293400047598e-08
DNA O 0 6.496707527503531e-08
repair O 0 3.338071473990567e-05
. O 0 3.6413812267710455e-06

Here O 0 3.4355386446804914e-07
, O 0 7.767648191325804e-10
it O 0 1.9699707143328027e-11
is O 0 5.67464087872227e-12
shown O 0 1.721858489123207e-10
that O 0 7.82523768005916e-11
mouse O 0 1.5584904033971725e-08
embryonic O 0 5.360431387657627e-08
stem O 0 1.4970257922186647e-08
cells O 0 5.85968651378721e-09
deficient B-Disease 0 1.3789897934657347e-07
in I-Disease 0 2.0916532506021213e-08
BRCA1 I-Disease 0 1.6384634093924433e-08
are O 0 1.8363591203218732e-10
defective O 0 6.0709646199086365e-09
in O 0 2.384813013733833e-09
the O 0 4.0830188119400646e-09
ability O 0 3.5066753945045548e-09
to O 0 2.254874509333149e-09
carry O 0 3.817737237454821e-09
out O 0 2.0299327496697828e-10
transcription O 0 6.107190841930787e-08
- O 0 5.6704875532886945e-06
coupled O 0 9.304520062869415e-06
repair O 0 0.0004052910953760147
of O 0 1.6137175862240838e-07
oxidative O 0 1.9889840530140646e-07
DNA O 0 1.6769602595445576e-08
damage O 0 2.7288317383522553e-08
, O 0 4.816900767146137e-10
and O 0 7.612455110717065e-10
are O 0 3.702120610071802e-09
hypersensitive O 0 0.00011527198512339965
to O 0 1.8773076590150595e-05
ionizing O 0 0.2435341626405716
radiation O 0 0.004331880249083042
and O 0 4.1859902211172084e-08
hydrogen O 0 9.126716804530588e-08
peroxide O 0 4.427043677424081e-06
. O 0 6.369482434820384e-07

These O 0 1.4490261435184948e-07
results O 0 4.5077154453565527e-08
suggest O 0 3.9584413968896115e-08
that O 0 6.100804861297604e-10
BRCA1 O 0 7.982766447867107e-09
participates O 0 1.9203638679243795e-09
, O 0 1.6506226940826707e-10
directly O 0 1.0496425950634602e-09
or O 0 9.389072852528102e-10
indirectly O 0 2.033724078032151e-09
, O 0 1.5118701429672754e-11
in O 0 1.8095552833941042e-10
transcription O 0 5.636944138132094e-07
- O 0 1.9040353436139412e-05
coupled O 0 1.3819804735248908e-05
repair O 0 0.00044104160042479634
of O 0 1.1388210197083026e-07
oxidative O 0 7.815493319185407e-08
DNA O 0 7.946368008049376e-09
damage O 0 1.0208049516791107e-08
. O 0 3.819973670715626e-09
. O 0 5.1924768484923334e-08

Truncation O 0 4.62841762782773e-06
mutations O 0 3.0796694971968464e-08
in O 0 5.052830154284038e-09
the O 0 2.936264342778827e-09
transactivation O 0 2.495978151273448e-06
region O 0 6.965072429920838e-08
of O 0 2.9100446496954646e-08
PAX6 O 0 3.168334296788089e-05
result O 0 2.33647643455015e-08
in O 0 1.214448275277391e-08
dominant O 0 3.03766341858136e-07
- O 0 5.232907938079734e-07
negative O 0 1.0042544573707346e-08
mutants O 0 2.1495218049949472e-07
. O 0 1.1204555505628377e-07

PAX6 O 0 0.000411664746934548
is O 0 1.5740907244321534e-08
a O 0 2.832408307895662e-09
transcription O 0 1.6045554218635516e-08
factor O 0 1.772967017643623e-08
with O 0 1.7016003883707498e-10
two O 0 2.875798488233272e-10
DNA O 0 1.0878309364414918e-09
- O 0 7.3135031364301994e-09
binding O 0 6.51194032030844e-09
domains O 0 2.6456159929466594e-08
( O 0 1.47611339817999e-10
paired O 0 4.264122832609019e-09
box O 0 6.206025915389546e-09
and O 0 2.2819926503991894e-10
homeobox O 0 7.334054430430115e-08
) O 0 4.771761805133501e-11
and O 0 5.721529153235316e-11
a O 0 1.1200058658289436e-09
proline O 0 5.1301327630426385e-08
- O 0 2.2417278700004317e-08
serine O 0 1.295457110472853e-07
- O 0 3.276135203122976e-07
threonine O 0 4.427531905548676e-07
( O 0 1.155985654421876e-10
PST O 0 6.420151748898206e-06
) O 0 1.681270123121692e-09
- O 0 1.557685749276061e-07
rich O 0 7.014186564902047e-08
transactivation O 0 4.516322223935276e-05
domain O 0 1.994043032027548e-06
. O 0 1.225845238650436e-07

PAX6 O 0 0.026582948863506317
regulates O 0 1.2902953130833339e-05
eye O 0 0.025128822773694992
development O 0 6.370739811245585e-07
in O 0 2.5754287591439606e-08
animals O 0 6.511493122474121e-09
ranging O 0 3.006107807124181e-09
from O 0 2.099889845341707e-10
jellyfish O 0 9.014995971945439e-10
to O 0 2.6770352601346303e-09
Drosophila O 0 1.8527062550788287e-08
to O 0 1.63624598314982e-08
humans O 0 5.4694101692120967e-08
. O 0 9.537118472735528e-08

Heterozygous O 0 3.9705332710582297e-07
mutations O 0 6.2153953095389625e-09
in O 0 4.9446482464077235e-09
the O 0 5.272382530563391e-09
human O 0 9.234595310658733e-09
PAX6 O 0 7.501229447370861e-06
gene O 0 1.6817519821188398e-08
result O 0 1.0550001761089334e-08
in O 0 2.9809625878840507e-09
various O 0 2.1319750409531935e-09
phenotypes O 0 9.668990053057769e-09
, O 0 6.621158482600364e-11
including O 0 2.1216298162762826e-10
aniridia B-Disease 1 1.0
, O 0 1.9200681933284613e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 5.44366187682499e-08
autosomal B-Disease 0 0.0002461750991642475
dominant I-Disease 0 3.968533928855322e-05
keratitis I-Disease 1 1.0
, O 0 1.4142472082312452e-08
and O 0 8.006279195171828e-09
familial B-Disease 1 0.9996362924575806
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9999998807907104

It O 0 1.3648055130488501e-08
is O 0 2.451819025584001e-10
believed O 0 1.329811594175112e-09
that O 0 2.8488820677519122e-11
the O 0 1.940603094885418e-10
mutated O 0 9.384224952668774e-09
allele O 0 7.03087579267958e-08
of O 0 3.8123548762314385e-08
PAX6 O 0 0.0001585819263709709
produces O 0 1.657517856301638e-08
an O 0 3.739305254324421e-10
inactive O 0 1.4825142891083942e-08
protein O 0 4.592956237559065e-09
and O 0 2.034949986295942e-09
aniridia B-Disease 1 1.0
is O 0 1.0810383699322301e-09
caused O 0 4.979284762285374e-10
due O 0 1.3089025419077416e-09
to O 0 2.8278577257623283e-09
genetic O 0 1.1493187734856747e-08
haploinsufficiency O 0 1.072303007276787e-06
. O 0 1.7165996268886374e-07

However O 0 6.881367653477355e-08
, O 0 1.6974324168472776e-09
several O 0 2.0216639473602527e-10
truncation O 0 3.914653134984292e-08
mutations O 0 5.10815889587235e-10
have O 0 4.56039997431823e-11
been O 0 2.5692918279029975e-11
found O 0 7.151028033614004e-12
to O 0 1.6886023829210117e-11
occur O 0 9.169675435627411e-12
in O 0 5.861044982680141e-11
the O 0 7.061174422950955e-10
C O 0 1.5841687073248067e-08
- O 0 3.079662080907042e-09
terminal O 0 1.1999447657728979e-08
half O 0 3.3799480991802966e-09
of O 0 7.242011990093999e-10
PAX6 O 0 9.142272574536037e-07
in O 0 2.474521254569595e-09
patients O 0 3.6185687779521913e-09
with O 0 4.7099487504587145e-11
Aniridia B-Disease 1 1.0
resulting O 0 2.0870505323955513e-08
in O 0 1.7775847460654859e-09
mutant O 0 2.115642105948723e-09
proteins O 0 9.5981292358438e-11
that O 0 1.2972281582257494e-10
retain O 0 6.04464602815824e-08
the O 0 2.675780841343567e-08
DNA O 0 1.9161278785873037e-08
- O 0 5.572255190600117e-08
binding O 0 9.706353054639294e-09
domains O 0 4.043972712253208e-09
but O 0 2.357473105618624e-10
have O 0 1.6011786341252332e-10
lost O 0 1.0749487522332402e-08
most O 0 2.6957358567614165e-10
of O 0 7.637485088807239e-10
the O 0 4.873804915206392e-09
transactivation O 0 1.224242714670254e-05
domain O 0 1.9189112663298147e-06
. O 0 4.486323348373844e-07

It O 0 6.1614779944818565e-09
is O 0 8.651725863506599e-11
not O 0 1.5659082364116728e-10
clear O 0 7.048041594792664e-10
whether O 0 2.43214032247252e-10
such O 0 2.594046644155412e-10
mutants O 0 3.597135034283383e-08
really O 0 7.658115031006218e-09
behave O 0 6.012777498121125e-10
as O 0 1.011848715926078e-09
loss O 0 5.317506435176256e-09
- O 0 2.3315704922310942e-08
of O 0 9.946734103039034e-09
- O 0 2.225046280557308e-08
function O 0 2.6170574596307006e-09
mutants O 0 8.64516902510104e-09
as O 0 3.5455333113887377e-10
predicted O 0 2.5238804379768e-09
by O 0 3.1463731620107183e-10
haploinsufficiency O 0 8.683869054948445e-06
. O 0 7.445315191034751e-07

Contrary O 0 5.174098873794719e-07
to O 0 4.444739687414767e-09
this O 0 4.6395640801444316e-11
theory O 0 3.8015676717684244e-10
, O 0 2.3138197954852835e-11
our O 0 1.6166766814151856e-09
data O 0 4.528411867710247e-09
showed O 0 1.858442510993541e-09
that O 0 3.3383126124553186e-11
these O 0 8.132956114126344e-11
mutants O 0 2.0901804731465745e-09
are O 0 1.646359160112354e-10
dominant O 0 1.0635606173536871e-08
- O 0 9.541084722286541e-08
negative O 0 7.845406102546804e-09
in O 0 2.5954534077499147e-09
transient O 0 7.132420876132528e-08
transfection O 0 8.916572369344067e-08
assays O 0 9.317894011928729e-09
when O 0 1.2056082798750367e-09
they O 0 4.900218564252157e-10
are O 0 7.86265566543598e-11
coexpressed O 0 1.0767755043161742e-07
with O 0 1.9063853273770803e-10
wild O 0 1.1334824989717163e-07
- O 0 5.483281029228237e-07
type O 0 2.1538114651775686e-06
PAX6 O 0 0.03235766664147377
. O 0 8.38501910038758e-06

We O 0 6.168711763621104e-08
found O 0 8.290790831644301e-10
that O 0 2.3657737227567033e-11
the O 0 5.352895904309207e-10
dominant O 0 5.3321240756076804e-08
- O 0 2.465924637817807e-07
negative O 0 2.4914903473671757e-09
effects O 0 2.2612713479475133e-08
result O 0 1.1478942241183177e-09
from O 0 6.456553625078243e-10
the O 0 1.2990262199252811e-09
enhanced O 0 6.74474076589604e-09
DNA O 0 7.219283504333873e-10
binding O 0 6.880861991298559e-10
ability O 0 7.3201462669203465e-09
of O 0 5.725890872554373e-09
these O 0 1.4228749289912912e-09
mutants O 0 1.461622787246597e-07
. O 0 2.29488506420239e-07

Kinetic O 0 4.876736170444929e-07
studies O 0 8.154994191045262e-08
of O 0 4.5706194384820265e-09
binding O 0 4.554728594285962e-09
and O 0 1.8420606151536845e-09
dissociation O 0 2.8260689788339732e-08
revealed O 0 4.225809480118414e-09
that O 0 1.5232572148082824e-11
various O 0 7.612277475033125e-11
truncation O 0 1.605078914224123e-08
mutants O 0 4.916067553040193e-10
have O 0 1.5301029540615296e-11
3 O 0 2.532873355498566e-10
- O 0 3.157068828585352e-09
5 O 0 3.6424466998141725e-08
- O 0 1.7166307486604637e-07
fold O 0 3.335504317192317e-08
higher O 0 1.697161344793585e-08
affinity O 0 3.131538584000282e-09
to O 0 2.7331590324308763e-09
various O 0 7.738559792969113e-10
DNA O 0 4.993008229092766e-10
- O 0 6.442775757342645e-10
binding O 0 2.4318760893926594e-10
sites O 0 3.114792035407987e-10
when O 0 3.701170619985206e-11
compared O 0 9.676692780402618e-11
with O 0 1.0860116625432958e-11
the O 0 1.4927509228712665e-09
wild O 0 4.0074180418514516e-08
- O 0 9.796787736604529e-08
type O 0 2.2618499428972427e-07
PAX6 O 0 0.0009545293287374079
. O 0 4.844043814955512e-06

These O 0 1.3471156634636827e-08
results O 0 4.81661865947558e-09
provide O 0 3.8730014750854025e-09
a O 0 4.744727943872817e-10
new O 0 6.139607711119766e-10
insight O 0 1.4232746536890772e-08
into O 0 2.0206232520525447e-10
the O 0 3.283532057363203e-10
role O 0 3.739392351320703e-09
of O 0 5.9243387973140216e-09
mutant O 0 1.1867822991007415e-07
PAX6 O 0 2.046644476649817e-05
in O 0 7.683722458295961e-08
causing O 0 7.448014827104998e-08
aniridia B-Disease 1 1.0
. O 0 2.527789177975137e-08
. O 0 1.0169127762083008e-07

Reversal O 0 1.5063867522258079e-06
of O 0 8.308243337751264e-08
severe O 0 1.4118829767539864e-06
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 6.162738372950116e-07
excellent O 0 1.453252593819343e-07
neuropsychologic O 0 9.779331122672374e-08
outcome O 0 1.905224067400013e-08
in O 0 8.050042410445712e-09
very B-Disease 0 6.948258413075337e-09
- I-Disease 0 9.630322210796294e-07
long I-Disease 0 1.1163230055899476e-06
- I-Disease 0 6.719718385284068e-06
chain I-Disease 0 2.7719372610590653e-06
acyl I-Disease 0 3.469167131697759e-05
- I-Disease 0 2.578710564193898e-06
coenzyme I-Disease 0 3.4788208722602576e-05
A I-Disease 0 2.9571283448603936e-06
dehydrogenase I-Disease 0 0.0003078733861912042
deficiency I-Disease 1 0.8339280486106873
. O 0 3.6275796446716413e-06

Very B-Disease 0 1.5040181722270063e-07
- I-Disease 0 4.6131256681292143e-07
long I-Disease 0 5.686321458142629e-08
- I-Disease 0 1.667160489660091e-07
chain I-Disease 0 4.640173045800111e-08
acyl I-Disease 0 3.9206315705087036e-07
- I-Disease 0 4.5939049897469886e-08
coenzyme I-Disease 0 4.1431019326410023e-07
A I-Disease 0 3.311845730991081e-08
dehydrogenase I-Disease 0 7.857059358684637e-08
( I-Disease 0 4.6282705445932493e-10
VLCAD I-Disease 0 8.22017409518594e-06
) I-Disease 0 2.8598770018817277e-09
deficiency I-Disease 0 5.604092052635679e-07
is O 0 8.060686007560491e-10
a O 0 1.2620944289665204e-08
disorder O 1 0.9999792575836182
of O 0 3.1377737741422607e-07
fatty O 0 4.4316143430478405e-06
acid O 0 1.1211668606847525e-06
beta O 0 1.0958056861909427e-07
oxidation O 0 4.200466818815585e-08
that O 0 1.995624998585299e-09
reportedly O 0 3.068646492465632e-08
has O 0 6.423104409458702e-11
high O 0 8.270952811528787e-10
rates O 0 6.259485374471296e-09
of O 0 2.0147927770608476e-10
morbidity O 0 5.758882366535545e-07
and O 0 1.65755176251281e-09
mortality O 0 3.622266376623884e-06
. O 0 1.1669285981952271e-07

We O 0 7.95716648127609e-09
describe O 0 1.6682182302218962e-09
the O 0 5.440259701061656e-11
outcome O 0 1.3978020962923665e-09
of O 0 1.2306771157710727e-09
a O 0 5.399100055925032e-10
5 O 0 4.711729895134908e-10
- O 0 2.4866561587622016e-10
year O 0 1.606850763558043e-10
- O 0 2.3571415930234707e-09
old O 0 5.830521843108727e-09
girl O 0 2.107949725882463e-08
with O 0 3.29245603003514e-10
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.1302981540193286e-08
was O 0 2.100909490820868e-08
first O 0 4.334859582399986e-09
seen O 0 2.206214322342248e-09
at O 0 1.1341335648396011e-09
5 O 0 1.1718507941793632e-08
months O 0 2.3518378355902314e-09
of O 0 2.243260993628482e-10
age O 0 8.731469436362715e-10
with O 0 5.897489441242243e-11
severe O 0 5.301124161860571e-08
hypertrophic B-Disease 1 0.9999016523361206
cardiomyopathy I-Disease 1 1.0
, O 0 7.254215688590193e-06
hepatomegaly B-Disease 1 1.0
, O 0 4.50343259217334e-06
encephalopathy B-Disease 0 2.156590562663041e-05
, O 0 2.102423568572931e-09
and O 0 1.1205832706195906e-08
hypotonia B-Disease 1 0.9999957084655762
. O 0 0.00011086228187195957

Biochemical O 0 1.0911731806118041e-05
studies O 0 3.3648584576440044e-06
indicated O 0 0.0002474713255651295
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 9.82920141723298e-07
by O 0 3.1411204193254605e-10
a O 0 3.7945571129682776e-09
stable O 0 2.3523691083937592e-07
yet O 0 6.11061423683168e-09
inactive O 0 6.195170954015339e-08
enzyme O 0 6.894439508187133e-08
. O 0 3.4305097074138757e-07

Molecular O 0 6.942921686459158e-07
genetic O 0 2.733900750229168e-08
analysis O 0 7.548365488219133e-09
of O 0 1.1026590307494644e-08
her O 0 2.6462823043971184e-08
VLCAD O 0 0.00012174929725006223
gene O 0 1.136102554255558e-07
revealed O 0 2.0145303381013946e-07
a O 0 4.355764104957416e-08
T1372C O 0 1.2093685199943138e-06
( O 0 1.3260224029920664e-09
F458L O 0 9.472522037867748e-07
) O 0 6.751331049770215e-09
missense O 0 5.80881305722869e-07
mutation O 0 1.0451242538067618e-08
and O 0 2.8924018735665413e-09
a O 0 7.651431133126607e-08
1668 O 0 0.006174953188747168
ACAG O 0 0.008290759287774563
1669 O 0 0.00040932156844064593
splice O 0 2.1847641619388014e-05
site O 0 1.6428574554083752e-06
mutation O 0 6.262641250032175e-08
. O 0 7.861827100441587e-08

After O 0 5.177908946052412e-08
initial O 0 2.280272148880158e-08
treatment O 0 5.8301910854652306e-08
with O 0 2.016853767328186e-10
intravenous O 0 7.295558379638578e-09
glucose O 0 1.6013206760590037e-08
and O 0 3.980439033934857e-10
carnitine O 0 2.8436971888368134e-07
, O 0 7.493934917057743e-10
the O 0 1.119015546890978e-08
patient O 0 6.887749037787216e-08
has O 0 1.8867421514023874e-11
thrived O 0 3.8244771238815645e-10
on O 0 6.52200460304897e-10
a O 0 1.3850262048364925e-09
low O 0 1.1750405803923059e-07
- O 0 1.2131475557453086e-07
fat O 0 5.238584890321363e-07
diet O 0 2.564478904787393e-07
supplemented O 0 5.520669255076882e-09
with O 0 5.31561496208699e-11
medium O 0 8.909855182537285e-07
- O 0 9.458286740482436e-07
chain O 0 2.9213708785391646e-07
triglyceride O 0 9.226268957718275e-07
oil O 0 3.9221686165547e-07
and O 0 3.487804711710396e-09
carnitine O 0 1.8402253942895186e-07
and O 0 4.78481532173447e-10
avoidance O 0 2.525698050703795e-07
of O 0 1.935064553038046e-08
fasting O 0 3.4920540770144726e-07
. O 0 1.090569679007558e-08

Her O 0 0.00010320618457626551
ventricular O 1 0.9999997615814209
hypertrophy O 1 0.9997628331184387
resolved O 0 3.2961168017209275e-07
significantly O 0 2.335335835823571e-08
over O 0 6.281821590681247e-11
1 O 0 3.259578607028857e-09
year O 0 1.133947491460674e-09
, O 0 5.0497998144161116e-11
and O 0 7.802598844808273e-11
cognitively O 0 1.2188694142878376e-07
, O 0 2.8087304704271787e-10
she O 0 4.835661870927765e-10
is O 0 1.89337521355748e-11
in O 0 2.833675308289152e-11
the O 0 1.5788521878778994e-10
superior O 0 1.8657233535890327e-09
range O 0 1.646203706684446e-08
for O 0 1.3515081276338492e-09
age O 0 6.465543833655829e-08
. O 0 5.343669613466773e-07

Clinical O 0 9.336893526779022e-06
recognition O 0 1.9592624084907584e-05
of O 0 0.074569471180439
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 9.774124620776092e-09
important O 0 1.0486800317011102e-09
because O 0 1.7891412310011567e-11
it O 0 2.718773340140701e-12
is O 0 9.626573626783652e-13
one O 0 1.2302440316469543e-11
of O 0 2.6974231182030906e-10
the O 0 3.915457735814698e-09
few O 0 1.3756988437307882e-08
directly O 0 2.1060879706880087e-09
treatable O 0 5.43035731936925e-08
causes O 0 1.3004864962695706e-09
of O 0 3.959542027587304e-09
cardiomyopathy B-Disease 1 1.0
in O 0 1.5397041579490178e-06
children O 0 3.3359737194871286e-09
. O 0 5.540857772601271e-10
. O 0 6.886130332617313e-09

Cloning O 0 2.1193482098169625e-06
of O 0 9.615876095381282e-09
a O 0 5.644399947435375e-10
novel O 0 1.7423588127840617e-09
member O 0 5.705853123316729e-09
of O 0 1.2851815611725215e-08
the O 0 1.3382751795631975e-08
low O 0 1.073039896937189e-07
- O 0 5.47737322165176e-09
density O 0 5.869146280090831e-10
lipoprotein O 0 3.353340005673999e-08
receptor O 0 1.0243585393254762e-06
family O 0 3.214153139197151e-06
. O 0 2.6812888336280594e-06

A O 0 4.890223976872221e-07
gene O 0 8.593252331934309e-09
encoding O 0 4.926858210296814e-08
a O 0 4.0606540352428055e-08
novel O 0 5.7739072190088336e-08
transmembrane O 0 1.0893638879849732e-08
protein O 0 2.3407928928520505e-09
was O 0 2.6618827142499413e-09
identified O 0 3.7538258612634934e-10
by O 0 3.783617082836477e-12
DNA O 0 1.043097830333295e-10
sequence O 0 2.500328069587887e-11
analysis O 0 2.3184330844028267e-10
within O 0 1.6806407654446076e-10
the O 0 1.4921388569177907e-09
insulin B-Disease 1 0.999767005443573
- I-Disease 1 0.9999998807907104
dependent I-Disease 1 1.0
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 4.589391977560808e-09
IDDM B-Disease 0 3.3729577353369677e-06
) O 0 3.3533240073602144e-10
locus O 0 3.10013774651452e-08
IDDM4 O 0 2.701643097680062e-06
on O 0 5.950979087288033e-08
chromosome O 0 1.2447766550849337e-07
11q13 O 0 1.4291103980212938e-05
. O 0 4.647515936540003e-07

Based O 0 1.1330141269638716e-08
on O 0 1.9968709352724545e-08
its O 0 1.0362372071526238e-09
chromosomal O 0 8.415113939008734e-08
position O 0 2.1634336917486507e-06
, O 0 9.980518633767588e-10
this O 0 7.607487556571257e-11
gene O 0 1.2190119746957606e-10
is O 0 2.4287225008912117e-11
a O 0 8.435043635790507e-11
candidate O 0 3.6215155874153027e-10
for O 0 3.01401792413003e-10
conferring O 0 4.9958138959027565e-08
susceptibility O 0 1.554547111481952e-06
to O 0 1.3008514088141965e-06
diabetes B-Disease 1 0.9924778342247009
. O 0 3.7711570257670246e-06

The O 0 1.1414364280426526e-06
gene O 0 9.756136165606222e-08
, O 0 1.2226807122317496e-08
termed O 0 2.242064169877267e-07
low O 0 2.4896965555853967e-07
- O 0 1.2574665753106729e-08
density O 0 2.2817228662042055e-10
lipoprotein O 0 3.237606849282315e-09
receptor O 0 6.801168073167219e-09
related O 0 2.9474769291937264e-08
protein O 0 3.550725491408002e-09
5 O 0 1.2619956635262497e-08
( O 0 6.47542020004721e-11
LRP5 O 0 1.37104976261071e-07
) O 0 6.421450871041401e-11
, O 0 5.059054911105143e-11
encodes O 0 2.7130209190318055e-10
a O 0 6.026394938629664e-10
protein O 0 3.0627038682951024e-09
of O 0 6.212740988331689e-09
1615 O 0 1.6248892279691063e-05
amino O 0 2.292369600809252e-07
acids O 0 6.771193028498601e-08
that O 0 2.1642344860683949e-10
contains O 0 1.6652100531810987e-10
conserved O 0 8.797312184283257e-11
modules O 0 9.368643638651974e-10
which O 0 8.582854912897453e-12
are O 0 2.2291027530763063e-12
characteristic O 0 1.803621696438995e-10
of O 0 7.757994247015176e-10
the O 0 5.0688733210790815e-09
low O 0 3.6581477047548105e-07
- O 0 1.496026769132186e-08
density O 0 5.364793609352603e-10
lipoprotein O 0 1.908701285913139e-08
( O 0 4.902789285665676e-10
LDL O 0 3.01101039212881e-07
) O 0 3.529638137322877e-09
receptor O 0 1.985007656912785e-06
family O 0 1.063572653947631e-06
. O 0 8.926967893785331e-07

These O 0 1.9470860479486873e-08
modules O 0 1.2637950241867202e-08
include O 0 1.3555327971204179e-09
a O 0 2.757959860488768e-09
putative O 0 4.5781774815623066e-08
signal O 0 1.632561286157852e-08
peptide O 0 1.2481514710671604e-09
for O 0 2.294510137446082e-10
protein O 0 4.344003490253101e-10
export O 0 1.1533951038700252e-07
, O 0 3.163096229386042e-09
four O 0 4.192668434654934e-09
epidermal O 0 8.152506580927366e-08
growth O 0 9.806075063067965e-09
factor O 0 1.5046394130635576e-09
( O 0 1.0332189964712413e-10
EGF O 0 1.9841074561099958e-07
) O 0 2.538323717882207e-10
repeats O 0 6.852288514380689e-09
with O 0 6.604370522689251e-11
associated O 0 3.6955192683763016e-08
spacer O 0 8.930313697419479e-07
domains O 0 2.393272211520525e-07
, O 0 8.888885738578267e-10
three O 0 6.137169245024054e-11
LDL O 0 2.6006763409469613e-09
- O 0 2.805970389374579e-08
receptor O 0 8.757526259728365e-09
( O 0 6.126915086390738e-10
LDLR O 0 6.479199782916112e-06
) O 0 4.2990894177918904e-10
repeats O 0 1.1831205348755702e-08
, O 0 3.7328559687743734e-10
a O 0 2.1818673534568234e-09
single O 0 1.2861918641249304e-08
transmembrane O 0 1.8892116315782914e-08
spanning O 0 6.106769312452798e-09
domain O 0 1.6860139950836128e-08
, O 0 3.6791983348827273e-10
and O 0 2.1653823178979792e-10
a O 0 4.553303956100763e-09
cytoplasmic O 0 1.8228564613309572e-07
domain O 0 1.4510799246636452e-06
. O 0 2.7075500952378206e-07

The O 0 5.96313611822552e-07
encoded O 0 2.125925746554458e-08
protein O 0 1.2697242368631123e-08
has O 0 2.1671094085906617e-10
a O 0 1.8272401647312364e-10
unique O 0 1.218494194432651e-09
organization O 0 8.096016079761625e-10
of O 0 2.699101830927475e-09
EGF O 0 3.7597592381644063e-06
and O 0 1.12207194646885e-08
LDLR O 0 4.4201413402333856e-05
repeats O 0 1.0908775216478261e-08
; O 0 1.604939514621151e-10
therefore O 0 4.3922283587960465e-09
, O 0 1.8739394758160444e-10
LRP5 O 0 4.944207603330142e-07
likely O 0 3.6510769962916356e-09
represents O 0 5.955704679427853e-11
a O 0 2.6121925802979895e-11
new O 0 1.780317906985296e-11
category O 0 1.3959130518159668e-09
of O 0 1.3086255412630976e-09
the O 0 1.1058099325111925e-08
LDLR O 0 5.504663204192184e-05
family O 0 1.316976181442442e-07
. O 0 1.7453324119287572e-07

Both O 0 2.91839967303531e-07
human O 0 5.191051144493031e-08
and O 0 9.319919946904065e-09
mouse O 0 6.525457365569309e-07
LRP5 O 0 3.415915489313193e-05
cDNAs O 0 1.1890497262356803e-06
have O 0 3.2162985608152894e-09
been O 0 1.5864539681942347e-09
isolated O 0 5.546316295124143e-09
and O 0 2.6070820502432923e-10
the O 0 2.6805506703198034e-09
encoded O 0 7.722547601396457e-10
mature O 0 4.398842623487553e-09
proteins O 0 3.808591289566898e-11
are O 0 1.858128755027888e-11
95 O 0 7.231939047613878e-09
% O 0 6.876581248871361e-11
identical O 0 1.123797027657858e-10
, O 0 3.206213419759685e-11
indicating O 0 1.5635392980328788e-09
a O 0 2.724943604093255e-10
high O 0 8.733667677951473e-10
degree O 0 3.451679120303197e-08
of O 0 3.967071116051102e-09
evolutionary O 0 5.25067589407513e-09
conservation O 0 3.0248925586562336e-09
. O 0 4.776827267072292e-10
. O 0 1.5606531178491423e-08

The O 0 2.3633001546841115e-06
APC B-Disease 0 1.4087665931583615e-06
variants O 0 2.100100573443342e-07
I1307K O 0 3.1960057640390005e-06
and O 0 1.203602550958749e-09
E1317Q O 0 2.0812078105336695e-07
are O 0 1.2764832246769942e-10
associated O 0 7.480275598936714e-08
with O 0 7.083343120939389e-07
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.3850030455841988e-08
but O 0 1.962058467086525e-11
not O 0 2.195750699318655e-11
always O 0 4.936106384745287e-11
with O 0 2.242296192472848e-12
a O 0 2.23653762176923e-09
family O 0 9.579483872812489e-09
history O 0 1.2053770603870362e-07
. O 0 1.3928982411925972e-07

Classical O 0 0.3569025993347168
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 6.618718373374577e-08
FAP B-Disease 0 8.143404102156637e-07
) O 0 1.2848028196899008e-10
is O 0 6.215578746138206e-11
a O 0 2.50040699256715e-09
high O 0 0.25699037313461304
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
that O 0 2.8173044452906026e-10
predisposes O 0 4.641631079493891e-09
to O 0 1.7964324472430349e-10
hundreds O 0 2.2886617601081127e-10
or O 0 3.065513398681219e-10
thousands O 0 2.8832911613818624e-09
of O 0 3.4751565181068145e-08
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9995498061180115
carcinoma I-Disease 1 1.0
and O 0 2.0306705650341428e-08
that O 0 7.580199662404752e-11
results O 0 9.301903691749658e-11
from O 0 6.891760079286158e-11
truncating O 0 3.3526730280897254e-09
mutations O 0 1.1518567349932951e-10
in O 0 9.20483689270668e-10
the O 0 2.0523906130165415e-08
APC B-Disease 0 2.248993951070588e-07
gene O 0 9.489595953482421e-08
. O 0 1.3545070487452904e-06

A O 0 9.294925007452548e-07
variant O 0 1.1145024814140925e-07
of O 0 2.3500724921632354e-08
FAP B-Disease 0 5.05012621943024e-07
is O 0 5.0077173519014195e-09
attenuated B-Disease 1 0.999800980091095
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 5.163684146936021e-09
which O 0 9.930573030558776e-11
results O 0 2.8802338292166496e-10
from O 0 1.2722198294845555e-10
germ O 0 3.130483605673362e-07
- O 0 7.302995896907305e-08
line O 0 6.109751815586151e-09
mutations O 0 1.3305313795175522e-10
in O 0 9.568882491928221e-11
the O 0 2.7368821098328056e-10
5 O 0 1.114505709942648e-09
and O 0 2.838359582091332e-11
3 O 0 3.133857173764909e-09
regions O 0 1.0152277907238272e-09
of O 0 3.984299556947235e-09
the O 0 1.4038009865657841e-08
APC B-Disease 0 1.3787294506073522e-07
gene O 0 9.22233027722541e-08
. O 0 1.9915096345357597e-06

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 6.226720870472491e-05
have O 0 7.002136648281976e-10
" O 0 2.8610391833439053e-09
multiple O 0 1.4301511974679215e-08
" O 0 0.2124786078929901
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 5.077814613230203e-09
typically O 0 4.573058320911372e-10
fewer O 0 9.075305090755492e-11
than O 0 5.027664048973257e-12
100 O 0 1.5212145987320014e-09
) O 0 3.8465390594932813e-11
without O 0 2.7593911600121146e-09
the O 0 6.451141398855498e-09
florid O 0 1.2372971696095192e-06
phenotype O 0 9.250782539993452e-08
of O 0 1.0877195144587404e-08
classical O 0 4.029184879073e-07
FAP B-Disease 0 3.992064193880651e-06
. O 0 3.245015420816344e-07

Another O 0 3.917791104868229e-07
group O 0 5.697565530482507e-09
of O 0 1.6443044703606802e-09
patients O 0 5.290596405416181e-09
with O 0 2.5733134373373545e-11
multiple O 0 1.8685163638565427e-08
adenomas B-Disease 1 0.8381415009498596
has O 0 6.176352229658733e-08
no O 0 9.093854558273051e-09
mutations O 0 4.4409495525421505e-10
in O 0 4.495718020081085e-09
the O 0 1.4249097901597452e-08
APC B-Disease 0 9.271976075808652e-09
gene O 0 1.023432338875807e-09
, O 0 4.4007036903437324e-10
and O 0 2.3518995084792493e-10
their O 0 2.022853218264231e-09
phenotype O 0 4.245975571137706e-09
probably O 0 2.7907252064807153e-09
results O 0 2.4459803626974974e-10
from O 0 8.151296998493152e-11
variation O 0 6.931021312439611e-10
at O 0 9.39652888831688e-09
a O 0 2.5797981528796754e-09
locus O 0 9.416515567295392e-09
, O 0 2.049313913010664e-10
or O 0 1.2106379787546473e-10
loci O 0 5.061123187211081e-10
, O 0 3.767869002913038e-11
elsewhere O 0 7.060447226869826e-10
in O 0 4.741444459277488e-10
the O 0 2.7669646573968976e-09
genome O 0 1.8051851125022722e-09
. O 0 6.964474863480064e-08

Recently O 0 9.872801456367597e-07
, O 0 1.1241705344389175e-09
however O 0 3.73690939303728e-10
, O 0 1.0204846689898517e-10
a O 0 7.65612462316767e-10
missense O 0 5.718581519431609e-08
variant O 0 3.081685804318113e-07
of O 0 1.7495347037765896e-06
APC B-Disease 0 5.116480224387487e-06
( O 0 4.853331070364675e-09
I1307K O 0 4.7366675062221475e-06
) O 0 2.1894044355263986e-09
was O 0 4.019719668235666e-08
described O 0 5.435359273775475e-09
that O 0 1.9871489870260106e-11
confers O 0 6.694499621318073e-09
an O 0 1.7889977693696935e-11
increased O 0 5.518476786647852e-10
risk O 0 3.3600624504970256e-08
of O 0 1.569471663742661e-07
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.361284311471536e-08
including O 0 1.867010990252993e-10
multiple O 0 9.54537227038088e-10
adenomas B-Disease 0 1.5586426798108732e-06
, O 0 3.4364635581596303e-09
in O 0 6.445485922768057e-08
Ashkenazim O 0 0.00010297850531060249
. O 0 7.011637421783234e-07

We O 0 2.4671808773746307e-07
have O 0 1.8849670713194655e-09
studied O 0 1.1932370647116386e-08
a O 0 5.079887177572573e-09
set O 0 6.701833310529537e-09
of O 0 6.465450952397589e-10
164 O 0 2.250423181138217e-09
patients O 0 6.537497765357614e-10
with O 0 8.248058486204357e-11
multiple O 0 9.892708476400003e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9993034601211548
/ I-Disease 1 1.0
or I-Disease 1 0.7368277907371521
carcinoma I-Disease 1 1.0
and O 0 1.746612099395861e-08
analyzed O 0 5.0436059773062425e-09
codons O 0 1.0315030607443987e-08
1263 O 0 5.762514092566562e-07
- O 0 2.4949210342128936e-07
1377 O 0 2.036296336882515e-06
( O 0 8.408704288420665e-10
exon O 0 7.378645960898211e-08
15G O 0 2.0315519577707164e-06
) O 0 5.759119292569892e-10
of O 0 4.044018453441822e-09
the O 0 1.2623447176451918e-08
APC B-Disease 0 7.115910705124406e-08
gene O 0 1.1326597437744113e-08
for O 0 1.0463728550291762e-08
germ O 0 0.00011826513946289197
- O 0 5.598265943262959e-06
line O 0 3.3741017091415415e-07
variants O 0 1.8398324641566433e-07
. O 0 1.1438584834877474e-07

Three O 0 2.1320575527283836e-08
patients O 0 1.8480008634469414e-09
with O 0 6.109905550250039e-12
the O 0 1.4466084996556106e-09
I1307K O 0 5.42362784017314e-07
allele O 0 1.273146033042849e-08
were O 0 2.3081712097194895e-09
detected O 0 2.019568512423575e-09
, O 0 6.238716487860785e-11
each O 0 4.757639421315574e-11
of O 0 1.6439908323562236e-09
Ashkenazi O 0 4.1353609958605375e-07
descent O 0 4.6764859007453197e-07
. O 0 3.762984306376893e-07

Four O 0 1.0563596930524e-07
patients O 0 2.2778248620625163e-08
had O 0 3.9383096783751625e-09
a O 0 9.037583459381437e-10
germ O 0 1.025161850520817e-06
- O 0 1.1395363799238112e-06
line O 0 4.971925591235049e-07
E1317Q O 0 5.47464605915593e-06
missense O 0 2.677841450804408e-07
variant O 0 3.374668438027584e-07
of O 0 4.18797085899314e-08
APC O 0 7.853374484056985e-08
that O 0 1.2899468992966234e-10
was O 0 1.119740966615268e-09
not O 0 1.4945306103797407e-10
present O 0 5.648457396256745e-11
in O 0 4.69159822102938e-10
controls O 0 1.077448885666854e-08
; O 0 1.9842563703242888e-10
one O 0 6.426710275064806e-10
of O 0 1.279139849597044e-10
these O 0 1.1920841050394593e-11
individuals O 0 1.402064922495505e-11
had O 0 1.099030311202398e-09
an O 0 5.6412863963517523e-11
unusually O 0 1.375813574178153e-09
large O 0 4.456214286463478e-10
number O 0 1.106848035448138e-08
of O 0 1.3017976030482714e-08
metaplastic B-Disease 0 1.0247023055853788e-05
polyps I-Disease 0 1.9479255115584238e-06
of I-Disease 0 4.740309478279414e-08
the I-Disease 0 1.540533958177548e-07
colorectum I-Disease 0 2.706261511775665e-05
. O 0 4.191063567304809e-07

There O 0 8.170516707650677e-08
is O 0 5.59794377519296e-10
increasing O 0 5.163839356114863e-10
evidence O 0 4.962673605390933e-10
that O 0 2.0372859649286923e-11
there O 0 5.0214471469800515e-11
exist O 0 7.552192204940411e-10
germ O 0 1.5283355025985657e-07
- O 0 1.9434239106885798e-08
line O 0 3.1728428773192263e-09
variants O 0 4.270911180270787e-09
of O 0 6.663442242427209e-09
the O 0 6.842884481272904e-09
APC B-Disease 0 3.6175908491031805e-08
gene O 0 1.4220501443062972e-09
that O 0 1.0446728204716038e-10
predispose O 0 3.914802704230169e-08
to O 0 8.689208463863451e-09
the O 0 1.7903958315912405e-09
development O 0 9.381414756148843e-09
of O 0 6.0136291502033146e-09
multiple O 0 3.946358265238814e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999402761459351
carcinoma I-Disease 1 1.0
, O 0 4.4274619526163406e-09
but O 0 1.1953633916039763e-10
without O 0 9.409151235928448e-10
the O 0 2.031990797846106e-09
florid O 0 5.590724754256371e-07
phenotype O 0 3.425340722174042e-08
of O 0 7.426450121528205e-09
classical O 0 9.038246417958362e-08
FAP B-Disease 0 1.0028728780753227e-07
, O 0 7.55462289947495e-11
and O 0 9.952943851032625e-12
possibly O 0 5.515846113191003e-10
with O 0 3.647598282446873e-12
importance O 0 5.433417982203537e-07
for O 0 0.0001138463121606037
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 5.52107167095528e-07
in O 0 8.236099025005217e-10
the O 0 7.726923545448017e-10
general O 0 1.4807923776061216e-09
population O 0 7.489526360204835e-12
. O 0 1.8284568303883475e-10
. O 0 1.3328442349802572e-08

Genomic O 0 4.6849672230564465e-07
structure O 0 1.6373700617577924e-08
of O 0 7.663930823298415e-09
the O 0 1.816618677707993e-08
human O 0 3.8636929389213037e-07
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 9.951272517128018e-08
CLD B-Disease 1 0.5572547912597656
) O 0 6.496630788888069e-09
gene O 0 4.114605189897702e-08
. O 0 1.1083374147347058e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 2.711456126291978e-08
CLD B-Disease 1 0.9974849224090576
) O 0 3.1497431329796655e-09
is O 0 4.885556958988957e-10
caused O 0 9.007433132701692e-10
by O 0 2.257919198833669e-11
mutations O 0 2.1956764184594135e-10
in O 0 2.5163342520784227e-09
a O 0 4.102519213233791e-09
gene O 0 6.660135221103758e-10
which O 0 8.564629561114145e-10
encodes O 0 5.5618465388818095e-09
an O 0 1.6517921475056596e-09
intestinal O 0 6.313011340353114e-07
anion O 0 1.6631872767902678e-07
transporter O 0 2.229915594398335e-07
. O 0 1.5137673869958235e-07

We O 0 1.9228686198857758e-07
report O 0 1.0581116427488269e-08
here O 0 4.462519243020324e-09
the O 0 1.0714029663461133e-09
complete O 0 3.039066776011623e-09
genomic O 0 3.0006443552110795e-08
organization O 0 6.647422168271078e-09
of O 0 3.112994084730758e-09
the O 0 4.1128296324188796e-09
human O 0 1.140198513382984e-08
CLD B-Disease 0 1.6997884813463315e-05
gene O 0 8.843298537897226e-09
which O 0 4.946636433800222e-10
spans O 0 3.447201690764956e-10
approximately O 0 3.343461271732018e-11
39kb O 0 2.558746992065153e-08
, O 0 1.7435880517169267e-10
and O 0 2.9576724402957666e-10
comprises O 0 2.0189754312838204e-09
21 O 0 2.834131862528011e-07
exons O 0 3.604848757277068e-07
. O 0 1.2723259601443715e-07

All O 0 3.486337050162547e-07
exon O 0 1.8855848793464247e-06
/ O 0 5.239282018010272e-06
intron O 0 1.1789045402110787e-06
boundaries O 0 3.2889930778878806e-09
conform O 0 9.666523226314894e-08
to O 0 5.716356810125944e-08
the O 0 5.925958035390977e-08
GT O 0 4.79401605844032e-05
/ O 0 3.499664308037609e-05
AG O 0 3.081201793975197e-05
rule O 0 9.691890227259137e-06
. O 0 1.0944246469080099e-06

An O 0 1.2077125077780693e-08
analysis O 0 3.3985398939506695e-09
of O 0 1.922379366803284e-09
the O 0 1.5384711282706576e-09
putative O 0 2.3239605795311036e-08
promoter O 0 5.19400238374601e-08
region O 0 6.6401484311029435e-09
sequence O 0 1.5456624868903646e-09
shows O 0 1.7924092432508587e-08
a O 0 2.637182205944555e-08
putative O 0 1.1303525297989836e-06
TATA O 0 3.233262987123453e-06
box O 0 1.7466095414420124e-07
and O 0 1.8927415190717056e-09
predicts O 0 4.875896575384786e-09
multiple O 0 4.343291004627048e-10
transcription O 0 1.706607477558464e-08
factor O 0 2.368558504883822e-08
binding O 0 4.811580467389831e-08
sites O 0 3.40600507797717e-07
. O 0 1.9208890478239482e-07

The O 0 3.4299569051654544e-07
genomic O 0 1.0290529672829507e-07
structure O 0 1.0300166941590305e-08
was O 0 1.3156738809527724e-08
determined O 0 1.1208135530793584e-09
using O 0 1.1840860514311657e-09
DNA O 0 2.498938389550176e-09
from O 0 9.953199375800637e-10
several O 0 1.3503144435933478e-10
sources O 0 5.454288687367637e-10
including O 0 1.7109527336578445e-11
multiple O 0 1.3566237022644145e-10
large O 0 1.2892319434243404e-09
- O 0 1.4295626726834598e-07
insert O 0 1.1649221960396972e-06
libaries O 0 4.3794480575343187e-07
and O 0 4.0334785511575433e-10
genomic O 0 3.743032106484634e-09
DNA O 0 3.6963490046559855e-09
from O 0 1.8529916490095388e-09
Finnish O 0 4.644007731258171e-06
CLD B-Disease 0 0.18449895083904266
patients O 0 1.561086946821888e-06
and O 0 1.088312995278784e-08
controls O 0 6.6558118305692915e-06
. O 0 1.7467207271693042e-06

Exon O 0 2.759003564278828e-06
- O 0 4.293767403851234e-07
specific O 0 1.6797260471435038e-08
primers O 0 9.461708572189309e-08
developed O 0 5.1942268264326685e-09
in O 0 5.693728266642495e-10
this O 0 9.644539333830693e-11
study O 0 1.3837131440652684e-10
will O 0 5.067650118983913e-11
facilitate O 0 2.105473351221576e-09
mutation O 0 1.709586916476269e-10
screening O 0 5.983398776443494e-10
studies O 0 1.0394701988047927e-08
of O 0 2.6178064160831127e-09
patients O 0 1.642160629700129e-09
with O 0 2.6052911564211634e-11
the O 0 3.516360536082175e-09
disease O 0 8.987153243822377e-09
. O 0 1.8977599935965372e-08

Genomic O 0 3.975496198904693e-08
sequencing O 0 1.866528620553254e-08
of O 0 2.2168114455212162e-08
a O 0 7.260690182420149e-08
BAC O 0 0.0005509508191607893
clone O 0 2.8879583624075167e-05
H O 1 1.0
_ O 0 1.1614480044386255e-08
RG364P16 O 0 6.149821274448186e-08
revealed O 0 1.2722496389727667e-09
the O 0 9.200233630490828e-11
presence O 0 2.3081786482137545e-10
of O 0 5.593780993962127e-10
another O 0 3.2124466975425037e-10
, O 0 3.477219900904771e-11
highly O 0 3.4207342514136485e-10
homologous O 0 4.463325542491958e-10
gene O 0 1.8759573894300274e-09
3 O 0 2.2525034637510544e-07
of O 0 7.904046128714981e-08
the O 0 8.836996556738086e-08
CLD B-Disease 0 3.612225555116311e-05
gene O 0 1.7608213553899077e-08
, O 0 6.231583582483324e-10
with O 0 3.1869108046977956e-11
a O 0 1.8256839373620437e-09
similar O 0 1.0124465849026265e-10
genomic O 0 2.0430939162707773e-09
structure O 0 1.9728680911157426e-09
, O 0 1.5018804255806373e-10
recently O 0 2.969577084233066e-10
identified O 0 3.2609076550116356e-10
as O 0 4.746782966691399e-10
the O 0 3.4551963068452096e-08
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 6.264014729140399e-08
( O 0 4.5556641792288133e-10
PDS B-Disease 0 1.9711995946636307e-07
) O 0 1.3124692999078036e-10
. O 0 1.1915306519227897e-09
. O 0 1.758136569662838e-08

The O 0 2.312501010237611e-06
APCI1307K O 1 0.5957181453704834
allele O 0 6.961632607271895e-06
and O 0 5.043355955081097e-09
cancer B-Disease 0 2.7915314149140613e-07
risk O 0 8.168004939079765e-09
in O 0 1.0507783532176518e-09
a O 0 1.5390875240939295e-09
community O 0 2.2765760110399214e-10
- O 0 1.3175992519265378e-09
based O 0 1.9629878278415447e-10
study O 0 7.247622502148943e-10
of O 0 4.209284587552986e-10
Ashkenazi O 0 5.42416671578394e-08
Jews O 0 5.102818079194549e-08
. O 0 4.859493429876238e-08

Mutations O 0 3.125673629256198e-06
in O 0 1.6770120225828578e-07
APC O 0 3.688386129852006e-07
are O 0 4.244030404887411e-10
classically O 0 3.3991096870522597e-07
associated O 0 3.544719220371917e-07
with O 0 1.098727295811841e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 6.705413113650138e-09
FAP B-Disease 0 2.0132588929300255e-07
) O 0 8.631090286925769e-11
, O 0 4.301564660025292e-11
a O 0 2.668165466346295e-09
highly O 0 0.008417859673500061
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 7.455132436007261e-05
by O 0 7.600500229187901e-10
multiple O 0 3.350168853444302e-08
intestinal O 0 0.0014680750900879502
polyps B-Disease 0 5.023849780627643e-07
and O 0 1.5036660805378688e-10
, O 0 1.3783388493060489e-11
without O 0 1.3492176820228963e-10
surgical O 0 5.435082428562055e-08
intervention O 0 8.417989192821551e-06
, O 0 4.833743405541213e-10
the O 0 1.0309248565931739e-08
development O 0 7.258167897816747e-05
of O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.718693987129427e-08
CRC B-Disease 0 2.48918195211445e-06
) O 0 2.7943685143583252e-09
. O 0 1.0710871833907731e-07

APC B-Disease 0 1.0314743121853098e-05
is O 0 1.5738356395900155e-08
a O 0 2.0665948952114377e-08
tumour O 1 1.0
- O 0 7.276292990354705e-07
suppressor O 0 5.248906518318108e-07
gene O 0 1.3470334181420185e-08
, O 0 3.2701757968212064e-10
and O 0 3.674079374071937e-10
somatic O 0 1.5395380614791065e-06
loss O 0 1.8173402338561573e-07
occurs O 0 1.6984341044690154e-08
in O 0 7.705457960582862e-08
tumours B-Disease 1 1.0
. O 0 3.2960931548586814e-06

The O 0 1.4796180494158762e-06
germline O 0 1.5203689827103517e-06
T O 0 4.946301856989521e-08
- O 0 4.734108660642278e-09
to O 0 9.069875406275685e-10
- O 0 3.8448999539753e-09
A O 0 2.0235477737884366e-09
transversion O 0 8.113024030365068e-09
responsible O 0 1.2452165687459882e-10
for O 0 1.216125256053857e-10
the O 0 4.068505088383745e-09
APC O 0 4.0988692262544646e-07
I1307K O 0 3.1109771043702494e-06
allele O 0 3.029293438316927e-08
converts O 0 5.7668820829803735e-09
the O 0 1.4092677025345779e-09
wild O 0 3.1625475571672723e-09
- O 0 6.294729737454929e-10
type O 0 5.881753972758474e-10
sequence O 0 2.315940217378909e-10
to O 0 4.536434783375398e-09
a O 0 3.31217435700637e-08
homopolymer O 0 3.776760786422528e-05
tract O 0 5.998922461003531e-07
( O 0 1.1691576595751485e-09
A8 O 0 1.4722606067607558e-07
) O 0 6.75207112443843e-11
that O 0 5.4215078607033895e-12
is O 0 7.2304380364929255e-12
genetically O 0 9.56388856998558e-10
unstable O 0 5.458123908397283e-08
and O 0 9.907804354725158e-09
prone O 0 1.421332740392245e-07
to O 0 8.93252263267641e-08
somatic O 0 4.427457497513387e-06
mutation O 0 9.914990783954636e-08
. O 0 2.8114195060879865e-07

The O 0 8.91075558229204e-07
I1307K O 0 5.814948053739499e-06
allele O 0 5.2964548302725234e-08
was O 0 4.499286276882231e-09
found O 0 2.741459004251823e-10
in O 0 8.297814657609592e-10
6 O 0 6.899463755871693e-07
. O 0 1.9835778175547603e-07

1 O 0 6.285429208219284e-06
% O 0 1.3601673742869025e-07
of O 0 7.515627942211722e-08
unselected O 0 0.0002919042017310858
Ashkenazi O 0 9.062618119060062e-06
Jews O 0 2.773362552943581e-07
and O 0 1.1669609722986252e-09
higher O 0 1.2501963908562175e-08
proportions O 0 2.796042508634855e-09
of O 0 2.4802768727738567e-09
Ashkenazim O 0 4.65174593955453e-07
with O 0 2.2080316741668327e-10
family O 0 1.1179830394780765e-08
or O 0 3.4401950177453955e-09
personal O 0 1.198088170895062e-07
histories O 0 9.278703316795145e-08
of O 0 2.8692376474737102e-08
CRC B-Disease 0 8.306725794682279e-05
( O 0 7.998093853878174e-10
ref O 0 7.98357461917476e-07
. O 0 1.7948098562925452e-09
2 O 0 7.51767785800439e-08
) O 0 3.4963034689639017e-09
. O 0 5.677987147123531e-08

To O 0 2.566224921451976e-08
evaluate O 0 3.540232285104139e-08
the O 0 2.531927778548493e-09
role O 0 2.9795828027090465e-08
of O 0 3.7968323596260234e-08
I1307K O 0 1.6616016864645644e-06
in O 0 1.9084818170256312e-09
cancer B-Disease 0 5.6581890284235214e-09
, O 0 8.18173376271325e-11
we O 0 8.70220728810267e-10
genotyped O 0 1.8622547770519304e-07
5 O 0 2.7706846594810486e-07
, O 0 1.3890242733793912e-08
081 O 0 2.8538399419630878e-05
Ashkenazi O 0 4.1600753775128396e-07
volunteers O 0 2.988855030139348e-08
in O 0 1.2972658502974355e-09
a O 0 2.8340025881590236e-09
community O 0 2.0765114072673896e-09
survey O 0 7.1440862114968695e-09
. O 0 2.6318458523633126e-08

Risk O 0 4.890101990895346e-06
of O 0 2.9337298812492918e-08
developing O 0 1.152761706180172e-05
colorectal B-Disease 1 1.0
, I-Disease 0 1.6518311895197257e-05
breast I-Disease 1 1.0
and I-Disease 0 3.212861088286445e-07
other I-Disease 0 3.866803055529999e-08
cancers I-Disease 0 2.8081713026040234e-06
were O 0 1.2477046062997488e-08
compared O 0 1.0779752201983683e-08
between O 0 1.4521790436816673e-09
genotyped O 0 1.1251557907598908e-06
I1307K O 0 1.2243788205523742e-07
carriers O 0 5.465692343165074e-10
and O 0 1.5207786419058067e-10
non O 0 3.445154206360712e-08
- O 0 6.351452253028356e-09
carriers O 0 1.0411961293144145e-09
and O 0 7.7082396021666e-11
their O 0 2.6482890880252796e-10
first O 0 9.289354285790807e-10
- O 0 2.0007357992568586e-09
degree O 0 1.6989750051266128e-08
relatives O 0 7.589888895154218e-08
. O 0 7.291959036592743e-08

Sperm O 0 5.725729934624724e-08
DNA O 0 3.3920510844609453e-09
analysis O 0 1.080762035421401e-09
in O 0 3.2216769252357835e-09
a O 0 8.708940413271193e-08
Friedreich B-Disease 0 0.0005872681504115462
ataxia I-Disease 0 0.0013032977003604174
premutation O 0 0.0003390508354641497
carrier O 0 3.7945090980429086e-07
suggests O 0 7.879000207822173e-08
both O 0 2.5175967977020264e-09
meiotic O 0 7.119535325728066e-07
and O 0 6.0733045259553364e-09
mitotic O 0 1.0928667393272917e-07
expansion O 0 1.0610769152208377e-07
in O 0 7.161931936394694e-09
the O 0 5.603052688485377e-09
FRDA B-Disease 0 1.758698658704816e-06
gene O 0 1.7480184411056143e-08
. O 0 1.8262042544847645e-07

Friedreich B-Disease 1 0.9999663829803467
ataxia I-Disease 1 0.9999985694885254
is O 0 6.696839705000457e-08
usually O 0 1.295661711253615e-08
caused O 0 4.1055386867938637e-10
by O 0 2.857865853689301e-12
an O 0 3.381155381718126e-12
expansion O 0 4.022875643716617e-10
of O 0 1.1047046610812572e-09
a O 0 1.8584850325353841e-09
GAA O 0 2.093229767297089e-08
trinucleotide O 0 1.4350702315368835e-07
repeat O 0 4.064813374782261e-09
in O 0 4.1941081718732676e-09
intron O 0 1.758694168074726e-07
1 O 0 3.149237670641014e-07
of O 0 4.03994988573686e-08
the O 0 5.7941843323305875e-08
FRDA B-Disease 0 1.4744829968549311e-05
gene O 0 1.0443754661082494e-07
. O 0 6.567686341441004e-07

Occasionally O 0 6.026929213476251e-07
, O 0 1.8215169372837181e-09
a O 0 3.4633631518232733e-09
fully O 0 6.195548962750763e-08
expanded O 0 4.8822364817624475e-08
allele O 0 7.13760570647537e-08
has O 0 2.1021900886708522e-10
been O 0 9.715973858792637e-11
found O 0 2.4562645320469478e-11
to O 0 1.407660515928555e-10
arise O 0 1.6242977796121494e-10
from O 0 5.58350310431166e-11
a O 0 4.772092165872266e-10
premutation O 0 4.477142567793635e-08
of O 0 7.88178855515298e-10
100 O 0 2.1369835678797244e-08
or O 0 8.48146164411645e-10
less O 0 1.5161692346055133e-08
triplet O 0 7.263944894475571e-07
repeats O 0 1.675240923759702e-07
. O 0 4.805187927559018e-07

We O 0 8.287366313197708e-07
have O 0 5.277373205103686e-09
examined O 0 9.142480550394794e-09
the O 0 1.087275047773062e-09
sperm O 0 4.092952643475201e-09
DNA O 0 3.5209373194788895e-09
of O 0 7.232863197259576e-09
a O 0 1.9800694417426712e-08
premutation O 0 1.097747599487775e-06
carrier O 0 4.5869004594578655e-08
. O 0 5.334265438250441e-07

This O 0 6.455402967731061e-08
mans O 0 1.5835183830859023e-06
leucocyte O 0 6.733405939485237e-07
DNA O 0 2.8310919830687453e-08
showed O 0 9.567067138505081e-09
one O 0 1.937969507093129e-10
normal O 0 4.452512136765563e-09
allele O 0 2.8906921301086186e-09
and O 0 2.2704746416302157e-10
one O 0 3.992102481920057e-10
allele O 0 1.4817304050396274e-09
of O 0 5.729361984840864e-10
approximately O 0 1.1931948484811272e-10
100 O 0 3.3631785356647015e-08
repeats O 0 1.3133420573296917e-08
. O 0 6.022447252007623e-08

His O 0 1.4633566252086894e-06
sperm O 0 1.0162259513890604e-06
showed O 0 4.427312205734779e-08
an O 0 5.383631040967174e-11
expanded O 0 4.786139262691336e-10
allele O 0 2.746620930693666e-09
in O 0 1.1484767581393385e-09
a O 0 1.536044180738827e-08
tight O 0 1.2062395171597018e-07
range O 0 2.120952125039821e-08
centering O 0 9.33126353963587e-10
on O 0 9.86683845738412e-10
a O 0 3.388130886960994e-10
size O 0 4.041287027245488e-10
of O 0 3.399640569057283e-10
approximately O 0 7.927648815186927e-11
320 O 0 1.4335815201604873e-08
trinucleotide O 0 3.0448845791397616e-06
repeats O 0 3.1231897423822375e-07
. O 0 8.470693160234077e-07

His O 0 2.13094313039619e-06
affected O 0 2.5693796601444774e-07
son O 0 5.098550445836736e-06
has O 0 1.3172248847226342e-09
repeat O 0 1.2901075763238623e-09
sizes O 0 3.905731293940562e-09
of O 0 3.191409136960033e-09
1040 O 0 6.998484280984485e-08
and O 0 4.440147360895708e-09
540 O 0 7.848011023270374e-07
. O 0 2.0785140009138559e-07

These O 0 1.6018788073779433e-07
data O 0 3.9931421724759275e-08
suggest O 0 7.371676047362996e-10
that O 0 2.00239716301176e-12
expansion O 0 1.0048799986561718e-10
occurs O 0 9.973352872727492e-12
in O 0 6.802065855016082e-12
two O 0 2.5327402935343413e-12
stages O 0 1.941590638265822e-11
, O 0 2.6956112689213718e-11
the O 0 3.1477537243418396e-10
first O 0 1.4390378888506916e-09
during O 0 2.7386590772948693e-09
meiosis O 0 2.580024416332094e-09
followed O 0 4.465045555512859e-10
by O 0 1.73269992104208e-11
a O 0 1.131922777730665e-09
second O 0 6.197094837290251e-09
mitotic O 0 3.101705488006701e-07
expansion O 0 1.3332912658370333e-06
. O 0 7.241962975967908e-07

We O 0 8.047021538004628e-08
also O 0 1.466418653173207e-09
show O 0 1.0782645887275066e-09
that O 0 1.8905821352888097e-11
in O 0 8.859125932847434e-11
all O 0 9.014252538852574e-11
informative O 0 1.4743555265539499e-09
carrier O 0 2.989490321958499e-10
father O 0 4.739954651000744e-09
to O 0 7.549718183952336e-09
affected O 0 2.1759491986017565e-09
child O 0 1.040589037160089e-08
transmissions O 0 5.976183814482283e-08
, O 0 9.050551280642694e-11
with O 0 1.0433003419518805e-11
the O 0 1.1781791098286476e-09
notable O 0 8.845859045258919e-10
exception O 0 2.87644175145374e-09
of O 0 3.860343988915105e-10
the O 0 3.426748607093799e-10
premutation O 0 3.359235734023969e-08
carrier O 0 1.903033286509981e-09
, O 0 2.2964803669811573e-10
the O 0 9.297686509590619e-10
expansion O 0 1.3374661378406927e-08
size O 0 2.5164061945304184e-09
decreases O 0 2.7648912048761076e-09
. O 0 1.164332963377035e-09
. O 0 5.327051511017089e-08

The O 0 7.704016411480552e-07
R496H O 0 1.7497050066594966e-05
mutation O 0 5.405081182630056e-08
of O 0 1.7864772772213655e-08
arylsulfatase O 0 6.666242825303925e-06
A O 0 2.807898624723748e-07
does O 0 3.917041357937023e-09
not O 0 3.0111120263853763e-09
cause O 0 2.4186860514419095e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 4.317815637477906e-06

Deficiency B-Disease 0 0.050608616322278976
of I-Disease 0 2.0620846044039354e-05
arylsulfatase I-Disease 1 0.5112345218658447
A I-Disease 0 0.0002019504754571244
( O 0 3.732333198058768e-08
ARSA O 0 0.00013003840285819024
) O 0 2.0190678018394692e-09
enzyme O 0 2.0930380983941177e-08
activity O 0 2.2299666113667627e-07
causes O 0 8.808000870885735e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.3753537803372637e-08
MLD B-Disease 1 1.0
) O 0 1.4837221229413444e-08
. O 0 7.355628639515999e-08

A O 0 7.046770633678534e-07
number O 0 1.7814956621009514e-08
of O 0 2.732206283440064e-08
ARSA O 0 0.00010481888602953404
gene O 0 6.326427381964095e-08
mutations O 0 2.983182412208407e-08
responsible O 0 7.324464945668296e-08
for O 0 3.0476599022222217e-07
MLD B-Disease 1 1.0
have O 0 8.396515482900213e-08
been O 0 4.50204185042935e-09
identified O 0 1.2982046548870585e-08
. O 0 5.995319440899038e-08

Recently O 0 2.9493054398699314e-07
, O 0 8.352405989064948e-10
the O 0 1.6572009320370285e-09
R496H O 0 6.703983217448695e-07
mutation O 0 9.896150565680273e-09
of O 0 1.0079581613808841e-08
ARSA O 0 5.8354555221740156e-05
was O 0 7.652715083850126e-08
proposed O 0 1.8844492633007803e-09
to O 0 5.356685650603765e-10
be O 0 3.1343935780192567e-10
a O 0 7.834784487847912e-10
cause O 0 3.589176733598265e-09
of O 0 1.1869810911946388e-08
MLD B-Disease 1 1.0
( O 0 6.642213445928746e-09
Draghia O 0 7.060075972731283e-07
et O 0 1.5553938226275932e-07
al O 0 2.3347708122400945e-07
. O 0 7.632446341609977e-10
, O 0 1.0076611767217969e-10
1997 O 0 3.8873744223622e-09
) O 0 1.6367135424744106e-09
. O 0 3.1095716224172065e-08

We O 0 3.601120681651082e-07
have O 0 3.290097305708173e-09
investigated O 0 7.870345264393563e-09
the O 0 7.657384060166805e-09
R496H O 0 2.516749191272538e-06
mutation O 0 3.0267623962743073e-09
and O 0 1.967268292712987e-10
found O 0 9.228635217128911e-11
this O 0 5.712750758557483e-11
mutation O 0 2.113882263676814e-10
at O 0 1.1323870729995633e-09
a O 0 2.373458374282933e-10
relatively O 0 5.994361951255911e-11
high O 0 2.706780979910839e-11
frequency O 0 1.0870878502933223e-10
in O 0 3.284451183249715e-11
an O 0 4.129552949594384e-11
African O 0 1.0418516049881532e-09
American O 0 3.479610211076789e-10
population O 0 1.618760030533406e-12
( O 0 6.290807718495328e-13
f O 0 1.3605865323285116e-09
= O 0 7.100343868415848e-09
0 O 0 1.010593053685227e-09
. O 0 1.012037328940174e-10
09 O 0 3.213957455727723e-08
, O 0 2.8894503456555753e-10
n O 0 6.2668923384023856e-09
= O 0 1.5954329057876748e-07
61 O 0 2.1016790086036963e-08
subjects O 0 2.4197284176352696e-08
) O 0 2.849716462804963e-09
. O 0 5.85484123405422e-08

The O 0 9.990932994696777e-06
ARSA O 0 5.678875822923146e-05
enzyme O 0 1.9430160591582535e-08
activity O 0 1.938366978038175e-08
in O 0 4.681202092626791e-10
subjects O 0 5.203726782809781e-09
with O 0 3.5891916608937757e-12
and O 0 1.8174199992171403e-11
without O 0 4.724229341057651e-10
the O 0 6.033110677705622e-10
R496H O 0 6.616206604803665e-08
mutation O 0 2.64306104780232e-10
was O 0 6.333086277621192e-10
determined O 0 1.2546772509836046e-09
and O 0 6.08291139680972e-10
found O 0 1.0378770065599952e-09
to O 0 3.4244111990489046e-09
be O 0 3.0489659685883908e-09
normal O 0 2.5601877950975904e-07
. O 0 4.1510000414746173e-07

It O 0 1.4806180281823345e-08
is O 0 5.592093108020002e-11
therefore O 0 2.2748571082420455e-10
concluded O 0 2.2195771887112414e-09
that O 0 4.814933174390745e-11
the O 0 1.3009007204800582e-09
R496H O 0 1.465691866542329e-06
mutation O 0 6.858567758172285e-08
of O 0 2.120887465650867e-08
ARSA O 0 4.1718263673828915e-05
does O 0 1.0319872068009772e-08
not O 0 1.1210273820339012e-09
negatively O 0 1.18683551875165e-09
influence O 0 1.825465467675258e-08
the O 0 6.098807237009396e-09
activity O 0 1.9443286092268863e-08
of O 0 2.4406037191226915e-09
ARSA O 0 4.865744813287165e-06
and O 0 1.1041780823006775e-09
is O 0 6.865638613184899e-11
not O 0 2.5375443413189203e-10
a O 0 1.0059832966646809e-09
cause O 0 2.0825767776955217e-08
of O 0 1.9620132718500827e-07
MLD B-Disease 1 1.0

Down O 0 1.3510828466678504e-05
- O 0 3.3577803151274566e-06
regulation O 0 2.3858190161263337e-06
of O 0 1.626274865884625e-07
transmembrane O 0 5.310819801707112e-07
carbonic O 0 6.811942148488015e-05
anhydrases O 0 6.628852133871987e-05
in O 0 7.113671358638385e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 2.316119207534939e-08
by O 0 1.0901280989017437e-09
wild O 0 1.2827649698010646e-07
- O 0 6.709304898322443e-07
type O 0 2.060034421447199e-05
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 0.9998652935028076
Lindau I-Disease 0 0.19320936501026154
transgenes O 0 0.0009176670573651791
. O 0 6.270042831602041e-06

To O 0 2.2982674181548646e-06
discover O 0 7.445670462402632e-07
genes O 0 2.2796371013100725e-08
involved O 0 2.0170404013697407e-08
in O 0 9.21833844813591e-08
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 0.9999984502792358
( O 0 8.440125043307489e-08
VHL B-Disease 0 0.00047940757940523326
) O 0 2.627582418313068e-08
- O 0 6.399927201528044e-07
mediated O 0 9.55868586061115e-07
carcinogenesis O 0 0.15697112679481506
, O 0 2.432990697798232e-09
we O 0 2.2340007621579616e-09
used O 0 2.590449987849297e-08
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 3.970419584220508e-07
stably O 0 1.5854933508308022e-06
transfected O 0 2.6481964710001193e-07
with O 0 4.870707726034595e-10
wild O 0 7.786034217360793e-08
- O 0 1.8732556839040626e-07
type O 0 2.8200495307828533e-06
VHL O 0 0.27941620349884033
- O 0 0.000849507050588727
expressing O 0 2.928843287008931e-06
transgenes O 0 4.386736691230908e-05
. O 0 1.0454072025822825e-06

Large O 0 2.7782194322867326e-08
- O 0 3.346975319118428e-08
scale O 0 1.8759868325446405e-08
RNA O 0 3.191136954683316e-08
differential O 0 8.966695475010056e-08
display O 0 5.318814721988474e-09
technology O 0 6.893755255532596e-08
applied O 0 3.0193550060175767e-07
to O 0 9.627622254981816e-09
these O 0 5.410831227514734e-10
cell O 0 1.1304259750488654e-08
lines O 0 1.2102391311330507e-09
identified O 0 8.705399956454585e-09
several O 0 5.757779253379169e-10
differentially O 0 2.2309622238481097e-07
expressed O 0 3.404950321694855e-09
genes O 0 7.002844415460174e-10
, O 0 3.8940806135201456e-10
including O 0 4.3769970980989115e-10
an O 0 6.371505545388345e-10
alpha O 0 3.8535358015678867e-08
carbonic O 0 8.923469181354449e-07
anhydrase O 0 4.865781647822587e-06
gene O 0 1.4614052190609073e-07
, O 0 1.4745531906612541e-08
termed O 0 2.725825424931827e-06
CA12 O 0 0.0004492293519433588
. O 0 1.7828540421760408e-06

The O 0 1.0185875680690515e-06
deduced O 0 2.004744317218865e-07
protein O 0 1.7898837967322834e-09
sequence O 0 3.1505648090401905e-10
was O 0 2.0888097918003723e-09
classified O 0 1.0957567075919883e-09
as O 0 7.396943058068928e-10
a O 0 3.0664739636421245e-09
one O 0 6.684417463986847e-10
- O 0 1.525181829720168e-07
pass O 0 1.8264341861140565e-07
transmembrane O 0 3.6795992741645023e-07
CA O 0 1.8291118976776488e-05
possessing O 0 8.9276829839946e-07
an O 0 1.0171859798902005e-08
apparently O 0 1.9804892303909583e-07
intact O 0 7.015538017185463e-08
catalytic O 0 8.956641650570418e-09
domain O 0 5.666442959295637e-08
in O 0 1.091689316723432e-08
the O 0 2.1288593998747274e-08
extracellular O 0 2.0643756215577014e-07
CA O 0 4.81258120998973e-06
module O 0 6.52461153549666e-07
. O 0 2.797490594730334e-07

Reintroduced O 0 1.4370589269674383e-05
wild O 0 2.366730768699199e-06
- O 0 1.4600250324292574e-06
type O 0 5.955560027359752e-07
VHL B-Disease 0 0.0007526029949076474
strongly O 0 2.0119766475090728e-07
inhibited O 0 2.1031912922353513e-07
the O 0 2.0571329528706883e-08
overexpression O 0 2.399543461706344e-07
of O 0 6.4643699282385114e-09
the O 0 2.5722119989524117e-09
CA12 O 0 1.9324721733937622e-07
gene O 0 3.911991841576423e-10
in O 0 1.0277162454386257e-09
the O 0 1.4395437730740923e-08
parental O 0 0.0008075397345237434
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 1.8804470300892717e-06
. O 0 1.7706811377138365e-06

Similar O 0 7.328867468459066e-08
results O 0 4.4624086648070715e-09
were O 0 7.18869686000545e-10
obtained O 0 6.211271497136295e-09
with O 0 1.5371856565415953e-10
CA9 O 0 2.2103271476225927e-05
, O 0 4.311442314275382e-09
encoding O 0 5.306262806925588e-08
another O 0 6.567548638258813e-08
transmembrane O 0 2.0574002235207445e-07
CA O 0 1.1076041118940338e-05
with O 0 1.4752951082996901e-09
an O 0 2.9046363092533056e-09
intact O 0 2.1025154239850963e-07
catalytic O 0 4.023831934318878e-07
domain O 0 3.6528106193145504e-06
. O 0 4.0364690789829183e-07

Although O 0 2.6211807835352374e-07
both O 0 5.478188125351835e-09
domains O 0 4.591452196223145e-08
of O 0 2.0653891041888528e-08
the O 0 1.0032800368264816e-08
VHL B-Disease 0 2.891724989240174e-06
protein O 0 5.805731007058057e-09
contribute O 0 7.606537621995813e-09
to O 0 7.149757230706655e-09
regulation O 0 4.156855197834375e-07
of O 0 2.0705250847186107e-07
CA12 O 0 7.883321814006194e-05
expression O 0 2.3672357940540678e-07
, O 0 2.0978010439876016e-09
the O 0 3.803013015613033e-09
elongin O 0 1.1355133722190658e-07
binding O 0 4.218071225636777e-09
domain O 0 3.1306804260111676e-08
alone O 0 3.6185687779521913e-09
could O 0 2.1345128442540329e-10
effectively O 0 3.526717584634298e-09
regulate O 0 7.243469468676267e-08
CA9 O 0 0.0006249037105590105
expression O 0 1.7295353245572187e-05
. O 0 2.3196730580821168e-06

We O 0 4.866700692218728e-06
mapped O 0 2.1859857497474877e-06
CA12 O 0 3.972502236138098e-05
and O 0 9.220571683954404e-08
CA9 O 0 0.00016481727652717382
loci O 0 3.692193786264397e-07
to O 0 8.524610706217572e-08
chromosome O 0 2.0709943981955803e-08
bands O 0 3.1353059171124187e-07
15q22 O 0 3.3700673611747334e-06
and O 0 1.9788686245192366e-08
17q21 O 0 1.5074106158863287e-05
. O 0 3.9991334688238567e-07

2 O 0 9.320826848124852e-07
respectively O 0 1.373258697867641e-07
, O 0 9.470799700039834e-10
regions O 0 1.2016917461110665e-09
prone O 0 8.2242364030094e-09
to O 0 3.460121300591368e-09
amplification O 0 5.8013281289959195e-08
in O 0 4.934485176022463e-08
some O 0 1.1621503759329244e-08
human O 0 1.5745353465490552e-08
cancers B-Disease 0 7.88695160736097e-07
. O 0 8.601012524422913e-08

Additional O 0 3.7052879520160786e-07
experiments O 0 1.0180477794108356e-08
are O 0 3.058713698989024e-11
needed O 0 1.5794673347002686e-09
to O 0 3.661612679728421e-10
define O 0 2.18667506324266e-09
the O 0 1.5041373702118221e-09
role O 0 2.447168157004853e-08
of O 0 1.3770264217782824e-07
CA O 0 4.309555151849054e-06
IX O 0 6.598805339308456e-05
and O 0 1.465782588638831e-07
CA O 0 8.132321454468183e-06
XII O 0 2.9169909794291016e-06
enzymes O 0 1.8620545105818564e-09
in O 0 8.472283319349572e-09
the O 0 9.797642697151332e-09
regulation O 0 1.192593543919429e-07
of O 0 4.0520173882896415e-09
pH O 0 5.142103987054725e-08
in O 0 1.5587156010354875e-09
the O 0 2.884930738744629e-09
extracellular O 0 1.3144246580054642e-08
microenvironment O 0 2.5115986090895603e-07
and O 0 2.357828376986504e-10
its O 0 1.263099763670894e-10
potential O 0 2.794783016124569e-10
impact O 0 9.733568617775745e-09
on O 0 5.30377377572222e-08
cancer B-Disease 0 1.2538194482658582e-07
cell O 0 1.905422664094658e-07
growth O 0 6.742672553627926e-08
. O 0 1.3124360975780291e-07

A O 0 6.562927978848165e-07
gene O 0 2.2541531308206686e-08
encoding O 0 2.3981570507203287e-07
a O 0 2.6176437017966236e-07
transmembrane O 0 5.0748830915381404e-08
protein O 0 1.9697971254117874e-08
is O 0 9.255887722936507e-11
mutated O 0 2.664854559242258e-09
in O 0 4.2591705162742244e-10
patients O 0 1.2563013740418683e-08
with O 0 5.250823664759707e-10
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.00028257883968763053
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 0 4.196929694444407e-06
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 7.873152796378236e-09
. O 0 7.047927397252352e-08

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.692034684059763e-07
WFS B-Disease 0 0.013239070773124695
; O 0 2.8320695122374673e-08
OMIM O 0 2.8828402719227597e-05
222300 O 0 5.523136223928304e-07
) O 0 1.674471949986156e-10
is O 0 1.1871134630858649e-10
an O 0 1.0231083757972215e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 6.414261832787815e-08
by O 0 6.182921535868857e-11
young O 0 4.9113837441439046e-09
- O 0 1.799414690140111e-06
onset O 1 1.0
non O 1 1.0
- O 1 0.9999983310699463
immune O 1 1.0
insulin B-Disease 1 1.0
- I-Disease 1 1.0
dependent I-Disease 1 1.0
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 5.9784924815176055e-06
progressive O 1 0.9999308586120605
optic B-Disease 0 0.021924149245023727
atrophy I-Disease 0 4.369468297227286e-05
. O 0 1.7121425344157615e-06

Linkage O 0 1.6300430161209079e-06
to O 0 3.391871672420166e-08
markers O 0 2.1218907519937602e-08
on O 0 7.815985725301289e-08
chromosome O 0 1.5326382651892345e-07
4p O 0 2.468443381076213e-05
was O 0 3.2203882227577196e-08
confirmed O 0 3.4575153851079676e-09
in O 0 5.950394066367437e-10
five O 0 1.7700130250375423e-09
families O 0 5.539758651806892e-10
. O 0 1.80861867704607e-08

On O 0 2.103777063666712e-07
the O 0 5.612186715353573e-09
basis O 0 2.1519293014193863e-08
of O 0 4.4660697362530755e-09
meiotic O 0 0.00011206790804862976
recombinants O 0 0.006879481486976147
and O 0 2.930284992430643e-08
disease O 0 7.602188247801678e-07
- O 0 1.07635656831917e-07
associated O 0 1.1658073617581977e-07
haplotypes O 0 5.52983976831456e-07
, O 0 2.3204955734712485e-09
the O 0 1.1790115550525115e-08
WFS B-Disease 0 3.2697153073968366e-05
gene O 0 4.105579876068077e-09
was O 0 6.792352902351695e-09
localized O 0 1.1890929130231598e-08
to O 0 7.362630061180653e-09
a O 0 5.9546234609797466e-08
BAC O 0 0.002064683008939028
/ O 0 5.695307845599018e-05
P1 O 0 5.079006768937688e-06
contig O 0 1.0137558092537802e-05
of O 0 1.4490587396664978e-08
less O 0 5.647752043813625e-09
than O 0 4.0957229274773965e-10
250 O 0 2.8239837135402013e-08
kb O 0 4.188724687992362e-06
. O 0 5.494870833899768e-07

Mutations O 0 6.920907935636933e-08
in O 0 5.914685630159511e-09
a O 0 1.991111719945593e-09
novel O 0 2.8206501578864618e-09
gene O 0 2.1195034616283692e-09
( O 0 2.851503755341156e-10
WFS1 O 0 1.5738319234515075e-06
) O 0 8.019785391333301e-10
encoding O 0 2.691063727411347e-08
a O 0 6.132684404747124e-08
putative O 0 7.550829081992561e-07
transmembrane O 0 8.986742017214056e-09
protein O 0 5.072149367180145e-10
were O 0 1.0565395780481879e-10
found O 0 5.264961383533162e-11
in O 0 5.086950999322326e-11
all O 0 4.7475412490172175e-11
affected O 0 2.8954236577782844e-11
individuals O 0 1.1190090737703273e-12
in O 0 3.19532372783371e-10
six O 0 1.5412915388424153e-08
WFS B-Disease 0 5.792874071630649e-05
families O 0 3.926883818117233e-10
, O 0 1.7258072748660425e-10
and O 0 8.990778954665046e-11
these O 0 2.544727484288245e-10
mutations O 0 4.709986844986247e-10
were O 0 4.18423018455627e-10
associated O 0 2.785152553030912e-09
with O 0 2.9097141363010337e-10
the O 0 4.923898799802373e-08
disease O 0 6.437021227156947e-08
phenotype O 0 1.2118290371176954e-08
. O 0 4.9087923059687455e-08

WFS1 O 0 6.275309715420008e-05
appears O 0 4.030744804595088e-08
to O 0 9.965605007877798e-10
function O 0 2.9756780373091374e-10
in O 0 8.732468637084878e-10
survival O 0 0.00020726815273519605
of O 0 1.0507046788177377e-08
islet O 0 3.143035343100564e-08
beta O 0 8.639469228910457e-08
- O 0 8.695462838659296e-08
cells O 0 1.2717457309463498e-08
and O 0 1.463571264181951e-09
neurons O 0 1.1382234710310968e-08
. O 0 1.1110614650533535e-08
. O 0 1.6532277413716656e-07

Stable O 0 1.390555189573206e-05
interaction O 0 5.683022497038337e-09
between O 0 1.5099803352125463e-10
the O 0 4.1451639343215163e-10
products O 0 3.355763222856467e-09
of O 0 1.3468889337175938e-09
the O 0 5.3862247995084545e-09
BRCA1 O 0 1.7706959454244497e-08
and O 0 8.557628383698557e-09
BRCA2 O 0 4.337640646667751e-08
tumor B-Disease 0 2.498568107967003e-08
suppressor O 0 3.360126399343244e-08
genes O 0 1.1604132099662934e-09
in O 0 5.068051756040859e-09
mitotic O 0 3.961448271638801e-07
and O 0 3.2040421871215585e-08
meiotic O 0 1.0714120435295627e-05
cells O 0 1.3339958968572319e-06
. O 0 1.123802348956815e-06

BRCA1 O 0 6.72693204251118e-05
and O 0 1.7122324891261087e-07
BRCA2 O 0 2.881427292322769e-07
account O 0 3.0590492361426413e-09
for O 0 7.00654118057642e-11
most O 0 4.012297005057119e-12
cases O 0 9.030338109228264e-12
of O 0 7.379409583396779e-11
familial O 0 1.8671044710316664e-09
, O 0 5.977007777602239e-11
early O 0 2.2169677649230835e-08
onset O 0 0.0099977757781744
breast B-Disease 0 0.47977983951568604
and I-Disease 0 3.162945358781144e-05
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.8403271724309889e-06
encode O 0 2.444941360479902e-09
products O 0 2.605224258545036e-09
that O 0 1.2437442568902224e-11
each O 0 3.1556855652897786e-12
interact O 0 9.684614221683319e-11
with O 0 1.7267094698514285e-10
hRAD51 O 0 1.5180899026745465e-06
. O 0 4.434745619619207e-07

Results O 0 5.3149541656694055e-08
presented O 0 8.908850546163194e-09
here O 0 4.602866088276869e-09
show O 0 9.7305052904062e-09
that O 0 3.399672765524997e-10
BRCA1 O 0 1.588065323687715e-08
and O 0 5.947537573547379e-09
BRCA2 O 0 1.2561126538912504e-07
coexist O 0 9.298719128025823e-09
in O 0 2.930071074658258e-09
a O 0 2.890912620401309e-09
biochemical O 0 1.1207350603115174e-08
complex O 0 2.1239925374061386e-08
and O 0 6.956108578037856e-09
colocalize O 0 3.0147509733069455e-06
in O 0 2.726454262358402e-08
subnuclear O 0 2.105000248775468e-06
foci O 0 2.365843130291978e-07
in O 0 4.040610512845433e-09
somatic O 0 1.7070078683900647e-08
cells O 0 1.4860324082377474e-09
and O 0 2.1154634988196364e-10
on O 0 1.1759460072369166e-08
the O 0 1.2295837681364219e-09
axial O 0 2.1099599845086914e-09
elements O 0 5.450786932925666e-09
of O 0 5.603512320817572e-09
developing O 0 3.257019542957096e-08
synaptonemal O 0 2.6307500320399413e-06
complexes O 0 1.9274439466698823e-07
. O 0 4.974658054379688e-07

Like O 0 1.2590236337928218e-06
BRCA1 O 0 1.0990140708599938e-06
and O 0 5.2737636480060246e-08
RAD51 O 0 2.720418524404522e-05
, O 0 4.893395910698928e-08
BRCA2 O 0 3.9560268305649515e-07
relocates O 0 1.2553917372315482e-07
to O 0 1.1073844952136369e-08
PCNA O 0 2.538917840411159e-07
+ O 0 1.5780830864287054e-08
replication O 0 2.1807512740057433e-10
sites O 0 1.2207179711509752e-09
following O 0 7.373109900399299e-10
exposure O 0 5.296838878621202e-08
of O 0 2.7294704274538617e-09
S O 0 1.6225382637458097e-07
phase O 0 4.383693763543306e-08
cells O 0 3.277547122593205e-08
to O 0 1.2261141080216476e-07
hydroxyurea O 0 1.7639344150666147e-05
or O 0 2.511315813080728e-07
UV O 0 0.00045318572665564716
irradiation O 0 3.817546712525655e-06
. O 0 4.7395772639902134e-07

Thus O 0 3.341672254464356e-07
, O 0 9.16983022847262e-09
BRCA1 O 0 3.6759896460125674e-08
and O 0 1.983712527575676e-09
BRCA2 O 0 3.176223017931079e-08
participate O 0 3.738123144358951e-09
, O 0 9.269066764128198e-11
together O 0 1.2477241462249822e-11
, O 0 3.180953070391901e-11
in O 0 1.4408663151499468e-10
a O 0 5.702934235962687e-10
pathway O 0 1.2736166565829876e-09
( O 0 1.2657526415882359e-10
s O 0 1.8046385719117097e-08
) O 0 2.6483433501756082e-11
associated O 0 7.031553117542444e-10
with O 0 1.6676056369124836e-11
the O 0 6.67339794535593e-10
activation O 0 4.699382660788842e-09
of O 0 5.209096487490683e-10
double O 0 2.606346249933722e-10
- O 0 1.1242007325051873e-09
strand O 0 8.586366617713281e-10
break O 0 1.8340331919830533e-08
repair O 0 2.2122372911326238e-07
and O 0 1.0116909088253578e-08
/ O 0 3.193288193870103e-06
or O 0 7.2962826891398436e-09
homologous O 0 2.8076714286839888e-09
recombination O 0 3.630203471161053e-09
. O 0 3.1986811421802486e-08

Dysfunction O 1 0.9999440908432007
of O 0 5.737531409977237e-06
this O 0 2.441916668871613e-09
pathway O 0 2.015728028936792e-09
may O 0 1.7018338127616772e-10
be O 0 7.281454605934101e-11
a O 0 1.4470354081641545e-10
general O 0 5.466640473628104e-10
phenomenon O 0 7.291979242651792e-10
in O 0 6.558702192460686e-11
the O 0 3.6588343466092965e-10
majority O 0 2.0241940068554953e-11
of O 0 1.3996875880550874e-10
cases O 0 1.1335057892303269e-10
of O 0 2.0227606256639774e-09
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9999796152114868
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.0227931599947624e-05
. O 0 8.926763825911621e-07

A O 0 4.072257695497683e-07
novel O 0 2.6315094103779302e-08
Arg362Ser O 0 5.251710604170512e-07
mutation O 0 5.279404136082633e-10
in O 0 1.7742439462065107e-10
the O 0 5.363954280745986e-10
sterol O 0 2.7958787285342623e-08
27 O 0 1.0665914942364907e-06
- O 0 2.902274047755782e-07
hydroxylase O 0 1.913018650157028e-06
gene O 0 1.0913728587524929e-08
( O 0 6.4156235879409e-11
CYP27 O 0 4.448236552434537e-07
) O 0 3.5040508689077043e-11
: O 0 2.0745695092361238e-11
its O 0 2.84406075079513e-11
effects O 0 1.9508321624783775e-09
on O 0 7.74770647637979e-09
pre O 0 1.0779303494246051e-07
- O 0 6.35064090204196e-09
mRNA O 0 2.162989343190702e-09
splicing O 0 1.1146699563369111e-08
and O 0 1.0464701327705939e-09
enzyme O 0 2.548172339800203e-09
activity O 0 2.6729649604817496e-08
. O 0 3.837194739730876e-08

A O 0 1.4068800169297901e-07
novel O 0 1.2291575757217288e-08
C O 0 3.774838432946126e-07
to O 0 8.338033041788151e-10
A O 0 5.408564263120752e-09
mutation O 0 2.3012421135337746e-10
in O 0 1.994775317148978e-10
the O 0 9.942403567109181e-10
sterol O 0 1.907478441864896e-08
27 O 0 8.489496394759044e-07
- O 0 4.900938392893295e-07
hydroxylase O 0 1.8623663891048636e-06
gene O 0 1.8145408731129464e-08
( O 0 2.6858973378729445e-10
CYP27 O 0 1.1917288702534279e-06
) O 0 3.242573709538732e-10
was O 0 3.4876648236092933e-09
identified O 0 1.1608338734703239e-09
by O 0 5.00346396259399e-11
sequencing O 0 1.4231090084138032e-08
amplified O 0 1.787708612255301e-07
CYP27 O 0 3.0534422421624186e-06
gene O 0 5.210589737458804e-09
products O 0 1.7355370474092524e-08
from O 0 8.482740065929306e-10
a O 0 1.6609952302459874e-09
patient O 0 8.146891161686654e-09
with O 0 3.214015720232055e-10
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 2.0358905672424044e-08
CTX B-Disease 0 8.493405766785145e-05
) O 0 1.0682509099524395e-08
. O 0 1.6792270685073163e-07

The O 0 3.0681493967676943e-07
mutation O 0 9.190982197537778e-09
changed O 0 5.660124102746522e-08
the O 0 6.615030301304614e-09
adrenodoxin O 0 1.4890866850691964e-07
cofactor O 0 2.6270711828146887e-08
binding O 0 1.1167000657508197e-08
residue O 0 4.519552732062948e-08
362Arg O 0 3.330469411366721e-08
to O 0 2.753324013227143e-09
362Ser O 0 7.480817743044099e-08
( O 0 2.549371547200252e-10
CGT O 0 1.4869495146285772e-07
362Arg O 0 2.8509390403996804e-07
to O 0 3.407258475363051e-08
AGT O 0 1.1627262210822664e-05
362Ser O 0 1.1256650367386101e-07
) O 0 5.979083200768898e-11
, O 0 1.4596419559143037e-11
and O 0 7.116060778827871e-12
was O 0 1.7446058486747518e-10
responsible O 0 2.1807262939876892e-10
for O 0 4.549030596656678e-10
deficiency O 0 1.4288445981947007e-06
in O 0 6.441620712394069e-07
the O 0 7.04509773186146e-07
sterol O 0 3.046439189802186e-07
27 O 0 2.8280887818254996e-06
- O 0 7.707104288101618e-08
hydroxylase O 0 1.4599928022107633e-07
activity O 0 2.044107327847655e-09
, O 0 5.530821026861199e-12
as O 0 6.209366788106907e-12
confirmed O 0 2.831811347914215e-11
by O 0 1.6630564113329083e-12
expression O 0 1.5993846247397414e-09
of O 0 8.4132278921345e-10
mutant O 0 6.458450441115815e-10
cDNA O 0 4.503587724968838e-09
into O 0 1.686669359735049e-09
COS O 0 7.944763069644978e-07
- O 0 4.0016365687733924e-07
1 O 0 2.2825571477369522e-07
cells O 0 1.8779456922857207e-07
. O 0 2.6030457433989795e-07

Quantitative O 0 1.7927840190168354e-06
analysis O 0 1.3372239315856405e-08
showed O 0 3.935831216494989e-09
that O 0 1.734121526930643e-11
the O 0 3.572503126658688e-10
expression O 0 1.7964710830042918e-09
of O 0 6.456184475922555e-10
CYP27 O 0 1.0804082073434529e-08
gene O 0 1.4177236641599311e-11
mRNA O 0 1.0689366058969085e-10
in O 0 1.4296323014306722e-09
the O 0 2.3898765189045434e-09
patient O 0 8.314644084350675e-09
represented O 0 5.471292863212796e-10
52 O 0 3.5124213582093944e-07
. O 0 2.9192514716669393e-07

5 O 0 2.3173814156507433e-07
% O 0 3.827120398369743e-09
of O 0 1.9343551205253107e-09
the O 0 1.8130593693044261e-09
normal O 0 1.368779152244315e-07
level O 0 7.589004553665291e-07
. O 0 1.2521633152573486e-07

As O 0 2.393855957905089e-08
the O 0 7.149290048857893e-10
mutation O 0 3.62454719016192e-11
occurred O 0 1.1455598275533774e-10
at O 0 1.8064379159188348e-10
the O 0 3.984896093656154e-11
penultimate O 0 1.5979211287486805e-09
nucleotide O 0 2.398997001051839e-09
of O 0 4.0232461806510855e-09
exon O 0 5.109739742437114e-09
6 O 0 4.6226467986798525e-08
( O 0 9.168910769519201e-11
- O 0 9.718819526938205e-09
2 O 0 3.2671238159309723e-08
position O 0 1.5907443184914882e-07
of O 0 7.461932405306015e-09
exon O 0 5.0362068293452467e-08
6 O 0 4.877434207628539e-07
- O 0 6.363217153193546e-07
intron O 0 1.9165483990946086e-06
6 O 0 3.853881764825928e-07
splice O 0 1.1302259395051806e-07
site O 0 1.350565614899324e-08
) O 0 1.5736149883149864e-10
of O 0 7.346803165830806e-10
the O 0 1.5166488065432304e-09
gene O 0 3.2017861695265992e-09
, O 0 1.0135290384738482e-09
we O 0 3.279784221987825e-09
hypothesized O 0 5.691223048387428e-09
that O 0 8.575806037525169e-11
the O 0 8.337381340872696e-10
mutation O 0 1.7609883551372718e-09
may O 0 1.944438832168771e-09
partially O 0 4.142115539451652e-09
affect O 0 6.16252049390198e-10
the O 0 3.0087796143440926e-10
normal O 0 6.880914171780717e-10
splicing O 0 2.972637136444689e-10
efficiency O 0 6.419375697674923e-09
in O 0 3.615560961733877e-09
exon O 0 6.319914547248118e-08
6 O 0 1.9806819295808964e-07
and O 0 1.3082361860483616e-09
cause O 0 1.104700553256066e-09
alternative O 0 1.606263122511109e-09
splicing O 0 1.4203207499008386e-09
elsewhere O 0 4.7791810509068e-09
, O 0 3.714607788030122e-11
which O 0 1.4613181541570097e-12
resulted O 0 1.554782691481904e-11
in O 0 7.40540528204603e-12
decreased O 0 5.015457493762199e-10
transcript O 0 1.0448366616344629e-09
in O 0 3.246138080559291e-10
the O 0 4.744214798790836e-09
patient O 0 4.022818700377684e-08
. O 0 8.051136290987415e-08

Transfection O 0 2.293421857757494e-05
of O 0 2.4003443854780926e-07
constructed O 0 8.295052822404614e-08
minigenes O 0 8.073461685853545e-07
, O 0 8.306551280146124e-11
with O 0 1.4047061040398101e-12
or O 0 5.424179161384046e-11
without O 0 1.3817306188101952e-09
the O 0 8.314323118874256e-10
mutation O 0 3.784682012231144e-10
, O 0 6.962698473333973e-11
into O 0 4.948986220831841e-10
COS O 0 6.632745339629764e-07
- O 0 8.305239020955923e-07
1 O 0 4.840580345444323e-07
cells O 0 8.558889419418847e-08
confirmed O 0 1.1699032853584868e-08
that O 0 4.105615153404685e-11
the O 0 2.8643518112936306e-10
mutant O 0 1.1766459806494822e-08
minigene O 0 2.2862388959765667e-07
was O 0 6.01669247757286e-09
responsible O 0 7.3744038653345e-10
for O 0 3.661305425506356e-10
a O 0 4.5603157361462365e-10
mRNA O 0 2.502143603422269e-09
species O 0 9.866795575019793e-11
alternatively O 0 1.9581228305476372e-10
spliced O 0 1.9858172883857605e-09
at O 0 2.1008453643389657e-08
an O 0 1.1573452196600442e-09
activated O 0 6.550647526637476e-07
cryptic O 0 2.468202069394465e-07
5 O 0 5.153493631837591e-08
splice O 0 1.9996919320419693e-07
site O 0 4.2103007302785045e-08
88 O 0 1.9035684317714185e-07
bp O 0 1.942934702015009e-08
upstream O 0 8.337826540305571e-10
from O 0 1.4237809542461122e-10
the O 0 9.283155355532813e-10
3 O 0 7.539501467590526e-09
end O 0 5.730690588734433e-08
of O 0 3.971613704578658e-09
exon O 0 4.6214832849500453e-08
6 O 0 4.627732437256782e-07
. O 0 3.699010164837091e-07

Our O 0 9.997365850722417e-07
data O 0 1.605890354028361e-08
suggest O 0 5.340169417777929e-10
that O 0 3.0613619278474502e-12
the O 0 7.69523889054824e-11
C O 0 3.043360763399505e-08
to O 0 4.708765599659159e-10
A O 0 3.211027221894369e-09
mutation O 0 9.685777874191004e-11
at O 0 9.941986123251922e-10
the O 0 2.0753224139191673e-10
penultimate O 0 3.95048971313372e-09
nucleotide O 0 3.8371781307944275e-09
of O 0 1.4114304169865477e-09
exon O 0 6.33112051673379e-09
6 O 0 1.0141507544858541e-07
of O 0 1.8698568027275542e-08
the O 0 9.965875236161992e-09
CYP27 O 0 1.2009783176836208e-06
gene O 0 2.1235093683458217e-09
not O 0 5.605080843906762e-10
only O 0 1.8896889608654988e-10
causes O 0 3.764221712110327e-10
the O 0 5.292611904295086e-10
deficiency B-Disease 0 4.027670641448822e-08
in I-Disease 0 2.6310829071007902e-08
the I-Disease 0 1.1817282796755535e-07
sterol I-Disease 0 3.994003350271669e-07
27 I-Disease 0 5.626365691568935e-06
- I-Disease 0 2.3727824327579583e-07
hydroxylase I-Disease 0 6.668059313597041e-07
activity I-Disease 0 7.20882997740091e-09
, O 0 1.582795179644325e-11
but O 0 7.956274528098106e-12
also O 0 4.148595009190181e-11
partially O 0 2.169724400147288e-09
leads O 0 4.943116055367014e-11
to O 0 2.706372972949289e-11
alternative O 0 3.6157521421387173e-10
pre O 0 5.0966968423438175e-09
- O 0 2.572593527094824e-10
mRNA O 0 2.0468921002603224e-10
splicing O 0 5.500499611343912e-09
of O 0 4.951934862162943e-09
the O 0 5.5012443489488305e-09
gene O 0 8.0090281073808e-09
. O 0 2.7874239094671793e-07

To O 0 9.9816688248211e-08
our O 0 1.6324616325391617e-08
knowledge O 0 3.42620132265381e-09
, O 0 6.338675244410563e-12
this O 0 1.7798279126554628e-12
is O 0 8.873693880390165e-13
the O 0 5.023619107508148e-12
first O 0 2.3184770769901775e-10
report O 0 9.664703759515447e-11
regarding O 0 3.401573189787399e-10
effects O 0 3.3913070129898415e-09
on O 0 4.320241941968561e-09
pre O 0 8.408002294402195e-09
- O 0 2.4126931008616737e-10
mRNA O 0 1.3180082025776585e-10
splicing O 0 3.1503140096589277e-09
of O 0 1.3079767269275067e-09
a O 0 5.00359031985198e-10
mutation O 0 3.9654026590119074e-11
at O 0 3.9663425321911916e-10
the O 0 1.7539514285402902e-10
- O 0 1.7284568221143104e-09
2 O 0 7.033623017349555e-09
position O 0 4.2532082744628497e-08
of O 0 2.631663775787274e-09
a O 0 6.757038040205998e-09
5 O 0 7.594204021188489e-08
splice O 0 3.43374040312483e-07
site O 0 3.7434054434015707e-07
. O 0 1.4008271875809442e-07

ATM O 0 0.00014070614997763187
germline O 0 1.996598075493239e-05
mutations O 0 3.457661890138297e-08
in O 0 4.743789361327799e-09
classical O 1 0.8528321385383606
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 1.0
in O 0 1.1239139396934661e-08
the O 0 1.72653258356803e-09
Dutch O 0 8.103300075390507e-08
population O 0 3.194505771020317e-11
. O 0 6.76132705379473e-10

Germline O 0 9.630258136894554e-05
mutations O 0 1.1807740918357013e-07
in O 0 1.569473973006552e-08
the O 0 1.0510313508405034e-08
ATM O 0 6.525706197635373e-08
gene O 0 1.575113373064596e-10
are O 0 1.6249283819533278e-12
responsible O 0 4.163622138037004e-12
for O 0 3.2405998023898874e-11
the O 0 4.344985882198671e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 5.316715032677166e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.924750550751924e-08
. O 0 2.0677430256910156e-07

In O 0 4.9488306785860914e-08
our O 0 1.7869680846160918e-08
study O 0 2.94999913386107e-10
, O 0 1.0118185803098534e-11
we O 0 2.871631231415872e-11
have O 0 8.31661475797496e-12
determined O 0 2.777257868125105e-10
the O 0 1.9863628519800614e-09
ATM O 0 3.0020098620298086e-06
mutation O 0 1.9798116479563532e-09
spectrum O 0 7.846479022077801e-10
in O 0 1.3894548012149954e-10
19 O 0 1.025140328181351e-08
classical O 0 1.9313313259772258e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.740748747484758e-07
, O 0 3.364289749563376e-11
including O 0 3.846368536175593e-12
some O 0 1.3375248174643528e-12
immigrant O 0 2.8320111880586474e-11
populations O 0 1.3733634889045998e-11
, O 0 2.4277303257991267e-12
as O 0 1.4219293277550893e-11
well O 0 4.2336634198392176e-11
as O 0 1.1103400837653155e-10
12 O 0 1.959722828459576e-09
of O 0 4.0695122272005335e-10
Dutch O 0 4.5350184052495024e-08
ethnic O 0 2.0970400416153723e-10
origin O 0 6.650795469909099e-09
. O 0 5.8532108937470184e-08

Both O 0 1.0282325213495369e-08
the O 0 2.3212924915583244e-09
protein O 0 5.142500869581568e-10
truncation O 0 4.649794149713671e-08
test O 0 9.0333482916094e-09
( O 0 1.5084036242285492e-09
PTT O 0 2.8448246212064987e-06
) O 0 1.9358414871106788e-10
and O 0 1.45146367147575e-10
the O 0 6.381137840349993e-10
restriction O 0 1.3389899855553722e-08
endonuclease O 0 5.494221255730736e-08
fingerprinting O 0 1.3189331582452724e-07
( O 0 5.163721117362741e-10
REF O 0 1.0185996757172688e-07
) O 0 3.171302803695042e-11
method O 0 3.289857275490249e-10
were O 0 4.7944235387342715e-11
used O 0 1.057644527513446e-10
and O 0 8.301289343426443e-12
compared O 0 7.130085410977927e-11
for O 0 7.401596696654522e-11
their O 0 2.1523705040493724e-10
detection O 0 3.688995775519288e-09
efficiency O 0 2.5737578734918998e-09
, O 0 6.774284605493008e-11
identifying O 0 1.5329936209340644e-09
76 O 0 2.8531932372288793e-08
% O 0 2.891606121213641e-10
and O 0 5.636253269658553e-11
60 O 0 2.53107779180084e-09
% O 0 1.1476287281597664e-10
of O 0 2.7815411085541086e-10
the O 0 5.485316090236836e-10
mutations O 0 5.448975159971781e-10
, O 0 7.348260333550627e-10
respectively O 0 8.739208823271838e-08
. O 0 3.2065617006082903e-07

Most O 0 2.5444483853220845e-08
patients O 0 7.294167048144118e-09
were O 0 2.737456650248049e-10
found O 0 1.0424475171966208e-10
to O 0 4.4498951745630677e-10
be O 0 1.865951171353686e-09
compound O 0 2.9728056460953667e-07
heterozygote O 0 3.0007072382431943e-06
. O 0 2.919697124070808e-07

Seventeen O 0 3.1625540941604413e-06
mutations O 0 1.015046269259301e-08
were O 0 1.5073682302357838e-09
distinct O 0 3.6098743438905956e-10
, O 0 1.2994814946321043e-10
of O 0 1.0039202802403224e-10
which O 0 3.1763923089012103e-12
10 O 0 2.0137747025472663e-10
were O 0 9.717308208090358e-11
not O 0 3.3310063041191995e-10
reported O 0 1.6026643345767866e-09
previously O 0 2.4972720780169766e-08
. O 0 1.8864108142224723e-07

Mutations O 0 6.548585815835395e-07
are O 0 4.0623095998171266e-09
small O 0 8.843636933875132e-09
deletions O 0 3.213480113117839e-07
or O 0 2.548393069901067e-07
point O 0 1.290019326916081e-06
mutations O 0 3.52136879655518e-08
frequently O 0 1.1406531719160284e-08
affecting O 0 5.934189140077706e-09
splice O 0 3.1337336281467287e-07
sites O 0 2.2655544285044016e-07
. O 0 1.308921184772771e-07

Moreover O 0 1.521726886721808e-07
, O 0 2.978870705661052e-09
a O 0 6.559659482263669e-09
16 O 0 2.2396385190859291e-07
. O 0 1.8443242311150243e-07

7 O 0 3.2379934964410495e-06
- O 0 7.028917252682731e-07
kb O 0 3.705319613800384e-06
genomic O 0 1.6769098465374555e-07
deletion O 0 8.113182303759459e-08
of O 0 4.064665937164591e-09
the O 0 1.1257927923224997e-09
3 O 0 1.3762972095321402e-08
end O 0 4.8018435450103425e-08
of O 0 1.2748658795302958e-09
the O 0 2.4979937562896737e-10
gene O 0 6.166785831984711e-11
, O 0 2.7507284644512353e-11
most O 0 9.470826900503937e-12
likely O 0 1.7492775283844963e-10
a O 0 7.957780961964644e-11
result O 0 1.233251972765359e-10
of O 0 1.0537381384123634e-10
recombination O 0 1.3394323844506673e-11
between O 0 6.53651022197721e-11
two O 0 9.222616420556662e-11
LINE O 0 2.129292742125699e-09
elements O 0 3.2516903059054414e-10
, O 0 9.979179982355646e-11
was O 0 3.4068083909488678e-09
identified O 0 6.622718817794748e-09
. O 0 6.19051689909611e-08

The O 0 1.4065459197354357e-07
most O 0 4.879764370357975e-10
frequently O 0 1.8511749078076178e-10
found O 0 2.429111772839221e-11
mutation O 0 1.875454479216554e-11
, O 0 1.936371635952172e-12
identified O 0 7.510558841516968e-11
in O 0 9.453145211058e-11
three O 0 3.567605239007676e-11
unrelated O 0 4.1519535032286115e-10
Turkish O 0 1.1776758412906929e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 1.4342171894554667e-10
, O 0 1.80250640802182e-11
was O 0 4.990361457402059e-10
previously O 0 5.555842452764637e-10
described O 0 8.668772644160327e-11
to O 0 5.092037555498585e-11
be O 0 1.7942603999787643e-11
a O 0 1.271831667759571e-10
Turkish O 0 4.535597497579147e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
founder O 0 1.7410779037163593e-05
mutation O 0 1.0839609387858218e-07
. O 0 5.2889642887521404e-08

The O 0 8.245868343692564e-08
presence O 0 2.7384148282294518e-08
of O 0 1.7718312150805104e-08
a O 0 2.4221803229806937e-08
founder O 0 7.786551350363879e-07
mutation O 0 6.829897092330839e-09
among O 0 1.6554490417375334e-11
relatively O 0 6.341241420848576e-11
small O 0 6.1876367744850835e-12
ethnic O 0 9.849111543697164e-13
population O 0 1.3551966081444544e-13
groups O 0 1.0926344193567389e-13
in O 0 4.2020449619872835e-12
Western O 0 1.8487200659222935e-09
Europe O 0 2.66601873910588e-09
could O 0 2.1003154770937726e-09
indicate O 0 2.2023798340597978e-09
a O 0 4.313940316080789e-10
high O 0 5.949349901612777e-10
carrier O 0 1.0901193142620613e-10
frequency O 0 4.293535749155808e-09
in O 0 2.593195658207037e-10
such O 0 5.980454464982188e-10
communities O 0 2.421703060306868e-09
. O 0 5.291628113468505e-08

In O 0 3.932989400823317e-08
patients O 0 1.5375126949379592e-08
of O 0 1.000147964447251e-09
Dutch O 0 7.458663020543099e-08
ethnic O 0 8.271990037389543e-11
origin O 0 3.81784492908821e-10
, O 0 3.1609340145344333e-11
however O 0 4.362842032090697e-11
, O 0 3.0394176758763436e-11
no O 0 6.042796263372452e-10
significant O 0 3.150031568921463e-09
founder O 0 1.1622439899383608e-07
effect O 0 1.438819108301459e-08
could O 0 2.7720092887761894e-09
be O 0 1.4576345686023728e-09
identified O 0 2.461915471485554e-08
. O 0 1.4422897720578476e-07

The O 0 2.3146471050949913e-07
observed O 0 5.360155341804784e-08
genetic O 0 5.9463807211557196e-09
heterogeneity O 0 5.8896265642260914e-09
including O 0 6.613572883784613e-11
the O 0 8.030960341187665e-10
relative O 0 1.8813838664755167e-07
high O 0 1.283961950093726e-07
percentage O 0 2.472381481766206e-07
of O 0 1.9153677754957243e-08
splice O 0 6.418961788767774e-07
- O 0 3.162092752972967e-06
site O 0 2.1098247771078604e-07
mutations O 0 5.463349772583115e-09
had O 0 1.0771858960367808e-08
no O 0 3.7087357629417284e-09
reflection O 0 7.149757230706655e-09
on O 0 3.575294371671589e-08
the O 0 1.2575767982525576e-08
phenotype O 0 1.7266840757201862e-07
. O 0 1.8804566082053498e-07

All O 0 9.659553157348455e-09
patients O 0 2.5144664128617933e-10
manifested O 0 6.883615205621751e-11
classical O 0 1.7884888237063024e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
and O 0 3.143113502801498e-08
increased O 0 2.4413924393229536e-07
cellular O 0 1.1127925603204858e-07
radioresistant O 0 1.6802059121800994e-07
DNA O 0 4.930296171323789e-09
synthesis O 0 2.772360403469065e-07
. O 0 2.806233680985315e-07

Determination O 0 1.8220029005533434e-06
of O 0 2.211950516084471e-07
the O 0 1.1055357518330311e-08
genomic O 0 9.917370924483748e-09
structure O 0 2.3442110475002664e-09
of O 0 2.7279611902741863e-09
the O 0 2.532990484027664e-09
COL4A4 O 0 3.266834767146065e-07
gene O 0 5.667215585702934e-10
and O 0 3.145688987071793e-10
of O 0 3.1545590584158845e-09
novel O 0 1.5512785012106178e-07
mutations O 0 2.1651674160239054e-06
causing O 0 1.3778962966171093e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0006482545868493617

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 6.724383894152197e-08
a O 0 2.8989260769662906e-08
progressive O 0 2.6183672162005678e-05
hematuric B-Disease 1 0.9999994039535522
glomerulonephritis I-Disease 1 1.0
characterized O 0 1.9111705114482902e-05
by O 0 4.015168286741755e-08
glomerular B-Disease 1 0.9999998807907104
basement I-Disease 1 1.0
membrane I-Disease 1 0.9999997615814209
abnormalities I-Disease 0 0.07495629787445068
and O 0 4.991217994465558e-10
associated O 0 5.9197219570705784e-08
with O 0 3.1638730524363723e-10
mutations O 0 1.7235023408446182e-09
in O 0 6.201612112732846e-09
either O 0 8.143846486063921e-09
the O 0 2.9592104766607008e-08
COL4A3 O 0 3.6516960335575277e-06
or O 0 1.0915186088311657e-08
the O 0 9.774907994142268e-09
COL4A4 O 0 6.984461151660071e-07
gene O 0 2.3701027807021546e-09
, O 0 1.9082042890250506e-10
which O 0 1.9608988044428344e-11
encode O 0 1.3904497553340889e-09
the O 0 1.049148679044265e-08
alpha3 O 0 5.101891474623699e-06
and O 0 1.796016135813261e-08
alpha4 O 0 2.0432784367585555e-05
type O 0 7.993372491910122e-06
IV O 1 0.999984622001648
collagen O 0 2.8676386136794463e-05
chains O 0 4.377495770313544e-06
, O 0 3.949645943635005e-09
respectively O 0 6.075959646523188e-08
. O 0 1.524710597777812e-07

To O 0 4.60605633634259e-08
date O 0 1.1445917635910519e-07
, O 0 5.174408679309295e-10
mutation O 0 2.3031028473230464e-11
screening O 0 5.268027680749299e-10
in O 0 2.2111095177024254e-09
the O 0 2.458865111520936e-08
two O 0 1.051762787973587e-09
genes O 0 9.070048601067526e-10
has O 0 1.3850440239160378e-10
been O 0 1.8472316731799054e-10
hampered O 0 4.363728489664709e-09
by O 0 6.555650466921747e-11
the O 0 4.857091173704475e-09
lack O 0 4.865493963279732e-08
of O 0 1.808548755199979e-09
genomic O 0 2.4916853025303e-09
structure O 0 1.260573201378179e-09
information O 0 1.0298556674115389e-08
. O 0 3.284756999732963e-08

We O 0 1.3937314236045495e-07
report O 0 2.0092367769564135e-09
here O 0 4.8224535476038e-10
the O 0 1.56449311838891e-10
complete O 0 6.726147971924945e-10
characterization O 0 1.2712454422469932e-09
of O 0 7.862688833348841e-10
the O 0 1.0591287846750674e-09
48 O 0 5.260713109578319e-08
exons O 0 1.4296602124375113e-08
of O 0 6.191849255543502e-09
the O 0 1.6479914322076183e-08
COL4A4 O 0 6.542720257129986e-06
gene O 0 9.048730653660186e-09
, O 0 1.1811357447655269e-09
a O 0 8.418509223062642e-10
comprehensive O 0 5.166620020702339e-09
gene O 0 3.292242589658656e-10
screen O 0 5.958221915847162e-09
, O 0 8.312515120678654e-10
and O 0 1.00627495225325e-09
the O 0 1.317229880726245e-09
subsequent O 0 1.3679192223392533e-09
detection O 0 6.783678507815694e-09
of O 0 1.211864775196858e-10
10 O 0 7.175738336862025e-10
novel O 0 7.326652062822347e-10
mutations O 0 5.587831308773161e-10
in O 0 7.424123538157801e-10
eight O 0 4.08510647531557e-09
patients O 0 4.847558354725834e-09
diagnosed O 0 1.6218265841416724e-07
with O 0 1.3652898367411126e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.992831473937258e-05

Furthermore O 0 5.892033527743479e-07
, O 0 2.9736595408280664e-09
we O 0 3.557864447500947e-09
identified O 0 5.004184622237062e-09
a O 0 2.1233390601338442e-09
glycine O 0 2.3193198472881704e-08
to O 0 2.3196605525299674e-08
alanine O 0 6.746840597315895e-08
substitution O 0 1.882248881202031e-07
in O 0 7.348799613282608e-08
the O 0 8.474678736547503e-08
collagenous O 0 8.726913733880792e-07
domain O 0 2.32582197945419e-09
that O 0 4.400598375281506e-12
is O 0 9.957456950995813e-13
apparently O 0 9.571254899753967e-11
silent O 0 1.4710073159562853e-09
in O 0 5.342645215122843e-10
the O 0 1.5016921040000852e-09
heterozygous O 0 2.070972837664442e-10
carriers O 0 5.926208829221125e-11
, O 0 2.987887021133062e-11
in O 0 6.301216770587814e-10
11 O 0 1.7247008088361326e-07
. O 0 1.8779725508011325e-07

5 O 0 4.1842463360808324e-07
% O 0 6.064819313422731e-09
of O 0 1.3274700227938752e-09
all O 0 1.2833774321041602e-10
control O 0 1.1533500821059306e-09
individuals O 0 9.542923742889009e-12
, O 0 1.7921466394232866e-11
and O 0 3.476715790262652e-11
in O 0 1.1918034337199401e-09
one O 0 1.1236047647855685e-09
control O 0 5.59113866316352e-09
individual O 0 5.332861374718334e-10
homozygous O 0 1.9142456508802752e-09
for O 0 5.795305901834524e-10
this O 0 4.658462504636418e-10
glycine O 0 2.4474061888213328e-08
substitution O 0 9.30638748286583e-08
. O 0 2.9809473289788e-07

There O 0 7.977259741664966e-08
has O 0 4.1029085684485267e-10
been O 0 8.339730989126437e-11
no O 0 1.6839972472038056e-10
previous O 0 8.2158596592663e-10
finding O 0 4.206357040459352e-09
of O 0 9.718574833783578e-10
a O 0 5.255151869221208e-10
glycine O 0 2.5654600666058514e-09
substitution O 0 9.610558571182537e-09
that O 0 1.2445801333971218e-10
is O 0 1.722784068181049e-11
not O 0 4.0827657227238134e-11
associated O 0 2.108916929977056e-10
with O 0 8.230343490067682e-12
any O 0 1.2960242878889972e-09
obvious O 0 8.979717414092647e-09
phenotype O 0 4.597092928548818e-09
in O 0 1.0602161371053853e-09
homozygous O 0 5.403408831483603e-09
individuals O 0 2.068296367507827e-10
. O 0 4.438633638415013e-08

Founder O 0 8.712548878975213e-05
BRCA1 O 0 2.1050825580459787e-06
and O 0 4.1078301649122295e-08
BRCA2 O 0 2.6332574520893104e-07
mutations O 0 3.1767604102839186e-09
in O 0 7.615959418671991e-09
French O 0 3.969832050643163e-06
Canadian O 0 0.00039564084727317095
breast B-Disease 1 1.0
and I-Disease 1 0.9999986886978149
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.202253762741748e-07
. O 0 5.930638735662797e-07

We O 0 9.60678647743407e-08
have O 0 8.088608116629814e-10
identified O 0 8.823985986339267e-10
four O 0 1.2334518129097916e-10
mutations O 0 5.28198006166658e-11
in O 0 1.0251511445291683e-10
each O 0 1.2871377574885656e-10
of O 0 5.692395443901432e-09
the O 0 3.9830788978179044e-07
breast B-Disease 1 0.9989628791809082
cancer I-Disease 0 0.00045101108844392
- O 0 7.745138645987026e-06
susceptibility O 0 8.479996154164837e-07
genes O 0 3.223571809485293e-08
, O 0 2.0426430324960165e-08
BRCA1 O 0 3.2255154991389645e-08
and O 0 1.9237374360159265e-08
BRCA2 O 0 1.2125576631660806e-07
, O 0 4.766997352412261e-10
in O 0 1.374620084426681e-09
French O 0 4.1177108300871623e-07
Canadian O 0 8.023509394661232e-07
breast B-Disease 0 9.112068255490158e-06
cancer I-Disease 0 5.18902879775851e-06
and O 0 1.0324436516384594e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.5557187655067537e-07
from O 0 1.2474096422465664e-08
Quebec O 0 8.323150382238964e-07
. O 0 3.327339754832792e-07

To O 0 8.685001944286341e-07
identify O 0 4.7312499873441993e-07
founder O 0 1.2062320138284122e-06
effects O 0 9.666680853115395e-06
, O 0 1.2281241801304077e-08
we O 0 2.0959623370231384e-08
examined O 0 3.0903375858315485e-08
independently O 0 3.389090608152401e-08
ascertained O 0 1.1040449408028508e-06
French O 0 4.5215443833512836e-07
Canadian O 0 3.6298803252066136e-07
cancer B-Disease 0 2.796652331937821e-08
families O 0 1.904000741792533e-11
for O 0 1.6040082456703075e-11
the O 0 3.2185660386874204e-11
distribution O 0 5.5110058877483326e-11
of O 0 2.027928241998822e-10
these O 0 2.0266290035042545e-10
eight O 0 4.029781841552449e-09
mutations O 0 3.861317932063457e-09
. O 0 1.6593531881881063e-07

Mutations O 0 3.2414146033943325e-08
were O 0 2.377736896264082e-09
found O 0 2.355410033683114e-10
in O 0 3.0742319800936e-10
41 O 0 3.548093729932589e-08
of O 0 4.846421042259408e-09
97 O 0 1.3746570175499073e-06
families O 0 6.085096426744485e-09
. O 0 9.910642262411784e-08

Six O 0 7.415886216222134e-07
of O 0 2.5628891009432664e-08
eight O 0 3.884157884215256e-09
mutations O 0 2.815198907324401e-10
were O 0 9.868194039697187e-10
observed O 0 1.4763196221068142e-09
at O 0 1.3631821893511642e-08
least O 0 3.4233924584015085e-09
twice O 0 3.5644884377461494e-08
. O 0 1.2373155300338112e-07

The O 0 3.290135509814718e-06
BRCA1 O 0 1.2551323607112863e-06
C4446T O 0 1.359295083602774e-06
mutation O 0 5.2926751870074895e-09
was O 0 4.828714761373476e-09
the O 0 1.1240334218953763e-09
most O 0 6.196190782681299e-11
common O 0 1.1789878795465114e-10
mutation O 0 1.2173367869294793e-10
found O 0 8.904658260755483e-12
, O 0 6.783745440386291e-12
followed O 0 1.4730505704108054e-10
by O 0 4.794268107510824e-11
the O 0 2.440931012870351e-08
BRCA2 O 0 4.310827534936834e-07
8765delAG O 0 6.603428346352302e-07
mutation O 0 1.6968700222719235e-08
. O 0 1.2346303890353738e-07

Together O 0 1.8511379096253222e-08
, O 0 6.956529796653399e-10
these O 0 4.300104369803215e-11
mutations O 0 3.299231027265037e-11
were O 0 7.275652302851654e-11
found O 0 3.7782752621007276e-11
in O 0 1.0486295165534898e-10
28 O 0 4.6007968990124937e-08
of O 0 2.780635277588317e-09
41 O 0 9.800035449814004e-09
families O 0 4.1131393430093866e-11
identified O 0 4.383630680671047e-10
to O 0 2.8470432678062707e-09
have O 0 8.590663291840883e-09
a O 0 5.091491672715165e-08
mutation O 0 8.54251425153052e-08
. O 0 2.849305644758715e-07

The O 0 2.2938829147278739e-07
odds O 0 5.526966901925334e-07
of O 0 4.08717992783636e-09
detection O 0 3.161982320420975e-08
of O 0 1.9887738123003373e-09
any O 0 1.6223821175387343e-09
of O 0 7.4467618738083274e-09
the O 0 9.862891836576182e-09
four O 0 7.610790220269337e-09
BRCA1 O 0 5.073264475186079e-09
mutations O 0 4.839131317879719e-10
was O 0 1.4994403940704615e-08
18 O 0 3.3623774697844055e-07
. O 0 8.454398425783438e-07

7x O 0 0.00032887980341911316
greater O 0 1.6749199005516857e-07
if O 0 1.5921779450422946e-08
one O 0 4.3189624099326807e-10
or O 0 8.483415359084034e-11
more O 0 5.746187813765458e-12
cases O 0 7.274625346553876e-11
of O 0 9.991151017629818e-09
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 5.674684899759086e-08
also O 0 1.951631217744776e-10
present O 0 5.2730816241242096e-11
in O 0 7.183955097467276e-10
the O 0 2.560485157232506e-08
family O 0 4.7362068045231354e-08
. O 0 3.071416472266719e-07

The O 0 3.803334891472332e-07
odds O 0 7.546525466750609e-07
of O 0 4.33650537701169e-09
detection O 0 5.362087662774684e-08
of O 0 1.9910662008015834e-09
any O 0 2.2491186690842824e-09
of O 0 8.65947757944241e-09
the O 0 1.6553252990547662e-08
four O 0 1.835618590462218e-08
BRCA2 O 0 5.0877638102519995e-08
mutations O 0 1.7096822846340842e-09
was O 0 2.548771504962133e-08
5 O 0 1.0364807394580566e-06
. O 0 7.255706009345886e-07

3x O 0 0.00018070818623527884
greater O 0 9.153198021749631e-08
if O 0 2.7091595633521592e-09
there O 0 2.335939219832994e-10
were O 0 4.863930924692283e-10
at O 0 6.934617879927885e-10
least O 0 6.025149823507547e-11
five O 0 1.606426970612862e-11
cases O 0 2.4322318464831127e-11
of O 0 2.440602442366213e-10
breast B-Disease 0 2.3056188069858763e-07
cancer I-Disease 0 7.872826301991154e-08
in O 0 6.803674779121138e-08
the O 0 1.195431650558021e-06
family O 0 4.3052153841927066e-07
. O 0 1.313870370722725e-06

Interestingly O 0 2.4129241182890837e-07
, O 0 7.414401870242671e-10
the O 0 4.579709944607657e-10
presence O 0 1.1522396370367005e-09
of O 0 4.159945277137922e-09
a O 0 8.287699415632233e-08
breast B-Disease 0 4.631300180335529e-05
cancer I-Disease 0 6.133550414233468e-07
case O 0 3.348966215455107e-09
< O 0 4.681885741320002e-07
36 O 0 6.490849102647189e-08
years O 0 5.9302744936928775e-09
of O 0 7.023082670976066e-10
age O 0 2.3751440814123725e-09
was O 0 2.284537226060479e-09
strongly O 0 2.6878191339285706e-10
predictive O 0 3.3676958999251383e-09
of O 0 1.7706343058421226e-09
the O 0 1.0158167640383908e-09
presence O 0 1.7420198616946436e-09
of O 0 5.381827206107914e-10
any O 0 6.735044744132779e-10
of O 0 5.562013072335503e-10
the O 0 1.077917088920799e-09
eight O 0 7.623222053609879e-10
mutations O 0 3.0558694463778124e-10
screened O 0 1.7900314119856375e-08
. O 0 7.971394211381266e-07

Carriers O 0 6.038042954514822e-08
of O 0 9.58368673309451e-09
the O 0 1.7571836208318814e-09
same O 0 1.2203058563642344e-09
mutation O 0 2.14084083793864e-10
, O 0 7.440758946486437e-12
from O 0 6.6760516385933055e-12
different O 0 6.591028070546123e-12
families O 0 1.1942257079067264e-11
, O 0 1.1412586153891624e-11
shared O 0 1.1008340072837797e-10
similar O 0 3.548738039538257e-11
haplotypes O 0 5.028640615023505e-09
, O 0 3.9830058695677906e-10
indicating O 0 8.580019361659197e-09
that O 0 1.0412114920255178e-10
the O 0 5.15117892785355e-10
mutant O 0 3.7092593441201416e-09
alleles O 0 1.0885527201853762e-10
were O 0 1.2755681233489469e-10
likely O 0 1.5158845012575028e-10
to O 0 1.16432349872575e-10
be O 0 4.389418342687357e-11
identical O 0 5.010673820304845e-11
by O 0 7.200752581010272e-12
descent O 0 1.6171917138763092e-09
for O 0 2.2824540868437992e-10
a O 0 3.2742197841884035e-10
mutation O 0 9.923642463327553e-11
in O 0 1.732968490930631e-10
the O 0 1.9532522266274555e-09
founder O 0 8.987534272364428e-08
population O 0 6.555375686723153e-11
. O 0 5.579611883632651e-09

The O 0 2.423127654083146e-08
identification O 0 4.0954848401497657e-08
of O 0 1.735010890513422e-08
common O 0 1.1293855095573235e-07
BRCA1 O 0 5.311731570145639e-07
and O 0 2.2745425098946725e-08
BRCA2 O 0 9.444399751146193e-08
mutations O 0 8.155967012868359e-10
will O 0 8.60190640938896e-10
facilitate O 0 1.981225317138069e-08
carrier O 0 1.5928089958094915e-09
detection O 0 1.0787653081933968e-07
in O 0 1.1321673376585295e-08
French O 0 5.459411568153882e-06
Canadian O 0 6.757517894584453e-06
breast B-Disease 0 0.00030408601742237806
cancer I-Disease 0 3.371258935658261e-05
and O 0 6.421278612833703e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.138019332662225e-06
. O 0 1.347666398032743e-06

Are O 0 1.200987043148416e-07
Dp71 O 0 3.401608773856424e-05
and O 0 4.8865874902048745e-08
Dp140 O 0 4.4970944145461544e-05
brain O 0 5.934604359936202e-06
dystrophin O 0 1.5575059251204948e-06
isoforms O 0 2.4159749045793433e-07
related O 0 7.987917882701367e-08
to O 0 1.1742986139040568e-08
cognitive B-Disease 0 1.8566348671811284e-06
impairment I-Disease 0 8.977868128567934e-05
in O 0 7.598160664201714e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999942779541016

Molecular O 0 1.761689986778947e-06
study O 0 3.510398016715044e-08
and O 0 1.0625178514800382e-09
neuropsychological O 0 3.8043136640908415e-08
analysis O 0 1.4106122936397014e-09
were O 0 1.565992557850393e-09
performed O 0 2.0672916711816924e-09
concurrently O 0 4.545095855235104e-09
on O 0 9.352882024415976e-09
49 O 0 2.281925404190588e-08
patients O 0 4.01236421865292e-09
with O 0 1.2672364269050718e-09
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.4863556998534477e-06
DMD B-Disease 1 1.0
) O 0 1.1235489205674298e-09
in O 0 3.8263156532103437e-10
order O 0 5.039429984421417e-10
to O 0 3.03969738268961e-10
find O 0 1.010893813102598e-09
a O 0 1.0929174232288119e-10
molecular O 0 3.091324696224973e-10
explanation O 0 1.0377106951509063e-09
for O 0 2.3537483073710064e-10
the O 0 2.3366846235717276e-09
cognitive B-Disease 0 9.652002290749806e-07
impairment I-Disease 0 8.997688638601176e-08
observed O 0 5.340067832371176e-10
in O 0 9.162901548620539e-10
most O 0 5.6521054503377854e-09
DMD B-Disease 1 1.0
patients O 0 1.2907339907997084e-07
. O 0 1.847614150563004e-08

Complete O 0 2.5338238174299477e-07
analysis O 0 1.847297070867171e-08
of O 0 3.767614220606674e-09
the O 0 3.020937278108704e-09
dystrophin O 0 2.3956465255992043e-08
gene O 0 2.1800952154649167e-09
was O 0 6.966238697003746e-09
performed O 0 3.1660842836345182e-09
to O 0 6.9018439852186475e-09
define O 0 3.9727822809254576e-08
the O 0 2.7714820660662554e-08
localization O 0 3.068893784075044e-05
of O 0 2.4560088718317274e-07
deletions O 0 1.3097903206471528e-07
and O 0 3.854357277788267e-09
duplications O 0 3.724069941313246e-08
in O 0 3.2032156926931066e-09
relation O 0 6.006522390578084e-09
to O 0 6.606544200593589e-09
the O 0 4.497733296915385e-09
different O 0 7.326417694741849e-09
DMD B-Disease 1 1.0
promoters O 0 1.4247883882489987e-05
. O 0 1.7550761413076543e-06

Qualitative O 0 1.072519808076322e-06
analysis O 0 2.8241723626365456e-08
of O 0 1.1890929130231598e-08
the O 0 1.2005330063402653e-08
Dp71 O 0 1.9960500594606856e-06
transcript O 0 4.0022769098868594e-08
and O 0 1.9051021871163698e-10
testing O 0 2.5045107654442234e-10
for O 0 2.5571721823380855e-11
the O 0 1.2104647839628058e-10
specific O 0 4.999660130344807e-10
first O 0 3.385716595971644e-09
exon O 0 1.6061170171610684e-08
of O 0 8.808284768235808e-09
Dp140 O 0 8.218184461838973e-07
were O 0 3.5617480076410857e-09
also O 0 5.077714915202591e-10
carried O 0 1.1514971198778312e-09
out O 0 8.923574101871168e-10
. O 0 2.4749191140926996e-08

Neuropsychological O 0 1.2296837667236105e-05
analysis O 0 6.15337683029793e-08
assessed O 0 3.325905595374934e-07
verbal O 0 2.3511827862421342e-07
and O 0 2.8878499591655782e-08
visuospatial O 0 5.221202445682138e-05
intelligence O 0 1.5658955589969992e-06
, O 0 1.0050210441647778e-08
verbal O 0 1.780823879471427e-07
memory O 0 1.652099126658868e-05
, O 0 4.5755124133961544e-09
and O 0 1.1687385503833525e-09
reading O 0 3.805395465406036e-07
skills O 0 1.2812583918275777e-05
. O 0 1.316457883149269e-06

Comparison O 0 2.8429424219211796e-06
of O 0 1.527653523680783e-07
molecular O 0 2.923553097389231e-07
and O 0 1.617103073670023e-08
psychometric O 0 1.4405001820705365e-05
findings O 0 2.8756841174981673e-07
demonstrated O 0 2.5926948410415207e-07
that O 0 2.20576401588346e-09
deletions O 0 2.2987613590430556e-08
and O 0 1.0537004602184652e-09
duplications O 0 1.093552448594437e-08
that O 0 6.060118379336288e-11
were O 0 5.7999254704510506e-11
localized O 0 2.293643608375362e-10
in O 0 2.0366110187186592e-10
the O 0 7.120602441013091e-10
distal O 0 2.2452022463426147e-08
part O 0 4.729463398689404e-08
of O 0 4.971736302650243e-07
the O 0 1.2037435226375237e-07
gene O 0 2.0153445134951653e-08
seemed O 0 1.331376040525356e-07
to O 0 2.7512767619697343e-09
be O 0 4.4984002633974285e-10
preferentially O 0 2.914764429817751e-09
associated O 0 2.3333232235245305e-08
with O 0 1.6141378234024728e-09
cognitive B-Disease 0 6.436378316720948e-05
impairment I-Disease 0 0.00021356719662435353
. O 0 5.84281508508866e-07

Two O 0 5.821612703016399e-08
altered O 0 1.919779322179238e-07
Dp71 O 0 3.9340657167485915e-06
transcripts O 0 1.2355845058209525e-07
and O 0 3.14494674746868e-09
two O 0 7.021206949175962e-10
deleted O 0 2.8428935650026688e-08
Dp140 O 0 5.5559223000045677e-08
DNA O 0 2.4100807460847307e-10
sequences O 0 3.2941881861203726e-11
were O 0 1.9667954764823747e-10
found O 0 7.443132915563311e-11
in O 0 1.4470244447117864e-10
four O 0 4.0105410659130314e-10
patients O 0 1.8877725771471177e-10
with O 0 3.51110251983755e-11
severe O 0 2.7335991603649745e-07
cerebral B-Disease 0 4.183882265351713e-05
dysfunction I-Disease 0 0.0006431664805859327
. O 0 4.189500032225624e-06

These O 0 4.1319077581647434e-07
findings O 0 6.456744472416176e-08
suggest O 0 6.655236806096809e-09
that O 0 2.5160292252413008e-11
some O 0 6.0362591661200504e-12
sequences O 0 3.549074879469205e-12
located O 0 8.007706303603257e-11
in O 0 2.228556644778834e-10
the O 0 1.344517164270087e-09
distal O 0 2.4109061413923882e-08
part O 0 1.9888091173925204e-08
of O 0 2.616958916235035e-08
the O 0 2.903888463023918e-09
gene O 0 1.8345003294228945e-10
and O 0 7.524653816703974e-11
, O 0 2.7359099361023986e-11
in O 0 1.0137103656493451e-10
particular O 0 5.582355133704198e-10
, O 0 1.3065248882782043e-10
some O 0 5.806657932261317e-10
DMD B-Disease 1 1.0
isoforms O 0 1.9069224777013005e-07
expressed O 0 5.541959335886304e-09
in O 0 3.058961750568301e-09
the O 0 1.901332424836255e-08
brain O 0 6.81220626574941e-08
may O 0 5.528379976027509e-10
be O 0 3.0770403586233286e-11
related O 0 1.7680416852794423e-10
to O 0 1.08739939275182e-09
the O 0 2.1408419481616647e-09
cognitive B-Disease 0 7.662266057195666e-07
impairment I-Disease 0 1.5248151896685158e-07
associated O 0 8.760883574154832e-09
with O 0 2.6090731797268063e-09
DMD B-Disease 1 1.0
. O 0 1.9087164560005476e-07
. O 0 1.7397022133991413e-07

I1307K O 0 6.184267112985253e-05
APC O 0 2.436383056192426e-06
and O 0 8.34069346922206e-09
hMLH1 O 0 1.9818268981453002e-07
mutations O 0 2.9192599448890633e-09
in O 0 1.0169022290895668e-09
a O 0 2.008849975254634e-09
non O 0 9.948747958787862e-08
- O 0 2.4574585921754988e-08
Jewish O 0 3.445962803994007e-08
family O 0 1.135770144600201e-09
with O 0 1.8621592115519725e-11
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.999953031539917

We O 0 1.4491961053408886e-07
describe O 0 1.116755896646282e-07
a O 0 1.284181827543307e-08
French O 0 3.2562934393354226e-07
Canadian O 0 1.3177252640161896e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.3881562210826814e-07
HNPCC B-Disease 0 0.3353249430656433
) O 0 1.6995188589774557e-09
kindred O 0 2.5926723878910707e-07
which O 0 1.0900112062950384e-10
carries O 0 6.11419873064456e-11
a O 0 5.077925580021514e-11
novel O 0 6.76914746478019e-10
truncating O 0 5.741642183920703e-08
mutation O 0 1.7008289221465134e-09
in O 0 5.646695999672602e-09
hMLH1 O 0 2.4545831820432795e-06
. O 0 3.090426616836339e-07

Interestingly O 0 2.6981982159668405e-07
, O 0 4.216220705899332e-09
the O 0 5.494575017195302e-09
I1307K O 0 1.6525829096281086e-06
APC O 0 2.187736356518144e-07
polymorphism O 0 1.0259564930947818e-07
, O 0 2.6956434306946164e-10
associated O 0 1.360890067303444e-09
with O 0 1.9541481280360706e-11
an O 0 1.371871106298217e-11
increased O 0 8.81224648807688e-10
risk O 0 2.485269234853149e-08
of O 0 1.4558328587099822e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.543655591187189e-09
is O 0 1.204140866878367e-11
also O 0 4.2631566679607324e-12
present O 0 5.30980598031916e-12
in O 0 9.067865208711723e-11
this O 0 4.1926823124427415e-10
family O 0 9.138959811139102e-09
. O 0 9.024173408533898e-08

The O 0 1.6824053545860806e-06
I1307K O 0 1.5072207133925986e-05
polymorphism O 0 1.6352903458027868e-06
has O 0 1.3410391686008438e-09
previously O 0 3.669834991448795e-10
only O 0 3.574348109158798e-11
been O 0 1.41673157580402e-11
identified O 0 4.109109233429997e-11
in O 0 1.2163658968944446e-11
individuals O 0 1.5056168117810742e-11
of O 0 3.762154476838475e-10
self O 0 1.6357256527044228e-07
- O 0 2.5806517101045756e-07
reported O 0 3.7061405055993646e-09
Ashkenazi O 0 7.046973138358226e-08
Jewish O 0 2.027891632394585e-08
origins O 0 6.065121738174639e-08
. O 0 2.7959908166508285e-08

In O 0 7.495510878641198e-09
addition O 0 1.580235831077914e-09
, O 0 3.776661275378679e-11
in O 0 4.612405943293929e-11
this O 0 7.012263686378972e-11
family O 0 2.699769852121392e-10
, O 0 2.4071853885199168e-11
there O 0 2.1829265825501487e-11
appears O 0 7.820836339655912e-11
to O 0 1.013182593379014e-10
be O 0 3.366377732128001e-10
no O 0 2.7636681831921805e-09
relationship O 0 4.1072772960504267e-10
between O 0 5.771336186732867e-10
the O 0 6.960063636540781e-09
I1307K O 0 3.621664035335925e-08
polymorphism O 0 1.7643906335962356e-09
and O 0 7.08102396163035e-11
the O 0 4.595302471877005e-10
presence O 0 1.9102082138289234e-09
or O 0 5.928510127262143e-09
absence O 0 1.647734393372957e-07
of O 0 1.4428416239553599e-09
cancer B-Disease 0 2.8044815358896358e-09
. O 0 1.7836097043755217e-09
. O 0 3.12814947278639e-08

Identification O 0 7.155795742619375e-07
of O 0 4.434986422552356e-08
a O 0 3.6287566285153616e-09
novel O 0 2.8697999532312224e-09
mutation O 0 1.1082396111916637e-09
of O 0 2.276776767118349e-09
the O 0 4.309452794615254e-09
CPO O 0 3.9139223417805624e-07
gene O 0 1.5163593714007106e-09
in O 0 9.798615252520904e-09
a O 0 3.5206031867573984e-08
Japanese O 0 2.0181100808258634e-06
hereditary B-Disease 0 0.0020457550417631865
coproporphyria I-Disease 0 0.0004131179302930832
family O 0 1.0113132020705962e-07
. O 0 1.532831390704814e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999160766601562
( O 0 3.2279647399491296e-08
HCP B-Disease 0 0.0005212204996496439
) O 0 8.780590476931138e-09
is O 0 1.975029251255478e-09
an O 0 4.505770423435251e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 1.7051693390612854e-08
by O 0 2.8653173583803593e-11
a O 0 2.218882855231641e-09
deficiency B-Disease 0 1.2851984365624958e-06
of I-Disease 0 6.85752013396268e-07
coproporphyrinogen I-Disease 0 1.3169488966013887e-06
oxidase I-Disease 0 1.9877964163583783e-08
( O 0 1.2798719029039063e-10
CPO O 0 8.248273388744565e-07
) O 0 3.634378908934366e-10
caused O 0 3.753997668276554e-10
by O 0 6.932349659594106e-12
a O 0 1.8409988811196598e-10
mutation O 0 2.1144216585944342e-11
in O 0 9.925194693893857e-11
the O 0 3.1980023074140718e-09
CPO O 0 1.468183427277836e-06
gene O 0 3.617494215291117e-08
. O 0 8.595262102062406e-07

Only O 0 1.8840340487713547e-07
11 O 0 1.390716164451078e-07
mutations O 0 3.423263805757415e-08
of O 0 2.7042101891083803e-08
the O 0 1.8745025087696376e-08
gene O 0 5.56110402172294e-09
have O 0 1.6871358754499965e-09
been O 0 6.904420923881105e-10
reported O 0 2.487386685512405e-10
in O 0 7.01611990727713e-10
HCP B-Disease 0 0.0014874252956360579
patients O 0 1.36498215397296e-06
. O 0 4.925580014969455e-07

We O 0 2.386591972936003e-07
report O 0 5.898563859574324e-09
another O 0 1.6467328889380184e-10
mutation O 0 1.984718223102533e-10
in O 0 4.50348230929265e-10
a O 0 3.4198095466564382e-09
Japanese O 0 7.377983024525747e-07
family O 0 5.525560098362803e-08
. O 0 9.460030270247444e-08

Polymerase O 0 7.782631428199238e-07
chain O 0 8.346043500750966e-08
reaction O 0 2.848754343531823e-09
- O 0 8.448125754512148e-09
single O 0 3.475877363712243e-09
strand O 0 1.8849024563394323e-09
conformational O 0 7.393557988066846e-10
polymorphism O 0 3.258246450421609e-10
and O 0 7.736323734408579e-12
direct O 0 9.603952355607959e-11
sequence O 0 2.3202897936336342e-11
analyses O 0 2.0335290396022998e-10
demonstrated O 0 1.8425524439535934e-09
a O 0 2.1113932824334825e-09
C O 0 3.62748515669864e-08
to O 0 3.5917085972059226e-10
T O 0 8.678802676520547e-10
substitution O 0 2.2913961006398864e-10
in O 0 1.451735121005271e-10
exon O 0 1.2312358910193666e-09
1 O 0 7.882694497141074e-09
of O 0 1.9721306809827865e-09
the O 0 3.794152103608894e-09
CPO O 0 3.524104386087856e-07
gene O 0 9.952915158706332e-10
at O 0 1.2188155373848986e-08
nucleotide O 0 4.009107357205721e-08
position O 0 2.1200830246925761e-07
85 O 0 1.1613021655421107e-07
, O 0 8.829486447536894e-11
which O 0 6.783408904031951e-12
lies O 0 6.131412738641373e-11
in O 0 5.489049492712894e-11
the O 0 4.572064393748576e-10
putative O 0 2.535176513163151e-08
presequence O 0 1.3366455675623e-07
for O 0 8.316956012777155e-10
targeting O 0 1.8440371007955036e-08
to O 0 3.96569639349309e-08
mitochondria O 0 8.040674970288819e-07
. O 0 4.2442857761670894e-07

This O 0 1.1607725447504436e-08
mutation O 0 1.60688218286964e-09
changes O 0 1.3796632725160407e-09
the O 0 6.963724596964482e-10
codon O 0 2.3556765427201753e-09
for O 0 1.0863623889356688e-10
glutamine O 0 8.733705314512008e-09
to O 0 1.508274172223878e-09
a O 0 1.0723065768658557e-09
termination O 0 1.313592612461889e-08
codon O 0 3.3661819998087594e-08
at O 0 1.863110377087196e-08
amino O 0 1.0462052557613788e-08
acid O 0 1.1831542856555188e-08
position O 0 6.478183678382265e-08
29 O 0 1.7094275790441316e-06
. O 0 5.355557277653133e-07

MaeI O 0 2.9447592169162817e-05
restriction O 0 8.528048169864633e-07
analysis O 0 3.490415068085895e-08
showed O 0 1.1247567321959195e-08
two O 0 4.284647289742871e-11
other O 0 2.1125017967554838e-12
carriers O 0 1.141334683013584e-11
in O 0 1.578864122775414e-10
the O 0 5.445382811331001e-09
family O 0 5.191704488538562e-08
. O 0 2.5320989038846164e-07

The O 0 1.485465759287763e-06
C O 0 0.000260692264419049
- O 0 1.8381189875071868e-05
T O 0 2.1452142391353846e-06
mutation O 0 1.6941075209331302e-09
is O 0 1.7636623064753998e-11
located O 0 5.037371214600128e-11
within O 0 2.3631410717150914e-10
a O 0 5.375055955880725e-10
recently O 0 2.994883507856372e-10
proposed O 0 5.785253179291239e-11
putative O 0 1.0099167058186254e-09
alternative O 0 4.7813419890019304e-09
translation O 0 3.0920754845453757e-09
initiation O 0 2.0144825807477673e-09
codon O 0 2.901365370178155e-08
( O 0 8.427726572168837e-11
TIC O 0 5.4497055756996815e-09
- O 0 8.738604506675074e-09
1 O 0 1.3179342062130672e-08
) O 0 6.610873654055993e-11
, O 0 7.598318675638982e-12
supporting O 0 7.528716539084712e-11
that O 0 6.6382134164544304e-12
TIC O 0 2.5912934020766443e-09
- O 0 2.349010408408958e-08
1 O 0 4.3211340994275815e-07
is O 0 4.857969027050046e-10
the O 0 1.338019250951561e-09
real O 0 1.9400314243966932e-08
TIC O 0 7.858213990630247e-08
rather O 0 1.677221583840094e-09
than O 0 2.1728874255444453e-10
TIC O 0 6.1919078753192025e-09
- O 0 1.028848473083599e-08
2 O 0 1.9003028484121387e-08
. O 0 4.589751245731577e-09
. O 0 2.6150230425514565e-08

Human B-Disease 0 1.6965634586085798e-07
complement I-Disease 0 3.0442961929111334e-07
factor I-Disease 0 7.269527941389242e-06
H I-Disease 1 1.0
deficiency I-Disease 0 0.0009301401441916823
associated O 0 3.2566274512646487e-06
with O 0 2.309656963461748e-07
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999997615814209

This O 0 1.0725198507088862e-08
study O 0 4.979486600831251e-09
reports O 0 3.0485630686527543e-10
on O 0 2.9268745760369086e-10
six O 0 2.0670540279432714e-10
cases O 0 1.606564881129202e-11
of O 0 1.2432065099599043e-10
deficiency B-Disease 0 6.348000347600191e-09
in I-Disease 0 7.408807789488492e-09
the I-Disease 0 1.708724717275345e-08
human I-Disease 0 4.3721576359345704e-10
complement I-Disease 0 3.702888273782179e-10
regulatory I-Disease 0 2.406384425057695e-09
protein I-Disease 0 1.1029404056728254e-09
Factor I-Disease 0 1.6325861551536036e-08
H I-Disease 1 0.9999618530273438
( O 0 3.663079561899707e-10
FH O 0 8.659083050588379e-07
) O 0 4.532019551306554e-11
in O 0 4.740275533210436e-11
the O 0 6.639647165407325e-11
context O 0 1.0334166855585636e-09
of O 0 2.5324518523883732e-11
an O 0 1.7318672537736113e-11
acute B-Disease 0 2.039478630422309e-07
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 7.483808985853102e-06

Five O 0 7.123426826183277e-07
of O 0 9.112919308051914e-09
the O 0 1.966226292893225e-09
cases O 0 6.157101217763028e-11
were O 0 1.3527633180299148e-10
observed O 0 5.388582635657002e-11
in O 0 5.951571874218686e-11
children O 0 1.4746333321102867e-10
presenting O 0 5.917683565392906e-10
with O 0 9.417265856015433e-10
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.314455281928531e-07
HUS B-Disease 1 1.0
) O 0 5.831436666881018e-08
. O 0 3.973070761276176e-07

Two O 0 1.2193293486006951e-08
of O 0 2.309435087610723e-09
the O 0 9.52184331382e-10
children O 0 3.4023195372157033e-10
exhibited O 0 1.1983345871158235e-08
a O 0 5.083369458702691e-08
homozygous O 0 5.4690522119926754e-06
deficiency O 0 5.67088648040226e-07
characterized O 0 5.97250970901797e-10
by O 0 2.4722404678989562e-11
the O 0 3.879670806838931e-09
absence O 0 1.1785667908270625e-07
of O 0 3.010709903605857e-09
the O 0 5.618738807555701e-10
150 O 0 1.5383596618789852e-09
- O 0 6.5537908433555e-10
kD O 0 7.034429927443853e-08
form O 0 4.102783113246744e-10
of O 0 1.0691961760400659e-09
Factor O 0 2.2120977050121837e-08
H O 1 1.0
and O 0 2.9465463402544856e-10
the O 0 2.8441382582400365e-10
presence O 0 1.5744675008200204e-10
, O 0 4.465807498105212e-12
upon O 0 1.1108972075568602e-10
immunoblotting O 0 1.031440088894442e-08
, O 0 2.2855502213037227e-11
of O 0 1.3602666215639658e-10
the O 0 1.7584834977046881e-10
42 O 0 2.1620323309434752e-09
- O 0 1.5733636615777868e-09
kD O 0 1.1235200503278975e-07
Factor O 0 2.624907580184299e-08
H O 1 0.9998891353607178
- O 0 1.566794161078633e-08
like O 0 4.159528624314568e-11
protein O 0 5.881112263850241e-11
1 O 0 1.4510381785015625e-09
( O 0 3.108410404073503e-11
FHL O 0 3.7857256529605365e-07
- O 0 2.467632143066112e-08
1 O 0 2.143118571495961e-08
) O 0 2.358692130499662e-10
and O 0 1.4278167537185027e-10
other O 0 1.2254763870345187e-10
FH O 0 1.271801011171192e-06
- O 0 4.004774112331688e-08
related O 0 5.59297319568941e-09
protein O 0 1.2449844488671147e-09
( O 0 3.228144487832374e-11
FHR O 0 2.598808919174189e-07
) O 0 9.276070883634802e-11
bands O 0 3.2659151827374444e-08
. O 0 7.935739176900825e-08

Southern O 0 5.585685357800685e-06
blot O 0 2.3660584247409133e-06
and O 0 1.8401151713476338e-09
PCR O 0 1.0271916650594903e-08
analysis O 0 3.925864910936383e-10
of O 0 1.054872300620957e-10
DNA O 0 8.333231882318159e-10
of O 0 6.505356253683203e-10
one O 0 5.007275150070711e-10
patient O 0 1.5085309001960923e-08
with O 0 2.402242016419365e-10
homozygous O 0 2.4963446776382625e-06
deficiency O 0 2.7306857646181015e-06
ruled O 0 2.7887155695793808e-08
out O 0 1.4501639888919726e-09
the O 0 2.751685990176611e-09
presence O 0 1.53909340827596e-09
of O 0 8.764858283605292e-10
a O 0 5.957616622254136e-10
large O 0 2.420981748407769e-10
deletion O 0 1.763207535532274e-08
of O 0 2.1511700865062267e-08
the O 0 4.676289577787429e-08
FH O 0 1.2787462765118107e-05
gene O 0 1.0507407388615775e-08
as O 0 5.578930650784741e-09
the O 0 6.9310774897246574e-09
underlying O 0 7.181673566947211e-08
defect O 0 2.7105151900741475e-08
for O 0 1.4070438147939512e-09
the O 0 5.605760122762149e-08
deficiency O 0 0.0005619102739728987
. O 0 2.090133239107672e-05

The O 0 2.22571742369837e-07
other O 0 9.07181385567668e-10
four O 0 8.92978399558153e-11
children O 0 3.704532514081649e-11
presented O 0 8.438684750977643e-10
with O 0 1.0903526970196253e-09
heterozygous O 0 9.43372072015336e-07
deficiency O 0 1.2934957567267702e-06
and O 0 4.264968378464573e-09
exhibited O 0 2.6474694436728896e-07
a O 0 6.434259347543048e-08
normal O 0 2.1025614671543735e-07
immunoblotting O 0 1.1567327362627111e-07
pattern O 0 5.695824367712987e-10
of O 0 2.106291946413208e-10
proteins O 0 1.1996522698842771e-11
of O 0 6.431799537409688e-10
the O 0 8.125599748609602e-09
FH O 0 0.00032307495712302625
family O 0 1.6965083204922848e-07
. O 0 2.761957773600443e-07

Factor B-Disease 0 0.00039003975689411163
H I-Disease 1 1.0
deficiency I-Disease 0 0.09550505131483078
is O 0 1.1659998522262072e-09
the O 0 1.0921885618131455e-09
only O 0 3.0762454805710604e-09
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 1.053530127137492e-06
with O 0 5.459745544555972e-09
HUS B-Disease 1 1.0
. O 0 3.587457104003988e-05

These O 0 1.353025851358325e-07
observations O 0 6.091229920457408e-08
suggest O 0 2.899792850286076e-09
a O 0 3.054389241530231e-10
role O 0 1.2913631275424109e-09
for O 0 4.341835335708311e-09
FH O 0 0.000982419354841113
and O 0 9.150370061661306e-08
/ O 0 0.0006008882191963494
or O 0 5.045686890525758e-08
FH O 0 8.574495041102637e-06
receptors O 0 9.61129220655721e-09
in O 0 4.857443336447886e-09
the O 0 1.0989511523007423e-08
pathogenesis O 0 4.114195689908229e-06
of O 0 4.6537400599788725e-09
idiopathic O 0 1.899139169836417e-05
HUS B-Disease 1 0.9995836615562439
. O 0 4.301144329588169e-08
. O 0 4.783907670002918e-08

Further O 0 2.1391822713212605e-07
evidence O 0 6.767756577374939e-09
for O 0 3.665679704223379e-10
a O 0 7.172126226251407e-10
major O 0 1.6353030041216243e-09
ancient O 0 1.0498917646373229e-07
mutation O 0 6.362173508023261e-07
underlying O 0 7.5114239734830335e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 4.357326588433352e-08
linkage O 0 3.1344804085620126e-08
disequilibrium O 0 2.62592383393212e-08
studies O 0 7.867369533620661e-10
in O 0 3.231287737381905e-10
the O 0 3.166058248904591e-10
Japanese O 0 8.323846500957188e-09
population O 0 8.011491643700186e-12
. O 0 5.17061005123054e-10

The O 0 1.4794749404245522e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.2761745438183425e-07
DM B-Disease 1 1.0
) O 0 2.6094910676732752e-09
mutation O 0 2.7646065436925937e-09
is O 0 5.83376402740754e-11
an O 0 5.3654660575608304e-11
unstable O 0 1.5545685627671446e-08
( O 0 4.712098489179084e-10
CTG O 0 4.219184006615251e-07
) O 0 1.1329719107333602e-10
n O 0 2.319345160373132e-09
repeat O 0 2.5251083446420353e-09
, O 0 3.631259182235169e-11
present O 0 4.323081129187223e-11
at O 0 3.5847413926148874e-10
a O 0 3.210178997625768e-11
copy O 0 9.54293311039578e-10
number O 0 3.821988558971867e-11
of O 0 1.1644961904477835e-11
5 O 0 2.195952725214667e-10
- O 0 4.148329679765084e-09
37 O 0 1.4295403971686937e-08
repeats O 0 2.675646815220034e-09
on O 0 4.489967952991947e-09
normal O 0 8.897575121125101e-09
chromosomes O 0 1.2993236486735782e-09
but O 0 3.9438927124102463e-10
amplified O 0 2.201389825984279e-08
to O 0 1.0745716316762355e-08
50 O 0 3.8678653169199606e-08
- O 0 1.064126742278404e-08
3000 O 0 1.2880994937347623e-08
copies O 0 4.6562462330257404e-08
on O 0 2.428324137326854e-07
DM B-Disease 1 1.0
chromosomes O 0 7.328831657105184e-07
. O 0 9.264384175367013e-07

Previous O 0 6.305490387603641e-07
findings O 0 9.76939062979909e-09
in O 0 3.0444666232476436e-10
Caucasian O 0 4.280061194350537e-09
populations O 0 4.3965928120393016e-10
of O 0 8.554555952500209e-10
a O 0 3.4486717481740925e-08
DM B-Disease 1 1.0
founder O 0 2.9710190574405715e-06
chromosome O 0 2.62664023864545e-08
raise O 0 2.552692812685109e-08
a O 0 2.882818428417977e-09
question O 0 2.521296948998497e-09
about O 0 8.241642784900804e-11
the O 0 2.40765019032807e-10
molecular O 0 2.7727639628771783e-10
events O 0 2.056310816067608e-10
involved O 0 1.1260112980915338e-10
in O 0 8.919336935697686e-10
the O 0 6.886091252766846e-09
expansion O 0 1.4846341400698293e-07
mutation O 0 2.0222598706709505e-08
. O 0 4.124654751080925e-08

To O 0 5.087138106318889e-07
investigate O 0 3.928843028688789e-08
whether O 0 8.759580616413132e-09
a O 0 2.2669933485985894e-08
founder O 0 2.0054577021255682e-07
chromosome O 0 3.41430386185948e-08
for O 0 1.0264512795288283e-08
the O 0 1.6060472773915535e-07
DM B-Disease 1 1.0
mutation O 0 2.601906912147456e-09
exists O 0 2.988508399082157e-11
in O 0 1.0866374640372545e-11
the O 0 4.16264002434108e-11
Japanese O 0 2.9013971225566593e-09
population O 0 2.6079299310366455e-12
, O 0 4.191958412336216e-12
we O 0 1.0266499456124123e-10
genotyped O 0 1.4362581346460956e-08
families O 0 3.295407349779289e-11
using O 0 8.783379579213602e-11
polymorphic O 0 5.162223981614034e-10
markers O 0 4.202692416299669e-09
near O 0 1.7182424016937148e-07
the O 0 3.23860298578893e-08
( O 0 9.872410666744713e-10
CTG O 0 6.164842716316343e-07
) O 0 3.8077943576020346e-10
n O 0 1.7256050810487977e-08
repeat O 0 5.567856931065762e-08
region O 0 1.56296451336857e-08
and O 0 2.4085471395096647e-09
constructed O 0 1.845511974352121e-07
haplotypes O 0 3.743134129763348e-06
. O 0 3.5641289741761284e-07

Six O 0 1.3608291737909894e-07
different O 0 2.9225233344476464e-10
haplotypes O 0 3.5646447571480167e-08
were O 0 4.156582633640937e-09
found O 0 9.639393727667311e-10
and O 0 2.160297052355986e-09
DM B-Disease 1 1.0
alleles O 0 2.6407459330357597e-08
were O 0 6.538062535810241e-09
always O 0 2.5431189598634774e-08
haplotype O 0 4.6150441335157666e-07
A O 0 5.671578833243984e-07
. O 0 4.443301122591947e-07

To O 0 2.655565545239824e-08
find O 0 2.448175440150635e-09
an O 0 5.588400835837559e-12
origin O 0 6.917915545967546e-11
of O 0 3.0632574254951805e-10
the O 0 1.0833377528385313e-09
( O 0 2.845082225366724e-10
CTG O 0 3.2526062909710163e-07
) O 0 5.514867451594796e-10
n O 0 1.4222082178605433e-08
repeat O 0 9.884624674327824e-09
mutation O 0 2.9422445035898193e-10
and O 0 3.009087770622365e-11
to O 0 1.3854198899210246e-09
investigate O 0 1.9120087735302604e-09
the O 0 1.380839997899841e-09
mechanism O 0 8.959738551084229e-08
of O 0 2.353444328306864e-09
the O 0 4.630283656492651e-10
expansion O 0 1.4587081542671854e-09
mutation O 0 3.258344288825654e-11
in O 0 1.6855260243087145e-11
the O 0 4.4818520422706953e-11
Japanese O 0 1.8136370183441386e-09
population O 0 6.957753058596527e-13
we O 0 6.040750798880223e-12
have O 0 3.7618710230225005e-12
studied O 0 3.994646280425229e-10
90 O 0 9.958730728953924e-09
Japanese O 0 1.6375970517401583e-06
DM B-Disease 1 1.0
families O 0 6.524496498627741e-09
comprising O 0 2.127444748145635e-10
190 O 0 2.4217956529071216e-09
affected O 0 1.2542800131853937e-09
and O 0 3.069392517929259e-10
130 O 0 6.1072725543454e-08
unaffected O 0 1.550148596152212e-07
members O 0 1.046145303718049e-08
. O 0 1.6275998859782703e-07

The O 0 1.0664856517905719e-06
results O 0 5.896452037745803e-08
suggest O 0 7.3926873511709346e-09
that O 0 5.5465011056243796e-11
a O 0 2.983862323890918e-10
few O 0 3.800886549942817e-10
common O 0 5.375548339792147e-10
ancestral O 0 2.9647075905359088e-08
mutations O 0 2.4306250345773606e-09
in O 0 7.066954799128666e-10
both O 0 4.3408893146690275e-10
Caucasian O 0 1.2404129279275367e-08
and O 0 1.1890788353952075e-09
Japanese O 0 1.1967772195475845e-07
populations O 0 3.842322640612572e-11
have O 0 1.0644655729780128e-12
originated O 0 3.1539768626659415e-12
by O 0 1.1547124476214699e-13
expansion O 0 1.425036200153329e-10
of O 0 6.924384676754158e-11
an O 0 1.0174211299840419e-11
ancestral O 0 2.1016137718987693e-09
n O 0 1.0458276467062433e-09
= O 0 5.586320739325856e-09
5 O 0 6.772066241111929e-10
repeat O 0 1.4900968237085976e-09
to O 0 1.2875707167125938e-09
n O 0 5.01775643257929e-09
= O 0 9.734370109981683e-08
19 O 0 6.834005006339794e-08
- O 0 1.0761041124851545e-07
37 O 0 9.538173628698132e-08
copies O 0 4.786737122230988e-07
. O 0 2.635106284287758e-07

These O 0 1.339301647362845e-08
data O 0 5.838333816399199e-09
support O 0 8.274677054664892e-10
multistep O 0 1.1900890939386954e-08
models O 0 9.13945115144088e-08
of O 0 2.3408125571222627e-07
triplet O 0 3.6797714528802317e-06
repeat O 0 2.576520330421772e-07
expansion O 0 4.7948333303793333e-08
that O 0 8.620149039018088e-11
have O 0 1.765499899053502e-11
been O 0 3.871267889588026e-12
proposed O 0 1.7897077916884108e-11
for O 0 6.044418437989307e-11
both O 0 2.835867984884999e-09
DM B-Disease 1 1.0
and O 0 1.0332185240713443e-07
Friedreichs B-Disease 0 4.508834899752401e-05
ataxia I-Disease 0 1.091639387595933e-05
. O 0 1.2477265443067154e-07
. O 0 3.2989032661134843e-07

The O 0 4.488548555059424e-08
molecular O 0 5.6796416458837484e-09
basis O 0 3.73592250468846e-08
of O 0 1.3280914856750314e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.1149169526779588e-08
the O 0 2.2135822064228705e-09
western O 0 1.0447530618407086e-09
Cape O 0 9.198979356028758e-09
, O 0 1.8412368851805638e-11
South O 0 1.1483430872871736e-09
Africa O 0 1.3650659269615062e-08
. O 0 5.074851650022083e-09

Deficiency B-Disease 0 0.00016449038230348378
of I-Disease 0 1.0197860547123128e-06
the I-Disease 0 2.297048382615685e-07
sixth I-Disease 0 7.207581234069949e-07
component I-Disease 0 1.0947277928607946e-07
of I-Disease 0 4.2880934358890954e-09
human I-Disease 0 5.598840835396857e-10
complement I-Disease 0 2.6999169122632338e-08
( O 0 2.883863370328754e-09
C6 O 0 0.0022326356265693903
) O 0 5.096781330315991e-10
has O 0 7.742749497108292e-11
been O 0 1.6743242209349418e-11
reported O 0 2.915818281268301e-11
in O 0 6.2357384880695754e-12
a O 0 3.131469736294967e-11
number O 0 1.474359696829186e-11
of O 0 4.205613288177368e-12
families O 0 4.1764259151727545e-13
from O 0 2.7134941429224346e-12
the O 0 2.2973815558269273e-11
western O 0 5.804067226833354e-10
Cape O 0 1.4877461040896378e-08
, O 0 5.558796825622103e-11
South O 0 1.8767662979257693e-09
Africa O 0 2.0459339111766894e-08
. O 0 1.5339274739289976e-08

Meningococcal B-Disease 0 0.015648093074560165
disease I-Disease 0 4.9994687287835404e-06
is O 0 5.0265545198380224e-11
endemic O 0 4.887894256011549e-11
in O 0 1.5516601892251458e-11
the O 0 7.268941559779307e-10
Cape O 0 3.0482059543146534e-08
and O 0 1.3113632402195208e-10
almost O 0 1.0705240166553054e-10
all O 0 1.2139137785249776e-11
pedigrees O 0 1.7456552869887787e-09
of O 0 5.747640696718292e-10
total O 0 5.979993034088693e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 8.223200786972029e-09
C6Q0 O 0 1.5542535038548522e-05
) O 0 3.4454530895011715e-10
have O 0 2.2280846612154903e-10
been O 0 8.644402554880415e-11
ascertained O 0 7.454592498845614e-09
because O 0 2.4705162915417134e-10
of O 0 1.483908218524732e-09
recurrent O 0 9.95729806163581e-07
disease O 0 1.3317637694854056e-06
. O 0 9.827761004999047e-08

We O 0 8.466439282983629e-08
have O 0 7.140949498385396e-10
sequenced O 0 6.606506897099962e-09
the O 0 4.5629717781991985e-09
expressed O 0 5.496231025858833e-09
exons O 0 2.425911560521854e-08
of O 0 7.703088833466154e-09
the O 0 9.172120840617026e-09
C6 O 0 1.8438564666212187e-06
gene O 0 6.177316436151159e-09
from O 0 6.401483787499274e-10
selected O 0 4.306009770971286e-09
cases O 0 9.394118122285633e-11
and O 0 6.590403223150076e-11
have O 0 4.206716364141272e-10
found O 0 4.4885870020827667e-10
three O 0 5.238339206847797e-10
molecular O 0 1.549944670387049e-07
defects O 0 1.0660734005796257e-05
leading O 0 2.837006434219802e-07
to O 0 4.503023376400961e-07
total O 0 2.121030547641567e-06
deficiency O 0 3.0158322260831483e-05
879delG O 0 8.454994713247288e-07
, O 0 3.597906972352405e-10
which O 0 5.4522782122479185e-11
is O 0 9.630141302452433e-12
the O 0 3.903470602306669e-11
common O 0 1.3193614256667985e-10
defect O 0 4.394415054065348e-09
in O 0 3.9453973421643695e-10
the O 0 5.021231874735577e-09
Cape O 0 3.8635743493387054e-08
and O 0 2.622382588857164e-10
hitherto O 0 1.8814334978856095e-08
unreported O 0 5.663166380287521e-09
, O 0 9.404780773603072e-12
and O 0 1.1181775123880744e-11
1195delC O 0 7.158571957432969e-09
and O 0 1.2403596205690093e-10
1936delG O 0 3.8387685918905845e-08
, O 0 4.4793821429855996e-11
which O 0 4.2542540670820195e-12
have O 0 4.11597839145017e-12
been O 0 6.796359482141856e-12
previously O 0 5.531710159378811e-11
reported O 0 6.282852016425977e-11
in O 0 1.5509508954902884e-10
African O 0 5.2096787328537175e-08
- O 0 2.2892498918736237e-07
Americans O 0 7.142890012801217e-08
. O 0 7.794012191197908e-08

We O 0 1.9172361476194055e-07
also O 0 3.435893347614183e-09
show O 0 2.367906759559446e-09
that O 0 2.402268488299608e-11
the O 0 3.1875443951001614e-10
879delG O 0 1.0725018739776715e-07
and O 0 2.4314135149694494e-09
1195delC O 0 5.1697287517527e-07
defects O 0 1.2486287914725835e-07
are O 0 3.884672097886899e-11
associated O 0 9.171084447423539e-10
with O 0 1.1271888977759659e-10
characteristic O 0 2.101353857142385e-06
C6 O 1 1.0
/ O 1 0.9329982995986938
C7 O 0 0.00011938640818698332
region O 0 5.1621114494082576e-08
DNA O 0 7.869868312582184e-08
marker O 0 1.102360869253971e-07
haplotypes O 0 1.4583589802441566e-07
, O 0 8.220498726174696e-10
although O 0 3.736895237693716e-10
small O 0 1.8961300585207397e-10
variations O 0 8.697295661441728e-10
were O 0 1.7345467284712868e-09
observed O 0 3.415515692495319e-08
. O 0 1.4706748174830864e-07

The O 0 2.9376138854786404e-07
1936delG O 0 1.8761480760076665e-06
defect O 0 8.539140594621131e-07
was O 0 1.4729058861462363e-08
observed O 0 2.8223384740400093e-10
only O 0 3.4337213627999574e-11
once O 0 5.259741947538643e-11
in O 0 4.693241975606277e-11
the O 0 2.6053170731898945e-10
Cape O 0 1.3102395612918372e-08
, O 0 4.462982761133105e-11
but O 0 8.420187290469894e-12
its O 0 2.8571206164840213e-11
associated O 0 1.462854060108043e-09
haplotype O 0 6.274525077287763e-08
could O 0 7.048825523270352e-09
be O 0 5.30126298414757e-09
deduced O 0 3.866029487653577e-07
. O 0 2.694192176022625e-07

The O 0 2.448569489388319e-07
data O 0 2.3403121218734668e-08
from O 0 6.384912043522206e-10
the O 0 2.5305662010310925e-09
haplotypes O 0 8.760922298733931e-08
indicate O 0 1.149913053666296e-08
that O 0 2.6796172919452133e-11
these O 0 4.786620752539328e-11
three O 0 8.170941701024503e-11
molecular O 0 1.8801771251020227e-09
defects O 0 1.5593407454161934e-08
account O 0 4.396609742940427e-10
for O 0 8.598199374709736e-10
the O 0 2.5153898519647555e-08
defects O 0 2.7861426588060567e-06
in O 0 4.994146962644663e-08
all O 0 1.266579818803848e-08
the O 0 2.7360915311192002e-08
38 O 0 4.030180207337253e-07
unrelated O 0 8.146238350548174e-09
C6Q0 O 0 1.5533319128735457e-06
individuals O 0 4.943492837305996e-11
we O 0 7.647090738416296e-10
have O 0 6.533505680916818e-11
studied O 0 1.7752704861706547e-09
from O 0 1.9415853369508795e-09
the O 0 2.9740581553028278e-08
Cape O 0 1.351088258161326e-06
. O 0 2.2529071941335133e-07

We O 0 1.5156351196310425e-07
have O 0 1.4507338663705127e-09
also O 0 1.5379100770651633e-10
observed O 0 1.1059037019478524e-10
the O 0 4.2652836818035667e-10
879delG O 0 8.584034105751925e-08
defect O 0 3.511134494260659e-08
in O 0 2.080689842642869e-09
two O 0 8.516821914383854e-09
Dutch O 1 0.9999774694442749
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 2.2603224351769313e-05
, O 0 3.65066421537108e-10
but O 0 2.788349585947092e-11
the O 0 1.6707074612654083e-10
879delG O 0 1.529901005881129e-08
defect O 0 1.2518666991923055e-08
in O 0 1.4510770363074244e-09
the O 0 2.72619402608143e-08
Cape O 0 2.360819451041607e-07
probably O 0 3.3063025650648115e-09
did O 0 4.3139075645015623e-10
not O 0 3.1865218796944816e-11
come O 0 2.0918387855228815e-10
from O 0 1.2831717632888484e-10
The O 0 1.903414315052032e-09
Netherlands O 0 8.887131031087847e-08
. O 0 1.286989448345821e-08
. O 0 2.39746640318117e-07

Complement B-Disease 1 0.9992029070854187
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.918864143135579e-07
seven O 0 1.226553347777326e-08
further O 0 3.4592566588997897e-09
molecular O 0 1.1733805038716127e-08
defects O 0 4.6508588980032073e-07
and O 0 1.3598678849646717e-09
their O 0 2.234641840459517e-07
associated O 0 1.0735322575783357e-05
marker O 0 2.8617880616366165e-06
haplotypes O 0 1.5695316051278496e-06
. O 0 1.5360052429969073e-06

Seven O 0 4.493585663567501e-07
further O 0 1.4162636396974904e-08
molecular O 0 1.7319360168244202e-08
bases O 0 3.711459157784702e-07
of O 0 1.9999943106085993e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.9783856330946037e-08
described O 0 4.232894568190204e-08
. O 0 7.396089074518386e-08

All O 0 1.9031035947136843e-07
these O 0 2.0811583567592606e-09
new O 0 1.1364640783995128e-08
molecular O 0 4.391937125092227e-08
defects O 0 3.799100056767202e-08
involve O 0 8.579769672500959e-10
single O 0 2.3595301268386493e-09
- O 0 1.5480825510394425e-08
nucleotide O 0 2.1020923668402247e-07
events O 0 1.1320101123146742e-07
, O 0 4.066627923293709e-09
deletions O 0 2.3789901604232e-08
and O 0 1.0833459684889135e-09
substitutions O 0 5.459235286053854e-09
, O 0 1.040727018453147e-10
some O 0 1.4525604330462016e-10
of O 0 7.150626202268029e-10
which O 0 3.224397138179569e-11
alter O 0 2.5528096969651415e-08
splice O 0 8.686478736308345e-08
sites O 0 2.3740401644545273e-08
, O 0 4.553214749680734e-10
and O 0 3.255749281283471e-10
others O 0 6.279335718062384e-09
codons O 0 5.68281905088952e-07
. O 0 5.154309974386706e-07

They O 0 1.2353955192168087e-08
are O 0 3.174982846076979e-11
distributed O 0 1.6222667653664757e-10
along O 0 3.357317479579791e-10
the O 0 4.0853556093622956e-09
C7 O 0 1.749112698234967e-06
gene O 0 2.6943083319963534e-09
, O 0 1.053028914066445e-10
but O 0 1.0068767868076645e-11
predominantly O 0 6.790800994443957e-12
towards O 0 1.7933546314630178e-10
the O 0 1.7019118059291571e-10
3 O 0 5.0155750663805065e-09
end O 0 1.6394270119235443e-07
. O 0 1.8793772937897302e-07

All O 0 9.683869706123005e-08
were O 0 4.464817848770508e-09
found O 0 3.605202247847217e-10
in O 0 4.273744969029991e-10
compound O 0 5.261736646389181e-08
heterozygous O 0 2.406774557428548e-09
individuals O 0 6.805001701026825e-11
. O 0 1.2146868400009225e-08

The O 0 1.2352031262707897e-05
C6 O 1 0.9999094009399414
/ O 1 0.9631927013397217
C7 O 0 0.0016405609203502536
marker O 0 2.403675807727268e-06
haplotypes O 0 1.2424632132024271e-06
associated O 0 2.0375424014673627e-07
with O 0 1.6597251351058162e-09
most O 0 6.147510589471494e-08
C7 B-Disease 1 0.999976396560669
defects I-Disease 0 1.5528074072790332e-05
are O 0 2.134473264803205e-09
tabulated O 0 2.2724568893295327e-08
. O 0 1.3336197923763393e-08
. O 0 1.5225134575302945e-07

A O 0 9.95428877104132e-07
genome O 0 6.154653231504881e-09
- O 0 1.1620466722206402e-07
wide O 0 1.0250504445252773e-08
search O 0 6.565129329061392e-09
for O 0 1.5434904743205635e-10
chromosomal O 0 1.0295516972291807e-07
loci O 0 1.6696999693976977e-07
linked O 0 3.2731984447309515e-06
to O 0 5.0150894992384565e-08
mental O 0 0.0005177827551960945
health O 0 1.1386425136095113e-08
wellness O 0 4.0060651684825643e-08
in O 0 8.793843986332206e-10
relatives O 0 1.6809567071618403e-08
at O 0 4.165290690139045e-08
high O 0 1.9850880050853448e-07
risk O 0 3.094573344242235e-07
for O 0 1.6890726328711025e-07
bipolar B-Disease 1 1.0
affective I-Disease 1 0.5888762474060059
disorder I-Disease 1 0.9958694577217102
among O 0 6.8493449800755e-10
the O 0 2.813745458851713e-09
Old O 0 1.1824576517938112e-07
Order O 0 1.524131931773809e-07
Amish O 0 3.7331701605580747e-06
. O 0 6.884295089548687e-08

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 5.031597893889739e-08
BPAD B-Disease 1 1.0
; O 0 3.083667252212763e-05
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 7.429892701082963e-09
is O 0 1.8069996887692952e-10
characterized O 0 8.02161739810181e-11
by O 0 1.1315827615210328e-11
episodes O 0 1.0142586326367109e-08
of O 0 1.8474025864634314e-08
mania B-Disease 0 1.6133621727476566e-07
and O 0 1.7768525539807456e-09
/ O 0 1.481670460634632e-05
or O 0 2.6145343667849374e-08
hypomania B-Disease 0 1.438118829355517e-06
interspersed O 0 4.881840487414024e-10
with O 0 3.551512816474256e-12
periods O 0 2.3750320821136484e-08
of O 0 5.983903594852791e-09
depression B-Disease 0 2.1133446637122688e-07
. O 0 1.515897629644769e-08

Compelling O 0 2.2300355340121314e-06
evidence O 0 1.2142403704729077e-07
supports O 0 2.7442240480013425e-08
a O 0 7.910704868940854e-10
significant O 0 2.154963540945687e-09
genetic O 0 3.9276648600150565e-09
component O 0 8.376021654044052e-09
in O 0 1.3978367352507348e-09
the O 0 5.6399471759505104e-09
susceptibility O 0 3.349594024371072e-08
to O 0 3.497179079658963e-08
develop O 0 2.4404805571975885e-06
BPAD B-Disease 1 1.0
. O 0 1.8886601537815295e-05

To O 0 1.8645431865138562e-08
date O 0 6.392619411599298e-08
, O 0 9.529436129085411e-10
however O 0 7.541827717894023e-10
, O 0 3.3288910517015324e-10
linkage O 0 1.0318178311763404e-08
studies O 0 1.3858401093358452e-09
have O 0 3.622296074201614e-10
attempted O 0 1.2053099851527804e-08
only O 0 4.692698452046784e-10
to O 0 2.4713893154171274e-09
identify O 0 1.487218437290494e-08
chromosomal O 0 8.298279681184795e-07
loci O 0 4.860805233874999e-07
that O 0 3.4958367312043492e-09
cause O 0 7.631270726449202e-09
or O 0 1.618774003731005e-10
increase O 0 5.588300378001065e-10
the O 0 4.798030306396583e-10
risk O 0 2.7781068556720356e-09
of O 0 4.003198661450824e-09
developing O 0 9.263933407055447e-07
BPAD B-Disease 1 1.0
. O 0 1.1212780918867793e-05

To O 0 8.919192140410814e-08
determine O 0 9.189439431622759e-09
whether O 0 2.768500761973769e-09
there O 0 5.633848387809337e-10
could O 0 4.396854880184264e-09
be O 0 2.5127322444973288e-09
protective O 0 4.490586746896952e-08
alleles O 0 1.704095531351868e-09
that O 0 7.514484867687798e-11
prevent O 0 6.767171822907869e-10
or O 0 1.0902482389107959e-10
reduce O 0 2.7559825532819104e-09
the O 0 7.237455079689425e-10
risk O 0 3.3879776761835956e-09
of O 0 2.288129269389927e-10
developing O 0 1.468955623806778e-08
BPAD B-Disease 1 1.0
, O 0 2.919938180134807e-10
similar O 0 3.1427010299678315e-11
to O 0 2.316629527099323e-10
what O 0 3.493113784336366e-11
is O 0 3.1486031230182343e-12
observed O 0 5.3036238595316476e-11
in O 0 2.0409819667666085e-10
other O 0 7.053989836691699e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.3514645786093524e-10
we O 0 3.221994893110036e-10
used O 0 3.3934359766618627e-09
mental O 0 1.4805438297571527e-07
health O 0 7.786605249471279e-10
wellness O 0 1.6415038217587608e-08
( O 0 1.4400750036891452e-10
absence O 0 1.7757801629159076e-07
of O 0 2.9712573734741454e-08
any O 0 3.547254934233024e-08
psychiatric B-Disease 0 0.00022542882652487606
disorder I-Disease 0 1.0189261701043506e-07
) O 0 4.7910659814465184e-12
as O 0 2.983775379550302e-11
the O 0 1.9689425090341217e-10
phenotype O 0 5.539737557569424e-10
in O 0 9.560277014486473e-10
our O 0 1.760559342756096e-08
genome O 0 1.408115068990412e-09
- O 0 5.97652629608092e-08
wide O 0 2.6802963404293223e-08
linkage O 0 8.236112876147672e-07
scan O 0 0.0004201562551315874
of O 0 1.368074435958988e-07
several O 0 1.5021733856812602e-09
large O 0 1.730713350411861e-09
multigeneration O 0 1.2778580185113242e-06
Old O 0 1.7105222127611341e-07
Order O 0 5.8006644820807196e-08
Amish O 0 4.82922871469782e-07
pedigrees O 0 9.214770102516923e-08
exhibiting O 0 2.3386254710544563e-08
an O 0 4.2326400717662693e-10
extremely O 0 5.9061857626829806e-09
high O 0 9.714987214692883e-08
incidence O 0 2.7787020826508524e-06
of O 0 2.4876085262803826e-06
BPAD B-Disease 1 1.0
. O 0 1.2527964827313554e-05

We O 0 6.718871077282529e-07
have O 0 4.076124771046352e-09
found O 0 6.778669292550887e-10
strong O 0 5.4230026025337e-10
evidence O 0 2.9163205184090657e-10
for O 0 1.0287139889930685e-10
a O 0 5.891713228400874e-10
locus O 0 1.4039616580419079e-08
on O 0 3.3137666832772084e-08
chromosome O 0 3.830968466900231e-07
4p O 0 5.1613900723168626e-05
at O 0 3.054075534691947e-07
D4S2949 O 0 4.1004020090440463e-07
( O 0 4.8405317948363447e-11
maximum O 0 1.9164421161121936e-08
GENEHUNTER O 0 1.8533997092617938e-07
- O 0 2.206981442043343e-08
PLUS O 0 3.736642284479785e-08
nonparametric O 0 1.3262183529150207e-07
linkage O 0 4.304408829369777e-09
score O 0 7.990302863802867e-10
= O 0 1.4626476696477653e-09
4 O 0 3.9409450702798665e-10
. O 0 3.205858842281195e-11
05 O 0 9.497074415776297e-08
, O 0 1.6220995380233916e-10
P O 0 1.1111823461362746e-08
= O 0 3.1197404659621952e-09
5 O 0 2.662907117034763e-10
. O 0 1.2429474116615324e-11
22 O 0 5.141343462078396e-10
x O 0 8.976052789932965e-09
10 O 0 2.4034534362726845e-09
( O 0 2.2164190621731805e-11
- O 0 4.125022545764523e-09
4 O 0 2.569368051652532e-09
) O 0 5.971879935007252e-11
; O 0 7.453702932647133e-11
SIBPAL O 0 3.253667273384053e-07
Pempirical O 0 3.425105532528505e-08
value O 0 6.159876497768835e-10
< O 0 3.9531129480963045e-09
3 O 0 1.9169603682200886e-09
x O 0 1.2863537790508417e-08
10 O 0 2.1080692746977547e-09
( O 0 2.5394217978425004e-11
- O 0 4.6413566323622035e-09
5 O 0 7.873047991324711e-09
) O 0 2.2560521506509446e-10
) O 0 1.467022198164969e-10
and O 0 1.0357110308278905e-10
suggestive O 0 6.787690853826689e-09
evidence O 0 3.3155841960841315e-10
for O 0 4.215139348673347e-11
a O 0 3.1541361189546535e-10
locus O 0 8.141610052803117e-09
on O 0 1.4262013792176731e-08
chromosome O 0 2.3321983633195487e-07
4q O 0 1.3846295587427448e-05
at O 0 4.369144335214514e-08
D4S397 O 0 2.973199570988072e-07
( O 0 1.0539391581687596e-10
maximum O 0 4.409135101468564e-08
GENEHUNTER O 0 8.780779126027483e-08
- O 0 1.1692742774016551e-08
PLUS O 0 2.8787759731585538e-08
nonparametric O 0 7.507733101874692e-08
linkage O 0 1.5436737443863535e-09
score O 0 2.1997172139354149e-10
= O 0 1.0195084776398744e-09
3 O 0 1.5004601727763855e-10
. O 0 1.2967325997703671e-11
29 O 0 1.6597442309418398e-09
, O 0 4.542074702462706e-11
P O 0 3.695058925501371e-09
= O 0 1.6341556996479767e-09
2 O 0 1.2443428232256082e-10
. O 0 2.305317915729521e-11
57 O 0 1.0184356691311791e-09
x O 0 6.803529295495991e-09
10 O 0 3.31511795792494e-09
( O 0 1.9512506194141466e-11
- O 0 4.701247391381003e-09
3 O 0 1.780088632052923e-09
) O 0 3.2183939541186035e-11
; O 0 5.7737661873780155e-11
SIBPAL O 0 1.1553965606481142e-07
Pempirical O 0 8.378354898752605e-09
value O 0 3.8758668496896576e-10
< O 0 1.8579817684383215e-09
1 O 0 9.666256683971142e-10
x O 0 1.5894169536068148e-08
10 O 0 5.0382213956368105e-09
( O 0 4.207276194101439e-11
- O 0 1.154435658179409e-08
3 O 0 6.258829010619138e-09
) O 0 1.5364938488193758e-10
) O 0 2.9261586209639034e-11
that O 0 4.139329070479425e-12
are O 0 6.481941285801929e-12
linked O 0 3.1005207290490944e-09
to O 0 8.91949447634488e-09
mental O 0 5.794758635602193e-06
health O 0 6.42052881971722e-08
wellness O 0 2.3246557248057798e-06
. O 0 6.090603221764468e-08

These O 0 9.772581677225389e-08
findings O 0 1.902108692775073e-08
are O 0 7.860256195924009e-11
consistent O 0 9.846031545635014e-09
with O 0 5.2619696794264925e-11
the O 0 1.6213302922452044e-09
hypothesis O 0 4.624143734588415e-09
that O 0 4.137213575200471e-12
certain O 0 1.6454833329238028e-10
alleles O 0 7.438552551697342e-10
could O 0 1.891907963624817e-09
prevent O 0 5.002218639305056e-09
or O 0 2.2825423773298326e-09
modify O 0 3.7639065908479097e-07
the O 0 1.2284427697295541e-08
clinical O 0 4.132427022796037e-08
manifestations O 0 2.4204143755923724e-07
of O 0 4.016424171027211e-08
BPAD B-Disease 1 1.0
and O 0 2.651899588812512e-09
perhaps O 0 2.3454365116748477e-09
other O 0 1.359135859413385e-10
related O 0 3.223374989147487e-08
affective B-Disease 0 5.011741905036615e-06
disorders I-Disease 0 0.08184520900249481
. O 0 8.979375820672431e-07

Segregation O 0 1.3263997061585542e-05
distortion O 0 4.401994374347851e-06
in O 0 5.950683430455683e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 7.284017192432657e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.223806275964307e-07
DM B-Disease 1 1.0
) O 0 1.4064113429412828e-08
is O 0 1.7913249772405493e-09
an O 0 1.3450712765816775e-09
autosomal B-Disease 1 0.993253767490387
dominant I-Disease 0 0.14845341444015503
disease I-Disease 1 0.7724955677986145
which O 0 7.713501712358628e-12
, O 0 6.653750900947886e-13
in O 0 4.890512474153841e-12
the O 0 1.216547557136849e-10
typical O 0 9.062405825766007e-10
pedigree O 0 1.0566045816062797e-09
, O 0 1.7224324397324686e-11
shows O 0 4.1028300201695345e-10
a O 0 9.989773452900863e-10
three O 0 3.1459293503566244e-10
generation O 0 5.8862827501116044e-08
anticipation O 0 1.796472446358166e-07
cascade O 0 2.3663463366574433e-07
. O 0 4.5217385036266933e-07

This O 0 8.50276560271368e-09
results O 0 1.2182599817833761e-08
in O 0 6.837848509633204e-09
infertility B-Disease 0 3.855293834931217e-05
and O 0 3.9629437509347554e-08
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 9.81737358074497e-10
CDM B-Disease 0 2.4971006595819745e-08
) O 0 1.0124441215952906e-11
with O 0 6.725448756933483e-12
the O 0 8.20862666728317e-09
disappearance O 0 6.010066044837004e-07
of O 0 2.6728733004688365e-08
DM B-Disease 1 1.0
in O 0 3.7629046545362144e-08
that O 0 8.700182796417266e-10
pedigree O 0 6.431289989450306e-08
. O 0 4.36002842718608e-08

The O 0 4.359155170163831e-08
concept O 0 9.229316333403403e-08
of O 0 3.5075853332955376e-09
segregation O 0 4.1917509463473834e-08
distortion O 0 3.974631823666641e-08
, O 0 3.4687672872957265e-11
where O 0 2.278194993765581e-11
there O 0 3.5096743219997784e-12
is O 0 6.0559288703535e-13
preferential O 0 1.735711685491026e-09
transmission O 0 6.54058229798693e-09
of O 0 2.7566924298838558e-09
the O 0 1.4297849570965582e-09
larger O 0 6.769793059469009e-10
allele O 0 2.2321522408219607e-09
at O 0 8.678707530407337e-09
the O 0 3.498166378790302e-08
DM B-Disease 1 1.0
locus O 0 3.931039884719212e-07
, O 0 7.930798240352033e-10
has O 0 6.464634383362977e-11
been O 0 3.3961132517301706e-11
put O 0 2.075195709716482e-10
forward O 0 3.852732799458636e-09
to O 0 9.390688227028932e-09
explain O 0 2.7190017348743822e-08
partially O 0 2.5786187407561556e-08
the O 0 8.924135874721628e-10
maintenance O 0 9.068067186035478e-08
of O 0 2.8032422605406282e-08
DM B-Disease 1 1.0
in O 0 2.337385751616239e-08
the O 0 4.360084293608679e-09
population O 0 4.7814557868619545e-11
. O 0 1.4347131260805668e-09

In O 0 4.514874163419336e-08
a O 0 1.2565889662141672e-08
survey O 0 1.6443326700255056e-09
of O 0 7.099447141278858e-10
DM B-Disease 1 1.0
in O 0 1.5995563984461114e-08
Northern O 0 4.150729893126481e-08
Ireland O 0 1.1292084600711405e-08
, O 0 5.804155489563811e-10
59 O 0 3.628301570302028e-08
pedigrees O 0 7.938766088955163e-08
were O 0 1.4773118728328427e-08
ascertained O 0 2.202084488089895e-06
. O 0 4.5390811465040315e-07

Sibships O 0 1.895942091323377e-06
where O 0 6.825700005208546e-10
the O 0 4.84241535758656e-11
status O 0 6.008352704256481e-10
of O 0 2.274275767710776e-10
all O 0 2.8241088287361826e-11
the O 0 1.4925166658130706e-10
members O 0 4.6782897000774426e-11
had O 0 2.443322766332301e-10
been O 0 1.6584513276574064e-11
identified O 0 3.6881619286388556e-11
were O 0 7.038191557340312e-11
examined O 0 6.997223356286497e-10
to O 0 7.616841601887359e-10
determine O 0 3.6115634927114115e-09
the O 0 5.664171354169412e-09
transmission O 0 1.0248455595274208e-07
of O 0 9.707981973861024e-09
the O 0 6.732199864245558e-08
DM B-Disease 1 1.0
expansion O 0 3.328939328639535e-07
from O 0 1.0760866642200995e-09
affected O 0 5.770653954684235e-10
parents O 0 9.781276483211698e-11
to O 0 6.062271240558914e-10
their O 0 2.739270366092228e-09
offspring O 0 1.0428605889956089e-07
. O 0 2.1137600469955942e-07

Where O 0 4.9717641559254844e-08
the O 0 8.81781581085761e-09
transmitting O 0 1.779246900923681e-07
parent O 0 9.109547782770733e-09
was O 0 2.6887754245308315e-08
male O 0 1.8683238067751518e-08
, O 0 2.3619255440365805e-09
58 O 0 2.3786391523117345e-07
. O 0 1.8792822231716855e-07

3 O 0 6.942074151083943e-07
% O 0 8.474141388603584e-09
of O 0 3.056535469170285e-09
the O 0 5.675848124830907e-10
offspring O 0 1.2761429690755222e-09
were O 0 6.01874383665546e-10
affected O 0 1.5253773244516822e-10
, O 0 7.0750939829000714e-12
and O 0 4.751289205823239e-12
in O 0 1.0177206299921693e-10
the O 0 4.844117884594823e-10
case O 0 3.5607136683601937e-10
of O 0 9.485076613025001e-11
a O 0 4.4824186029579494e-10
female O 0 9.339045092815468e-10
transmitting O 0 1.766614232678876e-08
parent O 0 6.814230957274958e-09
, O 0 5.848799666807736e-09
68 O 0 3.7406505271064816e-06
. O 0 4.5665537982131355e-06

7 O 0 2.156590426238836e-06
% O 0 8.223027592180188e-09
were O 0 3.6631022659605605e-09
affected O 0 7.005586777353301e-09
. O 0 7.557213876907554e-08

Studies O 0 2.3627654854863067e-07
on O 0 6.079437753214734e-08
meiotic O 0 1.1366644230292877e-06
drive O 0 2.346507699257927e-07
in O 0 2.304538782027521e-08
DM B-Disease 1 1.0
have O 0 4.06274391906436e-09
shown O 0 2.0227364228020406e-10
increased O 0 1.7448455180701927e-10
transmission O 0 1.5475593029279366e-09
of O 0 1.442521657679663e-10
the O 0 1.5215505244636773e-10
larger O 0 2.7983887429527954e-10
allele O 0 2.8166289300912695e-09
at O 0 5.924655432920645e-09
the O 0 1.517899583802773e-08
DM B-Disease 1 1.0
locus O 0 7.487741271461346e-08
in O 0 4.622186189351396e-09
non O 0 5.44601607543882e-06
- O 0 4.111806265427731e-05
DM O 1 1.0
heterozygotes O 0 1.946802149177529e-05
for O 0 3.8025870452429444e-08
CTGn O 0 3.2806532544782385e-05
. O 0 2.9816467872478825e-07

This O 0 5.050712914567157e-08
study O 0 3.264742920450203e-09
provides O 0 6.274301217468192e-11
further O 0 3.471322188031145e-11
evidence O 0 1.0014894469279056e-10
that O 0 3.673797377423682e-11
the O 0 1.691170403717024e-08
DM B-Disease 1 1.0
expansion O 0 2.842611820597085e-06
tends O 0 9.654104360379279e-08
to O 0 4.3888697121019504e-09
be O 0 1.019065276608444e-09
transmitted O 0 7.414009406403466e-09
preferentially O 0 2.630123230318304e-09
. O 0 1.0340742306880202e-07

Diagnosis O 1 1.0
of O 0 7.09039595676586e-05
hemochromatosis B-Disease 1 1.0
. O 0 0.00036659007309935987

If O 0 1.413297354702081e-06
untreated O 0 3.1890896934783086e-05
, O 0 1.23710970356683e-08
hemochromatosis B-Disease 1 1.0
can O 0 2.4467067305522505e-07
cause O 0 1.7987490252835414e-07
serious O 0 3.740450083000724e-08
illness O 0 1.3949906474408635e-07
and O 0 2.905148691056958e-11
early B-Disease 0 6.264334828642859e-09
death I-Disease 0 1.0151624429965977e-08
, O 0 4.2692616802897376e-11
but O 0 3.971140083436353e-11
the O 0 3.176359175682819e-10
disease O 0 3.9760530978760755e-10
is O 0 4.717345437887932e-12
still O 0 1.2419900177751408e-11
substantially O 0 2.565283985234146e-09
under O 0 3.3026427104232425e-07
- O 1 0.9995446801185608
diagnosed O 0 0.03228037804365158
. O 0 3.4521710858825827e-06

The O 0 7.17206376066315e-07
cornerstone O 0 7.63951084081782e-06
of O 0 1.7102571803206956e-08
screening O 0 7.328793572014547e-09
and O 0 3.405792869948243e-10
case O 0 3.0378888293824957e-10
detection O 0 2.0720179350064427e-08
is O 0 5.91131865679273e-11
the O 0 5.127251401226829e-10
measurement O 0 1.7369844229619957e-08
of O 0 7.326767192950001e-09
serum O 0 8.989762534383772e-08
transferrin O 0 2.3510773417001474e-07
saturation O 0 3.8282695413727197e-07
and O 0 1.7767305404703393e-09
the O 0 1.2685188011118953e-08
serum O 0 9.970138137305185e-08
ferritin O 0 3.998767397206393e-07
level O 0 2.425671539185714e-07
. O 0 1.9459540112620743e-07

Once O 0 1.5794491901033325e-06
the O 0 1.7815874997495484e-08
diagnosis O 0 6.847353233752074e-06
is O 0 1.5089324234551782e-10
suspected O 0 6.107491401508014e-09
, O 0 3.6272601589004694e-10
physicians O 0 2.9389383371380973e-08
must O 0 4.0289922509373355e-08
use O 0 7.509752322221175e-07
serum O 0 1.0847994417417794e-05
ferritin O 0 4.016169623355381e-05
levels O 0 3.33550306095276e-05
and O 0 6.808387098544699e-08
hepatic O 0 0.00013126478006597608
iron O 1 0.7026363611221313
stores O 0 1.9918112229788676e-05
on O 0 6.546937356688431e-07
liver O 0 3.035650877336593e-07
biopsy O 0 4.5133160142540873e-07
specimens O 0 1.5742170234034347e-08
to O 0 1.240267999413902e-09
assess O 0 1.0506606251681205e-08
patients O 0 1.4535866954545895e-09
for O 0 5.740355413230702e-10
the O 0 4.983705448324827e-09
presence O 0 5.154830873266292e-08
of O 0 1.609798090385084e-07
iron B-Disease 0 0.45060330629348755
overload I-Disease 0 9.755536302691326e-05
. O 0 8.115022751553624e-07

Liver O 1 0.9999756813049316
biopsy O 1 0.9999988079071045
is O 0 8.365803161325402e-09
also O 0 9.466046002604145e-11
used O 0 1.3458122116727367e-10
to O 0 3.608518206466016e-10
establish O 0 1.0991251464531615e-08
the O 0 2.4582262891925666e-09
presence O 0 9.849938642503275e-09
or O 0 5.427085270071075e-08
absence O 0 0.0005203664768487215
of O 0 5.421208726374971e-08
cirrhosis B-Disease 0 5.645396868203534e-06
, O 0 1.8643563082232362e-10
which O 0 3.6959064281250065e-12
can O 0 9.780003196180331e-12
affect O 0 4.241570150664842e-10
prognosis O 0 3.6955407267669216e-07
and O 0 4.66032235024727e-09
management O 0 2.898244133575645e-07
. O 0 4.075249080415233e-07

A O 0 3.760085576232086e-07
DNA O 0 8.51209591701263e-09
- O 0 1.175589314783565e-08
based O 0 7.49184825288296e-10
test O 0 2.8775775096079315e-09
for O 0 9.838311276766376e-10
the O 0 1.2911816504868057e-08
HFE O 0 4.996477218810469e-05
gene O 0 4.403143094577899e-08
is O 0 1.1466091270895262e-10
commercially O 0 3.44669737195602e-09
available O 0 5.512104550575714e-09
, O 0 3.032214063170002e-11
but O 0 1.1936198557327415e-11
its O 0 1.792762119312563e-11
place O 0 2.334376025814322e-10
in O 0 1.4960251093487642e-10
the O 0 5.403550384919242e-10
diagnosis O 0 8.721688686819107e-07
of O 0 5.5194480097497944e-09
hemochromatosis B-Disease 1 1.0
is O 0 2.402261722878052e-09
still O 0 3.511398671829369e-10
being O 0 1.5392981334017009e-10
evaluated O 0 4.50760984094245e-09
. O 0 1.3771328610800992e-07

Currently O 0 2.460245127622329e-07
, O 0 1.8336056006873491e-09
the O 0 1.185231579547974e-09
most O 0 3.096800246793485e-11
useful O 0 6.910296779238934e-10
role O 0 1.284383849275983e-10
for O 0 1.2160650264547712e-10
this O 0 5.607003056296023e-11
test O 0 2.1612643619217664e-10
is O 0 2.3828634378164626e-12
in O 0 1.9279293439478096e-11
the O 0 1.564081364424652e-10
detection O 0 1.9917699489724328e-08
of O 0 1.5637837691429013e-09
hemochromatosis B-Disease 1 1.0
in O 0 1.1397489174669317e-07
the O 0 4.009688581163573e-08
family O 0 7.449443284457402e-10
members O 0 9.487682167685918e-11
of O 0 1.366361745969158e-10
patients O 0 9.156607416738183e-11
with O 0 6.274678042775261e-13
a O 0 2.2975053803886425e-10
proven O 0 1.8850112581958456e-08
case O 0 3.1132671995948158e-09
of O 0 3.065528275669749e-08
the O 0 3.1953825896380295e-07
disease O 0 3.063024394123204e-07
. O 0 1.2701026719241781e-07

It O 0 1.5856198132269128e-08
is O 0 2.778773044997962e-10
crucial O 0 5.719061135778247e-08
to O 0 3.79413279461005e-07
diagnose O 1 0.9999957084655762
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 2.6352674353802286e-07
because O 0 1.2997449783114234e-09
phlebotomy O 0 5.9803628573718015e-06
therapy O 0 3.141620254609734e-06
can O 0 2.834629642123332e-09
avert O 0 9.99424855763209e-07
serious O 0 1.2605879646798712e-06
chronic O 1 0.9999997615814209
disease O 0 4.603401248459704e-05
and O 0 2.975093227330916e-10
can O 0 4.404902553822865e-10
even O 0 3.918100288657911e-10
lead O 0 1.1428062940410655e-09
to O 0 1.3940240073395671e-09
normal O 0 5.683846282522609e-09
life O 0 2.6837991828898566e-09
expectancy O 0 3.647408819418274e-09
. O 0 2.5559737659719417e-10
. O 0 3.5454423397141e-08

Prevalence O 0 8.610806980868801e-05
of O 0 8.371137738549805e-08
the O 0 6.878375558017069e-08
I1307K O 0 3.3695112051645992e-06
APC B-Disease 0 1.4902657596849167e-07
gene O 0 3.4667337889260352e-09
variant O 0 1.1103793440270238e-08
in O 0 2.5726043517693142e-09
Israeli O 0 1.3092532924474654e-07
Jews O 0 1.9768759962346394e-09
of O 0 2.4481822819000243e-11
differing O 0 3.038986813932998e-12
ethnic O 0 1.398437247078499e-12
origin O 0 2.8581560729268318e-11
and O 0 1.559385953697756e-11
risk O 0 1.5389935992260462e-09
for O 0 2.1246773229677274e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.4612055718898773

BACKGROUND O 0 6.884121103212237e-05
& O 0 1.23933286886313e-05
AIMS O 0 4.045829427923309e-06
Israeli O 0 3.4623022315827257e-07
Jews O 0 1.592023046725899e-08
of O 0 7.797900658523815e-10
European O 0 2.7905960875429514e-10
birth O 0 1.6181088469124916e-08
, O 0 2.4375321205916123e-10
i O 0 3.1173790215888175e-09
. O 0 3.248120106214003e-10
e O 0 5.930319346703072e-09
. O 0 3.407170379166047e-10
, O 0 3.8043823646916053e-10
Ashkenazim O 0 2.831514223089471e-07
, O 0 1.901344914845282e-10
have O 0 2.7695926108073365e-10
the O 0 1.3964109868425112e-09
highest O 0 1.4203562386683188e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.003812429029494524
of O 0 2.1954846829430608e-09
any O 0 1.914000957725648e-09
Israeli O 0 3.7917345707683126e-07
ethnic O 0 1.2942630300827318e-09
group O 0 3.0313382914926024e-09
. O 0 5.1693238134475905e-08

The O 0 3.2840475796547253e-06
I1307K O 0 1.6590332961641252e-05
APC B-Disease 0 4.609510710906761e-07
gene O 0 4.058793301453534e-09
variant O 0 2.824958933445032e-08
was O 0 3.382994151479579e-08
found O 0 6.559155441010489e-10
in O 0 9.580940485420797e-10
6 O 0 1.043297743308358e-06
. O 0 2.310013940132194e-07

1 O 0 4.2686130541369494e-07
% O 0 3.099816847651482e-09
of O 0 5.203794062325073e-10
American O 0 2.963839451641803e-10
Jews O 0 7.854355499326005e-10
, O 0 7.867181732457151e-12
28 O 0 5.289160776023039e-10
% O 0 2.784779074005428e-10
of O 0 1.0487259949343297e-09
their O 0 1.3287427691466291e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 5.792228421341861e-07
, O 0 4.2864947702447864e-11
but O 0 2.390083790604347e-11
not O 0 1.44988659966927e-10
in O 0 4.721877888691495e-10
non O 0 1.5308241074762918e-07
- O 0 1.2517681113877188e-07
Jews O 0 1.1912772635014335e-07
. O 0 9.350441132482956e-08

We O 0 1.2733772791762021e-07
assessed O 0 1.744056277175332e-07
the O 0 1.306025421143886e-08
I1307K O 0 1.570754989188572e-06
prevalence O 0 6.517259976135392e-08
in O 0 1.1750501960339221e-10
Israeli O 0 3.4686998162669624e-08
Jews O 0 7.90654652860212e-09
of O 0 1.6650511525106992e-10
differing O 0 2.324098899442184e-11
ethnic O 0 5.447514401374365e-12
origin O 0 1.113100930871802e-10
and O 0 5.919814638488674e-11
risk O 0 5.221364673957396e-09
for O 0 6.880173231138542e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.14800980687141418

METHODS O 0 1.101448333429289e-06
DNA O 0 4.210139792348855e-08
samples O 0 4.808210718465489e-09
from O 0 2.670974830198958e-10
500 O 0 6.1929119610226735e-09
unrelated O 0 6.410745823082209e-10
Jews O 0 7.471075313958409e-09
of O 0 2.684992006507514e-09
European O 0 7.03491087605812e-09
or O 0 8.315814148396328e-10
non O 0 4.350915361328589e-08
- O 0 1.4910414236624092e-08
European O 0 6.552903775158825e-10
origin O 0 6.630425097853276e-10
, O 0 1.5990474569460567e-11
with O 0 2.46328077293384e-13
or O 0 9.540011142172844e-12
without O 0 8.805571549697078e-11
a O 0 5.1331786043995464e-11
personal O 0 1.8226568032631008e-09
and O 0 5.6110893709160337e-11
/ O 0 3.7769629557260487e-07
or O 0 9.959073565823928e-09
family O 0 3.083082900090517e-09
history O 0 6.799481866437418e-09
of O 0 6.423487852735832e-10
neoplasia B-Disease 0 8.488429870112668e-08
, O 0 3.6959099669608975e-10
were O 0 5.674246073006373e-10
examined O 0 3.826668315554116e-09
for O 0 1.5374034267878756e-09
the O 0 2.556940437159483e-09
I1307K O 0 2.865343873281745e-08
variant O 0 1.3029221035409932e-09
by O 0 5.293012902973793e-11
the O 0 1.3061767223376819e-09
allele O 0 2.6839115374599487e-09
- O 0 1.0114709070307981e-08
specific O 0 5.033303995816141e-09
oligonucleotide O 0 7.431256108247908e-07
( O 0 6.308940481147829e-09
ASO O 0 3.9862666199042e-06
) O 0 2.533515897074068e-10
method O 0 2.8712413779885537e-08
. O 0 2.2116841691399713e-08

RESULTS O 0 3.268140460477298e-07
In O 0 3.674936355224645e-09
persons O 0 1.1590749471324102e-09
at O 0 1.2311185404456637e-09
average O 0 1.384426684403195e-09
risk O 0 1.1149543510668991e-09
for O 0 1.3422271294416532e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.1502183383527154e-07
I1307K O 0 5.880514208911336e-07
was O 0 4.9087804931957635e-09
found O 0 1.1645945319216366e-10
in O 0 3.8058847739996793e-10
5 O 0 1.457121783232651e-07
. O 0 1.5686980248119653e-07

0 O 0 8.599205330028781e-07
% O 0 2.3921475911237167e-09
of O 0 1.2270933158475827e-09
120 O 0 1.9731739797634873e-08
European O 0 4.4481236471938246e-09
and O 0 1.5074144155136082e-09
1 O 0 1.093631567528064e-06
. O 0 7.611982368871395e-07

6 O 0 8.457979561171669e-07
% O 0 5.482787557298252e-09
of O 0 1.6898734633841173e-09
188 O 0 9.402283396298117e-09
non O 0 4.3661287918439484e-07
- O 0 4.114291982659779e-07
European O 0 3.156016958882901e-08
Jews O 0 2.5685070070835536e-08
( O 0 4.2160479968300635e-11
P O 0 1.52729739966162e-08
= O 0 4.682901177943677e-09
0 O 0 7.534322610247557e-10
. O 0 3.0587251481639655e-11
08 O 0 1.0941616501725093e-08
) O 0 5.267786762352955e-10
. O 0 1.5543582421173596e-08

It O 0 2.690477174382977e-09
occurred O 0 2.751801675415777e-09
in O 0 9.671863310245499e-10
15 O 0 8.452223454469276e-08
. O 0 1.0148163198664406e-07

4 O 0 4.347514561686694e-07
% O 0 4.976504985876318e-09
of O 0 1.582066366800916e-09
52 O 0 2.1451022291785193e-08
Ashkenazi O 0 4.086667360070351e-08
Israelis O 0 3.0348866175700095e-07
with O 0 1.1112559761272678e-09
familial O 0 6.35167962173e-05
cancer B-Disease 1 0.999920129776001
( O 0 3.577009799471398e-10
P O 0 4.310248016281548e-07
= O 0 4.728065761128164e-08
0 O 0 4.035758394138611e-09
. O 0 1.3053341740842939e-10
02 O 0 2.2303963476133504e-07
) O 0 5.267803901420898e-11
and O 0 3.970216169713048e-11
was O 0 7.864158768633445e-10
not O 0 2.242204477642673e-10
detected O 0 1.2608762922639016e-09
in O 0 3.3605590532559404e-10
51 O 0 5.623762433515367e-08
non O 0 7.849337634979747e-06
- O 0 4.15499425798771e-06
European O 0 5.177493989094728e-08
Jews O 0 5.103450462229375e-08
at O 0 5.901107158479135e-09
increased O 0 1.5155787735920967e-09
cancer B-Disease 0 3.301928952481603e-09
risk O 0 5.160976979112775e-09
. O 0 4.643944606641526e-08

Colorectal B-Disease 1 0.7788519263267517
neoplasia I-Disease 0 8.204214100260288e-05
occurred O 0 2.682344984350493e-06
personally O 0 5.027377270039324e-08
or O 0 9.505687209587776e-11
in O 0 4.1296785435740446e-11
the O 0 3.757362476708437e-11
families O 0 6.0591440718960055e-12
of O 0 4.8058956120256013e-11
13 O 0 6.97140967176324e-09
of O 0 1.5575455591942955e-08
20 O 0 5.009105166209338e-07
Ashkenazi O 0 3.2966451612992387e-07
I1307K O 0 1.1752400297382337e-07
carriers O 0 4.321797364426061e-10
, O 0 6.354342052539153e-11
8 O 0 1.4569793371776996e-08
of O 0 5.747489595364641e-09
whom O 0 1.045858066817118e-08
also O 0 2.2850297209942028e-09
had O 0 2.0306618608856297e-09
a O 0 7.099609233840454e-10
personal O 0 2.5569566020067214e-08
or O 0 1.0760374813401086e-09
family O 0 3.2180827447270133e-10
history O 0 4.9062718332493205e-09
of O 0 4.4227528306350905e-09
noncolonic O 0 4.724261543742614e-06
neoplasia B-Disease 0 0.0001418968167854473
. O 0 9.27724704524735e-06

CONCLUSIONS O 0 9.613615475245751e-06
The O 0 4.304213803152379e-07
I1307K O 0 5.719502951251343e-06
APC O 0 3.491061590921163e-07
variant O 0 7.6910829704957e-08
may O 0 7.117048728133568e-09
represent O 0 2.3387134451269276e-09
a O 0 4.546742982114438e-09
susceptibility O 0 2.904421592120343e-08
gene O 0 7.766645104823056e-09
for O 0 5.5512192176365716e-08
colorectal B-Disease 1 1.0
, I-Disease 0 1.88745229934284e-06
or I-Disease 0 1.569558634173518e-07
other I-Disease 0 9.758012176064312e-09
, I-Disease 0 7.607940943898939e-10
cancers I-Disease 0 5.151155235694205e-08
in O 0 5.135945890799576e-09
Ashkenazi O 0 2.992009626723302e-07
Jews O 0 4.91405707236936e-08
, O 0 4.791482766108857e-10
and O 0 1.9008446205948104e-10
partially O 0 2.953425060070458e-08
explains O 0 1.706900398801281e-08
the O 0 1.9514090343619728e-09
higher O 0 2.881982368307945e-07
incidence O 0 6.91565583110787e-06
of O 0 3.6220553738530725e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.435980710899457e-06
European O 0 1.2823049644339335e-07
Israelis O 0 1.4708543858432677e-06
. O 0 1.068872919063324e-07

Systematic O 0 3.250175382163434e-07
analysis O 0 2.3648162539302575e-08
of O 0 1.5538363484779438e-08
coproporphyrinogen O 0 1.8532170997787034e-06
oxidase O 0 7.009103910604608e-07
gene O 0 4.945000000589062e-07
defects O 0 0.00017203300376422703
in O 0 3.0475455332634738e-06
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999991655349731
and O 0 8.598388490099751e-08
mutation O 0 5.130534219688343e-08
update O 0 1.778048499545548e-05
. O 0 5.353473397917696e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999996423721313
( O 0 2.952625521857044e-08
HC B-Disease 0 0.00032548734452575445
) O 0 1.7943110108831206e-08
is O 0 3.0577598231218417e-09
an O 0 9.456467831014947e-10
acute O 0 2.9893457394791767e-05
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 5.9971021983074024e-05
autosomal O 1 1.0
dominant O 1 0.9944486618041992
inheritance O 0 5.7209431361116e-06
caused O 0 1.059196392816375e-07
by O 0 6.53093594829568e-12
deficient B-Disease 0 1.0911391790102698e-09
activity I-Disease 0 2.0704287173600733e-09
of I-Disease 0 5.088654386753433e-09
coproporphyrinogen I-Disease 0 3.5834327150041645e-07
III I-Disease 0 1.8587590602692217e-05
oxidase I-Disease 0 1.7361371362767386e-07
( O 0 1.5666020702909123e-09
CPO O 0 6.402261988114333e-06
) O 0 6.686664555388688e-09
. O 0 7.958323777756959e-08

Clinical O 0 1.0840062714123633e-05
manifestations O 0 6.332581961032702e-06
of O 0 2.2073061245464487e-07
the O 0 2.916195462887572e-08
disease O 0 3.997714514980544e-08
are O 0 8.136567808403328e-12
characterized O 0 1.823983498960846e-11
by O 0 6.439649161138483e-12
acute O 0 3.232635137351281e-08
attacks O 0 5.1729138306200184e-08
of O 0 6.232777991499461e-07
neurological B-Disease 1 1.0
dysfunction I-Disease 1 0.9999794960021973
often O 0 1.8217297892419992e-08
precipitated O 0 5.8237197286814535e-09
by O 0 5.967242758947444e-12
drugs O 0 1.1600016502910648e-09
, O 0 6.719438894187135e-11
fasting O 0 5.139731129588654e-08
, O 0 7.761309372966707e-10
cyclical O 0 1.4510799246636452e-06
hormonal O 0 1.533186514279805e-05
changes O 0 8.143489935719117e-07
, O 0 2.04776888779179e-08
or O 0 5.8425921878324516e-08
infectious B-Disease 0 2.2634542347077513e-06
diseases I-Disease 0 1.4641019561167923e-06
. O 0 1.2776590097018925e-07

Skin O 1 1.0
photosensitivity O 1 0.9999810457229614
may O 0 1.4971706150390673e-06
also O 0 2.2376256403333628e-09
be O 0 2.762201856132407e-10
present O 0 1.293377072109081e-09
. O 0 5.138260661396998e-08

The O 0 5.910741265324759e-07
seven O 0 3.179605201353297e-08
exons O 0 1.5463680114180534e-08
, O 0 7.127994861022557e-10
the O 0 2.5167516959356817e-09
exon O 0 9.231904840589777e-08
/ O 0 1.0803853456309298e-06
intron O 0 2.9731120321230264e-07
boundaries O 0 7.7362283246174e-10
and O 0 9.612859119823014e-11
part O 0 1.665912130466296e-10
of O 0 1.0468095279492218e-09
3 O 0 6.475352698487313e-09
noncoding O 0 2.181667513312391e-09
sequence O 0 3.0738508960403976e-10
of O 0 4.235412021103002e-09
the O 0 1.5690819310520965e-08
CPO O 0 8.443263368462794e-07
gene O 0 5.629629651338064e-09
were O 0 5.510401912545149e-09
systematically O 0 1.1417067291574767e-08
analyzed O 0 1.0769594105397573e-09
by O 0 5.4956490747049e-11
an O 0 1.8175005944698341e-10
exon O 0 5.3935136357097235e-09
- O 0 1.7296844845304804e-08
by O 0 2.260291287470295e-09
- O 0 4.5580156893265666e-07
exon O 0 6.929968776603346e-07
denaturing O 0 1.4446288332692347e-05
gradient O 0 1.5309292678011843e-07
gel O 0 6.482176218014502e-07
electrophoresis O 0 1.9358250114009934e-08
( O 0 7.097141624390346e-11
DGGE O 0 1.8287870773292525e-07
) O 0 3.9653499234182377e-11
strategy O 0 1.3211903793219903e-09
followed O 0 1.539186555987726e-10
by O 0 1.1953348467291791e-12
direct O 0 2.5624157309889206e-11
sequencing O 0 2.155644829304748e-10
in O 0 1.7016854592100117e-09
seven O 0 1.3238800278259077e-08
unrelated O 0 3.4426715700419663e-08
heterozygous O 0 3.9845144073069605e-08
HC B-Disease 0 2.231988901257864e-06
patients O 0 1.4099006762080535e-07
from O 0 3.4640237345229252e-09
France O 0 2.5998051711439985e-08
, O 0 2.7816154934967585e-10
Holland O 0 4.068794368095041e-08
, O 0 2.558046829914673e-10
and O 0 1.792749421136719e-10
Czech O 0 6.417933207103488e-08
Republic O 0 1.810054641282477e-06
. O 0 2.92741924567963e-06

Seven O 0 2.2510818098453456e-07
novel O 0 1.2677593197452097e-08
mutations O 0 2.4197917003476732e-09
and O 0 4.986421830999177e-10
two O 0 1.9225250558196905e-10
new O 0 2.907635021642818e-09
polymorphisms O 0 3.499238232507196e-07
were O 0 1.9735057321668137e-07
detected O 0 3.842497733330674e-07
. O 0 7.701739264120988e-07

Among O 0 5.790163015717553e-08
these O 0 1.402403304595623e-09
mutations O 0 7.367936816216059e-10
two O 0 2.752892358515169e-10
are O 0 3.650314425729384e-11
missense O 0 2.6405595932033066e-08
( O 0 5.10701869682606e-10
G197W O 0 4.3387251480453415e-07
, O 0 3.7174449629695516e-10
W427R O 0 9.716116977642741e-08
) O 0 1.1356525442263177e-10
, O 0 7.260402695719037e-11
two O 0 9.482725715770357e-11
are O 0 5.710942482806125e-11
nonsense O 0 1.3039296753447616e-08
( O 0 1.6008304404291351e-10
Q306X O 0 2.3378656521799712e-07
, O 0 3.0933539063582316e-10
Q385X O 0 7.672519330981231e-08
) O 0 1.2083932465767333e-10
, O 0 7.399253432183173e-11
two O 0 4.6739015435726117e-11
are O 0 2.7874137026318024e-11
small O 0 4.009806653382242e-10
deletions O 0 3.067189169314588e-08
( O 0 4.3340803168590014e-10
662de14bp O 0 1.3139427323949349e-07
; O 0 2.3247562208617012e-10
1168del3bp O 0 5.101795963469158e-08
removing O 0 2.8142999042302108e-08
a O 0 2.2847288505545293e-09
glycine O 0 9.173713344523549e-09
at O 0 3.064411657760502e-08
position O 0 1.2476998989541244e-08
390 O 0 2.4036366230717476e-09
) O 0 8.039181299823728e-12
, O 0 6.549148376389091e-12
and O 0 3.3441866897215844e-12
one O 0 6.38976718758677e-12
is O 0 7.149524028360332e-13
a O 0 1.467682052280761e-11
splicing O 0 6.973550625843927e-09
mutation O 0 2.3576991470264375e-09
( O 0 7.974631371920893e-11
IVS1 O 0 4.798868644684262e-07
- O 0 5.347523668319809e-08
15c O 0 4.977589014742989e-06
- O 0 3.1346064588433364e-07
- O 0 1.4355686062117456e-07
> O 0 1.7621088943542418e-07
g O 0 2.1679881001546164e-08
) O 0 3.297934841883787e-11
which O 0 7.058716892244243e-12
creates O 0 4.103015843748281e-11
a O 0 1.3453220482073647e-10
new O 0 7.741556840024089e-10
acceptor O 0 8.72617889058347e-09
splice O 0 7.968824888848758e-07
site O 0 6.871477467029763e-07
. O 0 2.2346077344082005e-07

The O 0 1.1513093056692014e-07
pathological O 0 6.9477572139931e-08
significance O 0 4.7145846338025876e-08
of O 0 8.869786682907943e-09
the O 0 5.574803729757605e-09
point O 0 1.1793353849043342e-08
mutations O 0 5.790753432322049e-10
G197W O 0 4.848309842486742e-08
, O 0 1.409662109264076e-10
W427R O 0 7.184372208257628e-08
, O 0 1.0780274589672345e-10
and O 0 9.694112873548377e-11
the O 0 1.068848032304004e-08
in O 0 1.3885633087795668e-08
- O 0 2.842606932063063e-07
frame O 0 6.706234216835583e-07
deletion O 0 7.921025257928704e-08
390delGly O 0 1.8194690198924945e-08
were O 0 1.1019599122086277e-10
assessed O 0 6.324792911627242e-10
by O 0 1.0496395419501425e-11
their O 0 2.9906879750463133e-10
respective O 0 2.669137577626657e-09
expression O 0 3.822896665894859e-09
in O 0 3.3514824249181174e-10
a O 0 3.638582490861353e-10
prokaryotic O 0 2.3479732047526625e-10
system O 0 2.2109480912746449e-10
using O 0 3.139359328052649e-10
site O 0 1.605503618939963e-09
- O 0 8.234717352451071e-10
directed O 0 2.6819402254574243e-10
mutagenesis O 0 1.2975046104202193e-07
. O 0 2.4462869419039635e-07

These O 0 1.341863686832312e-08
mutations O 0 1.4982903806526338e-09
resulted O 0 7.01079583276254e-10
in O 0 1.0418809565093667e-10
the O 0 4.897461880482012e-10
absence O 0 3.914546464756086e-09
or O 0 1.1445552144939697e-10
a O 0 1.356111473116428e-10
dramatic O 0 3.7060113311504495e-10
decrease O 0 9.896472086268204e-09
of O 0 1.1858500670314243e-07
CPO O 0 4.312596865929663e-05
activity O 0 7.9735082181287e-07
. O 0 8.393535040340794e-07

The O 0 4.895982215202821e-07
two O 0 3.251723335040424e-09
polymorphisms O 0 1.3992245584404372e-08
were O 0 5.368703814845333e-10
localized O 0 1.6614165598838326e-09
in O 0 4.5965120598623344e-10
noncoding O 0 4.802271913462164e-09
part O 0 6.4918497244548234e-09
of O 0 1.122024784194764e-08
the O 0 7.972505988718126e-10
gene O 0 1.7342141611642603e-11
1 O 0 2.1402621896982055e-09
) O 0 6.919367856461633e-11
a O 0 1.3540031318370893e-09
C O 0 1.0018060692118524e-07
/ O 0 2.2955717327022285e-08
G O 0 6.960886533846633e-09
polymorphism O 0 2.5153743532513317e-09
in O 0 6.469127455943635e-10
the O 0 1.886823142172034e-09
promotor O 0 5.255809014670376e-07
region O 0 9.957211943856237e-09
, O 0 7.735092566463209e-10
142 O 0 1.1652245390791904e-08
bp O 0 1.1923725118379025e-08
upstream O 0 2.905844231904098e-09
from O 0 3.052933184033435e-10
the O 0 4.824670662983976e-10
transcriptional O 0 2.1145032946812137e-10
initiation O 0 9.79812453394402e-10
site O 0 1.7099170968037924e-09
( O 0 9.643964446470754e-12
- O 0 2.342785077047438e-09
142C O 0 6.063086743779422e-08
/ O 0 1.4408897186513059e-08
G O 0 4.544765896952185e-09
) O 0 1.0596509780746999e-11
, O 0 5.762926160585158e-12
and O 0 3.6226583798731893e-12
2 O 0 5.038132688817143e-10
) O 0 5.155353921537653e-11
a O 0 1.9473636037048436e-09
6 O 0 4.10974223541416e-08
bp O 0 1.525725146223067e-08
deletion O 0 9.062993133746033e-10
polymorphism O 0 7.363047949127122e-10
in O 0 3.96464860941137e-10
the O 0 4.907841910650745e-10
3 O 0 1.989684417225135e-09
noncoding O 0 2.934120058029066e-09
part O 0 1.650003467190686e-09
of O 0 3.4560647677039924e-09
the O 0 6.858380974250622e-09
CPO O 0 9.122380788539886e-07
gene O 0 2.73553202312371e-09
, O 0 1.6323489226977017e-09
574 O 0 9.5888466944416e-08
bp O 0 4.503023376400961e-08
downstream O 0 2.8014022213085354e-09
of O 0 1.9931978290088637e-09
the O 0 1.0964967822602034e-09
last O 0 9.39967992330537e-10
base O 0 4.89244156298696e-09
of O 0 9.080257379334711e-11
the O 0 3.5596799813353286e-11
normal O 0 1.2274139482570945e-09
termination O 0 7.147752612013392e-09
codon O 0 1.028442397910112e-08
( O 0 5.252045465198307e-10
+ O 0 2.1744698130987672e-07
574 O 0 2.677080601642956e-07
delATTCTT O 0 7.02153442944109e-07
) O 0 3.575169937874989e-09
. O 0 5.718712259294989e-08

Five O 0 1.6386186416639248e-06
intragenic O 0 3.3535625334479846e-06
dimorphisms O 0 8.105477604658518e-07
are O 0 1.6917785228276472e-10
now O 0 2.5804364200965324e-10
well O 0 2.604616800017112e-10
characterized O 0 2.3481033784023e-10
and O 0 5.5906643897651875e-11
the O 0 4.0223385733284545e-10
high O 0 9.55779677624946e-10
degree O 0 6.89153045740909e-09
of O 0 2.6251765206097843e-09
allelic O 0 8.255212513574861e-09
heterogeneity O 0 7.868840024016777e-10
in O 0 4.666706465705772e-10
HC B-Disease 0 1.2912353213323513e-06
is O 0 9.6372065883088e-10
demonstrated O 0 4.763473615554403e-09
with O 0 2.0540989048578595e-11
seven O 0 1.7608867142193674e-10
new O 0 3.2706604785603943e-11
different O 0 5.427219004067174e-12
mutations O 0 3.430081566002663e-11
making O 0 5.437977498856661e-11
a O 0 2.702902623941128e-10
total O 0 9.325890060196684e-10
of O 0 1.435589092046996e-09
nineteen O 0 5.335939476935891e-07
CPO O 0 0.00014397650375030935
gene B-Disease 0 2.431490202070563e-06
defects I-Disease 0 2.1743344404967502e-05
reported O 0 2.8217709058253604e-08
so O 0 3.035110163196464e-09
far O 0 2.5548052562385237e-09
. O 0 1.0819872775513772e-09
. O 0 2.8973504484497425e-08

Coincidence O 0 8.006921348169271e-07
of O 0 3.535312842473104e-08
two O 0 1.3271501952960563e-10
novel O 0 1.319946152378293e-09
arylsulfatase O 0 2.1784674686387007e-07
A O 0 1.6291769711074267e-08
alleles O 0 1.8628005804544046e-09
and O 0 2.642397189944745e-09
mutation O 0 2.0140650036637453e-08
459 O 0 1.2590329845352244e-07
+ O 0 2.3839925233914983e-06
1G O 0 6.521863269881578e-06
> O 0 2.9226919195934897e-07
A O 0 1.644462166439098e-08
within O 0 6.742525426872703e-10
a O 0 1.4819931948295562e-09
family O 0 1.5389437502122405e-09
with O 0 9.75285296966888e-10
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 1.7487512549152484e-09
molecular O 0 1.794748349936981e-09
basis O 0 2.85040657743707e-09
of O 0 1.4842591600228161e-09
phenotypic O 0 1.5855992785418493e-07
heterogeneity O 0 2.7622365905699553e-06
. O 0 2.5227375317626866e-06

In O 0 6.960464560279433e-08
a O 0 3.18151016642787e-08
family O 0 1.5830624588986097e-09
with O 0 7.99876137547173e-11
three O 0 7.805698865048782e-10
siblings O 0 3.729408248887012e-08
, O 0 4.1159822772307564e-10
one O 0 8.201012785535866e-11
developed O 0 2.417696043366391e-10
classical O 0 2.540896844038798e-07
late O 1 0.9999613761901855
infantile O 1 1.0
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 6.915310990507351e-09
MLD B-Disease 1 1.0
) O 0 3.604287701630682e-10
, O 0 6.923328577101984e-11
fatal O 0 3.953731120276416e-09
at O 0 3.2594107413075335e-09
age O 0 3.850066043753486e-09
5 O 0 1.6497651245117595e-08
years O 0 1.0876857192698708e-09
, O 0 9.557992591835429e-11
with O 0 1.8358014761132857e-11
deficient O 0 1.3836148582413443e-07
arylsulfatase O 0 1.2521682037913706e-05
A O 0 4.668269866670016e-06
( O 0 6.8523666740816225e-09
ARSA O 0 7.670157174288761e-06
) O 0 2.2281697320547522e-10
activity O 0 1.0053349264182998e-09
and O 0 4.2862002141985656e-11
increased O 0 1.8188506256677783e-09
galactosylsulfatide O 0 3.2949668593573733e-07
( O 0 1.448665520875636e-09
GS O 0 0.006791282445192337
) O 0 6.9688970150139085e-09
excretion O 0 8.18291567838969e-08
. O 0 3.8033633131817624e-08

The O 0 4.3171797869945294e-07
two O 0 6.467844038127168e-10
other O 0 2.1837302799365688e-11
siblings O 0 3.226805933564947e-09
, O 0 8.653310706874251e-11
apparently O 0 9.42103839385311e-10
healthy O 0 1.0882548195922936e-08
at O 0 7.350534403371967e-09
12 O 0 5.064894637030193e-08
( O 0 1.350304035252492e-10
1 O 0 9.825530611351496e-08
/ O 0 3.0536239137290977e-07
2 O 0 3.0871269984800165e-08
) O 0 4.8519934597868186e-11
and O 0 2.0631732433606942e-11
15 O 0 5.479230402727353e-10
years O 0 1.1582015208011498e-10
, O 0 8.983129344553031e-12
respectively O 0 1.1116348119788455e-10
, O 0 9.561835698224108e-12
and O 0 1.370176541670709e-11
their O 0 2.8579069666356816e-10
father O 0 1.0231284264250462e-08
, O 0 5.391567192702951e-10
apparently O 0 3.8880121344675445e-09
healthy O 0 6.105744354556464e-09
as O 0 8.199323858759655e-11
well O 0 2.3775723057006815e-10
, O 0 1.830278151260245e-10
presented O 0 3.9183884581461825e-08
ARSA O 0 0.0002935356751549989
and O 0 1.0640196279609881e-07
GS O 1 0.9999997615814209
values O 0 8.62103011201043e-09
within O 0 2.1932990146300568e-10
the O 0 2.0571699899107898e-10
range O 0 1.892055845331697e-09
of O 0 2.1364527924561116e-09
MLD B-Disease 1 1.0
patients O 0 6.557109486493573e-07
. O 0 1.4010022653110354e-07

Mutation O 0 1.7751597525261786e-08
screening O 0 3.780513679885189e-09
and O 0 1.8616984343022835e-10
sequence O 0 5.448182530121137e-11
analysis O 0 2.904972651318616e-10
disclosed O 0 1.1385208331660124e-08
the O 0 2.756792349956072e-09
involvement O 0 1.51674210968622e-08
of O 0 3.860081143614025e-09
three O 0 2.0964721625382765e-10
different O 0 2.807423460371439e-10
ARSA O 0 3.969616500398843e-06
mutations O 0 1.381150860346736e-09
being O 0 1.0598300015374207e-09
the O 0 3.512484192391696e-10
molecular O 0 8.273035589922983e-10
basis O 0 7.740247554011148e-09
of O 0 7.452459094281494e-09
intrafamilial O 0 4.079855898453388e-06
phenotypic O 0 1.1064154250561842e-06
heterogeneity O 0 3.071491619266453e-06
. O 0 3.416152139834594e-06

The O 0 1.3444440583043615e-07
late O 0 3.885281330440193e-06
infantile O 0 3.387322067283094e-06
patient O 0 2.811858479390139e-08
inherited O 0 1.1075957040418416e-08
from O 0 3.1487279450459482e-09
his O 0 7.88809728646811e-08
mother O 0 1.9428087583150955e-08
the O 0 1.098054447368213e-08
frequent O 0 2.249830766132277e-09
0 O 0 1.975052654756837e-08
- O 0 2.402299692505494e-08
type O 0 2.555358094014082e-07
mutation O 0 1.4080571020258503e-07
459 O 0 8.856993360950582e-08
+ O 0 6.845713187431102e-07
1G O 0 1.861052510321315e-06
> O 0 7.162562809526207e-08
A O 0 6.735407787061831e-09
, O 0 7.2753153328164455e-12
and O 0 4.746171337888239e-12
from O 0 5.659003821101294e-11
his O 0 1.747237687865777e-09
father O 0 1.458953757804693e-08
a O 0 6.177336420165602e-10
novel O 0 2.9610480734021394e-10
, O 0 2.7069822078340522e-11
single O 0 5.92856319592272e-10
basepair O 0 4.90638676353683e-08
microdeletion O 0 6.684665265765943e-08
of O 0 5.5499991269414295e-09
guanine O 0 1.6707728534015587e-08
at O 0 1.0627130286877673e-08
nucleotide O 0 8.533407758193334e-09
7 O 0 5.5397009646185325e-08
in O 0 3.988420704814644e-09
exon O 0 2.1545083939145115e-08
1 O 0 6.713862887863797e-08
( O 0 9.392117084061624e-10
7delG O 0 3.131110588583397e-07
) O 0 3.4001479409795365e-09
. O 0 6.580602018857462e-08

The O 0 3.812864406427252e-07
two O 0 9.055050043116353e-09
clinically O 0 9.508023140369914e-06
unaffected O 0 8.263280903975101e-08
siblings O 0 1.0723582910543428e-08
carried O 0 1.0568665942400912e-09
the O 0 1.2365122259438976e-09
maternal O 0 1.239616540260613e-05
mutation O 0 1.9766957848332822e-08
459 O 0 6.223583426390178e-08
+ O 0 6.242218546503864e-07
1G O 0 1.8481587176211178e-06
> O 0 1.0964307506355908e-07
A O 0 1.3469974469160206e-08
and O 0 5.0209874452589176e-11
, O 0 2.151417065332506e-11
on O 0 5.564804173019411e-10
their O 0 9.386744714845463e-10
paternal O 0 1.344138013337215e-06
allele O 0 5.2013088946978314e-08
, O 0 3.2760313906088356e-10
a O 0 6.373183092378554e-10
novel O 0 2.289632261565089e-09
cytosine O 0 1.4544083271061936e-08
to O 0 6.229634585963595e-10
thymidine O 0 4.1858864818777874e-08
transition O 0 2.1770629743400605e-08
at O 0 2.0554855595378285e-08
nucleotide O 0 5.298202765402493e-08
2435 O 0 2.3153700112743536e-06
in O 0 5.1158832725661796e-09
exon O 0 1.5879685122399678e-08
8 O 0 3.545300231166948e-08
, O 0 1.6245395306757615e-10
resulting O 0 5.0174069760045015e-11
in O 0 2.319652629700908e-11
substitution O 0 8.858758171470527e-10
of O 0 8.27908130940358e-10
alanine O 0 2.9384340294313915e-08
464 O 0 2.4531875197908448e-08
by O 0 1.9939470075058807e-09
valine O 0 1.4526815903082024e-05
( O 0 1.3285793576400806e-09
A464V O 0 1.334238845629443e-06
) O 0 2.9744082752358736e-09
. O 0 5.6053647057296985e-08

The O 0 3.718009224940033e-07
fathers O 0 3.5741771853281534e-07
genotype O 0 4.2566085767248296e-08
thus O 0 8.477665680572954e-09
was O 0 4.419836940883215e-08
7delG O 0 4.2383176150906365e-06
/ O 0 2.8936148737557232e-05
A464V O 0 5.885990321985446e-05
. O 0 6.926335345269763e-07

Mutation O 0 6.291794534263317e-07
A464V O 0 1.46613092510961e-06
was O 0 6.829428134125237e-09
not O 0 1.2845186025955968e-10
found O 0 2.354721799491255e-11
in O 0 9.806813000556858e-11
18 O 0 1.9225709024794924e-08
unrelated O 0 1.975015635480304e-07
MLD B-Disease 1 1.0
patients O 0 4.2553989487714716e-07
and O 0 2.2719268688575767e-09
50 O 0 6.19080083197332e-07
controls O 0 4.091935807082336e-06
. O 0 1.8809258790497552e-06

A464V O 0 2.825573210429866e-05
, O 0 6.431766230718949e-09
although O 0 3.4453631059250256e-09
clearly O 0 3.659340208628237e-08
modifying O 0 3.945431217289297e-06
ARSA O 1 0.729407787322998
and O 0 1.8629170881467871e-06
GS O 1 1.0
levels O 0 7.622830253239954e-06
, O 0 5.917480949690912e-10
apparently O 0 1.283941841734304e-08
bears O 0 2.688119238314357e-08
little O 0 2.1003074834879953e-09
significance O 0 4.411917498003959e-09
for O 0 2.6865273894394193e-10
clinical O 0 5.1240669485252965e-09
manifestation O 0 7.495743403751476e-08
of O 0 4.1170387987676804e-08
MLD B-Disease 1 1.0
, O 0 2.740567772718805e-08
mimicking O 0 5.811804726363334e-07
the O 0 1.6922811596487009e-07
frequent O 0 8.692857136338716e-07
ARSA O 0 0.0013485163217410445
pseudodeficiency O 0 0.00013769020733889192
allele O 0 2.8314216251601465e-06
. O 0 8.406977940467186e-07

Our O 0 6.14813302490802e-07
results O 0 6.280869158103997e-09
demonstrate O 0 1.1538935362764846e-09
that O 0 1.1994325671560446e-11
in O 0 1.6648599165947076e-11
certain O 0 1.8926396561091963e-10
genetic O 0 3.6051215346333265e-09
conditions O 0 6.643558236874014e-08
MLD B-Disease 1 1.0
- O 0 0.0005692284903489053
like O 0 6.203708267094044e-07
ARSA O 1 0.9998230338096619
and O 0 4.977704293196439e-07
GS O 1 1.0
values O 0 2.7729413432098227e-08
need O 0 3.274683635368092e-09
not O 0 1.3115558639142932e-10
be O 0 6.088143184035388e-11
paralleled O 0 8.470339429855755e-10
by O 0 6.518083989215384e-11
clinical O 0 3.0797458805409406e-08
disease O 0 8.949998964169481e-09
, O 0 6.271095448484587e-11
a O 0 4.428574451598166e-10
finding O 0 5.398546498724954e-09
with O 0 6.89007809140385e-11
serious O 0 6.400925567362492e-09
diagnostic O 0 1.1044925258829608e-06
and O 0 1.4814146354069635e-08
prognostic O 0 7.636629015905783e-05
implications O 0 2.8384563393046847e-06
. O 0 1.0114199540112168e-06

Moreover O 0 2.04060029318498e-06
, O 0 1.4316904994871038e-08
further O 0 7.569807536356166e-08
ARSA O 0 5.283883729134686e-05
alleles O 0 2.4313960622635022e-08
functionally O 0 5.711539685648859e-08
similar O 0 4.18838430604751e-09
to O 0 6.80255629603721e-09
A464V O 0 2.4505553142262215e-07
might O 0 1.5445956735860022e-09
exist O 0 2.950708288818049e-10
which O 0 1.1529045947089589e-11
, O 0 4.322930902134203e-12
together O 0 5.171857733743401e-12
with O 0 1.29820511979295e-11
0 O 0 6.32194030458777e-08
- O 0 1.897977739417911e-07
type O 0 1.4042983309536794e-07
mutations O 0 4.592065039332738e-08
, O 0 6.208615288549879e-10
may O 0 1.0281991258409562e-08
cause O 0 1.676564380659329e-07
pathological O 0 1.535380033601541e-05
ARSA O 0 0.038810890167951584
and O 0 3.17500621349609e-07
GS O 1 1.0
levels O 0 2.226667447757791e-06
, O 0 4.8169631478023334e-11
but O 0 5.152863812724062e-12
not O 0 1.2511319237573648e-11
clinical O 0 8.942418472379643e-10
outbreak O 0 4.41467584710864e-10
of O 0 1.0107563397365738e-10
the O 0 7.745353247656794e-10
disease O 0 1.1842848923748761e-09
. O 0 5.871789166000951e-10
. O 0 1.72402270237626e-08

Human O 0 0.00012282488751225173
MLH1 O 1 0.9999998807907104
deficiency O 1 0.9999990463256836
predisposes O 0 0.001688178163021803
to O 0 2.6123916541109793e-06
hematological B-Disease 1 0.9999806880950928
malignancy I-Disease 1 0.9999583959579468
and O 0 3.5131979103653066e-08
neurofibromatosis B-Disease 0 0.0005912429187446833
type I-Disease 0 1.4525542610499542e-05
1 I-Disease 1 0.9714215993881226
. O 0 6.004988790664356e-06

Heterozygous O 0 6.659212772319734e-07
germ O 0 7.258970072143711e-06
- O 0 9.182107874039502e-07
line O 0 4.9467452356566355e-08
mutations O 0 2.127969134235741e-09
in O 0 9.863452277159013e-10
the O 0 9.866951700132631e-10
DNA O 0 2.6555235788094933e-09
mismatch O 0 5.650685608316053e-08
repair O 0 6.301859230006812e-07
genes O 0 4.7125798374736405e-08
lead O 0 1.8112633597411332e-06
to O 0 4.784633802046301e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0010431990958750248

The O 0 4.225614702590974e-07
disease O 0 4.896813265986566e-07
susceptibility O 0 5.625929944130803e-08
of O 0 1.6592884843902311e-09
individuals O 0 6.254681494954895e-11
who O 0 2.400727172613415e-09
constitutionally O 0 2.367457682339591e-06
lack O 0 5.94075390836224e-06
both O 0 1.1402594424225754e-08
wild O 0 6.135257990536047e-08
- O 0 3.20808410947393e-08
type O 0 1.0581419296329386e-08
alleles O 0 1.2934929793928518e-09
is O 0 1.1943561417648851e-10
unknown O 0 4.742516424016685e-08
. O 0 1.1178363479302789e-07

We O 0 1.0024464103253194e-07
have O 0 7.842588800599515e-10
identified O 0 5.559043780856143e-10
three O 0 2.5946788120845277e-11
offspring O 0 1.4527551384091453e-09
in O 0 6.338221614221595e-10
a O 0 1.8935297774191895e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.9994300007820129
who O 0 2.189276138153673e-08
developed O 0 7.687695102731595e-08
hematological B-Disease 1 0.9992786049842834
malignancy I-Disease 0 0.0019492527935653925
at O 0 7.55274669472783e-08
a O 0 9.598115635611748e-10
very O 0 3.0512432858120775e-11
early O 0 1.1587566461912502e-09
age O 0 2.655988207145299e-10
, O 0 1.2550828432100758e-11
and O 0 2.0427567623548804e-11
at O 0 1.2393078785422063e-09
least O 0 2.2360202578397548e-10
two O 0 2.628064606213787e-11
of O 0 7.32009730608496e-11
them O 0 4.976661791000758e-11
displayed O 0 1.988979647649103e-08
signs O 0 1.0148201567972137e-07
of O 0 2.2433360058471408e-08
neurofibromatosis B-Disease 0 8.720810001250356e-05
type I-Disease 0 1.2055810429956182e-06
1 I-Disease 0 8.232985237555113e-06
( O 0 1.2679286065520046e-08
NF1 B-Disease 0 3.519847086863592e-05
) O 0 7.37280743123847e-08
. O 0 5.616311682388186e-07

DNA O 0 1.6339070540993816e-08
sequence O 0 3.3603411719873577e-10
analysis O 0 1.5559826760380702e-09
and O 0 1.59962779133771e-10
allele O 0 5.138451331099247e-10
- O 0 9.574693260461231e-10
specific O 0 5.205054720569535e-10
amplification O 0 4.285256149927363e-09
in O 0 6.829164456156889e-10
two O 0 1.747589989387066e-10
siblings O 0 1.9677019125197148e-08
revealed O 0 1.5192727076396295e-08
a O 0 1.5873204972649546e-08
homozygous O 0 7.173821359174326e-07
MLH1 O 0 0.00020512637274805456
mutation O 0 1.7594851797753108e-08
( O 0 1.323081089132927e-10
C676T O 0 7.36967137981992e-07
- O 0 5.347184014681261e-06
- O 0 8.952766620495822e-06
> O 0 9.021563528222032e-06
Arg226Stop O 0 6.6013594732794445e-06
) O 0 8.616751201451223e-10
. O 0 8.083769209576985e-09

Thus O 0 3.8226363585636136e-07
, O 0 4.958664145959801e-09
a O 0 8.946278384769357e-09
homozygous O 0 8.038354337713827e-08
germ O 0 9.625897655496374e-05
- O 0 6.798515096306801e-05
line O 0 5.043511464464245e-06
MLH1 O 0 0.0026637434493750334
mutation O 0 3.271045656561e-08
and O 0 1.9964195574484478e-10
consequent O 0 8.38465439301217e-07
mismatch O 0 7.549647125415504e-05
repair O 1 0.9999959468841553
deficiency O 1 0.999893069267273
results O 0 2.983017850510805e-07
in O 0 3.615107502241699e-08
a O 0 5.512349332548183e-08
mutator O 0 0.00045522782602347434
phenotype O 0 1.324024623272635e-07
characterized O 0 5.097025024269897e-10
by O 0 2.0430566960438767e-11
leukemia B-Disease 0 0.007234776858240366
and O 0 1.9175215015820868e-07
/ O 1 1.0
or O 1 0.9999997615814209
lymphoma B-Disease 1 1.0
associated O 1 1.0
with O 0 3.129050440975334e-08
neurofibromatosis B-Disease 1 0.9997656941413879
type I-Disease 0 3.1087620300240815e-05
1 I-Disease 0 0.000725032645277679
. O 0 5.7197595992874994e-08
. O 0 1.565337015563273e-07

Missense O 0 1.263270041818032e-05
mutations O 0 3.711454965582561e-08
in O 0 9.724327121318765e-09
the O 0 5.839380978756026e-09
most O 0 1.3361364792352504e-10
ancient O 0 1.1722502968325443e-09
residues O 0 4.366858874504942e-09
of O 0 2.6071329539689714e-09
the O 0 6.8545107367867786e-09
PAX6 O 0 2.6219353458145633e-05
paired O 0 2.4273097665172827e-07
domain O 0 1.7289036691181536e-07
underlie O 0 1.8396164023215533e-06
a O 0 7.572273474920621e-09
spectrum O 0 8.427321063209092e-08
of O 0 3.8625849185791594e-09
human O 0 6.363963507283188e-07
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.00026436662301421165

Mutations O 0 7.629694209754234e-07
of O 0 8.490145830819529e-08
the O 0 2.220425088239608e-08
human O 0 2.126615150643829e-08
PAX6 O 0 0.0001747646601870656
gene O 0 3.0505550512316404e-06
underlie O 1 0.9999994039535522
aniridia B-Disease 1 1.0
( O 0 1.378361616843904e-06
congenital B-Disease 1 1.0
absence I-Disease 1 1.0
of I-Disease 0 1.895646892080549e-05
the I-Disease 0 2.711477691264008e-07
iris I-Disease 0 1.2916623859382526e-07
) O 0 1.2013290362489215e-10
, O 0 3.697134959290693e-11
a O 0 1.1383770592843234e-09
rare O 0 7.840350804144691e-07
dominant O 1 0.9999998807907104
malformation B-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 1.0
eye I-Disease 1 1.0
. O 0 0.001302050077356398

The O 0 4.3325229626134387e-07
spectrum O 0 1.526705318610766e-06
of O 0 7.244906186087974e-08
PAX6 O 0 0.0007093634339980781
mutations O 0 1.274275405194203e-06
in O 0 1.7480192582297605e-07
aniridia B-Disease 1 1.0
patients O 0 1.804231288815572e-07
is O 0 3.539193590973433e-11
highly O 0 2.680242416897016e-10
biased O 0 1.9702883768957236e-09
, O 0 3.8157168397168206e-11
with O 0 1.1549756810669276e-11
92 O 0 2.0466956129894243e-07
% O 0 7.929512602089517e-10
of O 0 3.4220198896761644e-10
all O 0 6.815159547812755e-11
reported O 0 1.6830789539845625e-10
mutations O 0 1.1456165877055113e-10
leading O 0 1.9646406723694554e-09
to O 0 6.199246449511975e-09
premature O 0 5.12554606757476e-07
truncation O 0 5.734636943088844e-07
of O 0 1.6390767143548146e-07
the O 0 2.2596804427621464e-08
protein O 0 2.7760729270909223e-09
( O 0 1.6900530974695016e-10
nonsense O 0 1.492919565748707e-08
, O 0 1.033142182915725e-10
splicing O 0 3.5681260168729523e-09
, O 0 7.351933506427599e-10
insertions O 0 1.3887487604336002e-08
and O 0 2.433249435274121e-10
deletions O 0 8.52325265920939e-10
) O 0 1.2747502706189628e-11
and O 0 1.3885533348134693e-11
just O 0 1.404790589409899e-10
2 O 0 2.77219958100261e-09
% O 0 2.6633947824983295e-10
leading O 0 3.0801425299209484e-10
to O 0 7.334254037427712e-11
substitution O 0 5.4565179041787815e-09
of O 0 4.558161403878103e-09
one O 0 3.1240202091886715e-10
amino O 0 6.767662541484754e-10
acid O 0 6.349135661665173e-10
by O 0 1.546648920047744e-11
another O 0 1.689280493266665e-09
( O 0 2.9565105919004964e-10
missense O 0 1.071052508905268e-07
) O 0 3.2883658018789674e-09
. O 0 9.790454669200699e-08

The O 0 1.357158794235147e-07
extraordinary O 0 9.648872811851561e-09
conservation O 0 1.620889023001837e-08
of O 0 1.1658441989581547e-09
the O 0 1.562048934644622e-09
PAX6 O 0 8.975779337561107e-07
protein O 0 1.4375407531019846e-08
at O 0 3.0593600541806154e-08
the O 0 1.745892674875904e-08
amino O 0 8.737492152022241e-08
acid O 0 7.660892720195989e-07
level O 0 9.60357851909066e-07
amongst O 0 5.166268124412454e-08
vertebrates O 0 9.090724688576302e-07
predicts O 0 1.2556814965591911e-07
that O 0 6.693424703385631e-10
pathological O 0 4.478765447402111e-07
missense O 0 1.191583464787982e-06
mutations O 0 1.00772172828556e-08
should O 0 1.4841091688921892e-09
in O 0 8.511199522942547e-10
fact O 0 5.895737786865141e-10
be O 0 4.3097789226287375e-10
common O 0 3.171171381044502e-10
even O 0 5.0690809189068986e-11
though O 0 9.228102657021786e-12
they O 0 1.110521657271546e-11
are O 0 5.974657400764638e-12
hardly O 0 4.543049936245325e-09
ever O 0 2.6004978170846016e-09
seen O 0 4.373176931693479e-09
in O 0 9.984902682447228e-09
aniridia B-Disease 1 1.0
patients O 0 5.816085035803553e-07
. O 0 1.2317913444803708e-07

This O 0 3.443985008289019e-08
indicates O 0 2.145834621103404e-08
that O 0 1.4695362982042326e-11
there O 0 9.170585298090561e-12
is O 0 2.252352167622651e-12
a O 0 6.574708832918219e-11
heavy O 0 9.209196072390569e-09
ascertainment O 0 5.538812501981738e-07
bias O 0 1.0701413977187713e-08
in O 0 1.2024942153132656e-09
the O 0 2.6526885132938105e-09
selection O 0 3.1155482638212106e-09
of O 0 3.903956879991455e-10
patients O 0 1.3536512188938588e-10
for O 0 1.0000788391861803e-10
PAX6 O 0 5.949752335254743e-07
mutation O 0 1.0013485596260807e-09
analysis O 0 5.500580546602407e-10
and O 0 1.2260352455495394e-10
that O 0 1.552596523568539e-10
the O 0 6.8800392050150094e-09
missing O 0 8.453012014797423e-07
PAX6 O 0 0.001144672860391438
missense O 0 4.261761932866648e-05
mutations O 0 3.8673422864121676e-07
frequently O 0 1.7217256953472315e-08
may O 0 2.7386446888044702e-08
underlie O 0 9.558968940837076e-07
phenotypes O 0 1.2601080356944294e-07
distinct O 0 3.780643353934465e-09
from O 0 4.1479424339740945e-09
textbook O 0 1.2458551282179542e-05
aniridia B-Disease 1 1.0
. O 0 5.941995482316997e-07

Here O 0 1.019906150645511e-07
we O 0 9.083800378562046e-09
present O 0 7.798049428409115e-10
four O 0 7.065997786881439e-10
novel O 0 1.3306062918161388e-08
PAX6 O 0 8.49061252665706e-05
missense O 0 3.419581389607629e-06
mutations O 0 4.6279755139266854e-08
, O 0 1.312717823331866e-09
two O 0 3.8708874994242137e-10
in O 0 1.2754227673994478e-09
association O 0 9.29664012438991e-10
with O 0 7.058208878474304e-11
atypical O 0 5.255959649730357e-07
phenotypes O 0 6.686579126835568e-06
ectopia B-Disease 0 2.971235880977474e-05
pupillae I-Disease 0 3.894853307429003e-06
( O 0 6.17646211953371e-11
displaced B-Disease 0 2.322966707879459e-09
pupils I-Disease 0 8.696603437385875e-09
) O 0 2.3852180230932163e-09
and O 0 8.080766633611347e-08
congenital B-Disease 1 1.0
nystagmus I-Disease 1 1.0
( O 0 4.3636264046575945e-10
searching B-Disease 0 3.962588479566875e-08
gaze I-Disease 0 3.9835875043081614e-08
) O 0 6.916266864775977e-11
, O 0 8.184136701672173e-11
and O 0 6.38822258980376e-11
two O 0 1.9559465158636158e-10
in O 0 1.0102499947706178e-09
association O 0 7.958164127686018e-10
with O 0 1.7841589317058038e-11
more O 0 1.982267683331429e-09
recognizable O 0 3.178270389980753e-06
aniridia B-Disease 1 1.0
phenotypes O 0 2.8441736503737047e-06
. O 0 4.4791585196435335e-07

Strikingly O 0 6.472851509897737e-06
, O 0 1.6429698490583178e-08
all O 0 1.6320841345063286e-09
four O 0 4.4280171196398044e-10
mutations O 0 9.96263488373117e-11
are O 0 2.452500702521121e-11
located O 0 3.364740708278191e-10
within O 0 2.512971830626043e-09
the O 0 2.3149667072175362e-08
PAX6 O 0 2.6509091185289435e-05
paired O 0 1.7642915395299497e-07
domain O 0 1.2876577670795086e-07
and O 0 2.8312363564708676e-09
affect O 0 1.2911741897880802e-08
amino O 0 2.83593837302476e-09
acids O 0 7.909196630961901e-10
which O 0 1.2647239158725121e-11
are O 0 1.4787889879644411e-12
highly O 0 1.0008688322571402e-10
conserved O 0 2.6311403056311633e-10
in O 0 1.9496417813513744e-09
all O 0 1.1939012001249694e-09
known O 0 3.3327300918983838e-09
paired O 0 9.155883162748069e-09
domain O 0 1.4519415003633185e-08
proteins O 0 1.2188149378644653e-09
. O 0 1.610933786366786e-08

Our O 0 9.680192079031258e-07
results O 0 2.1735528932254056e-08
support O 0 5.008347958579407e-09
the O 0 7.831901238652961e-10
hypothesis O 0 5.098531596914313e-10
that O 0 1.2162957273298414e-12
the O 0 9.22456555585427e-12
under O 0 9.342442791604455e-11
- O 0 3.3999016935126747e-09
representation O 0 5.164344063501858e-09
of O 0 2.0732947803026036e-08
missense O 0 2.0550660337903537e-06
mutations O 0 3.0679967011337794e-08
is O 0 2.567348555970739e-10
caused O 0 8.06537614472802e-10
by O 0 1.8426429826412516e-10
ascertainment O 0 9.638401934353169e-06
bias O 0 1.2782123803845025e-07
and O 0 5.424182214497364e-10
suggest O 0 2.940776067106299e-09
that O 0 1.1361632988593495e-11
a O 0 6.755677961489681e-11
substantial O 0 2.666293186237567e-09
burden O 0 5.909698188588663e-07
of O 0 9.508780181022303e-07
PAX6 B-Disease 1 0.9999980926513672
- I-Disease 1 0.9970095157623291
related I-Disease 0 0.0007862913189455867
disease I-Disease 0 0.1280505359172821
remains O 0 2.0828588631616185e-08
to O 0 4.1035264075617306e-10
be O 0 1.8682934366243131e-10
uncovered O 0 4.554884469598619e-09
. O 0 3.0845825893521805e-09
. O 0 7.651416211729156e-08

The O 0 4.243686930749391e-07
chromosomal O 0 5.218320779931673e-07
order O 0 3.051775365747744e-07
of O 0 6.636162197537487e-08
genes O 0 1.649236658352038e-08
controlling O 0 3.208806731436198e-07
the O 0 2.181435093007167e-06
major O 0 5.2745458560821135e-06
histocompatibility O 0 0.015096006914973259
complex O 1 0.9877326488494873
, O 0 7.590450046279784e-09
properdin O 0 9.654442010287312e-07
factor O 0 1.0262990457476917e-07
B O 0 2.4070479867077665e-06
, O 0 5.577925274447004e-11
and O 0 2.2892904238958067e-10
deficiency B-Disease 0 6.143457721918821e-05
of I-Disease 1 0.9973651766777039
the I-Disease 1 0.9982885718345642
second I-Disease 0 7.445264054695144e-05
component I-Disease 0 6.69141911657789e-07
of I-Disease 0 4.5014605376536565e-08
complement I-Disease 0 5.430744636214513e-07
. O 0 4.1116246052297356e-07

The O 0 8.034415088786773e-08
relationship O 0 3.477051091493877e-09
of O 0 4.711957046765747e-09
the O 0 6.213993763992676e-10
genes O 0 1.579171238219601e-10
coding O 0 5.697478933086586e-09
for O 0 5.169535355342703e-10
HLA O 0 3.4080909472322674e-07
to O 0 1.613683053847126e-08
those O 0 8.920102434473165e-10
coding O 0 2.2853969383618278e-08
for O 0 1.6147967407675878e-09
properdin O 0 1.5154847687881556e-07
Factor O 0 1.8367007470487806e-08
B O 0 1.311037465256959e-07
allotypes O 0 1.4806575521220111e-08
and O 0 1.4591074876113552e-11
for O 0 1.576667268965437e-10
deficiency B-Disease 0 4.329969982563853e-08
of I-Disease 0 1.563815175131822e-07
the I-Disease 0 2.4398471509812225e-07
second I-Disease 0 6.272431818388213e-08
component I-Disease 0 2.9867919693060685e-08
of I-Disease 0 6.331918100954681e-09
complement I-Disease 0 1.6971297611689806e-07
( O 0 5.807879510655312e-09
C2 O 0 0.00012505266931839287
) O 0 2.652702502103921e-10
was O 0 3.3030185253579702e-09
studied O 0 5.7007620846150076e-09
in O 0 7.817826941369788e-10
families O 0 2.1377805081712609e-10
of O 0 6.071019242881448e-10
patients O 0 3.3202056659575874e-09
with O 0 1.4017748073413827e-09
connective O 1 0.7450645565986633
tissue O 1 1.0
disorders O 1 1.0
. O 0 4.017469109385274e-06

Patients O 0 9.038700454766513e-07
were O 0 2.3863966358561584e-09
selected O 0 2.145698507760585e-09
because O 0 5.401466079968387e-11
they O 0 2.637843554698094e-10
were O 0 2.0515678045285313e-09
heterozygous O 0 9.975460457667396e-09
or O 0 2.6732198676882035e-08
homozygous O 0 4.755414920509793e-06
for O 0 9.656941074354108e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.706697953020921e-06

12 O 0 1.0748359500212246e-06
families O 0 1.9836254860905456e-09
with O 0 1.8756020347954205e-10
15 O 0 6.872212310327086e-08
matings O 0 1.1427325716795167e-06
informative O 0 1.050745413522236e-05
for O 0 2.8835158900619717e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.1930828236472735e-07
found O 0 1.0559886298722176e-08
. O 0 1.6818320958122968e-08

Of O 0 2.1822279450134374e-06
57 O 0 2.567895307947765e-06
informative O 0 6.424081675504567e-07
meioses O 0 5.970259735477157e-06
, O 0 9.919465249197401e-10
two O 0 3.743242174558681e-11
crossovers O 0 1.4719946095365088e-10
were O 0 1.4124693081818407e-10
noted O 0 8.878549562219007e-10
between O 0 9.762233244003937e-10
the O 0 5.824122581543634e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.6065934683193746e-09
and O 0 2.654752528918891e-10
the O 0 2.0755370755409785e-09
HLA O 0 1.937306848276421e-07
- O 0 7.40290545309108e-07
B O 0 1.8269198562848032e-06
gene O 0 5.813151626732349e-10
, O 0 2.4479487881201578e-11
with O 0 1.3530045139820146e-12
a O 0 8.478659441202296e-11
recombinant O 0 1.698578083741964e-10
fraction O 0 2.0799082456335327e-09
of O 0 1.048772624301364e-08
0 O 0 4.3855501985490264e-07
. O 0 1.3310942392763536e-07

035 O 0 0.003927876241505146
. O 0 1.7490345271653496e-05

A O 0 5.2112039838903e-07
lod O 0 1.8669790733838454e-05
score O 0 2.5535359782224987e-07
of O 0 1.8508236721004323e-08
13 O 0 3.454748664921681e-08
was O 0 2.3827035899870452e-09
calculated O 0 6.737935764888903e-10
for O 0 1.7086609904737315e-10
linkage O 0 1.942425342349452e-06
between O 0 4.425675797392614e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.7538084318147185e-09
HLA O 0 4.281124859062402e-07
- O 0 7.348771191573178e-07
B O 0 3.883599674736615e-06
at O 0 3.204321696870238e-09
a O 0 3.965917177994882e-11
maximum O 0 2.5806137782247163e-10
likelihood O 0 3.8096518995001105e-11
value O 0 6.337013136459291e-10
of O 0 7.408407776132719e-10
the O 0 5.474800612859099e-10
recombinant O 0 5.769905109254125e-10
fraction O 0 2.2221271489542005e-09
of O 0 2.1236550296066525e-09
0 O 0 1.3552212863032764e-07
. O 0 1.195121228647622e-07

04 O 0 0.00487175676971674
. O 0 1.1294881915091537e-05

18 O 0 3.863501376599743e-07
families O 0 1.3144491051164664e-09
with O 0 5.8194726815230524e-11
21 O 0 3.506423240651202e-08
informative O 0 7.476064212141864e-09
matings O 0 2.6119124640899827e-08
for O 0 1.613688294099802e-09
both O 0 1.9140229401415354e-09
properdin O 0 8.137085956150258e-07
Factor O 0 1.3927015629633388e-07
B O 0 1.5483358311030315e-06
allotype O 0 2.4633487782921293e-07
and O 0 6.356818404995579e-10
HLA O 0 1.9023119648409192e-06
- O 0 1.2105570021958556e-05
B O 0 3.6884808650938794e-05
were O 0 4.4022838707746814e-09
found O 0 3.568976891799025e-09
. O 0 2.113723063246198e-08

Of O 0 2.0078375655430136e-06
72 O 0 5.109185622131918e-06
informative O 0 9.181961502235936e-08
meioses O 0 1.9211800008633872e-06
, O 0 1.0517607895721426e-09
three O 0 3.8098138532838277e-10
recombinants O 0 7.603392759847338e-08
were O 0 1.4398834347062461e-09
found O 0 5.941751535232243e-10
, O 0 6.138316938075761e-11
giving O 0 3.792992586681976e-10
a O 0 1.2911458013853405e-10
recombinant O 0 2.7024593673985464e-10
fraction O 0 1.388599790708156e-09
of O 0 9.416515567295392e-09
0 O 0 6.938738579265191e-07
. O 0 3.893624693773745e-07

042 O 0 0.0010321623412892222
. O 0 8.787010301603004e-06

A O 0 1.5359306360096525e-07
lod O 0 3.7520085243158974e-06
score O 0 3.289986238996789e-08
of O 0 6.2359624131147484e-09
16 O 0 2.9257837041996027e-08
between O 0 4.94652319105171e-10
HLA O 0 3.6143676425126614e-06
- O 0 1.1215561244171113e-05
B O 0 1.4530058251693845e-05
and O 0 3.55643764438085e-10
Factor O 0 2.0532677780238373e-08
B O 0 3.240104717860959e-07
allotypes O 0 2.6093234239965568e-08
was O 0 1.7620432890552706e-09
calculated O 0 2.6855655477220353e-09
at O 0 9.369555131755192e-10
a O 0 9.57213128205403e-11
maximum O 0 6.657023821077246e-10
likelihood O 0 7.507178906296375e-11
value O 0 9.571552439524567e-10
of O 0 3.816374161136338e-10
the O 0 1.6944684544384359e-10
recombinant O 0 2.1908654057600785e-10
fraction O 0 1.3245007313145152e-09
of O 0 3.2797593529920732e-09
0 O 0 1.5267389130713127e-07
. O 0 1.6162526605967287e-07

04 O 0 0.0042482768185436726
. O 0 1.2730831258522812e-05

A O 0 3.9278312158330664e-08
crossover O 0 1.8732435602686337e-09
was O 0 1.6742811581593742e-09
shown O 0 2.0236586018018698e-10
to O 0 1.455850162646044e-10
have O 0 1.1897399732063718e-11
occurred O 0 4.346379853248372e-11
between O 0 1.1555259787215943e-12
genes O 0 1.880856755065441e-11
for O 0 5.911724582086109e-11
Factor O 0 1.5624601612529432e-09
B O 0 3.443354401611032e-08
and O 0 5.5850365998644236e-11
HLA O 0 4.468389747103174e-08
- O 0 2.4686070787538483e-07
D O 0 2.766887803318241e-07
, O 0 7.294552739622873e-10
in O 0 2.936122733832036e-10
which O 0 1.8441539961777664e-11
HLA O 0 2.0134578448960383e-08
- O 0 1.1649382969380895e-07
D O 0 4.3430637219898927e-07
segregared O 0 2.2176775473781163e-06
with O 0 3.156122030389952e-10
HLA O 0 1.65070218827168e-06
- O 0 7.2083776103681885e-06
A O 0 6.527949153678492e-06
and O 0 1.1939928157289614e-08
B O 0 8.624126166978385e-06
. O 0 1.4106023016324798e-08

These O 0 1.1841544633739431e-08
studies O 0 5.012256387715297e-09
suggest O 0 1.5076040416062142e-09
that O 0 1.1515090964087094e-11
the O 0 4.8825176540701065e-11
genes O 0 1.8039347793319394e-10
for O 0 5.557103666120611e-10
Factor O 0 3.826787349225924e-07
B O 1 0.9999969005584717
and O 0 3.1227896215568762e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.0257006062027756e-10
located O 0 8.311289850793102e-11
outside O 0 4.199405267968359e-10
those O 0 1.1909750963212673e-11
for O 0 2.4033866910522228e-11
HLA O 0 1.2225710221969166e-08
, O 0 4.1991306265476425e-11
that O 0 7.240126467106256e-12
the O 0 4.220609972627187e-11
order O 0 8.085091485199314e-10
of O 0 2.568249501955222e-10
genese O 0 1.720071374222698e-08
is O 0 1.202965504987219e-11
HLA O 0 3.267340620283221e-09
- O 0 2.992214476194022e-08
A O 0 3.2463927368553414e-07
, O 0 1.2304042507071955e-10
- O 0 2.502640095158881e-09
B O 0 5.5144631971870695e-08
, O 0 1.1313755488018273e-11
- O 0 9.04575747640024e-10
D O 0 1.1405248301343818e-08
, O 0 3.139455362344279e-10
Factor O 0 6.054199985783271e-08
B O 0 1.6112082448671572e-05
allotype O 0 3.34712713083718e-05
, O 0 1.360814820827727e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.8374766985740365e-10
that O 0 6.115595443251243e-12
the O 0 5.211409775940368e-11
genes O 0 6.695364818121163e-10
coding O 0 9.617564273867174e-07
for O 0 8.690611252859526e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.2250705722370867e-09
Factor O 0 2.3826318695796544e-08
B O 0 9.374835485687072e-08
allotypes O 0 3.5280496302192432e-09
are O 0 3.9740986109565446e-13
approximately O 0 5.896650897597999e-13
3 O 0 1.6006708111748758e-11
- O 0 1.7707009469791757e-10
- O 0 6.7105569989678315e-09
5 O 0 2.0720653637340547e-08
centimorgans O 0 1.5356522453657817e-07
from O 0 2.2316530567945136e-10
the O 0 3.213942167956674e-10
HLA O 0 4.6019465571589535e-08
- O 0 1.0838389385980918e-07
A O 0 8.976689258588522e-08
and O 0 5.245998635494686e-10
HLA O 0 2.0360933206120535e-07
- O 0 2.0074764961464098e-07
B O 0 3.0442785714512866e-07
loci O 0 7.434496351876874e-10
, O 0 3.701055954763444e-12
and O 0 1.4049124277132341e-12
that O 0 1.3313956057428578e-12
the O 0 3.640732854082174e-11
apparent O 0 2.580575531041518e-09
lack O 0 4.325413271999423e-08
of O 0 4.231826888911883e-09
recombinants O 0 6.140409425370308e-08
between O 0 1.8041894367382127e-10
the O 0 2.2118518128166897e-09
Factor O 0 4.3896424273270895e-08
B O 0 1.9981178411399014e-05
gene O 0 1.8423764913677587e-06
and O 0 1.0450699846842326e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 8.935417099564802e-07
suggests O 0 3.8994507178813365e-08
that O 0 7.895412622305198e-12
these O 0 6.6919109142915545e-12
two O 0 1.1680241843170514e-11
genes O 0 7.556856529422618e-11
lie O 0 2.0049990556714192e-09
in O 0 7.806502111407099e-10
close O 0 1.8826828096507597e-08
proximity O 0 4.526980745822584e-08
to O 0 1.894505174959704e-08
one O 0 2.507542395946416e-09
another O 0 1.5826829624643324e-08
. O 0 1.93254962255196e-07

Distribution O 0 3.019245298219175e-08
of O 0 2.5868258646255526e-08
emerin O 0 2.270053755637491e-06
and O 0 3.1388820431743625e-09
lamins O 0 8.418182005698327e-06
in O 0 2.3114061775686423e-08
the O 0 8.35917148833687e-08
heart O 0 1.7145758590686455e-07
and O 0 4.3882653066873445e-10
implications O 0 2.6155804189187393e-09
for O 0 2.4098245621217984e-09
Emery B-Disease 1 0.9740387797355652
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00016719296399969608

Emerin O 0 0.0003506987704895437
is O 0 5.56001431561981e-08
a O 0 1.6751954490246135e-08
nuclear O 0 1.5335798764226638e-07
membrane O 0 3.3253407139000046e-08
protein O 0 1.5763734761975456e-09
which O 0 3.45466433238073e-11
is O 0 1.1020897736080393e-11
missing O 0 1.005864280756441e-09
or O 0 1.5208337367234037e-10
defective O 0 2.3209750565911236e-08
in O 0 2.2926313292259692e-08
Emery B-Disease 1 1.0
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.854050234508577e-08
EDMD B-Disease 1 1.0
) O 0 1.2084037770421219e-08
. O 0 1.192750431755485e-07

It O 0 4.556631516550169e-09
is O 0 4.846915577227939e-11
one O 0 1.8891114367258766e-11
member O 0 1.6743506581207157e-10
of O 0 2.045277280871005e-09
a O 0 4.5905764523013204e-08
family O 0 2.0135468048465555e-07
of O 0 9.980983151081091e-08
lamina O 0 0.0072356234304606915
- O 0 1.6984500689432025e-05
associated O 0 2.24069381715708e-07
proteins O 0 2.254271491697324e-10
which O 0 8.129559525560381e-11
includes O 0 1.2682271899322473e-10
LAP1 O 0 3.34343496888323e-07
, O 0 7.541511304332005e-10
LAP2 O 0 4.692909897130448e-06
and O 0 2.2623629192253247e-08
lamin O 0 7.808101508999243e-05
B O 0 2.576893621153431e-06
receptor O 0 2.0215427554148846e-08
( O 0 1.2745570154848451e-09
LBR O 0 6.198426035552984e-06
) O 0 7.290355874545185e-09
. O 0 1.617597291669881e-07

A O 0 1.2148361747676972e-05
panel O 0 3.3209423122571025e-07
of O 0 4.5246071778137775e-08
16 O 0 3.619675226218533e-08
monoclonal O 0 2.929869902246196e-09
antibodies O 0 6.060560386877967e-10
( O 0 2.749921956812784e-10
mAbs O 0 6.1324510625127e-07
) O 0 1.5982564161021173e-09
has O 0 3.7758277060540024e-10
been O 0 2.4349114391419846e-10
mapped O 0 1.2405186877728624e-09
to O 0 1.3800002252040144e-09
six O 0 1.224270962385532e-10
specific O 0 5.406908601401916e-11
sites O 0 4.397641140130304e-10
throughout O 0 7.541482438533365e-10
the O 0 5.98979255084231e-10
emerin O 0 1.1043597147875062e-08
molecule O 0 4.75735804916777e-11
using O 0 9.718500448840928e-10
phage O 0 2.48532607827201e-08
- O 0 1.4057247810228546e-08
displayed O 0 8.136176177231391e-09
peptide O 0 1.3359255923717228e-09
libraries O 0 5.217143606017771e-09
and O 0 1.5853642010288382e-10
has O 0 1.5214975113142515e-11
been O 0 5.297686768435117e-12
used O 0 5.114854026433413e-11
to O 0 1.2486609524131609e-09
localize O 0 3.53335877889549e-07
emerin O 0 1.929170139192138e-06
in O 0 9.217701268937617e-09
human O 0 2.2384890385751532e-08
and O 0 2.431192136498339e-08
rabbit O 0 2.5672979973023757e-06
heart O 0 8.833625543047674e-06
. O 0 2.9500301934604067e-06

Several O 0 1.2293831730403326e-07
mAbs O 0 1.1784485650423449e-05
against O 0 3.745147481026834e-08
different O 0 2.0065828998383495e-09
emerin O 0 3.7624708966177423e-06
epitopes O 0 1.3739754649577662e-06
did O 0 1.2537525151401496e-07
not O 0 1.0273718764608475e-08
recognize O 0 2.4949535770701914e-08
intercalated O 0 8.29506745958497e-07
discs O 0 1.210852474287094e-06
in O 0 1.7925664508311456e-08
the O 0 2.5846754070357747e-08
heart O 0 1.7221468340267165e-07
, O 0 3.316684704657291e-10
though O 0 1.4713208429384395e-10
they O 0 2.5968585615210316e-10
recognized O 0 7.68556596142389e-09
cardiomyocyte O 0 2.543333152971172e-07
nuclei O 0 4.8847983435962306e-08
strongly O 0 8.845597676554462e-08
, O 0 8.445866228612431e-10
both O 0 3.2654654535946293e-09
at O 0 3.310216811769351e-07
the O 0 1.3605799153992848e-07
rim O 0 2.2537625454788213e-07
and O 0 3.5700031819629885e-10
in O 0 1.3007642740703318e-09
intranuclear O 0 7.178632586146705e-07
spots O 0 4.3581906084000366e-08
or O 0 4.711876222529554e-09
channels O 0 1.0198574784681114e-07
. O 0 1.402372333814128e-07

A O 0 7.001327048783423e-06
polyclonal O 0 2.5558128982083872e-05
rabbit O 0 3.8060084079916123e-06
antiserum O 0 1.3515313185052946e-05
against O 0 5.001018976713567e-08
emerin O 0 3.3562373573658988e-06
did O 0 2.6977915013048914e-07
recognize O 0 3.470202614153095e-07
both O 0 1.9644955884245974e-08
nuclear O 0 1.523216496934765e-06
membrane O 0 2.3717552721791435e-07
and O 0 4.392253227791798e-09
intercalated O 0 1.1836942803711281e-07
discs O 0 1.3366225459776615e-07
but O 0 1.6066423191851698e-10
, O 0 2.3607253304969156e-11
after O 0 4.60941562696604e-11
affinity O 0 1.4591360064653003e-10
purification O 0 1.8483815589220853e-09
against O 0 3.8457634299327026e-10
a O 0 1.2245611191730177e-09
pure O 0 3.9047201028097334e-08
- O 0 5.038512540522788e-08
emerin O 0 3.643746708803519e-07
band O 0 3.3803303267632145e-08
on O 0 8.181663346817913e-09
a O 0 1.7293965148823531e-09
western O 0 1.245944769578955e-08
blot O 0 2.7211973474550177e-07
, O 0 4.4817688449327875e-10
it O 0 9.859345978524559e-11
stained O 0 7.688223035984265e-08
only O 0 3.2961839924183778e-09
the O 0 1.4650459734255605e-09
nuclear O 0 1.0803714189933089e-07
membrane O 0 3.753314672394481e-07
. O 0 5.114959549246123e-07

These O 0 6.276739838995127e-08
results O 0 8.56674109428468e-09
would O 0 8.286696329129484e-10
not O 0 9.580167908973536e-11
be O 0 7.512550304067389e-11
expected O 0 6.881531455782408e-10
if O 0 1.5706470568588315e-09
immunostaining O 0 8.962265383161139e-07
at O 0 2.851909108869677e-08
intercalated O 0 3.850130951832398e-07
discs O 0 4.80502365007851e-07
were O 0 4.2714978221169986e-09
due O 0 1.6046808326564133e-08
to O 0 2.9486111330356835e-09
a O 0 6.745972669364164e-10
product O 0 1.0637851710626478e-09
of O 0 7.533949020199771e-10
the O 0 1.5914060069732727e-09
emerin O 0 2.5067527076316765e-07
gene O 0 2.747983396389486e-09
and O 0 1.1386115383871243e-09
, O 0 2.1922950954600395e-10
therefore O 0 6.376441596955829e-10
, O 0 2.4543162641110783e-11
cast O 0 4.487568372457673e-10
some O 0 3.087730349182749e-10
doubt O 0 3.1085856111445764e-09
upon O 0 3.3169711421976444e-09
the O 0 3.0006657159020733e-09
hypothesis O 0 8.809545093413362e-09
that O 0 5.117673992915961e-11
cardiac B-Disease 0 4.6125146582198795e-06
defects I-Disease 0 1.6091794350359123e-06
in O 0 1.4917844737283303e-07
EDMD B-Disease 1 1.0
are O 0 1.6575043559896585e-09
caused O 0 1.0023499807942926e-09
by O 0 2.5183289481534032e-11
absence O 0 3.021965255811665e-07
of O 0 1.026367542067419e-07
emerin O 0 8.254762178694364e-06
from O 0 2.6562847921240973e-08
intercalated O 0 9.43454506341368e-06
discs O 0 4.941283987136558e-05
. O 0 4.146473600030731e-07

Although O 0 3.0719613164365e-07
emerin O 0 1.4212802170732175e-06
was O 0 2.850418923117104e-08
abundant O 0 2.727900216825674e-08
in O 0 1.9193091560509856e-09
the O 0 1.6477274655812835e-08
membranes O 0 1.2829680429149448e-07
of O 0 7.52926965219558e-09
cardiomyocyte O 0 2.0740422712606232e-08
nuclei O 0 5.631635158209747e-10
, O 0 9.219064400767252e-11
it O 0 6.519253192838192e-11
was O 0 8.572822451924367e-09
absent O 0 4.203075718578475e-07
from O 0 3.5167493361853985e-09
many O 0 1.8481162433747755e-10
non O 0 3.291429706564486e-08
- O 0 1.4812282067566684e-08
myocyte O 0 2.2270423016834684e-07
cells O 0 3.5469283066191792e-09
in O 0 1.251064030149962e-09
the O 0 2.980701019339449e-09
heart O 0 1.7037169186551182e-07
. O 0 3.3922930242624716e-07

This O 0 5.076942866111267e-09
distribution O 0 3.181326535539597e-09
of O 0 1.893709411504574e-09
emerin O 0 2.7536572133612935e-07
was O 0 4.307151524329811e-09
similar O 0 7.882671598791191e-11
to O 0 4.589608693095215e-10
that O 0 2.1383993534240808e-11
of O 0 2.7761243304169625e-10
lamin O 0 1.4389721627594554e-06
A O 0 5.4975654251165906e-08
, O 0 3.290108185893814e-10
a O 0 4.5043588303705917e-10
candidate O 0 3.286972083405004e-10
gene O 0 3.12294801130264e-10
for O 0 2.083612837822102e-09
an O 0 6.699324983650001e-10
autosomal O 0 6.929744955641581e-08
form O 0 2.4898241690607392e-08
of O 0 3.264718543505296e-06
EDMD B-Disease 1 1.0
. O 0 8.452053066321241e-07

In O 0 2.1896693169765058e-07
contrast O 0 1.456429998825115e-07
, O 0 1.8865110362753512e-08
lamin O 0 0.0006147783133201301
B1 O 0 0.0026538267266005278
was O 0 2.7263920401310315e-06
absent O 0 6.721538738929667e-06
from O 0 2.4472615933746056e-08
cardiomyocyte O 0 2.0007220769002743e-07
nuclei O 0 4.885494231388066e-09
, O 0 1.2451126796264589e-09
showing O 0 4.381536911068906e-08
that O 0 4.668783581962543e-09
lamin O 0 0.0001334350381512195
B1 O 0 2.3951404727995396e-05
is O 0 5.073339526262544e-10
not O 0 1.0982376813517547e-10
essential O 0 7.747721575412925e-09
for O 0 3.447464536066036e-10
localization O 0 1.2081983413736452e-06
of O 0 4.201556436100873e-08
emerin O 0 2.2491342406283366e-06
to O 0 3.552597149791836e-08
the O 0 1.0325265975552611e-08
nuclear O 0 8.982030976767419e-07
lamina O 0 0.002287127310410142
. O 0 4.233284471411025e-06

Lamin O 1 0.9972113966941833
B1 O 0 0.0037839114665985107
is O 0 1.3282861033303561e-08
also O 0 3.5868359393731453e-09
almost O 0 1.7144627939558177e-09
completely O 0 6.840630106808021e-08
absent O 0 4.7151331727945944e-07
from O 0 1.617565814626687e-08
skeletal O 0 2.6553507268545218e-06
muscle O 0 1.570280261375956e-07
nuclei O 0 3.209021031125303e-07
. O 0 7.49477067074622e-07

In O 0 6.238796572688443e-07
EDMD B-Disease 1 1.0
, O 0 2.722503333885129e-09
the O 0 5.701759620002633e-10
additional O 0 6.8975669620385816e-09
absence O 0 4.898681709164521e-07
of O 0 2.6359106186646386e-07
lamin O 1 0.9999853372573853
B1 O 1 0.9999991655349731
from O 0 9.146563684225839e-07
heart O 1 0.9999996423721313
and O 0 5.719274213333847e-06
skeletal O 1 0.9997976422309875
muscle O 0 6.596463663299801e-06
nuclei O 0 9.075559859184068e-08
which O 0 4.894793459442326e-09
already O 0 5.191523211323101e-09
lack O 0 8.716286004073481e-08
emerin O 0 4.769476618093904e-07
may O 0 4.969542999333498e-09
offer O 0 6.874844249438183e-09
an O 0 1.929522340515799e-11
alternative O 0 7.3012378365433506e-09
explanation O 0 2.211249672257054e-08
of O 0 1.8428548687055013e-09
why O 0 1.4463801711883661e-08
these O 0 7.52280626681312e-10
tissues O 0 1.3186860492453434e-08
are O 0 3.545774784896594e-11
particularly O 0 4.743450077171474e-11
affected O 0 9.341890455649704e-11
. O 0 8.349156921383383e-10
. O 0 3.292415584610353e-08

Genetic O 0 1.22234069976912e-07
mapping O 0 3.998934516857844e-08
of O 0 1.9456789956961984e-08
the O 0 3.59380898373729e-08
copper B-Disease 0 1.8501888916944154e-05
toxicosis I-Disease 0 0.0007551702437922359
locus O 0 3.744447951703478e-07
in O 0 3.690729144523175e-08
Bedlington O 0 7.291565907507902e-06
terriers O 0 5.27335146216501e-07
to O 0 3.442015028554124e-08
dog O 0 2.8391708539743377e-08
chromosome O 0 9.60179602493838e-10
10 O 0 4.896941518950371e-09
, O 0 4.402497810751527e-11
in O 0 1.0455977056400556e-10
a O 0 9.227055230986991e-10
region O 0 2.9283167002347454e-09
syntenic O 0 2.687696962766495e-07
to O 0 3.249745361699752e-09
human O 0 1.0519514148654707e-09
chromosome O 0 4.618476268092309e-09
region O 0 4.568808620319942e-08
2p13 O 0 2.2365966287907213e-05
- O 0 3.70757470591343e-06
p16 O 0 2.3886327653599437e-06
. O 0 5.578879722634156e-07

Abnormal O 1 0.9999994039535522
hepatic B-Disease 1 0.9999998807907104
copper I-Disease 0 0.11317958682775497
accumulation I-Disease 0 8.23289155960083e-06
is O 0 3.4892735922831264e-10
recognized O 0 3.755301070107464e-10
as O 0 1.4019212180027552e-10
an O 0 1.2817286121347138e-10
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 2.3514316183081974e-07
man O 0 5.065068009457718e-08
, O 0 1.3048668812132291e-09
mouse O 0 1.3353943018046266e-07
, O 0 9.792263000463208e-09
rat O 0 8.432637514488306e-06
and O 0 1.061712055161479e-06
dog O 0 0.04740048199892044
. O 0 8.140590944094583e-05

The O 0 5.531549049919704e-07
major O 0 1.290759712446743e-07
cause O 0 2.811532056057331e-07
of O 0 1.248995573632783e-07
hepatic B-Disease 1 0.9960035681724548
copper I-Disease 1 0.9997583031654358
accumulation I-Disease 0 0.3742976784706116
in O 0 1.4097381608735304e-06
man O 0 4.4887073613608663e-07
is O 0 1.2458276632543175e-09
a O 0 4.0064911388526525e-09
dysfunctional O 0 5.557713578241419e-08
ATP7B O 0 2.5342818844364956e-05
gene O 0 1.5784569029619888e-07
, O 0 1.4194601938299911e-08
causing O 0 1.3402861043232406e-07
Wilson B-Disease 0 4.558495220408076e-06
disease I-Disease 0 7.971052013999724e-07
( O 0 4.019608534910901e-10
WD B-Disease 0 8.800629984762054e-06
) O 0 2.5141524417904293e-08
. O 0 4.21518222992745e-07

Mutations O 0 3.388612981325423e-07
in O 0 4.3682110373310934e-08
the O 0 9.026600622519254e-08
ATP7B O 0 9.510235940979328e-06
genes O 0 3.5773937145933132e-09
have O 0 7.203823093604456e-10
also O 0 1.4034916284710874e-10
been O 0 6.935831076138044e-11
demonstrated O 0 1.9233989956290998e-09
in O 0 3.32552940740527e-09
mouse O 0 6.529392067022854e-07
and O 0 7.867062379318668e-08
rat O 0 1.2914624676341191e-05
. O 0 1.2183412536614924e-06

The O 0 4.174527930445038e-06
ATP7B O 0 7.851301779737696e-05
gene O 0 9.616044849281025e-08
has O 0 1.4051718677521308e-09
been O 0 1.493721257794789e-10
excluded O 0 1.0113084814022955e-09
in O 0 3.7570560551536403e-10
the O 0 2.0732502381548557e-09
much O 0 4.078535731366628e-09
rarer O 0 1.1393047998353723e-06
human O 0 2.3153756956162397e-07
copper B-Disease 0 0.2245699167251587
overload I-Disease 0 0.12501129508018494
disease O 0 0.00014163066225592047
non B-Disease 0 1.5015895769465715e-05
- I-Disease 0 1.4306390312412987e-06
Indian I-Disease 0 2.0988267124266713e-08
childhood I-Disease 0 1.4159660395307583e-06
cirrhosis I-Disease 0 4.354121301730629e-06
, O 0 4.739798553643482e-10
indicating O 0 4.582403345665398e-09
genetic O 0 1.0153619278696624e-08
heterogeneity O 0 2.2469744465070107e-07
. O 0 3.697402064517519e-07

By O 0 1.954284511995752e-09
investigating O 0 5.176799877659732e-09
the O 0 4.501544026425108e-09
common O 0 2.41073678353132e-07
autosomal O 1 0.9414398074150085
recessive O 0 0.40147799253463745
copper B-Disease 1 0.9999948740005493
toxicosis I-Disease 1 0.9999998807907104
( O 0 4.646041773526122e-09
CT B-Disease 0 0.00014691267278976738
) O 0 8.275481966357745e-10
in O 0 8.221130443075708e-09
Bedlington O 0 4.233699291944504e-05
terriers O 0 3.5771374768955866e-06
, O 0 1.924778780804104e-09
we O 0 1.742674560212265e-09
have O 0 7.896515386018876e-11
identified O 0 3.6223377075650376e-10
a O 0 2.16368964411906e-10
new O 0 5.428653082617529e-10
locus O 0 5.819988935229503e-09
involved O 0 7.422863435024851e-10
in O 0 1.1074098971164403e-08
progressive O 1 0.9999923706054688
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.1738023292527942e-07

We O 0 1.80969223606553e-07
examined O 0 1.0946379802589945e-07
whether O 0 5.303832040226553e-09
the O 0 1.5386127927285997e-08
WD B-Disease 0 9.753154881764203e-05
gene O 0 1.6085226661743945e-06
ATP7B O 0 0.0010225794976577163
was O 0 9.850374738107348e-08
also O 0 2.78989359392412e-10
causative O 0 1.2555606554442988e-09
for O 0 9.005818868423887e-10
CT B-Disease 0 6.498754373751581e-06
by O 0 3.009801297082504e-10
investigating O 0 2.5553901217278963e-09
the O 0 1.286000550493327e-08
chromosomal O 0 5.942137022429961e-07
co O 0 6.853533250250621e-06
- O 0 4.2451480112504214e-05
localization O 1 0.9999618530273438
of O 0 6.1612313402292784e-06
ATP7B O 0 1.9107659682049416e-05
and O 0 6.22450369025529e-10
C04107 O 0 9.431582270735817e-08
, O 0 2.7369643010310973e-11
using O 0 7.222944464757575e-11
fluorescence O 0 2.954539279897972e-09
in O 0 2.555536227077937e-09
situ O 0 6.700174139950832e-07
hybridization O 0 9.275885837212172e-09
( O 0 4.391061680930619e-10
FISH O 0 2.91294981025203e-07
) O 0 2.1778092662572135e-09
. O 0 8.002130158502041e-08

C04107 O 0 5.511875860975124e-05
is O 0 6.5530318948958666e-09
an O 0 3.2112582037946424e-10
anonymous O 0 7.253420530872745e-09
microsatellite O 0 1.7864985579763015e-07
marker O 0 1.9366567016732006e-07
closely O 0 1.8260053025187517e-08
linked O 0 3.883963586304162e-07
to O 0 4.0845796434041404e-07
CT B-Disease 1 0.9999998807907104
. O 0 1.0240918527415488e-05

However O 0 6.587044367734052e-07
, O 0 2.744124394382652e-08
BAC O 0 6.327142727968749e-06
clones O 0 3.8717374195584853e-07
containing O 0 4.566264877325921e-08
ATP7B O 0 4.770486157212872e-06
and O 0 1.7520364048451142e-09
C04107 O 0 9.390025752509246e-07
mapped O 0 6.858724788116888e-08
to O 0 3.604133169687884e-08
the O 0 5.007738934637018e-08
canine O 0 6.237249863261241e-07
chromosome O 0 1.6045990491875273e-07
regions O 0 3.5410629095622426e-08
CFA22q11 O 0 3.5590785500971833e-06
and O 0 3.04356251312754e-09
CFA10q26 O 0 1.0464416391187115e-06
, O 0 5.120058821361795e-10
respectively O 0 2.4575042001373504e-09
, O 0 1.2998881138148732e-10
demonstrating O 0 3.96527077839437e-09
that O 0 6.968012972174975e-11
WD B-Disease 0 2.131401402039046e-07
cannot O 0 2.0098283926017757e-08
be O 0 9.803994283075212e-10
homologous O 0 2.0120174415438896e-09
to O 0 6.822374132298137e-08
CT B-Disease 0 0.0033520066644996405
. O 0 5.1963779696961865e-06

The O 0 3.2585535336693283e-06
copper O 0 5.565909305005334e-06
transport O 0 1.214469591559464e-07
genes O 0 6.439353938958448e-08
CTR1 O 0 2.3497050278820097e-05
and O 0 5.211056919307566e-09
CTR2 O 0 6.128573659225367e-06
were O 0 9.609220974482469e-09
also O 0 1.4962513450456072e-09
excluded O 0 2.4898609840562358e-09
as O 0 2.1899881907927465e-10
candidate O 0 2.1564056096323725e-10
genes O 0 2.046509489650461e-10
for O 0 1.1348606498984282e-09
CT B-Disease 0 0.00013072167348582298
since O 0 2.1923857218553167e-07
they O 0 6.108435091078945e-09
both O 0 3.2231275426397588e-09
mapped O 0 9.078676299623112e-08
to O 0 5.1423981517473294e-08
canine O 0 3.7439551192619547e-07
chromosome O 0 3.180260819135583e-07
region O 0 8.876405672708643e-07
CFA11q22 O 0 0.0004095346957910806
. O 0 2.7872879400092643e-06

2 O 0 2.7031428544432856e-06
- O 0 5.092238097859081e-06
22 O 0 3.060223207285162e-06
. O 0 8.734173775337695e-07

5 O 0 3.521277540130541e-05
. O 0 2.7583564587985165e-06

A O 0 4.3774940650109784e-07
transcribed O 0 5.921074297532414e-09
sequence O 0 5.791658819198631e-10
identified O 0 4.846004930669778e-09
from O 0 4.994875069108673e-10
the O 0 1.2956387074325448e-09
C04107 O 0 8.871584356029416e-08
- O 0 2.1569425356915417e-08
containing O 0 4.191141211862259e-09
BAC O 0 2.6035945666080806e-06
was O 0 4.434645983764085e-09
found O 0 9.974537168444542e-11
to O 0 1.0557338336880662e-10
be O 0 2.06336996100287e-11
homologous O 0 5.072408118533822e-11
to O 0 1.812585748162121e-09
a O 0 4.771002704018201e-09
gene O 0 2.4215614402578467e-08
expressed O 0 4.4021413181383195e-09
from O 0 6.474681901735835e-10
human O 0 2.0366779374114685e-09
chromosome O 0 3.654706759448345e-09
2p13 O 0 1.1458389792551316e-07
- O 0 1.7581969657953778e-08
p16 O 0 8.71560068560484e-09
, O 0 1.203301069896412e-10
a O 0 4.5792380998221915e-10
region O 0 1.2378525982015276e-09
devoid O 0 6.641265315465716e-08
of O 0 4.675134168685702e-10
any O 0 2.214214367413092e-10
positional O 0 5.516620049661469e-08
candidate O 0 3.0643590775980556e-08
genes O 0 2.4868816339562727e-08
. O 0 1.4893311117702979e-06

Molecular O 0 4.537259101766722e-08
analysis O 0 1.0684647833159033e-08
of O 0 2.6172970457594147e-09
the O 0 4.972387390722588e-09
APC B-Disease 0 1.5082346038752803e-08
gene O 0 3.9854530786698206e-10
in O 0 7.683583214124212e-10
205 O 0 1.7303172228366748e-09
families O 0 2.887637906567875e-10
: O 0 3.796481184981104e-10
extended O 0 7.628509024470986e-08
genotype O 0 2.824415616942133e-07
- O 0 8.616066793365462e-07
phenotype O 0 2.852551084231436e-08
correlations O 0 2.1949990713920897e-09
in O 0 7.647892874551587e-10
FAP B-Disease 0 1.4454866636981478e-08
and O 0 3.044604499069514e-11
evidence O 0 1.2251118175488074e-10
for O 0 1.9985825494561738e-11
the O 0 1.285989370547469e-10
role O 0 6.1632641212838735e-09
of O 0 5.297273020232751e-08
APC B-Disease 0 2.218211818671989e-07
amino O 0 4.747892390355446e-08
acid O 0 5.516261936122646e-08
changes O 0 2.9085130748285337e-08
in O 0 1.2091334610886406e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.006440616212785244
. O 0 7.535982149420306e-07

BACKGROUND O 0 7.117154018487781e-05
/ O 0 4.7893187002046034e-05
AIMS O 0 5.353930191631662e-06
The O 0 1.3894058348284943e-08
development O 0 6.299347177218806e-08
of O 0 4.262369088792184e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.3922655028864028e-08
a O 0 1.3609575688633413e-09
variable O 0 5.73751224308694e-09
range O 0 4.6250785423751495e-09
of O 0 1.132987592633583e-09
extracolonic O 0 4.1369153791492863e-07
manifestations O 0 1.472454300710524e-07
in O 0 5.404596095104353e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 4.517283880289824e-09
FAP B-Disease 0 1.2483407374475064e-07
) O 0 2.443899423110185e-11
is O 0 9.603600033269988e-12
the O 0 4.092277211542594e-11
result O 0 1.633949087143094e-10
of O 0 1.2022969286817897e-09
the O 0 3.011835669752827e-09
dominant O 0 1.623048362375812e-08
inheritance O 0 1.6387515415772214e-06
of O 0 2.7381820473237894e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 4.906290484996134e-09
APC B-Disease 0 1.5317878876430768e-07
) O 0 9.125141753330013e-10
gene O 0 1.5852387846848615e-08
mutations O 0 1.236999338516398e-07
. O 0 2.8852543891844107e-06

In O 0 2.028765777595254e-08
this O 0 2.9593880124245686e-10
study O 0 1.0662121185944784e-10
, O 0 2.686719336592036e-12
direct O 0 7.896410608720927e-11
mutation O 0 2.174067870175378e-11
analysis O 0 6.873906305271404e-11
of O 0 4.766288475011038e-10
the O 0 1.7106216443352196e-09
APC B-Disease 0 2.0892329644084384e-08
gene O 0 2.4032791312578183e-09
was O 0 7.3017116797302606e-09
performed O 0 4.0927572442228666e-09
to O 0 3.367092160644347e-09
determine O 0 4.127824304589467e-09
genotype O 0 6.215837089484921e-08
- O 0 5.825399966852274e-07
phenotype O 0 2.4309414925482997e-08
correlations O 0 2.7946402969547535e-09
for O 0 4.848224044451399e-09
nine O 0 9.519359522869308e-09
extracolonic O 0 1.2624921907899989e-07
manifestations O 0 1.3112245511592846e-08
and O 0 1.427838403067483e-10
to O 0 1.6051667772742917e-09
investigate O 0 1.6213766995676338e-09
the O 0 2.6384388007727466e-09
incidence O 0 2.6228465230815345e-06
of O 0 8.350566105264079e-08
APC B-Disease 0 3.710337352913484e-07
mutations O 0 8.328833622783804e-09
in O 0 9.833554770466435e-08
non O 1 1.0
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.962016439298168e-05

METHODS O 0 5.1370834626141004e-06
The O 0 4.37603347336335e-07
APC B-Disease 0 5.77337800677924e-07
gene O 0 3.4765751166787595e-08
was O 0 9.751485663400672e-08
analysed O 0 2.2750633377199847e-08
in O 0 1.419150907899791e-09
190 O 0 8.947678153958805e-09
unrelated O 0 5.62137891790826e-09
FAP B-Disease 0 7.769921950284697e-08
and O 0 5.889803644798519e-10
15 O 0 4.0406982293461624e-07
non O 1 0.9999910593032837
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 3.524165322232875e-06
using O 0 2.2060291371417406e-09
denaturing O 0 2.919669270795566e-07
gradient O 0 7.99099275639037e-09
gel O 0 1.5281191423355267e-08
electrophoresis O 0 6.462048673938625e-10
, O 0 1.2260352455495394e-10
the O 0 2.6622673510168227e-10
protein O 0 2.8478674973797524e-10
truncation O 0 1.5043992718233312e-08
test O 0 1.7346625247327552e-09
, O 0 4.733255454247853e-11
and O 0 2.6992847193541003e-11
direct O 0 1.2585337216819426e-09
sequencing O 0 2.8061311496685448e-08
. O 0 2.797047500280314e-07

RESULTS O 0 1.3982253221911378e-05
Chain O 0 4.537146480743104e-07
terminating O 0 1.2633063306566328e-07
signals O 0 5.382992540603482e-08
were O 0 9.2839347320961e-10
only O 0 1.6398749025370307e-10
identified O 0 2.1268238559191133e-10
in O 0 5.3357783469376585e-11
patients O 0 1.1884478123835862e-10
belonging O 0 1.9053675304192552e-10
to O 0 1.1494190044203378e-09
the O 0 3.1316818027704585e-09
FAP B-Disease 0 1.4398517578229075e-07
group O 0 1.2675458460620348e-09
( O 0 7.171820776141757e-11
105 O 0 2.732431312324479e-07
patients O 0 8.095653214468257e-08
) O 0 1.8232061416156853e-09
. O 0 2.4808230136841303e-07

Amino O 0 1.1431052371335682e-06
acid O 0 5.3156739454607305e-08
changes O 0 4.018320676202336e-10
were O 0 1.8628493192451856e-10
identified O 0 3.259390257692729e-10
in O 0 1.39631445295052e-10
four O 0 8.525394973313283e-11
patients O 0 3.4544731658536776e-11
, O 0 2.204822695944797e-12
three O 0 9.808622664086997e-12
of O 0 4.1095893354992086e-10
whom O 0 8.130002449036056e-09
belonged O 0 2.3386980956274783e-06
to O 0 5.738691925216699e-06
the O 0 1.6950737062870758e-06
non O 1 0.9978112578392029
- O 0 0.0003697312786243856
FAP O 0 0.0001437814353266731
group O 0 1.0728537347404199e-07
of O 0 2.2843914848635904e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9999897480010986
. O 0 5.366620143831824e-07

Genotype O 0 0.00021999991440679878
- O 0 8.400212391279638e-05
phenotype O 0 5.018093816033797e-07
correlations O 0 1.8843424598458114e-08
identified O 0 5.25532506401305e-09
significant O 0 3.919148561237762e-09
differences O 0 1.717411768353827e-09
in O 0 4.440282808104712e-09
the O 0 8.887551139480365e-09
nature O 0 1.1936006627522033e-09
of O 0 8.963559339214555e-10
certain O 0 1.0937604155714098e-09
extracolonic O 0 2.3004946569926688e-07
manifestations O 0 1.1081175976812574e-08
in O 0 1.537855065514293e-09
FAP B-Disease 0 4.892014970891978e-08
patients O 0 1.9756696278960817e-09
belonging O 0 6.402558483387111e-10
to O 0 2.245171160097925e-09
three O 0 1.5958619981049083e-09
mutation O 0 6.8652004081570794e-09
subgroups O 0 1.008229659760218e-07
. O 0 2.1158494689643703e-07

CONCLUSIONS O 0 5.806270110042533e-06
Extended O 0 2.60229376181087e-06
genotype O 0 1.5741350125608733e-06
- O 0 1.7156729654743685e-06
phenotype O 0 7.638569599066614e-08
correlations O 0 3.799677905647059e-09
made O 0 1.0440935893640813e-09
in O 0 1.1912437702932266e-10
this O 0 2.0993521157586237e-11
study O 0 3.5684899479804244e-11
may O 0 4.854103924367692e-11
have O 0 2.286487839342488e-11
the O 0 3.326084199728463e-11
potential O 0 4.685898544187772e-11
to O 0 6.204732283521253e-10
determine O 0 2.9370483822788174e-09
the O 0 1.3137028354037739e-08
most O 0 1.2761527390381389e-09
appropriate O 0 9.338143769355156e-08
surveillance O 0 1.111568053602241e-06
and O 0 1.6831929627869613e-08
prophylactic O 0 3.618525079218671e-05
treatment O 0 2.6723182600107975e-07
regimens O 0 5.44366187682499e-08
for O 0 4.0999356687443367e-10
those O 0 1.1649921305423305e-10
patients O 0 3.1832733671244284e-10
with O 0 2.791450664368922e-12
mutations O 0 1.195320092906016e-10
associated O 0 1.3124299425015806e-09
with O 0 2.4073965043669432e-11
life O 0 1.5632238614671223e-08
threatening O 0 1.0688113505352703e-08
conditions O 0 7.949494573722404e-08
. O 0 8.533558570889e-08

This O 0 6.604555835565407e-08
study O 0 2.587150049748743e-09
also O 0 5.286555915251512e-11
provided O 0 8.452889083132575e-11
evidence O 0 7.83209122556805e-11
for O 0 5.476218437050484e-11
the O 0 1.1086837004015138e-09
pathological O 0 5.8141889525131774e-08
nature O 0 1.8038771587569613e-09
of O 0 1.0340219791515892e-09
amino O 0 1.2204944832561182e-09
acid O 0 3.642764756506267e-09
changes O 0 1.6707338845733943e-09
in O 0 1.072736655061135e-08
APC O 0 3.180473129305028e-07
associated O 0 7.068336316251589e-08
with O 0 1.4882554910666812e-10
both O 0 7.604415430684242e-10
FAP B-Disease 0 7.965278570054579e-08
and O 0 2.093803797009741e-09
non O 1 0.9996649026870728
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.998457264562603e-05
. O 0 2.5769311129408834e-09
. O 0 1.0013931017738287e-08

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 2.4708922410354717e-06
cancer B-Disease 0 0.03753483667969704
risk O 0 1.7237584870599676e-06
of O 0 1.4359014812725945e-06
the O 0 6.096906872699037e-06
APC O 0 1.0623689377098344e-05
I1307K O 0 2.3915888959891163e-05
polymorphism O 0 1.0041970881502493e-06
. O 0 3.6218304444446403e-07

Germ O 0 0.00013966830738354474
- O 0 3.479439328657463e-06
line O 0 6.029136301322069e-08
and O 0 9.028555125745186e-10
somatic O 0 6.798875062941079e-08
truncating O 0 1.9353180391590286e-07
mutations O 0 1.2780729363726095e-08
of O 0 2.0606751860441364e-08
the O 0 5.184856632922674e-08
APC B-Disease 0 1.0665208094451373e-07
gene O 0 3.605107767867821e-09
are O 0 1.0388513382864062e-09
thought O 0 1.4690453298271677e-08
to O 0 2.0786639964853748e-08
initiate O 0 3.0369153591891518e-06
colorectal B-Disease 1 1.0
tumor I-Disease 0 5.1617054850794375e-05
formation O 0 2.471858238095592e-07
in O 0 1.0337936373616685e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.4046709111426026e-06
sporadic O 1 0.9997941851615906
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 4.031385742564453e-06
respectively O 0 1.6821468307171017e-05
. O 0 2.980750650749542e-06

Recently O 0 6.588683731933997e-07
, O 0 1.2211930355832123e-09
an O 0 1.6807627511994383e-10
isoleucine O 0 3.4175624818999495e-07
- O 0 1.277824850376419e-07
- O 0 2.665349541075557e-07
> O 0 4.702487501617725e-07
lysine O 0 3.151181005023318e-08
polymorphism O 0 1.2106154967383986e-09
at O 0 1.2390903858516822e-09
codon O 0 4.647805695867646e-09
1307 O 0 2.048683569455534e-07
( O 0 8.33407023947963e-11
I1307K O 0 4.3475637312440085e-08
) O 0 1.7381424077811403e-10
of O 0 2.172005908462893e-09
the O 0 5.724995588707316e-09
APC B-Disease 0 6.164395216501362e-08
gene O 0 2.678792299093402e-09
has O 0 5.956670573459277e-11
been O 0 5.765608910440756e-12
identified O 0 1.310342459537317e-11
in O 0 1.1262942835321699e-11
6 O 0 1.5558699884010707e-09
% O 0 2.93147138508143e-11
- O 0 2.9436816872951965e-10
7 O 0 7.648567112994442e-09
% O 0 6.484705550313663e-10
of O 0 6.374070715686742e-10
the O 0 5.907185296472051e-10
Ashkenazi O 0 1.7051368317311244e-08
Jewish O 0 7.032697091347018e-09
population O 0 6.036745409110367e-11
. O 0 1.8194509232571932e-09

To O 0 1.2144093375354714e-07
assess O 0 4.3945263428213366e-07
the O 0 7.543816238353429e-09
risk O 0 2.097098139586251e-08
of O 0 8.567684339766402e-10
this O 0 1.645169556141468e-10
common O 0 1.6122301271792594e-09
APC B-Disease 0 5.249406953566904e-08
allelic O 0 8.857314526267146e-08
variant O 0 1.6017153825487185e-07
in O 0 1.4138903736693464e-07
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 3.235090062503332e-08
we O 0 9.376692311491297e-09
have O 0 4.770108197327261e-10
analyzed O 0 1.3078095273399981e-09
a O 0 1.1507088615303473e-09
large O 0 2.7389723822324186e-09
cohort O 0 5.120338073538733e-07
of O 0 1.458094800455001e-07
unselected O 0 0.00042902870336547494
Ashkenazi O 0 2.4647644750075415e-05
Jewish O 0 1.9174131011823192e-06
subjects O 0 3.9014144022075925e-06
with O 0 7.594259443521878e-09
adenomatous B-Disease 0 0.0003184558590874076
polyps I-Disease 0 1.581555807206314e-05
and O 0 1.943864180731225e-09
. O 0 1.653750558716638e-08
or O 0 1.5839814295759425e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 2.57949448467798e-08
for O 0 2.241107921463481e-08
the O 0 4.381587359603145e-07
APC O 0 1.987411451409571e-06
I1307K O 0 8.203516699722968e-06
polymorphism O 0 5.110966299071151e-07
. O 0 3.2143628914127476e-07

The O 0 2.8451395337469876e-06
APC O 0 4.142657871852862e-06
I1307K O 0 3.893891062034527e-06
allele O 0 1.8932517775738233e-08
was O 0 2.266706822240394e-09
identified O 0 4.3948825134698666e-10
in O 0 2.7982446915153503e-10
48 O 0 1.344292233085298e-08
( O 0 2.0078137069612367e-11
10 O 0 3.37962408059056e-10
. O 0 2.0321010499313452e-11
1 O 0 1.7210746161566703e-09
% O 0 6.520559092670908e-11
) O 0 3.366857834197212e-11
of O 0 1.8711784899316797e-10
476 O 0 1.7526790685451488e-08
patients O 0 1.2604200350097017e-08
. O 0 3.037428442098644e-08

Compared O 0 1.1532208077369432e-08
with O 0 7.94729559938645e-12
the O 0 4.3368898750006935e-11
frequency O 0 5.199319308424322e-10
in O 0 4.281338478184793e-11
two O 0 8.229919350177806e-12
separate O 0 1.0746805355343891e-11
population O 0 2.802424091397082e-12
control O 0 7.106650684596261e-11
groups O 0 4.4275568454599235e-12
, O 0 4.548333931708726e-11
the O 0 2.5604252051891763e-09
APC O 0 5.268836957839085e-07
I1307K O 0 3.979467692261096e-06
allele O 0 4.85564868313304e-08
is O 0 4.661882338496959e-11
associated O 0 2.334807902570901e-10
with O 0 2.8409416746172367e-12
an O 0 4.682107999920415e-12
estimated O 0 5.756170280007966e-12
relative O 0 7.527916068283957e-10
risk O 0 9.012812163256001e-10
of O 0 1.1532224064580987e-09
1 O 0 8.302602054754971e-07
. O 0 8.834854838823958e-07

5 O 0 1.706321654637577e-06
- O 0 2.3634422632312635e-06
1 O 0 3.2199388897424797e-06
. O 0 7.593435498165491e-07

7 O 0 2.396872559984331e-06
for O 0 7.226467602094999e-08
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9236319065093994
( O 0 1.0245070569681047e-08
both O 0 6.895041426702164e-09
P O 0 1.3386271575654973e-06
= O 0 1.1134358146591694e-07
. O 0 1.1626242191198344e-09
01 O 0 6.410226092157245e-07
) O 0 1.137808292028808e-09
. O 0 1.562416152012247e-08

Furthermore O 0 3.5845471302309306e-07
, O 0 1.0886820334121694e-09
compared O 0 1.86074089469912e-09
with O 0 1.3412994326333916e-10
noncarriers O 0 2.9783097943436587e-06
, O 0 1.710540864507948e-08
APC O 0 5.079338052382809e-07
I1307K O 0 1.4614151950809173e-06
carriers O 0 7.830157855437392e-09
had O 0 3.558488836929996e-09
increased O 0 2.317585234834496e-09
numbers O 0 2.6764839233806015e-09
of O 0 3.963380290628038e-09
adenomas B-Disease 0 0.004127171356230974
and O 0 1.1065568287449423e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999996423721313
per O 0 7.193552278295101e-07
patient O 0 1.235640411323402e-06
( O 0 3.0767485781346693e-10
P O 0 6.42918109861057e-07
= O 0 8.128734663159776e-08
. O 0 4.957791954751656e-10
03 O 0 1.980375827770331e-07
) O 0 7.782176986159683e-11
, O 0 1.4332183877197036e-11
as O 0 1.5884507251207047e-11
well O 0 1.7987835179700262e-11
as O 0 2.9866959599944565e-11
a O 0 1.0685370643859216e-10
younger O 0 1.609974598082431e-09
age O 0 3.3854195002902543e-09
at O 0 2.8222661541121852e-08
diagnosis O 0 3.4491467886255123e-06
. O 0 2.0009281342936447e-07

We O 0 2.665558156422776e-07
conclude O 0 6.545027417814708e-07
that O 0 4.245052309670427e-09
the O 0 4.7750834397675135e-08
APC O 0 5.299129952618387e-06
I1307K O 0 2.073179894068744e-05
variant O 0 8.47164210426854e-06
leads O 0 8.88148790068044e-08
to O 0 1.049667108787844e-08
increased O 0 3.176502048063412e-07
adenoma B-Disease 1 1.0
formation O 0 2.175859776798461e-07
and O 0 8.367027626299262e-10
directly O 0 4.755418836488445e-10
contributes O 0 3.033361062332318e-10
to O 0 4.788172983105632e-11
3 O 0 4.912224516040453e-10
% O 0 4.200364361883757e-11
- O 0 7.722414929745014e-10
4 O 0 2.4021975519872285e-09
% O 0 5.047164353122469e-10
of O 0 3.2696517715535833e-10
all O 0 3.5473729509405416e-10
Ashkenazi O 0 2.125850187439937e-06
Jewish O 0 4.4609671022044495e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.617486749542877e-06

The O 0 8.937021789279243e-08
estimated O 0 1.5738887970684345e-09
relative O 0 4.336085979161908e-08
risk O 0 5.686469961574403e-09
for O 0 1.8533864720726712e-10
carriers O 0 7.866979290227505e-10
may O 0 4.198646319508725e-09
justify O 0 1.7919306927183243e-08
specific O 0 2.3447957464561853e-10
clinical O 0 1.473376420868533e-10
screening O 0 1.2711769137307982e-10
for O 0 1.8975482296568202e-10
the O 0 3.9423583841902143e-10
360 O 0 6.078090031280681e-09
, O 0 2.6794077373493153e-11
000 O 0 3.3704077306850877e-09
Americans O 0 1.2820171313432382e-10
expected O 0 5.666088431777183e-11
to O 0 1.1485134371325145e-10
harbor O 0 8.664946093972503e-09
this O 0 4.918449536539526e-10
allele O 0 3.9198515544569545e-09
, O 0 9.811920720359524e-11
and O 0 3.630649947350406e-11
genetic O 0 4.462531733029351e-11
testing O 0 1.5680593976052926e-11
in O 0 1.0413738447956344e-11
the O 0 1.0411717321634484e-10
setting O 0 1.2092377099648388e-09
of O 0 1.2600726018163755e-10
long O 0 6.578095707032716e-11
- O 0 1.626865975268288e-09
term O 0 5.072880071566033e-08
- O 0 1.0134136196882082e-08
outcome O 0 5.09574160645343e-10
studies O 0 5.723201912388731e-10
may O 0 1.75611053476743e-10
impact O 0 4.536916953234993e-10
significantly O 0 3.5910680651340954e-08
on O 0 3.3759956750145648e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 5.783771825917938e-07
in O 0 8.090640657432147e-11
this O 0 2.8947609934104612e-11
population O 0 9.796320872557107e-12
. O 0 2.6295714494750655e-09

Localization O 0 7.80121044954285e-05
of O 0 1.4981060303398408e-07
human O 0 1.8916022526127563e-08
BRCA1 O 0 1.746801814306309e-08
and O 0 3.0530614147927793e-10
its O 0 1.7136129182304671e-09
loss O 0 8.879840862618948e-09
in O 0 1.119345838240804e-09
high O 0 1.1429420965214376e-08
- O 0 5.3815214506869324e-09
grade O 0 2.0308338832819572e-07
, O 0 4.371392581248301e-09
non B-Disease 1 0.9999958276748657
- I-Disease 1 1.0
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.27656519412994385

Although O 0 1.9690007846406843e-08
the O 0 2.7195345975172813e-09
link O 0 9.485212615345517e-09
between O 0 3.783628133025019e-10
the O 0 1.3020136080399425e-08
BRCA1 O 0 1.5286182986073982e-07
tumour B-Disease 1 1.0
- O 0 4.2450469095456356e-07
suppressor O 0 1.8196274140791502e-06
gene O 0 2.1101828906466835e-07
and O 0 6.901281324189767e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.0603527772777852e-08
established O 0 1.621747847124766e-09
, O 0 4.331623948417018e-11
the O 0 1.6565111782274045e-10
role O 0 9.856117033635314e-10
, O 0 8.186260697096159e-11
if O 0 1.9310179844023168e-10
any O 0 1.215103351270841e-09
, O 0 6.014165276901906e-10
of O 0 3.913546375855503e-09
BRCA1 O 0 1.1467922433894273e-07
in O 0 6.163254795410467e-08
non B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999504089355469
familial I-Disease 0 0.00048288932885043323
cancers I-Disease 1 0.9999998807907104
is O 0 1.9191552791397726e-09
unclear O 0 6.504320992917201e-08
. O 0 6.523205087205497e-08

BRCA1 O 0 2.0991163182770833e-05
mutations O 0 5.939390135267786e-08
are O 0 5.203069641801505e-10
rare O 0 4.60161952986482e-09
in O 0 3.469604603623111e-09
sporadic B-Disease 0 2.454667082929518e-07
cancers I-Disease 0 6.717275482515106e-07
, O 0 4.191610947223978e-10
but O 0 1.7328932733207125e-09
loss O 0 1.3705424350973772e-07
of O 0 2.5378477630511043e-07
BRCA1 O 0 3.4707909435383044e-08
resulting O 0 1.1613255912479303e-09
from O 0 2.0161036728971737e-10
reduced O 0 3.3452123293642444e-09
expression O 0 6.348533698741221e-09
or O 0 3.441816165405953e-09
incorrect O 0 1.0378877846051182e-07
subcellular O 0 1.7904329752127524e-06
localization O 0 2.156051959900651e-05
is O 0 1.3801396692159074e-09
postulated O 0 3.356640299045921e-09
to O 0 4.1172310005777035e-10
be O 0 5.7996378532987336e-11
important O 0 4.836916422945592e-10
in O 0 1.1961349688505152e-09
non B-Disease 0 0.12454710900783539
- I-Disease 1 0.9999512434005737
familial I-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 1.0

Epigenetic O 0 6.320562533801422e-05
loss O 0 1.0234473847958725e-05
, O 0 3.838700912695003e-09
however O 0 1.482668876562343e-09
, O 0 1.3132807341609265e-10
has O 0 2.509002554329509e-12
not O 0 1.986181618479632e-12
received O 0 9.67491625009087e-12
general O 0 4.368923001152325e-10
acceptance O 0 4.024244049105619e-09
due O 0 6.896343496265445e-09
to O 0 7.0685359787603375e-09
controversy O 0 1.269437888140601e-09
regarding O 0 2.3132529225478038e-09
the O 0 2.2356632101150353e-09
subcellular O 0 2.1205007669777842e-06
localization O 0 0.00015027279732748866
of O 0 2.989385734508687e-07
BRCA1 O 0 1.6436970895483682e-08
proteins O 0 7.820179226403212e-11
, O 0 1.1226530122199208e-10
reports O 0 1.987142395076802e-10
of O 0 2.5236820966334506e-10
which O 0 1.2816545567895243e-11
have O 0 3.2401983873775464e-11
ranged O 0 1.3457845948749991e-09
from O 0 3.5475608561874594e-11
exclusively O 0 4.807658160466133e-10
nuclear O 0 1.263366122827847e-08
, O 0 8.716759536397944e-10
to O 0 1.3075433180631535e-08
conditionally O 0 3.9785909677902964e-08
nuclear O 0 2.2191718684894113e-08
, O 0 4.5948905791348693e-10
to O 0 3.80740416972003e-09
the O 0 7.419469927327782e-09
ER O 0 4.78886568089365e-06
/ O 0 1.477963087381795e-05
golgi O 0 1.1291801456536632e-05
, O 0 1.074063415984483e-08
to O 0 1.5191336188991045e-08
cytoplasmic O 0 3.953378424625953e-08
invaginations O 0 6.104943395257578e-07
into O 0 3.5724911917611735e-09
the O 0 6.241055228173309e-09
nucleus O 0 3.358486111437742e-08
. O 0 1.580834236847295e-07

In O 0 7.058242879054433e-09
an O 0 1.9173471144107168e-10
attempt O 0 2.1966575225462748e-09
to O 0 9.044653914713763e-10
resolve O 0 5.4677906646816155e-09
this O 0 2.1639580405352632e-10
issue O 0 6.35952535077422e-09
, O 0 1.0748164164242624e-10
we O 0 6.642640881793227e-10
have O 0 2.897883599750628e-10
comprehensively O 0 7.849764926959324e-08
characterized O 0 1.3366577178430816e-08
19 O 0 5.498435484696529e-07
anti O 0 3.9545811887364835e-06
- O 0 1.311249434365891e-05
BRCA1 O 0 2.256885522911034e-07
antibodies O 0 3.563026851338691e-08
. O 0 3.642693968686217e-07

These O 0 4.2066723437983455e-08
reagents O 0 8.385550245293416e-07
detect O 0 1.2220422718201007e-07
a O 0 9.331979633486753e-09
220 O 0 2.2061984239485355e-08
- O 0 5.394596769292548e-08
kD O 0 8.29506745958497e-07
protein O 0 1.2044068853356293e-08
localized O 0 9.188987348807132e-08
in O 0 3.3901752516385386e-09
discrete O 0 1.08196305248498e-08
nuclear O 0 1.2074987409960158e-07
foci O 0 6.393070748345053e-07
in O 0 5.337618702583313e-08
all O 0 2.3797207759912453e-08
epithelial O 0 3.3758658446458867e-07
cell O 0 1.8924940548004088e-07
lines O 0 1.361848300795998e-09
, O 0 8.263884021530998e-11
including O 0 2.6461367819141657e-11
those O 0 1.2974112062469345e-10
derived O 0 1.18721423802981e-08
from O 0 1.7984019606842594e-08
breast B-Disease 0 2.370005631746608e-06
malignancies I-Disease 0 5.642076303047361e-06
. O 0 3.971396438373631e-07

Immunohistochemical O 0 0.0009084861958399415
staining O 0 4.6985620429040864e-05
of O 0 7.184043511188065e-07
human O 0 2.6398956265438756e-07
breast O 0 1.1857990102726035e-05
specimens O 0 5.406091077020392e-07
also O 0 4.079362625475369e-08
revealed O 0 1.0445586440255283e-07
BRCA1 O 0 7.931894430157627e-08
nuclear O 0 1.2585014701471664e-06
foci O 0 2.2974409148446284e-05
in O 0 8.69843006512383e-07
benign O 1 1.0
breast O 1 1.0
, O 0 7.367998478002846e-07
invasive B-Disease 1 0.9999982118606567
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 6.954021228011698e-05
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0022820516023784876

Conversely O 0 2.8889630812045652e-06
, O 0 3.494418621130535e-08
BRCA1 O 0 1.7320968481726595e-07
expression O 0 3.7094377347557383e-08
was O 0 4.866410385773179e-09
reduced O 0 3.6054033092369764e-09
or O 0 1.2829734497010747e-10
undetectable O 0 3.193558528735707e-09
in O 0 2.724038009049856e-11
the O 0 1.1269825350712637e-10
majority O 0 1.859532666736996e-11
of O 0 2.895049477924516e-10
high O 0 1.6776832367781935e-08
- O 0 7.614917052478631e-08
grade O 0 5.6850149121601135e-06
, O 0 5.75335015184919e-08
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 9.206737594524839e-09
suggesting O 0 5.536423319796313e-09
that O 0 4.084572957641086e-11
absence O 0 2.6226855354138934e-08
of O 0 1.1077964323646938e-08
BRCA1 O 0 6.193313861757588e-09
may O 0 7.424222348006992e-10
contribute O 0 3.199924103469698e-09
to O 0 5.731835450717426e-09
the O 0 5.878302733464125e-09
pathogenesis O 0 2.238647357444279e-05
of O 0 1.3751899174963e-08
a O 0 1.7343813052406176e-09
significant O 0 3.2168998576054264e-09
percentage O 0 4.211650050933713e-08
of O 0 7.03834635018552e-09
sporadic B-Disease 0 5.120746936881915e-05
breast I-Disease 0 0.0023164127487689257
cancers I-Disease 0 0.0003821731370408088
. O 0 4.801386239705607e-06
. O 0 1.4705988178320695e-05

